11058428
D013256_D013119 NONE steroid_2\NN|NONE (r_compound) myopathy_3\NN|naturally|,|Further|be|and (r_nsubj) recovers_4\VBZ|NONE (l_conj) be_15\VB|myopathy|naturally|,|Further|and (l_attr) recording_18\NN|may|.|improvement (l_cc) of_30\IN|,|just|a|of (l_pobj) protection_32\NN|instead (l_relcl) methylprednisolone_34\NN|any (l_dobj) offers_35\VBZ|that (l_prep) to_36\IN|NONE (l_pobj) injury_40\NN|NONE
D013256_D013119 NONE steroid_26\NN|NONE (r_compound) myopathy_27\NNS|NONE (r_pobj) from_24\IN|this|motor|natural (r_prep) recovery_23\NN|NONE (r_pobj) of_19\IN|of|,|just|a (r_prep) recording_18\NN|may|.|improvement (l_cc) of_30\IN|,|just|a|of (l_pobj) protection_32\NN|instead (l_relcl) methylprednisolone_34\NN|any (l_dobj) offers_35\VBZ|that (l_prep) to_36\IN|NONE (l_pobj) injury_40\NN|NONE
D013256_D009135 NONE steroid_2\NN|NONE (r_compound) myopathy_3\NN|naturally|,|Further|be|and
D013256_D009135 NONE steroid_2\NN|NONE (r_compound) myopathy_3\NN|naturally|,|Further|be|and (r_nsubj) recovers_4\VBZ|NONE (l_conj) be_15\VB|myopathy|naturally|,|Further|and (l_attr) recording_18\NN|may|.|improvement (l_prep) of_19\IN|of|,|just|a (l_pobj) recovery_23\NN|NONE (l_prep) from_24\IN|this|motor|natural (l_pobj) myopathy_27\NNS|NONE
D013256_D009135 NONE steroid_26\NN|NONE (r_compound) myopathy_27\NNS|NONE (r_pobj) from_24\IN|this|motor|natural (r_prep) recovery_23\NN|NONE (r_pobj) of_19\IN|of|,|just|a (r_prep) recording_18\NN|may|.|improvement (r_attr) be_15\VB|myopathy|naturally|,|Further|and (r_conj) recovers_4\VBZ|NONE (l_nsubj) myopathy_3\NN|naturally|,|Further|be|and
D013256_D009135 NONE steroid_26\NN|NONE (r_compound) myopathy_27\NNS|NONE
D000305_D009135 NONE corticosteroid_13\NN|NONE (r_pobj) of_11\IN|cause|myopathy|the (r_prep) possibility_10\NN|NONE (l_prep) myopathy_14\NNS|cause|of|the
D000305_D009135 NONE corticosteroid_21\NN|NONE (r_nsubj) myopathy_22\NNS|may|methylprednisolone|that
D008775_D009135 CID methylprednisolone_19\NN|that|may (r_nsubj) cause_21\VB|myopathy|of|the (r_acl) possibility_10\NN|NONE (l_prep) myopathy_14\NNS|cause|of|the
D008775_D009135 CID methylprednisolone_34\NN|any (r_relcl) protection_32\NN|instead (r_pobj) of_30\IN|,|just|a|of (r_cc) recording_18\NN|may|.|improvement (r_attr) be_15\VB|myopathy|naturally|,|Further|and (r_conj) recovers_4\VBZ|NONE (l_nsubj) myopathy_3\NN|naturally|,|Further|be|and
D008775_D009135 CID methylprednisolone_34\NN|any (r_relcl) protection_32\NN|instead (r_pobj) of_30\IN|,|just|a|of (r_cc) recording_18\NN|may|.|improvement (l_prep) of_19\IN|of|,|just|a (l_pobj) recovery_23\NN|NONE (l_prep) from_24\IN|this|motor|natural (l_pobj) myopathy_27\NNS|NONE
D008775_D009135 CID methylprednisolone_14\NN|myopathy|may|that (r_nsubj) cause_19\VB|the (l_ccomp) myopathy_22\NNS|may|methylprednisolone|that
D008775_D013119 NONE methylprednisolone_3\NN|harm|.|may (r_nsubj) do_5\VB|NONE (l_dobj) harm_7\NN|methylprednisolone|.|may (l_prep) for_8\IN|more (l_pobj) injury_11\NN|NONE
D008775_D013119 NONE methylprednisolone_16\NN|.|Because|standard (r_nsubj) became_17\VBD|NONE (l_prep) Because_0\IN|.|methylprednisolone|standard (l_pobj) Studies_8\NNP|of (l_compound) Injury_7\NNP|(|the|,|National|NASCIS
D008775_D013119 NONE methylprednisolone_16\NN|.|Because|standard (r_nsubj) became_17\VBD|NONE (l_attr) standard_19\NN|.|methylprednisolone|Because (l_prep) for_22\IN|of|the (l_pobj) injury_27\NN|NONE
D008775_D013119 NONE methylprednisolone_34\NN|any (l_dobj) offers_35\VBZ|that (l_prep) to_36\IN|NONE (l_pobj) injury_40\NN|NONE
7785794
D008790_D007022 CID metoprolol_32\NN|NONE (r_pobj) of_31\IN|concomitant (r_prep) use_30\NN|NONE (r_pobj) with_28\IN|a|therapeutic|of (r_prep) dose_22\NN|days (r_pobj) after_19\IN|with|.|woman (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|.|woman (l_pobj) block_13\NN|NONE (l_conj) hypotension_16\NN|heart|complete|and
D004298_D007022 NONE dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|of|multiple (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|to|,|hypotensive (r_prep) remain_4\VB|patient|. (l_acomp) hypotensive_5\JJ|to|,|with
D004280_D007022 NONE dobutamine_30\NN|and (r_conj) dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|of|multiple (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|to|,|hypotensive (r_prep) remain_4\VB|patient|. (l_acomp) hypotensive_5\JJ|to|,|with
D001285_D007022 NONE atropine_17\NN|NONE (r_pobj) of_15\IN|doses|multiple (r_prep) uses_14\NNS|even (r_pobj) with_12\IN|to|,|hypotensive (r_prep) remain_4\VB|patient|. (l_acomp) hypotensive_5\JJ|to|,|with
D008790_D006327 CID metoprolol_11\NN|Refractory|after|.|block|and|and|cardiogenic (r_conj) shock_2\NN|NONE (l_conj) block_6\NN|Refractory|after|metoprolol|.|and|and|cardiogenic
D008790_D006327 CID metoprolol_32\NN|NONE (r_pobj) of_31\IN|concomitant (r_prep) use_30\NN|NONE (r_pobj) with_28\IN|a|therapeutic|of (r_prep) dose_22\NN|days (r_pobj) after_19\IN|with|.|woman (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|.|woman (l_pobj) block_13\NN|NONE
D008790_D012770 NONE metoprolol_11\NN|Refractory|after|.|block|and|and|cardiogenic (r_conj) shock_2\NN|NONE
D004280_D006327 NONE dobutamine_30\NN|and (r_conj) dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|of|multiple (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|to|,|hypotensive (r_prep) remain_4\VB|patient|. (l_acomp) hypotensive_5\JJ|to|,|with (l_prep) with_6\IN|NONE (l_pobj) block_9\NN|NONE
D002122_D006327 NONE chloride_9\NN|NONE (l_conj) hypotension_13\NN|intravenous|calcium|, (l_conj) block_17\NN|the|and|refractory
D014700_D007022 CID verapamil_27\NN|NONE (r_pobj) of_23\IN|a|therapeutic|with (r_prep) dose_22\NN|days (r_pobj) after_19\IN|with|.|woman (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|.|woman (l_pobj) block_13\NN|NONE (l_conj) hypotension_16\NN|heart|complete|and
D002122_D007022 NONE chloride_9\NN|NONE (l_conj) hypotension_13\NN|intravenous|calcium|,
D004298_D006327 NONE dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|of|multiple (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|to|,|hypotensive (r_prep) remain_4\VB|patient|. (l_acomp) hypotensive_5\JJ|to|,|with (l_prep) with_6\IN|NONE (l_pobj) block_9\NN|NONE
D014700_D012770 NONE verapamil_8\NN|NONE (r_compound) SR_9\NNP|NONE (r_pobj) after_7\IN|Refractory|metoprolol|.|block|and|and|cardiogenic (r_prep) shock_2\NN|NONE
D001285_D006327 NONE atropine_17\NN|NONE (r_pobj) of_15\IN|doses|multiple (r_prep) uses_14\NNS|even (r_pobj) with_12\IN|to|,|hypotensive (r_prep) remain_4\VB|patient|. (l_acomp) hypotensive_5\JJ|to|,|with (l_prep) with_6\IN|NONE (l_pobj) block_9\NN|NONE
D014700_D006327 CID verapamil_8\NN|NONE (r_compound) SR_9\NNP|NONE (r_pobj) after_7\IN|Refractory|metoprolol|.|block|and|and|cardiogenic (r_prep) shock_2\NN|NONE (l_conj) block_6\NN|Refractory|after|metoprolol|.|and|and|cardiogenic
D014700_D006327 CID verapamil_27\NN|NONE (r_pobj) of_23\IN|a|therapeutic|with (r_prep) dose_22\NN|days (r_pobj) after_19\IN|with|.|woman (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|.|woman (l_pobj) block_13\NN|NONE
3057041
C020976_D006255 NONE azelastine_18\NN|NONE (r_pobj) of_17\IN|safety (r_prep) trial_16\NN|,|groups|and|,|in|dose (r_conj) efficacy_13\NN|.|,|blind (l_prep) in_24\IN|trial|,|groups|and|,|dose (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) rhinitis_30\NN|NONE
C020976_D006255 NONE Azelastine_0\NNP|with|.|was (r_nsubjpass) compared_8\VBN|NONE (l_prep) with_9\IN|.|Azelastine|was (l_pobj) maleate_11\NN|NONE (l_prep) for_14\IN|chlorpheniramine|placebo|and (l_pobj) efficacy_15\NN|NONE (l_prep) in_18\IN|and|safety (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|the|in (l_pobj) rhinitis_24\NN|NONE
C020976_D006255 NONE Azelastine_0\NNP|.|be (r_nsubj) appears_1\VBZ|NONE (l_xcomp) be_3\VB|Azelastine|. (l_attr) medication_8\NN|to (l_prep) for_9\IN|safe|,|efficacious|a (l_pobj) rhinitis_12\NN|NONE
C020976_D006970 CID azelastine_16\NN|dose|the (r_compound) group_17\NN|only (r_pobj) in_11\IN|significantly|.|over|were|Drowsiness (r_prep) increased_6\VBN|NONE (l_nsubjpass) Drowsiness_0\VB|significantly|.|over|were|in
D002744_D006255 NONE chlorpheniramine_20\NN|, (r_conj) azelastine_18\NN|NONE (r_pobj) of_17\IN|safety (r_prep) trial_16\NN|,|groups|and|,|in|dose (r_conj) efficacy_13\NN|.|,|blind (l_prep) in_24\IN|trial|,|groups|and|,|dose (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) rhinitis_30\NN|NONE
D002744_D006255 NONE maleate_11\NN|NONE (l_prep) for_14\IN|chlorpheniramine|placebo|and (l_pobj) efficacy_15\NN|NONE (l_prep) in_18\IN|and|safety (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|the|in (l_pobj) rhinitis_24\NN|NONE
C020976_D013651 CID azelastine_16\NN|dose|the (r_compound) group_17\NN|only (r_pobj) in_11\IN|significantly|.|over|were|Drowsiness (r_prep) increased_6\VBN|NONE (l_nsubjpass) Drowsiness_0\VB|significantly|.|over|were|in (l_conj) perception_4\NN|and
9214597
D004967_D009369 NONE estrogen_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) rat_17\NN|pituitary (r_nmod) tumors_19\NNS|NONE (r_pobj) of_13\IN|the (r_prep) development_12\NN|NONE (r_pobj) during_10\IN|its (r_prep) receptor_9\NN|endothelial|and|growth|vascular (r_conj) factor_6\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) expression_1\NN|NONE (r_pobj) Over_0\IN|may|angiogenesis|. (r_prep) mediate_21\VB|NONE (l_dobj) angiogenesis_26\NN|Over|may|. (l_compound) tumor_25\NN|initiated
D004967_D009369 NONE estrogen_22\NN| (r_npadvmod) initiated_24\VBN|tumor (r_amod) angiogenesis_26\NN|Over|may|. (l_compound) tumor_25\NN|initiated
D004967_D009369 NONE Estrogens_0\NNP|in|.|can|angiogenesis (l_relcl) associated_5\VBN|,|, (l_prep) with_6\IN|been|have|which (l_pobj) types_8\NNS|NONE (l_prep) of_9\IN|several (l_pobj) cancers_13\NNS|NONE
D004967_D009369 NONE Estrogens_0\NNP|in|.|can|angiogenesis (r_nsubj) induce_16\VB|NONE (l_dobj) angiogenesis_18\NN|Estrogens|in|.|can (l_compound) tumor_17\NN|NONE
D004967_D009369 NONE estrogen_9\NN|NONE (r_compound) carcinogenesis_10\NN|NONE (r_pobj) during_8\IN|still|unknown|.|,|details|, (r_prep) are_12\VBP|NONE (l_nsubj) details_2\NNS|still|unknown|.|during|,|, (l_prep) of_3\IN|induction|mechanistic|The (l_pobj) angiogenesis_5\NN|NONE (l_compound) tumor_4\NN|NONE
D004967_D009369 NONE estrogen_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) role_3\NN|To|in (r_dobj) elucidate_1\VB|was|density|,|using (l_prep) in_6\IN|role|To (l_pobj) regulation_8\NN|NONE (l_prep) of_9\IN|the|in (l_pobj) angiogenesis_11\NN|NONE (l_compound) tumor_10\NN|NONE
D004967_D009369 NONE estrogen_27\NN|NONE (r_pobj) of_26\IN|the (r_prep) regulation_25\NN|NONE (r_pobj) of_23\IN|the|initial (r_prep) step_22\NN|NONE (r_pobj) in_19\IN|may|over|that|role (r_prep) play_15\VB|.|induced|findings (r_ccomp) suggest_2\VBP|NONE (l_ccomp) induced_28\VBN|.|findings|play (l_dobj) angiogenesis_30\NN|in (l_compound) tumor_29\NN|NONE
D004967_D010911 NONE estrogen_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) rat_17\NN|pituitary (r_nmod) tumors_19\NNS|NONE
D004967_D010911 NONE estrogen_22\NN| (r_npadvmod) initiated_24\VBN|tumor (r_amod) angiogenesis_26\NN|Over|may|. (r_dobj) mediate_21\VB|NONE (l_prep) Over_0\IN|may|angiogenesis|. (l_pobj) expression_1\NN|NONE (l_prep) of_2\IN|NONE (l_pobj) factor_6\NN|NONE (l_conj) receptor_9\NN|endothelial|and|growth|vascular (l_prep) during_10\IN|its (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) tumors_19\NNS|NONE
D004967_D063646 NONE estrogen_9\NN|NONE (r_compound) carcinogenesis_10\NN|NONE
15893386
D015742_D008305 NONE propofol_5\JJ|NONE (r_amod) infusion_6\NN|NONE (r_pobj) with_4\IN|.|were|was|Anesthesia|uneventfully (r_prep) continued_2\VBN|NONE (l_advcl) were_10\VBD|.|was|Anesthesia|uneventfully|with (l_acomp) available_11\JJ|facilities|while (l_xcomp) detect_13\VB|NONE (l_conj) treat_15\VB|to|and (l_dobj) hyperthermia_17\NN|NONE
D013390_D014313 CID Succinylcholine_0\NN| (r_npadvmod) induced_2\VBN|during|masseter|.|muscle (r_amod) rigidity_5\NN|NONE
D013390_D014313 CID succinylcholine_17\NN|)|Sch|(|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|case|Here|we|.|, (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|Here|we|.|,|after (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE
D013390_D014313 CID succinylcholine_17\NN|)|Sch|(|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|case|Here|we|.|, (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|Here|we|.|,|after (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE (l_appos) jaw_12\NN|masseter|severe|)|muscle|( (l_prep) of_13\IN|NONE (l_pobj) steel_14\NN|NONE
D013390_D014313 CID Sch_19\NNP|)|(|succinylcholine|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|case|Here|we|.|, (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|Here|we|.|,|after (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE
D013390_D014313 CID Sch_19\NNP|)|(|succinylcholine|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|case|Here|we|.|, (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|Here|we|.|,|after (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE (l_appos) jaw_12\NN|masseter|severe|)|muscle|( (l_prep) of_13\IN|NONE (l_pobj) steel_14\NN|NONE
3461217
D013739_D011471 NONE testosterone_21\NN|N||nitroso||and (r_conj) methylurea_19\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treatments_11\NNS|NONE (r_pobj) by_10\IN|.|of (r_prep) Production_0\NN|NONE (l_prep) of_1\IN|.|by (l_pobj) cancer_4\NN|NONE
D043343_D009369 NONE TP_6\NNP|.|as|,|In|,|with (r_nsubj) acted_7\VBD|NONE (l_prep) as_8\IN|.|TP|,|In|,|with (l_pobj) agent_12\NN|NONE (l_compound) enhancement_11\NN|a (l_compound) tumor_10\NN|NONE
D043343_D011471 CID propionate_45\NN||(|and|)|: (r_conj) CAS_35\NN|nitroso|N|| (r_appos) methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|following|rats (l_nmod) adenocarcinomas_20\NNS|palpable|large|)|,|(|prostate
D043343_D011471 CID propionate_45\NN||(|and|)|: (r_conj) CAS_35\NN|nitroso|N|| (r_appos) methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|following|rats
D043343_D011471 CID TP_19\NNP|only (r_pobj) with_18\IN|when (r_prep) treated_16\VBN|PA|.|rat|,|Within (r_advcl) developed_10\VBD|NONE (l_dobj) PA_14\NNP|treated|.|rat|,|Within
D043343_D011471 CID TP_6\NNP|.|as|,|In|,|with (r_nsubj) acted_7\VBD|NONE (l_prep) with_14\IN|.|as|TP|,|In|, (l_pobj) emphasis_16\NN|NONE (l_prep) on_17\IN|primary (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) cancer_22\NN|NONE
D008770_D011471 CID methylurea_19\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treatments_11\NNS|NONE (r_pobj) by_10\IN|.|of (r_prep) Production_0\NN|NONE (l_prep) of_1\IN|.|by (l_pobj) cancer_4\NN|NONE
D008770_D011471 CID methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|following|rats (l_nmod) adenocarcinomas_20\NNS|palpable|large|)|,|(|prostate
D008770_D011471 CID methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|following|rats
8251368
D017311_D013684 CID amlodipine_6\NN|One|later|with|,|. (r_dobj) commenced_1\VBD|NONE (l_prep) with_11\IN|One|later|amlodipine|,|. (l_pobj) recurrence_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) telangiectasia_14\NN|NONE
D009543_D013684 CID nifedipine_1\RB| (r_advmod) induced_3\VBN|facial (r_amod) telangiectasia_5\NN|.
D009543_D013684 CID nifedipine_4\NN|Adalat (r_dobj) starting_3\VBG|months (r_pcomp) after_2\IN|patients|,|.|telangiectasia (r_prep) developed_11\VBD|NONE (l_dobj) telangiectasia_14\NN|patients|,|after|.
D009543_D013684 CID Adalat_6\NNP|nifedipine (r_oprd) starting_3\VBG|months (r_pcomp) after_2\IN|patients|,|.|telangiectasia (r_prep) developed_11\VBD|NONE (l_dobj) telangiectasia_14\NN|patients|,|after|.
17019386
D008353_D009362 NONE Mannitol_2\NN|: (r_appos) METHODS_0\NNS|was|had|.|as (r_nsubjpass) administered_14\VBN|NONE (l_parataxis) had_22\VBD|was|METHODS|.|as (l_dobj) glioma_24\NN|ten|(|before (l_conj) metastases_28\NNS|malignant|)|,
D008353_D009362 NONE mannitol_8\NN|NONE (r_pobj) of_7\IN|plasma|patients (r_prep) concentrations_6\NNS|higher|except|.|In (l_compound) patients_4\NNS|plasma|of (l_nmod) meningioma_1\NN|NONE (l_conj) metastases_3\NNS|and
D008353_D004487 NONE mannitol_13\NN|,|reversing|through|,|near|that|after|may (r_nsubj) leak_15\VB|of|.|The (l_advcl) reversing_23\VBG|,|through|,|near|that|after|may|mannitol (l_conj) aggravating_34\VBG|gradient|, (l_dobj) edema_36\NN|and|promoting
D008353_D005910 NONE mannitol_2\NN|NONE (r_pobj) of_1\IN|into (r_prep) Passage_0\NN|.|:|cause (r_nsubj) gliomas_7\NNS|NONE
D008353_D005910 NONE Mannitol_2\NN|: (r_appos) METHODS_0\NNS|was|had|.|as (r_nsubjpass) administered_14\VBN|NONE (l_parataxis) had_22\VBD|was|METHODS|.|as (l_dobj) glioma_24\NN|ten|(|before
D008353_D005910 NONE mannitol_5\NN|in (r_amod) concentrations_6\NNS|mean|,|In|higher|. (r_nsubj) were_10\VBD|NONE (l_prep) In_0\IN|mean|,|higher|concentrations|. (l_pobj) patients_3\NNS|NONE (l_compound) glioma_2\NN|most
D008353_D005910 NONE mannitol_13\NN|,|reversing|through|,|near|that|after|may (r_nsubj) leak_15\VB|of|.|The (l_prep) near_20\IN|,|reversing|through|,|that|after|may|mannitol (l_pobj) gliomas_21\NNS|NONE
D008353_D019586 CID mannitol_5\NN|NONE (r_pobj) of_4\IN|reduce|Widespread (r_prep) use_3\NN|continues|.|: (l_acl) reduce_7\VB|of|Widespread (l_dobj) edema_9\NN|to (l_conj) ICP_13\NNP|brain|and
D008353_D008579 NONE Mannitol_2\NN|: (r_appos) METHODS_0\NNS|was|had|.|as (r_nsubjpass) administered_14\VBN|NONE (l_parataxis) had_22\VBD|was|METHODS|.|as (l_dobj) glioma_24\NN|ten|(|before (l_conj) metastases_28\NNS|malignant|)|, (l_conj) meningioma_31\NN|brain|seven|and
D008353_D008579 NONE mannitol_8\NN|NONE (r_pobj) of_7\IN|plasma|patients (r_prep) concentrations_6\NNS|higher|except|.|In (l_compound) patients_4\NNS|plasma|of (l_nmod) meningioma_1\NN|NONE
D008353_D001929 NONE mannitol_5\NN|NONE (r_pobj) of_4\IN|reduce|Widespread (r_prep) use_3\NN|continues|.|: (l_acl) reduce_7\VB|of|Widespread (l_dobj) edema_9\NN|to
D008353_D001932 NONE mannitol_5\NN|NONE (r_pobj) of_4\IN|reduce|Widespread (r_prep) use_3\NN|continues|.|: (l_acl) reduce_7\VB|of|Widespread (l_dobj) edema_9\NN|to (l_conj) ICP_13\NNP|brain|and (l_prep) in_14\IN|lower|elevated (l_pobj) patients_17\NNS|NONE (l_compound) tumor_16\NN|NONE
D008353_D001932 NONE mannitol_14\NN|NONE (r_pobj) of_13\IN|the|into|possible (r_prep) passage_12\NN|to|after|to (r_dobj) research_9\VB|we|As|. (l_prep) to_20\IN|to|after|passage (l_pobj) patients_24\NNS|NONE (l_compound) tumor_23\NN|
9209318
D015215_D009190 CID azidothymidine_5\NN|NONE (r_pcomp) with_4\IN|Lifetime|AZT|of (r_prep) treatment_1\NN|myelodysplasia|. (r_nsubj) produces_9\VBZ|NONE (l_dobj) myelodysplasia_10\NN|.|treatment
D015215_D009190 CID AZT_7\NNP|Lifetime|with|of (r_appos) treatment_1\NN|myelodysplasia|. (r_nsubj) produces_9\VBZ|NONE (l_dobj) myelodysplasia_10\NN|.|treatment
D015215_D009190 CID AZT_2\NNP|NONE (r_compound) incorporation_3\NN|have|hemopoiesis|may (r_nsubj) induced_6\VBN|Above|. (l_dobj) hemopoiesis_9\NN|have|may|incorporation (l_prep) in_10\IN|ineffective|an (l_pobj) cells_15\NNS|NONE (l_relcl) known_19\VBN|the|primitive|progenitor|, (l_xcomp) seen_22\VBN|which|is (l_prep) in_24\IN|to|be|commonly (l_pobj) syndrome_27\NN|NONE
D015215_D000748 CID AZT_0\NNP|.|anemia|has (r_nsubj) induced_2\VBN|NONE (l_dobj) anemia_5\NN|.|has|AZT
D015215_D000748 CID AZT_12\NNP|NONE (r_compound) therapy_13\NN|long (r_appos) term_11\NN|NONE (r_pobj) on_9\IN|a|macrocytic|in (r_prep) anemia_5\NN|.|has|AZT
D015215_D000163 NONE AZT_0\NNP|.|anemia|has (r_nsubj) induced_2\VBN|NONE (l_dobj) anemia_5\NN|.|has|AZT (l_prep) in_6\IN|a|macrocytic|on (l_pobj) patients_8\NNS|NONE (l_compound) AIDS_7\NNP|NONE
D015215_D000163 NONE AZT_12\NNP|NONE (r_compound) therapy_13\NN|long (r_appos) term_11\NN|NONE (r_pobj) on_9\IN|a|macrocytic|in (r_prep) anemia_5\NN|.|has|AZT (l_prep) in_6\IN|a|macrocytic|on (l_pobj) patients_8\NNS|NONE (l_compound) AIDS_7\NNP|NONE
8514073
D003975_D010146 NONE diazepam_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) patients_15\NNS|NONE (r_pobj) of_14\IN|||(|) (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Pain|compared|. (r_prep) occurred_5\VBD|NONE (l_nsubj) Pain_0\NN|in|compared|.
D000431_D014652 NONE alcohol_19\NN|and|pain|, (r_compound) use_20\NN|of|,|dwell (r_conj) time_14\NN|intravenous|catheter|, (r_conj) site_11\NN|nonsteroidal|,|drug|inflammatory (r_conj) use_7\NN|, (r_appos) Smoking_0\NN|effect|. (r_nsubj) had_27\VBD|NONE (l_dobj) effect_29\NN|Smoking|. (l_prep) on_30\IN|no (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) complications_35\NNS|NONE
D008874_D010146 NONE midazolam_32\JJ|the (r_amod) group_33\NN|NONE (r_pobj) in_30\IN|)|patients|(||. (r_prep) %_23\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) compared_20\VBN|Pain|in|. (r_prep) occurred_5\VBD|NONE (l_nsubj) Pain_0\NN|in|compared|.
D000431_D010146 NONE alcohol_19\NN|and|pain|, (r_compound) use_20\NN|of|,|dwell (l_conj) pain_23\NN|and|alcohol|,
D008874_D014652 CID midazolam_3\FW|NONE (r_pobj) of_2\IN|.|Venous (r_prep) complications_1\NNS|NONE
D008874_D014652 CID midazolam_11\DT|NONE (r_pobj) with_10\IN|are|complications (r_prep) associated_9\VBN|Although|have|studies (l_nsubjpass) complications_7\NNS|are|with
D008874_D014652 CID midazolam_14\NN|or (r_conj) diazepam_12\NN|NONE (r_pobj) of_11\IN|in|intravenous (r_prep) injection_10\NN|NONE (r_pobj) after_8\IN|prospectively|.|We|incidence (r_prep) evaluated_2\VBD|NONE (l_dobj) incidence_4\NN|prospectively|.|We|after (l_prep) of_5\IN|the (l_pobj) complications_7\NNS|NONE
D008874_D014652 CID midazolam_17\NNP|NONE (r_pobj) with_16\IN|. (r_prep) than_15\IN|(|of|) (r_prep) 22_10\CD|frequent|,|complications|Overall|. (r_npadvmod) were_4\VBD|NONE (l_nsubj) complications_3\NNS||frequent|,|Overall|.
D003975_D014652 CID diazepam_5\NN|NONE (r_pobj) versus_4\FW|NONE (r_prep) midazolam_3\FW|NONE (r_pobj) of_2\IN|.|Venous (r_prep) complications_1\NNS|NONE
D003975_D014652 CID diazepam_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) than_12\IN|NONE (r_prep) midazolam_11\DT|NONE (r_pobj) with_10\IN|are|complications (r_prep) associated_9\VBN|Although|have|studies (l_nsubjpass) complications_7\NNS|are|with
D003975_D014652 CID diazepam_12\NN|NONE (r_pobj) of_11\IN|in|intravenous (r_prep) injection_10\NN|NONE (r_pobj) after_8\IN|prospectively|.|We|incidence (r_prep) evaluated_2\VBD|NONE (l_dobj) incidence_4\NN|prospectively|.|We|after (l_prep) of_5\IN|the (l_pobj) complications_7\NNS|NONE
D003975_D014652 CID diazepam_8\NN|NONE (r_pobj) with_7\IN|more (r_prep) frequent_6\JJ||,|complications|Overall|. (r_acomp) were_4\VBD|NONE (l_nsubj) complications_3\NNS||frequent|,|Overall|.
6892185
D002122_D015878 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|)|fighting|injected|into|upon|, (r_nsubj) injected_5\VBD|was|similarly|. (l_advcl) fighting_26\VBG|)|injected|into|upon|,|effect (l_conj) mydriasis_43\NN|attack|,
D002122_D015878 NONE chloride_24\NN|NONE (r_pobj) by_22\IN|significantly|On|not|were|mydriasis|.|, (r_agent) changed_21\VBN|NONE (l_nsubjpass) mydriasis_5\NN|significantly|On|not|by|were|.|,
D002122_D015878 NONE chloride_5\NN|caused|"|can|that|from|"|vocalization (r_nsubj) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such
D002217_D004830 CID carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and
D002217_D004830 CID carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|tremor|, (r_acl) mydriasis_5\NN|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN|evoked|, (l_conj) convulsions_12\NNS|and
D002217_D004830 CID carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|, (l_conj) convulsions_27\NNS|and
D002122_D014202 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|)|fighting|injected|into|upon|, (r_nsubj) injected_5\VBD|was|similarly|. (l_advcl) fighting_26\VBG|)|injected|into|upon|,|effect (l_conj) mydriasis_43\NN|attack|, (l_conj) tremor_45\NN|,
D002122_D014202 NONE chloride_24\NN|NONE (r_pobj) by_22\IN|significantly|On|not|were|mydriasis|.|, (r_agent) changed_21\VBN|NONE (l_nsubjpass) mydriasis_5\NN|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN|evoked|,
D002122_D014202 NONE chloride_5\NN|caused|"|can|that|from|"|vocalization (r_nsubj) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|,
D010830_D015878 CID eserine_55\NN|and (r_conj) carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|, (r_conj) mydriasis_43\NN|attack|,
D010830_D015878 CID eserine_17\NN|and (r_conj) carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|tremor|, (r_acl) mydriasis_5\NN|significantly|On|not|by|were|.|,
D010830_D015878 CID eserine_32\NN|and (r_conj) carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such
D010830_D014202 CID eserine_55\NN|and (r_conj) carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|,
D010830_D014202 CID eserine_17\NN|and (r_conj) carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|tremor|, (r_acl) mydriasis_5\NN|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN|evoked|,
D010830_D014202 CID eserine_32\NN|and (r_conj) carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|,
D002217_D015878 CID carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|, (r_conj) mydriasis_43\NN|attack|,
D002217_D015878 CID carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|tremor|, (r_acl) mydriasis_5\NN|significantly|On|not|by|were|.|,
D002217_D015878 CID carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such
D002217_D014202 CID carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|,
D002217_D014202 CID carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|tremor|, (r_acl) mydriasis_5\NN|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN|evoked|,
D002217_D014202 CID carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|,
D002122_D004830 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|)|fighting|injected|into|upon|, (r_nsubj) injected_5\VBD|was|similarly|. (l_advcl) fighting_26\VBG|)|injected|into|upon|,|effect (l_conj) mydriasis_43\NN|attack|, (l_conj) tremor_45\NN|, (l_conj) convulsions_50\NNS|and
D002122_D004830 NONE chloride_24\NN|NONE (r_pobj) by_22\IN|significantly|On|not|were|mydriasis|.|, (r_agent) changed_21\VBN|NONE (l_nsubjpass) mydriasis_5\NN|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN|evoked|, (l_conj) convulsions_12\NNS|and
D002122_D004830 NONE chloride_5\NN|caused|"|can|that|from|"|vocalization (r_nsubj) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|, (l_conj) convulsions_27\NNS|and
D010830_D004830 CID eserine_55\NN|and (r_conj) carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and
D010830_D004830 CID eserine_17\NN|and (r_conj) carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|tremor|, (r_acl) mydriasis_5\NN|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN|evoked|, (l_conj) convulsions_12\NNS|and
D010830_D004830 CID eserine_32\NN|and (r_conj) carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB|apparent|.|It (l_prep) from_13\IN|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|, (l_conj) convulsions_27\NNS|and
11337188
D010068_D011693 NONE oxacillin_9\NN|NONE (r_pobj) with_8\IN|was|who|because|for (r_prep) treated_7\VBN|A|old (r_relcl) man_4\NN|failure|. (r_nsubj) developed_19\VBD|NONE (l_dobj) failure_21\NN|man|. (l_appos) lesions_29\NNS|,|renal|diffuse|and
D010068_D051437 CID oxacillin_9\NN|NONE (r_pobj) with_8\IN|was|who|because|for (r_prep) treated_7\VBN|A|old (r_relcl) man_4\NN|failure|. (r_nsubj) developed_19\VBD|NONE (l_dobj) failure_21\NN|man|.
D010068_D013203 NONE oxacillin_9\NN|NONE (r_pobj) with_8\IN|was|who|because|for (r_prep) treated_7\VBN|A|old (l_prep) because_13\IN|was|who|with|for (l_pobj) bacteremia_17\NN|of
D010068_D018366 CID oxacillin_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|Cutaneous|leucocytoclastic (r_acl) vasculitis_2\NN|NONE
D010068_D018366 CID Oxacillin_0\NNP|should|be|among|. (r_nsubjpass) included_3\VBN|NONE (l_prep) among_4\IN|should|Oxacillin|be|. (l_pobj) drugs_6\NNS|NONE (l_relcl) cause_9\VB|the (l_dobj) vasculitis_11\NN|that|can
D010068_D016470 NONE oxacillin_9\NN|NONE (r_pobj) with_8\IN|was|who|because|for (r_prep) treated_7\VBN|A|old (l_prep) because_13\IN|was|who|with|for (l_pobj) bacteremia_17\NN|of
6111982
D011433_D001145 NONE propranolol_6\NN|NONE (l_conj) pindolol_8\NN|and (l_xcomp) inhibiting_9\VBG|NONE (l_dobj) arrhythmia_12\NN|in
D010042_D001145 CID ouabain_11\JJ|the (r_compound) arrhythmia_12\NN|in
D010869_D001145 NONE pindolol_8\NN|and (l_xcomp) inhibiting_9\VBG|NONE (l_dobj) arrhythmia_12\NN|in
10533019
D004110_D013746 CID diltiazem_6\NN| (r_npadvmod) induced_8\VBN|threatening|with (r_amod) tetany_9\NN|NONE
D004110_D013746 CID diltiazem_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) infusion_13\NN|NONE (r_pobj) after_11\IN|who|with|tetany (r_prep) developed_5\VBD|a (l_dobj) tetany_6\NN|after|who|with
D004110_D013746 CID diltiazem_17\NN|NONE (r_pobj) of_15\IN|the (r_prep) administration_14\NN|tetany|and|may|that|be (r_dobj) accompany_12\VB|NONE (l_nsubj) tetany_10\NN|and|administration|may|that|be
D004110_D012131 NONE diltiazem_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) infusion_13\NN|NONE (r_pobj) after_11\IN|who|with|tetany (r_prep) developed_5\VBD|a (l_prep) with_7\IN|after|who|tetany (l_pobj) arrest_10\NN|NONE
D002122_D013746 NONE chloride_12\NN|NONE (r_pobj) with_10\IN|threatening|induced (r_prep) tetany_9\NN|NONE
D002122_D013746 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) administration_1\NN|.|tetany|rapidly|,|averting (r_nsubj) resolved_6\VBD|NONE (l_dobj) tetany_10\NN|.|rapidly|administration|,|averting
D002122_D013746 NONE chloride_21\NN|may|remedy|that (r_nsubj) be_23\VB|tetany|and|administration|may|that (r_conj) accompany_12\VB|NONE (l_nsubj) tetany_10\NN|and|administration|may|that|be
14982270
D011433_D006980 NONE propranolol_21\NN|(|)|tid|methimazole|and (l_prep) for_27\IN|tid (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) hyperthyroidism_30\NN|NONE
D008713_D011537 CID methimazole_14\NN|(|)|propranolol|tid|and (r_dobj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|woman|jaundice|and|.
D011433_D007565 NONE propranolol_21\NN|(|)|tid|methimazole|and (r_conj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|woman|jaundice|and|. (r_conj) had_5\VBD|NONE (l_dobj) jaundice_7\NN|woman|itching|and|.
D008713_D002779 NONE Methimazole_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) cholestasis_3\NN|,|was|propranolol|and
D011433_D002779 NONE propranolol_8\NN|,|was|cholestasis|and (r_conj) diagnosed_5\VBN|was|. (l_nsubjpass) cholestasis_3\NN|,|was|propranolol|and
D008713_D041781 CID Methimazole_0\NN| (r_npadvmod) induced_2\VBN|cholestatic|. (r_amod) jaundice_4\NN|NONE
D008713_D007565 NONE methimazole_14\NN|(|)|propranolol|tid|and (r_dobj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|woman|jaundice|and|. (r_conj) had_5\VBD|NONE (l_dobj) jaundice_7\NN|woman|itching|and|.
D008713_D006980 NONE methimazole_14\NN|(|)|propranolol|tid|and (r_dobj) receiving_13\VBG|NONE (l_conj) propranolol_21\NN|(|)|tid|methimazole|and (l_prep) for_27\IN|tid (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) hyperthyroidism_30\NN|NONE
D011433_D011537 NONE propranolol_21\NN|(|)|tid|methimazole|and (r_conj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|woman|jaundice|and|.
8638876
D011374_D012640 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (l_dobj) hemiparesis_17\NN|after (l_conj) seizure_19\NN|and
D011374_D014839 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|.|,|woman|left (l_conj) nausea_12\NN|, (l_conj) vomiting_14\NN|and
D011374_D009325 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|.|,|woman|left (l_conj) nausea_12\NN|,
D011374_D002341 CID progesterone_13\NN|and (r_conj) estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|thrombogenicity|that (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|use|that (l_relcl) provided_23\VBD|,|vascular (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|common|a (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|both|the
D004958_D009325 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|.|,|woman|left (l_conj) nausea_12\NN|,
D011374_D003920 NONE progesterone_13\NN|and (r_conj) estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|thrombogenicity|that (l_conj) DM_17\NNP|of|and|the
D004958_D010291 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (l_dobj) hemiparesis_17\NN|after
D004958_D006261 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|.|,|woman|left
D011374_D006261 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|.|,|woman|left
D004958_D002341 CID estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|thrombogenicity|that (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|use|that (l_relcl) provided_23\VBD|,|vascular (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|common|a (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|both|the
D004958_D014839 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|.|,|woman|left (l_conj) nausea_12\NN|, (l_conj) vomiting_14\NN|and
D011374_D010291 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (l_dobj) hemiparesis_17\NN|after
D004958_D003920 NONE estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|thrombogenicity|that (l_conj) DM_17\NNP|of|and|the
D011374_D012851 CID progesterone_13\NN|and (r_conj) estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|thrombogenicity|that (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|use|that (l_relcl) provided_23\VBD|,|vascular (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|common|a (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|both|the
D004958_D012851 CID estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|thrombogenicity|that (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|use|that (l_relcl) provided_23\VBD|,|vascular (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|common|a (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|both|the
D004958_D012640 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|.|,|woman (l_dobj) hemiparesis_17\NN|after (l_conj) seizure_19\NN|and
6732043
D000728_D020181 CID androgen_12\JJ|exogenous (r_compound) administration_13\NN|NONE (r_pobj) by_10\IN|a (r_prep) woman_9\NN|NONE (r_pobj) in_7\IN|apnea|the (r_prep) syndrome_6\NN|NONE
D000728_D020181 CID androgens_36\NNS|being|while (r_dobj) administered_34\VBN|had|who|changes (r_advcl) developed_22\VBN|a|old (l_dobj) changes_24\NNS|had|administered|who (l_conj) syndrome_27\NN|and|physical (l_prep) of_28\IN|the (l_pobj) apnea_31\NN|NONE
D000728_D020181 CID androgen_3\NN|of|produced|abated (r_nmod) symptoms_5\NNS|NONE (l_prep) of_6\IN|androgen|produced|abated (l_pobj) apnea_9\NN|NONE
D000728_D020181 CID androgen_15\NN|NONE (r_compound) therapy_16\NN|NONE (r_pobj) of_14\IN|side|a|possible (r_prep) effect_13\NN|.|Development|be|must (r_oprd) considered_9\VBN|NONE (l_nsubjpass) Development_0\NN|effect|.|be|must (l_prep) of_1\IN|NONE (l_pobj) syndrome_6\NN|NONE
D000728_D012891 NONE androgens_7\NNS|NONE (r_pobj) of_6\IN|a (r_prep) role_5\NN|have|in|reports|. (r_dobj) favored_3\VBN|NONE (l_prep) in_8\IN|have|reports|role|. (l_pobj) pathogenesis_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) apnea_13\NN|NONE
15814210
D003907_D009422 CID dexamethasone_19\NN|in (r_compound) treatment_20\NN|NONE (r_pobj) after_18\IN|at|Minor|,|development|.|neurological (r_prep) dysfunction_2\NN|NONE
D003907_D009422 CID dexamethasone_19\NN|in (r_compound) therapy_20\NN|NONE (r_pobj) after_18\IN|dysfunction|to (r_prep) assess_7\VB|.|objective (l_dobj) dysfunction_10\NN|after|to
D003907_D009422 CID dexamethasone_1\NN|NONE (r_compound) treatment_2\NN|NONE (r_pobj) After_0\IN|rate|,|.|children (r_prep) showed_5\VBD|NONE (l_dobj) rate_8\NN|,|After|.|children (l_prep) of_9\IN|a|higher (l_pobj) dysfunctions_12\NNS|NONE
6153967
D004737_D012640 CID enflurane_4\NN|.|In|,|in (r_nsubj) resulted_10\VBD|NONE (l_prep) in_11\IN|.|enflurane|In|, (l_pobj) seizures_15\NNS|NONE
D004737_D012640 CID enflurane_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) activated_4\VBN|are|and|ablated|and|foci (r_conj) delineated_2\VBN|NONE (l_conj) are_13\VBP|and|ablated|and|activated|foci (l_acomp) free_17\JJ|patients|now|. (l_npadvmod) seizure_15\NN|
D004737_D004827 NONE enflurane_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) activated_4\VBN|are|and|ablated|and|foci (r_conj) delineated_2\VBN|NONE (l_nsubj) foci_1\NN|are|and|ablated|and|activated (l_amod) Epileptic_0\JJ|NONE
D004737_D004827 NONE enflurane_5\NN|On|be|.|,|may (r_nsubj) prove_7\VB|NONE (l_xcomp) be_9\VB|On|.|,|enflurane|may (l_attr) activator_14\NN|to (l_prep) of_15\IN|a|during|safe|fast|acting (l_pobj) foci_17\VBD|NONE (l_amod) epileptic_16\JJ|NONE
17574447
D010634_D004827 NONE PB_15\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|of|a|long (r_acl) history_10\NN|NONE (l_prep) of_11\IN|a|treated|long (l_pobj) epilepsy_12\NN|NONE
D010634_D006323 NONE PB_15\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|of|a|long (r_acl) history_10\NN|NONE (r_pobj) with_7\IN|:|we|Here|.|one|of (r_prep) report_2\VBP|NONE (l_appos) one_20\CD|:|we|with|Here|.|of (l_prep) as_21\IN|other|, (l_pobj) consequence_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) arrest_25\NN|NONE
D010634_D056487 NONE PB_15\NNP| (r_npadvmod) related_17\VBN|asymptomatic|chronic|enzyme (r_amod) dysfunction_22\NN|NONE
D010634_-1 NONE phenobarbital_8\JJ|term|report|: (r_amod) therapy_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) related_3\VBN|cholangitis|.|and (r_acl) Hepatonecrosis_0\NNP|NONE
D010634_D008107 CID Phenobarbital_0\NNP|and|reputation|believed|, (r_nsubj) has_4\VBZ|NONE (l_conj) believed_14\VBN|and|reputation|Phenobarbital|, (l_ccomp) indicate_26\VB|it|is|.|commonly (l_conj) predict_28\VB|increases|do|or|not|that (l_dobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) disease_35\NN|NONE
D010634_D008107 CID PB_2\NNP|(|) (r_appos) Phenobarbital_0\NNP|and|reputation|believed|, (r_nsubj) has_4\VBZ|NONE (l_conj) believed_14\VBN|and|reputation|Phenobarbital|, (l_ccomp) indicate_26\VB|it|is|.|commonly (l_conj) predict_28\VB|increases|do|or|not|that (l_dobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) disease_35\NN|NONE
D010634_D008107 CID PB_16\NNP| (r_npadvmod) related_18\VBN|in (r_amod) increases_19\NNS|predict|do|or|not|that (r_nsubj) indicate_26\VB|it|is|.|commonly (l_conj) predict_28\VB|increases|do|or|not|that (l_dobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) disease_35\NN|NONE
D010634_D008107 CID PB_4\NNP|be|with|may|that (r_nsubjpass) associated_7\VBN|.|findings (l_prep) with_8\IN|be|may|that|PB (l_pobj) damage_11\NN|NONE
D010634_D001996 NONE PB_15\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|of|a|long (r_acl) history_10\NN|NONE (r_pobj) with_7\IN|:|we|Here|.|one|of (r_prep) report_2\VBP|NONE (l_appos) one_20\CD|:|we|with|Here|.|of (l_appos) other_28\JJ|as|, (l_prep) of_29\IN|the (l_pobj) bronchopneumonia_31\NN|NONE
D010634_D002761 CID phenobarbital_8\JJ|term|report|: (r_amod) therapy_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) related_3\VBN|cholangitis|.|and (r_acl) Hepatonecrosis_0\NNP|NONE (l_conj) cholangitis_2\NN|related|.|and
2220369
C015173_D020246 CID epinephrine_6\NN|Central|vein|and|. (r_conj) thrombosis_2\NN|NONE
C015173_D020246 CID epinephrine_28\NN|NONE (r_pobj) with_26\IN|having|medication (r_prep) started_23\VBN|NONE (r_pcomp) after_21\IN|who|day|thrombosis|in (r_prep) acquired_11\VBD|an|old (l_dobj) thrombosis_14\NN|who|day|after|in
C015173_D005901 NONE epinephrine_28\NN|NONE (l_prep) for_29\IN|dipivalyl (l_pobj) glaucoma_31\NN|NONE
17366349
C092292_D009459 CID ziprasidone_5\NN|NONE (r_pobj) by_4\IN|syndrome|. (r_prep) induced_3\VBN|NONE (l_nsubj) syndrome_2\NN|by|.
C092292_D009459 CID ziprasidone_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) use_14\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|neuroleptic|NMS|malignant (r_acl) syndrome_7\NN|NONE
C092292_D009459 CID ziprasidone_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) use_14\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|neuroleptic|NMS|malignant (r_acl) syndrome_7\NN|NONE (l_appos) NMS_9\NNP|neuroleptic|malignant|associated
C092292_D009459 CID ziprasidone_14\NN|NONE (r_pobj) like_13\IN|NMS|,|atypical|antipsychotic (r_prep) drugs_12\NNS|NONE (l_nmod) NMS_8\NNP|,|like|atypical|antipsychotic
C092292_D009459 CID ziprasidone_34\NNP|NONE (r_pobj) of_31\IN|an|day (r_prep) dose_30\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) treatment_24\NN|NONE (r_pobj) of_23\IN| (r_prep) days_22\NNS|NONE (r_pobj) after_20\IN|signs|who (r_prep) developed_14\VBD|NONE (l_dobj) signs_15\NNS|after|who (l_prep) of_18\IN|and|symptoms (l_pobj) NMS_19\NNP|NONE
C092292_D009459 CID ziprasidone_3\NNP|NONE (r_xcomp) due_1\IN|NONE (r_amod) NMS_0\NNP|.|in
C092292_D012559 NONE ziprasidone_34\NNP|NONE (r_pobj) of_31\IN|an|day (r_prep) dose_30\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) treatment_24\NN|NONE (r_pobj) of_23\IN| (r_prep) days_22\NNS|NONE (r_pobj) after_20\IN|signs|who (r_prep) developed_14\VBD|NONE (r_relcl) schizophrenia_12\NN|NONE
19370593
D004967_D001943 NONE oestrogen_3\NN|term (r_nmod) HT_6\NNP|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD|NONE (l_conj) increase_42\VB|after|but|risk|HT|significantly|,|. (l_dobj) risk_44\NN|significantly|did|not (l_prep) of_45\IN|the (l_pobj) cancer_47\NN|NONE
D004967_D020521 CID oestrogen_3\NN|term (r_nmod) HT_6\NNP|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD|NONE (l_dobj) risk_10\NN|after|but|HT|increase|significantly|,|. (l_prep) of_11\IN|the (l_pobj) embolism_15\NN|NONE (l_appos) disease_20\NN|venous||(|,|thrombo (l_nmod) stroke_17\NN|gallbladder
D004967_D005705 CID oestrogen_3\NN|term (r_nmod) HT_6\NNP|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD|NONE (l_dobj) risk_10\NN|after|but|HT|increase|significantly|,|. (l_prep) of_11\IN|the (l_pobj) embolism_15\NN|NONE (l_appos) disease_20\NN|venous||(|,|thrombo
D004967_D054556 CID oestrogen_3\NN|term (r_nmod) HT_6\NNP|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD|NONE (l_dobj) risk_10\NN|after|but|HT|increase|significantly|,|. (l_prep) of_11\IN|the (l_pobj) embolism_15\NN|NONE
2466960
D005472_D009369 NONE 5-FU_11\CD|for (r_compound) infusion_12\NN|NONE (l_prep) for_13\IN|FU (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|NONE (l_pobj) tumors_17\NNS|NONE
D005472_D003324 NONE 5-FU_3\CD|NONE (r_compound) infusion_4\NN|is|with|that (r_nsubjpass) associated_6\VBN|We|. (l_prep) with_7\IN|is|infusion|that (l_pobj) increase_10\NN|NONE (l_prep) among_21\IN|in|significant|,|a (l_pobj) patients_22\NNS|particularly (l_prep) with_23\IN|NONE (l_pobj) disease_26\NN|NONE
D005472_D066126 NONE fluorouracil_11\NN|)|(|FU (r_nmod) therapy_15\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|cardiac (r_acl) toxicity_8\NN|NONE
D005472_D066126 NONE 5-FU_13\CD|fluorouracil|)|( (r_nmod) therapy_15\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|cardiac (r_acl) toxicity_8\NN|NONE
D005472_D000787 CID 5-FU_12\CD|NONE (r_nummod) infusion_13\NN|NONE (r_pobj) during_11\IN|:|angina|)|(|were|patient|. (r_prep) had_8\VBD|NONE (l_ccomp) were_2\VBD|:|during|angina|)|(|patient|. (l_nsubj) episodes_1\NNS|rare (l_compound) Anginal_0\JJ|NONE
D005472_D000787 CID 5-FU_12\CD|NONE (r_nummod) infusion_13\NN|NONE (r_pobj) during_11\IN|:|angina|)|(|were|patient|. (r_prep) had_8\VBD|NONE (l_dobj) angina_9\NN|:|during|)|(|were|patient|.
D005472_D007511 CID 5-FU_11\CD|for (r_compound) infusion_12\NN|NONE (r_dobj) undergoing_10\VBG| (r_acl) patients_9\NNS|NONE (r_pobj) on_7\IN|continuous|ECG (r_prep) monitoring_6\NN|in|.|prospectively|We (r_dobj) performed_2\VBD|NONE (l_prep) in_18\IN|.|prospectively|We|monitoring (l_pobj) order_19\NN|NONE (l_acl) assess_21\VB|NONE (l_dobj) incidence_23\NN|to (l_prep) of_24\IN|the (l_pobj) changes_27\NNS|NONE (l_compound) ST_26\NNP|NONE (l_amod) ischemic_25\JJ|NONE
D005472_D007511 CID 5-FU_15\CD|during|v (r_nummod) infusion_16\NN|NONE (r_pobj) to_14\IN|. (r_prep) prior_13\RB|incidence (r_advmod) was_9\VBD|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_22\CD|(|P|) (r_nummod) infusion_23\NN|NONE (r_pobj) during_21\IN|FU|v (r_prep) infusion_16\NN|NONE (r_pobj) to_14\IN|. (r_prep) prior_13\RB|incidence (r_advmod) was_9\VBD|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_46\CD|NONE (r_pobj) before_45\IN|v|was|;|duration|during|+/|. (r_prep) was_36\VBD|NONE (l_ccomp) was_9\VBD|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_57\CD|NONE (r_pobj) during_56\IN|v|was|before|;|duration|+/|. (r_prep) was_36\VBD|NONE (l_ccomp) was_9\VBD|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_3\CD|NONE (r_compound) infusion_4\NN|is|with|that (r_nsubjpass) associated_6\VBN|We|. (l_prep) with_7\IN|is|infusion|that (l_pobj) increase_10\NN|NONE (l_prep) in_11\IN|significant|,|among|a (l_pobj) deviation_15\NN|NONE (l_amod) suggestive_16\JJ|silent|segment (l_prep) of_17\IN|NONE (l_pobj) ischemia_18\NN|NONE
12448656
D013792_D002292 NONE thalidomide_5\NN|NONE (r_pobj) of_4\IN|A|in|II|phase|. (r_prep) study_3\NN|NONE (l_prep) in_6\IN|A|of|II|phase|. (l_pobj) carcinoma_11\NN|NONE
D013792_D002292 NONE thalidomide_9\NN|NONE (r_pobj) of_8\IN|activity|the|and (r_prep) toxicity_5\NN|To|in (r_dobj) evaluate_3\VB|.|: (l_prep) in_10\IN|To|toxicity (l_pobj) patients_11\NNS|and|measure (l_prep) with_12\IN|NONE (l_pobj) cancer_17\NN|NONE
D013792_D002292 NONE thalidomide_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) activity_9\NN|NONE (r_pobj) of_8\IN|a|in|low (r_prep) level_7\NN|NONE (l_prep) in_12\IN|of|a|low (l_pobj) carcinoma_15\NN|NONE
D013792_D002292 NONE thalidomide_10\NN|NONE (l_prep) for_11\IN|NONE (l_pobj) carcinoma_14\NN|NONE
D013792_D064420 NONE thalidomide_9\NN|NONE (r_pobj) of_8\IN|activity|the|and (r_prep) toxicity_5\NN|To|in
6942642
D011188_D007008 NONE potassium_13\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) depletion_10\NN|and (r_conj) hypokalemia_8\NN|that|thiazide
D049971_D001145 NONE Thiazide_0\NNP|.|hypokalemia|, (r_compound) diuretics_1\NNS|NONE (l_conj) hypokalemia_3\JJ|.|,|Thiazide (l_conj) arrhythmias_6\NNS|and
D006852_C563897 NONE hydrochlorothiazide_18\NN|NONE (r_pobj) with_17\IN|moderate|diastolic (r_prep) hypertension_16\NN|NONE
D006852_C563897 NONE HCTC_20\NNP|administered (r_appos) hydrochlorothiazide_18\NN|NONE (r_pobj) with_17\IN|moderate|diastolic (r_prep) hypertension_16\NN|NONE
D049971_D007008 NONE Thiazide_0\NNP|.|hypokalemia|, (r_compound) diuretics_1\NNS|NONE (l_conj) hypokalemia_3\JJ|.|,|Thiazide
D049971_D007008 NONE thiazide_9\NN|chronic (r_compound) therapy_10\NN|NONE (r_pobj) of_7\IN|a|encountered|metabolic (r_prep) consequence_6\NN|.|Hypokalemia (r_attr) is_1\VBZ|NONE (l_nsubj) Hypokalemia_0\NNP|.|consequence
D049971_D007008 NONE thiazide_5\JJ|that|hypokalemia (r_csubj) cause_7\VBP|.|we|In (l_dobj) hypokalemia_8\NN|that|thiazide
2598570
D013496_D021501 CID suprofen_9\NN|NONE (r_pobj) from_8\IN|.|of|The (r_prep) epidemiology_1\NN|NONE (l_prep) of_2\IN|.|The|from (l_pobj) syndrome_7\NN|NONE (l_compound) pain_6\NN|flank
D007052_D007674 NONE ibuprofen_15\NNP|analgesic|)|other|( (r_appos) agents_12\NNS|NONE (r_pobj) of_9\IN|concurrent (r_prep) use_8\NN|,|disease|,|young (r_appos) age_5\NN|.|factors (l_conj) disease_20\NN|,|,|use|young
D007052_D006073 NONE ibuprofen_15\NNP|analgesic|)|other|( (r_appos) agents_12\NNS|NONE (r_pobj) of_9\IN|concurrent (r_prep) use_8\NN|,|disease|,|young (r_appos) age_5\NN|.|factors (l_conj) disease_20\NN|,|,|use|young (l_conj) history_29\NN|,|,|history|increase|,|renal|,|preexisting|increase (l_prep) of_30\IN|a (l_pobj) gout_31\NN|NONE
D000431_D006255 NONE alcohol_83\NN|to (r_dobj) use_82\VB|were|;|to|.|;|and|in (r_conj) participate_47\VB|NONE (l_ccomp) were_2\VBD|;|to|.|;|use|and|in (l_conj) suffer_24\VB|likely|patients (l_prep) from_25\IN|NONE (l_pobj) fever_27\NN|NONE
D007052_D007669 NONE ibuprofen_15\NNP|analgesic|)|other|( (r_appos) agents_12\NNS|NONE (r_pobj) of_9\IN|concurrent (r_prep) use_8\NN|,|disease|,|young (r_appos) age_5\NN|.|factors (l_conj) disease_20\NN|,|,|use|young (l_conj) history_23\NN|,|,|history|increase|,|renal|,|preexisting|increase (l_prep) of_24\IN|a (l_pobj) stones_26\NNS|NONE
D000431_D001249 NONE alcohol_83\NN|to (r_dobj) use_82\VB|were|;|to|.|;|and|in (r_conj) participate_47\VB|NONE (l_ccomp) were_2\VBD|;|to|.|;|use|and|in (l_conj) suffer_24\VB|likely|patients (l_prep) from_25\IN|NONE (l_pobj) fever_27\NN|NONE (l_conj) asthma_29\NN|(|ratio|and|hay
458486
D063325_D010300 NONE Tiapride_0\NNP|NONE (l_appos) movements_18\NNS|.|, (l_prep) in_19\IN|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D008787_D010300 NONE metoclopramide_9\NN|NONE (r_pobj) to_8\IN|closely (r_prep) related_7\JJ|substituted|,|a|benzamide (r_acl) derivative_5\JJ|peak|in|involuntary|dose (r_amod) movements_18\NNS|.|, (l_prep) in_19\IN|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|involuntary (r_amod) movements_6\NNS|NONE
D007980_D004409 CID levodopa_12\NN| (r_npadvmod) induced_14\VBN|reduced (r_amod) peak_15\NN|derivative|in|involuntary|dose (r_nmod) movements_18\NNS|.|,
D007980_D004409 CID levodopa_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) dyskinesias_11\NNS|are|by|that
C037689_D004409 NONE benzamide_4\RB|substituted|,|a|related (r_amod) derivative_5\JJ|peak|in|involuntary|dose (r_amod) movements_18\NNS|.|,
C037689_D010300 NONE benzamide_4\RB|substituted|,|a|related (r_amod) derivative_5\JJ|peak|in|involuntary|dose (r_amod) movements_18\NNS|.|, (l_prep) in_19\IN|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D063325_D004421 NONE Tiapride_0\NNP|.|effect|induced (r_nsubj) had_1\VBD|NONE (l_advcl) induced_7\VBN|Tiapride|.|effect (l_prep) of_10\IN|morning|levodopa| (l_pobj) dystonia_17\NN|NONE
D008787_D004409 NONE metoclopramide_9\NN|NONE (r_pobj) to_8\IN|closely (r_prep) related_7\JJ|substituted|,|a|benzamide (r_acl) derivative_5\JJ|peak|in|involuntary|dose (r_amod) movements_18\NNS|.|,
D007980_D004421 NONE levodopa_5\NN|morning|of| (r_npadvmod) induced_7\VBN|Tiapride|.|effect (l_prep) of_10\IN|morning|levodopa| (l_pobj) dystonia_17\NN|NONE
D004298_D004409 NONE dopamine_21\NN|NONE (r_compound) receptors_22\NNS|NONE (r_pobj) of_20\IN|separate|a (r_prep) group_19\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) overstimulation_15\NN|NONE (r_pobj) by_14\IN|dyskinesias|are|that (r_agent) caused_13\VBN|the (l_nsubjpass) dyskinesias_11\NNS|are|by|that
D063325_D004409 NONE Tiapride_0\NNP|NONE (l_prep) in_1\IN|. (l_pobj) movements_6\NNS|NONE
D063325_D004409 NONE Tiapride_0\NNP|NONE (l_appos) movements_18\NNS|.|,
D007980_D010300 NONE levodopa_12\NN| (r_npadvmod) induced_14\VBN|reduced (r_amod) peak_15\NN|derivative|in|involuntary|dose (r_nmod) movements_18\NNS|.|, (l_prep) in_19\IN|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
17786501
D004221_D000437 NONE disulfiram_15\NN|NONE (r_pobj) of_14\IN|for|chronic (r_prep) use_13\NN|NONE (l_prep) for_16\IN|of|chronic (l_pobj) management_19\NN|NONE (l_compound) dependence_18\NN|alcohol
D004221_D000437 NONE disulfiram_4\NN|.|for|been|had|He (r_dobj) taking_3\VBG|NONE (l_prep) for_5\IN|disulfiram|.|been|had|He (l_pobj) dependence_7\NN|NONE
D004221_D009901 NONE Disulfiram_0\NNP| (r_npadvmod) induced_2\VBN|and|transient|neuropathy (r_amod) optic_4\JJ|:|case|a|. (l_conj) neuropathy_7\NN|and|transient|induced
D004221_D009901 NONE disulfiram_15\NN|NONE (r_pobj) of_14\IN|for|chronic (r_prep) use_13\NN|NONE (r_pobj) after_11\IN|To|case (r_prep) report_3\VB|.|: (l_dobj) case_5\NN|after|To (l_prep) of_6\IN|a (l_pobj) optic_7\JJ|NONE (l_conj) neuropathy_10\NN|and
D004221_D010523 NONE Disulfiram_0\NNP| (r_npadvmod) induced_2\VBN|and|transient|neuropathy (r_amod) optic_4\JJ|:|case|a|. (l_conj) neuropathy_7\NN|and|transient|induced
D004221_D010523 NONE disulfiram_15\NN|NONE (r_pobj) of_14\IN|for|chronic (r_prep) use_13\NN|NONE (r_pobj) after_11\IN|To|case (r_prep) report_3\VB|.|: (l_dobj) case_5\NN|after|To (l_prep) of_6\IN|a (l_pobj) optic_7\JJ|NONE (l_conj) neuropathy_10\NN|and
3961813
C025541_D020258 NONE TOTP_6\NNP|hr (r_pobj) after_5\IN|esterase (r_prep) activities_2\NNS|.|given|% (l_compound) esterase_1\NN|after (l_amod) Neurotoxic_0\JJ|NONE
D003345_D009422 NONE corticosterone_9\NN|NONE (l_prep) on_10\IN|dietary (l_pobj) neuropathy_15\NN|NONE
D003345_D009422 NONE corticosterone_13\NN|NONE (r_pobj) of_12\IN|low|)|less|( (r_prep) concentrations_2\NNS|effects|Although|signs|. (r_nsubj) had_14\VBD|NONE (l_dobj) effects_16\NNS|concentrations|Although|signs|. (l_prep) on_17\IN|beneficial (l_pobj) neuropathy_21\NN|NONE
D007531_D009422 CID DFP_39\NNP|or|either (r_conj) TOTP_37\NNP|NONE (r_pobj) given_35\VBN|clinical|in|exacerbated (r_acl) signs_32\NNS|effects|concentrations|Although|. (r_dobj) had_14\VBD|NONE (l_dobj) effects_16\NNS|concentrations|Although|signs|. (l_prep) on_17\IN|beneficial (l_pobj) neuropathy_21\NN|NONE
C025541_D009410 CID TOTP_16\NNP|NONE (r_pobj) given_15\VBN|.|fibers|also|evident (r_prep) were_3\VBD|NONE (l_nsubj) fibers_2\NNS|.|given|also|evident
D010755_D020258 NONE organophosphorous_21\JJ|NONE (r_amod) compounds_22\NNS|not (r_dobj) given_20\VBN|.|%|activities (r_prep) were_9\VBD|NONE (l_nsubj) activities_2\NNS|.|given|% (l_compound) esterase_1\NN|after (l_amod) Neurotoxic_0\JJ|NONE
D007531_D009410 CID DFP_18\NNP|or (r_conj) TOTP_16\NNP|NONE (r_pobj) given_15\VBN|.|fibers|also|evident (r_prep) were_3\VBD|NONE (l_nsubj) fibers_2\NNS|.|given|also|evident
C025541_D009422 CID TOTP_18\NNP| (r_npadvmod) induced_20\VBN|greater|, (r_amod) neuropathy_21\NN|NONE
C025541_D009422 CID TOTP_37\NNP|NONE (r_pobj) given_35\VBN|clinical|in|exacerbated (r_acl) signs_32\NNS|effects|concentrations|Although|. (r_dobj) had_14\VBD|NONE (l_dobj) effects_16\NNS|concentrations|Although|signs|. (l_prep) on_17\IN|beneficial (l_pobj) neuropathy_21\NN|NONE
D010755_D009422 NONE organophosphorus_11\NN| (r_npadvmod) induced_13\VBN|delayed|in (r_amod) neuropathy_15\NN|NONE
D007531_D020258 NONE DFP_8\NNP|or (r_conj) TOTP_6\NNP|hr (r_pobj) after_5\IN|esterase (r_prep) activities_2\NNS|.|given|% (l_compound) esterase_1\NN|after (l_amod) Neurotoxic_0\JJ|NONE
1504402
D007741_D004342 CID dilevalol_7\NN| (r_npadvmod) associated_9\VBN|NONE (r_amod) hepatitis_10\NN|NONE (r_pobj) for_6\IN|a (r_prep) mechanism_5\NN|NONE (r_pobj) as_3\IN|Hypersensitivity|immune|. (r_prep) reaction_2\NN|NONE (l_nmod) Hypersensitivity_0\NN|immune|as|.
D007741_D056486 CID dilevalol_7\NN| (r_npadvmod) associated_9\VBN|NONE (r_amod) hepatitis_10\NN|NONE
D007741_D056486 CID dilevalol_7\VB|To|reactivity (l_conj) serum_10\VB|to|and (l_prep) in_19\IN|to|containing (l_pobj) case_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) injury_27\NN|NONE
D007741_D056486 CID dilevalol_15\JJ|or|ex|metabolites|putative|vivo (r_compound) antigens_16\NNS|NONE (r_dobj) containing_11\VBG|to|in (r_xcomp) serum_10\VB|to|and (l_prep) in_19\IN|to|containing (l_pobj) case_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) injury_27\NN|NONE
D007741_D056486 CID dilevalol_23\NN| (r_npadvmod) induced_25\VBN|liver (r_amod) injury_27\NN|NONE
D007741_D056486 CID dilevalol_10\NN| (r_npadvmod) induced_12\VBN|liver (r_amod) injury_14\NN|NONE
D007741_D056486 CID dilevalol_16\JJ|prepared|ex (r_compound) antigens_17\NNS|NONE (r_dobj) containing_11\VBG|NONE (r_acl) sera_10\NN|NONE (r_pobj) to_9\IN|lymphocyte (r_prep) sensitization_8\NN|NONE (r_pobj) of_6\IN|the (r_prep) detection_5\NN|,|.|suggesting|methodology (r_dobj) allowed_3\VBD|NONE (l_advcl) suggesting_19\VBG|,|detection|.|methodology (l_dobj) involvement_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) mechanism_25\NN|NONE (l_prep) in_26\IN|an|immunologic (l_pobj) injury_31\NN|NONE
D007741_D056486 CID dilevalol_27\NN| (r_npadvmod) induced_29\VBN|liver (r_amod) injury_31\NN|NONE
12760988
D003907_D063806 NONE dexamethasone_18\NN|or (r_conj) saline_16\NN|NONE (r_pobj) with_15\IN|before (r_prep) pretreated_14\VBN| (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|incidence|.|was (r_prep) determined_10\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|in (l_prep) of_4\IN|and|severity|The (l_pobj) myalgia_8\NN|NONE
D003907_D063806 NONE dexamethasone_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN| (r_prep) patients_15\NNS|,|reported|compared|of|and (r_nsubj) complained_20\VBD|two|the|: (r_acl) groups_12\NNS|NONE (r_pobj) between_9\IN|not|Incidence|did|significantly (r_prep) differ_7\VB|NONE (l_nsubj) Incidence_0\NN|not|did|between|significantly (l_conj) severity_2\NN|and (l_prep) of_3\IN|NONE (l_pobj) myalgia_4\NN|NONE
D003907_D063806 NONE dexamethasone_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN| (r_prep) patients_15\NNS|,|reported|compared|of|and (r_nsubj) complained_20\VBD|two|the|: (l_prep) of_21\IN|,|reported|compared|and|patients (l_pobj) myalgia_22\NN|NONE
D003907_D063806 NONE dexamethasone_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN| (r_prep) patients_15\NNS|,|reported|compared|of|and (r_nsubj) complained_20\VBD|two|the|: (l_conj) reported_36\VBN|,|compared|of|and|patients (l_nsubjpass) myalgia_34\NN|by|was|.
D003907_D010149 NONE dexamethasone_4\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) Administration_2\NN|:|before (r_appos) IMPLICATIONS_0\NNS|not|effective|. (r_nsubj) was_7\VBD|NONE (l_acomp) effective_9\JJ|IMPLICATIONS|not|. (l_prep) in_10\IN|NONE (l_pcomp) decreasing_11\VBG|NONE (l_dobj) incidence_13\NN|NONE (l_conj) severity_16\NN|the|or (l_prep) of_17\IN|the (l_pobj) myalgia_22\NN|NONE
D003907_D010149 NONE dexamethasone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|not|justified|. (r_nsubj) is_3\VBZ|NONE (l_acomp) justified_5\VBN|Pretreatment|not|. (l_xcomp) prevent_7\VB|NONE (l_dobj) myalgia_9\NN|after|to
D013390_D010149 CID succinylcholine_3\NN|NONE (r_pobj) after_2\IN|Postoperative|:|evidence|. (r_prep) myalgia_1\NN|NONE
D013390_D010149 CID succinylcholine_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|A|common|side (r_acl) effect_3\NN|myalgia|. (r_nsubj) is_7\VBZ|NONE (l_attr) myalgia_9\NN|.|effect
D013390_D010149 CID succinylcholine_6\NN|NONE (r_pobj) before_5\IN|:|Administration (r_punct) IMPLICATIONS_0\NNS|not|effective|. (r_nsubj) was_7\VBD|NONE (l_acomp) effective_9\JJ|IMPLICATIONS|not|. (l_prep) in_10\IN|NONE (l_pcomp) decreasing_11\VBG|NONE (l_dobj) incidence_13\NN|NONE (l_conj) severity_16\NN|the|or (l_prep) of_17\IN|the (l_pobj) myalgia_22\NN|NONE
D013390_D010149 CID succinylcholine_18\NN| (r_npadvmod) induced_20\VBN|postoperative (r_amod) myalgia_22\NN|NONE
D013390_D010149 CID succinylcholine_11\NN|NONE (r_pobj) after_10\IN|myalgia|to (r_prep) prevent_7\VB|NONE (l_dobj) myalgia_9\NN|after|to
D013390_D063806 CID succinylcholine_5\NN| (r_npadvmod) associated_7\VBN|NONE (r_amod) myalgia_8\NN|NONE
D013390_D063806 CID succinylcholine_20\NN|NONE (r_pobj) before_19\IN|with (r_prep) pretreated_14\VBN| (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|incidence|.|was (r_prep) determined_10\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|in (l_prep) of_4\IN|and|severity|The (l_pobj) myalgia_8\NN|NONE
D013390_D063806 CID succinylcholine_12\NN| (r_npadvmod) associated_14\VBN|NONE (r_amod) myalgia_15\NN|NONE
11827497
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|onset|. (r_amod) thrombocytopenia_6\NN|NONE
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) thrombocytopenia_3\NN|after|.
D006493_D013921 CID heparin_10\JJ|,|with (r_compound) exposure_11\NN|days (r_pobj) after_9\IN|.|thrombocytopenia (r_prep) presents_4\VBZ|NONE (l_nsubj) thrombocytopenia_3\NN|after|.
D006493_D013921 CID heparin_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) thrombocytopenia_8\NN|NONE
D006493_D013921 CID heparin_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) thrombocytopenia_19\NN|NONE
D006493_D013921 CID heparin_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) thrombocytopenia_12\NN|on|in|apparent
D006493_D013921 CID heparin_9\JJ|NONE (r_compound) exposure_10\NN|had|that (r_dobj) included_8\VBN|NONE (r_relcl) hospitalizations_5\NNS|NONE (r_pobj) after_4\IN|||home|Patients|,|:|with|return|.|in (r_prep) went_2\VBD|NONE (l_prep) with_16\IN||after||home|Patients|,|:|return|.|in (l_pobj) thrombocytopenia_18\NN|NONE
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|onset (r_amod) thrombocytopenia_6\NN|.|increasingly|being|is
D006493_D013921 CID heparin_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) thrombocytopenia_11\NN|must|physicians|avoid|,|returns
D006493_D013921 CID heparin_27\VBN|alternative|not|, (r_appos) anticoagulants_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) therapy_21\NN|consider|.|should|;|,|be (r_nsubjpass) initiated_31\VBN|NONE (l_ccomp) consider_7\VB|.|should|;|therapy|,|be (l_dobj) thrombocytopenia_11\NN|must|physicians|avoid|,|returns
D006493_D001157 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) thrombocytopenia_3\NN|after|. (r_nsubj) presents_4\VBZ|NONE (l_prep) after_9\IN|.|thrombocytopenia (l_pobj) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D001157 CID heparin_10\JJ|,|with (r_compound) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D054556 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) thrombocytopenia_3\NN|after|. (r_nsubj) presents_4\VBZ|NONE (l_prep) after_9\IN|.|thrombocytopenia (l_pobj) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D054556 CID heparin_10\JJ|,|with (r_compound) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D013923 NONE heparin_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) thrombocytopenia_12\NN|on|in|apparent (r_nsubj) became_13\VBD|year|a (l_prep) on_15\IN|thrombocytopenia|in|apparent (l_pobj) presentation_17\NN|NONE (l_prep) with_18\IN|delayed (l_pobj) complications_20\NNS|NONE (l_compound) thromboembolic_19\JJ|NONE
D006493_D013923 NONE heparin_13\NN| (r_npadvmod) induced_15\VBN|platelet|tests (r_nmod) factor_17\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) results_11\NNS|Platelet|,|onset|, (r_appos) counts_3\VBZ|:|. (l_appos) onset_5\NN|results|Platelet|,|, (l_prep) of_6\IN|NONE (l_pobj) thromboembolism_9\NN|NONE
D006493_D013923 NONE heparin_9\JJ|NONE (r_compound) exposure_10\NN|had|that (r_dobj) included_8\VBN|NONE (r_relcl) hospitalizations_5\NNS|NONE (r_pobj) after_4\IN|||home|Patients|,|:|with|return|.|in (r_prep) went_2\VBD|NONE (l_advcl) return_23\VB||after||home|Patients|,|:|with|.|in (l_prep) with_33\IN|only|to|to (l_pobj) complications_35\NNS|NONE (l_compound) thromboembolic_34\JJ|NONE
D006493_D013923 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) thrombocytopenia_11\NN|must|physicians|avoid|,|returns (r_dobj) consider_7\VB|.|should|;|therapy|,|be (l_advcl) returns_17\NNS|thrombocytopenia|must|physicians|avoid|, (l_prep) with_18\IN|whenever|patient|hospitalized|a (l_pobj) thromboembolism_19\NN|NONE
D006493_D013923 NONE heparin_27\VBN|alternative|not|, (r_appos) anticoagulants_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) therapy_21\NN|consider|.|should|;|,|be (r_nsubjpass) initiated_31\VBN|NONE (l_ccomp) consider_7\VB|.|should|;|therapy|,|be (l_advcl) returns_17\NNS|thrombocytopenia|must|physicians|avoid|, (l_prep) with_18\IN|whenever|patient|hospitalized|a (l_pobj) thromboembolism_19\NN|NONE
1355091
D009638_D001919 CID noradrenaline_33\NN|bradycardia|kg|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor (r_conj) responses_2\NNS|with|were|in|. (l_conj) bradycardia_4\NNS|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
D009638_D001919 CID noradrenaline_7\NN| (r_npadvmod) induced_9\VBN|in|pressor|the (r_amod) effect_11\NN|that (r_dobj) accompanied_5\VBD|the (r_relcl) bradycardia_3\NN|despite|similar|,|Furthermore
C014282_D001919 CID cirazoline_9\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) bradycardia_4\NNS|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
C014282_D001919 CID cirazoline_7\NN|NONE (r_pobj) of_6\IN|bradycardia (r_prep) effects_5\NNS|and|Both|the (l_amod) bradycardia_4\NN|of
D015016_D007024 NONE rauwolscine_33\JJ|NONE (r_pobj) with_32\IN|NONE (r_prep) treated_31\VBN|the (r_acl) SHR_30\NN|not (r_pobj) in_28\IN|.|hypotension|but|,|,|However|tilt (r_conj) induced_7\VBN|NONE (l_dobj) hypotension_9\NN|.|in|but|,|,|However|tilt
D011224_D006973 NONE prazosin_9\NN| (r_npadvmod) pretreated_11\VBN|NONE (r_amod) conscious_12\JJ|hypertensive (r_amod) rats_15\NNS|NONE (l_amod) hypertensive_14\JJ|conscious
D011224_D006973 NONE prazosin_7\NN|chronic (r_compound) treatment_8\NN|function|whether|for (r_nsubj) alters_9\VBZ|to (l_prep) for_14\IN|function|whether|treatment (l_pobj) control_16\NN|NONE (l_prep) in_21\IN|of|orthostatic (l_pobj) rats_25\NNS|NONE (l_amod) hypertensive_24\JJ|(|)|SHR|conscious
D011224_D001919 NONE prazosin_51\NN|chronic (r_compound) pretreatment_52\NN|NONE (r_pobj) without_49\IN|and (r_conj) with_47\IN|responses|were|in|. (r_prep) determined_43\VBN|NONE (l_nsubjpass) responses_2\NNS|with|were|in|. (l_conj) bradycardia_4\NNS|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
D011224_D001919 NONE prazosin_12\NN|NONE (r_pobj) in_10\IN|.|were|pressor|treated|compared (r_prep) abolished_9\VBN|NONE (l_nsubjpass) pressor_2\NN|.|were|in|treated|compared (l_conj) effects_5\NNS|and|Both|the (l_amod) bradycardia_4\NN|of
D011224_D001919 NONE prazosin_28\NN|chronic (r_compound) treatment_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) SHR_25\NNP|NONE (r_pobj) in_24\IN|than (r_prep) greater_23\JJR|.|bradycardia (r_acomp) was_22\VBD|similar|,|but|On|effects|, (l_nsubj) bradycardia_21\NN|.|greater
D011224_D001919 NONE prazosin_20\NN|chronic (r_compound) treatment_21\NN|NONE (r_pobj) without_18\IN|and (r_conj) with_16\IN|NONE (r_prep) similar_15\JJ|bradycardia|despite|,|Furthermore (r_acomp) was_14\VBD|NONE (l_nsubj) bradycardia_3\NN|despite|similar|,|Furthermore
D011224_D007024 CID prazosin_9\NN| (r_npadvmod) pretreated_11\VBN|NONE (r_amod) conscious_12\JJ|hypertensive (r_amod) rats_15\NNS|NONE (r_pobj) in_7\IN|adrenoceptor|alpha (r_prep) blockade_6\NN|NONE (r_pobj) following_3\VBG|hypotension|. (r_prep) occurs_2\VBZ|NONE (l_nsubj) hypotension_1\NN|.|following
D011224_D007024 CID prazosin_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|orthostatic|in (r_acl) hypotension_9\NN|.|in|but|,|,|However|tilt
D011224_D007024 CID prazosin_22\NN|NONE (r_pobj) of_21\IN|acute (r_prep) dosing_20\NN|NONE (r_pobj) after_18\IN|or (r_conj) to_16\IN|either (r_prep) prior_15\RB|when (r_advmod) performed_13\VBN|not|tilts|hypotension|.|did (r_advcl) produce_9\VB|NONE (l_dobj) hypotension_11\NN|not|tilts|.|performed|did
C056299_D001919 CID Abbott-53693_22\NNP|bradycardia|kg|noradrenaline|i.v.|and|,|and|,|micrograms|)|kg|The|pressor (r_appos) responses_2\NNS|with|were|in|. (l_conj) bradycardia_4\NNS|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
C056299_D001919 CID Abbott-53693_9\NNP|NONE (r_pobj) of_8\IN|the|pressor (r_prep) effects_7\NNS|similar|,|was|but|On|, (r_nsubj) were_10\VBD|NONE (l_conj) was_22\VBD|similar|,|but|On|effects|, (l_nsubj) bradycardia_21\NN|.|greater
15579441
D011692_D000860 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|nephrotic|hypoxia|and (r_amod) syndrome_19\NN|the (r_appos) puromycin_14\NNS|NONE (r_pobj) in_12\IN|to|hypoxia (r_prep) identify_8\VB|NONE (l_dobj) hypoxia_11\NN|in|to
D011692_D000860 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|nephrotic|hypoxia|and (r_amod) syndrome_19\NN|the (l_conj) hypoxia_24\NN|nephrotic|and|induced
D011692_D000860 CID aminonucleoside_21\NN|puromycin (r_compound) model_22\NN|and|.fold (r_pobj) in_18\IN|,|at|showed|.fold (r_prep) reaching_13\VBG|Expression|,|.|throughout (r_advcl) increased_7\VBD|NONE (l_nsubj) Expression_0\NN|,|.|throughout|reaching (l_prep) of_1\IN|NONE (l_pobj) transgene_6\NN|NONE (l_amod) responsive_5\JJ|the (l_npadvmod) hypoxia_3\NN|
D011692_D009404 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|nephrotic|hypoxia|and (r_amod) syndrome_19\NN|the
8988571
D003042_D064420 NONE cocaine_4\NN|NONE (r_compound) use_5\NN|NONE (r_dobj) following_3\VBG|Fatal|excited (r_acl) delirium_2\NN|findings|evidence|:|. (r_dep) provide_9\VBP|NONE (l_dobj) evidence_11\NN|findings|:|delirium|. (l_prep) for_12\IN|new (l_pobj) mechanisms_13\NNS|NONE (l_prep) of_14\IN|NONE (l_pobj) toxicity_16\NN|NONE
D003042_D064420 NONE cocaine_15\NN|NONE (r_compound) toxicity_16\NN|NONE
D003042_D003645 CID cocaine_11\NN|chronic (r_compound) use_12\NN|function|that|and (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|precipitate|.|,|findings (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant (l_conj) death_38\NN|and|,
D003042_D003645 CID cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|,|agitation|may (r_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant (l_conj) death_38\NN|and|,
D003042_D062787 NONE cocaine_5\NN| (r_npadvmod) related_7\VBN|all|in (r_amod) deaths_8\NNS|NONE (r_pobj) of_3\IN|a (r_prep) registry_2\NN|NONE (r_pobj) From_0\IN|,|from|,|EDDs|.|were|with (r_prep) compared_23\VBN|NONE (l_prep) with_24\IN|,|from|,|EDDs|From|.|were (l_pobj) victims_26\NNS|NONE (l_prep) of_27\IN|without| (l_pobj) overdose_30\NN|NONE
D003042_D062787 NONE cocaine_29\NN|accidental (r_compound) overdose_30\NN|NONE
C005618_D003693 NONE benzoylecgonine_6\NN|and (r_conj) cocaine_4\NN|NONE (r_pobj) of_3\IN|in|were (r_prep) concentrations_2\NNS|.|EDDs (r_dobj) had_1\VBD|NONE (l_nsubj) EDDs_0\NNS|.|concentrations
D003042_D012206 CID cocaine_11\NN|chronic (r_compound) use_12\NN|function|that|and (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|precipitate|.|,|findings (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant
D003042_D012206 CID cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|,|agitation|may (r_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant
D003042_D003693 CID cocaine_4\NN|NONE (r_compound) use_5\NN|NONE (r_dobj) following_3\VBG|Fatal|excited (r_acl) delirium_2\NN|findings|evidence|:|.
D003042_D003693 CID cocaine_15\NN|NONE (r_compound) toxicity_16\NN|NONE (r_pobj) of_14\IN|NONE (r_prep) mechanisms_13\NNS|NONE (r_pobj) for_12\IN|new (r_prep) evidence_11\NN|findings|:|delirium|. (r_dobj) provide_9\VBP|NONE (l_dep) delirium_2\NN|findings|evidence|:|.
D003042_D003693 CID cocaine_7\NN| (r_npadvmod) induced_9\VBN|between|EDDs|excited|( (r_amod) delirium_11\NN|NONE
D003042_D003693 CID cocaine_7\NN| (r_npadvmod) induced_9\VBN|between|EDDs|excited|( (r_amod) delirium_11\NN|NONE (l_appos) EDDs_13\NNP|induced|between|excited|(
D003042_D003693 CID cocaine_5\NN| (r_npadvmod) related_7\VBN|all|in (r_amod) deaths_8\NNS|NONE (r_pobj) of_3\IN|a (r_prep) registry_2\NN|NONE (r_pobj) From_0\IN|,|from|,|EDDs|.|were|with (r_prep) compared_23\VBN|NONE (l_nsubjpass) EDDs_21\NNS|,|from|,|From|.|were|with
D003042_D003693 CID cocaine_5\NN| (r_npadvmod) related_7\VBN|all|in (r_amod) deaths_8\NNS|NONE (r_pobj) of_3\IN|a (r_prep) registry_2\NN|NONE (r_pobj) From_0\IN|,|from|,|EDDs|.|were|with (r_prep) compared_23\VBN|NONE (l_prep) with_24\IN|,|from|,|EDDs|From|.|were (l_pobj) victims_26\NNS|NONE (l_prep) without_31\IN||of (l_pobj) delirium_33\NN|NONE
D003042_D003693 CID cocaine_29\NN|accidental (r_compound) overdose_30\NN|NONE (r_pobj) of_27\IN|without| (r_prep) victims_26\NNS|NONE (r_pobj) with_24\IN|,|from|,|EDDs|From|.|were (r_prep) compared_23\VBN|NONE (l_nsubjpass) EDDs_21\NNS|,|from|,|From|.|were|with
D003042_D003693 CID cocaine_29\NN|accidental (r_compound) overdose_30\NN|NONE (r_pobj) of_27\IN|without| (r_prep) victims_26\NNS|NONE (l_prep) without_31\IN||of (l_pobj) delirium_33\NN|NONE
D003042_D003693 CID cocaine_4\NN|NONE (r_pobj) of_3\IN|in|were (r_prep) concentrations_2\NNS|.|EDDs (r_dobj) had_1\VBD|NONE (l_nsubj) EDDs_0\NNS|.|concentrations
D003042_D003693 CID cocaine_11\NN|chronic (r_compound) use_12\NN|function|that|and (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|precipitate|.|,|findings (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may (l_conj) delirium_29\NN|,
D003042_D003693 CID cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|,|agitation|may (r_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may (l_conj) delirium_29\NN|,
D003042_D011595 NONE cocaine_11\NN|chronic (r_compound) use_12\NN|function|that|and (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|precipitate|.|,|findings (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may
D003042_D011595 NONE cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|,|agitation|may (r_advcl) precipitate_26\VB|.|consistent|,|findings (l_dobj) agitation_27\NN|,|coupled|may
3934126
D000617_D006311 NONE aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|.|occurred|;|were (l_conj) ototoxicity_11\NN|and
D014640_D006311 CID vancomycin_20\NNP|an|plus (r_appos) aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|.|occurred|;|were (l_conj) ototoxicity_11\NN|and
D014640_D007674 NONE vancomycin_20\NNP|an|plus (r_appos) aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|.|occurred|;|were
D000617_D007674 NONE aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|.|occurred|;|were
D014640_D013924 CID vancomycin_20\NNP|an|plus (r_appos) aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN|NONE (l_ccomp) occurred_1\VBD|to|nephrotoxicity|.|;|were (l_nsubj) Thrombophlebitis_0\NNP|with
D014640_D007239 NONE Vancomycin_0\NNP|curative|. (r_nsubj) was_1\VBD|NONE (l_acomp) curative_2\JJ|Vancomycin|. (l_prep) in_3\IN|NONE (l_pobj) %_5\NN|NONE (l_prep) of_6\IN| (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN| (l_pobj) infection_11\NN|NONE
D014640_D007239 NONE vancomycin_3\NNP|therapy|administered|that|,|, (r_nsubj) constitutes_8\VBZ|.|We (l_dobj) therapy_12\NN|administered|that|vancomycin|,|, (l_prep) for_13\IN|safe|,|effective (l_pobj) infections_14\NNS|NONE
D000617_D013924 NONE aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN|NONE (l_ccomp) occurred_1\VBD|to|nephrotoxicity|.|;|were (l_nsubj) Thrombophlebitis_0\NNP|with
16844102
D003676_D009422 NONE DFO_7\NNP||alpha|and (r_conj) TC_5\NNP|by|that|damage (r_nsubj) ameliorate_8\VB|This|. (l_dobj) damage_14\NN|by|that|TC
D008694_D020258 NONE methamphetamine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) neurotoxicity_11\NN|NONE
D008694_D020258 NONE Methamphetamine_0\NN|is|.|associated (l_appos) neurotoxicity_4\NN|NONE
D008694_D020258 NONE MA)-induced_2\VBN|dopaminergic (r_amod) neurotoxicity_4\NN|NONE
D008694_D020258 NONE MA_34\NNP| (r_npadvmod) induced_36\VBN|the (r_amod) neurotoxicity_37\NN|NONE
D003676_D005334 NONE DFO_4\NNP|alpha|and| (r_conj) TC_2\NNP|alterations|as|.|hyperthermia (r_nsubj) attenuated_5\VBD|NONE (l_dobj) hyperthermia_10\NN|alterations|as|.|TC
D024502_D009422 NONE TC_5\NNP|by|that|damage (r_nsubj) ameliorate_8\VB|This|. (l_dobj) damage_14\NN|by|that|TC
D024502_D020258 NONE tocopherol_4\NN|NONE (l_conj) deferoxamine_6\NN|alpha|and| (l_prep) on_7\IN|NONE (l_pobj) neurotoxicity_11\NN|NONE
D024502_D020258 NONE tocopherol_8\NN|NONE (r_pobj) of_5\IN|the|on (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|of|the (l_pobj) neurotoxicity_37\NN|NONE
D024502_D020258 NONE TC_12\NNP|(|scavenger|chelator|,|,|)|alpha||, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|the|on (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|of|the (l_pobj) neurotoxicity_37\NN|NONE
D008694_D005334 CID MA_7\NNP| (r_npadvmod) induced_9\VBN|the (r_amod) hyperthermia_10\NN|alterations|as|.|TC
D010100_D020258 NONE oxygen_19\NN|reactive (r_compound) species_20\NNS|NONE (r_pobj) of_17\IN|a|and|DFO|, (r_prep) scavenger_16\NN|(|chelator|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|the|on (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|of|the (l_pobj) neurotoxicity_37\NN|NONE
D007501_D020258 NONE iron_29\NN|an (r_compound) chelator_30\NN|(|scavenger|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|the|on (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|of|the (l_pobj) neurotoxicity_37\NN|NONE
D024502_D005334 NONE TC_2\NNP|alterations|as|.|hyperthermia (r_nsubj) attenuated_5\VBD|NONE (l_dobj) hyperthermia_10\NN|alterations|as|.|TC
D003676_D020258 NONE deferoxamine_6\NN|alpha|and| (l_prep) on_7\IN|NONE (l_pobj) neurotoxicity_11\NN|NONE
D003676_D020258 NONE deferoxamine_23\NN|)|( (r_nmod) DFO_25\NNP|a|of|and|, (r_conj) scavenger_16\NN|(|chelator|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|the|on (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|of|the (l_pobj) neurotoxicity_37\NN|NONE
D003676_D020258 NONE DFO_25\NNP|a|of|and|, (r_conj) scavenger_16\NN|(|chelator|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|the|on (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|of|the (l_pobj) neurotoxicity_37\NN|NONE
D008694_D009422 CID MA_10\NNP| (r_npadvmod) induced_12\VBN|the|neuronal (r_amod) damage_14\NN|by|that|TC
15867025
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|who|were|to (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (r_conj) dose_22\NN|for|prenatal|, (r_conj) screening_8\NN|on|Assessment|was|.|: (l_prep) for_9\IN|dose|prenatal|, (l_pobj) B_11\NNP|NONE (l_conj) rubella_13\NN|hepatitis|and
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (l_conj) immunity_48\NN|B|positive|,|surface (l_compound) rubella_47\NN|administration|and|,
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (l_conj) immunity_48\NN|B|positive|,|surface (l_conj) administration_51\NN|rubella|and|, (l_prep) of_52\IN|NONE (l_pobj) vaccine_58\NN|NONE (l_compound) rubella_57\NN|in
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|who|were|to (r_prep) born_37\VBN|NONE (l_prep) to_59\TO|who|to|were (l_pobj) women_62\NNS|NONE (l_compound) rubella_60\VB|nonimmune
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|who|were|to (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (r_conj) dose_22\NN|for|prenatal|, (r_conj) screening_8\NN|on|Assessment|was|.|: (l_prep) for_9\IN|dose|prenatal|, (l_pobj) B_11\NNP|NONE
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|who|were|to (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (r_conj) dose_22\NN|for|prenatal|, (l_nsubj) administration_15\NN|to|,|administration (l_prep) of_16\IN|NONE (l_pobj) birth_21\NN|NONE (l_compound) vaccine_20\NN|the (l_compound) B_19\NNP|NONE
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|B|,|surface (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|who|were|to (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (l_prep) of_28\IN|to (l_pobj) globulin_32\NN|NONE (l_compound) B_30\NNP|immune
D006514_D006509 CID antigen_9\NN| (r_npadvmod) positive_11\JJ|B|surface (r_amod) mothers_12\NNS|NONE (r_pobj) to_5\IN|were|who (r_prep) born_4\VBN|All (r_relcl) infants_1\NNS|.|globulin|also (r_nsubj) received_14\VBD|NONE (l_dobj) globulin_18\NN|infants|.|also (l_compound) B_16\NN|immune
16471092
C099041_D053201 NONE tolterodine_14\JJ|NONE (r_amod) treatment_15\NN|NONE (r_pobj) after_13\IN|.|Urinary|quality|and (r_prep) symptoms_1\NNS|NONE (l_conj) quality_3\NN|.|Urinary|after|and (l_prep) of_4\IN|NONE (l_pobj) changes_6\NNS|NONE (l_prep) with_10\IN|life|in (l_pobj) bladder_12\NN|NONE
C099041_D053201 NONE tolterodine_22\JJ|NONE (r_amod) treatment_23\NN|NONE (r_pobj) after_21\IN|To|symptoms (r_prep) study_3\VB|:|. (l_dobj) symptoms_6\NNS|To|after (l_conj) quality_8\NN|and|the|urinary (l_prep) of_9\IN|NONE (l_pobj) changes_11\NNS|NONE (l_prep) with_15\IN|life|in (l_pobj) bladder_17\NN|NONE
C099041_D053201 NONE tolterodine_22\JJ|NONE (r_amod) treatment_23\NN|NONE (r_pobj) after_21\IN|To|symptoms (r_prep) study_3\VB|:|. (l_dobj) symptoms_6\NNS|To|after (l_conj) quality_8\NN|and|the|urinary (l_prep) of_9\IN|NONE (l_pobj) changes_11\NNS|NONE (l_prep) with_15\IN|life|in (l_pobj) bladder_17\NN|NONE (l_appos) OAB_19\NNP|)|(|overactive
C099041_D053201 NONE Tolterodine_0\NNP|well|was|and|improved (r_nsubjpass) tolerated_3\VBN|NONE (l_conj) improved_7\VBD|Tolterodine|well|was|and (l_dobj) quality_9\NN|effects|. (l_prep) with_15\IN|in|the|of (l_pobj) OAB_16\NNP|NONE
15974569
D005557_D006930 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|paw (r_amod) licking_21\NN|NONE (r_pobj) of_16\IN|hyperalgesia|, (r_prep) reversal_15\NN|:|three|of (l_conj) hyperalgesia_27\NN|,|of
D005557_D006930 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|paw (r_amod) licking_21\NN|NONE (r_pobj) of_16\IN|hyperalgesia|, (r_prep) reversal_15\NN|:|three|of (l_conj) hyperalgesia_27\NN|,|of (l_conj) hyperalgesia_34\NN|,|and|thermal|induced
D002211_D006930 CID capsaicin_30\NN| (r_npadvmod) induced_32\VBN|mechanical (r_amod) hyperalgesia_34\NN|,|and|thermal|induced (r_conj) hyperalgesia_27\NN|,|of
D002211_D006930 CID capsaicin_30\NN| (r_npadvmod) induced_32\VBN|mechanical (r_amod) hyperalgesia_34\NN|,|and|thermal|induced
D002351_D006930 CID carrageenan_23\NN| (r_npadvmod) induced_25\VBN|,|and|thermal|hyperalgesia (r_amod) hyperalgesia_27\NN|,|of
D002351_D006930 CID carrageenan_23\NN| (r_npadvmod) induced_25\VBN|,|and|thermal|hyperalgesia (r_amod) hyperalgesia_27\NN|,|of (l_conj) hyperalgesia_34\NN|,|and|thermal|induced
D002351_D010146 NONE carrageenan_23\NN| (r_npadvmod) induced_25\VBN|,|and|thermal|hyperalgesia (r_amod) hyperalgesia_27\NN|,|of (r_conj) reversal_15\NN|:|three|of (r_appos) models_11\NNS|NONE (l_prep) of_12\IN|:|three|reversal (l_pobj) pain_13\NN|NONE
D007608_D010146 NONE kainate_7\NN|GluR|potent|receptor (r_compound) antagonists_9\NNS|in (r_compound) actives_10\NNS|NONE (l_prep) in_11\IN|antagonists (l_pobj) models_14\NNS|NONE (l_prep) of_15\IN|animal|three (l_pobj) pain_16\NN|NONE
D005557_D010146 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|paw (r_amod) licking_21\NN|NONE (r_pobj) of_16\IN|hyperalgesia|, (r_prep) reversal_15\NN|:|three|of (r_appos) models_11\NNS|NONE (l_prep) of_12\IN|:|three|reversal (l_pobj) pain_13\NN|NONE
D002211_D010146 NONE capsaicin_30\NN| (r_npadvmod) induced_32\VBN|mechanical (r_amod) hyperalgesia_34\NN|,|and|thermal|induced (r_conj) hyperalgesia_27\NN|,|of (r_conj) reversal_15\NN|:|three|of (r_appos) models_11\NNS|NONE (l_prep) of_12\IN|:|three|reversal (l_pobj) pain_13\NN|NONE
6504332
D010634_D004409 CID Phenobarbital_0\NN| (r_npadvmod) induced_2\VBN|.|in (r_amod) dyskinesia_3\NN|NONE
D010634_D004409 CID phenobarbital_15\JJ|for (r_amod) therapy_16\NN|NONE (r_dobj) starting_14\VBG|soon (r_pcomp) after_13\IN|child|dyskinesia|. (r_prep) developed_9\VBD|NONE (l_dobj) dyskinesia_11\JJ|child|after|.
D010634_D004409 CID phenobarbital_4\JJ|NONE (r_pobj) with_3\IN|repeat (r_prep) challenge_2\NN|NONE (r_pobj) On_0\IN|,|.|dyskinesia (r_prep) recurred_8\VBD|NONE (l_nsubj) dyskinesia_7\NN|,|.|On
D010634_D009069 NONE Phenobarbital_0\NN|be|.|to|should (r_nsubjpass) added_3\VBN|NONE (l_prep) to_4\IN|be|Phenobarbital|.|should (l_pobj) list_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) drugs_9\NNS|NONE (l_relcl) cause_12\VB|anticonvulsant (l_dobj) disorders_14\NNS|that|can
D010634_D012640 NONE phenobarbital_15\JJ|for (r_amod) therapy_16\NN|NONE (l_prep) for_17\IN|phenobarbital (l_pobj) seizures_18\NNS|NONE
D010634_D009422 NONE Phenobarbital_0\NN| (r_npadvmod) induced_2\VBN|.|in (r_amod) dyskinesia_3\NN|NONE (l_prep) in_4\IN|induced|. (l_pobj) child_9\NN|NONE (l_amod) impaired_8\VBN|a
D010634_D009422 NONE phenobarbital_15\JJ|for (r_amod) therapy_16\NN|NONE (r_dobj) starting_14\VBG|soon (r_pcomp) after_13\IN|child|dyskinesia|. (r_prep) developed_9\VBD|NONE (l_nsubj) child_4\NN|after|dyskinesia|. (l_prep) with_5\IN|old|A (l_pobj) impairment_8\NN|NONE
18356633
D000583_D007674 CID amikacin_3\JJ|in (r_amod) nephrotoxicity_4\NN|NONE
D000583_D007674 CID amikacin_2\RB| (r_npadvmod) associated_4\VBN|NONE (r_amod) nephrotoxicity_5\NN|To|in
D000583_D007674 CID amikacin_17\JJ|NONE (r_prep) via_16\IN|of (r_prep) evaluation_13\NN|serum|and (r_conj) creatinine_11\NN|NONE (r_pobj) in_9\IN|an (r_prep) increase_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) means_5\NNS|NONE (r_pobj) by_4\IN|The|of (r_prep) occurrence_1\NN|.|were (l_prep) of_2\IN|by|The (l_pobj) nephrotoxicity_3\NN|NONE
D000617_D009369 NONE aminoglycoside_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|that (r_dobj) required_13\VBD|oncologic|a (r_relcl) disorder_11\NN|NONE
D000583_D009503 NONE Amikacin_0\NNP|.|aminoglycoside (r_nsubj) is_1\VBZ|NONE (l_attr) aminoglycoside_3\NN|.|Amikacin (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|empirical|double|negative (l_pobj) neutropenia_16\NN|NONE
D003404_D007674 NONE creatinine_11\NN|NONE (r_pobj) in_9\IN|an (r_prep) increase_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) means_5\NNS|NONE (r_pobj) by_4\IN|The|of (r_prep) occurrence_1\NN|.|were (l_prep) of_2\IN|by|The (l_pobj) nephrotoxicity_3\NN|NONE
D000583_D007239 NONE Amikacin_0\NNP|.|aminoglycoside (r_nsubj) is_1\VBZ|NONE (l_attr) aminoglycoside_3\NN|.|Amikacin (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|empirical|double|negative (l_pobj) neutropenia_16\NN|NONE (l_conj) infections_20\NNS|febrile|and
D000617_D007239 NONE aminoglycoside_3\NN|.|Amikacin (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|empirical|double|negative (l_pobj) neutropenia_16\NN|NONE (l_conj) infections_20\NNS|febrile|and
D000617_D006402 NONE aminoglycoside_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|that (r_dobj) required_13\VBD|oncologic|a (r_relcl) disorder_11\NN|NONE
D000583_D006402 NONE amikacin_27\JJ|NONE (r_pobj) to_20\IN|.|were|patients (r_prep) randomized_19\VBN|NONE (l_nsubjpass) patients_1\NNS|.|were|to (l_prep) with_2\IN|Forty (l_pobj) diagnosis_4\NN|NONE (l_amod) consistent_5\JJ|a (l_prep) with_6\IN|NONE (l_pobj) disorder_11\NN|NONE
D000617_D009503 NONE aminoglycoside_3\NN|.|Amikacin (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|empirical|double|negative (l_pobj) neutropenia_16\NN|NONE
D000583_D009369 NONE amikacin_27\JJ|NONE (r_pobj) to_20\IN|.|were|patients (r_prep) randomized_19\VBN|NONE (l_nsubjpass) patients_1\NNS|.|were|to (l_prep) with_2\IN|Forty (l_pobj) diagnosis_4\NN|NONE (l_amod) consistent_5\JJ|a (l_prep) with_6\IN|NONE (l_pobj) disorder_11\NN|NONE
1564236
D013793_D023921 NONE thallium-201_18\JJ|emission (r_amod) tomography_23\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) correlation_16\NN|Relation|with|:|. (r_appos) observed_4\VBN|NONE (l_prep) with_5\IN|Relation|correlation|:|. (l_pobj) contrast_7\NN|NONE (l_prep) to_9\IN|echocardiography|myocardial (l_pobj) severity_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) stenosis_14\NN|NONE
D004176_D023921 NONE dipyridamole_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperemia_4\NN|NONE (r_pobj) During_0\IN|area|,||.|by (r_prep) had_16\VBD|NONE (l_nsubj) 12_6\CD|area|During|,|.|by (l_prep) of_7\IN|NONE (l_pobj) dogs_10\NNS|NONE (l_prep) with_11\IN||the (l_pobj) stenosis_15\NN|NONE
D004176_D006940 CID dipyridamole_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperemia_4\NN|NONE
D004176_D006940 CID dipyridamole_24\NN| (r_npadvmod) induced_26\VBN|NONE (r_amod) hyperemia_27\NN|NONE
D004176_D006940 CID dipyridamole_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) hyperemia_14\NN|NONE
9305828
D010862_D012640 NONE pilocarpine_1\NN|model|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|is|. (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|acute|of (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE
D010862_D012640 NONE PILO_3\NNP|)|(|of (r_nmod) model_5\NN|pilocarpine|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|is|. (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|acute|of (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE
D010862_D004827 NONE pilocarpine_1\NN|model|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_nsubjpass) model_5\NN|pilocarpine|is|by|. (l_prep) of_6\IN|)|(|PILO (l_pobj) epilepsy_7\NN|NONE
D010862_D004827 NONE PILO_3\NNP|)|(|of (r_nmod) model_5\NN|pilocarpine|is|by|. (l_prep) of_6\IN|)|(|PILO (l_pobj) epilepsy_7\NN|NONE
D010862_D013226 NONE pilocarpine_1\NN|model|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|is|. (l_pobj) period_13\NN|NONE (l_prep) of_14\IN|an|acute|followed (l_pobj) epilepticus_16\NN|NONE
D010862_D013226 NONE PILO_3\NNP|)|(|of (r_nmod) model_5\NN|pilocarpine|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|is|. (l_pobj) period_13\NN|NONE (l_prep) of_14\IN|an|acute|followed (l_pobj) epilepticus_16\NN|NONE
D010862_D004833 CID pilocarpine_6\NN|of|the (r_amod) model_7\NN|NONE (l_prep) of_8\IN|the|pilocarpine (l_pobj) epilepsy_11\NN|NONE
D010862_D004833 CID PILO_30\NNP|the|of (r_amod) model_31\NN|NONE (l_prep) of_32\IN|the|PILO (l_pobj) TLE_33\NNP|NONE
D010862_D001930 NONE pilocarpine_1\NN|model|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|is|. (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|acute|of (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE (l_conj) damage_25\NN|spontaneous|and|recurrent
D010862_D001930 NONE PILO_3\NNP|)|(|of (r_nmod) model_5\NN|pilocarpine|is|by|. (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|is|. (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|acute|of (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE (l_conj) damage_25\NN|spontaneous|and|recurrent
7791169
D016595_D010146 NONE misoprostol_2\NNP|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|can|without|impairment|. (r_nsubj) minimize_4\VB|NONE (l_prep) without_8\IN|can|impairment|.|Addition (l_pcomp) affecting_9\VBG|NONE (l_dobj) control_11\NN|NONE (l_compound) pain_10\NN|NONE
D016595_D007674 NONE misoprostol_3\NNP|NONE (r_pobj) of_2\IN|Protective (r_prep) effect_1\NN|dysfunction|. (r_nsubj) induced_6\VBD|NONE (l_dobj) dysfunction_8\NN|effect|.
D016595_D007674 NONE misoprostol_2\NNP|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|can|without|impairment|. (r_nsubj) minimize_4\VB|NONE (l_dobj) impairment_7\NN|can|without|.|Addition
D007213_D007674 CID indomethacin_5\NN|NONE (r_pobj) on_4\IN|NONE (r_prep) misoprostol_3\NNP|NONE (r_pobj) of_2\IN|Protective (r_prep) effect_1\NN|dysfunction|. (r_nsubj) induced_6\VBD|NONE (l_dobj) dysfunction_8\NN|effect|.
D007213_D007674 CID indomethacin_8\NN|related|renal (r_nmod) dysfunction_11\NN|NONE
2021202
D007530_D007022 CID isoflurane_6\RB| (r_npadvmod) induced_8\VBN|prolonged|in (r_amod) hypotension_9\NN|NONE
D007530_D007022 CID isoflurane_3\RB| (r_npadvmod) induced_5\VBN|on (r_amod) hypotension_6\NN|NONE
D007530_D007022 CID isoflurane_11\NN|the|inspired (r_amod) concentration_13\NN|maintain (r_dobj) increasing_9\VBG|NONE (r_pcomp) by_8\IN|.|was|mmHg|for|Hypotension (r_prep) induced_2\VBN|NONE (l_nsubjpass) Hypotension_0\NNP|.|was|mmHg|by|for
D007530_D007022 CID isoflurane_9\RB| (r_npadvmod) induced_11\VBN|and (r_amod) hypotension_12\NN|NONE
17285209
D000809_D000799 NONE angiotensin_3\NN| (r_npadvmod) converting_5\VBG|(|)|ACE|and|blocker (r_amod) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|.|(|recognition|challenge
D000809_D000799 NONE angiotensin_11\NN|receptor (r_compound) blocker_13\NN|(|)|ACE|and|converting (r_conj) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|.|(|recognition|challenge
D000809_D007410 NONE angiotensin_3\NN| (r_npadvmod) converting_5\VBG|(|)|ACE|and|blocker (r_amod) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|.|(|recognition|challenge
D000809_D007410 NONE angiotensin_11\NN|receptor (r_compound) blocker_13\NN|(|)|ACE|and|converting (r_conj) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|.|(|recognition|challenge
C044946_D006973 NONE benazapril_28\NN|/ (r_compound) mg._30\CD|/|a|of|combination (r_appos) pill_24\NN|NONE (r_pobj) on_21\IN|who|was (r_prep) started_20\VBN|old|,|American|with|year|a (r_relcl) female_12\NN|NONE (l_prep) with_13\IN|old|,|American|started|year|a (l_pobj) hypertension_16\NN|NONE
D017311_D006973 NONE amlodipine_26\NN|NONE (r_pobj) of_25\IN|/|a|combination|mg. (r_prep) pill_24\NN|NONE (r_pobj) on_21\IN|who|was (r_prep) started_20\VBN|old|,|American|with|year|a (r_relcl) female_12\NN|NONE (l_prep) with_13\IN|old|,|American|started|year|a (l_pobj) hypertension_16\NN|NONE
7752389
D011453_D053201 NONE Prostanoids_0\NNS|to|.|,|,|via|may (r_nsubj) contribute_8\VBP|NONE (l_prep) to_9\IN|Prostanoids|.|,|,|via|may (l_pobj) urge_11\VB|NONE (l_conj) hyperactivity_14\NN|seen|both|and
D015232_D053201 CID E2-induced_1\JJ|in|?|bladder|Prostaglandin (r_amod) hyperactivity_3\NN|NONE
D015320_D053201 NONE tachykinins_12\NNS|NONE (r_pobj) of_11\IN|NONE (r_prep) involvement_10\NN|:|conscious|normal|, (r_appos) rats_8\NNS|NONE (r_pobj) in_4\IN|?|Einduced|bladder|Prostaglandin (r_prep) hyperactivity_3\NN|NONE
D015320_D053201 NONE tachykinins_6\NNS|NONE (r_pobj) of_5\IN|NONE (r_prep) release_4\NN|NONE (r_pobj) via_3\IN|to|Prostanoids|.|,|,|may (r_prep) contribute_8\VBP|NONE (l_prep) to_9\IN|Prostanoids|.|,|,|via|may (l_pobj) urge_11\VB|NONE (l_conj) hyperactivity_14\NN|seen|both|and
12907924
D008774_D000544 NONE methylphenidate_18\NN|NONE (r_pobj) on_17\IN|was|man|. (r_prep) started_16\VBN|NONE (l_nsubjpass) man_4\NN|on|was|. (l_prep) with_5\IN|An|old (l_pobj) depression_9\NN|NONE (l_conj) disease_14\NN|and|resistant
D008774_D009771 CID Methylphenidate_0\NNP| (r_npadvmod) induced_2\VBN|compulsive|in|. (r_amod) symptoms_6\NNS|NONE
D008774_D009771 CID methylphenidate_12\NN|was|by|when (r_nsubjpass) replaced_14\VBN|over (r_advcl) diminished_7\VBN|but|.|behavior (r_conj) ensued_5\VBD|NONE (l_nsubj) behavior_4\NN|but|.|diminished
D016666_D009771 NONE fluvoxamine_16\NN|NONE (r_pobj) by_15\IN|was|methylphenidate|when (r_agent) replaced_14\VBN|over (r_advcl) diminished_7\VBN|but|.|behavior (r_conj) ensued_5\VBD|NONE (l_nsubj) behavior_4\NN|but|.|diminished
D008774_D061218 NONE methylphenidate_18\NN|NONE (r_pobj) on_17\IN|was|man|. (r_prep) started_16\VBN|NONE (l_nsubjpass) man_4\NN|on|was|. (l_prep) with_5\IN|An|old (l_pobj) depression_9\NN|NONE
8643973
D017239_D010051 NONE Paclitaxel_0\NNP|NONE (l_acl) combined_1\VBD|. (l_prep) in_4\IN|with (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the|line (l_pobj) cancer_13\NN|NONE
D017239_D010051 NONE paclitaxel_12\NN|NONE (r_pobj) of_11\IN|maximum|Taxol|tolerated|the (r_prep) dose_10\NN|given|to (r_dobj) determine_6\VB|escalated|I|In (l_prep) given_26\VBN|to|dose (l_prep) as_27\IN|NONE (l_pobj) infusion_30\NN|NONE (l_acl) administered_35\VBN|a|in|hour (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
D017239_D010051 NONE Taxol_14\NNP|maximum|tolerated|of|the (r_appos) dose_10\NN|given|to (r_dobj) determine_6\VB|escalated|I|In (l_prep) given_26\VBN|to|dose (l_prep) as_27\IN|NONE (l_pobj) infusion_30\NN|NONE (l_acl) administered_35\VBN|a|in|hour (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
D017239_D010051 NONE paclitaxel_46\NN|NONE (r_compound) doses_47\NNS|level|.|were|follows (r_nsubjpass) escalated_49\VBN|I|determine|In (r_conj) study_4\VBP|NONE (l_xcomp) determine_6\VB|escalated|I|In (l_prep) given_26\VBN|to|dose (l_prep) as_27\IN|NONE (l_pobj) infusion_30\NN|NONE (l_acl) administered_35\VBN|a|in|hour (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
D016190_D010051 NONE carboplatin_3\NN|NONE (r_pobj) with_2\IN|in (r_prep) combined_1\VBD|. (l_prep) in_4\IN|with (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the|line (l_pobj) cancer_13\NN|NONE
D016190_D010051 NONE carboplatin_34\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) combination_32\NN|NONE (r_pobj) in_31\IN|a|administered|hour (r_prep) infusion_30\NN|NONE (l_acl) administered_35\VBN|a|in|hour (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
11912119
D007980_D004409 CID levodopa_3\RB| (r_npadvmod) induced_5\VBN|in (r_amod) dyskinesias_6\NNS|Force|.|and
D007980_D004409 CID levodopa_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|motor (r_prep) complications_16\NNS|NONE (r_pobj) to_14\IN|its (r_prep) relationship_13\NN|Parkinson|and (r_conj) disease_10\NN|NONE (r_pobj) in_7\IN|coordination|We|,|to|. (r_prep) assessed_1\VBD|NONE (l_prep) to_22\IN|coordination|We|,|in|. (l_pobj) dyskinesias_26\NNS|particularly
D007980_D004409 CID levodopa_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|motor (r_prep) complications_16\NNS|NONE (r_pobj) to_14\IN|its (r_prep) relationship_13\NN|Parkinson|and (r_conj) disease_10\NN|NONE (r_pobj) in_7\IN|coordination|We|,|to|. (r_prep) assessed_1\VBD|NONE (l_prep) to_22\IN|coordination|We|,|in|. (l_pobj) dyskinesias_26\NNS|particularly (l_appos) LID_28\NNP|)|induced|(
D007980_D004409 CID levodopa_23\VB| (r_npadvmod) induced_25\VBN|)|LID|( (r_amod) dyskinesias_26\NNS|particularly
D007980_D004409 CID levodopa_23\VB| (r_npadvmod) induced_25\VBN|)|LID|( (r_amod) dyskinesias_26\NNS|particularly (l_appos) LID_28\NNP|)|induced|(
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|(|LID (r_amod) dyskinesias_26\NNS|NONE (r_pobj) without_22\IN|)|and|disease (r_conj) with_9\IN|We|.|groups (l_pobj) disease_13\NN|without|)|and (l_conj) LID_15\NNP||(|Parkinson|n|+|,
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|(|LID (r_amod) dyskinesias_26\NNS|NONE
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|(|LID (r_amod) dyskinesias_26\NNS|NONE (l_appos) LID_32\NNP|(|induced
D007980_D004409 CID levodopa_28\RB|score|.|were (r_dobj) assessed_24\VBN|NONE (l_nsubjpass) score_2\NN|levodopa|.|were (l_prep) of_3\IN|motor|The (l_pobj) Scale_10\NNP|NONE (l_appos) score_14\NN|Parkinson|,|Rating (l_compound) dyskinesia_13\JJ|force|and|a|in
D007980_D004409 CID levodopa_21\NN|NONE (r_pobj) by_20\IN|.|significantly|)|was|force|In|, (r_agent) increased_19\VBN|NONE (l_prep) In_0\IN|.|significantly|)|was|force|by|, (l_pobj) disease_3\NN|NONE (l_conj) LID_5\NNP|+|Parkinson
D007980_D010300 NONE levodopa_3\RB| (r_npadvmod) induced_5\VBN|in (r_amod) dyskinesias_6\NNS|Force|.|and (l_prep) in_7\IN|induced (l_pobj) disease_10\NN|NONE
D007980_D010300 NONE levodopa_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|motor (r_prep) complications_16\NNS|NONE (r_pobj) to_14\IN|its (r_prep) relationship_13\NN|Parkinson|and (r_conj) disease_10\NN|NONE
D007980_D010300 NONE levodopa_23\VB| (r_npadvmod) induced_25\VBN|)|LID|( (r_amod) dyskinesias_26\NNS|particularly (r_pobj) to_22\IN|coordination|We|,|in|. (r_prep) assessed_1\VBD|NONE (l_prep) in_7\IN|coordination|We|,|to|. (l_pobj) disease_10\NN|NONE
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|(|LID (r_amod) dyskinesias_26\NNS|NONE (r_pobj) without_22\IN|)|and|disease (r_conj) with_9\IN|We|.|groups (r_prep) studied_1\VBD|NONE (l_dobj) groups_3\NNS|We|with|. (l_prep) of_4\IN|two (l_pobj) patients_8\NNS|NONE (l_compound) disease_7\NN|Parkinson
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|(|LID (r_amod) dyskinesias_26\NNS|NONE (r_pobj) without_22\IN|)|and|disease (r_conj) with_9\IN|We|.|groups (l_pobj) disease_13\NN|without|)|and
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|(|LID (r_amod) dyskinesias_26\NNS|NONE (l_appos) LID_32\NNP|(|induced (l_compound) disease_30\NN|)|Parkinson|controls|,|and|||n|,
D007980_D010300 NONE levodopa_28\RB|score|.|were (r_dobj) assessed_24\VBN|NONE (l_nsubjpass) score_2\NN|levodopa|.|were (l_prep) of_3\IN|motor|The (l_pobj) Scale_10\NNP|NONE (l_compound) Rating_9\NNP|score|Parkinson|, (l_compound) Disease_8\NNP|NONE
D007980_D010300 NONE levodopa_21\NN|NONE (r_pobj) by_20\IN|.|significantly|)|was|force|In|, (r_agent) increased_19\VBN|NONE (l_prep) In_0\IN|.|significantly|)|was|force|by|, (l_pobj) disease_3\NN|NONE
3108839
D016685_D013274 NONE C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|.|course|We|and|died|in (r_advcl) describe_1\VBP|NONE (l_prep) in_8\IN|.|on|course|We|and|died (l_pobj) man_14\NN|NONE (l_prep) with_15\IN|old|developed||a (l_pobj) adenocarcinoma_17\NN|NONE
D016685_D000743 NONE C_15\NN|mitomycin (r_compound) treatment_16\NN|NONE (r_pobj) with_13\IN|and (r_prep) associated_12\VBN|progressive|renal (r_acl) failure_11\NN|and (r_conj) thrombocytopenia_7\JJ|,|microangiopathic|hemolytic (r_conj) anemia_5\NN|NONE
D016685_D011654 NONE C_14\NN|mitomycin (r_compound) treatment_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) start_11\NN|NONE (r_pobj) after_10\IN|usually|is|mth|and|failure (r_prep) develops_4\VBZ|NONE (l_conj) is_19\VBZ|usually|after|mth|and|failure (l_attr) %_22\NN|.|mortality (l_prep) from_23\IN| (l_pobj) failure_25\NN|NONE (l_conj) edema_28\NN|renal|or
D016685_D011654 NONE C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|.|course|We|and|died|in (r_advcl) describe_1\VBP|NONE (l_conj) died_31\VBD|.|on|course|We|and|in (l_prep) in_32\IN|NONE (l_pobj) edema_34\NN|NONE
D016685_D006463 CID C_1\NNP|syndrome|. (r_nsubj) associated_2\VBD|NONE (l_dobj) syndrome_5\NN|C|.
D016685_D006463 CID C_1\NNP|Syndrome (r_nsubj) associated_2\VBD|.|condition (l_dobj) Syndrome_5\NNP|C
D016685_D006463 CID C_1\NNP|Syndrome (r_nsubj) associated_2\VBD|.|condition (l_dobj) Syndrome_5\NNP|C (l_appos) HUS_7\NNP|Hemolytic|Uremic|)
D016685_D051437 CID C_15\NN|mitomycin (r_compound) treatment_16\NN|NONE (r_pobj) with_13\IN|and (r_prep) associated_12\VBN|progressive|renal (r_acl) failure_11\NN|and
D016685_D051437 CID C_14\NN|mitomycin (r_compound) treatment_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) start_11\NN|NONE (r_pobj) after_10\IN|usually|is|mth|and|failure (r_prep) develops_4\VBZ|NONE (l_nsubj) failure_2\NN|usually|is|after|mth|and
D016685_D051437 CID C_14\NN|mitomycin (r_compound) treatment_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) start_11\NN|NONE (r_pobj) after_10\IN|usually|is|mth|and|failure (r_prep) develops_4\VBZ|NONE (l_conj) is_19\VBZ|usually|after|mth|and|failure (l_attr) %_22\NN|.|mortality (l_prep) from_23\IN| (l_pobj) failure_25\NN|NONE
D016685_D051437 CID C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|.|course|We|and|died|in (r_advcl) describe_1\VBP|NONE (l_prep) in_8\IN|.|on|course|We|and|died (l_pobj) man_14\NN|NONE (l_relcl) developed_19\VBD|with|old||a (l_dobj) failure_21\NN|who|thrombocytopenia|and
D016685_D013921 NONE C_15\NN|mitomycin (r_compound) treatment_16\NN|NONE (r_pobj) with_13\IN|and (r_prep) associated_12\VBN|progressive|renal (r_acl) failure_11\NN|and (r_conj) thrombocytopenia_7\JJ|,|microangiopathic|hemolytic
D016685_D013921 NONE C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|.|course|We|and|died|in (r_advcl) describe_1\VBP|NONE (l_prep) in_8\IN|.|on|course|We|and|died (l_pobj) man_14\NN|NONE (l_relcl) developed_19\VBD|with|old||a (l_conj) thrombocytopenia_23\NN|failure|who|and
17682013
D008727_D002544 NONE methotrexate_21\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) recipients_18\NNS|commonly (r_pobj) in_17\IN|has|leukoencephalopathy|as|,|.|been (r_prep) described_8\VBN|NONE (l_nsubjpass) leukoencephalopathy_2\JJ|has|as|,|.|been|in (l_acl) mimicking_3\VBG|A|transient (l_dobj) accident_5\NN|NONE
D008727_D056784 CID methotrexate_21\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) recipients_18\NNS|commonly (r_pobj) in_17\IN|has|leukoencephalopathy|as|,|.|been (r_prep) described_8\VBN|NONE (l_nsubjpass) leukoencephalopathy_2\JJ|has|as|,|.|been|in
D008727_D056784 CID methotrexate_12\NNP|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|toxic (r_prep) leukoencephalopathy_7\JJ|NONE
C017367_D056784 CID carmofur_23\NN|and|fluorouracil|.|:|reports|We (r_conj) identified_2\VBD|NONE (l_dobj) reports_4\NNS|and|fluorouracil|.|:|We|carmofur (l_prep) of_5\IN| (l_pobj) leukoencephalopathy_7\JJ|NONE
D005472_D056784 CID 5-fluorouracil_19\CD|and|.|:|reports|We|carmofur (r_punct) identified_2\VBD|NONE (l_dobj) reports_4\NNS|and|fluorouracil|.|:|We|carmofur (l_prep) of_5\IN| (l_pobj) leukoencephalopathy_7\JJ|NONE
C110904_D056784 CID capecitabine_26\NN|its|,|and|derivative (r_conj) carmofur_23\NN|and|fluorouracil|.|:|reports|We (r_conj) identified_2\VBD|NONE (l_dobj) reports_4\NNS|and|fluorouracil|.|:|We|carmofur (l_prep) of_5\IN| (l_pobj) leukoencephalopathy_7\JJ|NONE
D008727_D007938 NONE methotrexate_21\NN|NONE (l_prep) for_22\IN|intrathecal (l_pobj) leukaemia_24\NN|NONE
6216862
D010396_D006527 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (r_pobj) in_25\IN|but|as|been|has|which (r_conj) reported_11\VBN|,|elastosis|perforans (l_prep) as_12\IN|in|but|been|has|which (l_pobj) effect_16\NN|NONE (l_prep) in_17\IN|side|a|rare (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) disease_22\NN|NONE
D010396_D017285 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|been|all|.|have|rashes (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|been|all|.|have|as (l_conj) proteinuria_3\NN|,|Skin (l_conj) erythematosus_7\NN|, (l_conj) polymyositis_9\NN|lupus|,|systemic
D010396_D005076 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|been|all|.|have|rashes (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|been|all|.|have|as
D010396_D001172 NONE penicillamine_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_pobj) of_3\IN|in|Multiple|side|. (r_prep) effects_2\NNS|NONE (l_prep) in_6\IN|of|Multiple|side|. (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|one (l_pobj) arthritis_11\NN|NONE
D010396_D001172 NONE penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (l_prep) in_22\IN|of (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) arthritis_26\NN|NONE
D010396_D001172 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (l_prep) with_27\IN|treated (l_pobj) arthritis_29\NN|NONE
D010396_D012871 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (r_pobj) in_25\IN|but|as|been|has|which (r_conj) reported_11\VBN|,|elastosis|perforans (r_relcl) serpiginosa_6\NN|lesion|. (r_dobj) resembled_3\VBD|NONE (l_nsubj) lesion_2\NN|serpiginosa|.
D010396_D011507 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|been|all|.|have|rashes (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|been|all|.|have|as (l_conj) proteinuria_3\NN|,|Skin
D010396_D008180 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|been|all|.|have|rashes (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|been|all|.|have|as (l_conj) proteinuria_3\NN|,|Skin (l_conj) erythematosus_7\NN|,
D010396_C536202 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (r_pobj) in_25\IN|but|as|been|has|which (r_conj) reported_11\VBN|,|elastosis|perforans (r_relcl) serpiginosa_6\NN|lesion|.
D010396_D009157 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|been|all|.|have|rashes (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|been|all|.|have|as (l_conj) proteinuria_3\NN|,|Skin (l_conj) erythematosus_7\NN|, (l_conj) polymyositis_9\NN|lupus|,|systemic (l_conj) gravis_12\NN|and|myasthenia
9636837
D016190_D010523 CID CBDCA_5\NNP|intensity|association|and (r_nmod) schedules_9\NNS|NONE (r_pobj) of_4\IN|the (r_prep) use_3\NN|concern|may|.|,|However (r_nsubj) cause_20\VB|NONE (l_dobj) concern_22\NN|use|may|.|,|However (l_prep) about_23\IN|some (l_pobj) safety_25\NN|NONE (l_prep) with_26\IN|its (l_pobj) respect_27\NN|NONE (l_prep) to_28\IN|NONE (l_pobj) damage_32\NN|NONE
D016190_D010523 CID CBDCA_0\JJ|NONE (r_compound) administration_1\NN|.|neurotoxicity (r_nsubj) induced_2\VBD|NONE (l_dobj) neurotoxicity_7\NN|administration|.
D016190_D020258 NONE carboplatin_4\NN|)|CBDCA|( (r_poss) advantages_6\NNS|NONE (r_pobj) of_3\IN|The|over|most (r_prep) striking_2\JJ|)|rate|. (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|)|.|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D016190_D020258 NONE CBDCA_8\NNP|carboplatin|)|( (r_appos) advantages_6\NNS|NONE (r_pobj) of_3\IN|The|over|most (r_prep) striking_2\JJ|)|rate|. (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|)|.|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D016190_D020258 NONE CBDCA_5\NNP|intensity|association|and (r_nmod) schedules_9\NNS|NONE (l_conj) association_12\NN|intensity|CBDCA|and (l_prep) with_13\IN|in|the (l_pobj) drugs_16\NNS|NONE (l_amod) neurotoxic_15\JJ|other
D016190_D020258 NONE CBDCA_0\NNP|in|,|are|neurotoxic|and (r_nsubj) is_1\VBZ|NONE (l_acomp) neurotoxic_2\JJ|in|,|are|and|CBDCA
D016190_D020258 NONE CBDCA_0\NNP|in|,|are|neurotoxic|and (r_nsubj) is_1\VBZ|NONE (l_conj) are_15\VBP|in|,|neurotoxic|and|CBDCA (l_ccomp) is_26\VBZ|.|similar|type (l_ccomp) induced_31\VBN|that|probable|it (l_nsubjpass) neurotoxicity_29\NN|by|that|is|in
D002945_D020258 NONE cisplatin_11\NN|( (r_nmod) CDDP_13\NNP|NONE (r_pobj) over_10\IN|The|of|most (r_prep) striking_2\JJ|)|rate|. (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|)|.|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D002945_D020258 NONE CDDP_13\NNP|NONE (r_pobj) over_10\IN|The|of|most (r_prep) striking_2\JJ|)|rate|. (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|)|.|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D002945_D020258 NONE CDDP_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) caused_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) to_19\IN|closely (r_prep) similar_18\JJ|is|.|type (r_acomp) are_15\VBP|in|,|neurotoxic|and|CBDCA (r_conj) is_1\VBZ|NONE (l_acomp) neurotoxic_2\JJ|in|,|are|and|CBDCA
D002945_D020258 NONE CDDP_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) caused_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) to_19\IN|closely (r_prep) similar_18\JJ|is|.|type (r_acomp) are_15\VBP|in|,|neurotoxic|and|CBDCA (l_ccomp) is_26\VBZ|.|similar|type (l_ccomp) induced_31\VBN|that|probable|it (l_nsubjpass) neurotoxicity_29\NN|by|that|is|in
1728915
D002220_D062787 NONE carbamazepine_12\NN|a|massive (r_compound) overdose_13\NN|NONE
D002220_D001523 NONE carbamazepine_1\NN|widely|in|Because|is (r_nsubjpass) used_4\VBN|,|implications|.|recognition (l_prep) in_5\IN|widely|carbamazepine|Because|is (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) conditions_13\NNS|NONE (l_amod) neurologic_10\JJ|many (l_conj) psychiatric_12\JJ|and
D002220_D013616 CID carbamazepine_12\NN|a|massive (r_compound) overdose_13\NN|NONE (r_pobj) of_9\IN|the (r_prep) setting_8\NN|NONE (r_pobj) in_6\IN|.|group|tachycardias (r_prep) developed_3\VBD|NONE (l_dobj) tachycardias_5\NNS|in|.|group
D002220_D001919 CID carbamazepine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|,|,|A|with (r_acl) patient_1\NN|review|. (l_prep) with_2\IN|induced|,|,|A (l_pobj) bradycardia_4\NNP|NONE
D002220_D001919 CID carbamazepine_28\NN|therapeutic|serum (r_compound) levels_30\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|exclusively|group|. (r_advcl) consisted_3\VBD|NONE (l_advmod) exclusively_5\RB|associated|group|. (l_prep) of_6\IN|almost (l_pobj) women_8\NNS|NONE (l_relcl) developed_10\VBD|elderly|, (l_dobj) bradyarrhythmias_15\NNS|who
D002220_D054537 CID carbamazepine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|,|,|A|with (r_acl) patient_1\NN|review|. (l_prep) with_2\IN|induced|,|,|A (l_pobj) bradycardia_4\NNP|NONE (l_conj) block_7\NN|sinus|and
D002220_D054537 CID carbamazepine_28\NN|therapeutic|serum (r_compound) levels_30\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|exclusively|group|. (r_advcl) consisted_3\VBD|NONE (l_advmod) exclusively_5\RB|associated|group|. (l_prep) of_6\IN|almost (l_pobj) women_8\NNS|NONE (l_relcl) developed_10\VBD|elderly|, (l_dobj) bradyarrhythmias_15\NNS|who (l_conj) delay_19\NN|threatening|or
D002220_D006331 NONE Carbamazepine_0\NNP| (r_npadvmod) induced_2\VBN|.|cardiac (r_amod) dysfunction_4\NN|NONE
D002220_D006331 NONE carbamazepine_11\NN| (r_npadvmod) associated_13\VBN|cardiac (r_amod) dysfunction_15\NN|NONE
6323692
D009020_D000699 NONE morphine_11\NN|NHAc (r_appos) pretreatment_9\NN|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ|NONE
D014700_D000699 NONE verapamil_1\NN|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ|NONE
D014700_D000699 NONE verapamil_29\NN|action|. (r_nsubj) affected_32\VBD|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ|NONE
D002118_D022124 NONE calcium_7\NN|a|blocking|enhances (r_compound) channel_8\NN|hyperammonemia (r_dobj) exerts_5\VBZ|.|data (l_nsubj) hyperammonemia_4\NN|channel
D000079_D003866 NONE acetaldehyde_18\NN|NONE (r_pobj) by_17\IN|catecholamine|independent (r_prep) release_16\NN|was|.|by|not (r_nsubjpass) blocked_21\VBN|depression|Addition|,|but (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|Addition|blocked|,|but
D003975_D000699 NONE diazepam_14\NN| (r_npadvmod) induced_16\VBN|muscular (r_amod) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|, (r_conj) analgesia-_12\JJ|NONE
D002395_D003866 NONE catecholamine_15\NN|by|independent (r_compound) release_16\NN|was|.|by|not (r_nsubjpass) blocked_21\VBN|depression|Addition|,|but (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|Addition|blocked|,|but
C018824_D003866 NONE NH4Ac_23\NNPS|NONE (r_pobj) by_22\IN|release|was|.|not (r_agent) blocked_21\VBN|depression|Addition|,|but (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|Addition|blocked|,|but
D014700_D001259 NONE verapamil_1\NN|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
D014700_D001259 NONE verapamil_29\NN|action|. (r_nsubj) affected_32\VBD|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
D010433_D000699 NONE metrazol_37\NN|NONE (r_pobj) of_36\IN|convulsant|the (r_prep) action_35\NN|.|verapamil (r_dobj) affected_32\VBD|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ|NONE
D000661_D000699 NONE amphetamine_21\NN| (r_npadvmod) induced_23\VBN|motor (r_amod) activity_25\NN|NONE (r_dobj) antagonized_20\VBN|and|and|incoordination|verapamil|affected|and|, (r_conj) analgesia-_12\JJ|NONE
D010433_D001259 NONE metrazol_37\NN|NONE (r_pobj) of_36\IN|convulsant|the (r_prep) action_35\NN|.|verapamil (r_dobj) affected_32\VBD|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
C018824_D000699 NONE NH4Ac_8\NNP|morphine (r_nmod) pretreatment_9\NN|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ|NONE
C018824_D000699 NONE NH4Ac_31\NNP|neither|nor (r_conj) verapamil_29\NN|action|. (r_nsubj) affected_32\VBD|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ|NONE
C018824_D001259 CID acetate_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|time|.|approximately (r_nsubj) doubled_15\VBD|NONE (l_npadvmod) time_17\NN|Pretreatment|.|approximately (l_relcl) remained_22\VBD|the (l_conj) incoordination_31\NN|on|had|and|mice
C018824_D001259 CID NH4Ac_5\NNP|ammonium|(|)|s.c. (r_appos) acetate_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|time|.|approximately (r_nsubj) doubled_15\VBD|NONE (l_npadvmod) time_17\NN|Pretreatment|.|approximately (l_relcl) remained_22\VBD|the (l_conj) incoordination_31\NN|on|had|and|mice
C018824_D001259 CID NH4Ac_36\NNP|alone (r_compound) treatment_37\NN|effect (r_nsubj) had_39\VBD|on|and|mice|incoordination (r_conj) remained_22\VBD|the (l_conj) incoordination_31\NN|on|had|and|mice
C018824_D001259 CID NH4Ac_8\NNP|morphine (r_nmod) pretreatment_9\NN|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
C018824_D001259 CID NH4Ac_31\NNP|neither|nor (r_conj) verapamil_29\NN|action|. (r_nsubj) affected_32\VBD|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
D009020_D001259 NONE morphine_18\NN| (r_npadvmod) treated_20\VBN|NONE (r_amod) mice_21\NNS|on|had|and|incoordination (r_nsubj) remained_22\VBD|the (l_conj) incoordination_31\NN|on|had|and|mice
D009020_D001259 NONE morphine_11\NN|NHAc (r_appos) pretreatment_9\NN|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
D000661_D001259 NONE amphetamine_21\NN| (r_npadvmod) induced_23\VBN|motor (r_amod) activity_25\NN|NONE (r_dobj) antagonized_20\VBN|and|and|incoordination|verapamil|affected|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
D003975_D001259 CID diazepam_33\NN|NONE (r_pobj) by_32\IN|muscular|but|increased|, (r_prep) incoordination_31\NN|on|had|and|mice
D003975_D001259 CID diazepam_14\NN| (r_npadvmod) induced_16\VBN|muscular (r_amod) incoordination_18\NN|and|antagonized|and|verapamil|affected|and|,
D002118_D003866 NONE calcium_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|depression|blocked|,|but (r_nsubj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|Addition|blocked|,|but
D002118_D003866 NONE calcium_12\NN| (r_npadvmod) independent_14\JJ|by|catecholamine (r_amod) release_16\NN|was|.|by|not (r_nsubjpass) blocked_21\VBN|depression|Addition|,|but (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|Addition|blocked|,|but
7072798
D002701_D001855 NONE chloramphenicol_13\NN|NONE (r_pobj) with_12\IN|topical|for (r_prep) treatment_11\NN|NONE (r_pobj) after_9\IN|of|second|the (r_prep) report_4\NN|.|reported|,|This (r_attr) was_1\VBD|NONE (l_advcl) reported_29\VBN|.|,|report|This (l_nsubjpass) cases_20\NNS|although|been|also|have (l_prep) of_21\IN|two (l_pobj) hypoplasia_25\NN|NONE
D002701_D002386 NONE chloramphenicol_22\NN|NONE (r_pobj) with_21\IN|topical (r_prep) therapy_20\NN|NONE (r_dobj) beginning_18\VBG|extraction|and (r_conj) undergoing_14\VBG|months (l_dobj) extraction_16\NN|beginning|and (l_compound) cataract_15\NN|NONE
D002701_D005128 NONE chloramphenicol_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|ocular (r_acl) toxicity_6\NN|NONE
D002701_D000741 CID chloramphenicol_8\NN|NONE (r_pobj) of_6\IN|topical (r_prep) administration_5\NN|NONE (r_pobj) following_3\VBG|Fatal|.|aplastic (r_prep) anemia_2\NN|NONE
D002701_D000741 CID chloramphenicol_22\NN|NONE (r_pobj) with_21\IN|topical (r_prep) therapy_20\NN|NONE (r_dobj) beginning_18\VBG|extraction|and (r_conj) undergoing_14\VBG|months (r_pcomp) after_13\IN|woman|.|of (r_prep) died_5\VBD|NONE (l_prep) of_6\IN|woman|.|after (l_pobj) anemia_8\NN|NONE
D002701_D000741 CID chloramphenicol_13\NN|an|idiosyncratic (r_acl) response_11\NN|NONE (r_pobj) with_8\IN|was|.|pattern (r_prep) associated_7\VBN|NONE (l_nsubjpass) pattern_1\NN|was|.|with (l_prep) of_2\IN|The (l_pobj) anemia_5\NN|NONE
D002701_D000741 CID chloramphenicol_13\NN|NONE (r_pobj) with_12\IN|topical|for (r_prep) treatment_11\NN|NONE (r_pobj) after_9\IN|of|second|the (r_prep) report_4\NN|.|reported|,|This (l_prep) of_5\IN|after|second|the (l_pobj) anemia_8\NN|NONE
8441146
D010396_D000741 CID penicillamine_19\NN|and|one|in (r_conj) case_15\NN|NONE (r_pobj) in_13\IN|was|which|by (r_prep) caused_10\VBN|aplastic|severe (r_relcl) anemia_7\NN|to
D006046_D000741 CID gold_12\NN|NONE (r_pobj) by_11\IN|was|which|in (r_agent) caused_10\VBN|aplastic|severe (r_relcl) anemia_7\NN|to
8911359
D003520_D014523 NONE cyclophosphamide_13\NN|NONE (r_pobj) of_12\IN|,|treatment|the (r_prep) etiology_7\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) knowledge_4\NN|We|cancer|. (r_dobj) gained_3\VBD|: (l_dobj) cancer_16\NN|We|.|knowledge
D003520_D001749 CID Cyclophosphamide_0\NN|.|associated|bladder|disease| (r_nmod) cancer_3\NN|NONE
D003520_D001749 CID cyclophosphamide_17\NN|cancer (r_pobj) with_16\IN|The|of|age|medical (l_pobj) cancer_20\NN|cyclophosphamide
D003520_D001749 CID Cyclophosphamide_0\NN|bladder|associated (r_nmod) tumor_3\NN|.|disease
10193809
D011692_D011507 CID aminonucleoside_1\NN|NONE (r_amod) Puromycin_0\NNP|was|.|to|induce (r_nsubjpass) administered_6\VBN|NONE (l_advcl) induce_12\VB|was|.|to|Puromycin (l_dobj) proteinuria_13\NN|to
D011692_D011507 CID PAN_3\NNP|NONE (r_appos) aminonucleoside_1\NN|NONE (r_amod) Puromycin_0\NNP|was|.|to|induce (r_nsubjpass) administered_6\VBN|NONE (l_advcl) induce_12\VB|was|.|to|Puromycin (l_dobj) proteinuria_13\NN|to
3780814
D010634_D011230 NONE PB_22\NNP|was|when|for|simultaneously|with (r_nsubjpass) given_24\VBN|significantly|.|number|After|,|was (r_advcl) reduced_20\VBN|NONE (l_nsubjpass) number_8\NN|significantly|.|After|given|,|was (l_conj) size_11\NN|and|the (l_prep) of_12\IN|the (l_pcomp) induced_13\VBN|NONE (l_dobj) foci_17\NN|NONE
D010634_D063646 NONE phenobarbital_5\JJ|NONE (r_pobj) of_4\IN|carcinogenic|.|given (r_prep) action_3\NN|NONE (l_amod) carcinogenic_2\JJ|.|of|given
D010634_D063646 NONE phenobarbital_13\JJ|NONE (r_pobj) of_12\IN|on|the (r_prep) effect_11\NN|administered|to (l_prep) on_25\IN|of|the (l_pobj) carcinogenesis_26\NN|NONE
D010634_D063646 NONE PB_15\NNP|(|) (r_appos) phenobarbital_13\JJ|NONE (r_pobj) of_12\IN|on|the (r_prep) effect_11\NN|administered|to (l_prep) on_25\IN|of|the (l_pobj) carcinogenesis_26\NN|NONE
D010634_D063646 NONE PB_15\NNP|+ (r_conj) DEN_13\NNP|NONE (r_pobj) by_12\IN|or|DEN (r_conj) by_8\IN|rats|were|according|.|during (r_agent) treated_7\VBN|NONE (l_prep) according_23\VBG|rats|by|were|.|during (l_prep) to_24\IN|NONE (l_pobj) schedule_26\NN|NONE (l_prep) for_27\IN|our (l_pobj) hepatocarcinogenesis_28\NN|NONE
D010634_D063646 NONE PB_4\NNP|given|effect|that (l_relcl) promotes_7\VBZ|,|, (l_dobj) carcinogenesis_8\NN|which|administered
D004052_D011230 CID DEN_27\NNP|NONE (r_pobj) with_26\IN|PB|was|when|for|simultaneously (r_prep) given_24\VBN|significantly|.|number|After|,|was (r_advcl) reduced_20\VBN|NONE (l_nsubjpass) number_8\NN|significantly|.|After|given|,|was (l_conj) size_11\NN|and|the (l_prep) of_12\IN|the (l_pcomp) induced_13\VBN|NONE (l_dobj) foci_17\NN|NONE
D004052_D009369 NONE DEN_1\NNP|rats (r_nsubj) treated_4\VBN|survival|prolonged|In|,|decreased|and (r_ccomp) was_9\VBD|NONE (l_conj) decreased_15\VBD|survival|prolonged|treated|In|,|and (l_nsubj) incidence_14\NN|.|as (l_compound) tumor_13\NN|the
D004052_D009369 NONE DEN_23\NNP|NONE (r_pobj) by_22\IN|alone (r_agent) obtained_21\VBN|the (r_acl) results_20\NNS|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|NONE (r_prep) as_16\IN|incidence|. (r_prep) decreased_15\VBD|survival|prolonged|treated|In|,|and (l_nsubj) incidence_14\NN|.|as (l_compound) tumor_13\NN|the
D004052_D063646 NONE diethylnitrosamine_9\NN|NONE (r_pobj) with_8\IN|simultaneously (r_prep) given_6\VBN|carcinogenic|.|of (r_prep) action_3\NN|NONE (l_amod) carcinogenic_2\JJ|.|of|given
D004052_D063646 NONE diethylnitrosamine_33\JJ|NONE (r_pobj) with_32\IN|simultaneously|it|when|is (r_prep) administered_30\VBN|effect|to (r_advcl) elucidate_9\VB|NONE (l_dobj) effect_11\NN|administered|to (l_prep) on_25\IN|of|the (l_pobj) carcinogenesis_26\NN|NONE
D004052_D063646 NONE DEN_35\NNP|work|has|.|been|in (r_parataxis) planned_5\VBN|NONE (l_prep) in_6\IN|work|DEN|has|.|been (l_pobj) order_7\NN|NONE (l_acl) elucidate_9\VB|NONE (l_dobj) effect_11\NN|administered|to (l_prep) on_25\IN|of|the (l_pobj) carcinogenesis_26\NN|NONE
D004052_D063646 NONE DEN_9\NNP|by|or (r_pobj) by_8\IN|rats|were|according|.|during (r_agent) treated_7\VBN|NONE (l_prep) according_23\VBG|rats|by|were|.|during (l_prep) to_24\IN|NONE (l_pobj) schedule_26\NN|NONE (l_prep) for_27\IN|our (l_pobj) hepatocarcinogenesis_28\NN|NONE
D004052_D063646 NONE DEN_13\NNP|NONE (r_pobj) by_12\IN|or|DEN (r_conj) by_8\IN|rats|were|according|.|during (r_agent) treated_7\VBN|NONE (l_prep) according_23\VBG|rats|by|were|.|during (l_prep) to_24\IN|NONE (l_pobj) schedule_26\NN|NONE (l_prep) for_27\IN|our (l_pobj) hepatocarcinogenesis_28\NN|NONE
D004052_D063646 NONE DEN_13\NNP|the (r_compound) treatment_14\NN|NONE (r_pobj) after_11\IN|when (r_prep) administered_10\VBN|which|carcinogenesis (r_advcl) promotes_7\VBZ|,|, (l_dobj) carcinogenesis_8\NN|which|administered
D004052_D063646 NONE DEN_24\NNP|NONE (r_pobj) with_23\IN|simultaneously|when (r_prep) given_21\VBN|effect|that|PB (r_advcl) reduces_16\VBZ|is|It|. (l_nsubj) PB_4\NNP|given|effect|that (l_relcl) promotes_7\VBZ|,|, (l_dobj) carcinogenesis_8\NN|which|administered
D010634_D009369 NONE PB_3\NNP|+ (r_conj) DEN_1\NNP|rats (r_nsubj) treated_4\VBN|survival|prolonged|In|,|decreased|and (r_ccomp) was_9\VBD|NONE (l_conj) decreased_15\VBD|survival|prolonged|treated|In|,|and (l_nsubj) incidence_14\NN|.|as (l_compound) tumor_13\NN|the
20683499
C029036_D008569 NONE crocin_3\NNS|NONE (l_prep) in_4\IN|In|,|. (l_pobj) impairment_14\NN|NONE
C029036_D007859 NONE crocin_3\NNS|NONE (l_prep) in_4\IN|In|,|. (l_pobj) impairment_14\NN|NONE
D013311_D008569 NONE STZ_17\NNP| (r_npadvmod) injected_19\VBN|in|treated (r_amod) group_20\NN|NONE (r_pobj) in_15\IN|learning|attenuated|dose (r_prep) impairment_14\NN|NONE
D013311_D000544 CID streptozocin_11\NNS| (r_npadvmod) induced_13\VBN|of (r_amod) model_14\NN|NONE (l_prep) of_15\IN|induced (l_pobj) disease_19\NN|NONE
D013311_D000544 CID streptozocin_20\NNP|of|the (r_appos) effect_6\NN|was|In|,|. (l_prep) of_7\IN|the|streptozocin (l_pobj) crocins_8\NNS|NONE (l_prep) on_9\IN|NONE (l_pobj) disease_13\NN|NONE
D013311_D000544 CID STZ_22\NNP|icv|(|) (r_appos) streptozocin_20\NNP|of|the (r_appos) effect_6\NN|was|In|,|. (l_prep) of_7\IN|the|streptozocin (l_pobj) crocins_8\NNS|NONE (l_prep) on_9\IN|NONE (l_pobj) disease_13\NN|NONE
D013311_D000544 CID STZ_10\NNP| (r_compound) icv_12\NN|NONE (r_pobj) with_9\IN|bilaterally|in|)|rats|,|were|In (r_prep) injected_8\VBN|was|,|application|. (l_prep) In_0\IN|bilaterally|in|with|)|rats|,|were (l_pobj) groups_4\NNS|NONE (l_compound) disease_3\NN|Alzheimer
D013311_D000544 CID STZ_28\NNP| (r_compound) icv_30\NN|a|similar (r_compound) application_31\NN|was|,|.|injected (r_nsubjpass) repeated_33\VBN|NONE (l_ccomp) injected_8\VBN|was|,|application|. (l_prep) In_0\IN|bilaterally|in|with|)|rats|,|were (l_pobj) groups_4\NNS|NONE (l_compound) disease_3\NN|Alzheimer
D013311_D000544 CID STZ_20\NNP| (r_compound) icv_22\NN|NONE (r_pobj) by_19\IN|in (r_agent) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE (l_prep) as_35\IN|neurodegenerative (l_pobj) disease_38\NN|such
C029036_D000544 NONE crocin_9\NNS|,|sativus (l_prep) on_10\IN|NONE (l_pobj) model_14\NN|NONE (l_prep) of_15\IN|induced (l_pobj) disease_19\NN|NONE
C029036_D000544 NONE crocins_8\NNS|NONE (l_prep) on_9\IN|NONE (l_pobj) disease_13\NN|NONE
C029036_D000544 NONE crocin_8\NNS|NONE (r_pobj) of_7\IN|the|)|mg/kg|in|( (r_prep) effectiveness_6\NN|Therefore|,|results|. (l_prep) in_13\IN|the|)|mg/kg|of|( (l_pcomp) antagonizing_14\VBG|NONE (l_dobj) deficits_17\NNS|NONE (l_acl) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE (l_prep) as_35\IN|neurodegenerative (l_pobj) disease_38\NN|such
D013311_D019636 NONE STZ_20\NNP| (r_compound) icv_22\NN|NONE (r_pobj) by_19\IN|in (r_agent) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE
D013311_D003072 CID STZ_20\NNP| (r_compound) icv_22\NN|NONE (r_pobj) by_19\IN|in (r_agent) caused_18\VBN|the|cognitive (r_acl) deficits_17\NNS|NONE
C029036_D019636 NONE crocin_8\NNS|NONE (r_pobj) of_7\IN|the|)|mg/kg|in|( (r_prep) effectiveness_6\NN|Therefore|,|results|. (l_prep) in_13\IN|the|)|mg/kg|of|( (l_pcomp) antagonizing_14\VBG|NONE (l_dobj) deficits_17\NNS|NONE (l_acl) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE
D013311_D007859 NONE STZ_17\NNP| (r_npadvmod) injected_19\VBN|in|treated (r_amod) group_20\NN|NONE (r_pobj) in_15\IN|learning|attenuated|dose (r_prep) impairment_14\NN|NONE
C029036_D003072 NONE crocin_8\NNS|NONE (r_pobj) of_7\IN|the|)|mg/kg|in|( (r_prep) effectiveness_6\NN|Therefore|,|results|. (l_prep) in_13\IN|the|)|mg/kg|of|( (l_pcomp) antagonizing_14\VBG|NONE (l_dobj) deficits_17\NNS|NONE
19674115
D011718_D033461 NONE Pyrazinamide_0\NNP|effects|can|. (r_nsubj) have_2\VB|NONE (l_dobj) effects_4\NNS|can|.|Pyrazinamide (l_prep) as_6\IN|adverse (l_pobj) toxicity_8\NN|such (l_conj) disorders_13\NNS|hepatic|, (l_nmod) hyperuricemia_10\NN|NONE
D011718_D000857 CID pyrazinamide_4\NN|NONE (r_pobj) by_3\IN|dysosmia|. (r_agent) induced_2\VBN|NONE (l_nsubj) dysosmia_1\NN|by|.
D011718_D000857 CID pyrazinamide_10\VB|NONE (r_xcomp) related_8\VBN|reversible|olfactory (r_acl) disorder_7\NN|NONE
D011718_D000857 CID pyrazinamide_4\JJ|NONE (r_compound) withdrawal_5\NN|completely (r_pobj) after_3\IN|recurred|and|Dysosmia|. (r_prep) disappeared_1\VBD|NONE (l_nsubj) Dysosmia_0\NNP|recurred|and|after|.
D011718_D056486 NONE Pyrazinamide_0\NNP|effects|can|. (r_nsubj) have_2\VB|NONE (l_dobj) effects_4\NNS|can|.|Pyrazinamide (l_prep) as_6\IN|adverse (l_pobj) toxicity_8\NN|such
19944736
D018021_D012640 CID LiCl_4\NNP|NONE (r_pobj) in_3\IN|NONE (r_prep) administered_2\VBN|rats|,|, (r_acl) Tacrine_0\NNP|and|seizures|.|delayed (r_nsubj) induces_10\VBZ|NONE (l_dobj) seizures_12\NNS|and|.|Tacrine|delayed
D013619_D004827 NONE tacrine_5\NN| (r_npadvmod) loaded_7\VBN|NONE (r_amod) nanoparticles_8\NNS|NONE (r_pobj) with_4\IN|animals (r_prep) treated_3\VBN|.|outcome (r_csubj) showed_9\VBD|NONE (l_dobj) outcome_12\NN|treated|. (l_prep) of_13\IN|an|earlier|with (l_pobj) symptoms_16\NNS|NONE (l_appos) onset_20\NN|CNS|,|adverse|, (l_amod) epileptic_19\JJ|i.e.
D013619_D004827 NONE tacrine_22\NN| (r_compound) lithium_24\NN|the|in|of (r_compound) model_25\NN|NONE (l_prep) of_26\IN|the|in|lithium (l_pobj) epilepsy_27\NN|NONE
D008094_D004827 NONE lithium_24\NN|the|in|of (r_compound) model_25\NN|NONE (l_prep) of_26\IN|the|in|lithium (l_pobj) epilepsy_27\NN|NONE
D013619_D001930 CID Tacrine_0\NNP|and|seizures|.|delayed (r_nsubj) induces_10\VBZ|NONE (l_conj) delayed_14\VBD|and|seizures|.|Tacrine (l_dobj) damage_16\NN|NONE
D013619_D001930 CID tacrine_3\NN| (r_npadvmod) loaded_5\VBN|nanoparticles (r_amod) administration_7\NN|,|.|In|solution|damage|, (r_nsubj) induced_8\VBD|NONE (l_dobj) damage_9\NN|administration|,|.|In|solution|, (l_prep) of_10\IN|in (l_pobj) cells_12\NNS|NONE
D013619_D001930 CID tacrine_29\NN|NONE (r_pobj) of_28\IN|the|%|while|saline (r_prep) solution_27\NN|administration|,|.|In|damage|, (r_advcl) induced_8\VBD|NONE (l_dobj) damage_9\NN|administration|,|.|In|solution|, (l_prep) of_10\IN|in (l_pobj) cells_12\NNS|NONE
D018021_D001930 CID LiCl_4\NNP|NONE (r_pobj) in_3\IN|NONE (r_prep) administered_2\VBN|rats|,|, (r_acl) Tacrine_0\NNP|and|seizures|.|delayed (r_nsubj) induces_10\VBZ|NONE (l_conj) delayed_14\VBD|and|seizures|.|Tacrine (l_dobj) damage_16\NN|NONE
D013619_D012640 CID Tacrine_0\NNP|and|seizures|.|delayed (r_nsubj) induces_10\VBZ|NONE (l_dobj) seizures_12\NNS|and|.|Tacrine|delayed
1141447
D008094_D003919 CID lithium_7\NN| (r_npadvmod) induced_9\VBN|diabetes (r_amod) insipidus_11\NN|NONE
D008094_D003919 CID lithium_3\NN| (r_npadvmod) induced_5\VBN|diabetes (r_amod) insipidus_7\NN|NONE
8686832
D000431_D010146 NONE alcohol_27\NN|a|high|,|be (r_compound) intake_28\NN|NONE (r_pobj) to_24\IN|NONE (r_prep) admitted_23\VBD|NONE (r_acl) pain_22\NN|NONE (r_pobj) without_21\IN|seven|and (r_prep) pain_10\NN|NONE
D000431_D010146 NONE alcohol_27\NN|a|high|,|be (r_compound) intake_28\NN|NONE (r_pobj) to_24\IN|NONE (r_prep) admitted_23\VBD|NONE (r_acl) pain_22\NN|NONE
D008012_D001416 CID lignocaine_11\NN|NONE (r_dobj) involving_7\VBG|spinal (r_acl) anaesthesia_6\NN|NONE (r_pobj) after_4\IN|back (r_prep) pain_3\NN|.|and
D008012_D001416 CID lignocaine_14\NN|NONE (r_pobj) of_10\IN|intrathecal|the (r_prep) use_9\NN|NONE (r_pobj) with_6\IN|is|.|Leg (r_prep) associated_5\VBN|NONE (l_nsubjpass) Leg_0\NNP|is|with|. (l_conj) pain_3\NN|back|and/or
11185967
D000431_D019969 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|or|underlying (r_conj) drug_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) history_3\NN|,|,|Patient (r_appos) demographics_1\NNS|from|time|,|results|.|recorded (r_nsubj) estimated_14\VBN|NONE (l_prep) from_16\IN|demographics|time|,|results|.|recorded (l_prep) to_18\IN|seizure (l_pobj) collection_20\NN|NONE (l_conj) history_22\NN|,|sample (l_conj) suspicion_24\NN|or (l_prep) of_25\IN|NONE (l_pobj) cocaine_26\NN|NONE (l_conj) abuse_29\NN|or
D000431_D012640 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|or|underlying (l_compound) seizure_11\NN|related
D000431_D012640 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|or|underlying (r_conj) drug_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) history_3\NN|,|,|Patient (r_appos) demographics_1\NNS|from|time|,|results|.|recorded (r_nsubj) estimated_14\VBN|NONE (l_prep) from_16\IN|demographics|time|,|results|.|recorded (l_pobj) seizure_17\NN|to
D000431_D019970 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|or|underlying (r_conj) drug_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) history_3\NN|,|,|Patient (r_appos) demographics_1\NNS|from|time|,|results|.|recorded (r_nsubj) estimated_14\VBN|NONE (l_prep) from_16\IN|demographics|time|,|results|.|recorded (l_prep) to_18\IN|seizure (l_pobj) collection_20\NN|NONE (l_conj) history_22\NN|,|sample (l_conj) suspicion_24\NN|or (l_prep) of_25\IN|NONE (l_pobj) cocaine_26\NN|NONE (l_conj) abuse_29\NN|or
D003042_D012640 NONE cocaine_16\NN|NONE (l_prep) in_19\IN|or|amphetamine (l_pobj) patients_24\NNS|NONE (l_compound) seizure_23\NN|emergency
D003042_D012640 NONE cocaine_9\NN|NONE (l_prep) in_12\IN|and|amphetamines (l_pobj) patients_15\NNS|NONE (l_compound) seizure_14\NN|NONE
D000661_D012640 NONE amphetamine_18\NN|or|in (r_conj) cocaine_16\NN|NONE (l_prep) in_19\IN|or|amphetamine (l_pobj) patients_24\NNS|NONE (l_compound) seizure_23\NN|emergency
D000662_D012640 NONE amphetamines_11\NNS|and|in (r_conj) cocaine_9\NN|NONE (l_prep) in_12\IN|and|amphetamines (l_pobj) patients_15\NNS|NONE (l_compound) seizure_14\NN|NONE
9564988
D064704_D012852 NONE levofloxacin_5\NN|NONE (r_pobj) of_4\IN|label|for|. (r_prep) assessment_3\NN|NONE (l_prep) for_6\IN|of|label|. (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|in|the (l_pobj) sinusitis_12\NN|NONE
D064704_D012852 NONE levofloxacin_7\NN|NONE (r_pobj) of_6\IN|and|safety|the (r_prep) efficacy_3\NN|in|To|.|daily (r_dobj) evaluate_1\VB|NONE (l_prep) in_20\IN|To|efficacy|.|daily (l_pcomp) treating_21\VBG|NONE (l_prep) with_24\IN|outpatients (l_pobj) sinusitis_27\NN|NONE
D064704_D012852 NONE levofloxacin_7\VBZ|.|is|results (r_ccomp) indicate_5\VBP|NONE (l_ccomp) is_12\VBZ|levofloxacin|.|results (l_attr) treatment_17\NN|NONE (l_prep) for_18\IN|effective|an (l_pobj) sinusitis_21\NN|NONE
10565806
C076029_D001714 CID olanzapine_6\NN|NONE (r_pobj) by_5\IN|Hypomania|. (r_prep) induced_4\VBN|NONE (l_nsubj) Hypomania_0\NNP|by|.
C076029_D001714 CID olanzapine_28\JJ|NONE (r_compound) treatment_29\NN|NONE (r_pobj) of_27\IN|the (r_prep) introduction_26\NN|shortly (r_pobj) after_24\IN|who|hypomania (r_prep) developed_21\VBD|a|IV|specified|psychotic (l_dobj) hypomania_22\NN|who|after
C076029_D011618 NONE olanzapine_28\JJ|NONE (r_compound) treatment_29\NN|NONE (r_pobj) of_27\IN|the (r_prep) introduction_26\NN|shortly (r_pobj) after_24\IN|who|hypomania (r_prep) developed_21\VBD|a|IV|specified|psychotic (r_relcl) disorder_14\NN|NONE
9672273
D013629_D014652 CID tamoxifen_20\NN|NONE (r_pobj) on_19\IN|NONE (r_prep) women_18\NNS|NONE (r_pobj) among_17\IN|hypertriglyceridaemia|and|vascular (r_prep) events_14\NNS|NONE
D013629_D016889 NONE Tamoxifen_0\NNP|agent|,|associated|. (r_nsubj) is_1\VBZ|NONE (l_advcl) associated_15\VBN|agent|Tamoxifen|,|. (l_prep) with_16\IN|may|drug|although|be (l_pobj) development_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) cancer_21\NN|NONE
D013629_D001943 NONE tamoxifen_5\NN|NONE (r_pobj) with_4\IN|:|of|.|findings (r_prep) Prevention_0\NN|NONE (l_prep) of_1\IN|with|:|.|findings (l_pobj) cancer_3\NN|NONE
D013629_D001943 NONE Tamoxifen_0\NNP|agent|,|associated|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_5\NN|Tamoxifen|,|associated|. (l_prep) in_6\IN|a|chemopreventive|candidate (l_pobj) cancer_8\NN|NONE
D013629_D001943 NONE tamoxifen_18\NN|NONE (r_pobj) of_17\IN|blind|a|randomised|controlled|,|)|(|have|in|in (r_prep) trial_16\NN|,|.|we|In (l_relcl) have_29\VB|blind|a|randomised|controlled|,|)|(|in|of|in (l_dobj) cancer_31\NN|and|did|who|not|had
D013629_D001943 NONE tamoxifen_17\NN||(|) (r_nmod) arms_21\NNS|the|cases|(|)|and (r_conj) placebo_11\NN|NONE (r_pobj) between_9\IN|cancer (r_prep) frequency_8\NN|NONE (l_compound) cancer_7\NN|between
D013629_D001943 NONE tamoxifen_12\NN|NONE (r_dobj) receiving_11\VBG|used (r_acl) women_10\NNS|NONE (r_pobj) among_9\IN|among|of|:|a|significant (r_prep) reduction_5\NN|There (l_prep) of_6\IN|among|:|among|a|significant (l_pobj) cancer_8\NN|NONE
D013629_D001943 NONE tamoxifen_12\NN|NONE (r_dobj) receiving_11\VBG|used (r_acl) women_10\NNS|NONE (r_pobj) among_9\IN|among|of|:|a|significant (r_prep) reduction_5\NN|There (r_attr) is_1\VBZ|we|compared|.|cases|, (r_ccomp) found_36\VBD|NONE (l_dobj) cases_38\NNS|we|compared|is|.|, (l_prep) of_39\IN|eight (l_pobj) cancer_41\NN|NONE
D013629_D001943 NONE tamoxifen_51\NN|NONE (r_pobj) to_50\IN|NONE (r_prep) allocated_49\VBN| (r_acl) women_48\NNS|NONE (r_pobj) among_46\IN|one (r_prep) case_45\NN|NONE (r_pobj) with_43\IN|NONE (r_prep) compared_42\VBN|we|is|.|cases|, (r_prep) found_36\VBD|NONE (l_ccomp) is_1\VBZ|we|compared|.|cases|, (l_attr) reduction_5\NN|There (l_prep) of_6\IN|among|:|among|a|significant (l_pobj) cancer_8\NN|NONE
D013629_D001943 NONE tamoxifen_51\NN|NONE (r_pobj) to_50\IN|NONE (r_prep) allocated_49\VBN| (r_acl) women_48\NNS|NONE (r_pobj) among_46\IN|one (r_prep) case_45\NN|NONE (r_pobj) with_43\IN|NONE (r_prep) compared_42\VBN|we|is|.|cases|, (r_prep) found_36\VBD|NONE (l_dobj) cases_38\NNS|we|compared|is|.|, (l_prep) of_39\IN|eight (l_pobj) cancer_41\NN|NONE
D013629_D001943 NONE tamoxifen_29\NN|NONE (r_pobj) of_28\IN|postulated|the|protective (r_prep) effects_27\NNS|in|has|,|,|apparent|.|not (r_nsubj) are_30\VBP|NONE (l_prep) in_8\IN|effects|has|,|,|apparent|.|not (l_prep) at_13\IN|cohort (l_pobj) risk_19\NN|NONE (l_prep) of_20\IN|low (l_pobj) cancer_22\NN|NONE
D013629_D015228 CID tamoxifen_20\NN|NONE (r_pobj) on_19\IN|NONE (r_prep) women_18\NNS|NONE (r_pobj) among_17\IN|hypertriglyceridaemia|and|vascular (r_prep) events_14\NNS|NONE (l_conj) hypertriglyceridaemia_16\NN|and|vascular|among
11077455
D020888_D014786 CID vigabatrin_16\NN| (r_npadvmod) attributed_18\VBN|field (r_amod) constriction_21\NN|NONE
D020888_D014786 CID vigabatrin_9\NN|NONE (r_pobj) with_8\IN|to|be (r_prep) associated_7\VBN|constriction (r_xcomp) thought_4\NN|.|been|has (l_nsubj) constriction_3\NN|associated
D020888_D014786 CID vigabatrin_15\NN| (r_npadvmod) attributed_17\VBN|known|field (r_amod) loss_20\NN|NONE
D020888_D014786 CID vigabatrin_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) with_8\IN|to|be (r_prep) associated_7\VBN|.|constriction (r_xcomp) appears_4\VBZ|NONE (l_nsubj) constriction_3\NN|.|associated
1423339
D011433_D064420 NONE propranolol_4\JJ|NONE (r_amod) toxicity_5\NN|NONE
D011433_D064420 NONE propranolol_14\JJ|NONE (r_amod) toxicity_15\NN|NONE
D011433_D003704 NONE propranolol_14\JJ|NONE (r_amod) toxicity_15\NN|NONE (r_pobj) of_13\IN|a (r_prep) result_12\NN|NONE (r_pobj) as_10\IN|woman|dementia|. (r_prep) developed_3\VBD|NONE (l_dobj) dementia_9\NN|as|woman|.
D011433_D000647 CID propranolol_4\JJ|NONE (r_amod) toxicity_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Amnestic|.|report|: (r_acl) syndrome_1\NN|NONE
D011433_D000544 NONE propranolol_14\JJ|NONE (r_amod) toxicity_15\NN|NONE (r_pobj) of_13\IN|a (r_prep) result_12\NN|NONE (r_pobj) as_10\IN|woman|dementia|. (r_prep) developed_3\VBD|NONE (l_dobj) dementia_9\NN|as|woman|. (l_amod) like_7\JJ|subacute|an (l_npadvmod) Alzheimer_5\NNP|
7710775
D001241_D007511 NONE acetylsalicylate_4\VBP|NONE (l_prep) before_7\IN|other|.|,|of (l_pobj) ischemia_8\NN|intravenously|immediately
D008315_D007022 NONE malondialdehyde_23\NN|NONE (r_pobj) in_19\IN|higher|although (r_prep) was_24\VBD|.|of|/|during|,|intravenously (r_advcl) min_13\NN|NONE (l_prep) of_0\IN|.|/|during|,|intravenously|was (l_pobj) drug_3\NN|NONE (l_amod) hypotensive_2\JJ|the|nitroprusside
D009705_D002545 NONE nucleosides_9\NNS|dependence|.|and|, (l_prep) during_10\IN|NONE (l_pobj) ischemia_13\NN|NONE
-1_D007511 NONE oxypurines_10\NNS|NONE (r_pobj) of_8\IN|dependent|a (r_prep) increase_7\NN|was|.|,|During (r_nsubjpass) observed_14\VBN|NONE (l_prep) During_0\IN|was|.|increase|, (l_pobj) ischemia_1\NN|NONE
-1_D007511 NONE oxypurines_10\NNS|, (r_conj) malondialdehyde_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) determination_6\NN|,|that|may|monitor|be (r_nsubjpass) used_20\VBN|data|. (l_xcomp) monitor_22\VB|,|that|may|determination|be (l_dobj) alterations_25\NNS|to (l_acl) occurring_28\VBG|the|metabolic|of (l_prep) during_29\IN|NONE (l_pobj) phenomena_31\NNS|NONE (l_amod) ischemic_30\JJ|NONE
D008315_D007511 NONE malondialdehyde_1\NN|after|,|resulting|. (r_nsubj) increased_23\VBD|NONE (l_prep) after_24\IN|,|malondialdehyde|resulting|. (l_pobj) min_26\NN|NONE (l_prep) of_27\IN| (l_pobj) ischemia_28\NN|NONE
D008315_D007511 NONE malondialdehyde_23\NN|NONE (r_pobj) in_19\IN|higher|although (r_prep) was_24\VBD|.|of|/|during|,|intravenously (r_advcl) min_13\NN|NONE (l_prep) during_15\IN|.|of|/|,|intravenously|was (l_pobj) ischemia_16\NN|NONE
D008315_D007511 NONE malondialdehyde_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) determination_6\NN|,|that|may|monitor|be (r_nsubjpass) used_20\VBN|data|. (l_xcomp) monitor_22\VB|,|that|may|determination|be (l_dobj) alterations_25\NNS|to (l_acl) occurring_28\VBG|the|metabolic|of (l_prep) during_29\IN|NONE (l_pobj) phenomena_31\NNS|NONE (l_amod) ischemic_30\JJ|NONE
-1_D002545 NONE oxypurines_6\NNS|NONE (l_conj) nucleosides_9\NNS|dependence|.|and|, (l_prep) during_10\IN|NONE (l_pobj) ischemia_13\NN|NONE
D008315_D002545 CID malondialdehyde_4\NN|NONE (r_pobj) of_2\IN|Time (r_prep) dependence_1\NN|.|and|,|nucleosides (r_nsubj) oxypurines_6\NNS|NONE (l_conj) nucleosides_9\NNS|dependence|.|and|, (l_prep) during_10\IN|NONE (l_pobj) ischemia_13\NN|NONE
D009599_D007511 NONE nitroprusside_4\NN|the|hypotensive (r_acl) drug_3\NN|NONE (r_pobj) of_0\IN|.|/|during|,|intravenously|was (r_prep) min_13\NN|NONE (l_prep) during_15\IN|.|of|/|,|intravenously|was (l_pobj) ischemia_16\NN|NONE
D009705_D007511 NONE nucleosides_12\NNS|plasma|and (r_conj) oxypurines_10\NNS|NONE (r_pobj) of_8\IN|dependent|a (r_prep) increase_7\NN|was|.|,|During (r_nsubjpass) observed_14\VBN|NONE (l_prep) During_0\IN|was|.|increase|, (l_pobj) ischemia_1\NN|NONE
D009705_D007511 NONE nucleosides_13\NNS|and|, (r_conj) oxypurines_10\NNS|, (r_conj) malondialdehyde_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) determination_6\NN|,|that|may|monitor|be (r_nsubjpass) used_20\VBN|data|. (l_xcomp) monitor_22\VB|,|that|may|determination|be (l_dobj) alterations_25\NNS|to (l_acl) occurring_28\VBG|the|metabolic|of (l_prep) during_29\IN|NONE (l_pobj) phenomena_31\NNS|NONE (l_amod) ischemic_30\JJ|NONE
D009599_D007022 NONE nitroprusside_4\NN|the|hypotensive (r_acl) drug_3\NN|NONE (l_amod) hypotensive_2\JJ|the|nitroprusside
8888541
D012701_D011595 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|.|syndrome (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|.|stimulation (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|,
D012701_D011595 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|,
D014191_D003866 NONE tranylcypromine_22\NN|who|was (l_prep) for_23\IN|NONE (l_pobj) depression_24\NN|NONE
D012701_D012798 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|.|syndrome (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|.|stimulation (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle
D012701_D012798 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle
C047426_D020230 CID venlafaxine_3\NNP| (r_compound) tranylcypromine_5\NN|NONE (r_compound) interaction_6\NN|NONE (r_pobj) from_2\IN|.|Serotonin (r_prep) syndrome_1\NN|NONE
C047426_D020230 CID venlafaxine_3\NNP| (r_compound) MAOI_5\NNP|resulted|a (r_compound) interaction_6\NN|.|We (l_relcl) resulted_8\VBD|MAOI|a (l_prep) in_9\IN|in|that (l_pobj) syndrome_12\NN|NONE
D012701_D005334 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|.|syndrome (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|.|stimulation (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|, (l_conj) hyperthermia_26\NN|and
D012701_D005334 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|, (l_conj) hyperthermia_26\NN|and
D012701_D003221 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|.|syndrome (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|.|stimulation (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|,
D012701_D003221 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|,
D012701_D009127 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|.|syndrome (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|.|stimulation (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|,
D012701_D009127 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|,
C047426_D003866 NONE venlafaxine_3\NNP| (r_compound) MAOI_5\NNP|resulted|a (r_compound) interaction_6\NN|.|We (l_relcl) resulted_8\VBD|MAOI|a (l_prep) in_13\IN|in|that (l_pobj) male_18\NN|NONE (l_relcl) taking_21\VBG|a|old (l_dobj) tranylcypromine_22\NN|who|was (l_prep) for_23\IN|NONE (l_pobj) depression_24\NN|NONE
D003975_D009127 NONE diazepam_4\NN|NONE (r_pobj) of_3\IN|i.v.| (r_prep) mg_2\NN|NONE (r_pobj) After_0\IN|.|he|tremulous (r_prep) remained_7\VBD|NONE (l_acomp) tremulous_8\JJ|.|he|After (l_prep) with_9\IN|NONE (l_pobj) rigidity_11\NN|NONE
D014191_D020230 CID tranylcypromine_5\NN|NONE (r_compound) interaction_6\NN|NONE (r_pobj) from_2\IN|.|Serotonin (r_prep) syndrome_1\NN|NONE
D014191_D020230 CID tranylcypromine_22\NN|who|was (r_dobj) taking_21\VBG|a|old (r_relcl) male_18\NN|NONE (r_pobj) in_13\IN|in|that (r_prep) resulted_8\VBD|MAOI|a (l_prep) in_9\IN|in|that (l_pobj) syndrome_12\NN|NONE
7282516
D004317_D009202 CID doxorubicin_9\NN|NONE (r_compound) cardiomyopathy_10\NN|NONE
D004317_D009202 CID doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|)|DXR (l_amod) cardiomyopathy_1\NN|)|produced|(|The
D004317_D009202 CID doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|)|DXR
D004317_D009202 CID DXR_12\NN|)|CM (r_appos) doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|)|DXR (l_amod) cardiomyopathy_1\NN|)|produced|(|The
D004317_D009202 CID DXR_12\NN|)|CM (r_appos) doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|)|DXR
D004317_D009202 CID Adriamycin_1\NNP|opportunity|)|(|. (r_nsubj) provides_3\VBZ|NONE (l_dobj) opportunity_6\NN|)|Adriamycin|(|. (l_acl) analyze_8\VB|a|unique (l_dobj) relationships_16\NNS|to (l_prep) during_17\IN|effect (l_pobj) development_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) disease_21\NN|NONE
D004317_D009202 CID DXR_1\NNP| (r_compound) CM_3\NNP|myocardial
D004317_D009202 CID DXR_1\NNP| (r_compound) CM_3\NNP|myocardial (r_nmod) damage_5\NN|NONE
D004317_D009202 CID DXR_15\NNP|NONE (r_compound) dose_16\NN|)|(|cytotoxic (r_appos) insult_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) degree_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) proportional_7\JJ|.|preserved|In (r_acomp) is_6\VBZ|NONE (l_prep) In_0\IN|proportional|.|preserved (l_pobj) damage_5\NN|NONE (l_nmod) CM_3\NNP|myocardial
D004317_D009202 CID DXR_15\NNP|NONE (r_compound) dose_16\NN|)|(|cytotoxic (r_appos) insult_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) degree_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) proportional_7\JJ|.|preserved|In (r_acomp) is_6\VBZ|NONE (l_prep) In_0\IN|proportional|.|preserved (l_pobj) damage_5\NN|NONE
11838826
C047047_D011605 NONE cabergoline_55\NN|NONE (r_pobj) with_54\IN|were|)|.|dose|males (r_prep) treated_53\VBN|NONE (l_nsubjpass) males_1\NNS|were|)|.|with|dose (l_prep) with_9\IN|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN|NONE (l_conj) psychoses_24\NNS|edition|Diagnostic|or|bipolar
D018967_D001714 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|in (r_amod) elevations_30\NNS|NONE (r_pobj) with_26\IN|Four|mL|(|age|with|,|(|,|)|) (r_prep) males_1\NNS|were|)|.|with|dose (l_prep) with_9\IN|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN|NONE
D018967_D001523 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|in (r_amod) elevations_30\NNS|NONE (r_pobj) with_26\IN|Four|mL|(|age|with|,|(|,|)|) (r_prep) males_1\NNS|were|)|.|with|dose (l_prep) with_9\IN|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN|NONE (l_amod) Diagnostic_10\NNP|edition|or|psychoses|bipolar (l_conj) Manual_13\NNP|and (l_prep) of_14\IN|Statistical (l_pobj) Disorders_16\NNPS|NONE
C047047_D001714 NONE cabergoline_55\NN|NONE (r_pobj) with_54\IN|were|)|.|dose|males (r_prep) treated_53\VBN|NONE (l_nsubjpass) males_1\NNS|were|)|.|with|dose (l_prep) with_9\IN|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN|NONE
C047047_D006966 NONE cabergoline_11\NN|NONE (r_pobj) with_10\IN|induced (r_prep) hyperprolactinemia_9\NN|NONE
C047047_D006966 NONE cabergoline_16\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treated_14\VBN|induced (r_acl) hyperprolactinemia_13\NN|NONE
C047047_D006966 NONE Cabergoline_0\NNP|may|for|useful (r_nsubj) be_2\VB|,|however|is|;|.|research (l_prep) for_4\IN|may|Cabergoline|useful (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the|in (l_pobj) hyperprolactinemia_11\NN|NONE
D004298_D006966 NONE dopamine_8\NN|a|in (r_compound) agonist_9\NN|NONE (r_pobj) with_6\IN|induced (r_prep) hyperprolactinemia_5\NN|NONE
D018967_D006966 CID risperidone_2\NN| (r_npadvmod) induced_4\VBN|with (r_amod) hyperprolactinemia_5\NN|NONE
D018967_D006966 CID Risperidone_0\NNP|.|is|with (r_nsubjpass) associated_16\VBN|NONE (l_prep) with_17\IN|.|is|Risperidone (l_pobj) hyperprolactinemia_18\NN|NONE
D018967_D006966 CID risperidone_6\NN| (r_npadvmod) induced_8\VBN|with (r_amod) hyperprolactinemia_9\NN|NONE
D018967_D006966 CID risperidone_10\NN| (r_npadvmod) induced_12\VBN|treated (r_amod) hyperprolactinemia_13\NN|NONE
D018967_D006966 CID risperidone_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) hyperprolactinemia_11\NN|NONE
D018967_D011605 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|in (r_amod) elevations_30\NNS|NONE (r_pobj) with_26\IN|Four|mL|(|age|with|,|(|,|)|) (r_prep) males_1\NNS|were|)|.|with|dose (l_prep) with_9\IN|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN|NONE (l_conj) psychoses_24\NNS|edition|Diagnostic|or|bipolar
C047047_D001523 NONE cabergoline_55\NN|NONE (r_pobj) with_54\IN|were|)|.|dose|males (r_prep) treated_53\VBN|NONE (l_nsubjpass) males_1\NNS|were|)|.|with|dose (l_prep) with_9\IN|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN|NONE (l_amod) Diagnostic_10\NNP|edition|or|psychoses|bipolar (l_conj) Manual_13\NNP|and (l_prep) of_14\IN|Statistical (l_pobj) Disorders_16\NNPS|NONE
16192988
D008694_D001523 CID Methamphetamine_0\NN|.|alterations (r_nsubj) causes_1\VBZ|NONE (l_dobj) alterations_2\NNS|Methamphetamine|. (l_relcl) display_16\VBP|in (l_dobj) aggressiveness_18\NN|that
D008694_D001523 CID methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN|NONE (l_nsubjpass) behaviors_1\NNS|are|,|in|been|and|have|.
D008694_D001523 CID methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN|NONE (l_prep) in_5\IN|are|,|been|and|behaviors|have|. (l_pobj) patients_6\NNS|NONE (l_relcl) suffer_8\VBP|NONE (l_prep) from_9\IN|who (l_pobj) disorders_12\NNS|NONE
D008694_D001523 CID METH_20\NN|NONE (r_nmod) abusers_22\NNS|( (r_appos) methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN|NONE (l_nsubjpass) behaviors_1\NNS|are|,|in|been|and|have|.
D008694_D001523 CID METH_20\NN|NONE (r_nmod) abusers_22\NNS|( (r_appos) methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN|NONE (l_prep) in_5\IN|are|,|been|and|behaviors|have|. (l_pobj) patients_6\NNS|NONE (l_relcl) suffer_8\VBP|NONE (l_prep) from_9\IN|who (l_pobj) disorders_12\NNS|NONE
D008694_D001523 CID METH_13\NNP|NONE (r_pobj) of_12\IN|)|single|multiple|( (r_prep) injections_11\NNS|that|aggressiveness|significantly (r_nsubj) increased_15\VBD|we|Herein|,|. (l_dobj) aggressiveness_16\NN|that|injections|significantly
D008694_D001523 CID METH_8\NNP| (r_npadvmod) induced_10\VBN|NONE (r_amod) hyperactivity_11\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|.|increase|not (r_acomp) was_4\VBD|NONE (l_nsubj) increase_1\NN|secondary|.|not (l_prep) in_2\IN|This (l_pobj) aggressiveness_3\NN|NONE
D008694_D006948 NONE METH_8\NNP| (r_npadvmod) induced_10\VBN|NONE (r_amod) hyperactivity_11\NN|NONE
1732442
D004317_D009202 CID adriamycin_8\NNS| (r_npadvmod) induced_10\VBN|with (r_amod) cardiomyopathy_11\NN|NONE
D004317_D009202 CID adriamycin_5\NNS| (r_amod) induced_7\VBN|NONE (r_amod) cardiomyopathy_8\NN|NONE
D004317_D009202 CID adriamycin_5\NNS| (r_amod) induced_7\VBN|NONE (r_amod) cardiomyopathy_8\NN|NONE (r_pobj) of_4\IN|rat|a (r_prep) model_3\NN|NONE (r_dobj) Using_0\VBG|.|we|hypothesis|, (r_advcl) tested_11\VBD|NONE (l_dobj) hypothesis_13\NN|Using|.|we|, (l_acl) appear_21\VB|the (l_conj) exacerbated_24\VBN|activity|and|may|that (l_advmod) dependently_27\RB|be (l_prep) in_28\IN||dose (l_pobj) cardiomyopathy_30\NN|NONE
D004317_D009202 CID adriamycin_29\FW|NONE (r_amod) cardiomyopathy_30\NN|NONE (r_pobj) in_28\IN||dose (r_prep) dependently_27\RB|be (r_advmod) exacerbated_24\VBN|activity|and|may|that (r_conj) appear_21\VB|the (r_acl) hypothesis_13\NN|Using|.|we|, (r_dobj) tested_11\VBD|NONE (l_advcl) Using_0\VBG|.|we|hypothesis|, (l_dobj) model_3\NN|NONE (l_prep) of_4\IN|rat|a (l_pobj) cardiomyopathy_8\NN|NONE
D004317_D009202 CID adriamycin_29\FW|NONE (r_amod) cardiomyopathy_30\NN|NONE
D004317_D009202 CID adriamycin_34\NNS| (r_amod) induced_36\VBN|NONE (r_amod) cardiomyopathy_37\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) detection_32\NN|NONE (r_pobj) for_31\IN|a|useful (r_prep) method_30\NN|that|may|scintigraphy (r_attr) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|neuron|impaired|cardiac (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE
D004317_D009202 CID adriamycin_34\NNS| (r_amod) induced_36\VBN|NONE (r_amod) cardiomyopathy_37\NN|NONE
D004317_C536522 NONE adriamycin_16\JJ|NONE (r_amod) treatment_17\NN|NONE (r_pobj) of_15\IN|the (r_prep) duration_14\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) relation_11\NN|NONE (r_pobj) in_10\IN|mg/kg|was|degree|. (r_prep) analyzed_9\VBN|NONE (l_nsubjpass) degree_1\NN|mg/kg|was|in|. (l_prep) of_2\IN|The (l_pobj) degeneration_4\NN|NONE (l_prep) of_5\IN|vacuolar (l_pobj) cells_7\NNS|NONE
D004317_C536522 NONE adriamycin_34\NNS| (r_amod) induced_36\VBN|NONE (r_amod) cardiomyopathy_37\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) detection_32\NN|NONE (r_pobj) for_31\IN|a|useful (r_prep) method_30\NN|that|may|scintigraphy (r_attr) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|neuron|impaired|cardiac (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE (l_appos) degeneration_20\NN|myocardial|)|slight|(
D019797_C536522 NONE MIBG_24\NNP|NONE (r_compound) scintigraphy_25\NN|that|may|method (r_nsubj) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|neuron|impaired|cardiac (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE (l_appos) degeneration_20\NN|myocardial|)|slight|(
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_13\NNP|NONE (r_pcomp) with_12\IN|induced (r_prep) cardiomyopathy_11\NN|NONE
D019797_D009202 NONE MIBG_24\NNP|NONE (r_compound) scintigraphy_25\NN|that|may|method (r_nsubj) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|neuron|impaired|cardiac (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE
D019797_D009202 NONE MIBG_24\NNP|NONE (r_compound) scintigraphy_25\NN|that|may|method (r_nsubj) be_27\VB|appearance|. (l_attr) method_30\NN|that|may|scintigraphy (l_prep) for_31\IN|a|useful (l_pobj) detection_32\NN|NONE (l_prep) of_33\IN|NONE (l_pobj) cardiomyopathy_37\NN|NONE
11890511
33969
D011352_D001008 NONE procyclindine_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) during_16\IN|their (r_prep) condition_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) compared_12\VBN|increase|,|,|However|benztropine|and|treated (r_prep) had_5\VBD|NONE (l_conj) treated_28\VBN|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN|than|.|patients
D011352_D010302 NONE procyclidine_18\NN|NONE (r_pobj) as_17\IN|as (r_prep) efficacious_16\JJ|,|drug (r_acomp) were_14\VBD|were|Ethopropazine|.|be|and (r_conj) found_4\VBN|NONE (l_xcomp) be_6\VB|were|Ethopropazine|.|were|and (l_acomp) effective_8\JJ|to (l_prep) in_9\IN|equally (l_pcomp) controlling_10\VBG|NONE (l_dobj) symptoms_12\NNS|NONE
C084820_D003866 NONE ethopropazine_27\NN|NONE (r_pobj) than_26\IN|anxiety|.|patients (r_mark) treated_28\VBN|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN|than|.|patients (l_conj) depression_25\NN|and|more
C017610_D010302 CID enanthate_18\NN|NONE (r_amod) fluphenazine_17\JJ|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|to|in (r_advcl) benztropine_9\VB|.|In|was (l_prep) in_10\IN|induced|to (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) parkinsonism_14\NN|NONE
C084820_D004409 NONE ethopropazine_27\NN|NONE (r_pobj) than_26\IN|anxiety|.|patients (r_mark) treated_28\VBN|increase|,|,|However|benztropine|and|compared (r_conj) had_5\VBD|NONE (l_dobj) increase_8\NN|,|,|However|benztropine|and|treated|compared (l_prep) in_9\IN|a|significant (l_pobj) dyskinesia_11\JJ|NONE
C084820_D001008 NONE ethopropazine_27\NN|NONE (r_pobj) than_26\IN|anxiety|.|patients (r_mark) treated_28\VBN|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN|than|.|patients
D001590_D010302 NONE benztropine_2\NN|.|and (l_prep) in_3\IN|NONE (l_pobj) parkinsonism_7\NN|NONE
D001590_D010302 NONE benztropine_9\VB|.|In|was (l_prep) in_10\IN|induced|to (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) parkinsonism_14\NN|NONE
D001590_D010302 NONE benztropine_2\NN|and (r_conj) Ethopropazine_0\NN|were|.|were|be|and (r_nsubjpass) found_4\VBN|NONE (l_xcomp) be_6\VB|were|Ethopropazine|.|were|and (l_acomp) effective_8\JJ|to (l_prep) in_9\IN|equally (l_pcomp) controlling_10\VBG|NONE (l_dobj) symptoms_12\NNS|NONE
D001590_D010302 NONE benztropine_3\NN|,|that|not|because|drug (r_nsubj) is_4\VBZ|.|This (l_attr) drug_8\NN|benztropine|,|that|not|because (l_prep) in_11\IN|of|anticholinergic|the (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) symptoms_19\NNS|NONE
C084820_D012559 NONE ethopropazine_5\NN|NONE (r_pobj) In_0\IN|.|benztropine|was (r_prep) compared_7\VBN|NONE (l_xcomp) benztropine_9\VB|.|In|was (l_advcl) induced_15\VBN|to|in (l_agent) by_16\IN|NONE (l_pobj) fluphenazine_17\JJ|NONE (l_amod) enanthate_18\NN|NONE (l_prep) in_19\IN|NONE (l_pobj) outpatients_22\NNS|NONE (l_amod) schizophrenic_21\JJ|
D011352_D003866 NONE procyclindine_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) during_16\IN|their (r_prep) condition_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) compared_12\VBN|increase|,|,|However|benztropine|and|treated (r_prep) had_5\VBD|NONE (l_conj) treated_28\VBN|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN|than|.|patients (l_conj) depression_25\NN|and|more
D011352_D004409 NONE procyclindine_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) during_16\IN|their (r_prep) condition_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) compared_12\VBN|increase|,|,|However|benztropine|and|treated (r_prep) had_5\VBD|NONE (l_dobj) increase_8\NN|,|,|However|benztropine|and|treated|compared (l_prep) in_9\IN|a|significant (l_pobj) dyskinesia_11\JJ|NONE
C017610_D012559 NONE enanthate_18\NN|NONE (l_prep) in_19\IN|NONE (l_pobj) outpatients_22\NNS|NONE (l_amod) schizophrenic_21\JJ|
D001590_D004409 CID benztropine_2\NN|increase|,|,|However|and|treated|compared (r_nsubj) had_5\VBD|NONE (l_dobj) increase_8\NN|,|,|However|benztropine|and|treated|compared (l_prep) in_9\IN|a|significant (l_pobj) dyskinesia_11\JJ|NONE
C084820_D010302 NONE Ethopropazine_0\NN|NONE (l_conj) benztropine_2\NN|.|and (l_prep) in_3\IN|NONE (l_pobj) parkinsonism_7\NN|NONE
C084820_D010302 NONE ethopropazine_5\NN|NONE (r_pobj) In_0\IN|.|benztropine|was (r_prep) compared_7\VBN|NONE (l_xcomp) benztropine_9\VB|.|In|was (l_prep) in_10\IN|induced|to (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) parkinsonism_14\NN|NONE
C084820_D010302 NONE Ethopropazine_0\NN|were|.|were|be|and (r_nsubjpass) found_4\VBN|NONE (l_xcomp) be_6\VB|were|Ethopropazine|.|were|and (l_acomp) effective_8\JJ|to (l_prep) in_9\IN|equally (l_pcomp) controlling_10\VBG|NONE (l_dobj) symptoms_12\NNS|NONE
D001590_D001008 CID benztropine_2\NN|increase|,|,|However|and|treated|compared (r_nsubj) had_5\VBD|NONE (l_conj) treated_28\VBN|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN|than|.|patients
D001590_D012559 NONE benztropine_9\VB|.|In|was (l_advcl) induced_15\VBN|to|in (l_agent) by_16\IN|NONE (l_pobj) fluphenazine_17\JJ|NONE (l_amod) enanthate_18\NN|NONE (l_prep) in_19\IN|NONE (l_pobj) outpatients_22\NNS|NONE (l_amod) schizophrenic_21\JJ|
D001590_D003866 CID benztropine_2\NN|increase|,|,|However|and|treated|compared (r_nsubj) had_5\VBD|NONE (l_conj) treated_28\VBN|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN|than|.|patients (l_conj) depression_25\NN|and|more
591536
D006493_D001791 NONE heparin_8\VBN| (r_npadvmod) induced_10\VBN|platelet (r_amod) aggregation_12\NN|factor|.
D006493_D013921 CID heparin_6\JJ|systemic (r_compound) therapy_7\NN|NONE (r_dobj) receiving_4\VBG|NONE (r_acl) patients_3\NNS|NONE (r_pobj) in_2\IN|Arterial|:|complication|. (r_prep) thromboembolism_1\NN|NONE (l_appos) complication_10\NN|Arterial|:|in|. (l_acl) associated_11\VBN|a (l_prep) with_12\IN|NONE (l_pobj) thrombocytopenia_16\NN|NONE
D006493_D013921 CID heparin_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) thrombocytopenia_16\NN|NONE
D006493_D013921 CID heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|arterial|, (r_prep) occlusion_6\NN|.|Characteristic (l_acl) preceded_27\VBN|by|arterial|, (l_agent) by_28\IN|NONE (l_pobj) thrombocytopenia_30\NN|NONE
D006493_D013921 CID heparin_8\VBN| (r_npadvmod) induced_10\VBN|platelet (r_amod) aggregation_12\NN|factor|. (r_attr) is_7\VBZ|NONE (l_nsubj) factor_2\NN|aggregation|. (l_acl) relating_3\VBG|common|The (l_dobj) thromboembolism_4\NN|NONE (l_conj) thrombocytopenia_6\NN|and
D006493_D001157 CID heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|arterial|, (r_prep) occlusion_6\NN|.|Characteristic
D006493_D013923 NONE heparin_6\JJ|systemic (r_compound) therapy_7\NN|NONE (r_dobj) receiving_4\VBG|NONE (r_acl) patients_3\NNS|NONE (r_pobj) in_2\IN|Arterial|:|complication|. (r_prep) thromboembolism_1\NN|NONE
D006493_D013923 NONE heparin_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) thrombocytopenia_16\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|a (r_acl) complication_10\NN|Arterial|:|in|. (r_appos) thromboembolism_1\NN|NONE
D006493_D013923 NONE heparin_8\JJ|systemic (r_compound) therapy_9\NN|NONE (r_pobj) of_6\IN|recognized|a (r_prep) complication_5\NN|.|thromboembolism (r_attr) is_2\VBZ|NONE (l_nsubj) thromboembolism_1\NN|complication|.
D006493_D013923 NONE heparin_8\VBN| (r_npadvmod) induced_10\VBN|platelet (r_amod) aggregation_12\NN|factor|. (r_attr) is_7\VBZ|NONE (l_nsubj) factor_2\NN|aggregation|. (l_acl) relating_3\VBG|common|The (l_dobj) thromboembolism_4\NN|NONE
D006493_D013927 NONE heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|arterial|, (l_pobj) thrombi_11\NN|occurring
D006493_D007511 NONE heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|arterial|, (l_pobj) thrombi_11\NN|occurring (l_prep) with_12\IN|fibrin (l_pobj) ischemia_14\NN|NONE
133615
D003276_D013923 NONE contraceptive_6\NN|oral (r_amod) therapy_7\NN|NONE (r_pobj) of_4\IN|Thromboembolic|in|report|.|: (r_prep) complications_3\NNS|NONE (l_amod) Thromboembolic_0\JJ|of|in|report|.|:
D003276_D001778 CID contraceptive_6\NN|oral (r_amod) therapy_7\NN|NONE (r_pobj) of_4\IN|Thromboembolic|in|report|.|: (r_prep) complications_3\NNS|NONE (l_prep) in_8\IN|of|Thromboembolic|report|.|: (l_pobj) relationship_9\NN|NONE (l_prep) to_10\IN|NONE (l_pobj) levels_12\NNS|NONE (l_prep) of_13\IN|pretreatment (l_pobj) factors_16\NNS|NONE (l_compound) coagulation_15\NN|NONE
19944333
C471405_D003329 CID Sorafenib_0\NNP||infarction|.|due (r_npadvmod) induced_2\VBN|NONE (l_prep) due_6\IN||Sorafenib|infarction|. (l_pobj) spasm_10\NN|to
C471405_D003329 CID sorafenib_6\NN| (r_npadvmod) induced_8\VBN|coronary|artery (r_amod) spasm_11\NN|NONE
D020108_D060050 NONE nicorandil_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|and|maintained|.|symptoms (r_nsubj) reduced_4\VBD|NONE (l_conj) maintained_8\VBD|and|Addition|.|symptoms (l_dobj) status_11\NN|NONE (l_compound) angina_10\NN|NONE
C471405_D009203 NONE Sorafenib_0\NNP||infarction|.|due (r_npadvmod) induced_2\VBN|NONE (l_dobj) infarction_5\NN||Sorafenib|.|due
16174948
D003042_D013345 CID cocaine_6\NN| (r_npadvmod) associated_8\VBN|subarachnoid (r_amod) hemorrhage_10\NN|NONE
D003042_D013345 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|subarachnoid|SAH|underwent (r_amod) hemorrhage_16\NN|NONE
D003042_D013345 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|subarachnoid|SAH|underwent (r_amod) hemorrhage_16\NN|NONE (l_appos) SAH_18\NNP|subarachnoid|underwent|associated
D003042_D013345 CID cocaine_25\NN|NONE (r_compound) use_26\NN|shortly (r_pobj) after_24\IN|angiography|who (r_prep) underwent_21\VBD|subarachnoid|SAH|associated (r_relcl) hemorrhage_16\NN|NONE
D003042_D013345 CID cocaine_25\NN|NONE (r_compound) use_26\NN|shortly (r_pobj) after_24\IN|angiography|who (r_prep) underwent_21\VBD|subarachnoid|SAH|associated (r_relcl) hemorrhage_16\NN|NONE (l_appos) SAH_18\NNP|subarachnoid|underwent|associated
D003042_D013345 CID cocaine_14\NN|NONE (r_pobj) for_13\IN|urine|positive (r_prep) toxicology_12\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) those_8\DT|NONE (r_dobj) identified_7\VBD|retrospectively|and|.|patients|We (r_conj) screened_1\VBD|NONE (l_dobj) patients_2\NNS|retrospectively|and|.|We|identified (l_prep) with_3\IN|NONE (l_pobj) SAH_4\NNP|NONE
D003042_D013345 CID cocaine_31\NN|NONE (r_compound) use_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) associated_29\VBN|aneurysmal (r_acl) SAH_28\NNP|NONE
D003042_D014657 NONE Cocaine_0\NN|NONE (r_compound) use_1\NN|.|has|with|been (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|.|has|use|been (l_pobj) complications_7\NNS|NONE (l_prep) including_9\VBG|,|neurovascular (l_pobj) vasoconstriction_11\NN|NONE (l_conj) vasculitis_13\NN|arterial|and
D003042_D014657 NONE cocaine_31\NN|NONE (r_compound) use_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) associated_29\VBN|aneurysmal (r_acl) SAH_28\NNP|NONE (r_pobj) after_26\IN|who|angiography (r_prep) underwent_24\VBD|NONE (r_relcl) patients_22\NNS|NONE (r_pobj) in_21\IN|be|.|evidence|could (r_prep) found_20\VBN|NONE (l_nsubjpass) evidence_2\NN|be|.|in|could (l_prep) for_3\IN|quantitative|No (l_pobj) narrowing_4\VBG|NONE (l_prep) of_5\IN|NONE (l_pobj) arteries_8\NNS|NONE (l_conj) evidence_12\NN|large|cerebral|or (l_prep) for_13\IN|angiographic|qualitative (l_pobj) narrowing_15\NN|NONE (l_conj) vasculitis_17\NN|distal|or
D003042_D017542 CID cocaine_31\NN|NONE (r_compound) use_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) associated_29\VBN|aneurysmal (r_acl) SAH_28\NNP|NONE (l_amod) aneurysmal_27\NN|associated
D003042_D013901 NONE Cocaine_0\NN|NONE (r_compound) use_1\NN|.|has|with|been (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|.|has|use|been (l_pobj) complications_7\NNS|NONE
8267029
D010396_D001172 NONE Penicillamine_0\NN|.||glomerulonephritis|in (r_nsubj) induced_2\VBN|NONE (l_prep) in_6\IN|.||glomerulonephritis|Penicillamine (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|a (l_pobj) arthritis_11\NN|NONE
D010396_D001172 NONE penicillamine_21\NN|)|(|day (r_nmod) treatment_28\NN|NONE (r_pobj) of_18\IN| (r_prep) months_17\NNS|NONE (r_pobj) after_15\IN|woman|glomerulonephritis|. (r_prep) presented_8\VBD|NONE (l_nsubj) woman_4\NN|after|glomerulonephritis|. (l_prep) with_5\IN|A|old (l_pobj) arthritis_7\NN|NONE
D010396_D005921 CID Penicillamine_0\NN|.||glomerulonephritis|in (r_nsubj) induced_2\VBN|NONE (l_dobj) glomerulonephritis_5\NN|.||in|Penicillamine
D010396_D005921 CID penicillamine_21\NN|)|(|day (r_nmod) treatment_28\NN|NONE (r_pobj) of_18\IN| (r_prep) months_17\NNS|NONE (r_pobj) after_15\IN|woman|glomerulonephritis|. (r_prep) presented_8\VBD|NONE (l_dobj) glomerulonephritis_11\NN|woman|after|.
D010396_D005921 CID penicillamine_21\NN|)|(|day (r_nmod) treatment_28\NN|NONE (r_pobj) of_18\IN| (r_prep) months_17\NNS|NONE (r_pobj) after_15\IN|woman|glomerulonephritis|. (r_prep) presented_8\VBD|NONE (l_dobj) glomerulonephritis_11\NN|woman|after|. (l_appos) RPGN_13\NNP|progressive
D010396_D005921 CID penicillamine_11\NN|NONE (r_compound) treatment_12\NN|NONE (r_pobj) of_8\IN|the (r_prep) course_7\NN|NONE (r_pobj) in_5\IN|new|of|This (r_prep) case_2\NN|need|. (l_prep) of_3\IN|in|new|This (l_pobj) RPGN_4\NNP|NONE
D010396_D011507 NONE penicillamine_11\NN|NONE (r_compound) treatment_12\NN|NONE (r_pobj) of_8\IN|the (r_prep) course_7\NN|NONE (r_pobj) in_5\IN|new|of|This (r_prep) case_2\NN|need|. (r_nsubj) emphasizes_13\VBZ|NONE (l_dobj) need_15\NN|case|. (l_prep) for_16\IN|the (l_pobj) monitoring_18\NN|NONE (l_prep) of_19\IN|frequent (l_pobj) function_21\NN|NONE (l_conj) evaluation_23\NN|and|renal (l_prep) of_24\IN|NONE (l_pobj) sediment_26\NN|NONE (l_conj) proteinuria_28\NN|urinary|in|and
2435991
D004837_D001145 CID adrenaline_10\RB| (r_npadvmod) induced_12\VBN|and|, (r_conj) digitalis-_7\NN|coronary|stage|, (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE
D004837_D001145 CID adrenaline_10\RB| (r_npadvmod) induced_12\VBN|and|, (r_conj) digitalis-_7\NN|coronary|stage|, (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE (r_dobj) Using_0\VBG|were|determined|effects|and|, (r_advcl) examined_22\VBN|NONE (l_conj) determined_34\VBN|were|effects|and|Using|, (l_nsubjpass) concentration_28\NN|.|was (l_prep) for_29\IN|effective|minimum|the|plasma (l_pobj) model_32\NN|NONE (l_compound) arrhythmia_31\NN|each
D004837_D001145 CID adrenaline_27\NN|and|, (r_conj) digitalis_24\NN|,|h|coronary (r_conj) ligation_22\NN|h|coronary|, (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|.|Cibenzoline|were|arrhythmias|,|and (r_conj) suppressed_1\VBD|NONE (l_dobj) arrhythmias_4\NNS|.|Cibenzoline|induced|were|,|and
D004837_D001145 CID adrenaline_27\NN|and|, (r_conj) digitalis_24\NN|,|h|coronary (r_conj) ligation_22\NN|h|coronary|, (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|.|Cibenzoline|were|arrhythmias|,|and (l_nsubj) concentrations_11\NNS|by (l_prep) for_12\IN|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS|NONE
D004837_D001145 CID adrenaline_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) arrhythmia_6\NN|NONE
D004837_D001145 CID adrenaline_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) arrhythmia_6\NN|NONE (r_pobj) for_2\IN|The (r_prep) concentration_1\NN|higher|. (r_nsubj) was_7\VBD|NONE (l_acomp) higher_9\JJR|concentration|. (l_prep) than_10\IN|significantly (l_pobj) those_11\DT|NONE (l_prep) for_12\IN|NONE (l_pobj) types_15\NNS|NONE (l_prep) of_16\IN|other|the (l_pobj) arrhythmias_17\NNS|NONE
C032151_D007022 NONE cibenzoline_1\NN|effects|found|Because|given|and (r_nsubj) had_2\VBD|.|,|usefulness|is (l_dobj) effects_10\NNS|found|cibenzoline|Because|given|and (l_nmod) node_8\NN|depressive (l_amod) hypotensive_5\JJ|weak|only
D004071_D001145 CID digitalis-_7\NN|coronary|stage|, (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE
D004071_D001145 CID digitalis-_7\NN|coronary|stage|, (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE (r_dobj) Using_0\VBG|were|determined|effects|and|, (r_advcl) examined_22\VBN|NONE (l_conj) determined_34\VBN|were|effects|and|Using|, (l_nsubjpass) concentration_28\NN|.|was (l_prep) for_29\IN|effective|minimum|the|plasma (l_pobj) model_32\NN|NONE (l_compound) arrhythmia_31\NN|each
D004071_D001145 CID digitalis_24\NN|,|h|coronary (r_conj) ligation_22\NN|h|coronary|, (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|.|Cibenzoline|were|arrhythmias|,|and (r_conj) suppressed_1\VBD|NONE (l_dobj) arrhythmias_4\NNS|.|Cibenzoline|induced|were|,|and
D004071_D001145 CID digitalis_24\NN|,|h|coronary (r_conj) ligation_22\NN|h|coronary|, (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|.|Cibenzoline|were|arrhythmias|,|and (l_nsubj) concentrations_11\NNS|by (l_prep) for_12\IN|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS|NONE
C032151_D003866 NONE cibenzoline_1\NN|effects|found|Because|given|and (r_nsubj) had_2\VBD|.|,|usefulness|is (l_dobj) effects_10\NNS|found|cibenzoline|Because|given|and (l_amod) depressive_9\JJ|node
C032151_D001145 NONE cibenzoline_4\NN|NONE (r_pobj) of_3\IN|Antiarrhythmic|plasma|on|. (r_prep) concentrations_2\NNS|NONE (l_prep) on_5\IN|Antiarrhythmic|plasma|of|. (l_pobj) arrhythmias_8\NNS|NONE
C032151_D001145 NONE cibenzoline_20\NN|NONE (r_pobj) of_19\IN|antiarrhythmic (r_prep) effects_18\NNS|were|determined|and|Using|, (r_nsubjpass) examined_22\VBN|NONE (l_advcl) Using_0\VBG|were|determined|effects|and|, (l_dobj) arrhythmias_15\NNS|NONE
C032151_D001145 NONE cibenzoline_20\NN|NONE (r_pobj) of_19\IN|antiarrhythmic (r_prep) effects_18\NNS|were|determined|and|Using|, (r_nsubjpass) examined_22\VBN|NONE (l_conj) determined_34\VBN|were|effects|and|Using|, (l_nsubjpass) concentration_28\NN|.|was (l_prep) for_29\IN|effective|minimum|the|plasma (l_pobj) model_32\NN|NONE (l_compound) arrhythmia_31\NN|each
C032151_D001145 NONE Cibenzoline_0\NNP|.|induced|were|arrhythmias|,|and (r_nsubj) suppressed_1\VBD|NONE (l_dobj) arrhythmias_4\NNS|.|Cibenzoline|induced|were|,|and
C032151_D001145 NONE Cibenzoline_0\NNP|.|induced|were|arrhythmias|,|and (r_nsubj) suppressed_1\VBD|NONE (l_conj) induced_14\VBN|.|Cibenzoline|were|arrhythmias|,|and (l_nsubj) concentrations_11\NNS|by (l_prep) for_12\IN|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS|NONE
C032151_D001145 NONE cibenzoline_1\NN|effects|found|Because|given|and (r_nsubj) had_2\VBD|.|,|usefulness|is (l_advcl) given_19\VBN|effects|found|cibenzoline|Because|and (l_prep) to_20\IN|when (l_pobj) dogs_24\NNS|NONE (l_compound) arrhythmia_23\NN|coronary
7102237
D012601_D001049 NONE scopolamine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) premedicated_2\VBN|NONE (r_acl) patients_1\NNS|NONE (r_pobj) In_0\IN|,|,|occurred|effect|)|.|found|,|slower|but|mg/kg (r_prep) was_28\VBD|NONE (l_advcl) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
D009567_D001049 NONE nitrazepam_11\NN|evening| (r_amod) mg_10\IN|(|+|+|morphine (r_conj) scopolamine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) premedicated_2\VBN|NONE (r_acl) patients_1\NNS|NONE (r_pobj) In_0\IN|,|,|occurred|effect|)|.|found|,|slower|but|mg/kg (r_prep) was_28\VBD|NONE (l_advcl) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
D009020_D001049 NONE morphine_6\NN|mg|(|+|+ (r_conj) scopolamine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) premedicated_2\VBN|NONE (r_acl) patients_1\NNS|NONE (r_pobj) In_0\IN|,|,|occurred|effect|)|.|found|,|slower|but|mg/kg (r_prep) was_28\VBD|NONE (l_advcl) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
D008874_D001049 CID midazolam_24\JJ|NONE (r_pobj) of_23\IN|the|inducing (r_prep) effect_22\NN|,|,|occurred|)|.|found|,|In|slower|but|mg/kg (r_nsubj) was_28\VBD|NONE (l_advcl) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
D008874_D001049 CID midazolam_50\JJ|the (r_amod) group_51\NN|NONE (r_pobj) in_48\IN|sequelae|were (r_prep) found_47\VBN|,|,|occurred|effect|)|.|,|In|slower|but|mg/kg (r_conj) was_28\VBD|NONE (l_advcl) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
D008874_D001049 CID midazolam_62\JJ|lasted|the (r_amod) group_63\NN|NONE (r_pobj) in_60\IN|apnoea|often|although (r_prep) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
D013874_D001049 CID thiopentone_36\NN|NONE (r_pobj) of_35\IN|NONE (r_prep) that_34\DT|NONE (r_pobj) than_33\IN|NONE (r_prep) onset_32\NN|NONE (r_pobj) in_31\IN|clearly (r_prep) slower_30\JJR|,|,|occurred|effect|)|.|found|,|In|but|mg/kg (r_acomp) was_28\VBD|NONE (l_advcl) occurred_57\VBD|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN|often|in|although
2051906
D001379_D017285 NONE azathioprine_30\NN|NONE (r_amod) therapy_31\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) initiation_28\NN|months (r_pobj) after_27\IN|.|patient|features (r_prep) developed_17\VBD|NONE (l_nsubj) patient_4\NN|.|after|features (l_prep) with_6\IN|,|A|old (l_pobj) polymyositis_8\NN|without|and
D001379_D002779 CID azathioprine_7\JJ|NONE (r_amod) therapy_8\NN|NONE (r_pobj) following_6\VBG|Reversible|with|. (r_prep) cholestasis_1\NN|NONE
D001379_D002779 CID azathioprine_7\JJ|NONE (r_amod) therapy_8\NN|NONE (r_pobj) following_6\VBG|Reversible|with|. (r_prep) cholestasis_1\NN|NONE (l_prep) with_2\IN|Reversible|following|. (l_pobj) injury_5\NN|NONE
D001379_D002779 CID azathioprine_30\NN|NONE (r_amod) therapy_31\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) initiation_28\NN|months (r_pobj) after_27\IN|.|patient|features (r_prep) developed_17\VBD|NONE (l_dobj) features_21\NNS|.|after|patient (l_prep) of_22\IN|clinical (l_pobj) cholestasis_24\NN|NONE
D001379_D002779 CID azathioprine_12\RB| (r_advmod) induced_14\VBN|associated|reversible (r_amod) cholestasis_15\NN|NONE
D001379_D002779 CID azathioprine_12\RB| (r_advmod) induced_14\VBN|associated|reversible (r_amod) cholestasis_15\NN|NONE (l_acl) associated_16\VBN|reversible|induced (l_prep) with_17\IN|NONE (l_pobj) evidence_19\NN|NONE (l_prep) of_20\IN|histological (l_pobj) injury_23\NN|NONE
D001379_D008107 NONE azathioprine_30\NN|NONE (r_amod) therapy_31\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) initiation_28\NN|months (r_pobj) after_27\IN|.|patient|features (r_prep) developed_17\VBD|NONE (l_nsubj) patient_4\NN|.|after|features (l_prep) with_6\IN|,|A|old (l_conj) without_10\IN|and|polymyositis (l_pobj) evidence_12\NN|NONE (l_prep) of_13\IN|previous (l_pobj) disease_15\NN|NONE
803783
D010121_D001247 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|.|carried|is (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|.|administration|is (l_conj) instructed_33\VBD|,|out|can|be|if|only|and|aware|under|it (l_xcomp) watch_35\VB|NONE (l_conj) report_39\VB|and|diuresis|to (l_dobj) signs_42\NNS|NONE (l_prep) as_46\IN|such|of|early (l_pobj) asthenia_47\NNP|NONE
D010121_D001523 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|.|carried|is (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|.|administration|is (l_conj) instructed_33\VBD|,|out|can|be|if|only|and|aware|under|it (l_xcomp) watch_35\VB|NONE (l_conj) report_39\VB|and|diuresis|to (l_dobj) signs_42\NNS|NONE (l_prep) as_46\IN|such|of|early (l_pobj) asthenia_47\NNP|NONE (l_conj) irritability_50\NN|,
D010121_D000031 NONE oxytocin_4\NN|NONE (r_compound) administration_5\NN|NONE (r_pobj) with_3\IN|during (r_prep) associated_2\VBN|Water|. (l_prep) during_6\IN|with (l_pobj) abortion_10\NN|NONE
D010121_D000031 NONE oxytocin_8\NN|NONE (r_compound) administration_9\NN|NONE (r_pobj) with_7\IN|during (r_prep) connection_6\NN|NONE (l_prep) during_10\IN|with (l_pobj) abortions_14\NNS|NONE
D010121_D000031 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|.|carried|is (l_prep) during_2\IN|Oxytocin (l_pobj) abortions_6\NNS|NONE
D010121_D014869 CID oxytocin_4\NN|NONE (r_compound) administration_5\NN|NONE (r_pobj) with_3\IN|during (r_prep) associated_2\VBN|Water|. (r_acl) intoxication_1\NN|NONE
D010121_D014869 CID oxytocin_8\NN|NONE (r_compound) administration_9\NN|NONE (r_pobj) with_7\IN|during (r_prep) connection_6\NN|NONE (r_pobj) in_5\IN|water (r_prep) intoxication_4\NN|NONE
D010121_D014869 CID Oxytocin_0\NN|during (r_compound) administration_1\NN|.|carried|is (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|.|administration|is (l_advcl) aware_25\JJ|,|out|can|instructed|be|if|only|and|under|it (l_prep) of_26\IN|NONE (l_pobj) symptoms_28\NNS|NONE (l_prep) of_29\IN|the (l_pobj) intoxication_31\NN|NONE
D010121_D006261 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|.|carried|is (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|.|administration|is (l_conj) instructed_33\VBD|,|out|can|be|if|only|and|aware|under|it (l_xcomp) watch_35\VB|NONE (l_conj) report_39\VB|and|diuresis|to (l_dobj) signs_42\NNS|NONE (l_prep) as_46\IN|such|of|early (l_pobj) asthenia_47\NNP|NONE (l_conj) irritability_50\NN|, (l_conj) headaches_53\NNS|,|or|muscular
3001299
D008094_D007037 CID lithium_22\NN|NONE (r_compound) treatment_23\NN|NONE (r_pobj) during_21\IN|of|the (r_prep) development_13\NN|NONE (l_prep) of_14\IN|the|during (l_pobj) insipidus_18\NN|NONE (l_conj) hypothyroidism_20\NN|nephrogenic|and|both|diabetes
D008094_D007037 CID lithium_9\NN|they|were|while (r_dobj) taking_8\VBG|in|Hypothyroidism|. (r_advcl) developed_1\VBD|NONE (l_nsubj) Hypothyroidism_0\NN|in|taking|.
D008094_D018500 NONE lithium_22\NN|NONE (r_compound) treatment_23\NN|NONE (r_pobj) during_21\IN|of|the (r_prep) development_13\NN|NONE (l_prep) of_14\IN|the|during (l_pobj) insipidus_18\NN|NONE
1711760
D010656_D006973 CID phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate
D007530_D006973 NONE isoflurane_1\JJ|NONE (r_amod) anesthesia_2\NN|NONE (r_pobj) Under_0\IN|.|MCA|was|, (r_prep) occluded_12\VBN|NONE (l_nsubjpass) MCA_5\NNP|.|Under|was|, (l_prep) of_6\IN|the (l_pobj) rats_10\NNS| (l_amod) hypertensive_9\JJ|NONE
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8\CD|NONE (r_nummod) staining_9\VBG|NONE (r_pobj) by_7\IN|was|extent|. (r_agent) determined_6\VBN|NONE (l_nsubjpass) extent_1\NN|was|by|. (l_prep) of_2\IN|The (l_pobj) injury_4\NN|NONE
D010656_D009410 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|hypertension|h|,|that (l_dobj) edema_16\NN|does|after|MCAO|not (l_acl) improves_24\VBZ|in (l_conj) reduces_37\VBZ|it|edema|,|that|and (l_dobj) area_39\NN|that|it (l_prep) of_40\IN|the (l_pobj) dysfunction_43\NN|NONE
D010656_D007511 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|hypertension|h|,|that (l_dobj) edema_16\NN|does|after|MCAO|not (l_prep) in_17\IN|improves (l_pobj) core_20\NN|NONE (l_amod) ischemic_19\JJ|the
D010656_D007511 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|hypertension|h|,|that (l_dobj) edema_16\NN|does|after|MCAO|not (l_acl) improves_24\VBZ|in (l_dobj) edema_25\NN|reduces|it|,|that|and (l_prep) in_26\IN|NONE (l_pobj) periphery_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) territory_32\NN|NONE (l_amod) ischemic_31\JJ|the
D010656_D020244 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|hypertension|h|,|that (l_nsubj) MCAO_12\NNP|does|after|edema|not
D010656_D004487 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|hypertension|h|,|that (l_dobj) edema_16\NN|does|after|MCAO|not
D010656_D004487 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|h|,|that|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|hypertension|h|,|that (l_dobj) edema_16\NN|does|after|MCAO|not (l_acl) improves_24\VBZ|in (l_dobj) edema_25\NN|reduces|it|,|that|and
20735774
D000082_D056486 NONE paracetamol_9\NN| (r_npadvmod) induced_11\VBN|acute|liver (r_amod) injury_14\NN|NONE
D000082_D056486 NONE paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure
D000082_D017114 CID paracetamol_10\NN| (r_npadvmod) induced_12\VBN|acute|liver (r_amod) failure_15\NN|NONE
D000082_D017114 CID paracetamol_8\NN| (r_npadvmod) induced_10\VBN|liver|acute (r_amod) failure_13\NN|NONE
D000082_D017114 CID paracetamol_5\NN||whether (r_advmod) induced_7\VBN|failure|mortality (r_nmod) increases_11\VBZ|To (l_nsubj) failure_10\NN|induced|mortality
D000082_D017114 CID paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure (r_nsubj) caused_22\VBN||the (l_dobj) failure_26\NN|had|injury
D000082_D017114 CID paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure (r_nsubj) caused_22\VBN||the (r_relcl) patients_14\NNS|NONE (r_pobj) for_11\IN|slightly (r_prep) higher_10\JJR|was|but|rates|On|,|, (r_acomp) were_8\VBD|NONE (l_conj) was_46\VBD|higher|but|rates|On|,|, (l_conj) died_58\VBD|,|and|association|dependent (l_nsubj) survivors_53\NNS|of|,|.|were (l_prep) of_54\IN|no (l_pobj) failure_57\NN|NONE
D000082_D017114 CID Paracetamol_0\NNP| (r_npadvmod) induced_2\VBN|liver|acute (r_amod) failure_5\NN|did|not|.|mortality
D000082_D008107 NONE paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure (r_nsubj) caused_22\VBN||the (r_relcl) patients_14\NNS|NONE (r_pobj) for_11\IN|slightly (r_prep) higher_10\JJR|was|but|rates|On|,|, (r_acomp) were_8\VBD|NONE (l_conj) was_46\VBD|higher|but|rates|On|,|, (l_conj) died_58\VBD|,|and|association|dependent (l_prep) of_59\IN|,|.|were|survivors (l_pobj) disease_61\NN|NONE
20705401
D012701_D006948 NONE serotonin_1\NN|therapeutically|is|corrected|by|. (r_nsubjpass) targeted_9\VBN|NONE (l_agent) by_10\IN|serotonin|therapeutically|is|corrected|. (l_pobj) antipsychotics_14\NNS|NONE (l_prep) as_17\IN|several|,|generation (l_pobj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|,|olanzapine|and|and
D012701_D006948 NONE 5-HT6_4\CD|(||) (r_nummod) receptor_6\NN|The (r_appos) serotonin_1\NN|therapeutically|is|corrected|by|. (r_nsubjpass) targeted_9\VBN|NONE (l_agent) by_10\IN|serotonin|therapeutically|is|corrected|. (l_pobj) antipsychotics_14\NNS|NONE (l_prep) as_17\IN|several|,|generation (l_pobj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|,|olanzapine|and|and
D012701_D006948 NONE 5-HT6_39\CD|a|receptor|selective (r_nummod) antagonist_41\NN|NONE (r_pobj) of_36\IN|the (r_prep) use_35\NN|NONE (r_pobj) with_33\IN|is (r_prep) corrected_32\VBN|serotonin|therapeutically|is|by|. (r_conj) targeted_9\VBN|NONE (l_agent) by_10\IN|serotonin|therapeutically|is|corrected|. (l_pobj) antipsychotics_14\NNS|NONE (l_prep) as_17\IN|several|,|generation (l_pobj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|,|olanzapine|and|and
D012701_D012559 NONE 5-HT6_20\CD|altered (r_nummod) receptors_21\NNS|that|are|in (r_nsubjpass) involved_23\VBN|evidence|. (r_ccomp) suggests_17\VBZ|models|,|and|reflect|were (r_conj) considered_4\VBN|NONE (l_xcomp) reflect_6\VB|models|suggests|,|and|were (l_dobj) symptoms_9\NNS|to (l_prep) of_10\IN|the|positive (l_pobj) schizophrenia_11\NN|NONE
C076029_D006948 NONE olanzapine_20\NN|hyperactivity|induced|,|and|and (r_conj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|,|olanzapine|and|and
D008694_D011605 CID methamphetamine_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) psychosis_10\NN|NONE
D008694_D011605 CID methamphetamine_3\NN|NONE (r_pobj) of_2\IN|psychosis|The (r_prep) symptoms_1\NNS|similar|. (l_appos) psychosis_6\NN|The|of
D008694_D011605 CID METH)-induced_5\JJ|( (r_amod) psychosis_6\NN|The|of
D008694_D011605 CID METH_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) psychosis_20\NN|NONE
D008694_D011605 CID METH_29\NN| (r_npadvmod) induced_31\VBN|in|)|and|(|psychosis||controls (r_amod) patients_33\NNS|control (l_compound) psychosis_32\NN|in|)|and|(|induced||controls
D008694_D011605 CID METH_4\NNP| (r_npadvmod) induced_6\VBN|psychosis|in (r_amod) patients_8\NNS|NONE (l_compound) psychosis_7\NN|induced|in
D008694_D011605 CID METH_32\NNP| (r_npadvmod) induced_34\VBN|psychosis (r_amod) patients_36\NNS|between|,|an (l_compound) psychosis_35\NN|induced
D008694_D011605 CID METH_10\NNP| (r_npadvmod) induced_12\VBN|in (r_amod) psychosis_13\NN|NONE
D012701_D011605 NONE Serotonin_0\NN||receptor (r_nmod) gene_3\NN|with|is|. (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|is|gene|. (l_pobj) psychosis_10\NN|NONE
D012701_D011605 NONE 5-HT6_20\CD|altered (r_nummod) receptors_21\NNS|that|are|in (r_nsubjpass) involved_23\VBN|evidence|. (l_prep) in_24\IN|that|receptors|are (l_pobj) pathophysiology_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) disorders_29\NNS|NONE
D012701_D011605 NONE 5-HT6_11\CD|the|with|(|HTR|) (r_nummod) gene_12\NN|NONE (l_prep) with_16\IN|the|(|HT|HTR|) (l_pobj) psychosis_20\NN|NONE
D003024_D006948 NONE clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|,|olanzapine|and|and
D003913_D006948 NONE amphetamine_25\NN|||d (r_npadvmod) induced_27\VBN|hyperactivity|,|olanzapine|and|and (r_conj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|,|olanzapine|and|and
D008694_D012563 NONE methamphetamine_3\NN|NONE (r_pobj) of_2\IN|psychosis|The (r_prep) symptoms_1\NNS|similar|. (r_nsubj) are_7\VBP|NONE (l_acomp) similar_8\JJ|.|symptoms (l_prep) to_9\IN|NONE (l_pobj) those_10\DT|NONE (l_prep) of_11\IN|NONE (l_pobj) schizophrenia_14\NN|NONE
D008694_D012563 NONE METH)-induced_5\JJ|( (r_amod) psychosis_6\NN|The|of (r_appos) symptoms_1\NNS|similar|. (r_nsubj) are_7\VBP|NONE (l_acomp) similar_8\JJ|.|symptoms (l_prep) to_9\IN|NONE (l_pobj) those_10\DT|NONE (l_prep) of_11\IN|NONE (l_pobj) schizophrenia_14\NN|NONE
14704468
C066440_D012640 NONE Loreclezole_0\NNP|.|action|reducing|, (r_nsubj) exerted_5\VBD|NONE (l_advcl) reducing_16\VBG|.|action|Loreclezole|, (l_dobj) seizure_18\NN|NONE
18006530
D015742_D010146 CID propofol_9\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) induction_4\NN|NONE (r_pobj) during_3\IN|.|of (r_prep) Reduction_0\NN|NONE (l_prep) of_1\IN|during|. (l_pobj) pain_2\NN|NONE
D015742_D010146 CID propofol_4\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) injection_2\NN|NONE (r_pobj) on_1\IN|NONE (r_prep) Pain_0\NN|.|unpleasant
D015742_D010146 CID propofol_3\JJ|infusion (r_amod) pain_5\NN|be|that|might|by
D015742_D010146 CID propofol_15\JJ|the|in (r_amod) infusion_16\NN|NONE (r_dobj) starting_13\VBG|NONE (r_pcomp) before_12\IN|remifentanil (r_prep) infusing_10\VBG|NONE (r_pcomp) by_9\IN|be|that|might|pain (r_prep) prevented_8\VBN|.|We (l_nsubjpass) pain_5\NN|be|that|might|by
D015742_D010146 CID propofol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) caused_13\VBN|NONE (r_acl) pain_12\NN|was|using|.
D015742_D010146 CID propofol_26\JJ|the (r_amod) infusion_27\NN|NONE (r_pobj) during_24\IN|scale (r_prep) using_18\VBG|was|pain|. (r_advcl) evaluated_17\VBN|,|and|complications|during|were (l_nsubjpass) pain_12\NN|was|using|.
D015742_D010146 CID propofol_7\NN|NONE (r_pobj) of_6\IN|with (r_prep) anaesthesia_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) induction_1\NN|NONE (r_pobj) During_0\IN|without|was|,|.|reduction|) (r_prep) achieved_19\VBN|NONE (l_nsubjpass) reduction_13\NN|without|was|,|During|.|) (l_prep) in_14\IN|significant|a (l_pobj) pain_17\NN|NONE
D015742_D010146 CID propofol_15\JJ|infusion (r_amod) pain_17\NN|NONE
C071741_D010146 NONE remifentanil_11\NN|controlled|and (r_conj) propofol_9\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) induction_4\NN|NONE (r_pobj) during_3\IN|.|of (r_prep) Reduction_0\NN|NONE (l_prep) of_1\IN|during|. (l_pobj) pain_2\NN|NONE
C071741_D010146 NONE remifentanil_11\NN|before (r_dobj) infusing_10\VBG|NONE (r_pcomp) by_9\IN|be|that|might|pain (r_prep) prevented_8\VBN|.|We (l_nsubjpass) pain_5\NN|be|that|might|by
C071741_D010146 NONE remifentanil_26\NN|NONE (r_pobj) of_25\IN|)|( (r_prep) Ce_23\NNP|prevent|site|the (r_appos) concentration_21\NN|to (l_relcl) prevent_28\VB|Ce|site|the (l_dobj) pain_30\NN|without|to
C071741_D010146 NONE Remifentanil_0\NN| (r_npadvmod) related_2\VBN|NONE (r_amod) complications_3\NNS|evaluated|,|and|during|were (r_nsubjpass) assessed_5\VBN|NONE (l_conj) evaluated_17\VBN|,|and|complications|during|were (l_nsubjpass) pain_12\NN|was|using|.
C071741_D010146 NONE remifentanil_8\NN|the (r_compound) infusion_9\NN|NONE (r_pobj) during_6\IN|evaluated|,|and|complications|were (r_prep) assessed_5\VBN|NONE (l_conj) evaluated_17\VBN|,|and|complications|during|were (l_nsubjpass) pain_12\NN|was|using|.
C071741_D010146 NONE remifentanil_9\NN|and (r_conj) propofol_7\NN|NONE (r_pobj) of_6\IN|with (r_prep) anaesthesia_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) induction_1\NN|NONE (r_pobj) During_0\IN|without|was|,|.|reduction|) (r_prep) achieved_19\VBN|NONE (l_nsubjpass) reduction_13\NN|without|was|,|During|.|) (l_prep) in_14\IN|significant|a (l_pobj) pain_17\NN|NONE
C071741_D010146 NONE remifentanil_27\NN|NONE (r_pobj) of_26\IN|prior (r_prep) administration_25\NN|NONE (r_pobj) by_23\IN|at|significant (r_prep) complications_22\NNS|NONE (r_pobj) without_20\IN|was|,|During|.|reduction|) (r_prep) achieved_19\VBN|NONE (l_nsubjpass) reduction_13\NN|without|was|,|During|.|) (l_prep) in_14\IN|significant|a (l_pobj) pain_17\NN|NONE
8045270
C061282_D002375 CID 21680_29\CD|(|)|micrograms (r_nummod) CGS_28\NNP|adenosine|an|,|AA|receptor (r_appos) agonist_26\NN|NONE (r_pobj) of_21\IN|intracerebroventricular (r_prep) administration_20\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|the|cataleptic (r_acl) responses_16\NNS|.|,|significantly|administration|in (l_amod) cataleptic_15\JJ|the|induced
D006220_D002375 CID haloperidol_7\NN|and|by (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|the (r_acl) catalepsy_4\NN|also|.|KF
D000241_D002375 NONE adenosine_23\NN|an|,|CGS|AA|receptor (r_amod) agonist_26\NN|NONE (r_pobj) of_21\IN|intracerebroventricular (r_prep) administration_20\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|the|cataleptic (r_acl) responses_16\NNS|.|,|significantly|administration|in (l_amod) cataleptic_15\JJ|the|induced
C081198_D010302 NONE KF17837_2\NN|Furthermore|,|may|drug|. (r_nsubj) be_4\VB|NONE (l_attr) drug_7\NN|Furthermore|,|may|.|KF (l_prep) in_8\IN|useful|a (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) parkinsonism_12\NN|NONE
C081198_D002375 NONE KF17837_3\NNP|NONE (r_pobj) of_2\IN|.|Oral (r_prep) administration_1\NN|.|,|significantly|responses|in (r_nsubj) ameliorated_13\VBD|NONE (l_dobj) responses_16\NNS|.|,|significantly|administration|in (l_amod) cataleptic_15\JJ|the|induced
C081198_D002375 NONE KF17837_0\NN|catalepsy|also|. (r_nsubj) reduced_2\VBD|NONE (l_dobj) catalepsy_4\NN|also|.|KF
D012110_D002375 CID reserpine_15\NN|NONE (r_pobj) by_14\IN|haloperidol|and (r_conj) by_6\IN|NONE (r_agent) induced_5\VBN|the (r_acl) catalepsy_4\NN|also|.|KF
17344330
D008691_D008133 CID methadone_8\NN|NONE (r_pobj) with_7\IN|for (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|prolongation|.|and (r_prep) Syncope_0\NNP|NONE (l_conj) prolongation_3\NN|.|and|among
D008691_D008133 CID methadone_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) treated_3\VBN|the (r_acl) subjects_2\NNS|NONE (r_pobj) Among_0\IN|.|interval (r_prep) had_14\VBD|NONE (l_dobj) interval_17\NN|.|Among
D008691_D008133 CID Methadone_0\NNP|.|is|with (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|.|is|Methadone (l_pobj) prolongation_5\NN|NONE
D003932_D016171 NONE heroin_1\NN|NONE (r_compound) addicts_2\NNS|using|As|sometimes (r_nsubj) faint_4\JJ|and|episodes|doctors|,|and|caused|,|underestimate|might (r_advcl) attribute_12\VB|NONE (l_conj) underestimate_24\VBP|and|episodes|faint|doctors|,|and|caused|,|might (l_dobj) incidence_26\NN|thereby (l_prep) of_27\IN|the|in (l_pobj) TdP_28\NNP|NONE
D003932_D013575 NONE heroin_10\NN|in (r_compound) dependence_11\NN|NONE (r_pobj) for_9\IN|with (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|prolongation|.|and (r_prep) Syncope_0\NNP|NONE
D003932_D013575 NONE heroin_1\NN|NONE (r_compound) addicts_2\NNS|using|As|sometimes (r_nsubj) faint_4\JJ|and|episodes|doctors|,|and|caused|,|underestimate|might (r_advcl) attribute_12\VB|NONE (l_dobj) episodes_15\NNS|and|faint|doctors|,|and|caused|,|underestimate|might (l_prep) of_16\IN|many (l_pobj) syncope_17\NN|NONE
D003932_D013575 NONE heroin_15\NN|NONE (r_compound) addicts_16\NNS|NONE (r_pobj) of_14\IN|a (r_prep) population_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) syncope_10\NN|NONE
D008691_D013575 CID methadone_8\NN|NONE (r_pobj) with_7\IN|for (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|prolongation|.|and (r_prep) Syncope_0\NNP|NONE
D008691_D013575 CID methadone_53\NN|NONE (r_pobj) of_52\IN|proarrhythmic|the (r_prep) effect_51\NN|NONE (r_pobj) by_48\IN|,|.|may|,|be|mortality|in (r_agent) caused_47\VBN|and|episodes|faint|doctors|,|and|,|underestimate|might (r_conj) attribute_12\VB|NONE (l_dobj) episodes_15\NNS|and|faint|doctors|,|and|caused|,|underestimate|might (l_prep) of_16\IN|many (l_pobj) syncope_17\NN|NONE
D008691_D013575 CID methadone_9\NN|and|reporting (r_compound) dose_10\NN|QT|opioid|and|,|and (l_conj) reporting_12\NN|methadone|and (l_prep) of_13\IN|NONE (l_pobj) syncope_14\NN|NONE
D008691_D013575 CID methadone_4\NN|NONE (r_compound) dose_5\NN|was|with|. (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|dose|was|. (l_pobj) CI_14\NNP|NONE (l_appos) odds_21\NNS|%|)|to|a|. (l_prep) for_22\IN|higher (l_pobj) syncope_23\NN|NONE
D008691_D013575 CID Methadone_0\NNP|.|is|with (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|.|is|Methadone (l_pobj) prolongation_5\NN|NONE (l_conj) reporting_8\NN|and|QT (l_prep) of_9\IN|higher (l_pobj) syncope_10\NN|NONE
D003932_D008133 NONE heroin_10\NN|in (r_compound) dependence_11\NN|NONE (r_pobj) for_9\IN|with (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|prolongation|.|and (r_prep) Syncope_0\NNP|NONE (l_conj) prolongation_3\NN|.|and|among
D003932_D008133 NONE heroin_15\NN|NONE (r_compound) addicts_16\NNS|NONE (r_pobj) of_14\IN|a (r_prep) population_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) syncope_10\NN|NONE (r_pobj) of_9\IN|higher (r_prep) reporting_8\NN|and|QT (r_conj) prolongation_5\NN|NONE
D008691_D016171 NONE methadone_21\NN|NONE (r_compound) users_22\NNS|NONE (r_pobj) in_20\IN|Prolongation|has|been|. (r_prep) reported_19\VBN|NONE (l_nsubjpass) Prolongation_0\NN|in|has|been|. (l_prep) of_1\IN|NONE (l_pobj) interval_4\NN|NONE (l_prep) in_5\IN|the|QT (l_pobj) ECG_7\NNP|NONE (l_prep) of_8\IN|the (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) pointes_13\FW|NONE
D008691_D016171 NONE methadone_21\NN|NONE (r_compound) users_22\NNS|NONE (r_pobj) in_20\IN|Prolongation|has|been|. (r_prep) reported_19\VBN|NONE (l_nsubjpass) Prolongation_0\NN|in|has|been|. (l_prep) of_1\IN|NONE (l_pobj) interval_4\NN|NONE (l_prep) in_5\IN|the|QT (l_pobj) ECG_7\NNP|NONE (l_prep) of_8\IN|the (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) pointes_13\FW|NONE (l_appos) TdP_15\NN|)|(|torsade|de
D008691_D016171 NONE methadone_53\NN|NONE (r_pobj) of_52\IN|proarrhythmic|the (r_prep) effect_51\NN|NONE (r_pobj) by_48\IN|,|.|may|,|be|mortality|in (r_agent) caused_47\VBN|and|episodes|faint|doctors|,|and|,|underestimate|might (r_conj) attribute_12\VB|NONE (l_conj) underestimate_24\VBP|and|episodes|faint|doctors|,|and|caused|,|might (l_dobj) incidence_26\NN|thereby (l_prep) of_27\IN|the|in (l_pobj) TdP_28\NNP|NONE
9799166
D000661_D020521 CID amphetamine_4\NN|or (r_conj) cocaine_2\NN|and (r_conj) Stroke_0\NN|.
D000661_D020521 CID amphetamine_5\NN|NONE (r_compound) use_6\NN|and (r_conj) cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|is|on|. (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE
D000661_D020521 CID amphetamine_13\NN|and/or (r_conj) cocaine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) use_9\NN|and (r_conj) stroke_7\NN|NONE
D000661_D020521 CID amphetamine_15\NN|and/or (r_conj) cocaine_13\NN|NONE (r_dobj) using_12\VBG|NONE (r_pcomp) to_11\IN|who (r_prep) admitted_10\VBD|in (r_relcl) stroke_6\NN|NONE
D000661_D020521 CID amphetamine_5\NN|and/or (r_conj) cocaine_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|.|factor (r_nsubj) is_6\VBZ|NONE (l_attr) factor_10\NN|.|use (l_prep) for_11\IN|strong|risk|a (l_pobj) stroke_12\NN|NONE
D003042_D007511 NONE cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|is|on|. (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE (l_amod) hemorrhagic_8\JJ|NONE (l_conj) ischemic_10\JJ|and
D000661_D007511 NONE amphetamine_5\NN|NONE (r_compound) use_6\NN|and (r_conj) cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|is|on|. (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE (l_amod) hemorrhagic_8\JJ|NONE (l_conj) ischemic_10\JJ|and
D003042_D020521 CID cocaine_2\NN|and (r_conj) Stroke_0\NN|.
D003042_D020521 CID cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|is|on|. (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE
D003042_D020521 CID cocaine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) use_9\NN|and (r_conj) stroke_7\NN|NONE
D003042_D020521 CID cocaine_13\NN|NONE (r_dobj) using_12\VBG|NONE (r_pcomp) to_11\IN|who (r_prep) admitted_10\VBD|in (r_relcl) stroke_6\NN|NONE
D003042_D020521 CID cocaine_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|.|factor (r_nsubj) is_6\VBZ|NONE (l_attr) factor_10\NN|.|use (l_prep) for_11\IN|strong|risk|a (l_pobj) stroke_12\NN|NONE
11226639
D008550_D053608 CID melatonin_3\NN|NONE (l_prep) on_4\IN|NONE (l_pobj) narcosis_8\NN|NONE
D008550_D053608 CID Melatonin_0\NNP|cycle|but|,|is (r_nsubj) affects_1\VBZ|NONE (l_conj) is_11\VBZ|cycle|Melatonin|but|, (l_ccomp) influence_17\VB|.|it|clear|not (l_dobj) narcosis_21\NN|whether|it|may
D008550_D053608 CID Melatonin_0\NNP|correlation|,|.|,|however|was (r_nsubjpass) found_20\VBN|NONE (l_punct) ,_11\,|correlation|.|,|Melatonin|however|was (l_punct) affected_4\VBN|NONE (l_prep) in_5\IN|treatment (l_pobj) narcosis_10\NN|NONE
D008550_D053608 CID melatonin_7\NN|NONE (r_pobj) of_6\IN|the|highest (r_prep) dose_5\NN|.|reduction|produced|and|and|increase|,|In (r_nsubj) caused_12\VBD|NONE (l_conj) produced_20\VBD|dose|.|reduction|and|and|increase|,|In (l_dobj) reduction_23\NN|, (l_prep) of_24\IN|sustained|a (l_pobj) duration_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) narcosis_28\NN|NONE
D008550_D053608 CID Melatonin_0\NNP|.|duration (r_nsubj) influenced_5\VBD|NONE (l_dobj) duration_7\NN|.|Melatonin (l_conj) latency_11\NN|the|but (l_prep) of_12\IN|not|the (l_pobj) narcosis_18\NN|NONE
D008550_D053608 CID melatonin_6\NN|NONE (l_prep) on_7\IN|NONE (l_pobj) narcosis_9\NN|NONE
D007649_D053608 CID ketamine-_13\NNS|NONE (r_nmod) narcosis_18\NN|NONE
C032232_D053608 NONE barbiturate_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) narcosis_8\NN|NONE
C032232_D053608 NONE barbiturate_9\NN|a|manner (r_compound) narcosis_10\NN|NONE
C032232_D053608 NONE barbiturate_14\NN|NONE (r_compound) narcosis_15\NN|NONE
C032232_D053608 NONE barbiturate_16\JJ|of|the (r_compound) mechanism_17\NN|NONE (r_pobj) for_14\IN|NONE (r_prep) specific_13\JJ|to (r_acomp) be_12\VB|action|.|,|Thus (r_xcomp) seems_10\VBZ|NONE (l_nsubj) action_4\NN|.|be|,|Thus (l_prep) of_5\IN|dual|the (l_pobj) melatonin_6\NN|NONE (l_prep) on_7\IN|NONE (l_pobj) narcosis_9\NN|NONE
D003975_D053608 CID diazepam_15\NN| (r_npadvmod) induced_17\VBN|or (r_conj) ketamine-_13\NNS|NONE (r_nmod) narcosis_18\NN|NONE
2894433
D001569_D001919 NONE benzodiazepine_36\JJ|macromolecular|chloride|channel|the (r_amod) complex_43\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) associated_33\VBN|NONE (r_acl) sites_32\NNS|NONE (r_pobj) to_31\IN|NONE (r_prep) binding_30\VBG|NONE (r_pcomp) by_29\IN|agent|channels (r_prep) blocks_26\NNS|)|( (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|intravenous|an (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|was|enhancement|,|.|However (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|by|was|,|.|However (l_prep) of_5\IN|diazepam|the (l_pobj) bradycardia_10\NN|NONE
D001569_D001919 NONE benzodiazepine_8\JJ|the|channel|macromolecular|chloride|within (r_amod) complex_15\NN|NONE (r_pobj) through_6\IN|that|facilitate|diazepam (r_prep) acts_5\VBZ|.|data (l_advcl) facilitate_22\VB|that|through|diazepam (l_dobj) bradycardia_24\NN|to
D005680_D001919 NONE GABA_38\NNP|| (r_compound) chloride_40\NN|macromolecular|benzodiazepine|channel|the (r_compound) complex_43\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) associated_33\VBN|NONE (r_acl) sites_32\NNS|NONE (r_pobj) to_31\IN|NONE (r_prep) binding_30\VBG|NONE (r_pcomp) by_29\IN|agent|channels (r_prep) blocks_26\NNS|)|( (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|intravenous|an (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|was|enhancement|,|.|However (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|by|was|,|.|However (l_prep) of_5\IN|diazepam|the (l_pobj) bradycardia_10\NN|NONE
D005680_D001919 NONE GABA_10\NNP|| (r_compound) chloride_12\NN|benzodiazepine|the|channel|macromolecular|within (r_compound) complex_15\NN|NONE (r_pobj) through_6\IN|that|facilitate|diazepam (r_prep) acts_5\VBZ|.|data (l_advcl) facilitate_22\VB|that|through|diazepam (l_dobj) bradycardia_24\NN|to
D004837_D001919 CID adrenaline_12\NN|NONE (r_pobj) of_11\IN|intravenous|(|)|micrograms (r_prep) infusion_10\NN|NONE (r_pobj) by_8\IN|.|was|Also|in|bradycardia|, (r_agent) produced_5\VBN|NONE (l_nsubjpass) bradycardia_3\NN|.|was|Also|in|,|by
D004837_D001919 CID adrenaline_14\NN| (r_npadvmod) induced_16\VBN|pressor|the (r_amod) effect_18\NN|NONE (r_pobj) in_12\IN|no (r_prep) change_11\NN|although (r_dobj) causing_9\VBG|with|of|Intravenous|, (r_advcl) pretreatment_1\NN|did|bradycardia|.|, (r_nsubj) enhance_21\VB|NONE (l_dobj) bradycardia_27\NN|did|.|,|pretreatment
D004837_D001919 CID adrenaline_23\NN| (r_npadvmod) induced_25\VBN|reflex|the (r_amod) bradycardia_27\NN|did|.|,|pretreatment
D004837_D001919 CID adrenaline_6\NN| (r_npadvmod) induced_8\VBN|reflex (r_amod) bradycardia_10\NN|NONE
D010852_D001919 NONE picrotoxin_22\NN|NONE (r_pobj) of_21\IN|intravenous|an (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|was|enhancement|,|.|However (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|by|was|,|.|However (l_prep) of_5\IN|diazepam|the (l_pobj) bradycardia_10\NN|NONE
D002712_D001919 NONE chloride_27\NN|NONE (r_compound) channels_28\NNS|agent|by (r_dobj) blocks_26\NNS|)|( (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|intravenous|an (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|was|enhancement|,|.|However (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|by|was|,|.|However (l_prep) of_5\IN|diazepam|the (l_pobj) bradycardia_10\NN|NONE
D002712_D001919 NONE chloride_40\NN|macromolecular|benzodiazepine|channel|the (r_compound) complex_43\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) associated_33\VBN|NONE (r_acl) sites_32\NNS|NONE (r_pobj) to_31\IN|NONE (r_prep) binding_30\VBG|NONE (r_pcomp) by_29\IN|agent|channels (r_prep) blocks_26\NNS|)|( (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|intravenous|an (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|was|enhancement|,|.|However (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|by|was|,|.|However (l_prep) of_5\IN|diazepam|the (l_pobj) bradycardia_10\NN|NONE
D002712_D001919 NONE chloride_12\NN|benzodiazepine|the|channel|macromolecular|within (r_compound) complex_15\NN|NONE (r_pobj) through_6\IN|that|facilitate|diazepam (r_prep) acts_5\VBZ|.|data (l_advcl) facilitate_22\VB|that|through|diazepam (l_dobj) bradycardia_24\NN|to
D003975_D001919 CID Diazepam_0\NNP|bradycardia|. (r_nsubj) facilitates_1\VBZ|NONE (l_dobj) bradycardia_3\NN|Diazepam|.
D003975_D001919 CID diazepam_6\NN|NONE (r_pobj) with_5\IN|causing|of|Intravenous|, (r_prep) pretreatment_1\NN|did|bradycardia|.|, (r_nsubj) enhance_21\VB|NONE (l_dobj) bradycardia_27\NN|did|.|,|pretreatment
D003975_D001919 CID diazepam_3\NN|the|of (r_compound) enhancement_4\NN|by|was|,|.|However (l_prep) of_5\IN|diazepam|the (l_pobj) bradycardia_10\NN|NONE
D003975_D001919 CID diazepam_4\NN|that|facilitate|through (r_nsubj) acts_5\VBZ|.|data (l_advcl) facilitate_22\VB|that|through|diazepam (l_dobj) bradycardia_24\NN|to
7905523
D015215_D015658 NONE zidovudine_15\NN|||butyl|N|and|SC (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|and (l_pobj) infection_20\NN|NONE
C059896_D007153 NONE SC-48334_2\VBP|mean|The|trough|ml|state (r_nmod) level_7\NN|below|. (r_nsubj) was_16\VBD|NONE (l_prep) below_17\IN|level|. (l_pobj) concentration_22\NN|NONE (l_prep) for_23\IN|the|vitro|inhibitory (l_pobj) virus_26\NN|NONE (l_compound) immunodeficiency_25\NN|HIV|)|human|(
C059896_D015658 NONE deoxynojirimycin_10\NNP|.|/|cells|safety (l_conj) zidovudine_15\NN|||butyl|N|and|SC (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|and (l_pobj) infection_20\NN|NONE
C059896_D015658 NONE SC-48334_12\NNP|||butyl|zidovudine|N|and (r_appos) deoxynojirimycin_10\NNP|.|/|cells|safety (l_conj) zidovudine_15\NN|||butyl|N|and|SC (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|and (l_pobj) infection_20\NN|NONE
19289093
D002809_D007022 CID sulfate_19\NN|an|oversulfated|elicit (r_nmod) derivative_23\NN|NONE (l_relcl) elicit_26\VB|an|sulfate|oversulfated (l_dobj) response_29\NN|could|that|following (l_amod) hypotensive_28\JJ|a|in
D006493_D007022 NONE heparin_8\JJ|NONE (r_compound) products_9\NNS|NONE (r_pobj) of_7\IN|commercial (r_prep) lots_6\NNS|NONE (r_pobj) of_4\IN|a (r_prep) number_3\NN|Recently|,|.|were|contaminated (r_nsubjpass) found_11\VBN|NONE (l_xcomp) contaminated_14\VBN|Recently|,|number|.|were (l_prep) with_15\IN|to|be (l_pobj) derivative_23\NN|NONE (l_relcl) elicit_26\VB|an|sulfate|oversulfated (l_dobj) response_29\NN|could|that|following (l_amod) hypotensive_28\JJ|a|in
D006493_D007022 NONE heparin_3\JJ|both|contaminated|derivative|and (r_compound) products_4\NNS|NONE (r_dobj) Using_0\VBG|.|,|produces|we (r_advcl) showed_12\VBD|NONE (l_ccomp) produces_16\VBZ|.|Using|,|we (l_dobj) hypotension_20\NN|OSCS|that
12231232
C095756_D009127 NONE AIDA_0\NNP|rigidity|. (r_nsubj) diminished_9\VBD|NONE (l_dobj) rigidity_15\NN|AIDA|.
D006220_D009127 CID Haloperidol_0\NN|.|rigidity (r_nsubj) induced_6\VBD|NONE (l_dobj) rigidity_11\NN|.|Haloperidol
D006220_D009127 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|the|muscle (r_amod) rigidity_15\NN|AIDA|.
D006220_D010300 NONE Haloperidol_0\NN|.|rigidity (r_nsubj) induced_6\VBD|NONE (l_dobj) rigidity_11\NN|.|Haloperidol (l_amod) parkinsonian_7\JJ|measured|,|muscle
871943
D013390_D001049 CID succinylcholine_6\NN|NONE (r_compound) apnoea_7\NN|NONE
D013390_D001049 CID succinylcholine_10\NN|by|have|after|hours|been (r_nsubjpass) treated_13\VBN|.|apnoea|patients (r_advcl) demonstrating_2\VBG|NONE (l_dobj) apnoea_5\NN|.|patients|treated
D013390_D001049 CID succinylcholine_6\NN|NONE (r_compound) apnoea_7\NN|NONE
19692487
D015232_D011141 NONE )_29\-RRB-|NONE (r_punct) PGE(2_28\NNP|and|high|output (r_appos) urine_27\NN|NONE (r_pobj) of_25\IN|complete (r_prep) blockade_24\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) accompanied_20\VBN|resistant|.|mPGES|,|,|mice|In (r_advcl) were_6\VBD|NONE (l_acomp) resistant_8\JJ|.|mPGES|,|,|mice|In|accompanied (l_prep) to_9\IN|largely (l_pobj) polyuria_13\NN|NONE
D015232_D011141 NONE )_5\-RRB-|mPGESderived (r_punct) PGE(2_4\NNP|via|that|polyuria (r_nsubj) mediates_6\VBZ|We|. (l_dobj) polyuria_10\NN|via|that|PGE(
D008094_D011141 NONE lithium_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) polyuria_9\NN|NONE
D008094_D011141 NONE lithium_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) polyuria_11\NN|NONE
D008094_D011141 NONE lithium_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) polyuria_10\NN|to
D008094_D011141 NONE lithium_10\NN| (r_npadvmod) induced_12\VBN|and|urine (r_amod) polyuria_13\NN|NONE
D008094_D011141 NONE lithium_7\NN| (r_npadvmod) induced_9\VBN|likely (r_amod) polyuria_10\NN|via|that|PGE(
D011458_D011141 NONE E_17\NN|NONE (r_appos) microsomal_15\JJ|NONE (r_pobj) in_14\IN|mice (r_prep) deficient_13\JJ|NONE (r_pobj) in_11\IN|induced (r_prep) polyuria_10\NN|to
2907585
-1_D002375 NONE piperazine_10\NN|novel|anxiolytic (r_nmod) drugs_12\NNS|NONE (r_pobj) by_6\IN|of|. (r_prep) Reversal_0\NN|NONE (l_prep) of_1\IN|.|by (l_pobj) catalepsy_5\NN|NONE
-1_D002375 NONE piperazine_5\NN|of (r_compound) analogues_6\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|.|were|induced|for (r_nsubjpass) tested_14\VBN|NONE (l_conj) induced_21\VBN|.|were|series|for (l_dobj) catalepsy_22\NN|NONE
D006220_D002375 CID haloperidol_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|NONE (r_acl) catalepsy_8\NN|.|drug
D006220_D002375 CID haloperidol_20\NN|to (r_dobj) reverse_19\VB|their (r_acl) ability_17\NN|NONE (r_pobj) for_15\IN|.|were|induced|series (r_prep) tested_14\VBN|NONE (l_conj) induced_21\VBN|.|were|series|for (l_dobj) catalepsy_22\NN|NONE
D002065_D002375 NONE buspirone_5\NN|,|,|anxiolytic|novel|The (r_appos) drug_3\NN|catalepsy|. (r_nsubj) reverses_7\VBZ|NONE (l_dobj) catalepsy_8\NN|.|drug
D002065_D002375 NONE buspirone_8\NN|NONE (r_pobj) of_7\IN|piperazine (r_prep) analogues_6\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|.|were|induced|for (r_nsubjpass) tested_14\VBN|NONE (l_conj) induced_21\VBN|.|were|series|for (l_dobj) catalepsy_22\NN|NONE
D058825_D002375 NONE agonists_12\NNS|and (r_conj) buspirone_8\NN|NONE (r_pobj) of_7\IN|piperazine (r_prep) analogues_6\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|.|were|induced|for (r_nsubjpass) tested_14\VBN|NONE (l_conj) induced_21\VBN|.|were|series|for (l_dobj) catalepsy_22\NN|NONE
D012701_D002375 NONE 5-hydroxytryptamine1a_6\CD|NONE (r_compound) receptors_7\NNS|NONE (r_pobj) for_5\IN|strong (r_prep) affinity_4\NN|NONE (r_pobj) with_2\IN|Those (r_prep) drugs_1\NNS|able|. (r_nsubj) were_8\VBD|NONE (l_acomp) able_9\JJ|drugs|. (l_xcomp) reverse_11\VB|NONE (l_dobj) catalepsy_12\NN|to
D012701_D002375 NONE 5-HT_5\CD|postsynaptic (r_compound) receptors_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) inhibition_2\NN|.|,|neither|potentiated|However|nor (r_nsubj) inhibited_8\VBN|NONE (l_conj) potentiated_10\VBN|inhibition|.|,|neither|However|nor (l_dobj) reversal_11\NN|leaves|and (l_prep) of_12\IN|NONE (l_pobj) catalepsy_13\NN|NONE
9098464
D005473_D062788 CID hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|.|A|:|of (r_appos) model_2\NN|NONE (l_prep) of_3\IN|effects|murine|.|A|: (l_pobj) adenomyosis_4\NN|NONE
D005473_D062788 CID hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (l_prep) on_21\IN|by (l_pobj) induction_23\NN|NONE (l_compound) adenomyosis_22\NN|in
D005473_D062788 CID fluoxetine_9\NN|whether|hyperprolactinemia (r_nsubj) caused_16\VBD|to (l_dobj) hyperprolactinemia_17\NN|whether|fluoxetine (l_conj) effects_20\NNS|and (l_prep) with_21\IN|its (l_pobj) respect_22\NN|NONE (l_prep) to_23\IN|NONE (l_pobj) adenomyosis_24\NN|NONE
D005473_D062788 CID fluoxetine_14\NN|NONE (r_dobj) receiving_13\VBG|noncastrated|the (r_acl) group_12\NN|all (r_pobj) within_9\IN|.|cases|studies (r_prep) revealed_2\VBD|NONE (l_dobj) cases_4\NNS|.|within|studies (l_prep) of_5\IN||, (l_pobj) adenomyosis_6\NN|NONE
D005473_D006966 CID hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|.|A|:|of (l_prep) of_8\IN|induced|the (l_pobj) hyperprolactinemia_9\NN|NONE
D005473_D006966 CID fluoxetine_9\NN|whether|hyperprolactinemia (r_nsubj) caused_16\VBD|to (l_dobj) hyperprolactinemia_17\NN|whether|fluoxetine
D005473_D006966 CID Fluoxetine_0\NNP|was|produce|for|.|to (r_nsubjpass) given_8\VBN|NONE (l_advcl) produce_17\VB|Fluoxetine|was|for|.|to (l_dobj) hyperprolactinemia_18\NN|to
D012701_D062788 NONE serotonin_17\NN|a|selective|reuptake (r_compound) inhibitor_19\NN|fluoxetine|,|, (r_appos) hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|.|A|:|of (r_appos) model_2\NN|NONE (l_prep) of_3\IN|effects|murine|.|A|: (l_pobj) adenomyosis_4\NN|NONE
D012701_D062788 NONE serotonin_17\NN|a|selective|reuptake (r_compound) inhibitor_19\NN|fluoxetine|,|, (r_appos) hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (l_prep) on_21\IN|by (l_pobj) induction_23\NN|NONE (l_compound) adenomyosis_22\NN|in
D012701_D006966 NONE serotonin_17\NN|a|selective|reuptake (r_compound) inhibitor_19\NN|fluoxetine|,|, (r_appos) hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|.|A|:|of (l_prep) of_8\IN|induced|the (l_pobj) hyperprolactinemia_9\NN|NONE
D012701_D006966 NONE serotonin_3\NN|a|reuptake (r_compound) inhibitor_5\NN|,|, (r_appos) Fluoxetine_0\NNP|was|produce|for|.|to (r_nsubjpass) given_8\VBN|NONE (l_advcl) produce_17\VB|Fluoxetine|was|for|.|to (l_dobj) hyperprolactinemia_18\NN|to
28952
D011188_D007008 NONE potassium_1\NN|influence|:|and|.|hypokalaemia|Initial (r_compound) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|influence|:|and|.|potassium|Initial
D011188_D007008 NONE potassium_4\NN|development|and|initial|during|the (r_compound) loss_5\NN|To (l_conj) development_7\NN|potassium|and|initial|during|the (l_prep) of_8\IN|NONE (l_pobj) hypokalaemia_9\NN|NONE
D011188_D007008 NONE potassium_4\NN|development|and|initial|during|the (r_compound) loss_5\NN|To (r_dobj) investigate_1\VB|.|were|in (r_csubjpass) performed_22\VBN|NONE (l_prep) in_23\IN|.|were|investigate (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|ten (l_pobj) hypertension_28\NN|NONE (l_relcl) shown_31\VBN|essential (l_dobj) hypokalaemia_32\NN|who|under|had
D002752_D006973 NONE chlorthalidone_6\NN|in (r_compound) administration_7\NN|NONE (l_prep) in_8\IN|chlorthalidone (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) hypertension_12\NN|NONE
D012964_D007008 NONE sodium_18\NN|dietary (r_compound) restriction_19\NN|NONE (r_pobj) of_16\IN|the (r_prep) influence_15\NN|:|and|.|potassium|hypokalaemia|Initial (r_appos) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|influence|:|and|.|potassium|Initial
D011188_D006973 NONE potassium_1\NN|influence|:|and|.|hypokalaemia|Initial (r_compound) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|influence|:|and|.|potassium|Initial (l_prep) during_5\IN|NONE (l_pobj) administration_7\NN|NONE (l_prep) in_8\IN|chlorthalidone (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D006973 NONE potassium_4\NN|development|and|initial|during|the (r_compound) loss_5\NN|To (r_dobj) investigate_1\VB|.|were|in (r_csubjpass) performed_22\VBN|NONE (l_prep) in_23\IN|.|were|investigate (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|ten (l_pobj) hypertension_28\NN|NONE
D002752_D007008 CID chlorthalidone_6\NN|in (r_compound) administration_7\NN|NONE (r_pobj) during_5\IN|NONE (r_prep) hypokalaemia_4\NN|influence|:|and|.|potassium|Initial
D012964_D006973 NONE sodium_18\NN|dietary (r_compound) restriction_19\NN|NONE (r_pobj) of_16\IN|the (r_prep) influence_15\NN|:|and|.|potassium|hypokalaemia|Initial (r_appos) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|influence|:|and|.|potassium|Initial (l_prep) during_5\IN|NONE (l_pobj) administration_7\NN|NONE (l_prep) in_8\IN|chlorthalidone (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) hypertension_12\NN|NONE
12042105
C052342_D053040 CID Topiramate_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) nephrolithiasis_3\NN|NONE
C052342_D053040 CID topiramate_7\RB| (r_npadvmod) induced_9\VBN|in (r_amod) nephrolithiasis_10\NN|NONE
C052342_D004827 NONE Topiramate_0\NNP|.|medication (r_nsubj) is_1\VBZ|NONE (l_attr) medication_6\NN|.|Topiramate (l_relcl) becoming_9\VBG|a|antiepileptic|developed (l_prep) because_13\IN|prescribed|is|that (l_pobj) efficacy_16\NN|of (l_prep) in_17\IN|its (l_pcomp) treating_18\VBG|NONE (l_dobj) seizures_20\NNS|NONE
C020243_D053040 NONE phosphate_29\NN|NONE (r_compound) nephrolithiasis_30\NN|NONE
15858223
D005978_D056486 NONE glutathione_11\NN|)||GST|(|S (r_compound) transferase_14\NNP|NONE (r_pobj) of_8\IN|serum (r_prep) levels_7\NNS|and|by (r_pobj) on_5\IN|NONE (r_prep) based_4\VBN|toxicity|was|. (r_prep) evaluated_3\VBN|NONE (l_nsubjpass) toxicity_1\NN|was|based|.
C075750_D009336 NONE 15-F(2t)-IsoP_18\CD|NONE (r_pobj) of_17\IN|,|precedes (r_prep) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE
D014635_D005234 CID VPA_6\NNP|treatment|,|that|in|measured (r_compound) results_8\NNS|.|,|findings|Overall (l_advcl) measured_14\VBN|treatment|VPA|,|that|in (l_agent) by_15\IN|as (l_pobj) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE (l_conj) steatosis_27\NN|,
D014635_D056486 CID acid_14\NN|NONE (r_compound) metabolite_15\NN|valproic|in (r_amod) levels_16\NNS|liver|,|and (r_conj) toxicity_10\NN|,|peroxidation
D014635_D056486 CID VPA_9\NNP| (r_npadvmod) associated_11\VBN|and|oxidative|hepatotoxicity|, (r_amod) stress_13\NN|NONE (l_conj) hepatotoxicity_15\NN|and|oxidative|associated|,
D014635_D056486 CID VPA_27\NNP|NONE (r_pobj) with_26\IN|rats|ip|were|.|daily|for|determine (r_prep) treated_24\VBN|NONE (l_advcl) determine_1\VB|rats|ip|with|were|.|daily|for (l_ccomp) was_4\VBD|To (l_attr) relationship_7\NN|whether|there (l_prep) between_8\IN|a|temporal (l_pobj) stress_13\NN|NONE (l_conj) hepatotoxicity_15\NN|and|oxidative|associated|,
D014635_D009336 CID VPA_6\NNP|treatment|,|that|in|measured (r_compound) results_8\NNS|.|,|findings|Overall (l_advcl) measured_14\VBN|treatment|VPA|,|that|in (l_agent) by_15\IN|as (l_pobj) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE
C075750_D005234 NONE 15-F(2t)-IsoP_18\CD|NONE (r_pobj) of_17\IN|,|precedes (r_prep) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE (l_conj) steatosis_27\NN|,
16820346
D013481_D006973 NONE superoxide_25\RB|plasma (r_advmod) decreased_23\VBD|)|mmHg|,|mmHg|hypertension|and|Atorva|vs. (r_conj) reversed_1\VBN|NONE (l_dobj) hypertension_5\NN|)|mmHg|,|mmHg|decreased|and|Atorva|vs.
D003907_D006973 CID dexamethasone_4\NN| (r_npadvmod) induced_6\VBN|in (r_amod) hypertension_7\NN|NONE
D003907_D006973 CID dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
D003907_D006973 CID dex)-induced_13\VBN|, (r_amod) hypertension_14\NN|(
D003907_D006973 CID dex_2\NN| (r_npadvmod) induced_4\VBN|+/ (r_amod) hypertension_5\NN|)|mmHg|,|mmHg|decreased|and|Atorva|vs.
D003907_D006973 CID dexamethasone_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypertension_9\NN|NONE
C065179_D006973 NONE Atorvastatin_0\NNS|reversed|and|. (r_nsubj) prevented_1\VBD|NONE (l_conj) reversed_3\VBD|and|.|Atorvastatin (l_dobj) hypertension_7\NN|NONE
C065179_D006973 NONE atorvastatin_6\NN|)|( (r_nmod) atorva_8\NN|NONE (r_pobj) of_5\IN|antioxidant|on|the (r_prep) effects_4\NNS|To (l_prep) on_10\IN|antioxidant|the|of (l_pobj) dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
C065179_D006973 NONE atorva_8\NN|NONE (r_pobj) of_5\IN|antioxidant|on|the (r_prep) effects_4\NNS|To (l_prep) on_10\IN|antioxidant|the|of (l_pobj) dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
C065179_D006973 NONE atorva_25\NN|tap|kg (r_nmod) water_34\NN|NONE (r_pobj) with_24\IN|were|assess|.|for|rats (r_prep) treated_23\VBN|NONE (l_advcl) assess_1\VB|were|with|.|for|rats (l_dobj) effects_4\NNS|To (l_prep) on_10\IN|antioxidant|the|of (l_pobj) dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
C065179_D006973 NONE Atorva_0\NN|)|mmHg|,|mmHg|decreased|hypertension|and|vs. (r_nsubj) reversed_1\VBN|NONE (l_dobj) hypertension_5\NN|)|mmHg|,|mmHg|decreased|and|Atorva|vs.
C065179_D006973 NONE atorvastatin_2\NN|,|.|and|reversed|Thus (r_nsubj) prevented_3\VBN|NONE (l_conj) reversed_5\VBN|,|.|atorvastatin|and|Thus (l_dobj) hypertension_9\NN|NONE
18674790
D004317_D009765 NONE doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|NONE (r_compound) cardiotoxicity_14\NN|NONE (r_pobj) to_10\IN|highly (r_prep) sensitive_9\JJ|rats|. (r_acomp) are_7\VBP|NONE (l_nsubj) rats_6\NNS|sensitive|. (l_amod) obese_5\JJ|fed|fat|High
D004317_D009765 NONE doxorubicin_40\RB| (r_npadvmod) induced_42\VBN|NONE (r_compound) cardiotoxicity_43\NN|NONE (r_pobj) to_39\IN|intervention|,|whether (r_prep) sensitizes_38\VBZ|we|.|,|In (l_nsubj) intervention_10\NN|to|,|whether (l_prep) by_11\IN|physiological|a (l_pcomp) feeding_12\VBG|NONE (l_dobj) diet_17\NN|NONE (l_relcl) induces_23\VBZ|,|HFD|fat|)|(|high|% (l_dobj) obesity_24\NN|g|which
D004317_D009765 NONE doxorubicin_7\NN|/|mg|ip|(|)|, (r_nmod) kg_9\NNS|.|LD(|administered|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|.|LD(|kg|A (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|HFD|feeding (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|lipid|,|and (l_prep) in_37\IN|in|% (l_pobj) rats_43\NNS|NONE (l_amod) obese_39\JJ|the|)|OB|(
D004317_D009765 NONE doxorubicin_7\NN|/|mg|ip|(|)|, (r_nmod) kg_9\NNS|.|LD(|administered|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|.|LD(|kg|A (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|HFD|feeding (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|lipid|,|and (l_prep) in_37\IN|in|% (l_pobj) rats_43\NNS|NONE (l_nmod) OB_41\NNP|the|)|obese|(
D004317_D009765 NONE Doxorubicin_0\NNP|NONE (r_compound) toxicokinetics_1\NNS|NONE (r_compound) studies_2\NNS|.|change (r_nsubj) revealed_3\VBD|NONE (l_dobj) change_5\NN|.|studies (l_conj) hearts_27\NNS|no|and|in|)|in (l_compound) OB_26\NNP|NONE
D004317_D009765 NONE doxorubicin_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) accumulation_7\NN|NONE (r_pobj) in_6\IN|hearts|no|and|in|) (r_prep) change_5\NN|.|studies (l_conj) hearts_27\NNS|no|and|in|)|in (l_compound) OB_26\NNP|NONE
D004317_D009765 NONE doxorubicin_109\NN|NONE (r_compound) administration_110\NN|NONE (r_pobj) after_108\IN|ADP|decreased (r_prep) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|%|)|in||( (r_acl) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|studies|decreased|. (l_nsubjpass) rats_5\NNS|that|due|are (l_compound) OB_4\NNP|NONE
D004317_D009765 NONE doxorubicin_109\NN|NONE (r_compound) administration_110\NN|NONE (r_pobj) after_108\IN|ADP|decreased (r_prep) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|%|)|in||( (r_acl) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (l_nsubj) stress_16\NN|drop|,|and|kinase (l_acl) activated_35\VBN|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN|min|g|)|in (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|g|.+/. (l_pobj) OB_76\NNP|NONE
D004317_D009765 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE (r_pobj) to_11\IN|highly|by (r_prep) sensitized_10\JJ|.|,|In|rats (r_acomp) are_8\VBP|NONE (l_nsubj) rats_7\NNS|.|sensitized|,|In (l_amod) obese_6\JJ|induced
D004317_D066126 NONE doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|NONE (r_compound) cardiotoxicity_14\NN|NONE
D004317_D066126 NONE doxorubicin_4\NN|NONE (r_pobj) by_3\IN|NONE (r_prep) chemotherapy_2\NN|due|Often|,|is|. (r_nsubjpass) limited_9\VBN|NONE (l_prep) due_10\IN|Often|,|chemotherapy|is|. (l_pobj) life_12\NN|to (l_acl) threatening_13\VBG|NONE (l_dobj) cardiotoxicity_14\NN|during
D004317_D066126 NONE Adriamycin_6\NNP|NONE (r_punct) )_7\-RRB-|NONE (r_punct) is_8\VBZ|due|Often|,|chemotherapy|. (r_auxpass) limited_9\VBN|NONE (l_prep) due_10\IN|Often|,|chemotherapy|is|. (l_pobj) life_12\NN|to (l_acl) threatening_13\VBG|NONE (l_dobj) cardiotoxicity_14\NN|during
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE
D004317_D066126 NONE doxorubicin_40\RB| (r_npadvmod) induced_42\VBN|NONE (r_compound) cardiotoxicity_43\NN|NONE
D004317_D066126 NONE doxorubicin_7\NN|/|mg|ip|(|)|, (r_nmod) kg_9\NNS|.|LD(|administered|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|.|LD(|kg|A (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|HFD|feeding (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE
C010013_D009765 NONE doxorubicinol_11\NN|and (r_conj) doxorubicin_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) accumulation_7\NN|NONE (r_pobj) in_6\IN|hearts|no|and|in|) (r_prep) change_5\NN|.|studies (l_conj) hearts_27\NNS|no|and|in|)|in (l_compound) OB_26\NNP|NONE
D004317_D056486 NONE doxorubicin_7\NN|/|mg|ip|(|)|, (r_nmod) kg_9\NNS|.|LD(|administered|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|.|LD(|kg|A (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|HFD|feeding (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|lipid|,|and (l_prep) in_44\IN|%|in (l_pobj) absence_46\NN|NONE (l_prep) of_47\IN|the (l_pobj) toxicity_53\NN|NONE
D000255_D066126 NONE ATP_21\NNP|mitochondrial|cardiac (r_compound) generation_22\NN|substantially|,|increasing (r_dobj) downregulating_18\VBG|NONE (r_pcomp) by_16\IN|to|highly (r_prep) sensitized_10\JJ|.|,|In|rats (l_prep) to_11\IN|highly|by (l_pobj) cardiotoxicity_15\NN|NONE
D004041_D066126 NONE fat_1\JJ|fed|High|obese (r_amod) rats_6\NNS|sensitive|. (r_nsubj) are_7\VBP|NONE (l_acomp) sensitive_9\JJ|rats|. (l_prep) to_10\IN|highly (l_pobj) cardiotoxicity_14\NN|NONE
D004041_D066126 NONE fat_16\JJ|,|HFD|)|(|high|%|induces (r_amod) diet_17\NN|NONE (r_dobj) feeding_12\VBG|NONE (r_pcomp) by_11\IN|physiological|a (r_prep) intervention_10\NN|to|,|whether (r_nsubj) sensitizes_38\VBZ|we|.|,|In (l_prep) to_39\IN|intervention|,|whether (l_pobj) cardiotoxicity_43\NN|NONE
D004317_D007674 NONE doxorubicin_7\NN|/|mg|ip|(|)|, (r_nmod) kg_9\NNS|.|LD(|administered|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|.|LD(|kg|A (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|HFD|feeding (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|lipid|,|and (l_prep) in_44\IN|%|in (l_pobj) absence_46\NN|NONE (l_prep) of_47\IN|the (l_pobj) toxicity_53\NN|NONE
D000244_D009765 NONE ADP_106\NNP|after|decreased (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|%|)|in||( (r_acl) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|studies|decreased|. (l_nsubjpass) rats_5\NNS|that|due|are (l_compound) OB_4\NNP|NONE
D000244_D009765 NONE ADP_106\NNP|after|decreased (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|%|)|in||( (r_acl) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (l_nsubj) stress_16\NN|drop|,|and|kinase (l_acl) activated_35\VBN|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN|min|g|)|in (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|g|.+/. (l_pobj) OB_76\NNP|NONE
D004041_D009765 CID fat_1\JJ|fed|High|obese (r_amod) rats_6\NNS|sensitive|. (l_amod) obese_5\JJ|fed|fat|High
D004041_D009765 CID fat_16\JJ|,|HFD|)|(|high|%|induces (r_amod) diet_17\NN|NONE (l_relcl) induces_23\VBZ|,|HFD|fat|)|(|high|% (l_dobj) obesity_24\NN|g|which
D004317_D006331 CID doxorubicin_7\NN|/|mg|ip|(|)|, (r_nmod) kg_9\NNS|.|LD(|administered|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|.|LD(|kg|A (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|HFD|feeding (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|,
D000255_D009765 NONE ATP_99\NNP|cardiac (r_compound) levels_100\NNS|NONE (r_pobj) in_97\IN|%|)||accompanied|( (r_prep) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|studies|decreased|. (l_nsubjpass) rats_5\NNS|that|due|are (l_compound) OB_4\NNP|NONE
D000255_D009765 NONE ATP_99\NNP|cardiac (r_compound) levels_100\NNS|NONE (r_pobj) in_97\IN|%|)||accompanied|( (r_prep) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (l_nsubj) stress_16\NN|drop|,|and|kinase (l_acl) activated_35\VBN|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN|min|g|)|in (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|g|.+/. (l_pobj) OB_76\NNP|NONE
D000255_D009765 NONE ATP_104\NNP|/ (r_nmod) ADP_106\NNP|after|decreased (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|%|)|in||( (r_acl) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|studies|decreased|. (l_nsubjpass) rats_5\NNS|that|due|are (l_compound) OB_4\NNP|NONE
D000255_D009765 NONE ATP_104\NNP|/ (r_nmod) ADP_106\NNP|after|decreased (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|%|)|in||( (r_acl) drop_96\NN|stress|,|and|kinase (r_conj) decreased_82\VBD|studies|sensitized|. (l_nsubj) stress_16\NN|drop|,|and|kinase (l_acl) activated_35\VBN|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN|min|g|)|in (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|g|.+/. (l_pobj) OB_76\NNP|NONE
D000255_D009765 NONE ATP_21\NNP|mitochondrial|cardiac (r_compound) generation_22\NN|substantially|,|increasing (r_dobj) downregulating_18\VBG|NONE (r_pcomp) by_16\IN|to|highly (r_prep) sensitized_10\JJ|.|,|In|rats (r_acomp) are_8\VBP|NONE (l_nsubj) rats_7\NNS|.|sensitized|,|In (l_amod) obese_6\JJ|induced
D000249_D009765 NONE AMP_84\NN| (r_compound) alpha2_86\NN|mitochondrial|protein (r_compound) kinase_88\NN|drop|stress|,|and (r_dobj) decreased_82\VBD|studies|sensitized|. (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|studies|decreased|. (l_nsubjpass) rats_5\NNS|that|due|are (l_compound) OB_4\NNP|NONE
D000249_D009765 NONE AMP_84\NN| (r_compound) alpha2_86\NN|mitochondrial|protein (r_compound) kinase_88\NN|drop|stress|,|and (r_dobj) decreased_82\VBD|studies|sensitized|. (l_nsubj) stress_16\NN|drop|,|and|kinase (l_acl) activated_35\VBN|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN|min|g|)|in (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|g|.+/. (l_pobj) OB_76\NNP|NONE
8424298
D007530_D007022 CID isoflurane_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) labetalol_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|deliberate (r_acl) hypotension_3\NN|NONE
D007530_D007022 CID isoflurane_18\JJ|(|hypotensive (r_amod) group_21\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) labetalol_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|deliberate (r_acl) hypotension_13\NN|NONE
D007530_D007022 CID isoflurane_18\JJ|(|hypotensive (r_amod) group_21\NN|NONE (l_amod) hypotensive_20\JJ|(|isoflurane
D007530_D007022 CID isoflurane_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) labetalol_7\NN|NONE (r_pobj) by_6\IN|hypotension|that (r_prep) induced_5\VBN|has|.|results (l_nsubj) hypotension_4\NN|that|by
D007741_D007022 CID labetalol_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|deliberate (r_acl) hypotension_3\NN|NONE
D007741_D007022 CID labetalol_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|deliberate (r_acl) hypotension_13\NN|NONE
D007741_D007022 CID labetalol_16\NN|NONE (l_prep) with_17\IN|NONE (l_pobj) group_21\NN|NONE (l_amod) hypotensive_20\JJ|(|isoflurane
D007741_D007022 CID labetalol_7\NN|NONE (r_pobj) by_6\IN|hypotension|that (r_prep) induced_5\VBN|has|.|results (l_nsubj) hypotension_4\NN|that|by
9758264
D005492_D008180 CID acid_4\NN|NONE (r_pobj) of_2\IN|Epileptogenic (r_prep) activity_1\NN|SLE|after|) (r_nsubj) induces_7\VBZ|NONE (l_dobj) SLE_8\NNP|activity|after|)
D005492_D008180 CID acid_11\NN|( (r_appos) SLE_8\NNP|activity|after|)
D005492_D008180 CID acid_35\NN|NONE (r_pobj) of_33\IN|>|(|therapeutic|the|) (r_prep) dose_25\NN|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD|NONE (l_ccomp) damage_15\VB|cluster|therefore|.|,|dose (l_nsubj) disease_6\NN|barrier|could (l_appos) lupus_12\NN|)|(|autoimmune|patient
D005492_D012640 CID acid_35\NN|NONE (r_pobj) of_33\IN|>|(|therapeutic|the|) (r_prep) dose_25\NN|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD|NONE (l_dobj) cluster_38\NN|damage|therefore|.|,|dose (l_prep) of_39\IN|a (l_pobj) seizures_40\NNS|NONE
D005492_D001327 NONE acid_35\NN|NONE (r_pobj) of_33\IN|>|(|therapeutic|the|) (r_prep) dose_25\NN|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD|NONE (l_ccomp) damage_15\VB|cluster|therefore|.|,|dose (l_nsubj) disease_6\NN|barrier|could
D005492_D001327 NONE acid_9\NN|NONE (r_pobj) of_7\IN|(|)|<| (r_prep) mg_5\NN|,|in|,|Physiological|without (r_appos) dose_1\NN|did|not|risk|. (l_prep) without_19\IN|mg|,|in|,|Physiological (l_pobj) disease_22\NN|all
D005492_D004827 NONE acid_4\NN|NONE (r_pobj) of_2\IN|Epileptogenic (r_prep) activity_1\NN|SLE|after|) (r_nsubj) induces_7\VBZ|NONE (l_dobj) SLE_8\NNP|activity|after|) (l_appos) acid_11\NN|( (l_conj) epilepsy_13\NN|folic|and
D005492_D004827 NONE acid_11\NN|( (l_conj) epilepsy_13\NN|folic|and
D005492_D004827 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|folic|multivitamin|in (r_amod) supplementation_10\NN|NONE (l_prep) in_11\IN|folic|multivitamin|containing (l_pobj) women_13\NNS|NONE (l_amod) epileptic_12\JJ|NONE
D005492_D004827 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|folic|multivitamin|in (r_amod) supplementation_10\NN|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To|in|.|before (r_dobj) study_1\VB|NONE (l_prep) in_18\IN|effect|To|.|before (l_pobj) order_19\NN|NONE (l_acl) determine_21\VB|NONE (l_dobj) rate_23\NN|to (l_prep) of_24\IN|the (l_pobj) defects_27\NNS|NONE (l_conj) effects_33\NNS|and|birth|structural (l_amod) related_31\VBN|side (l_npadvmod) epilepsy_29\NN|
D005492_D004827 NONE acid_7\NN|NONE (r_pobj) with_4\IN|.||epileptic (r_prep) women_3\NNS|NONE (l_amod) epileptic_2\JJ|.||with
D005492_D004827 NONE acid_7\NN|NONE (l_appos) effects_21\NNS|supplementation|folic|,|periconceptional|( (l_amod) related_19\VBN|during|developed|side (l_npadvmod) epilepsy_17\NN|
D005492_D004827 NONE acid_14\NN|and (r_conj) carbamazepine_10\NN|NONE (r_pobj) by_9\IN|was|.|continuously|woman (r_agent) treated_7\VBN|NONE (l_nsubjpass) woman_5\NN|by|was|.|continuously (l_amod) epileptic_4\JJ|old|This
D005492_D004827 NONE acid_35\NN|NONE (r_pobj) of_33\IN|>|(|therapeutic|the|) (r_prep) dose_25\NN|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD|NONE (l_ccomp) damage_15\VB|cluster|therefore|.|,|dose (l_nsubj) disease_6\NN|barrier|could (l_poss) patient_3\NN|)|lupus|(|autoimmune (l_amod) epileptic_1\JJ|'s|pregnant|The
D005492_D004827 NONE acid_9\NN|NONE (r_pobj) of_7\IN|(|)|<| (r_prep) mg_5\NN|,|in|,|Physiological|without (r_appos) dose_1\NN|did|not|risk|. (l_prep) in_11\IN|mg|,|,|Physiological|without (l_pobj) women_16\NNS|both (l_amod) epileptic_15\JJ|healthy|
D005492_D004827 NONE acid_9\NN|NONE (r_pobj) of_7\IN|(|)|<| (r_prep) mg_5\NN|,|in|,|Physiological|without (r_appos) dose_1\NN|did|not|risk|. (r_nsubj) increase_26\VB|NONE (l_dobj) risk_28\NN|did|not|.|dose (l_prep) for_29\IN|the (l_pobj) seizures_31\NNS|NONE
D002220_D004827 NONE carbamazepine_10\NN|NONE (r_pobj) by_9\IN|was|.|continuously|woman (r_agent) treated_7\VBN|NONE (l_nsubjpass) woman_5\NN|by|was|.|continuously (l_amod) epileptic_4\JJ|old|This
D005492_D000014 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|folic|multivitamin|in (r_amod) supplementation_10\NN|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To|in|.|before (r_dobj) study_1\VB|NONE (l_prep) in_18\IN|effect|To|.|before (l_pobj) order_19\NN|NONE (l_acl) determine_21\VB|NONE (l_dobj) rate_23\NN|to (l_prep) of_24\IN|the (l_pobj) defects_27\NNS|NONE
9875685
D014031_D064420 NONE tobramicyn_17\NN|NONE (l_prep) on_18\IN|NONE (l_pobj) concentrations_23\NNS|NONE (l_conj) toxicity_25\NN|and|serum|state
D003404_D007674 NONE creatinine_2\NN|.|was|versus|in|,|without (r_nsubjpass) observed_4\VBN|NONE (l_prep) without_20\IN|.|creatinine|was|versus|in|, (l_pobj) evidence_21\NN|NONE (l_prep) of_22\IN|NONE (l_pobj) nephrotoxicity_23\NN|NONE
20331935
D013739_D006966 NONE testosterone_1\NN|Serum (r_compound) concentration_2\NN|.|affected|but|with (r_nsubj) increased_3\VBD|NONE (l_conj) affected_10\VBN|.|but|with|concentration (l_agent) by_11\IN|was|not (l_pobj) hyperprolactinemia_12\NN|NONE
D018967_D050723 NONE risperidone_8\NN|were|after (r_nsubjpass) started_12\VBN||and|occurred|fractures|, (r_advcl) occurred_6\VBD|NONE (l_nsubj) fractures_3\NNS||and|occurred|started|,
D018967_D006966 CID risperidone_12\NN| (r_npadvmod) induced_14\VBN|on (r_amod) hyperprolactinemia_15\NN|NONE
D018967_D006966 CID risperidone_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|of| (r_acl) %_6\NN|NONE (r_pobj) in_4\IN|NONE (r_prep) present_3\JJ|:|Hyperprolactinemia|. (r_acomp) was_2\VBD|NONE (l_nsubj) Hyperprolactinemia_1\NNP|:|.|present
D018967_D006966 CID risperidone_8\NN|were|after (r_nsubjpass) started_12\VBN||and|occurred|fractures|, (r_advcl) occurred_6\VBD|NONE (l_conj) occurred_16\VBD||and|fractures|started|, (l_prep) in_17\IN|none|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) hyperprolactinemia_20\NN|NONE
D018967_D006966 CID risperidone_7\NN| (r_npadvmod) induced_9\VBN|treatment|and (r_amod) hyperprolactinemia_10\NN|to|lower
16225977
C076029_D013981 NONE olanzapine_13\NN|, (r_conj) risperidone_11\NN|such (r_pobj) as_10\IN|atypical (r_prep) antipsychotics_8\NNS|NONE (r_pobj) by_6\IN|can|disorders|be|.|effectively (r_agent) treated_5\VBN|NONE (l_nsubjpass) disorders_1\NNS|can|by|be|.|effectively
C092292_D013981 NONE ziprasidone_15\NN|and (r_conj) olanzapine_13\NN|, (r_conj) risperidone_11\NN|such (r_pobj) as_10\IN|atypical (r_prep) antipsychotics_8\NNS|NONE (r_pobj) by_6\IN|can|disorders|be|.|effectively (r_agent) treated_5\VBN|NONE (l_nsubjpass) disorders_1\NNS|can|by|be|.|effectively
C012052_D012559 NONE Amisulpride_0\NNP|.|in|like|related (r_amod) symptoms_5\NNS|NONE (l_prep) in_6\IN|Amisulpride|.|like|related (l_pobj) schizophrenic_9\NN|NONE
C012052_D012559 NONE amisulpride_20\JJ|NONE (r_amod) treatment_21\NN|NONE (r_pobj) of_19\IN| (r_prep) months_18\NNS|NONE (r_pobj) after_16\IN|movements|who (r_prep) developed_9\VBD|mg|old|girl|a (r_relcl) schizophrenic_7\NN|We|.
C012052_D020820 NONE amisulpride_20\JJ|NONE (r_amod) treatment_21\NN|NONE (r_pobj) of_19\IN| (r_prep) months_18\NNS|NONE (r_pobj) after_16\IN|movements|who (r_prep) developed_9\VBD|mg|old|girl|a (l_dobj) movements_15\NNS|after|who
D003024_D013981 NONE clozapine_26\NN|or (r_conj) quetiapine_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|NONE (r_prep) occurring_20\VBG|symptoms|that (r_xcomp) show_8\VBP|case (l_dobj) symptoms_12\NNS|occurring|that
D003024_D013981 NONE clozapine_29\NN|, (r_conj) quetiapine_27\NN|such (r_pobj) as_26\IN|atypical (r_prep) antipsychotics_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) during_20\IN|in|that|might|symptoms (r_prep) occur_15\VB|with|,|patient|. (l_nsubj) symptoms_13\NNS|in|during|that|might
C069541_D013981 NONE quetiapine_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|NONE (r_prep) occurring_20\VBG|symptoms|that (r_xcomp) show_8\VBP|case (l_dobj) symptoms_12\NNS|occurring|that
C069541_D013981 NONE quetiapine_27\NN|such (r_pobj) as_26\IN|atypical (r_prep) antipsychotics_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) during_20\IN|in|that|might|symptoms (r_prep) occur_15\VB|with|,|patient|. (l_nsubj) symptoms_13\NNS|in|during|that|might
C012052_D013981 CID Amisulpride_0\NNP|.|in|like|related (r_amod) symptoms_5\NNS|NONE
C012052_D013981 CID amisulpride_13\NN|NONE (r_pobj) of_12\IN|the|mg (r_prep) dose_11\NN|we|completely|after (r_dobj) reduced_9\VBD|symptoms|. (r_advcl) resolved_5\VBN|NONE (l_nsubj) symptoms_4\NNS|.|reduced
C012052_D013981 CID amisulpride_32\NN|,|or (r_conj) clozapine_29\NN|, (r_conj) quetiapine_27\NN|such (r_pobj) as_26\IN|atypical (r_prep) antipsychotics_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) during_20\IN|in|that|might|symptoms (r_prep) occur_15\VB|with|,|patient|. (l_nsubj) symptoms_13\NNS|in|during|that|might
D018967_D013981 NONE risperidone_11\NN|such (r_pobj) as_10\IN|atypical (r_prep) antipsychotics_8\NNS|NONE (r_pobj) by_6\IN|can|disorders|be|.|effectively (r_agent) treated_5\VBN|NONE (l_nsubjpass) disorders_1\NNS|can|by|be|.|effectively
6540303
D007649_D002389 CID ketamine_5\NN|NONE (r_compound) catatonia_6\NN|NONE
D007649_D002389 CID ketamine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) catatonia_18\NN|NONE
D007649_D002389 CID ketamine_17\NN|NONE (r_pobj) after_16\IN|duration|,|but|In|,|pretreatment|did (r_prep) increased_8\VBD|NONE (l_dobj) duration_10\NN|,|but|In|,|pretreatment|did|after (l_prep) of_11\IN|the (l_pobj) catatonia_12\NNP|NONE
D007649_D002389 CID ketamine_15\NN|than (r_compound) catatonia_16\NNP|NONE
D004298_D002389 CID dopamine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) pretreatment_5\NN|duration|,|but|In|,|did|after (r_nsubj) increased_8\VBD|NONE (l_dobj) duration_10\NN|,|but|In|,|pretreatment|did|after (l_prep) of_11\IN|the (l_pobj) catatonia_12\NNP|NONE
D004298_D002389 CID dopamine_2\NN|.|act|,|Furthermore (r_nsubj) appeared_3\VBD|NONE (l_xcomp) act_5\VB|.|dopamine|,|Furthermore (l_prep) on_6\IN|to (l_pobj) systems_7\NNS|NONE (l_acl) involved_10\JJ|NONE (l_prep) with_11\IN|closely (l_pobj) induction_13\NN|NONE (l_prep) of_14\IN|on|the (l_pobj) catatonia_16\NNP|NONE
D002395_D002389 NONE catecholamines_10\NNS|NONE (r_pobj) of_9\IN|the|on (r_prep) role_8\NN|to|in (l_prep) on_14\IN|the|of (l_pobj) catatonia_18\NN|NONE
D009638_D002389 NONE norepinephrine_22\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) pretreatment_20\NN|.|not (r_nsubj) did_23\VBD|duration|,|but|In|,|pretreatment|after (r_conj) increased_8\VBD|NONE (l_dobj) duration_10\NN|,|but|In|,|pretreatment|did|after (l_prep) of_11\IN|the (l_pobj) catatonia_12\NNP|NONE
D000588_D002389 NONE amine_2\NN|on (r_compound) pretreatment_3\NN|NONE (l_prep) on_4\IN|amine (l_pobj) catatonia_6\NN|NONE
6292680
D004317_D009202 CID Doxorubicin_0\JJ|.|in (r_nsubj) cardiomyopathy_1\NN|NONE
D004317_D009202 CID doxorubicin_23\NN|NONE (r_pobj) of_22\IN|conventional (r_prep) dosage_21\NN|tumor|the|and (r_conj) bed_18\NN|NONE (r_pobj) to_15\IN|NONE (r_prep) irradiation_14\NN|NONE (r_pobj) after_13\IN|.|children|cardiomyopathy (r_prep) experienced_9\VBD|NONE (l_dobj) cardiomyopathy_12\NN|.|after|children
D004317_D009202 CID doxorubicin_30\NN|NONE (r_pobj) of_29\IN|the|on (r_prep) interaction_28\NN|NONE (r_pobj) to_26\IN|fields|that|portion (r_prep) include_16\VBP|the (r_acl) fact_8\NN|NONE (r_pobj) to_6\IN|cardiomyopathy||)|.|is (r_prep) attributed_3\VBN|NONE (l_nsubjpass) cardiomyopathy_1\NN||to|)|.|is
D018943_D009202 NONE anthracycline_11\NN|severe (r_amod) cardiomyopathy_12\NN|.|after|children
D004317_D009369 NONE doxorubicin_23\NN|NONE (r_pobj) of_22\IN|conventional (r_prep) dosage_21\NN|tumor|the|and (r_conj) bed_18\NN|NONE (l_compound) tumor_17\NN|dosage|the|and
D004317_D009396 NONE Doxorubicin_0\JJ|.|in (r_nsubj) cardiomyopathy_1\NN|NONE (l_prep) in_2\IN|.|Doxorubicin (l_pobj) children_3\NNS|NONE (l_prep) with_4\IN|NONE (l_pobj) tumor_9\NN|NONE
D004317_D009396 NONE doxorubicin_23\NN|NONE (r_pobj) of_22\IN|conventional (r_prep) dosage_21\NN|tumor|the|and (r_conj) bed_18\NN|NONE (r_pobj) to_15\IN|NONE (r_prep) irradiation_14\NN|NONE (r_pobj) after_13\IN|.|children|cardiomyopathy (r_prep) experienced_9\VBD|NONE (l_nsubj) children_1\NNS|.|after|cardiomyopathy (l_prep) with_2\IN|Two (l_pobj) tumor_4\NN|NONE
D004317_D009396 NONE doxorubicin_30\NN|NONE (r_pobj) of_29\IN|the|on (r_prep) interaction_28\NN|NONE (r_pobj) to_26\IN|fields|that|portion (r_prep) include_16\VBP|the (l_nsubj) fields_11\VBZ|that|to|portion (l_prep) for_12\IN|radiation (l_pobj) tumor_15\NN|NONE
D004317_D009396 NONE doxorubicin_4\NN|NONE (r_compound) dosage_5\NN|sharply|in|be|that (r_nsubjpass) restricted_8\VBN|is|.|It (l_prep) in_9\IN|sharply|dosage|be|that (l_pobj) children_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) tumor_13\NN|NONE
D018943_D009369 NONE anthracycline_11\NN|severe (r_amod) cardiomyopathy_12\NN|.|after|children (r_dobj) experienced_9\VBD|NONE (l_prep) after_13\IN|.|children|cardiomyopathy (l_pobj) irradiation_14\NN|NONE (l_prep) to_15\IN|NONE (l_pobj) bed_18\NN|NONE (l_compound) tumor_17\NN|dosage|the|and
D018943_D009396 NONE anthracycline_11\NN|severe (r_amod) cardiomyopathy_12\NN|.|after|children (r_dobj) experienced_9\VBD|NONE (l_nsubj) children_1\NNS|.|after|cardiomyopathy (l_prep) with_2\IN|Two (l_pobj) tumor_4\NN|NONE
2826064
D013726_D007008 CID terbutaline_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) hypokalemia_12\NN|NONE
D013726_D007008 CID terbutaline_4\JJ|higher|after (r_compound) concentrations_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) spite_1\NN|NONE (r_pobj) In_0\IN|.|,|was|completely|by|hypokalemia (r_prep) antagonized_15\VBN|NONE (l_nsubjpass) hypokalemia_11\NN|.|In|,|was|completely|by
D010096_D007008 NONE oxprenolol_8\NN|NONE (r_pobj) by_7\IN|its (r_prep) abolishment_6\NN|mediated|and|. (r_conj) hypokalemia_3\NN|NONE
D010096_D007008 NONE oxprenolol_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) efficacy_4\NN|.|we|with|,|in|Subsequently (r_dobj) investigated_2\VBD|NONE (l_prep) in_7\IN|.|we|with|,|Subsequently|efficacy (l_pcomp) antagonizing_8\VBG|NONE (l_dobj) hypokalemia_10\NN|NONE
D010096_D007008 NONE oxprenolol_7\NN|NONE (r_amod) pretreatment_8\NN|NONE (r_pobj) after_6\IN|higher|terbutaline (r_prep) concentrations_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) spite_1\NN|NONE (r_pobj) In_0\IN|.|,|was|completely|by|hypokalemia (r_prep) antagonized_15\VBN|NONE (l_nsubjpass) hypokalemia_11\NN|.|In|,|was|completely|by
9915601
D005680_D001919 NONE acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|.|,|of|High|hypotension (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High (l_conj) change_10\VB|induced|increase|and (l_prep) to_15\IN|tachycardia (l_pobj) bradycardia_16\NNP|NONE
D005680_D001919 NONE GABA_31\NNP|aminobutyric|brain (r_appos) acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|.|,|of|High|hypotension (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High (l_conj) change_10\VB|induced|increase|and (l_prep) to_15\IN|tachycardia (l_pobj) bradycardia_16\NNP|NONE
D007538_D001919 CID isoniazid_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) pretreated_10\VBD|NONE (r_acl) rats_9\NNS|NONE (r_pobj) in_8\IN|adrenoceptor (r_prep) antagonists_7\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Enhanced (r_acl) bradycardia_1\NNS|NONE
D007538_D001919 CID isoniazid_3\NN|NONE (r_pobj) of_2\IN|.|,|interaction|High|hypotension (r_prep) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High (l_conj) change_10\VB|induced|increase|and (l_prep) to_15\IN|tachycardia (l_pobj) bradycardia_16\NNP|NONE
D007538_D001919 CID isoniazid_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) bradycardia_11\NN|NONE
D007538_D001919 CID Isoniazid_0\NNP|,|bradycardia|significantly|,|but|propranolol|as|after|. (r_nsubj) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D018738_D001919 NONE hexamethonium_22\NN|not (r_pobj) after_21\IN|,|bradycardia|significantly|,|but|propranolol|Isoniazid|as|. (r_conj) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D001262_D001919 NONE atenolol_11\NN|and (r_conj) labetalol_9\JJ|, (r_conj) pindolol_7\NN|after|, (r_conj) propranolol_5\NN|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D003000_D001919 NONE clonidine_17\NN|NONE (r_pobj) after_16\IN|as|well (r_prep) as_15\IN|,|bradycardia|significantly|,|but|propranolol|Isoniazid|after|. (r_cc) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D007538_D013610 NONE isoniazid_3\NN|NONE (r_pobj) of_2\IN|.|,|interaction|High|hypotension (r_prep) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High (l_conj) change_10\VB|induced|increase|and (l_dobj) tachycardia_14\NN|to
D007538_D007022 CID isoniazid_3\NN|NONE (r_pobj) of_2\IN|.|,|interaction|High|hypotension (r_prep) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High
D011433_D001919 NONE propranolol_5\NN|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D007741_D001919 NONE labetalol_9\JJ|, (r_conj) pindolol_7\NN|after|, (r_conj) propranolol_5\NN|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D010869_D001919 NONE pindolol_7\NN|after|, (r_conj) propranolol_5\NN|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D014520_D001919 NONE urethane_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) anaesthetised_22\VBN|NONE (r_acl) rats_21\NNS|NONE (r_pobj) in_20\IN|.|was|In|,|enhancement (r_prep) determined_19\VBN|NONE (l_nsubjpass) enhancement_7\NN|.|was|In|in|, (l_prep) by_8\IN|induced|the|possible (l_pobj) isoniazid_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) bradycardia_11\NN|NONE
D005680_D007022 NONE acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|.|,|of|High|hypotension (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High
D005680_D007022 NONE GABA_31\NNP|aminobutyric|brain (r_appos) acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|.|,|of|High|hypotension (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High
D002217_D001919 NONE carbachol_24\NN|or (r_conj) hexamethonium_22\NN|not (r_pobj) after_21\IN|,|bradycardia|significantly|,|but|propranolol|Isoniazid|as|. (r_conj) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D002698_D001919 NONE chloralose_24\NN| (r_compound) urethane_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) anaesthetised_22\VBN|NONE (r_acl) rats_21\NNS|NONE (r_pobj) in_20\IN|.|was|In|,|enhancement (r_prep) determined_19\VBN|NONE (l_nsubjpass) enhancement_7\NN|.|was|In|in|, (l_prep) by_8\IN|induced|the|possible (l_pobj) isoniazid_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) bradycardia_11\NN|NONE
D005680_D013610 NONE acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|.|,|of|High|hypotension (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High (l_conj) change_10\VB|induced|increase|and (l_dobj) tachycardia_14\NN|to
D005680_D013610 NONE GABA_31\NNP|aminobutyric|brain (r_appos) acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|.|,|of|High|hypotension (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|.|,|of|interaction|High (l_conj) change_10\VB|induced|increase|and (l_dobj) tachycardia_14\NN|to
6496797
D014196_D006327 CID trazodone_8\NN|NONE (r_pobj) of_7\IN|a|single (r_prep) dose_6\NN|NONE (r_pobj) following_3\VBG|heart|Complete|. (r_prep) block_2\NN|NONE
D014196_D006327 CID trazodone_9\NN|NONE (r_pobj) of_8\IN|a|single|starting (r_prep) dose_7\NN|NONE (r_dobj) receiving_3\VBG|minutes (r_pcomp) after_2\IN|block|.|,|patient (r_prep) developed_13\VBD|NONE (l_dobj) block_16\NN|after|.|,|patient
7604176
D017035_D009220 CID pravastatin_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|of|,|A|inhibitor (r_acl) case_1\NN|is|.|, (l_prep) of_2\IN|associated|,|A|inhibitor (l_pobj) myopathy_5\NNS|NONE
D017035_D009135 NONE Pravastatin_0\NNP| (r_npadvmod) associated_2\VBN|. (r_amod) myopathy_3\NN|NONE
D017035_D009135 NONE pravastatin_17\JJ|NONE (r_amod) discontinuation_18\NN|NONE (r_pobj) after_16\IN|in|which (r_prep) resolved_11\VBD|lower|the (r_relcl) limbs_9\NNS|NONE (r_pobj) of_6\IN|acute (r_prep) myopathy_5\NN|NONE
D017035_D009135 NONE pravastatin_11\RB| (r_npadvmod) associated_13\VBN|NONE (r_amod) myopathy_14\NNS|entity|associated|.|,|could (r_nsubj) represent_16\VB|NONE (l_advcl) associated_6\VBN|entity|myopathy|.|,|could (l_prep) with_7\IN|have|been|While|lovastatin (l_pobj) myopathy_9\NNS|NONE
D017035_D009135 NONE pravastatin_11\RB| (r_npadvmod) associated_13\VBN|NONE (r_amod) myopathy_14\NNS|entity|associated|.|,|could
D019821_D009135 NONE simvastatin_3\NN|and (r_conj) lovastatin_1\NN|with|have|been|While (r_nsubjpass) associated_6\VBN|entity|myopathy|.|,|could (l_prep) with_7\IN|have|been|While|lovastatin (l_pobj) myopathy_9\NNS|NONE
D019821_D009135 NONE simvastatin_3\NN|and (r_conj) lovastatin_1\NN|with|have|been|While (r_nsubjpass) associated_6\VBN|entity|myopathy|.|,|could (r_advcl) represent_16\VB|NONE (l_nsubj) myopathy_14\NNS|entity|associated|.|,|could
D008148_D009135 NONE lovastatin_1\NN|with|have|been|While (r_nsubjpass) associated_6\VBN|entity|myopathy|.|,|could (l_prep) with_7\IN|have|been|While|lovastatin (l_pobj) myopathy_9\NNS|NONE
D008148_D009135 NONE lovastatin_1\NN|with|have|been|While (r_nsubjpass) associated_6\VBN|entity|myopathy|.|,|could (r_advcl) represent_16\VB|NONE (l_nsubj) myopathy_14\NNS|entity|associated|.|,|could
D017035_D006937 NONE pravastatin_2\RB|.|day|He|because (r_dobj) assumed_1\VBD|NONE (l_prep) because_9\IN|pravastatin|.|day|He (l_pobj) hypercholesterolemia_11\NN|of
20466178
D016559_D003872 NONE tacrolimus_5\NN|topical (r_compound) treatment_6\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Rosaceiform|. (r_acl) dermatitis_1\NN|NONE
D016559_D003872 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|while|for (r_dobj) using_13\VBG|eruptions|who (r_advcl) developed_6\VBD| (l_dobj) eruptions_11\NNS|who|using (l_compound) dermatitis_10\NN|like
D016559_D003872 NONE tacrolimus_7\NN|such (r_pobj) as_6\IN|NONE (r_prep) immunomodulators_4\NNS|NONE (r_pobj) of_3\IN|Continuous|topical (r_prep) use_2\NN|.|as|should|reported|,|be (r_nsubjpass) regarded_12\VBN|NONE (l_prep) as_13\IN|use|.|should|reported|,|be (l_pobj) cause_16\NN|NONE (l_prep) of_17\IN|potential|a (l_pobj) dermatitis_19\NN|NONE
C117268_D003872 CID pimecrolimus_9\NN|or (r_conj) tacrolimus_7\NN|such (r_pobj) as_6\IN|NONE (r_prep) immunomodulators_4\NNS|NONE (r_pobj) of_3\IN|Continuous|topical (r_prep) use_2\NN|.|as|should|reported|,|be (r_nsubjpass) regarded_12\VBN|NONE (l_prep) as_13\IN|use|.|should|reported|,|be (l_pobj) cause_16\NN|NONE (l_prep) of_17\IN|potential|a (l_pobj) dermatitis_19\NN|NONE
D016559_D003875 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|while|for (r_dobj) using_13\VBG|eruptions|who (r_advcl) developed_6\VBD| (l_dobj) eruptions_11\NNS|who|using
D016559_D005148 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|while|for (r_dobj) using_13\VBG|eruptions|who (l_prep) for_21\IN|ointment|while (l_pobj) dermatitis_23\NN|NONE
D016559_D012393 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|while|for (r_dobj) using_13\VBG|eruptions|who (r_advcl) developed_6\VBD| (l_dobj) eruptions_11\NNS|who|using (l_amod) like_9\JJ|dermatitis (l_npadvmod) rosacea_7\NN|
663266
D003974_D014693 NONE Renografin_7\NNP|NONE (r_pobj) with_6\IN|.|often|,|fibrillation|suggesting (r_prep) occurred_2\VBD|NONE (l_nsubj) fibrillation_1\NN|.|often|,|with|suggesting
C027278_D064420 NONE %_5\NN|The|of (r_appos) toxicity_1\NN|.|into|%|was|with
C027278_D064420 NONE %_13\NN|.|into|toxicity|was|with (r_npadvmod) compared_7\VBN|NONE (l_nsubjpass) toxicity_1\NN|.|into|%|was|with
D003973_D014693 NONE diatrizoate_3\JJ|with (r_pobj) from_2\IN|Ventricular|. (r_prep) fibrillation_1\NN|NONE
D003974_D064420 NONE Renografin_7\NNP|NONE (r_pobj) with_6\IN|.|often|,|fibrillation|suggesting (r_prep) occurred_2\VBD|NONE (l_advcl) suggesting_9\VBG|.|often|,|fibrillation|with (l_ccomp) contribute_13\VBP|NONE (l_prep) to_14\IN|in|that|agents (l_pobj) toxicity_15\NN|NONE
15638391
D006220_D006966 CID haloperidol_16\NN|NONE (r_pobj) by_15\IN|.|process (r_agent) induced_14\VBN|NONE (l_nsubj) process_1\NN|by|. (l_prep) of_2\IN|Aging (l_pobj) cells_4\NNS|NONE (l_prep) of_5\IN|epithelial (l_pobj) lobe_10\NN|NONE (l_prep) in_11\IN|the|rat|lateral|prostate (l_pobj) hyperprolactinemia_13\NN|NONE
D006220_D006966 CID haloperidol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|examine|aim|. (r_advcl) was_5\VBD|NONE (l_xcomp) examine_7\VB|aim|induced|. (l_dobj) influence_9\NN|,|to (l_prep) of_10\IN|the (l_pobj) hyperprolactinemia_11\NN|NONE
D006220_D006966 CID HAL_17\NNP|on (r_appos) haloperidol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|examine|aim|. (r_advcl) was_5\VBD|NONE (l_xcomp) examine_7\VB|aim|induced|. (l_dobj) influence_9\NN|,|to (l_prep) of_10\IN|the (l_pobj) hyperprolactinemia_11\NN|NONE
15266362
D004280_D004342 CID dobutamine_13\NN|hypersensitivity|that|was (r_xcomp) related_11\VBN|NONE (l_nsubjpass) hypersensitivity_5\NN|that|was|dobutamine
D004280_D004802 CID dobutamine_13\NN|hypersensitivity|that|was (r_xcomp) related_11\VBN|NONE (l_nsubjpass) hypersensitivity_5\NN|that|was|dobutamine (l_amod) eosinophilic_7\JJ|the|(|myocarditis|)
D004280_D018754 NONE dobutamine_22\NN|drugs|and (r_compound) infusion_23\NN|NONE (r_pobj) with_21\IN|assessed|aggressively (r_prep) managed_19\VBD|.|and|was|patient|with (r_conj) admitted_14\VBN|NONE (l_prep) with_15\IN|managed|.|and|was|patient (l_pobj) failure_17\NN|NONE
D004280_D009205 CID dobutamine_13\NN|hypersensitivity|that|was (r_xcomp) related_11\VBN|NONE (l_nsubjpass) hypersensitivity_5\NN|that|was|dobutamine (l_amod) myocarditis_9\NN|the|eosinophilic|(|)
D004280_D002312 NONE dobutamine_22\NN|drugs|and (r_compound) infusion_23\NN|NONE (r_pobj) with_21\IN|assessed|aggressively (r_prep) managed_19\VBD|.|and|was|patient|with (r_conj) admitted_14\VBN|NONE (l_nsubjpass) patient_5\NN|managed|.|and|was|with (l_acl) known_7\VBN|The|old|female|,|, (l_xcomp) have_9\VB|NONE (l_dobj) cardiomyopathy_11\NN|to
2004015
D015215_D007239 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|if|in|, (r_nsubj) is_32\VBZ|to (r_ccomp) determine_26\VB|have|.|model|We|,|decreased (r_xcomp) used_2\VBN|NONE (l_dobj) model_5\NN|have|determine|.|We|,|decreased (l_prep) of_6\IN|a|murine (l_pobj) AIDS_7\NNP|NONE (l_appos) infection_9\NN|,
D015215_C565469 NONE azidothymidine_8\NN|Sensitivity|.|mice (r_advmod) treated_9\VBN|NONE (l_dobj) mice_11\NNS|Sensitivity|.|azidothymidine (l_amod) immunodeficient_10\JJ|NONE
D015215_D000163 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|if|in|, (r_nsubj) is_32\VBZ|to (r_ccomp) determine_26\VB|have|.|model|We|,|decreased (r_xcomp) used_2\VBN|NONE (l_dobj) model_5\NN|have|determine|.|We|,|decreased (l_prep) of_6\IN|a|murine (l_pobj) AIDS_7\NNP|NONE
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) anaemia_1\NN|.|poorly|is
D015215_D000740 CID AZT_6\NNP|NONE (r_appos) 3'-azido-3'dideoxythymidine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) anaemia_1\NN|.|poorly|is
D015215_D000740 CID AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|if|in|,
D015215_D000740 CID AZT_0\NNP|.|anaemia|in|,|in (r_nsubj) produced_1\VBD|NONE (l_dobj) anaemia_2\NN|.|in|,|in|AZT
D015215_D000740 CID AZT_15\NNP|NONE (r_pobj) in_14\IN|BFU||marrow (r_prep) e_13\NNP|NONE (r_pobj) of_6\IN|the (r_prep) number_5\NN|,|mice|Despite (r_nsubj) treated_16\VBD|.|up|to|observed|over (l_prep) Despite_0\IN|,|number|mice (l_pobj) anaemia_2\NN|NONE
D015215_D000740 CID AZT_8\NNP|NONE (r_pobj) in_7\IN|treated|levels|were|treated|. (r_prep) observed_6\VBD|NONE (l_conj) were_11\VBD|treated|levels|in|treated|. (l_acomp) appropriate_12\JJ|NONE (l_prep) for_13\IN|NONE (l_pobj) degree_15\NN|NONE (l_prep) of_16\IN|observed|the (l_pobj) anaemia_17\NN|NONE
D015215_D000740 CID AZT_17\NNP|with|mice (r_nsubj) treated_20\VBD|numbers|.|were (l_prep) with_22\IN|AZT|mice (l_pobj) degrees_24\NNS|NONE (l_prep) of_25\IN|similar (l_pobj) anaemia_26\NN|NONE
D015215_D000740 CID AZT_12\NNP|NONE (r_pobj) in_11\IN|NONE (r_prep) observed_10\VBN|of|the (r_acl) degree_7\NN|NONE (l_prep) of_8\IN|the|observed (l_pobj) anaemia_9\NN|NONE
D015215_D000740 CID AZT_0\NNP|and||in|levels|anaemia (r_npadvmod) induced_2\VBN|NONE (l_dobj) anaemia_4\NN|and||in|levels|AZT
D015215_D007938 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|if|in|, (r_nsubj) is_32\VBZ|to (r_ccomp) determine_26\VB|have|.|model|We|,|decreased (r_xcomp) used_2\VBN|NONE (l_dobj) model_5\NN|have|determine|.|We|,|decreased (l_prep) of_6\IN|a|murine (l_pobj) AIDS_7\NNP|NONE (l_appos) infection_9\NN|, (l_prep) of_10\IN|NONE (l_pobj) mice_13\NNS|NONE (l_prep) with_14\IN|female|CBL/ (l_pobj) leukaemia_19\NN|NONE
D015215_D045262 NONE AZT_12\NNP|NONE (r_pobj) in_11\IN|NONE (r_prep) observed_10\VBN|of|the (r_acl) degree_7\NN|NONE (r_pobj) for_5\IN|NONE (r_prep) inappropriate_4\JJ|treated|.|However|,|reticulocytosis (r_acomp) was_3\VBD|NONE (l_nsubj) reticulocytosis_2\NN|treated|.|However|inappropriate|,
C030299_D000740 NONE phenylhydrazine_22\NN|PHZ|mice|(|) (r_npadvmod) treated_26\VBD|levels|were|in|treated|. (r_conj) observed_6\VBD|NONE (l_conj) were_11\VBD|treated|levels|in|treated|. (l_acomp) appropriate_12\JJ|NONE (l_prep) for_13\IN|NONE (l_pobj) degree_15\NN|NONE (l_prep) of_16\IN|observed|the (l_pobj) anaemia_17\NN|NONE
C030299_D000740 NONE PHZ_24\NNP|mice|(|phenylhydrazine|) (r_nsubj) treated_26\VBD|levels|were|in|treated|. (r_conj) observed_6\VBD|NONE (l_conj) were_11\VBD|treated|levels|in|treated|. (l_acomp) appropriate_12\JJ|NONE (l_prep) for_13\IN|NONE (l_pobj) degree_15\NN|NONE (l_prep) of_16\IN|observed|the (l_pobj) anaemia_17\NN|NONE
C030299_D000740 NONE PHZ_19\NNP|and (r_conj) AZT_17\NNP|with|mice (r_nsubj) treated_20\VBD|numbers|.|were (l_prep) with_22\IN|AZT|mice (l_pobj) degrees_24\NNS|NONE (l_prep) of_25\IN|similar (l_pobj) anaemia_26\NN|NONE
188339
D013256_D008113 NONE steroids_19\NNS|NONE (r_dobj) using_16\VBG|have|,|been|previously|tumors|in|.|Within (r_advcl) seen_12\VBN|NONE (l_nsubjpass) tumors_9\NNS|have|,|been|previously|using|in|.|Within
D003276_D008113 CID contraceptives_11\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|liver (r_acl) tumors_7\NNS|NONE
D003276_D008113 CID contraceptive_18\JJ|oral (r_amod) steroids_19\NNS|NONE (r_dobj) using_16\VBG|have|,|been|previously|tumors|in|.|Within (r_advcl) seen_12\VBN|NONE (l_nsubjpass) tumors_9\NNS|have|,|been|previously|using|in|.|Within
6293644
D006220_D002375 CID haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|NONE
D001058_D006948 CID apomorphine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) hyperactivity_19\NN|NONE
D001058_D002375 NONE apomorphine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) hyperactivity_19\NN|NONE (r_pobj) of_15\IN|partial|a (r_prep) prevention_14\NN|a|of|and (r_conj) potentiation_5\NN|NONE (l_prep) of_6\IN|a|and|prevention (l_pobj) catalepsy_10\NN|NONE
D006220_D006948 NONE haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|NONE (r_pobj) of_6\IN|a|and|prevention (r_prep) potentiation_5\NN|NONE (l_conj) prevention_14\NN|a|of|and (l_prep) of_15\IN|partial|a (l_pobj) hyperactivity_19\NN|NONE
11243580
D009569_D012640 NONE oxide_20\NN|methyl|)|(|NAME (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|on|,|.|were (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|effects|,|.|were (l_pobj) convulsions_41\NNS|NONE
D009569_D012640 NONE NO_22\NNP|)|and|arginine|synthase (r_intj) inhibitor_25\NN|a|,|precursor|nitric|( (r_appos) oxide_20\NN|methyl|)|(|NAME (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|on|,|.|were (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|effects|,|.|were (l_pobj) convulsions_41\NNS|NONE
D009569_D012640 NONE NO_32\JJ|a (r_det) precursor_33\NN|inhibitor|a|,|nitric|( (r_appos) oxide_20\NN|methyl|)|(|NAME (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|on|,|.|were (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|effects|,|.|were (l_pobj) convulsions_41\NNS|NONE
D009569_D012640 NONE NO_5\DT|mediator|that (r_nsubj) is_6\VBZ|results|may|. (l_attr) mediator_9\NN|that|NO (l_prep) in_10\IN|proconvulsant|a (l_pobj) convulsions_14\NNS|NONE
D001120_D012640 NONE arginine_29\NN|)|NO|and|synthase (r_conj) inhibitor_25\NN|a|,|precursor|nitric|( (r_appos) oxide_20\NN|methyl|)|(|NAME (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|on|,|.|were (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|effects|,|.|were (l_pobj) convulsions_41\NNS|NONE
D001120_D012640 NONE arginine_6\NN|the (r_compound) treatment_7\NN|incidence|.|,|In (r_nsubj) increased_8\VBD|NONE (l_dobj) incidence_10\NN|treatment|.|,|In (l_appos) convulsions_18\NNS|of|the|mg/kg|(|,
D019331_D012640 NONE ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|on|,|.|were (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|effects|,|.|were (l_pobj) convulsions_41\NNS|NONE
D019331_D012640 NONE NAME_16\NN|oxide|methyl|)|( (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|on|,|.|were (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|effects|,|.|were (l_pobj) convulsions_41\NNS|NONE
D019331_D012640 NONE NAME_2\NNP|.|incidence|significantly (r_nsubj) decreased_16\VBD|NONE (l_dobj) incidence_18\NN|NAME|.|significantly (l_appos) convulsions_26\NNS|of|the
D003975_D012640 NONE diazepam_10\NN|and|i.p.|L|)|mg/kg| (r_conj) NAME_2\NNP|.|incidence|significantly (r_nsubj) decreased_16\VBD|NONE (l_dobj) incidence_18\NN|NAME|.|significantly (l_appos) convulsions_26\NNS|of|the
D008012_D012640 CID lidocaine_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) convulsion_9\NN|NONE
D008012_D012640 CID lidocaine_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) convulsions_41\NNS|NONE
D008012_D012640 CID lidocaine_20\NN|NONE (r_pobj) of_19\IN|convulsions|the (r_prep) incidence_18\NN|NAME|.|significantly (l_appos) convulsions_26\NNS|of|the
D008012_D012640 CID lidocaine_12\NN|NONE (r_pobj) of_11\IN|the|mg/kg|(|,|convulsions (r_prep) incidence_10\NN|treatment|.|,|In (l_appos) convulsions_18\NNS|of|the|mg/kg|(|,
D008012_D012640 CID lidocaine_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) convulsions_14\NNS|NONE
326460
D001539_D007008 CID bendrofluazide_2\NN| (r_advmod) induced_4\VBN|NONE (r_amod) hypokalemia_5\NN|NONE
D001539_D007008 CID bendrofluazide_17\NN|in|term (r_amod) treatment_18\NN|NONE (r_pobj) of_13\IN|the (r_prep) hypokalemia_12\NN|to
D013999_D007008 NONE timolol_7\NN|NONE (r_pobj) by_6\IN|.|of (r_prep) Amelioration_0\NN|NONE (l_prep) of_1\IN|.|by (l_pobj) hypokalemia_5\NN|NONE
D013999_D007008 NONE timolol_6\NN|blocking|The|beta|,|, (r_appos) drug_4\NN|correct|was|and (r_nsubj) tended_8\VBD|NONE (l_xcomp) correct_10\VB|was|drug|and (l_dobj) hypokalemia_12\NN|to
17923537
D005446_D009798 CID acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (r_pobj) in_13\IN|and|of|the|management (r_prep) incidence_3\NN|To|. (l_prep) of_6\IN|and|the|management|in (l_pobj) pressure_9\NN|NONE
D005446_D009798 CID FA_23\NNP|(|)|intravitreal (r_nmod) implant_26\NN|the|fluocinolone (r_appos) acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (r_pobj) in_13\IN|and|of|the|management (r_prep) incidence_3\NN|To|. (l_prep) of_6\IN|and|the|management|in (l_pobj) pressure_9\NN|NONE
D005446_D014605 NONE acetonide_9\NN|fluocinolone (r_compound) implants_10\NNS|NONE (r_pobj) with_7\IN|NONE (r_prep) treated_6\VBN|in|.|Intraocular (r_acl) pressure_1\NN|NONE (l_prep) in_2\IN|.|Intraocular|treated (l_pobj) patients_3\NNS|NONE (l_prep) with_4\IN|NONE (l_pobj) uveitis_5\NN|NONE
D005446_D014605 NONE acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (l_prep) with_15\IN|treated (l_pobj) uveitis_16\NN|NONE
D005446_D014605 NONE FA_23\NNP|(|)|intravitreal (r_nmod) implant_26\NN|the|fluocinolone (r_appos) acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (l_prep) with_15\IN|treated (l_pobj) uveitis_16\NN|NONE
14736955
D013481_D007674 NONE superoxide_41\JJ|and|activities (r_amod) production_42\NN|NONE (r_pobj) with_40\IN|positively|Injury|.|was (r_prep) correlated_39\VBN|were|activities|inversely|with|Among (r_conj) correlated_10\VBN|NONE (l_prep) Among_0\IN|were|activities|inversely|correlated|with (l_pobj) injury_7\NN|animals
D013481_D007674 NONE superoxide_25\NN|NONE (l_prep) in_26\IN|NONE (l_pobj) lesions_31\NNS|NONE
C102006_D007674 NONE citrate_32\NN|NONE (r_compound) synthase_33\NN|increased (r_compound) activity_34\NN|depressed|of|and (r_conj) activities_15\NNS|,|significant|glomerular (r_appos) lesions_12\NNS|group|.
D004317_D009401 CID doxorubicin_10\NN|NONE (r_compound) nephrosis_11\NN|NONE
D004317_D007674 NONE Doxorubicin_0\NNP|nephropathy|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) nephropathy_6\NN|Doxorubicin|.
D004317_D007674 NONE Doxorubicin_0\NNP|nephropathy|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) nephropathy_6\NN|Doxorubicin|. (l_acl) characterized_7\VBN|a|perpetuating (l_agent) by_8\IN|NONE (l_pobj) lesions_16\NNS|NONE
D004317_D007674 NONE doxorubicin_27\RB| (r_npadvmod) induced_29\VBN|renal (r_amod) lesions_31\NNS|NONE
20727411
-1_D011605 NONE ketamine_5\NN|NONE (r_pobj) of_2\IN|Neural (r_prep) correlates_1\NNS|psychosis|during|. (r_nsubj) induced_6\VBD|NONE (l_dobj) psychosis_7\NN|correlates|during|.
D016202_D012559 NONE aspartate_8\NNP|glutamatergic|)|(|NMDA|The (r_nmod) receptor_12\NN|been|has|in|. (r_nsubjpass) implicated_15\VBN|NONE (l_prep) in_16\IN|been|has|receptor|. (l_pobj) pathophysiology_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) schizophrenia_20\NN|NONE
D016202_D012559 NONE NMDA_10\NNP|aspartate|glutamatergic|)|(|The (r_nmod) receptor_12\NN|been|has|in|. (r_nsubjpass) implicated_15\VBN|NONE (l_prep) in_16\IN|been|has|receptor|. (l_pobj) pathophysiology_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) schizophrenia_20\NN|NONE
D016202_D012559 NONE NMDA_13\NNP|competitive|receptor (r_compound) antagonist_15\NN|the (r_compound) ketamine_16\NN|NONE (r_pobj) of_8\IN|a|subanesthetic (r_prep) dose_7\NN|Administered|.|to|, (r_nsubj) leads_17\VBZ|NONE (l_prep) to_18\IN|Administered|dose|.|, (l_pobj) symptoms_20\NNS|NONE (l_amod) similar_21\JJ|psychopathological (l_prep) to_22\IN|NONE (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) schizophrenia_26\NN|NONE
D016202_D012559 NONE NMDA_10\NNP|an|receptor|in (r_compound) dysfunction_12\NN|NONE (l_prep) in_13\IN|NMDA|an|receptor (l_pobj) pathophysiology_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) schizophrenia_17\NN|NONE
D007649_D011605 CID Ketamine_0\NN|psychosis|. (r_nsubj) elicited_1\VBD|NONE (l_dobj) psychosis_2\NN|Ketamine|.
D007649_D012559 NONE ketamine_16\NN|NONE (r_pobj) of_8\IN|a|subanesthetic (r_prep) dose_7\NN|Administered|.|to|, (r_nsubj) leads_17\VBZ|NONE (l_prep) to_18\IN|Administered|dose|.|, (l_pobj) symptoms_20\NNS|NONE (l_amod) similar_21\JJ|psychopathological (l_prep) to_22\IN|NONE (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) schizophrenia_26\NN|NONE
D007649_D012559 NONE ketamine_5\NN|symptoms|.|In|supporting|,|, (r_nsubj) exacerbates_6\VBZ|NONE (l_prep) In_0\IN|symptoms|.|supporting|,|,|ketamine (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) schizophrenia_3\NN|NONE
D007649_D012559 NONE Ketamine_0\NN|,|in|changes|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) changes_3\NNS|,|in|.|Ketamine (l_prep) in_4\IN|activation (l_pobj) subjects_6\NNS|NONE (l_amod) similar_7\JJ|healthy (l_prep) to_8\IN|NONE (l_pobj) those_9\DT|NONE (l_acl) observed_10\VBN|NONE (l_prep) in_11\IN|NONE (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) schizophrenia_14\NN|NONE
D007649_D018754 NONE ketamine_5\NN|symptoms|.|In|supporting|,|, (r_nsubj) exacerbates_6\VBZ|NONE (l_advcl) supporting_13\VBG|symptoms|.|In|,|,|ketamine (l_dobj) hypothesis_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) dysfunction_19\NN|NONE
3969369
D013739_D063646 NONE testosterone_3\NN|NONE (r_pobj) of_2\IN|.|on|Promotional (r_prep) effects_1\NNS|NONE (l_prep) on_7\IN|.|Promotional|of (l_pobj) carcinogenesis_9\NN|NONE
D013739_D011471 CID testosterone_6\NN|NONE (r_pobj) with_5\IN|at|months (r_prep) implanted_4\VBN|,|LW|, (r_acl) rats_2\NNS|incidence|after (r_nsubj) developed_12\VBD|%|,|:|%|and|.|tumors|had (l_dobj) incidence_15\NN|rats|after (l_prep) of_16\IN|higher|a (l_pobj) cancer_18\NN|NONE
D013739_D011471 CID testosterone_4\NN| (r_npadvmod) treated_6\VBN|LW|that|fed (r_amod) rats_8\NNS|results|. (l_relcl) fed_11\VBN|LW|treated|that (l_dobj) diet_14\NN|were|that (l_relcl) supplemented_18\VBN|same|,|the (l_dobj) fat_26\NN|was|with|which (l_conj) cancer_30\NN|%|,
D013739_D009369 NONE testosterone_6\NN|NONE (r_pobj) with_5\IN|at|months (r_prep) implanted_4\VBN|,|LW|, (r_acl) rats_2\NNS|incidence|after (r_nsubj) developed_12\VBD|%|,|:|%|and|.|tumors|had (r_ccomp) developed_30\VBN|NONE (l_dobj) tumors_32\NNS|%|,|:|%|developed|and|.|had
D013739_D009369 NONE testosterone_6\NN|NONE (r_pobj) with_5\IN|at|months (r_prep) implanted_4\VBN|,|LW|, (r_acl) rats_2\NNS|incidence|after (r_nsubj) developed_12\VBD|%|,|:|%|and|.|tumors|had (r_ccomp) developed_30\VBN|NONE (l_conj) %_36\NN|%|,|:|developed|and|.|tumors|had (l_advcl) included_39\VBD| (l_dobj) tumors_41\NNS|when|it
D013739_D011472 CID testosterone_9\NN|NONE (r_pobj) with_8\IN|developed (r_prep) treated_7\VBN|rats|and|L|.|diet (l_advcl) developed_10\VBD|with (l_dobj) prostatitis_12\NN|NONE
2339463
D015119_D008595 NONE acid_22\NN|prolonged|for|aminocaproic (r_compound) therapy_23\NN|NONE (l_prep) for_24\IN|acid|prolonged|aminocaproic (l_pobj) menorrhagia_25\NN|NONE
D015119_D020227 NONE acid_22\NN|prolonged|for|aminocaproic (r_compound) therapy_23\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) associated_16\VBN|transverse|sinus (r_acl) thrombosis_15\NN|NONE
D015119_D020225 NONE acid_22\NN|prolonged|for|aminocaproic (r_compound) therapy_23\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) associated_16\VBN|transverse|sinus (r_acl) thrombosis_15\NN|NONE
D015119_D012851 NONE acid_15\NN|NONE (l_appos) thrombosis_19\NN|,|aminocaproic
D015119_D013923 NONE acid_15\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) treatment_10\NN|NONE (r_pobj) during_9\IN|has|been|risk|increased (r_prep) reported_8\VBN|been|.|has|previously|not (l_nsubjpass) risk_2\NN|during|has|been|increased (l_prep) of_3\IN|NONE (l_pobj) disease_5\NN|NONE
8268147
D010396_D003882 NONE penicillamine_14\NN|NONE (r_compound) treatment_15\NN|NONE (r_pobj) of_11\IN|autoimmune|the (r_prep) complications_10\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) one_6\CD|NONE (r_pobj) as_5\IN|remains|but|,|dermatomyositis|can (r_prep) develop_4\VB|NONE (l_nsubj) dermatomyositis_2\NN|remains|but|,|as|can
D010396_D003882 NONE penicillamine_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_dobj) receiving_1\VBG|NONE (r_acl) Patients_0\NNS|carefully|.|should|for|be (r_nsubjpass) followed_8\VBN|NONE (l_prep) for_10\IN|carefully|Patients|.|should|be (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) complications_15\NNS|NONE (l_prep) like_16\IN|autoimmune (l_pobj) dermatomyositis_19\NN|NONE
D010396_D017285 CID penicillamine_15\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|primary|biliary (r_acl) cirrhosis_10\NN|NONE (r_pobj) with_7\IN|a (r_prep) patient_6\NN|NONE (r_pobj) in_4\IN|A|of|. (r_prep) case_1\NN|NONE (l_prep) of_2\IN|A|in|. (l_pobj) polymyositis_3\NN|NONE
D010396_D017285 CID penicillamine_14\NN|NONE (r_compound) treatment_15\NN|NONE (r_pobj) of_11\IN|autoimmune|the (r_prep) complications_10\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) one_6\CD|NONE (r_pobj) as_5\IN|remains|but|,|dermatomyositis|can (r_prep) develop_4\VB|NONE (l_nsubj) dermatomyositis_2\NN|remains|but|,|as|can (l_nmod) Polymyositis_0\NNP|/
D010396_D017285 CID penicillamine_16\NN|NONE (r_compound) therapy_17\NN|while (r_dobj) receiving_13\VBG|polymyositis|who (r_advcl) developed_10\VBD|,|biliary|primary (l_dobj) polymyositis_11\NN|receiving|who
D010396_D017285 CID penicillamine_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_dobj) receiving_1\VBG|NONE (r_acl) Patients_0\NNS|carefully|.|should|for|be (r_nsubjpass) followed_8\VBN|NONE (l_prep) for_10\IN|carefully|Patients|.|should|be (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) complications_15\NNS|NONE (l_prep) like_16\IN|autoimmune (l_pobj) dermatomyositis_19\NN|NONE (l_nmod) polymyositis_17\NN|/
D010396_D012216 NONE penicillamine_3\NN|been|Although|for|has (r_nsubjpass) used_6\VBN|.|,|usefulness|toxicity (l_prep) for_7\IN|been|Although|penicillamine|has (l_pobj) diseases_10\NNS|NONE
D010396_D008105 NONE penicillamine_15\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|primary|biliary (r_acl) cirrhosis_10\NN|NONE
D010396_D008105 NONE penicillamine_16\NN|NONE (r_compound) therapy_17\NN|while (r_dobj) receiving_13\VBG|polymyositis|who (r_advcl) developed_10\VBD|,|biliary|primary (r_relcl) cirrhosis_7\NN|NONE
D010396_D064420 NONE penicillamine_3\NN|been|Although|for|has (r_nsubjpass) used_6\VBN|.|,|usefulness|toxicity (r_advcl) limits_13\VBZ|NONE (l_nsubj) toxicity_12\NN|.|,|used|usefulness
9165568
D018967_D001480 NONE risperidone_14\NN|NONE (r_pobj) with_13\IN|the|low|of (r_prep) frequency_9\NN|to (l_prep) of_10\IN|the|with|low (l_pobj) symptoms_12\NNS|NONE
D004298_D009459 NONE dopamine_10\NN|receptor|D|in (r_compound) blockade_13\NN|NONE (r_pobj) of_9\IN|a (r_prep) result_8\NN|to (r_attr) be_6\VB|syndrome|is|. (r_xcomp) thought_4\VBN|NONE (l_nsubjpass) syndrome_2\NN|be|is|.
D018967_D009459 CID risperidone_4\NN|NONE (r_pobj) with_3\IN|.|Neuroleptic|malignant (r_prep) syndrome_2\NN|NONE
D018967_D009459 CID risperidone_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) monotherapy_10\NN|NONE (r_pobj) after_9\IN|woman|syndrome|. (r_prep) developed_5\VBD|NONE (l_dobj) syndrome_8\NN|woman|.|after
D018967_D009459 CID risperidone_11\NN|NONE (r_pobj) with_10\IN|protection|that (r_prep) observed_9\VBN|.|It|ensure (r_ccomp) appears_1\VBZ|NONE (l_conj) ensure_14\VB|.|It|observed (l_dobj) protection_15\NN|not|does (l_prep) from_16\IN|NONE (l_pobj) syndrome_19\NN|NONE
20164825
D008687_D014652 NONE metformin_3\NN|apoptosis|induced|can|.|and|prevent (r_nsubj) diminish_5\VB|NONE (l_conj) prevent_15\VB|apoptosis|induced|can|metformin|.|and (l_dobj) dysfunction_17\NN|in
D005839_D058186 CID gentamicin_4\NN| (r_npadvmod) mediated_6\VBN|renal|acute (r_amod) failure_9\NN|fully|treatment|.
D005839_D007674 NONE gentamicin_3\NN| (r_npadvmod) induced_5\VBN|experimental (r_amod) nephropathy_6\NN|Metformin|by|.
D005839_D007674 NONE gentamicin_12\NN|NONE (r_amod) nephrotoxicity_13\NN|can|and|improve|effects|that
D008687_D007674 NONE Metformin_0\NNP|by|nephropathy|. (r_nsubj) prevents_1\VBZ|NONE (l_dobj) nephropathy_6\NN|Metformin|by|.
D008687_D007674 NONE metformin_11\NN|NONE (r_pobj) by_10\IN|their (r_prep) correction_9\NN|of|vivo|and (r_conj) markers_3\NNS|NONE (l_prep) of_4\IN|vivo|and|correction (l_pobj) dysfunction_6\NN|NONE
D008687_D007674 NONE metformin_9\NN|NONE (r_pobj) of_8\IN|pleiotropic (r_prep) effects_7\NNS|can|and|improve|that|nephrotoxicity (r_nsubj) lessen_11\VB|.|study|,|Thus (l_dobj) nephrotoxicity_13\NN|can|and|improve|effects|that
D005839_D064420 NONE gentamicin_14\NN|NONE (r_amod) toxicity_15\NN|NONE
D008687_D058186 NONE Metformin_0\NNP|NONE (r_compound) treatment_1\NN|fully|.|failure (r_nsubj) blocked_3\VBD|NONE (l_dobj) failure_9\NN|fully|treatment|.
6728084
D000617_D007674 NONE aminoglycoside_3\NN|on (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|.|Nephrotoxic (r_prep) effects_1\NNS|NONE (l_amod) Nephrotoxic_0\JJ|.|of
D000617_D007674 NONE aminoglycosides_2\NNS|,|.|may|as|Thus (r_nsubj) act_4\VB|NONE (l_prep) as_5\IN|,|.|may|aminoglycosides|Thus (l_pobj) nephrotoxicants_6\NNS|NONE (l_prep) at_7\IN|NONE (l_pobj) impairment_13\NN|NONE (l_prep) of_14\IN|glomerular|inducing (l_pobj) reabsorption_16\NN|NONE
625456
D002119_D006934 CID ate_24\VBN|carbon|| (r_amod) sodium_26\NN|calcium|bicarbonate (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|for|who|had|regularly (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|case|.|two|are (r_prep) reported_11\VBN|NONE (l_nsubjpass) case_1\NN|in|.|two|are (l_prep) of_2\IN|One|and (l_pobj) hypercalcaemia_4\NN|NONE
D017693_D006934 CID bicarbonate_27\NN|calcium|sodium (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|for|who|had|regularly (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|case|.|two|are (r_prep) reported_11\VBN|NONE (l_nsubjpass) case_1\NN|in|.|two|are (l_prep) of_2\IN|One|and (l_pobj) hypercalcaemia_4\NN|NONE
D002119_D053040 CID ate_24\VBN|carbon|| (r_amod) sodium_26\NN|calcium|bicarbonate (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|for|who|had|regularly (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|case|.|two|are (r_prep) reported_11\VBN|NONE (l_nsubjpass) two_6\CD|in|case|.|are (l_prep) of_7\IN|NONE (l_pobj) nephrolithiasis_9\NN|NONE
D017693_D053040 CID bicarbonate_27\NN|calcium|sodium (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|for|who|had|regularly (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|case|.|two|are (r_prep) reported_11\VBN|NONE (l_nsubjpass) two_6\CD|in|case|.|are (l_prep) of_7\IN|NONE (l_pobj) nephrolithiasis_9\NN|NONE
18363626
D010100_D001919 NONE oxygen_30\NN|NONE (r_compound) saturations_31\NNS|adjusted|and|normal (r_conj) range_28\NN|NONE (r_pobj) of_23\IN| (r_prep) %_22\NN|NONE (r_pobj) within_20\IN|,|associated|were|pressures|. (r_prep) were_19\VBD|NONE (l_advcl) associated_4\VBN|,|within|were|pressures|. (l_prep) with_5\IN|sedation|Although|was (l_pobj) incidence_9\NN|NONE (l_prep) of_10\IN|a|% (l_pobj) bradycardia_11\NN|NONE
D020927_D001919 CID dexmedetomidine_1\NN|NONE (r_amod) sedation_2\NN|with|Although|was (r_nsubjpass) associated_4\VBN|,|within|were|pressures|. (l_prep) with_5\IN|sedation|Although|was (l_pobj) incidence_9\NN|NONE (l_prep) of_10\IN|a|% (l_pobj) bradycardia_11\NN|NONE
1286498
D005442_D009325 CID flumazenil_11\JJ|the|and|pain (r_compound) group_12\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) vomiting_8\VBG|and (r_conj) nausea_6\NN|.|effects
D005442_D009325 CID flumazenil_11\JJ|the|and|pain (r_compound) group_12\NN|NONE (l_conj) pain_19\NN|the|flumazenil|and (l_nmod) nausea_14\NN|in
D005442_D010146 NONE flumazenil_11\JJ|the|and|pain (r_compound) group_12\NN|NONE (l_conj) pain_19\NN|the|flumazenil|and
D005442_D014839 CID flumazenil_11\JJ|the|and|pain (r_compound) group_12\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) vomiting_8\VBG|and
8599504
D004329_D000799 CID droperidol_3\NN|NONE (r_compound) administration_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBD|. (r_acl) Angioedema_0\NNP|NONE
D004329_D000799 CID droperidol_39\NN|NONE (r_pobj) of_38\IN|a|single|IV (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|angioedema|in (r_prep) developed_26\VBN|no|drug|known (l_nsubj) angioedema_19\NN|within|in
D004329_D004487 NONE droperidol_39\NN|NONE (r_pobj) of_38\IN|a|single|IV (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|angioedema|in (r_prep) developed_26\VBN|no|drug|known (l_nsubj) angioedema_19\NN|within|in (l_prep) with_20\IN|NONE (l_pobj) swelling_23\NN|NONE
D004329_D004342 NONE droperidol_39\NN|NONE (r_pobj) of_38\IN|a|single|IV (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|angioedema|in (r_prep) developed_26\VBN|no|drug|known (r_relcl) allergies_16\NNS|NONE
D004329_D014060 NONE droperidol_39\NN|NONE (r_pobj) of_38\IN|a|single|IV (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|angioedema|in (r_prep) developed_26\VBN|no|drug|known (l_nsubj) angioedema_19\NN|within|in (l_prep) with_20\IN|NONE (l_pobj) swelling_23\NN|NONE
9514561
D002211_D010146 CID capsaicin_5\NN|NONE (r_pobj) by_4\IN|NONE (r_agent) elicited_3\VBN|study|cranial|.|:|Experimental (r_acl) pain_2\NN|NONE
D002211_D010146 CID capsaicin_4\NN|NONE (r_pobj) of_3\IN|small|A (r_prep) amount_2\NN|evoke|was|in|subcutaneously|. (r_nsubjpass) administered_6\VBN|NONE (l_advcl) evoke_13\VB|amount|was|in|subcutaneously|. (l_dobj) sensation_17\NN|to (l_amod) painful_16\JJ|in|burning|a
9848575
D004317_D009202 CID doxorubicin_15\RB| (r_npadvmod) induced_17\VBN|in (r_amod) cardiomyopathy_18\NN|normal|and
D004317_D009202 CID doxorubicin_7\NN|NONE (r_pobj) of_6\IN|six (r_prep) courses_5\NNS|which (r_dobj) received_2\VBD|NONE (r_relcl) Animals_0\NNS|.|electrocardiogram|show|decrease|, (r_nsubj) demonstrated_8\VBD|NONE (l_dobj) decrease_16\NN|.|electrocardiogram|show|,|Animals (l_prep) of_17\IN|NONE (l_pobj) pressure_19\NN|NONE (l_conj) cardiomyopathy_25\NN|and|blood
D004317_D009202 CID doxorubicin_22\NN|NONE (r_pobj) of_21\IN|four|mg/kg|)|( (r_prep) courses_20\NNS|NONE (r_pobj) by_18\IN|examine|in|.|was (r_agent) induced_15\VBN|NONE (l_csubjpass) examine_1\VB|by|in|.|was (l_dobj) effect_6\NN|To (l_prep) of_7\IN|deteriorating|a|cardiotoxic (l_pobj) cardiomyopathy_13\NN|NONE
D018943_D009202 NONE anthracycline_6\NN|(|SM|a|novel|)|synthetic (r_amod) derivative_7\JJ|NONE (r_pobj) of_2\IN|Chronic|on|. (r_prep) effects_1\NNS|NONE (l_prep) on_11\IN|Chronic|of|. (l_pobj) heart_13\NN|NONE (l_conj) cardiomyopathy_18\NN|normal|and
D004317_D066126 NONE doxorubicin_28\NN|effect|of|cardiotoxic|chronic|and|the (r_appos) potential_9\NN|to (l_amod) cardiotoxic_8\JJ|effect|of|doxorubicin|chronic|and|the
D004317_D066126 NONE doxorubicin_28\NN|effect|of|cardiotoxic|chronic|and|the (r_appos) potential_9\NN|to (l_conj) effect_16\NN|of|cardiotoxic|doxorubicin|chronic|and|the (l_prep) on_19\IN|a|of|deteriorating|possible (l_pobj) cardiotoxicity_23\NN|NONE
D004317_D066126 NONE doxorubicin_22\NN|NONE (r_pobj) of_21\IN|four|mg/kg|)|( (r_prep) courses_20\NNS|NONE (r_pobj) by_18\IN|examine|in|.|was (r_agent) induced_15\VBN|NONE (l_csubjpass) examine_1\VB|by|in|.|was (l_dobj) effect_6\NN|To (l_amod) cardiotoxic_5\JJ|deteriorating|a|of
D004317_D066126 NONE doxorubicin_11\NN|additional|the (r_compound) treatment_12\NN|NONE (r_pobj) by_8\IN|were|changes|. (r_agent) enhanced_7\VBN|NONE (l_nsubjpass) changes_5\NNS|were|by|. (l_amod) cardiotoxic_4\JJ|grade|The
D004317_D066126 NONE doxorubicin_16\RB| (r_npadvmod) induced_18\VBN|in (r_amod) cardiotoxicity_19\NN|NONE (r_pobj) on_15\IN|deteriorating (r_prep) effect_14\NN|chronic|and (r_conj) cardiotoxicity_11\NN|NONE
D004317_D066126 NONE doxorubicin_16\RB| (r_npadvmod) induced_18\VBN|in (r_amod) cardiotoxicity_19\NN|NONE
C055866_D009202 NONE SM-5887_9\NNP|(|a|novel|anthracycline|)|synthetic (r_appos) derivative_7\JJ|NONE (r_pobj) of_2\IN|Chronic|on|. (r_prep) effects_1\NNS|NONE (l_prep) on_11\IN|Chronic|of|. (l_pobj) heart_13\NN|NONE (l_conj) cardiomyopathy_18\NN|normal|and
C055866_D009202 NONE SM-5887_35\NNP|the (r_compound) administration_36\NN|animals|while|not|changes|did (r_nsubj) show_39\VB|.|electrocardiogram|decrease|,|Animals (r_advcl) demonstrated_8\VBD|NONE (l_dobj) decrease_16\NN|.|electrocardiogram|show|,|Animals (l_prep) of_17\IN|NONE (l_pobj) pressure_19\NN|NONE (l_conj) cardiomyopathy_25\NN|and|blood
C055866_D009202 NONE SM-5887_8\NNP|grade|, (r_nmod) cardiomyopathy_13\NN|NONE
C055866_D009202 NONE SM-5887_5\NNP|the (r_compound) treatment_6\NN|,|On|.|did|not|grade (r_nsubj) progress_9\VB|NONE (l_dobj) grade_11\NN|,|On|.|did|not|treatment (l_prep) of_12\IN|the (l_pobj) cardiomyopathy_13\NN|NONE
C055866_D066126 NONE SM-5887_11\NNP|NONE (r_pobj) of_10\IN|effect|cardiotoxic|doxorubicin|chronic|and|the (r_prep) potential_9\NN|to (l_amod) cardiotoxic_8\JJ|effect|of|doxorubicin|chronic|and|the
C055866_D066126 NONE SM-5887_11\NNP|NONE (r_pobj) of_10\IN|effect|cardiotoxic|doxorubicin|chronic|and|the (r_prep) potential_9\NN|to (l_conj) effect_16\NN|of|cardiotoxic|doxorubicin|chronic|and|the (l_prep) on_19\IN|a|of|deteriorating|possible (l_pobj) cardiotoxicity_23\NN|NONE
C055866_D066126 NONE SM-5887_18\NNP|NONE (r_pobj) of_17\IN|a|deteriorating|possible|on (r_prep) effect_16\NN|of|cardiotoxic|doxorubicin|chronic|and|the (r_conj) potential_9\NN|to (l_amod) cardiotoxic_8\JJ|effect|of|doxorubicin|chronic|and|the
C055866_D066126 NONE SM-5887_18\NNP|NONE (r_pobj) of_17\IN|a|deteriorating|possible|on (r_prep) effect_16\NN|of|cardiotoxic|doxorubicin|chronic|and|the (l_prep) on_19\IN|a|of|deteriorating|possible (l_pobj) cardiotoxicity_23\NN|NONE
C055866_D066126 NONE SM-5887_8\NNP|grade|, (r_nmod) cardiomyopathy_13\NN|NONE (r_pobj) of_7\IN|deteriorating|a|cardiotoxic (r_prep) effect_6\NN|To (l_amod) cardiotoxic_5\JJ|deteriorating|a|of
C055866_D066126 NONE SM-5887_3\NNP|does|.|potential|In|,|not (r_nsubj) have_6\VB|NONE (l_dobj) potential_8\NN|does|SM|.|In|,|not (l_prep) of_9\IN|any (l_pobj) cardiotoxicity_11\NN|NONE
C055866_D066126 NONE SM-5887_3\NNP|does|.|potential|In|,|not (r_nsubj) have_6\VB|NONE (l_dobj) potential_8\NN|does|SM|.|In|,|not (l_prep) of_9\IN|any (l_pobj) cardiotoxicity_11\NN|NONE (l_conj) effect_14\NN|chronic|and (l_prep) on_15\IN|deteriorating (l_pobj) cardiotoxicity_19\NN|NONE
11573852
D000666_D004830 NONE B_18\NNP|NONE (r_pobj) of_16\IN|intravenous (r_prep) infusion_15\NN|NONE (r_pobj) during_13\IN|man|,|seizures|stopped|then|. (r_prep) experienced_8\VBD|NONE (l_dobj) seizures_12\NNS|man|,|stopped|then|.|during
D000666_D012640 CID B_1\NN| (r_npadvmod) induced_3\VBN|in|. (r_amod) seizures_4\NNS|NONE
D000666_D012640 CID B_16\NNP|NONE (r_compound) infusion_17\NN|NONE (r_pobj) following_14\VBG|a|of (r_prep) case_3\NN|.|To (l_prep) of_4\IN|following|a (l_pobj) episodes_6\NNS|NONE (l_prep) of_7\IN|in|multiple (l_pobj) activity_9\NN|NONE (l_compound) seizure_8\NN|NONE
D000666_D012640 CID B_18\NNP|NONE (r_pobj) of_16\IN|intravenous (r_prep) infusion_15\NN|NONE (r_pobj) during_13\IN|man|,|seizures|stopped|then|. (r_prep) experienced_8\VBD|NONE (l_conj) stopped_28\VBN|man|,|seizures|then|.|during (l_nsubjpass) seizures_23\NNS|and|decreased|was
D000666_D012640 CID B_15\NNP|amphotercin (r_compound) administration_16\NN|only (r_pobj) during_13\IN|NONE (r_prep) occurred_11\VBD|.|,|and|seizures|Despite (r_conj) persisted_9\VBD|NONE (l_nsubj) seizures_8\NNS|.|,|and|occurred|Despite
D000666_D012640 CID B_8\NNP|cause|that (r_nsubj) was_9\VBD|.|course (l_attr) cause_11\NN|B|that (l_prep) of_12\IN|the (l_pobj) seizures_14\NNS|NONE
D000666_D012640 CID B_1\NNP|be|. (r_nsubj) seems_2\VBZ|NONE (l_xcomp) be_4\VB|B|. (l_attr) cause_7\NN|to (l_prep) of_8\IN|probable|the (l_pobj) seizures_10\NNS|NONE
D000666_D012640 CID B_11\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|NONE (r_acl) seizures_7\NNS|NONE
D000431_D012640 NONE alcohol_9\NN|as|withdrawal (r_compound) intake_10\NN|a|of|; (r_conj) history_4\NN|patient|.|cause (r_dobj) had_2\VBD|NONE (l_conj) cause_17\VB|patient|.|history (l_dobj) seizures_18\NNS|can|also
D016049_D012640 NONE Didanosine_0\NNP|potential|also|. (r_nsubj) has_2\VBZ|NONE (l_dobj) potential_4\NN|Didanosine|also|. (l_prep) for_5\IN|a (l_pcomp) inducing_6\VBG|NONE (l_dobj) seizures_7\NNS|NONE
D000666_D000163 NONE B_1\NN| (r_npadvmod) induced_3\VBN|in|. (r_amod) seizures_4\NNS|NONE (l_prep) in_5\IN|induced|. (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) AIDS_9\NNP|NONE
D000666_D000163 NONE B_16\NNP|NONE (r_compound) infusion_17\NN|NONE (r_pobj) following_14\VBG|a|of (r_prep) case_3\NN|.|To (l_prep) of_4\IN|following|a (l_pobj) episodes_6\NNS|NONE (l_prep) in_10\IN|multiple|of (l_pobj) patent_13\NN|NONE (l_compound) AIDS_12\NNP|an
D000666_D000163 NONE B_8\NNP|cause|that (r_nsubj) was_9\VBD|.|course (l_attr) cause_11\NN|B|that (l_prep) of_12\IN|the (l_pobj) seizures_14\NNS|NONE (l_prep) in_15\IN|the (l_pobj) patient_18\NN|NONE (l_compound) AIDS_17\NNP|this
D000431_D000437 NONE alcohol_9\NN|as|withdrawal (r_compound) intake_10\NN|a|of|; (r_conj) history_4\NN|patient|.|cause (l_prep) of_5\IN|a|;|intake (l_pobj) abuse_7\NN|NONE
D008140_D012640 NONE lorazepam_5\NN|and (r_conj) phenytoin_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) administration_1\NN|NONE (r_pobj) Despite_0\IN|.|,|and|seizures|occurred (r_prep) persisted_9\VBD|NONE (l_nsubj) seizures_8\NNS|.|,|and|occurred|Despite
D010672_D012640 NONE phenytoin_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) administration_1\NN|NONE (r_pobj) Despite_0\IN|.|,|and|seizures|occurred (r_prep) persisted_9\VBD|NONE (l_nsubj) seizures_8\NNS|.|,|and|occurred|Despite
8012887
D006493_D013927 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|arterial (r_amod) thrombosis_11\NN|NONE
D006493_D013927 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) thrombosis_9\NN|NONE
D006493_D013927 CID heparin_14\JJ|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|NONE (r_pobj) in_11\IN|successfully|induced|,|defined|has|been|but|for|Ancrod (r_prep) used_3\VBN|NONE (l_prep) for_5\IN|successfully|induced|,|defined|has|been|but|in|Ancrod (l_pobj) prophylaxis_6\NN|NONE (l_prep) against_7\IN|NONE (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) thrombosis_10\NN|NONE
D006493_D013927 CID heparin_14\JJ|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|NONE (r_pobj) in_11\IN|successfully|induced|,|defined|has|been|but|for|Ancrod (r_prep) used_3\VBN|NONE (l_conj) defined_39\VBN|successfully|induced|,|has|been|but|for|in|Ancrod (l_auxpass) is_36\VBZ|not|well|. (l_nsubj) success_27\NN|NONE (l_prep) in_28\IN|its (l_pobj) patients_29\NNS|NONE (l_relcl) developed_32\VBN|NONE (l_dobj) syndrome_35\NN|who|have (l_compound) thrombosis_34\NN|the
D006493_D013927 CID heparin_23\NN|NONE (r_pobj) to_22\IN|brief (r_prep) reexposure_21\NN|who (r_dobj) require_19\VBP|platelet (r_relcl) aggregation_17\NN|NONE (r_dobj) induced_15\VBN|successfully|,|defined|has|been|but|for|in|Ancrod (r_advcl) used_3\VBN|NONE (l_prep) for_5\IN|successfully|induced|,|defined|has|been|but|in|Ancrod (l_pobj) prophylaxis_6\NN|NONE (l_prep) against_7\IN|NONE (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) thrombosis_10\NN|NONE
D006493_D013927 CID heparin_23\NN|NONE (r_pobj) to_22\IN|brief (r_prep) reexposure_21\NN|who (r_dobj) require_19\VBP|platelet (r_relcl) aggregation_17\NN|NONE (r_dobj) induced_15\VBN|successfully|,|defined|has|been|but|for|in|Ancrod (r_advcl) used_3\VBN|NONE (l_conj) defined_39\VBN|successfully|induced|,|has|been|but|for|in|Ancrod (l_auxpass) is_36\VBZ|not|well|. (l_nsubj) success_27\NN|NONE (l_prep) in_28\IN|its (l_pobj) patients_29\NNS|NONE (l_relcl) developed_32\VBN|NONE (l_dobj) syndrome_35\NN|who|have (l_compound) thrombosis_34\NN|the
D006493_D013927 CID heparin_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) thrombosis_17\NN|NONE
D006493_D001791 NONE heparin_14\JJ|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|NONE (r_pobj) in_11\IN|successfully|induced|,|defined|has|been|but|for|Ancrod (r_prep) used_3\VBN|NONE (l_advcl) induced_15\VBN|successfully|,|defined|has|been|but|for|in|Ancrod (l_dobj) aggregation_17\NN|NONE
D006493_D001791 NONE heparin_23\NN|NONE (r_pobj) to_22\IN|brief (r_prep) reexposure_21\NN|who (r_dobj) require_19\VBP|platelet (r_relcl) aggregation_17\NN|NONE
8766220
D017374_-1 NONE paroxetine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|.|was|dosulepine|drug|and (r_prep) initiated_3\VBN|NONE (l_conj) dosulepine_9\JJ|.|was|drug|and|in (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_amod) tetraparetic_13\JJ|with|a
D014147_D006212 CID tramadol_9\NN|NONE (r_pobj) of_8\IN|term (r_prep) intake_7\NN|NONE (r_pobj) after_3\IN|hallucinations|and|combined|. (r_prep) Nightmares_0\NNS|NONE (l_conj) hallucinations_2\NNS|and|combined|after|.
D014147_D006212 CID tramadol_25\NN|active|and (r_conj) drugs_23\NNS|NONE (r_pobj) of_19\IN|the (r_prep) withdrawal_18\NN|NONE (r_pobj) after_16\IN|only|that (r_prep) stopped_15\VBD|NONE (r_relcl) hallucinations_12\NNS|after|patient|.
D004308_D059350 NONE hydrochloride_10\NN|in (r_dobj) dosulepine_9\JJ|.|was|drug|and|in (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a|tetraparetic (l_pobj) pain_17\NN|NONE
D004308_-1 NONE hydrochloride_10\NN|in (r_dobj) dosulepine_9\JJ|.|was|drug|and|in (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_amod) tetraparetic_13\JJ|with|a
D017374_D059350 NONE paroxetine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|.|was|dosulepine|drug|and (r_prep) initiated_3\VBN|NONE (l_conj) dosulepine_9\JJ|.|was|drug|and|in (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a|tetraparetic (l_pobj) pain_17\NN|NONE
D014147_D010146 NONE Tramadol_0\NNP|.|opioid (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_4\NN|.|Tramadol (l_prep) with_5\IN|a|weak (l_pobj) effects_6\NNS|NONE (l_relcl) used_14\VBN|on (l_xcomp) treat_16\VB|that|is (l_dobj) pain_18\NN|to
D014147_D010146 NONE Tramadol_0\NNP|.|opioid (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_4\NN|.|Tramadol (l_prep) with_5\IN|a|weak (l_pobj) effects_6\NNS|NONE (l_relcl) used_14\VBN|on (l_xcomp) treat_16\VB|that|is (l_dobj) pain_18\NN|to (l_conj) pain_23\NN|and|cancer
D014147_D009369 NONE Tramadol_0\NNP|.|opioid (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_4\NN|.|Tramadol (l_prep) with_5\IN|a|weak (l_pobj) effects_6\NNS|NONE (l_relcl) used_14\VBN|on (l_xcomp) treat_16\VB|that|is (l_dobj) pain_18\NN|to (l_compound) cancer_17\NN|and|pain
3088349
D000661_-1 NONE amphetamine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_prep) exhaustion_15\NN|NONE (r_pobj) to_14\TO|rotation|susceptibility|. (r_prep) reflects_8\VBZ|NONE (l_nsubj) rotation_2\NN|to|susceptibility|. (l_prep) following_3\VBG|Transient|contralateral (l_pobj) lesion_7\NN|NONE
D000661_D009069 CID amphetamine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_prep) exhaustion_15\NN|NONE (r_pobj) to_14\TO|rotation|susceptibility|. (r_prep) reflects_8\VBZ|NONE (l_nsubj) rotation_2\NN|to|susceptibility|.
D000661_D009069 CID amphetamine_26\NN| (r_npadvmod) induced_28\VBN|rotational (r_amod) behavior_30\NN|NONE (r_pobj) on_25\IN|,|we|effect|In|. (r_prep) examined_12\VBD|NONE (l_prep) In_0\IN|,|we|effect|on|. (l_pobj) order_1\NN|NONE (l_acl) clarify_3\VB|NONE (l_dobj) nature_5\NN|to (l_prep) of_6\IN|the (l_pobj) rotation_10\NN|NONE
D000661_D009069 CID amphetamine_26\NN| (r_npadvmod) induced_28\VBN|rotational (r_amod) behavior_30\NN|NONE
D000661_D009069 CID amphetamine_10\NN|was|for|when (r_nsubjpass) administered_12\VBN|evident|still|indicating|degree|.|, (r_advcl) was_6\VBD|NONE (l_advcl) indicating_22\VBG|administered|evident|still|degree|.|, (l_dobj) involvement_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) cells_26\NNS|NONE (l_prep) in_27\IN|spared (l_pobj) rotation_30\NN|NONE
D000661_D009069 CID amphetamine_16\NN|or|exercise|, (r_compound) dose_17\NN|either|,|lesion (r_conj) volume_14\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) irrespective_10\RB|and|(|of|the (r_conj) duration_5\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) regardless_2\RB|become|,|,|rotation|and|,|However|circled (r_advmod) tended_31\VBD|NONE (l_nsubj) rotation_30\NN|become|,|,|and|,|regardless|However|circled
D000661_D009069 CID amphetamine_27\NN| (r_npadvmod) induced_29\VBN|NONE (r_amod) rotation_30\NN|become|,|,|and|,|regardless|However|circled
D000661_D009069 CID amphetamine_55\NN|further (r_compound) injections_56\NNS|NONE (r_pobj) to_53\IN|NONE (r_prep) response_52\NN|NONE (r_pobj) in_51\IN|to|rats|.|ipsilaterally (r_prep) circled_46\VBD|become|,|,|rotation|and|,|regardless|However (r_conj) tended_31\VBD|NONE (l_nsubj) rotation_30\NN|become|,|,|and|,|regardless|However|circled
D000661_D009069 CID amphetamine_4\NN|effect|that (r_nsubj) has_5\VBZ|findings|. (l_dobj) effect_8\NN|amphetamine|that (l_prep) on_9\IN|irreversible|an (l_pobj) pool_15\NN|NONE (l_acl) contributing_16\VBG|lesion|the|DA (l_prep) to_17\IN|NONE (l_pobj) rotation_19\NN|NONE
D016627_-1 NONE 6-OHDA_2\CD|NONE (r_pobj) Following_0\VBG|lesion (r_prep) induced_3\VBN|has|period|been|precede|. (l_dobj) lesion_5\NN|Following
D016627_D009069 NONE 6-OHDA_2\CD|NONE (r_pobj) Following_0\VBG|lesion (r_prep) induced_3\VBN|has|period|been|precede|. (r_ccomp) reported_15\VBN|NONE (l_nsubjpass) period_9\NN|induced|has|been|precede|. (l_prep) of_10\IN|a|transient (l_pobj) rotation_12\NN|NONE
D016627_D009069 NONE 6-OHDA_2\CD|NONE (r_pobj) Following_0\VBG|lesion (r_prep) induced_3\VBN|has|period|been|precede|. (r_ccomp) reported_15\VBN|NONE (l_xcomp) precede_17\VB|induced|has|period|been|. (l_dobj) circling_21\NN|to
12739036
D003401_D008180 NONE creatine_5\NN|kinase|in (r_compound) levels_7\NNS|NONE (l_prep) in_8\IN|creatine|kinase (l_pobj) erythematosus_11\NN|NONE
D003520_D007674 NONE cyclophosphamide_25\NN|and (r_conj) azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG|NONE (l_prep) with_14\IN|from|and|Since|,|had|undergone|been|she|. (l_pobj) involvement_16\NN|NONE
D001379_D007674 NONE azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG|NONE (l_prep) with_14\IN|from|and|Since|,|had|undergone|been|she|. (l_pobj) involvement_16\NN|NONE
D013256_D009220 NONE steroids_10\NNS|NONE (r_pobj) with_9\IN|was|.|patient (r_prep) treated_8\VBN|,|Myositis|and|was (r_conj) suspected_2\VBN|NONE (l_nsubjpass) Myositis_0\NNP|treated|,|and|was
D002738_D009135 NONE chloroquine_15\NN| (r_advmod) induced_17\VBN|severe (r_amod) myopathy_18\NN|NONE
D002738_D009135 NONE chloroquine_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_compound) myopathy_6\NN|As|it
D003520_D008180 NONE cyclophosphamide_25\NN|and (r_conj) azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN|NONE
D003520_D008180 NONE cyclophosphamide_25\NN|and (r_conj) azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN|NONE (l_appos) SLE_12\NNP|(|systemic|lupus|)
D002738_D018771 NONE chloroquine_3\NN|( (r_amod) CQ_5\NNP|NONE (r_pobj) with_2\IN|)|Additional (r_prep) therapy_1\NN|was|because|. (r_nsubjpass) started_8\VBN|NONE (l_prep) because_9\IN|was|therapy|. (l_pobj) arthralgia_11\NN|of
D002738_D018771 NONE CQ_5\NNP|NONE (r_pobj) with_2\IN|)|Additional (r_prep) therapy_1\NN|was|because|. (r_nsubjpass) started_8\VBN|NONE (l_prep) because_9\IN|was|therapy|. (l_pobj) arthralgia_11\NN|of
D001379_D008180 NONE azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN|NONE
D001379_D008180 NONE azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN|NONE (l_appos) SLE_12\NNP|(|systemic|lupus|)
3220106
D009538_D006948 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|in|locomotor (r_amod) hyperactivity_7\NN|NONE
D009538_D006948 CID nicotine_10\NN| (r_npadvmod) treated_12\VBN|chronic (r_amod) rats_13\NNS|NONE (r_pobj) in_8\IN|induced|locomotor (r_prep) hyperactivity_7\NN|NONE
D009538_D006948 CID nicotine_5\NN| (r_npadvmod) treated_7\VBN|chronic (r_amod) rats_8\NNS|initially|hyperactivity|that|,|due|in (r_nsubj) develop_9\VBP|results|followed|. (l_dobj) hyperactivity_11\NN|initially|rats|that|,|due|in
D009538_D006948 CID nicotine_15\NN|NONE (r_pobj) to_14\IN|NONE (r_prep) response_13\NN|NONE (r_pobj) in_12\IN|initially|hyperactivity|rats|that|,|due (r_prep) develop_9\VBP|results|followed|. (l_dobj) hyperactivity_11\NN|initially|rats|that|,|due|in
D004298_D006948 NONE DA_28\NNP|NONE (r_compound) concentration_29\NN|and|nicotinic (r_conj) receptors_26\NNS|NONE (r_pobj) of_24\IN|the|both (r_prep) density_23\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) increases_19\NNS|to (r_pobj) due_17\JJ|initially|hyperactivity|rats|that|,|in (r_prep) develop_9\VBP|results|followed|. (l_dobj) hyperactivity_11\NN|initially|rats|that|,|due|in
D004298_D006948 NONE DA_34\NNP|in|receptor (r_compound) supersensitivity_36\NN|NONE (r_dobj) inducing_33\VBG|NONE (r_pcomp) by_32\IN|NONE (r_agent) followed_31\VBN|results|.|develop (r_advcl) suggest_2\VBP|NONE (l_ccomp) develop_9\VBP|results|followed|. (l_dobj) hyperactivity_11\NN|initially|rats|that|,|due|in
2790457
D003042_D012640 CID cocaine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) kindled_9\VBN|local|anesthetic (r_acl) seizures_8\NNS|NONE
D003042_D012640 CID cocaine_10\NN| (r_npadvmod) induced_12\VBN|both|and (r_conj) lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE
D003042_D012640 CID cocaine_10\NN| (r_npadvmod) induced_12\VBN|both|and (r_conj) lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE (r_pobj) of_6\IN|the (r_prep) development_5\NN|CBZ|,|.|but|had (r_dobj) inhibited_3\VBD|NONE (l_conj) had_16\VBD|CBZ|development|,|.|but (l_dobj) effect_18\NN|NONE (l_prep) on_19\IN|little (l_pobj) seizures_25\NNS|NONE
D003042_D012640 CID cocaine_13\NN| (r_npadvmod) injected_15\VBN|the (r_amod) rats_16\NNS|NONE (r_pobj) in_11\IN|related (r_prep) mortality_10\NN|NONE (l_amod) related_9\VBN|in (l_npadvmod) seizure_7\NN|
D003042_D012640 CID cocaine_23\NN| (r_npadvmod) induced_25\VBN|kindled|completed (r_amod) seizures_26\NNS|NONE
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) kindled_21\VBN|lidocaine (r_amod) seizures_22\NNS|NONE
D002220_D012640 NONE carbamazepine_1\NN|development|. (r_nsubj) inhibits_2\VBZ|NONE (l_dobj) development_4\NN|carbamazepine|. (l_prep) of_5\IN|the (l_pobj) seizures_8\NNS|NONE
D002220_D012640 NONE carbamazepine_3\NN|NONE (l_appos) treatment_7\NN|NONE (l_prep) on_8\IN|)|CBZ|( (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_5\NNP|)|on|( (r_nmod) treatment_7\NN|NONE (l_prep) on_8\IN|)|CBZ|( (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_30\NNP|NONE (r_compound) administration_31\NN|NONE (r_pobj) of_29\IN|different (r_prep) methods_28\NNS|NONE (r_pobj) under_26\IN|and|stages (r_conj) in_18\IN|effects|were|. (r_prep) evaluated_17\VBN|NONE (l_nsubjpass) effects_1\NNS|were|in|. (l_prep) of_2\IN|The (l_pobj) carbamazepine_3\NN|NONE (l_appos) treatment_7\NN|NONE (l_prep) on_8\IN|)|CBZ|( (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_2\NN|development|,|.|but|had (r_nsubj) inhibited_3\VBD|NONE (l_dobj) development_5\NN|CBZ|,|.|but|had (l_prep) of_6\IN|the (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_2\NN|development|,|.|but|had (r_nsubj) inhibited_3\VBD|NONE (l_conj) had_16\VBD|CBZ|development|,|.|but (l_dobj) effect_18\NN|NONE (l_prep) on_19\IN|little (l_pobj) seizures_25\NNS|NONE
D002220_D012640 NONE CBZ_1\NN|incidence|also|. (r_nsubj) decreased_3\VBD|NONE (l_dobj) incidence_5\NN|CBZ|also|. (l_prep) of_6\IN|the (l_pobj) mortality_10\NN|NONE (l_amod) related_9\VBN|in (l_npadvmod) seizure_7\NN|
D002220_D012640 NONE CBZ_1\NN|.|effect (r_nsubj) had_13\VBD|NONE (l_dobj) effect_15\NN|.|CBZ (l_prep) on_16\IN|no (l_pobj) seizures_26\NNS|NONE
D002220_D012640 NONE CBZ_4\NNP|NONE (r_pobj) of_3\IN|Repeated|)|i.p. (r_prep) injection_2\NN|without|.|also (r_nsubj) was_10\VBD|NONE (l_prep) without_11\IN|injection|.|also (l_pobj) effect_12\NN|NONE (l_prep) on_13\IN|NONE (l_pobj) development_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) seizures_22\NNS|NONE
D002220_D012640 NONE CBZ_4\NN|NONE (r_pobj) of_3\IN|differential|The|depending (r_prep) effects_2\NNS|.|underlie (l_prep) depending_5\VBG|of|differential|The (l_prep) upon_6\IN|NONE (l_pobj) stage_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) development_10\NN|NONE (l_compound) seizure_9\NN|NONE
D002220_D012640 NONE CBZ_4\NN|NONE (r_pobj) of_3\IN|differential|The|depending (r_prep) effects_2\NNS|.|underlie (r_nsubj) suggest_11\VBP|NONE (l_ccomp) underlie_15\VBP|.|effects (l_dobj) development_17\NN|that|mechanisms (l_prep) versus_18\IN|the (l_pobj) maintenance_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) seizures_25\NNS|NONE
D008012_D012640 CID lidocaine_13\NN|and (r_conj) cocaine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) kindled_9\VBN|local|anesthetic (r_acl) seizures_8\NNS|NONE
D008012_D012640 CID lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE
D008012_D012640 CID lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE (r_pobj) of_6\IN|the (r_prep) development_5\NN|CBZ|,|.|but|had (r_dobj) inhibited_3\VBD|NONE (l_conj) had_16\VBD|CBZ|development|,|.|but (l_dobj) effect_18\NN|NONE (l_prep) on_19\IN|little (l_pobj) seizures_25\NNS|NONE
D008012_D012640 CID lidocaine_18\NN|acute||or (r_npadvmod) kindled_20\VBN|induced|completed (r_amod) seizures_26\NNS|NONE
D008012_D012640 CID lidocaine-_17\NN|kindled (r_nmod) seizures_22\NNS|NONE
16116131
D007980_D004409 CID levodopa_7\RB| (r_npadvmod) induced_9\VBN|NONE (r_amod) dyskinesia_10\NN|NONE
D001058_D004409 NONE apomorphine_46\NN|continuous (r_compound) infusion_47\NN|NONE (r_pobj) by_44\IN|NONE (r_agent) induced_43\VBN|a|dyskinetic (r_acl) state_42\NN|NONE (l_amod) dyskinetic_41\JJ|a|induced
D001058_D010300 NONE apomorphine_46\NN|continuous (r_compound) infusion_47\NN|NONE (r_pobj) by_44\IN|NONE (r_agent) induced_43\VBN|a|dyskinetic (r_acl) state_42\NN|NONE (r_pobj) of_39\IN|a (r_prep) modification_38\NN|NONE (r_pobj) in_36\IN|modulation|whether|may (r_prep) result_35\VB|,|Using|authors|. (r_ccomp) investigated_28\VBN|NONE (l_advcl) Using_0\VBG|result|,|authors|. (l_parataxis) rTMS_6\NN|stimulation (l_prep) over_8\IN|(|) (l_pobj) area_12\NN|NONE (l_prep) in_16\IN|supplementary|SMA|the|motor (l_pobj) group_18\NN|NONE (l_prep) of_19\IN|a (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) disease_24\NN|NONE
9867728
D005277_D006349 NONE fenfluramine_8\NN|NONE (r_pobj) of_7\IN|underwent (r_prep) users_6\NNS|NONE (r_pobj) among_5\IN|valvular|heart (r_prep) disease_4\NN|NONE
D005277_D006349 NONE fenfluramine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) users_14\NNS|NONE (r_pobj) of_13\IN| (r_prep) %_12\NN|disease (r_nsubj) had_19\VBD|Because|surveys (l_dobj) disease_21\NN|%
D005277_D006349 NONE fenfluramine_13\NN|NONE (r_pobj) of_12\IN|underwent (r_prep) users_11\NNS|NONE (r_pobj) among_10\IN|new|valvular (r_prep) abnormalities_9\NNS|NONE
D005277_D006349 NONE fenfluramine_18\JJ| (r_compound) phentermine_20\NN|NONE (r_dobj) receiving_17\VBG|%|(|]|Two|) (r_acl) patients_1\NNS|.|disease (r_nsubj) developed_21\VBD|NONE (l_dobj) disease_24\NN|.|patients
D010645_D006349 NONE phentermine_20\NN|NONE (r_dobj) receiving_17\VBG|%|(|]|Two|) (r_acl) patients_1\NNS|.|disease (r_nsubj) developed_21\VBD|NONE (l_dobj) disease_24\NN|.|patients
D020372_D006349 NONE dexfenfluramine_10\NN|and (r_conj) fenfluramine_8\NN|NONE (r_pobj) of_7\IN|underwent (r_prep) users_6\NNS|NONE (r_pobj) among_5\IN|valvular|heart (r_prep) disease_4\NN|NONE
D020372_D006349 NONE dexfenfluramine_18\NN|and (r_conj) fenfluramine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) users_14\NNS|NONE (r_pobj) of_13\IN| (r_prep) %_12\NN|disease (r_nsubj) had_19\VBD|Because|surveys (l_dobj) disease_21\NN|%
D020372_D006349 NONE dexfenfluramine_15\NN|or (r_conj) fenfluramine_13\NN|NONE (r_pobj) of_12\IN|underwent (r_prep) users_11\NNS|NONE (r_pobj) among_10\IN|new|valvular (r_prep) abnormalities_9\NNS|NONE
804391
D012293_D011507 CID rifampin_8\NN|NONE (r_advmod) treated_9\VBN|with (r_amod) patients_10\NNS|NONE (r_pobj) in_7\IN|chain|.|Light|and|immunity (r_prep) proteinuria_2\NN|NONE
D012293_D011507 CID rifampin_13\NN|NONE (r_pobj) with_12\IN|patients (r_prep) treated_11\VBN|in|was|proteinuria|. (r_advcl) found_4\VBN|NONE (l_nsubjpass) proteinuria_2\NN|in|treated|was|.
D012293_D014376 NONE rifampin_8\NN|NONE (r_advmod) treated_9\VBN|with (r_amod) patients_10\NNS|NONE (l_prep) with_11\IN|treated (l_pobj) tuberculosis_12\NN|NONE
D012293_D014376 NONE rifampin_13\NN|NONE (r_pobj) with_12\IN|patients (r_prep) treated_11\VBN|in|was|proteinuria|. (l_nsubj) patients_10\NNS|with (l_compound) tuberculosis_9\NN|
9523850
D008775_D063806 NONE methylprednisolone_2\NN|NONE (r_pobj) of_1\IN|:|in|.|trial (r_prep) Value_0\NN|NONE (l_prep) in_3\IN|:|.|trial|of (l_pobj) prevention_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated
D008775_D063806 NONE MP_6\NNP|NONE (r_pobj) of_5\IN|before (r_prep) administration_4\NN|frequency|after|TDI|that (r_nsubj) reduces_11\VBZ|.|data (l_dobj) frequency_13\NN|administration|after|TDI|that (l_prep) of_16\IN|severity|and|the (l_pobj) syndrome_21\NN|NONE (l_compound) myalgia_20\NN|the
D008775_D018771 NONE methylprednisolone_2\NN|NONE (r_pobj) of_1\IN|:|in|.|trial (r_prep) Value_0\NN|NONE (l_prep) in_3\IN|:|.|trial|of (l_pobj) prevention_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated (l_compound) arthralgia_7\JJ|
D008775_D018771 NONE MP_6\NNP|NONE (r_pobj) of_5\IN|before (r_prep) administration_4\NN|frequency|after|TDI|that (r_nsubj) reduces_11\VBZ|.|data (l_dobj) frequency_13\NN|administration|after|TDI|that (l_prep) of_16\IN|severity|and|the (l_pobj) syndrome_21\NN|NONE (l_compound) myalgia_20\NN|the (l_compound) arthralgia_18\JJ|
D007505_D018771 CID dextran_19\NN|NONE (r_pobj) of_17\IN|total|the|dose (r_prep) infusion_16\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|myalgia|the (r_acl) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated (l_compound) arthralgia_7\JJ|
D007505_D063806 NONE dextran_19\NN|NONE (r_pobj) of_17\IN|total|the|dose (r_prep) infusion_16\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|myalgia|the (r_acl) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated
2569282
D020927_D009123 NONE dexmedetomidine_7\NN|capable|. (r_nsubj) is_13\VBZ|NONE (l_acomp) capable_14\JJ|dexmedetomidine|. (l_prep) of_15\IN|NONE (l_pcomp) inducing_16\VBG|NONE (l_dobj) flaccidity_18\NN|NONE
D020927_D009123 NONE MED_11\NNP|agonist|The|selective|alpha (r_appos) dexmedetomidine_7\NN|capable|. (r_nsubj) is_13\VBZ|NONE (l_acomp) capable_14\JJ|dexmedetomidine|. (l_prep) of_15\IN|NONE (l_pcomp) inducing_16\VBG|NONE (l_dobj) flaccidity_18\NN|NONE
D015760_D009127 CID alfentanil_23\NN|dose|in (r_compound) anesthesia_24\NN|NONE (r_pobj) by_19\IN|NONE (r_agent) caused_18\VBN|muscle|the (r_acl) rigidity_17\NN|treatment|if
D015760_D009127 CID alfentanil_7\NN| (r_npadvmod) induced_9\VBN|in|muscle (r_amod) rigidity_11\NN|.|,|MED|In
D020927_D009127 NONE Dexmedetomidine_0\NNP|rigidity|,|.|,|acting (r_nsubj) prevents_8\VBZ|NONE (l_dobj) rigidity_13\NN|,|.|Dexmedetomidine|,|acting
D020927_D009127 NONE MED_13\NNP|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|rigidity|if (r_nsubj) prevents_14\VBZ|.|authors|,|In (l_dobj) rigidity_17\NN|treatment|if
D020927_D009127 NONE MED_5\NNP|.|,|In|rigidity (r_nsubj) prevented_6\VBD|NONE (l_dobj) rigidity_11\NN|.|,|MED|In
D020927_D018476 NONE MED_6\NNP|The|dose (r_compound) animals_7\NNS|flaccid|,|and|lacked|. (r_nsubj) were_8\VBD|NONE (l_acomp) flaccid_9\JJ|,|and|lacked|animals|. (l_conj) akinetic_11\JJ|,
D020927_D012021 NONE MED_6\NNP|The|dose (r_compound) animals_7\NNS|flaccid|,|and|lacked|. (r_nsubj) were_8\VBD|NONE (l_conj) lacked_14\VBD|flaccid|,|and|animals|. (l_dobj) response_17\NN|NONE (l_compound) startle_16\JJ|during|a
12481039
D012964_D012640 NONE sodium_1\NN|NONE (r_compound) channel_2\NN|dependence|.|Reduced|, (r_compound) density_3\NN|NONE (l_appos) dependence_7\NN|.|Reduced|channel|, (l_conj) susceptibility_13\NN|,|voltage|of|and|altered (l_prep) to_14\IN|increased (l_pobj) seizures_15\NNS|NONE
D012964_D012640 NONE sodium_19\NN|NONE (r_compound) channel_20\NN|beta (r_compound) 2-subunits_22\NNS|mice (r_dobj) lacking_18\VBG|NONE (r_pcomp) in_16\IN|NONE (r_prep) seizures_15\NNS|NONE
D010862_D012640 CID pilocarpine_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) seizures_20\NNS|NONE (r_pobj) for_16\IN|NONE (r_prep) threshold_15\NN|reduced|and (r_conj) latency_13\NN|NONE (r_pobj) by_11\IN|as (r_agent) indicated_10\VBN|mice|,|.|but|seemed|,|susceptibility (r_advcl) displayed_3\VBD|NONE (l_dobj) susceptibility_5\NN|mice|,|.|but|seemed|,|indicated (l_prep) to_6\IN|increased (l_pobj) seizures_7\NNS|NONE
D010862_D012640 CID pilocarpine_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) seizures_20\NNS|NONE
20195852
C038192_D003490 NONE iopromide_17\JJ|,|two|CM|(|contrast (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|,|.|study (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|dosage|the|and|and (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D007472_D003490 NONE iohexol_19\NN|and (r_conj) iopromide_17\JJ|,|two|CM|(|contrast (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|,|.|study (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|dosage|the|and|and (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D007472_D007674 CID iohexol_19\NN|and (r_conj) iopromide_17\JJ|,|two|CM|(|contrast (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (l_prep) of_6\IN|the|for (l_pobj) CIN_7\NNP|NONE
C038192_D007674 CID iopromide_17\JJ|,|two|CM|(|contrast (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (l_prep) of_6\IN|the|for (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID media_8\NNS|Risk|by|. (r_dobj) contrast_7\NN|NONE (l_nsubj) Risk_0\NN|media|by|. (l_prep) of_1\IN|after (l_pobj) nephropathy_2\NN|NONE
D003287_D007674 CID media_6\NNS| (r_npadvmod) induced_8\VBN|in|CIN|( (r_amod) nephropathy_9\NN|nonionic
D003287_D007674 CID media_6\NNS| (r_npadvmod) induced_8\VBN|in|CIN|( (r_amod) nephropathy_9\NN|nonionic (l_appos) CIN_11\NNP|in|induced|(
D003287_D007674 CID media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (l_prep) of_6\IN|the|for (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_14\NNP|,|two|(|iopromide|contrast (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (l_prep) of_6\IN|the|for (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_43\NNP|NONE (r_pobj) of_42\IN|presence|dosage|the|and|and (r_prep) type_39\NN|NONE (r_pobj) to_37\IN|NONE (r_prep) relation_36\NN|NONE (r_pobj) in_35\IN|this (r_prep) complication_34\NN|NONE (r_pobj) for_32\IN|the (r_prep) rates_31\NNS|NONE (r_dobj) compared_29\VBD|patients|and (r_conj) among_21\IN|incidence|,|.|study (r_prep) determined_3\VBD|NONE (l_dobj) incidence_5\NN|among|,|.|study (l_prep) of_6\IN|the|for (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_17\NNP|NONE (r_pobj) of_16\IN|the|proper (r_prep) dosage_15\NN|who (r_dobj) received_12\VBD|NONE (r_relcl) those_10\DT|NONE (r_pobj) among_9\IN|Whereas|% (r_prep) were_8\VBD|percentage|,|.|among|with|,|to|) (l_nsubj) %_2\NN|among|Whereas (l_prep) of_3\IN|. (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_17\NNP|NONE (r_pobj) of_16\IN|the|proper (r_prep) dosage_15\NN|who (r_dobj) received_12\VBD|NONE (r_relcl) those_10\DT|NONE (r_pobj) among_9\IN|Whereas|% (r_prep) were_8\VBD|percentage|,|.|among|with|,|to|) (r_advcl) increased_21\VBD|NONE (l_prep) with_32\IN|percentage|,|.|among|were|,|to|) (l_pobj) difference_35\NN|NONE (l_prep) in_36\IN|significant|a (l_pobj) incidence_38\NN|NONE (l_prep) of_39\IN|related|the (l_pobj) CIN_40\NNP|NONE
D003287_D007674 CID CM_47\NNP|NONE (r_pobj) of_46\IN|the|different (r_prep) dosages_45\NNS|NONE (r_pobj) to_42\IN|NONE (r_prep) related_41\VBN|of|the (r_acl) incidence_38\NN|NONE (r_pobj) in_36\IN|significant|a (r_prep) difference_35\NN|NONE (r_pobj) with_32\IN|percentage|,|.|among|were|,|to|) (r_prep) increased_21\VBD|NONE (l_advcl) were_8\VBD|percentage|,|.|among|with|,|to|) (l_nsubj) %_2\NN|among|Whereas (l_prep) of_3\IN|. (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_47\NNP|NONE (r_pobj) of_46\IN|the|different (r_prep) dosages_45\NNS|NONE (r_pobj) to_42\IN|NONE (r_prep) related_41\VBN|of|the (r_acl) incidence_38\NN|NONE (l_prep) of_39\IN|related|the (l_pobj) CIN_40\NNP|NONE
D003287_D007674 CID CM_13\NNP|NONE (r_pobj) of_10\IN|the (r_prep) type_9\NN|on|not|nor|, (r_pobj) on_7\IN|dosage|but (r_conj) on_3\IN|and|incidence|needed|, (r_prep) depends_2\VBZ|NONE (l_conj) needed_32\VBN|and|incidence|on|, (l_advcl) is_26\VBZ|concern|for|.|is|, (l_nsubj) CIN_24\NNP|although|usually|reversible
D003287_D003490 NONE media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|,|.|study (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|dosage|the|and|and (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE CM_14\NNP|,|two|(|iopromide|contrast (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|the|of (r_prep) incidence_5\NN|among|,|.|study (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|,|.|study (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|dosage|the|and|and (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE CM_43\NNP|NONE (r_pobj) of_42\IN|presence|dosage|the|and|and (r_prep) type_39\NN|NONE (l_conj) presence_46\NN|of|dosage|the|and|and (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE CM_13\NNP|NONE (r_pobj) of_10\IN|the (r_prep) type_9\NN|on|not|nor|, (r_pobj) on_7\IN|dosage|but (l_conj) on_16\IN|not|nor|type|, (l_pobj) presence_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) cyanosis_20\NN|NONE
15673851
D016202_D020760 NONE aspartate_10\NN|spinal (r_compound) receptors_11\NNS|NONE (r_pobj) of_2\IN|The (r_prep) activation_1\NN|.|may|to (r_nsubj) contribute_13\VB|NONE (l_prep) to_14\IN|activation|.|may (l_pobj) degeneration_15\NN|NONE (l_acl) induced_20\VBN|of (l_prep) after_24\IN|by (l_pobj) interval_27\NN|NONE (l_prep) of_28\IN|a|noninjurious (l_pobj) ischemia_31\NN|NONE
D016202_D020760 NONE NMDA_15\NNP|receptor (r_compound) activation_17\NN|NONE (r_pobj) via_14\IN|cord (r_prep) ischemia_13\NN|NONE
D016202_D020258 NONE NMDA_15\NNP|receptor (r_compound) activation_17\NN|NONE (r_pobj) via_14\IN|cord (r_prep) ischemia_13\NN|NONE (r_pobj) of_10\IN|the (r_prep) setting_9\NN|NONE (r_pobj) in_7\IN|neurotoxic|that|may|opioids (r_prep) be_5\VB|We|. (l_acomp) neurotoxic_6\JJ|that|may|in|opioids
D016202_D001157 NONE aspartate_20\NNP|(|)|NMDA (r_nmod) receptors_24\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) activation_12\NN|motor|spinal|and (r_conj) neurons_10\NNS|NONE (r_pobj) of_7\IN|after|the|following (r_prep) degeneration_6\NN|NONE (l_prep) following_28\VBG|of|after|the (l_pobj) interval_31\NN|NONE (l_prep) of_32\IN|noninjurious|a (l_pobj) occlusion_34\NN|NONE
D016202_D001157 NONE NMDA_22\NNP|(|)|aspartate (r_nmod) receptors_24\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) activation_12\NN|motor|spinal|and (r_conj) neurons_10\NNS|NONE (r_pobj) of_7\IN|after|the|following (r_prep) degeneration_6\NN|NONE (l_prep) following_28\VBG|of|after|the (l_pobj) interval_31\NN|NONE (l_prep) of_32\IN|noninjurious|a (l_pobj) occlusion_34\NN|NONE
D018698_D020336 NONE glutamate_15\NN|NONE (r_pobj) in_13\IN|concomitant|a (r_prep) increase_12\NN|NONE (r_pobj) with_9\IN|that|morphine|paraparesis (r_prep) induces_6\VBZ|.|data (l_dobj) paraparesis_8\NN|that|morphine|with
D016202_D020336 NONE NMDA_21\NNP|receptor (r_compound) activation_23\NN|NONE (r_pobj) in_20\IN|is|which (r_prep) involved_19\VBN|CSF|, (r_relcl) glutamate_15\NN|NONE (r_pobj) in_13\IN|concomitant|a (r_prep) increase_12\NN|NONE (r_pobj) with_9\IN|that|morphine|paraparesis (r_prep) induces_6\VBZ|.|data (l_dobj) paraparesis_8\NN|that|morphine|with
D009020_D020760 NONE morphine_23\NN|NONE (r_pobj) by_21\IN|after (r_agent) induced_20\VBN|of (l_prep) after_24\IN|by (l_pobj) interval_27\NN|NONE (l_prep) of_28\IN|a|noninjurious (l_pobj) ischemia_31\NN|NONE
D016291_D020336 NONE MK-801_8\NNP|NONE (r_punct) (_9\-LRB-|on|)| (r_punct) mug_11\NN|Second|,|we|.|effect (l_prep) on_13\IN|)|(| (l_pobj) changes_16\NNS|NONE (l_prep) after_21\IN|the|in|histopathologic (l_pobj) paraparesis_26\NN|NONE
D016291_D020336 NONE MK-801_1\NNP|.|number|after|significantly|IT|compared (r_punct) reduced_3\VBD|NONE (l_prep) after_13\IN|.|number|significantly|MK|IT|compared (l_pobj) paraparesis_18\NN|NONE
D009020_D020336 CID morphine_22\NN| (r_npadvmod) induced_24\VBN|spastic (r_amod) paraparesis_26\NN|NONE
D009020_D020336 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|spastic (r_amod) paraparesis_18\NN|NONE
D009020_D020336 CID morphine_5\NN|that|with|paraparesis (r_nsubj) induces_6\VBZ|.|data (l_dobj) paraparesis_8\NN|that|morphine|with
D009020_D001157 NONE morphine_27\NN|NONE (r_pobj) after_25\IN|of|the|following (r_prep) degeneration_6\NN|NONE (l_prep) following_28\VBG|of|after|the (l_pobj) interval_31\NN|NONE (l_prep) of_32\IN|noninjurious|a (l_pobj) occlusion_34\NN|NONE
7647582
D014269_D056486 NONE trifluoroacetyl_11\JJ|NONE (r_compound) adduct_12\NN|a|biotransformation|)|bound|( (r_appos) product_9\NN|NONE (r_pobj) to_3\IN|An|antibody (r_prep) response_2\NN|has|on|been|. (r_nsubjpass) detected_16\VBN|NONE (l_prep) on_17\IN|has|been|response|. (l_pobj) patients_20\NNS|NONE (l_compound) hepatitis_19\NN|halothane
D006221_D056486 CID halothane_25\NN|previous (r_relcl) exposure_23\NN|NONE (r_pobj) following_21\VBG|alone|with|anesthetics|have|been|. (r_agent) associated_10\VBN|NONE (l_prep) with_11\IN|following|alone|anesthetics|have|been|. (l_pobj) injury_17\NN|NONE
D006221_D056486 CID Halothane_0\NNP|NONE (r_compound) hepatitis_1\NN|.|involve
D006221_D056486 CID halothane_18\NN|hepatitis (r_amod) patients_20\NNS|NONE (l_compound) hepatitis_19\NN|halothane
D006221_D056486 CID halothane_23\NN|NONE (r_compound) hepatitis_24\NN|NONE
D006221_D056486 CID halothane_30\NN|alone|could|condition|supports|enflurane|. (r_advcl) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_amod) similar_19\JJ|hypersensitivity|a (l_prep) to_20\IN|NONE (l_pobj) that_21\DT|NONE (l_prep) of_22\IN|NONE (l_pobj) hepatitis_24\NN|NONE
D004737_D004342 NONE enflurane_10\NN|NONE (l_conj) isoflurane_12\RB|and (l_prep) with_13\IN|NONE (l_pobj) hypersensitivity_15\NN|NONE
D004737_D004342 NONE enflurane_11\NN|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN|a|similar
D007530_D056486 CID isoflurane_6\RB|and (r_conj) enflurane_4\NN|halogenated|,|Two|, (r_conj) anesthetics_2\NNS|following|alone|with|have|been|. (r_nsubjpass) associated_10\VBN|NONE (l_prep) with_11\IN|following|alone|anesthetics|have|been|. (l_pobj) injury_17\NN|NONE
D007530_D056486 CID isoflurane_13\NN|by|and/or (r_conj) enflurane_11\NN|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_amod) similar_19\JJ|hypersensitivity|a (l_prep) to_20\IN|NONE (l_pobj) that_21\DT|NONE (l_prep) of_22\IN|NONE (l_pobj) hepatitis_24\NN|NONE
D007530_D004342 NONE isoflurane_12\RB|and (l_prep) with_13\IN|NONE (l_pobj) hypersensitivity_15\NN|NONE
D007530_D004342 NONE isoflurane_13\NN|by|and/or (r_conj) enflurane_11\NN|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN|a|similar
D006221_D004342 NONE halothane_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|the (r_acl) hypersensitivity_15\NN|NONE
D006221_D004342 NONE halothane_23\NN|NONE (r_compound) hepatitis_24\NN|NONE (r_pobj) of_22\IN|NONE (r_prep) that_21\DT|NONE (r_pobj) to_20\IN|NONE (r_prep) similar_19\JJ|hypersensitivity|a (r_amod) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN|a|similar
D006221_D004342 NONE halothane_30\NN|alone|could|condition|supports|enflurane|. (r_advcl) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN|a|similar
D004737_D056486 CID enflurane_4\NN|halogenated|,|Two|, (r_conj) anesthetics_2\NNS|following|alone|with|have|been|. (r_nsubjpass) associated_10\VBN|NONE (l_prep) with_11\IN|following|alone|anesthetics|have|been|. (l_pobj) injury_17\NN|NONE
D004737_D056486 CID enflurane_11\NN|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|enflurane|.|halothane (l_amod) similar_19\JJ|hypersensitivity|a (l_prep) to_20\IN|NONE (l_pobj) that_21\DT|NONE (l_prep) of_22\IN|NONE (l_pobj) hepatitis_24\NN|NONE
7059267
D002747_D003924 NONE chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (l_nsubj) woman_4\NN|with (l_prep) with_5\IN|A|old (l_pobj) diabetes_9\NNS|NONE
D002747_D003924 NONE Diabenese_14\NNP|(|) (r_appos) chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (l_nsubj) woman_4\NN|with (l_prep) with_5\IN|A|old (l_pobj) diabetes_9\NNS|NONE
D002747_D003924 NONE chlorpropamide_26\NN|NONE (r_amod) therapy_27\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) discontinuation_24\NN|NONE (r_pobj) with_23\IN|that (r_prep) resolved_22\VBD|a|toxic|optic (r_relcl) neuropathy_20\NN|treated|. (r_dobj) had_16\VBD|NONE (l_csubj) treated_10\VBN|neuropathy|. (l_nsubj) woman_4\NN|with (l_prep) with_5\IN|A|old (l_pobj) diabetes_9\NNS|NONE
D002747_D009901 CID Chlorpropamide_0\NN| (r_npadvmod) induced_2\VBN|.|optic (r_amod) neuropathy_4\NN|NONE
D002747_D009901 CID chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (r_csubj) had_16\VBD|NONE (l_dobj) neuropathy_20\NN|treated|.
D002747_D009901 CID Diabenese_14\NNP|(|) (r_appos) chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (r_csubj) had_16\VBD|NONE (l_dobj) neuropathy_20\NN|treated|.
D002747_D009901 CID chlorpropamide_26\NN|NONE (r_amod) therapy_27\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) discontinuation_24\NN|NONE (r_pobj) with_23\IN|that (r_prep) resolved_22\VBD|a|toxic|optic (r_relcl) neuropathy_20\NN|treated|.
2528969
11208990
D000109_D007674 NONE acetylcholine_5\NN|NONE (r_npadvmod) related_6\VBN|IPRK|and (r_conj) phenylephrine_3\NN|the (r_nmod) responses_7\NNS|NONE (r_pobj) In_0\IN|impaired|. (r_prep) were_8\VBD|NONE (l_acomp) impaired_10\VBN|In|. (l_prep) in_11\IN|significantly (l_pobj) group_16\NN|NONE (l_compound) nephropathy_15\NN|the
D004317_D009401 NONE ADR_15\NNP| (r_npadvmod) induced_17\VBN|the (r_amod) nephrosis_18\NN|NONE
D009569_D007674 NONE oxide_3\NN|NONE (r_compound) production_4\NN|NONE (r_pobj) of_1\IN|.|apoptosis|and (r_prep) Association_0\NN|NONE (l_conj) apoptosis_6\NN|of|.|and (l_prep) in_7\IN|NONE (l_pobj) model_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) nephropathy_12\NN|NONE
D004317_D009395 NONE ADR_9\NNP|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|NONE (r_acl) rats_6\NNS|NONE (r_pobj) of_5\IN|the (r_prep) kidneys_4\NNS|NONE (r_pobj) of_2\IN|Histopathological (r_prep) examination_1\NN|areas|. (r_nsubj) revealed_10\VBD|NONE (l_dobj) areas_12\NNS|examination|. (l_prep) of_13\IN|focal (l_pobj) proliferation_15\NN|NONE (l_conj) inflammation_19\NN|and|mesangial
D009569_D009401 NONE NO_5\UH|NONE (r_intj) between_4\IN|NONE (r_prep) interactions_3\NNS|important|in|that (r_nsubj) are_8\VBP|.|We (l_prep) in_10\IN|interactions|important|that (l_pobj) pathogenesis_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) nephrosis_18\NN|NONE
D010656_D007674 NONE phenylephrine_3\NN|the (r_nmod) responses_7\NNS|NONE (r_pobj) In_0\IN|impaired|. (r_prep) were_8\VBD|NONE (l_acomp) impaired_10\VBN|In|. (l_prep) in_11\IN|significantly (l_pobj) group_16\NN|NONE (l_compound) nephropathy_15\NN|the
D004317_D007674 NONE ADR_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) nephropathy_10\NN|NONE
D004317_D007674 NONE ADR_8\NNP| (r_compound) nephropathy_10\NN|(|P|the|)
D004317_D007674 NONE ADR_13\NNP| (r_compound) nephropathy_15\NN|the
D004317_D007674 NONE ADR_4\NNP| (r_compound) nephropathy_6\NN|the
D009569_D009404 NONE NO_6\DT|association (r_intj) of_5\IN|the (l_pobj) association_9\NN|NO (l_prep) with_10\IN|its (l_pobj) apoptosis_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) model_15\NN|NONE (l_prep) of_16\IN|experimental|induced|an (l_pobj) syndrome_18\NN|NONE
D009573_D007674 NONE nitrite_1\NN|Urine (r_compound) levels_2\NNS|were|in|.|significantly (r_nsubjpass) increased_5\VBN|NONE (l_prep) in_6\IN|levels|were|.|significantly (l_pobj) group_11\NN|NONE (l_compound) nephropathy_10\NN|(|P|the|)
D004317_D009404 CID adriamycin_25\NNS|NONE (r_pobj) of_24\IN|single|a (r_prep) injection_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|experimental|of|an (r_acl) model_15\NN|NONE (l_prep) of_16\IN|experimental|induced|an (l_pobj) syndrome_18\NN|NONE
D004317_D009404 CID ADR_27\NNP|)|( (r_appos) adriamycin_25\NNS|NONE (r_pobj) of_24\IN|single|a (r_prep) injection_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|experimental|of|an (r_acl) model_15\NN|NONE (l_prep) of_16\IN|experimental|induced|an (l_pobj) syndrome_18\NN|NONE
D004317_C537346 NONE ADR_9\NNP|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|NONE (r_acl) rats_6\NNS|NONE (r_pobj) of_5\IN|the (r_prep) kidneys_4\NNS|NONE (r_pobj) of_2\IN|Histopathological (r_prep) examination_1\NN|areas|. (r_nsubj) revealed_10\VBD|NONE (l_dobj) areas_12\NNS|examination|. (l_prep) of_13\IN|focal (l_pobj) proliferation_15\NN|NONE
16634859
D000431_D006130 CID alcohol_9\NN| (r_npadvmod) related_11\VBN|growth (r_amod) impairment_14\NN|NONE
D000431_D006130 CID alcohol_1\NN|NONE (r_compound) consumption_2\NN|postpregnancy|among|Any (r_compound) recognition_4\NN|.|in (r_nsubj) resulted_9\VBD|NONE (l_prep) in_10\IN|recognition|. (l_pobj) growth_13\NN|NONE
D000431_D006130 CID alcohol_1\NN|NONE (r_compound) consumption_2\NN|postpregnancy|among|Any (r_compound) recognition_4\NN|.|in (r_nsubj) resulted_9\VBD|NONE (l_prep) in_10\IN|recognition|. (l_pobj) growth_13\NN|NONE (l_conj) cranial_18\JJ|cerebellar|as|reduced (l_acl) body_20\NN|decreased (l_dobj) growth_21\NN|in|to
16428827
D012601_D007859 NONE scopolamine_12\NN| (r_npadvmod) induced_14\VBN|of (r_amod) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
D012601_D000647 CID scopolamine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) amnesia_19\NN|to
D012601_D000647 CID scopolamine_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) amnesia_25\NN|also|it|that
D000109_D000544 NONE acetylcholine_20\NN|( (r_nmod) ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|)|(|ChAT|,|) (r_relcl) activator_6\NN|The|choline|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|acetyltransferase|. (l_prep) in_29\IN|an|important (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE
D000109_D000544 NONE acetylcholine_20\NN|( (r_nmod) ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|)|(|ChAT|,|) (r_relcl) activator_6\NN|The|choline|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|acetyltransferase|. (l_prep) in_29\IN|an|important (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE (l_appos) AD_37\NN|)|Alzheimer
D000109_D000544 NONE ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|)|(|ChAT|,|) (r_relcl) activator_6\NN|The|choline|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|acetyltransferase|. (l_prep) in_29\IN|an|important (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE
D000109_D000544 NONE ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|)|(|ChAT|,|) (r_relcl) activator_6\NN|The|choline|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|acetyltransferase|. (l_prep) in_29\IN|an|important (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE (l_appos) AD_37\NN|)|Alzheimer
D000109_D000647 NONE acetylcholine_10\NN|NONE (r_compound) biosynthesis_11\NN|NONE (r_pobj) in_9\IN|a (r_prep) role_8\NN|and|as|daidzein|might|ameliorates|that|, (r_dobj) play_6\VB|results|. (l_conj) ameliorates_21\VBZ|and|as|daidzein|role|might|that|, (l_dobj) amnesia_25\NN|also|it|that
C004742_D008569 NONE daidzein_7\NN|NONE (r_pobj) of_6\IN|from|the (r_prep) effects_5\NNS|to (l_prep) from_8\IN|the|of (l_pobj) thunbergiana_10\NNS|NONE (l_prep) on_11\IN|Pueraria (l_pobj) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
D002794_D000647 NONE choline_2\NN|NONE (r_compound) acetyltransferase_3\NN|and|Daidzein|from|.|improves (r_dobj) activates_1\VBZ|NONE (l_conj) improves_10\VBZ|and|Daidzein|from|.|acetyltransferase (l_dobj) amnesia_14\NN|NONE
D012601_D008569 NONE scopolamine_12\NN| (r_npadvmod) induced_14\VBN|of (r_amod) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
D002794_D000544 NONE choline_1\NN|The|,|activator (r_compound) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|acetyltransferase|. (l_prep) in_29\IN|an|important (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE
D002794_D000544 NONE choline_1\NN|The|,|activator (r_compound) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|acetyltransferase|. (l_prep) in_29\IN|an|important (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE (l_appos) AD_37\NN|)|Alzheimer
C004742_D000647 NONE Daidzein_0\NNP|and|from|.|improves|acetyltransferase (r_nsubj) activates_1\VBZ|NONE (l_conj) improves_10\VBZ|and|Daidzein|from|.|acetyltransferase (l_dobj) amnesia_14\NN|NONE
C004742_D000647 NONE daidzein_2\NN|NONE (r_pobj) of_1\IN|weight|to (r_prep) Administration_0\NN|reverse|,|.|was|according|significantly (r_nsubjpass) shown_12\VBN|NONE (l_xcomp) reverse_15\VB|,|Administration|.|was|according|significantly (l_dobj) amnesia_19\NN|to
C004742_D000647 NONE daidzein_4\NN|and|as|role|might|ameliorates|that|, (r_nsubj) play_6\VB|results|. (l_conj) ameliorates_21\VBZ|and|as|daidzein|role|might|that|, (l_dobj) amnesia_25\NN|also|it|that
C004742_D007859 NONE daidzein_7\NN|NONE (r_pobj) of_6\IN|from|the (r_prep) effects_5\NNS|to (l_prep) from_8\IN|the|of (l_pobj) thunbergiana_10\NNS|NONE (l_prep) on_11\IN|Pueraria (l_pobj) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
7910951
D003473_D009468 CID NMBA_21\NNP|to (r_pobj) due_17\IN|likely|(|most (r_prep) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (l_prep) at_9\IN|likely (l_pobj) junction_13\NN|NONE
D000305_D009468 NONE corticosteroids_30\NNS|to (r_pobj) due_28\IN|)|most|( (r_prep) likely_27\JJ|(|due|most (r_parataxis) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (l_prep) at_9\IN|likely (l_pobj) junction_13\NN|NONE
D003473_D018908 CID agents_9\NNS|NONE (r_pobj) of_5\IN|term|The (r_prep) use_4\NN|been|recently|,|been|.|as|has (r_nsubjpass) implicated_18\VBN|NONE (l_prep) as_19\IN|been|use|recently|,|been|.|has (l_pobj) cause_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) weakness_25\NN|NONE
D003473_D018908 CID NMBA_13\NNP|)|neuromuscular|(|blocking (r_appos) agents_9\NNS|NONE (r_pobj) of_5\IN|term|The (r_prep) use_4\NN|been|recently|,|been|.|as|has (r_nsubjpass) implicated_18\VBN|NONE (l_prep) as_19\IN|been|use|recently|,|been|.|has (l_pobj) cause_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) weakness_25\NN|NONE
D003473_D018908 CID NMBAs_25\NNP|NONE (r_pobj) of_22\IN|the (r_prep) discontinuation_21\NN|NONE (r_pobj) following_19\VBG|prolonged (r_prep) weakness_18\NN|who
D003473_D018908 CID NMBA_21\NNP|to (r_pobj) due_17\IN|likely|(|most (r_prep) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (r_pobj) due_6\JJ|.|weakness (r_acomp) is_5\VBZ|NONE (l_nsubj) weakness_1\NN|.|due
D000305_D018908 NONE corticosteroids_30\NNS|to (r_pobj) due_28\IN|)|most|( (r_prep) likely_27\JJ|(|due|most (r_parataxis) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (r_pobj) due_6\JJ|.|weakness (r_acomp) is_5\VBZ|NONE (l_nsubj) weakness_1\NN|.|due
D003473_D012131 NONE NMBAs_25\NNP|NONE (r_pobj) of_22\IN|the (r_prep) discontinuation_21\NN|NONE (r_pobj) following_19\VBG|prolonged (r_prep) weakness_18\NN|who (r_dobj) developed_16\VBD|acute|respiratory (r_relcl) insufficiency_14\NN|NONE
D003473_D010243 NONE agents_7\NNS|nondepolarizing (r_appos) neuromuscular_5\JJ|to (r_pobj) due_2\IN|.|Prolonged (r_prep) paralysis_1\NN|NONE
D000305_D010243 NONE corticosteroids_9\NNS|and|blocking (r_conj) agents_7\NNS|nondepolarizing (r_appos) neuromuscular_5\JJ|to (r_pobj) due_2\IN|.|Prolonged (r_prep) paralysis_1\NN|NONE
7437994
6127992
D014700_D007022 CID verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|cardiac|profound
D014700_D001919 CID verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and
D000319_D007022 CID drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|cardiac|profound
D000319_D006333 CID drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|cardiac|profound (r_conj) failure_9\NN|.|patients
D014700_D006333 CID verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|cardiac|profound (r_conj) failure_9\NN|.|patients
D000319_D017202 NONE drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|cardiac|profound (r_conj) failure_9\NN|.|patients (r_dobj) developed_6\VBD|NONE (l_nsubj) patients_1\NNS|failure|. (l_prep) with_2\IN|Three (l_pobj) disease_5\NN|NONE
D014700_D017202 NONE verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|cardiac|profound (r_conj) failure_9\NN|.|patients (r_dobj) developed_6\VBD|NONE (l_nsubj) patients_1\NNS|failure|. (l_prep) with_2\IN|Three (l_pobj) disease_5\NN|NONE
D000319_D001919 CID drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and
15764424
D000661_D006948 CID amphetamine_2\NN|NONE (r_compound) levels_3\NNS|or (r_conj) Methamphetamine_0\NN|were|to|. (r_nsubjpass) related_5\VBN|NONE (l_prep) to_6\IN|were|.|Methamphetamine (l_pobj) scores_9\NNS|NONE (l_conj) rating_14\NN|several|psychopathology|and (l_compound) hyperkinesia_13\NN|global|the
D002395_D006948 NONE catecholamines_12\NNS|,|symptom (l_conj) hyperkinesia_14\NN|and
D002395_D011605 NONE catecholamines_12\NNS|,|symptom (r_conj) severity_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) relationship_7\NN|Quantitative|in|drug|:|. (r_appos) levels_2\NNS|NONE (l_prep) in_3\IN|Quantitative|relationship|drug|:|. (l_pobj) psychosis_5\NN|NONE
D002395_D011605 NONE catecholamines_10\NNS|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS|,|and
D002395_D011605 NONE catecholamines_10\NNS|,|drug|quantitative|stimulant (r_conj) levels_8\NNS|NONE (r_pobj) between_4\IN|the (r_prep) relationship_3\NN|To (r_dobj) examine_1\VB|patients|were|,|and|,|collected (r_advcl) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|were|,|and|,|collected (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_prep) with_23\IN|emergency|a|psychiatric (l_pobj) diagnosis_25\NN|NONE (l_prep) of_26\IN|a (l_pobj) psychosis_32\NN|NONE
D002395_D011605 NONE catecholamine_49\NN|stimulant|and (r_conj) drug_47\NN|metabolite (r_nmod) levels_51\NNS|NONE (r_pobj) of_45\IN|quantitative (r_prep) assays_44\NNS|NONE (r_pobj) for_42\IN|.|plasma|were (r_prep) collected_41\VBN|patients|examine|were|,|and|, (r_conj) interviewed_34\VBN|NONE (l_advcl) examine_1\VB|patients|were|,|and|,|collected (l_dobj) relationship_3\NN|To (l_prep) between_4\IN|the (l_pobj) levels_8\NNS|NONE (l_conj) catecholamines_10\NNS|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS|,|and
D002395_D011605 NONE catecholamine_49\NN|stimulant|and (r_conj) drug_47\NN|metabolite (r_nmod) levels_51\NNS|NONE (r_pobj) of_45\IN|quantitative (r_prep) assays_44\NNS|NONE (r_pobj) for_42\IN|.|plasma|were (r_prep) collected_41\VBN|patients|examine|were|,|and|, (r_conj) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|were|,|and|,|collected (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_prep) with_23\IN|emergency|a|psychiatric (l_pobj) diagnosis_25\NN|NONE (l_prep) of_26\IN|a (l_pobj) psychosis_32\NN|NONE
D003042_D001523 NONE cocaine_29\NN|or (r_conj) amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D000661_D001523 NONE amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D003042_D011605 CID cocaine_29\NN|or (r_conj) amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (r_pobj) in_18\IN|nineteen (r_prep) patients_17\NNS|examine|were|,|and|,|collected (r_nsubjpass) interviewed_34\VBN|NONE (l_advcl) examine_1\VB|patients|were|,|and|,|collected (l_dobj) relationship_3\NN|To (l_prep) between_4\IN|the (l_pobj) levels_8\NNS|NONE (l_conj) catecholamines_10\NNS|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS|,|and
D003042_D011605 CID cocaine_29\NN|or (r_conj) amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE
D008694_D006948 CID Methamphetamine_0\NN|were|to|. (r_nsubjpass) related_5\VBN|NONE (l_prep) to_6\IN|were|.|Methamphetamine (l_pobj) scores_9\NNS|NONE (l_conj) rating_14\NN|several|psychopathology|and (l_compound) hyperkinesia_13\NN|global|the
D002395_D001523 NONE catecholamines_10\NNS|,|drug|quantitative|stimulant (r_conj) levels_8\NNS|NONE (r_pobj) between_4\IN|the (r_prep) relationship_3\NN|To (r_dobj) examine_1\VB|patients|were|,|and|,|collected (r_advcl) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|were|,|and|,|collected (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D002395_D001523 NONE catecholamine_49\NN|stimulant|and (r_conj) drug_47\NN|metabolite (r_nmod) levels_51\NNS|NONE (r_pobj) of_45\IN|quantitative (r_prep) assays_44\NNS|NONE (r_pobj) for_42\IN|.|plasma|were (r_prep) collected_41\VBN|patients|examine|were|,|and|, (r_conj) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|were|,|and|,|collected (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D000661_D011605 CID amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (r_pobj) in_18\IN|nineteen (r_prep) patients_17\NNS|examine|were|,|and|,|collected (r_nsubjpass) interviewed_34\VBN|NONE (l_advcl) examine_1\VB|patients|were|,|and|,|collected (l_dobj) relationship_3\NN|To (l_prep) between_4\IN|the (l_pobj) levels_8\NNS|NONE (l_conj) catecholamines_10\NNS|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS|,|and
D000661_D011605 CID amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE
2343592
C044650_D006259 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|trauma|and|patients (r_conj) head_15\NN|NONE (l_dobj) trauma_16\NN|and|patients|developed
C044650_D012640 CID cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|trauma|and|patients (l_dobj) seizures_24\NNS|receiving|evidence|.
C044650_D020521 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|trauma|and|patients (r_conj) head_15\NN|NONE (l_nsubj) patients_2\NNS|trauma|and|developed (l_prep) with_3\IN|elderly|Two (l_pobj) history_5\NN|NONE (l_prep) of_6\IN|a (l_pobj) accident_10\NN|NONE
C044650_D020521 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|trauma|and|patients (r_conj) head_15\NN|NONE (l_nsubj) patients_2\NNS|trauma|and|developed (l_prep) with_3\IN|elderly|Two (l_pobj) history_5\NN|NONE (l_prep) of_6\IN|a (l_pobj) accident_10\NN|NONE (l_appos) CVA_12\NNP|either|cerebral|vascular|or|(
D047090_D012640 NONE lactam_10\NN|other (r_compound) antibiotics_11\NNS|NONE (r_pobj) of_6\IN|maximum (r_prep) doses_5\NNS|.|had|without|patients (r_dobj) received_3\VBN|NONE (l_prep) without_12\IN|.|had|doses|patients (l_pobj) evidence_13\NN|NONE (l_prep) of_14\IN|NONE (l_pobj) activity_16\NN|NONE (l_compound) seizure_15\NN|NONE
C044650_D007674 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|trauma|and|patients (l_nsubj) evidence_19\NN|receiving|seizures|. (l_prep) of_20\IN|no (l_pobj) disease_22\NN|NONE
D015378_D012640 NONE imipenem_3\NN|:|factors (r_compound) therapy_4\NN|NONE (r_pobj) with_2\IN|Seizure|. (r_prep) activity_1\NN|NONE (l_compound) Seizure_0\NN|.|with
D010672_D012640 NONE phenytoin_8\NN|NONE (r_pobj) of_7\IN|therapeutic (r_prep) doses_6\NNS|NONE (r_pobj) with_4\IN|were|.|seizures (r_prep) controlled_3\VBN|NONE (l_nsubjpass) seizures_1\NNS|were|.|with
18161408
D002996_D013927 NONE CC_9\NN|NONE (r_pobj) of_8\IN|a|rare (r_prep) complication_7\NN|.|might|Thrombosis (r_attr) be_2\VB|NONE (l_nsubj) Thrombosis_0\NN|complication|.|might
D002996_D013923 CID CC_17\NN|NONE (r_pobj) with_16\IN|ovulation (r_prep) induction_15\NN|NONE (r_pobj) after_13\IN|been|has|that (r_prep) reported_12\VBN|a|rare (r_relcl) complication_8\NN|.|Thromboembolism (r_attr) is_1\VBZ|NONE (l_nsubj) Thromboembolism_0\NN|.|complication
D002996_D009203 CID citrate_7\NN|NONE (r_pobj) with_5\IN|for (r_prep) associated_4\VBN|report|:|in|Myocardial|. (r_acl) infarction_1\NN|NONE
D002996_D009203 CID CC_13\NN|NONE (l_conj) infarction_16\NN|and
D002996_D002637 NONE CC_12\NN|woman|recently|.|presented|had|and|for (r_dobj) received_11\VBN|NONE (l_conj) presented_17\VBD|woman|recently|.|CC|had|and|for (l_prep) with_18\IN|NONE (l_pobj) pain_20\NN|NONE
16960342
D019259_D005355 NONE lamivudine_17\NN|NONE (r_amod) monotherapy_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) after_14\IN|clinical|Sustained|of|. (r_prep) improvement_2\NN|NONE (l_prep) of_3\IN|clinical|Sustained|.|after (l_pobj) patient_5\NN|NONE (l_prep) with_6\IN|a (l_pobj) cirrhosis_13\NN|NONE
D019259_D005355 NONE lamivudine_3\NN|NONE (r_pobj) of_2\IN|The|to (r_prep) administration_1\NN|like|,|in|,|be|.|,|should|as (l_prep) to_4\IN|of|The (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) cirrhosis_10\NN|NONE
D019259_D006509 NONE lamivudine_17\NN|NONE (r_amod) monotherapy_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) after_14\IN|clinical|Sustained|of|. (r_prep) improvement_2\NN|NONE (l_prep) of_3\IN|clinical|Sustained|.|after (l_pobj) patient_5\NN|NONE (l_prep) with_6\IN|a (l_pobj) cirrhosis_13\NN|NONE (l_amod) related_12\VBN|decompensated (l_npadvmod) virus_10\NN| (l_compound) B_9\NNP|NONE
3300918
D004876_D008881 CID ergot_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) history_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) discussion_1\NN|discovery|. (r_nsubj) includes_7\VBZ|NONE (l_dobj) discovery_10\NN|.|discussion (l_appos) epidemics_13\NNS|,|original|its (l_relcl) caused_19\VBN|the|of (l_prep) through_20\IN|has|it|that (l_pobj) ages_22\NNS|NONE (l_conj) role_28\NN|the|and (l_prep) in_29\IN|past|its (l_pobj) management_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) headache_34\NN|NONE
D004876_D008881 CID ergot_13\NN|NONE (r_compound) preparations_14\NNS|.|persists|play|,|Despite|, (r_nsubj) continue_15\VBP|NONE (l_xcomp) play_17\VB|.|persists|,|Despite|preparations|, (l_dobj) role_20\NN|to (l_prep) in_21\IN|a|major (l_pobj) therapy_23\NN|NONE (l_compound) migraine_22\NN|NONE
D002118_D004881 NONE calcium_4\NN|NONE (r_compound) channel_5\NN|and|antagonists (r_compound) blockers_6\NNS|NONE (r_pobj) of_3\IN|the (r_prep) advent_2\NN|NONE (r_pobj) Despite_0\IN|.|persists|play|,|preparations|, (r_prep) continue_15\VBP|NONE (l_advcl) persists_34\VBZ|.|play|,|Despite|preparations|, (l_nsubj) danger_28\NN|so|that (l_prep) of_29\IN|the (l_pobj) fire_33\NN|NONE
D004876_D004881 NONE ergot_13\NN|NONE (r_compound) preparations_14\NNS|.|persists|play|,|Despite|, (r_nsubj) continue_15\VBP|NONE (l_advcl) persists_34\VBZ|.|play|,|Despite|preparations|, (l_nsubj) danger_28\NN|so|that (l_prep) of_29\IN|the (l_pobj) fire_33\NN|NONE
D002118_D008881 NONE calcium_4\NN|NONE (r_compound) channel_5\NN|and|antagonists (r_compound) blockers_6\NNS|NONE (r_pobj) of_3\IN|the (r_prep) advent_2\NN|NONE (r_pobj) Despite_0\IN|.|persists|play|,|preparations|, (r_prep) continue_15\VBP|NONE (l_xcomp) play_17\VB|.|persists|,|Despite|preparations|, (l_dobj) role_20\NN|to (l_prep) in_21\IN|a|major (l_pobj) therapy_23\NN|NONE (l_compound) migraine_22\NN|NONE
D008784_D014652 CID methysergide_20\NN|NONE (r_pobj) of_19\IN|the|by (r_prep) ingestion_18\NN|NONE (r_pobj) to_16\IN|secondary|,|case|is|. (r_prep) described_14\VBN|NONE (l_nsubjpass) case_2\NN|secondary|to|,|is|. (l_prep) of_3\IN|rare|with|,|A (l_pobj) vasospasm_5\NN|NONE
D004876_D005734 NONE ergot_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) history_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) discussion_1\NN|discovery|. (r_nsubj) includes_7\VBZ|NONE (l_dobj) discovery_10\NN|.|discussion (l_appos) epidemics_13\NNS|,|original|its (l_prep) of_14\IN|the|caused (l_pobj) gangrene_15\NN|NONE
19642243
D014640_D051437 NONE vancomycin_8\NNP|NONE (r_amod) therapy_9\NN|NONE (r_pobj) of_7\IN|prolonged|a|in (r_prep) course_6\NN|NONE (r_pobj) after_3\IN|.|failure (r_prep) developed_2\VBD|NONE (l_nsubj) failure_1\NN|after|.
D014640_D051437 NONE vancomycin_17\NNP|NONE (r_pobj) of_16\IN|prolonged (r_prep) administration_15\NN|NONE (r_pobj) during_13\IN|tenofovir|that|may|risk (r_prep) raise_7\VB|NONE (l_dobj) risk_9\NN|tenofovir|that|may|during (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
C418563_D051437 NONE fumarate_18\NN|as|who|were (r_dobj) receiving_15\VBG| (r_relcl) patients_12\NNS|NONE (r_pobj) in_10\IN|prolonged|a|of (r_prep) course_6\NN|NONE (r_pobj) after_3\IN|.|failure (r_prep) developed_2\VBD|NONE (l_nsubj) failure_1\NN|after|.
D014640_D007674 NONE Vancomycin_0\NNP|NONE (r_compound) nephrotoxicity_1\NN|result|infrequent|but|.
D014640_D007674 NONE Vancomycin_0\NNP|NONE (r_compound) nephrotoxicity_1\NN|result|infrequent|but|. (r_nsubj) is_2\VBZ|NONE (l_conj) result_6\VB|infrequent|nephrotoxicity|but|. (l_prep) from_7\IN|may (l_pobj) coadministration_8\NN|NONE (l_prep) with_9\IN|NONE (l_pobj) agent_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a
D014640_D058186 CID vancomycin_12\NNP|prolonged (r_amod) course_13\NN|while|for (r_dobj) receiving_10\VBG|.|in|Acute|renal (r_advcl) failure_2\NN|NONE
C096918_D005198 NONE Tenofovir_0\NNP|because|in|been|has|. (r_nsubjpass) implicated_3\VBN|NONE (l_prep) in_4\IN|because|Tenofovir|been|has|. (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) syndrome_9\NN|NONE
D014640_D010019 NONE vancomycin_12\NNP|prolonged (r_amod) course_13\NN|while|for (r_dobj) receiving_10\VBG|.|in|Acute|renal (l_prep) for_14\IN|while|course (l_pobj) osteomyelitis_15\NN|NONE
C096918_D058186 NONE tenofovir_8\NNS|NONE (r_pobj) on_7\IN|with (r_prep) patients_4\NNS|NONE (r_pobj) in_3\IN|.|Acute|receiving|renal (r_prep) failure_2\NN|NONE
D014640_D000163 NONE vancomycin_12\NNP|prolonged (r_amod) course_13\NN|while|for (r_dobj) receiving_10\VBG|.|in|Acute|renal (r_advcl) failure_2\NN|NONE (l_prep) in_3\IN|.|Acute|receiving|renal (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|on (l_pobj) AIDS_6\NNP|NONE
C096918_D010019 NONE tenofovir_8\NNS|NONE (r_pobj) on_7\IN|with (r_prep) patients_4\NNS|NONE (r_pobj) in_3\IN|.|Acute|receiving|renal (r_prep) failure_2\NN|NONE (l_advcl) receiving_10\VBG|.|in|Acute|renal (l_prep) for_14\IN|while|course (l_pobj) osteomyelitis_15\NN|NONE
C096918_D000163 NONE tenofovir_8\NNS|NONE (r_pobj) on_7\IN|with (r_prep) patients_4\NNS|NONE (l_prep) with_5\IN|on (l_pobj) AIDS_6\NNP|NONE
C096918_D051437 NONE Tenofovir_0\NNP|because|in|been|has|. (r_nsubjpass) implicated_3\VBN|NONE (l_prep) in_4\IN|because|Tenofovir|been|has|. (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) syndrome_9\NN|NONE (l_conj) insufficiency_12\NN|Fanconi|and
C096918_D051437 NONE tenofovir_5\NNS|that|may|risk|during (r_nsubj) raise_7\VB|NONE (l_dobj) risk_9\NN|tenofovir|that|may|during (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
6454943
D002216_D011507 NONE captopril_2\NN|NONE (r_pobj) of_1\IN|on (r_prep) Effect_0\NN|.||proteinuria|in (r_nsubj) induced_10\VBN|NONE (l_dobj) proteinuria_11\NN|.||Effect|in
D002216_D011507 NONE captopril_6\NN|in (r_compound) treatment_7\NN|NONE (r_pobj) of_5\IN|side|a (r_prep) effect_4\NN|.|Proteinuria (r_attr) is_1\VBZ|NONE (l_nsubj) Proteinuria_0\NNP|.|effect
D002216_D011507 NONE captopril_3\NN|NONE (r_pobj) of_2\IN|Oral|for|at (r_prep) administration_1\NN|.|aggravate (r_nsubj) failed_10\VBD|NONE (l_xcomp) aggravate_12\VB|.|administration (l_dobj) proteinuria_13\JJ|to
D002216_D011507 NONE captopril_2\NN|NONE (r_compound) treatment_3\NN|.|Also|potentiate|, (r_nsubj) failed_4\VBD|NONE (l_xcomp) potentiate_6\VB|.|Also|,|treatment (l_conj) facilitate_8\VB|or|to (l_dobj) development_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) proteinuria_12\NN|NONE
D011692_D006973 NONE aminonucleoside_8\RB|existing (r_punct) -_9\HYPH|.|proteinuria|Effect|in (r_punct) induced_10\VBN|NONE (l_prep) in_12\IN|.||proteinuria|Effect (l_pobj) rats_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002216_D007674 NONE captopril_9\NN|NONE (r_pobj) with_8\IN|same|renal|the (r_prep) abnormality_7\NN|NONE
D002216_D006973 NONE captopril_2\NN|NONE (r_pobj) of_1\IN|on (r_prep) Effect_0\NN|.||proteinuria|in (r_nsubj) induced_10\VBN|NONE (l_prep) in_12\IN|.||proteinuria|Effect (l_pobj) rats_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002216_D006973 NONE captopril_6\NN|in (r_compound) treatment_7\NN|NONE (l_prep) in_8\IN|captopril (l_pobj) patients_10\NNS|NONE (l_amod) hypertensive_9\JJ|NONE
D011692_D011507 CID aminonucleoside_8\RB|existing (r_punct) -_9\HYPH|.|proteinuria|Effect|in (r_punct) induced_10\VBN|NONE (l_dobj) proteinuria_11\NN|.||Effect|in
D011692_D011507 CID aminonucleoside_16\NN|NONE (r_amod) puromycin_15\NNS|NONE (r_pobj) by_14\IN|NONE (r_agent) invoked_13\VBN|massive (r_acl) proteinuria_12\NN|NONE
10328196
D003907_D011565 NONE dexamethasone_15\NN| (r_npadvmod) induced_17\VBN|greater|or (r_conj) spontaneous_13\JJ|did (r_amod) apoptosis_18\NN|to (r_oprd) exhibit_11\VB|NONE (r_xcomp) tended_9\VBD|.|cells (r_ccomp) Activated_0\VBN|NONE (l_dobj) cells_4\NNS|tended|. (l_prep) from_5\IN|peripheral|T (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) psoriasis_8\NN|NONE
D020123_D011565 NONE sirolimus_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_dobj) following_2\VBG|)|(|association|Systemic|for|.|:|rapamycin (r_prep) toxicity_1\NN|NONE (l_prep) for_10\IN|)|(|following|association|Systemic|.|:|rapamycin (l_pobj) psoriasis_11\NN|NONE
D020123_D011565 NONE rapamycin_8\VBZ|)|(|following|association|Systemic|for|.|: (r_appos) toxicity_1\NN|NONE (l_prep) for_10\IN|)|(|following|association|Systemic|.|:|rapamycin (l_pobj) psoriasis_11\NN|NONE
D020123_D011565 NONE sirolimus_14\NN|skin|lesional (r_nmod) cells_17\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|NONE (r_pobj) following_10\VBG|a|leak (r_acl) syndrome_9\NN|analyzed|individuals|After|.|and (r_dobj) developed_5\VBD|NONE (l_nsubj) individuals_2\NNS|analyzed|syndrome|After|.|and (l_prep) with_3\IN| (l_pobj) psoriasis_4\NN|NONE
D020123_D011565 NONE sirolimus_8\NN| (r_npadvmod) induced_10\VBN|leak (r_amod) syndrome_13\NN|NONE (r_pobj) with_7\IN| (r_prep) patient_6\NN|NONE (r_pobj) from_4\IN|keratome|skin|A (r_prep) specimen_3\NN|compared|.|increase (r_nsubj) had_14\VBD|NONE (l_prep) compared_28\VBN|.|specimen|increase (l_prep) with_29\IN|NONE (l_pobj) patient_35\NN|NONE (l_prep) with_36\IN|unaffected|%|treated|)|an|( (l_pobj) psoriasis_37\NN|NONE
D020123_D011565 NONE sirolimus_32\NN| (r_npadvmod) treated_34\VBN|unaffected|%|)|an|with|( (r_amod) patient_35\NN|NONE (l_prep) with_36\IN|unaffected|%|treated|)|an|( (l_pobj) psoriasis_37\NN|NONE
D020123_D011565 NONE sirolimus_30\NN|NONE (r_pobj) of_29\IN|the (r_prep) presence_28\NN|particularly (r_pobj) in_26\IN|cells|,|than (r_prep) did_20\VBD|spontaneous (r_advcl) apoptosis_18\NN|to (r_oprd) exhibit_11\VB|NONE (r_xcomp) tended_9\VBD|.|cells (r_ccomp) Activated_0\VBN|NONE (l_dobj) cells_4\NNS|tended|. (l_prep) from_5\IN|peripheral|T (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) psoriasis_8\NN|NONE
D020123_D019559 CID sirolimus_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_dobj) following_2\VBG|)|(|association|Systemic|for|.|:|rapamycin (r_prep) toxicity_1\NN|NONE (l_appos) association_13\NN|)|(|following|Systemic|for|.|:|rapamycin (l_prep) of_14\IN|with (l_pobj) syndrome_17\NN|NONE
D020123_D019559 CID rapamycin_8\VBZ|)|(|following|association|Systemic|for|.|: (r_appos) toxicity_1\NN|NONE (l_appos) association_13\NN|)|(|following|Systemic|for|.|:|rapamycin (l_prep) of_14\IN|with (l_pobj) syndrome_17\NN|NONE
D020123_D019559 CID sirolimus_14\NN|skin|lesional (r_nmod) cells_17\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|NONE (r_pobj) following_10\VBG|a|leak (r_acl) syndrome_9\NN|analyzed|individuals|After|.|and
D020123_D019559 CID sirolimus_8\NN| (r_npadvmod) induced_10\VBN|leak (r_amod) syndrome_13\NN|NONE
D020123_D019559 CID sirolimus_32\NN| (r_npadvmod) treated_34\VBN|unaffected|%|)|an|with|( (r_amod) patient_35\NN|NONE (r_pobj) with_29\IN|NONE (r_prep) compared_28\VBN|.|specimen|increase (r_prep) had_14\VBD|NONE (l_nsubj) specimen_3\NN|compared|.|increase (l_prep) from_4\IN|keratome|skin|A (l_pobj) patient_6\NN|NONE (l_prep) with_7\IN| (l_pobj) syndrome_13\NN|NONE
D020123_D019559 CID sirolimus_4\NN|NONE (r_pobj) of_3\IN|Severe|adverse (r_prep) effects_2\NNS|fever|. (r_nsubj) include_5\VBP|NONE (l_dobj) fever_6\NN|effects|. (l_conj) anemia_8\NN|, (l_conj) syndrome_13\NN|,|and
D020123_D005334 NONE sirolimus_4\NN|NONE (r_pobj) of_3\IN|Severe|adverse (r_prep) effects_2\NNS|fever|. (r_nsubj) include_5\VBP|NONE (l_dobj) fever_6\NN|effects|.
D020123_D000740 NONE sirolimus_4\NN|NONE (r_pobj) of_3\IN|Severe|adverse (r_prep) effects_2\NNS|fever|. (r_nsubj) include_5\VBP|NONE (l_dobj) fever_6\NN|effects|. (l_conj) anemia_8\NN|,
D020123_D064420 NONE sirolimus_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_dobj) following_2\VBG|)|(|association|Systemic|for|.|:|rapamycin (r_prep) toxicity_1\NN|NONE
D020123_D064420 NONE rapamycin_8\VBZ|)|(|following|association|Systemic|for|.|: (r_appos) toxicity_1\NN|NONE
2716967
D009020_D009127 NONE morphine_21\NN|or (r_conj) ketamine_19\NN|NONE (r_pobj) of_18\IN|the|relative|in (r_prep) predominance_17\NN|Latency|.|, (r_dobj) reflected_14\VBD|NONE (l_nsubj) Latency_0\NN|.|,|predominance (l_prep) to_1\IN|NONE (l_pobj) loss_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reflex_6\NN|NONE (l_conj) rigidity_8\NN|,|righting
D009270_D002375 NONE Naloxone_0\NN|.|effects (r_nsubj) inhibited_1\VBD|NONE (l_dobj) effects_5\NNS|Naloxone|. (l_amod) cataleptic_4\JJ|induced|the
D009270_D002375 NONE naloxone_36\NN|NONE (r_pobj) for_35\IN|different|a (r_prep) ID50_34\NNP|of|and (r_conj) asymmetry_24\NN|in|, (r_conj) differences_16\NNS|the|induced|, (r_conj) catalepsy_14\NN|NONE
D009020_D000699 NONE morphine_7\NN|and|both (r_conj) ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009020_D000699 NONE morphine_26\NN|NONE (r_pobj) to_25\IN||cross|produced (r_prep) tolerance_24\NN|studies|,|induce|induced (r_dobj) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009020_D000699 NONE morphine_31\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) pretreatment_29\NN|but|tolerance|not|did|augmented|whereas (r_nsubj) induce_34\VB|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009020_D000699 NONE morphine_53\NN|NONE (r_pobj) to_51\IN|was|;|demonstrated|.|augmentation (r_prep) attributed_50\VBN|NONE (l_ccomp) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D007649_D000699 NONE ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D007649_D000699 NONE ketamine_20\NN|NONE (r_pobj) with_19\IN| (r_prep) treatment_18\NN|NONE (r_nsubj) produced_21\VBD||cross|to (r_amod) tolerance_24\NN|studies|,|induce|induced (r_dobj) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D007649_D000699 NONE ketamine_39\NN|NONE (r_pobj) to_38\IN||cross (r_prep) tolerance_37\NN|but|pretreatment|not|did|augmented|whereas (r_dobj) induce_34\VB|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009270_D009127 NONE naloxone_36\NN|NONE (r_pobj) for_35\IN|different|a (r_prep) ID50_34\NNP|of|and (r_conj) asymmetry_24\NN|in|, (r_conj) differences_16\NNS|the|induced|, (l_prep) in_17\IN|asymmetry|, (l_pobj) latency_18\NN|NONE (l_conj) rigidity_20\NN|,
D007649_D002375 CID ketamine_5\NN|NONE (r_pobj) of_4\IN|potentiation|: (r_prep) combinations_3\NNS|NONE (r_pobj) by_2\IN|.|Catalepsy (r_agent) induced_1\VBN|NONE (l_nsubj) Catalepsy_0\NNP|by|.
D007649_D002375 CID ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D007649_D002375 CID ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|studies|,|induce|tolerance (r_ccomp) demonstrated_2\VBD|was|;|to|.|augmentation (l_advcl) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D007649_D002375 CID ketamine_20\NN|NONE (r_pobj) with_19\IN| (r_prep) treatment_18\NN|NONE (r_nsubj) produced_21\VBD||cross|to (r_amod) tolerance_24\NN|studies|,|induce|induced (r_dobj) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D007649_D002375 CID ketamine_20\NN|NONE (r_pobj) with_19\IN| (r_prep) treatment_18\NN|NONE (r_nsubj) produced_21\VBD||cross|to (r_amod) tolerance_24\NN|studies|,|induce|induced (r_dobj) demonstrated_2\VBD|was|;|to|.|augmentation (l_advcl) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D007649_D002375 CID ketamine_39\NN|NONE (r_pobj) to_38\IN||cross (r_prep) tolerance_37\NN|but|pretreatment|not|did|augmented|whereas (r_dobj) induce_34\VB|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D007649_D002375 CID ketamine_39\NN|NONE (r_pobj) to_38\IN||cross (r_prep) tolerance_37\NN|but|pretreatment|not|did|augmented|whereas (r_dobj) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_7\NN|and (r_conj) ketamine_5\NN|NONE (r_pobj) of_4\IN|potentiation|: (r_prep) combinations_3\NNS|NONE (r_pobj) by_2\IN|.|Catalepsy (r_agent) induced_1\VBN|NONE (l_nsubj) Catalepsy_0\NNP|by|.
D009020_D002375 CID morphine_7\NN|and|both (r_conj) ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D009020_D002375 CID morphine_7\NN|and|both (r_conj) ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|studies|,|induce|tolerance (r_ccomp) demonstrated_2\VBD|was|;|to|.|augmentation (l_advcl) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_26\NN|NONE (r_pobj) to_25\IN||cross|produced (r_prep) tolerance_24\NN|studies|,|induce|induced (r_dobj) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D009020_D002375 CID morphine_26\NN|NONE (r_pobj) to_25\IN||cross|produced (r_prep) tolerance_24\NN|studies|,|induce|induced (r_dobj) demonstrated_2\VBD|was|;|to|.|augmentation (l_advcl) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_31\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) pretreatment_29\NN|but|tolerance|not|did|augmented|whereas (r_nsubj) induce_34\VB|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D009020_D002375 CID morphine_31\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) pretreatment_29\NN|but|tolerance|not|did|augmented|whereas (r_nsubj) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_53\NN|NONE (r_pobj) to_51\IN|was|;|demonstrated|.|augmentation (r_prep) attributed_50\VBN|NONE (l_ccomp) demonstrated_2\VBD|was|;|to|.|augmentation (l_ccomp) induced_8\VBN|studies|,|induce|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|in|and
D009020_D002375 CID morphine_53\NN|NONE (r_pobj) to_51\IN|was|;|demonstrated|.|augmentation (r_prep) attributed_50\VBN|NONE (l_ccomp) demonstrated_2\VBD|was|;|to|.|augmentation (l_advcl) induce_34\VB|studies|,|induced|tolerance (l_conj) augmented_42\VBD|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D007649_D009127 NONE ketamine_19\NN|NONE (r_pobj) of_18\IN|the|relative|in (r_prep) predominance_17\NN|Latency|.|, (r_dobj) reflected_14\VBD|NONE (l_nsubj) Latency_0\NN|.|,|predominance (l_prep) to_1\IN|NONE (l_pobj) loss_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reflex_6\NN|NONE (l_conj) rigidity_8\NN|,|righting
11861791
D004317_D006333 CID doxorubicin_11\NN| (r_npadvmod) induced_13\VBN|heart (r_amod) failure_15\NN|NONE
D004317_D006331 NONE DOX_36\NNP|NONE (r_pobj) by_35\IN|NONE (r_agent) induced_34\VBN|cardiac (r_acl) dysfunction_33\NN|NONE
D004317_D005117 NONE DOX_16\NNP|the (r_compound) treatment_17\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|severe|cardiac (r_acl) complications_12\NNS|NONE
D004317_D066126 NONE doxorubicin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) cardiotoxicity_10\NN|NONE
D004317_D066126 NONE DOX_14\NNP|,|antibiotic (r_appos) doxorubicin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) cardiotoxicity_10\NN|NONE
D004317_D066126 NONE DOX_13\NNP| (r_npadvmod) induced_15\VBN|the (r_amod) cardiotoxicity_16\NN|NONE
D004317_D066126 NONE DOX_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) cardiotoxicity_7\NN|NONE
C434926_D006331 NONE PJ34_19\NNP|NONE (r_pobj) with_14\IN|pharmacological (r_prep) inhibition_13\NN|genetic|or (r_conj) deletion_10\NN|NONE (r_pobj) by_8\IN|,|approach (r_prep) Using_0\VBG|.|role|we|,|now (r_advcl) demonstrate_23\VBP|NONE (l_dobj) role_25\NN|Using|.|we|,|now (l_prep) in_28\IN|of|the (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) dysfunction_33\NN|NONE
C434926_D006331 NONE PJ34_3\NNP|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|significantly|and|.|dysfunction|increased (r_nsubj) improved_5\VBD|NONE (l_dobj) dysfunction_7\NN|significantly|and|.|Treatment|increased
D018943_D066126 NONE anthracycline_21\NN|used|a|antitumor (r_amod) antibiotic_22\NN|,|DOX (r_appos) doxorubicin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) cardiotoxicity_10\NN|NONE
D011064_D006333 NONE )_5\-RRB-|ribose (r_punct) polymerase_6\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Activation_0\NN|.|to (r_nsubj) contributes_7\VBZ|NONE (l_prep) to_8\IN|Activation|. (l_pobj) development_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) failure_15\NN|NONE
12109865
3131282
C009166_D013274 NONE acetate_6\NN|NONE (r_pobj) of_4\IN|on|carcinogenic (r_prep) effect_3\NN|with|. (l_prep) on_7\IN|carcinogenic|of (l_pobj) carcinogenesis_9\NN|NONE
C009166_D013274 NONE acetate_6\NN|NONE (r_pobj) of_4\IN|on|potential|modifying|The (r_prep) effect_3\NN|tumorigenesis|was|(|. (r_nsubjpass) examined_19\VBN|NONE (l_nsubjpass) tumorigenesis_17\NN|was|(|.|effect
C009166_D013274 NONE RA_8\NNP|retinyl (r_appos) acetate_6\NN|NONE (r_pobj) of_4\IN|on|potential|modifying|The (r_prep) effect_3\NN|tumorigenesis|was|(|. (r_nsubjpass) examined_19\VBN|NONE (l_nsubjpass) tumorigenesis_17\NN|was|(|.|effect
C009166_D013274 NONE RA_27\NNP|from|incidence|to (r_nsubj) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_prep) of_38\IN|)|papilloma|the|( (l_pobj) tumors_40\NNS|NONE
C009166_D013274 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|incidence|to|RA (r_prep) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_prep) of_38\IN|)|papilloma|the|( (l_pobj) tumors_40\NNS|NONE
C009166_D013274 NONE RA_4\NNP|carcinogenesis|that|as (r_nsubj) acted_5\VBD|findings|. (l_dobj) carcinogenesis_15\NN|RA|that|as
D002083_D063646 NONE hydroxyanisole_17\NN|NONE (r_pobj) with_15\IN|effect|. (r_prep) induced_14\VBN|NONE (l_nsubj) effect_3\NN|with|. (l_amod) carcinogenic_2\JJ|on|of
D002083_D013274 CID hydroxyanisole_17\NN|NONE (r_pobj) with_15\IN|effect|. (r_prep) induced_14\VBN|NONE (l_nsubj) effect_3\NN|with|. (l_prep) on_7\IN|carcinogenic|of (l_pobj) carcinogenesis_9\NN|NONE
D002083_D013274 CID hydroxyanisole_12\NN|NONE (r_pobj) on_10\IN|of|potential|modifying|The (r_prep) effect_3\NN|tumorigenesis|was|(|. (r_nsubjpass) examined_19\VBN|NONE (l_nsubjpass) tumorigenesis_17\NN|was|(|.|effect
D002083_D013274 CID BHA)-induced_14\JJ|NONE (r_amod) rat_15\NN|forestomach (r_compound) tumorigenesis_17\NN|was|(|.|effect
D002083_D013274 CID BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_prep) of_38\IN|)|papilloma|the|( (l_pobj) tumors_40\NNS|NONE
D002083_D013274 CID BHA_13\NNP|of|the|forestomach (r_compound) carcinogenesis_15\NN|RA|that|as
C009166_D063646 NONE acetate_6\NN|NONE (r_pobj) of_4\IN|on|carcinogenic (r_prep) effect_3\NN|with|. (l_amod) carcinogenic_2\JJ|on|of
C009166_D017573 NONE RA_7\NNP|NONE (r_punct) co_8\NNP|NONE (r_punct) -_9\HYPH|NONE (r_punct) administered_10\VBN|dose (r_punct) at_11\IN|BHA (r_prep) given_2\VBN|NONE (r_acl) rats_1\NNS|NONE (r_pobj) In_0\IN|effect|%|. (r_prep) showed_23\VBD|NONE (l_dobj) effect_29\NN|%|In|. (l_prep) on_30\IN|dependent|a|enhancing (l_pobj) development_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) hyperplasia_39\NN|NONE
D002083_D017573 NONE BHA_5\NNP|at (r_dobj) given_2\VBN|NONE (r_acl) rats_1\NNS|NONE (r_pobj) In_0\IN|effect|%|. (r_prep) showed_23\VBD|NONE (l_dobj) effect_29\NN|%|In|. (l_prep) on_30\IN|dependent|a|enhancing (l_pobj) development_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) hyperplasia_39\NN|NONE
D002083_D017573 NONE BHA_35\NNP| (r_npadvmod) induced_37\VBN|epithelial|the (r_amod) hyperplasia_39\NN|NONE
C009166_D002277 NONE RA_27\NNP|from|incidence|to (r_nsubj) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|)|of|the|( (l_conj) carcinoma_46\NN|squamous|cell|and
C009166_D002277 NONE RA_27\NNP|from|incidence|to (r_nsubj) increased_35\VBD|were|in|marked|,|changes|.|In (l_prep) to_48\IN|from|incidence|RA (l_pobj) %_50\NN|NONE (l_appos) rats_55\NNS| (l_prep) with_56\IN||/|)|,|( (l_pobj) carcinoma_57\NN|NONE
C009166_D002277 NONE RA_27\NNP|from|incidence|to (r_nsubj) increased_35\VBD|were|in|marked|,|changes|.|In (l_prep) from_59\IN|incidence|to|RA (l_pobj) %_61\NN|in (l_appos) rat_66\NN||,|(|/|) (l_prep) with_67\IN|one (l_pobj) carcinoma_68\NN|NONE
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|incidence|to|RA (r_prep) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|)|of|the|( (l_conj) carcinoma_46\NN|squamous|cell|and
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|incidence|to|RA (r_prep) increased_35\VBD|were|in|marked|,|changes|.|In (l_prep) to_48\IN|from|incidence|RA (l_pobj) %_50\NN|NONE (l_appos) rats_55\NNS| (l_prep) with_56\IN||/|)|,|( (l_pobj) carcinoma_57\NN|NONE
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|incidence|to|RA (l_pobj) %_61\NN|in (l_appos) rat_66\NN||,|(|/|) (l_prep) with_67\IN|one (l_pobj) carcinoma_68\NN|NONE
C009166_D009369 NONE RA_17\NN|and|in (r_pobj) with_14\IN|)|%|(| (r_prep) rats_9\NNS|NONE (r_pobj) in_7\IN|Tumors|were|. (r_prep) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|in|were|.
C009166_D009369 NONE RA_29\NNP|%| (r_compound) administration_32\NN|NONE (r_punct) ._33\.|in|Tumors|were (r_punct) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|in|were|.
D002083_D002277 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|)|of|the|( (l_conj) carcinoma_46\NN|squamous|cell|and
D002083_D002277 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|were|in|marked|,|changes|.|In (l_prep) to_48\IN|from|incidence|RA (l_pobj) %_50\NN|NONE (l_appos) rats_55\NNS| (l_prep) with_56\IN||/|)|,|( (l_pobj) carcinoma_57\NN|NONE
D002083_D002277 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|were|in|marked|,|changes|.|In (l_prep) from_59\IN|incidence|to|RA (l_pobj) %_61\NN|in (l_appos) rat_66\NN||,|(|/|) (l_prep) with_67\IN|one (l_pobj) carcinoma_68\NN|NONE
D002083_D010212 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|)|of|the|(
C009166_D010212 NONE RA_27\NNP|from|incidence|to (r_nsubj) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|)|of|the|(
C009166_D010212 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|incidence|to|RA (r_prep) increased_35\VBD|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|)|of|the|(
C009166_D010212 NONE RA_17\NN|and|in (r_pobj) with_14\IN|)|%|(| (r_prep) rats_9\NNS|NONE (r_pobj) in_7\IN|Tumors|were|. (r_prep) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|in|were|. (l_appos) papillomas_3\NNS|,|,
C009166_D010212 NONE RA_29\NNP|%| (r_compound) administration_32\NN|NONE (r_punct) ._33\.|in|Tumors|were (r_punct) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|in|were|. (l_appos) papillomas_3\NNS|,|,
19234905
D014635_D006423 NONE Valproate_33\NNP|NONE (r_pobj) with_32\IN|partly|within|which (r_prep) improved_28\VBD|after|one|movements (r_advcl) developed_18\VBN|hemianopsia|observed|after|one|and|:|. (r_conj) had_8\VBD|NONE (l_dobj) hemianopsia_12\NN|observed|after|one|and|:|.|developed
D007980_D004409 CID levodopa_55\RB| (r_npadvmod) induced_57\VBN|NONE (r_amod) dyskinesias_58\NNS|were|.
8600333
C053519_D001859 NONE protocol_23\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) according_16\VBG|were|who (r_prep) treated_15\VBN|term|of (r_relcl) survivors_8\NNS|NONE (l_prep) of_9\IN|term|treated (l_pobj) tumors_12\NNS|NONE
D004317_D066126 NONE doxorubicin_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_compound) cardiotoxicity_6\NN|NONE
D004317_D001859 NONE doxorubicin_27\NN|NONE (r_pobj) including_26\VBG|NONE (r_prep) both_25\DT|T|,|Rosen (r_appos) protocol_23\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) according_16\VBG|were|who (r_prep) treated_15\VBN|term|of (r_relcl) survivors_8\NNS|NONE (l_prep) of_9\IN|term|treated (l_pobj) tumors_12\NNS|NONE
6308526
D009020_D007035 CID morphine_5\NN|Pretreatment|at|significantly|analgesia|. (r_dobj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN|, (l_conj) hypothermia_10\VBN|and
D009020_D000699 NONE morphine_5\NN|Pretreatment|at|significantly|analgesia|. (r_dobj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|Pretreatment|at|significantly|.|morphine
D009020_D012131 NONE morphine_6\NN| (r_npadvmod) induced_8\VBN|hypotension|the (r_amod) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone
D009020_D012131 NONE morphine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) bradycardia_18\NN|whereas|affected (r_nsubj) was_19\VBD|,|Moreover|depression|significantly|,|.|naloxazone (r_advcl) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone
D009020_D007022 CID morphine_6\NN| (r_npadvmod) induced_8\VBN|hypotension|the (r_amod) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone (l_nmod) hypotension_9\NN|induced|the
D009020_D007022 CID morphine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) bradycardia_18\NN|whereas|affected (r_nsubj) was_19\VBD|,|Moreover|depression|significantly|,|.|naloxazone (r_advcl) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone (l_nmod) hypotension_9\NN|induced|the
C024224_D007022 NONE naloxazone_2\NN|,|Moreover|depression|significantly|,|was|. (r_nsubj) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone (l_nmod) hypotension_9\NN|induced|the
D009020_D002375 CID morphine_5\NN|Pretreatment|at|significantly|analgesia|. (r_dobj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN|,
C024224_D002375 NONE naloxazone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|at|significantly|analgesia|.|morphine (r_nsubj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN|,
C024224_D000699 NONE naloxazone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|at|significantly|analgesia|.|morphine (r_nsubj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|Pretreatment|at|significantly|.|morphine
C024224_D007035 NONE naloxazone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|at|significantly|analgesia|.|morphine (r_nsubj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN|, (l_conj) hypothermia_10\VBN|and
D009020_D001919 CID morphine_6\NN| (r_npadvmod) induced_8\VBN|hypotension|the (r_amod) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone (r_dobj) attenuated_4\VBD|NONE (l_advcl) was_19\VBD|,|Moreover|depression|significantly|,|.|naloxazone (l_nsubj) bradycardia_18\NN|whereas|affected
D009020_D001919 CID morphine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) bradycardia_18\NN|whereas|affected
C024224_D001919 NONE naloxazone_2\NN|,|Moreover|depression|significantly|,|was|. (r_nsubj) attenuated_4\VBD|NONE (l_advcl) was_19\VBD|,|Moreover|depression|significantly|,|.|naloxazone (l_nsubj) bradycardia_18\NN|whereas|affected
C024224_D012131 NONE naloxazone_2\NN|,|Moreover|depression|significantly|,|was|. (r_nsubj) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|Moreover|significantly|,|was|.|naloxazone
9326871
D004917_D005759 CID erythromycin_7\NNP|NONE (r_pobj) of_6\IN|effect|the (r_prep) profile_5\NN|Although|is (r_nsubjpass) established_9\VBN|.|still|being|experience|is (r_advcl) recorded_35\VBN|NONE (l_nsubjpass) experience_27\NN|.|still|being|established|is (l_prep) including_11\VBG|with|,|, (l_pobj) gastroenteritis_12\JJ|NONE
D004917_D066126 NONE erythromycin_11\NNP|NONE (r_pobj) of_10\IN|intravenous (r_prep) administration_9\NN|NONE (r_pobj) after_4\IN|but|Cardiotoxicity|reported|been|.|has (r_prep) demonstrated_3\VBN|NONE (l_nsubjpass) Cardiotoxicity_0\NN|but|reported|been|.|after|has
D017291_D001145 NONE clarithromycin_14\NN|NONE (r_pobj) of_13\IN|six|therapeutic (r_prep) doses_12\NNS|NONE (r_pobj) after_9\IN|that (r_prep) occurred_8\VBD|ventricular (r_relcl) dysrhythmias_6\NNS|NONE
D018942_D005759 NONE macrolides_31\NNS|NONE (r_pobj) with_28\IN|including|,|, (r_prep) experience_27\NN|.|still|being|established|is (l_prep) including_11\VBG|with|,|, (l_pobj) gastroenteritis_12\JJ|NONE
D017291_D017180 CID Clarithromycin_0\NN| (r_npadvmod) induced_2\VBN|ventricular|. (r_amod) tachycardia_4\NN|NONE
D018942_D066126 NONE macrolides_20\NNS|NONE (r_pobj) with_17\IN|been|never|has (r_prep) reported_16\VBN|but|Cardiotoxicity|been|.|after|has (r_conj) demonstrated_3\VBN|NONE (l_nsubjpass) Cardiotoxicity_0\NN|but|reported|been|.|after|has
2594614
D002045_D007022 CID bupivacaine_5\NN|NONE (r_pobj) of_1\IN|mg/kg|(|to|) (r_prep) Administration_0\NN|.|decrease (r_nsubj) elicited_16\VBD|NONE (l_dobj) decrease_19\NN|Administration|. (l_prep) of_20\IN|marked|)|(|in|a (l_pobj) pressure_24\NN|NONE (l_appos) MBP_26\NNP|(|blood|mean|arterial|leading (l_conj) rate_30\NN|)|and (l_punct) )_33\-RRB-|(|heart|HR
D002045_D007022 CID bupivacaine_23\NN|NONE (r_compound) administration_24\NN|NONE (r_pobj) before_22\IN||)|i.v. (r_prep) min_21\NN|Intravenous|antagonist|of|, (r_appos) injection_1\NN|.|decrease (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|both|the (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
D002045_D007022 CID bupivacaine_12\NN|NONE (r_pobj) after_11\IN|mg/kg|was|BN|When|immediately (r_prep) injected_9\VBN|was|reversion|,|,|.|was (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|was|,|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
D002045_D002318 NONE bupivacaine_15\NN| (r_npadvmod) induced_17\VBN|in|cardiovascular (r_amod) impairments_19\NNS|NONE
D002045_D002318 NONE bupivacaine_44\NN| (r_npadvmod) induced_46\VBN|cardiovascular (r_amod) toxicity_48\NN|NONE
C045856_D002318 NONE 52021_12\CD|NONE (r_nummod) BN_11\NNP|,|on|factor|,|a|activating|specific (r_appos) antagonist_9\NN|NONE (l_prep) on_14\IN|,|factor|BN|,|a|activating|specific (l_pobj) impairments_19\NNS|NONE
C045856_D002318 NONE 52021_5\CD|NONE (r_nummod) BN_4\NNP|NONE (r_pobj) of_3\IN|the (r_prep) administration_2\NN|not|Since|at|MBP|at|,|,|did (r_nsubj) alter_14\VB|clearly|bulk|action|.|, (r_advcl) demonstrate_29\VBP|NONE (l_dobj) action_32\NN|clearly|bulk|alter|.|, (l_prep) against_43\IN|of|,|protective|,|a|antagonist (l_pobj) toxicity_48\NN|NONE
C045856_D002318 NONE 52021_35\CD|NONE (r_nummod) BN_34\NNP|NONE (r_pobj) of_33\IN|,|protective|,|a|against|antagonist (r_prep) action_32\NN|clearly|bulk|alter|.|, (l_prep) against_43\IN|of|,|protective|,|a|antagonist (l_pobj) toxicity_48\NN|NONE
C045856_D001919 NONE 52021_14\CD|)|mg/kg|)|PAF|( (r_appos) antagonist_12\NN|min|Intravenous|of|, (r_appos) injection_1\NN|.|decrease (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|both|the (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
C045856_D001919 NONE 52021_2\CD|mg/kg|)|i.v. (r_nummod) BN_1\NNP|mg/kg|was|after|When|immediately (r_nsubjpass) injected_9\VBN|was|reversion|,|,|.|was (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|was|,|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
D002045_D018376 NONE bupivacaine_16\NN| (r_npadvmod) induced_18\VBN|cardiovascular (r_amod) alterations_20\NNS|NONE
D002045_D001919 CID bupivacaine_5\NN|NONE (r_pobj) of_1\IN|mg/kg|(|to|) (r_prep) Administration_0\NN|.|decrease (r_nsubj) elicited_16\VBD|NONE (l_dobj) decrease_19\NN|Administration|. (l_prep) of_20\IN|marked|)|(|in|a (l_pobj) pressure_24\NN|NONE (l_appos) MBP_26\NNP|(|blood|mean|arterial|leading (l_conj) rate_30\NN|)|and (l_punct) )_33\-RRB-|(|heart|HR
D002045_D001919 CID bupivacaine_23\NN|NONE (r_compound) administration_24\NN|NONE (r_pobj) before_22\IN||)|i.v. (r_prep) min_21\NN|Intravenous|antagonist|of|, (r_appos) injection_1\NN|.|decrease (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|both|the (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
D002045_D001919 CID bupivacaine_12\NN|NONE (r_pobj) after_11\IN|mg/kg|was|BN|When|immediately (r_prep) injected_9\VBN|was|reversion|,|,|.|was (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|was|,|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
C045856_D007022 NONE 52021_14\CD|)|mg/kg|)|PAF|( (r_appos) antagonist_12\NN|min|Intravenous|of|, (r_appos) injection_1\NN|.|decrease (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|both|the (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
C045856_D007022 NONE 52021_2\CD|mg/kg|)|i.v. (r_nummod) BN_1\NNP|mg/kg|was|after|When|immediately (r_nsubjpass) injected_9\VBN|was|reversion|,|,|.|was (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|was|,|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
9061311
D010100_D017114 NONE oxygen_5\NN|radical|in|due (r_nmod) production_7\NN|with|,|was|In|. (l_prep) in_8\IN|oxygen|radical|due (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) ALF_11\NNP|NONE
D013481_D001424 NONE superoxide_2\NN|peroxide (r_amod) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|may|be|.|in (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|Defects|may|be|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE
D006861_D001424 NONE peroxide_5\NN|superoxide (r_compound) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|may|be|.|in (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|Defects|may|be|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE
D009240_D017114 NONE phenylalanine_15\NN|(|) (r_nmod) fMLP_17\NN|NONE (r_pobj) with_8\IN|from (r_prep) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP|further||a
D009240_D017114 NONE fMLP_17\NN|NONE (r_pobj) with_8\IN|from (r_prep) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP|further||a
D000082_D017114 CID paracetamol_14\JJ|NONE (r_compound) overdose_15\NN|to (r_pobj) due_12\IN|oxygen|radical|in (r_amod) production_7\NN|with|,|was|In|. (l_prep) in_8\IN|oxygen|radical|due (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) ALF_11\NNP|NONE
D000082_D017114 CID paracetamol_10\JJ|NONE (r_compound) overdose_11\NN|to (r_pobj) due_8\IN|results|defect|.|,|complement (r_prep) demonstrate_2\VBP|NONE (l_dobj) defect_5\NN|due|results|.|,|complement (l_prep) in_6\IN|neutrophil|a (l_pobj) ALF_7\NNP|NONE
D010100_D062787 NONE oxygen_5\NN|radical|in|due (r_nmod) production_7\NN|with|,|was|In|. (l_amod) due_12\IN|oxygen|radical|in (l_pobj) overdose_15\NN|to
D006861_D017114 NONE peroxide_4\NN|and (r_conj) superoxide_1\NN|in|.|Neutrophil (r_nmod) production_5\NN|NONE (l_prep) in_6\IN|.|superoxide|Neutrophil (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) failure_11\NN|NONE
D006861_D017114 NONE peroxide_5\NN|superoxide (r_compound) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|may|be|.|in (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|Defects|may|be|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE
D006861_D017114 NONE peroxide_5\NN|superoxide (r_compound) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|may|be|.|in (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|Defects|may|be|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE (l_appos) ALF_24\NNP|(|acute|liver|)
D006861_D017114 NONE peroxide_3\NN|NONE (r_compound) production_4\NN|by|and (r_conj) Superoxide_0\NN|reduced|with|.|opsonized (l_prep) by_5\IN|and|production (l_pobj) neutrophils_7\NNS|NONE (l_compound) ALF_6\NNP|NONE
D006861_D017114 NONE peroxide_3\NN|NONE (r_compound) production_4\NN|by|and (r_conj) Superoxide_0\NN|reduced|with|.|opsonized (r_nsubj) stimulated_8\VBN|NONE (l_dobj) opsonized_11\VBN|reduced|Superoxide|with|. (l_prep) with_12\IN|NONE (l_pobj) serum_14\NN|NONE (l_compound) ALF_13\NNP|NONE
D006861_D017114 NONE peroxide_3\NN|NONE (r_compound) production_4\NN|in|and (r_conj) Superoxide_0\NN|.|compared|unaffected (l_prep) in_5\IN|and|production (l_pobj) neutrophils_6\NNS|NONE (l_acl) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP|further||a
D013481_D017114 NONE superoxide_1\NN|in|.|Neutrophil (r_nmod) production_5\NN|NONE (l_prep) in_6\IN|.|superoxide|Neutrophil (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) failure_11\NN|NONE
D013481_D017114 NONE superoxide_2\NN|peroxide (r_amod) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|may|be|.|in (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|Defects|may|be|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE
D013481_D017114 NONE superoxide_2\NN|peroxide (r_amod) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|may|be|.|in (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|Defects|may|be|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE (l_appos) ALF_24\NNP|(|acute|liver|)
D013481_D017114 NONE Superoxide_0\NN|reduced|with|.|opsonized (l_prep) by_5\IN|and|production (l_pobj) neutrophils_7\NNS|NONE (l_compound) ALF_6\NNP|NONE
D013481_D017114 NONE Superoxide_0\NN|reduced|with|.|opsonized (r_nsubj) stimulated_8\VBN|NONE (l_dobj) opsonized_11\VBN|reduced|Superoxide|with|. (l_prep) with_12\IN|NONE (l_pobj) serum_14\NN|NONE (l_compound) ALF_13\NNP|NONE
D013481_D017114 NONE Superoxide_0\NN|.|compared|unaffected (l_prep) in_5\IN|and|production (l_pobj) neutrophils_6\NNS|NONE (l_acl) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP|further||a
D000082_D062787 NONE paracetamol_14\JJ|NONE (r_compound) overdose_15\NN|to
D000082_D062787 NONE paracetamol_10\JJ|NONE (r_compound) overdose_11\NN|to
18483878
D003520_D001745 NONE CYP_22\NNP|NONE (r_pobj) with_21\IN|NONE (r_prep) WT_20\NNP|NONE (r_pobj) in_19\IN|that (r_prep) observed_18\VBD|,|are|mediators|above|mice (r_advcl) increased_15\VBN|.|data (l_advcl) mice_7\NNS|,|are|mediators|above|observed (l_prep) with_8\IN|in|that (l_pobj) inflammation_10\NN|NONE
D003520_D003556 CID cyclophosphamide_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) mice_13\NNS|(|cystitis|polypeptide|)|VIP/ (r_appos) knockout_9\NN|NONE (l_appos) cystitis_18\NN|mice|(|polypeptide|)|VIP/
D003520_D003556 CID CYP)-induced_17\VBN|NONE (r_compound) cystitis_18\NN|mice|(|polypeptide|)|VIP/
D003520_D003556 CID cyclophosphamide_14\NN|NONE (r_pobj) after_13\IN|cystitis|function|.|VIP(/ (r_prep) altered_4\JJ|NONE (l_dobj) cystitis_17\NN|function|after|.|VIP(/
D003520_D003556 CID CYP)-induced_16\VBN|( (r_amod) cystitis_17\NN|function|after|.|VIP(/
D003520_D003556 CID CYP_32\NNP| (r_npadvmod) induced_34\VBN|;|i.p.|(|)|h|;|mg/kg (r_amod) cystitis_35\NN|NONE
19300240
D002395_D054549 NONE catecholamines_9\NNS|NONE (r_pobj) of_7\IN|both|supraphysiologic|caused (r_prep) levels_6\NNS|may|development|have|.|In|, (r_nsubj) contributed_24\VBN|NONE (l_dobj) development_26\NN|may|have|levels|.|In|, (l_prep) of_27\IN|the (l_pobj) ABS_28\NN|NONE
D002395_D009369 NONE catecholamines_9\NNS|NONE (r_pobj) of_7\IN|both|supraphysiologic|caused (r_prep) levels_6\NNS|may|development|have|.|In|, (l_acl) caused_14\VBN|both|of|supraphysiologic (l_agent) by_15\IN|NONE (l_pobj) diagnosis_17\NN|NONE (l_compound) cancer_16\NN|chemotherapy|as
D005472_D015179 NONE fluorouracil_5\NN|NONE (r_pobj) with_4\IN|She|for|chemotherapy|. (r_prep) underwent_1\VBD|NONE (l_prep) for_6\IN|She|chemotherapy|.|with (l_pobj) cancer_9\NN|NONE
D005472_D054549 CID flourouracil_1\NN| (r_npadvmod) induced_3\VBN|ballooning|.||report|: (r_amod) syndrome_6\NN|NONE
11078231
D000109_D023921 NONE acetylcholine_8\NN|NONE (r_pobj) of_7\IN|intracoronary (r_prep) injection_6\NN|NONE (r_pobj) by_4\IN|spasm|,|was|and|documented (r_agent) induced_3\VBN|NONE (l_conj) documented_17\VBN|spasm|,|by|was|and (l_nsubjpass) stenosis_15\NN|was|.|on
D004280_D003329 CID dobutamine_8\NN|NONE (r_compound) stress_9\NN|NONE (r_compound) echocardiography_10\RB|NONE (r_pobj) during_7\IN|artery|coronary (r_prep) spasm_6\NN|to
D004280_D003329 CID dobutamine_19\NN|NONE (r_pobj) by_18\IN|ischemia|is|whether (r_agent) induced_17\VBN|to (l_nsubjpass) ischemia_11\NN|is|whether|by (l_amod) due_12\IN|myocardial (l_pcomp) to_13\IN|NONE (l_pobj) spasm_15\NN|NONE
D004280_D003329 CID dobutamine_4\NN|can|spasm|in (r_nsubj) provoke_6\VB|.|findings (l_dobj) spasm_8\NN|can|dobutamine|in
D004280_D000788 CID dobutamine_4\NN|can|spasm|in (r_nsubj) provoke_6\VB|.|findings (l_prep) in_9\IN|can|spasm|dobutamine (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|some (l_pobj) angina_15\NN|NONE
D004280_D017202 NONE dobutamine_8\NN|NONE (r_compound) stress_9\NN|NONE (r_compound) echocardiography_10\RB|NONE (r_pobj) during_7\IN|artery|coronary (r_prep) spasm_6\NN|to (r_pobj) due_2\IN|Myocardial|. (r_amod) ischemia_1\NN|NONE
D004280_D017202 NONE Dobutamine_0\NNP|echocardiography (r_nsubj) stress_1\NN|.|test (r_nsubj) is_6\VBZ|NONE (l_attr) test_12\NN|.|stress (l_prep) for_13\IN|useful|a|provocation (l_pobj) ischemia_15\NN|NONE
D004280_D017202 NONE dobutamine_19\NN|NONE (r_pobj) by_18\IN|ischemia|is|whether (r_agent) induced_17\VBN|to (l_nsubjpass) ischemia_11\NN|is|whether|by
9630698
D006220_D009127 CID haloperidol_5\NN|NONE (r_pobj) by_4\IN|.|)|rigidity|was (r_agent) induced_3\VBN|NONE (l_nsubjpass) rigidity_1\NN|.|)|by|was
D006220_D009127 CID haloperidol_34\NN| (r_advmod) induced_36\VBN|and|the|activity|(|muscle|)|MMG|both (r_amod) rigidity_38\NN|NONE
C066192_D009127 NONE acid_1\NN|in|decreased|,|into|.|, (r_nsubj) injected_12\VBN|NONE (l_conj) decreased_31\VBD|in|acid|,|into|.|, (l_dobj) rigidity_38\NN|NONE
C066192_D009127 NONE 5,7-DCKA_3\CD|,|,dichlorokynurenic|,|)|antagonist (r_appos) acid_1\NN|in|decreased|,|into|.|, (r_nsubj) injected_12\VBN|NONE (l_conj) decreased_31\VBD|in|acid|,|into|.|, (l_dobj) rigidity_38\NN|NONE
D005998_D009127 NONE glycine_8\NN|NONE (r_compound) site_9\NN|a|selective (r_compound) antagonist_10\NN|,|,dichlorokynurenic|,DCKA|,|) (r_appos) acid_1\NN|in|decreased|,|into|.|, (r_nsubj) injected_12\VBN|NONE (l_conj) decreased_31\VBD|in|acid|,|into|.|, (l_dobj) rigidity_38\NN|NONE
12139551
D008787_D006323 CID metoclopramide_4\NN|intravenous|of|a|causing (r_compound) case_7\NN|NONE (r_pobj) after_2\IN|.|Cardiac (r_prep) arrest_1\NN|NONE
D008787_D006323 CID metoclopramide_4\NN|intravenous|of|a|causing (r_compound) case_7\NN|NONE (l_acl) causing_14\VBG|intravenous|of|metoclopramide|a (l_dobj) episodes_16\NNS|NONE (l_prep) of_17\IN|five (l_pobj) arrest_19\NN|NONE
D008787_D006323 CID metoclopramide_13\NN|NONE (r_pobj) of_12\IN|repeated|five (r_prep) injections_11\NNS|NONE (r_pobj) of_8\IN|intravenous|metoclopramide|a|causing (r_prep) case_7\NN|NONE (r_pobj) after_2\IN|.|Cardiac (r_prep) arrest_1\NN|NONE
D008787_D006323 CID metoclopramide_13\NN|NONE (r_pobj) of_12\IN|repeated|five (r_prep) injections_11\NNS|NONE (r_pobj) of_8\IN|intravenous|metoclopramide|a|causing (r_prep) case_7\NN|NONE (l_acl) causing_14\VBG|intravenous|of|metoclopramide|a (l_dobj) episodes_16\NNS|NONE (l_prep) of_17\IN|five (l_pobj) arrest_19\NN|NONE
D008787_D006323 CID metoclopramide_8\NN|NONE (r_pobj) of_7\IN|intravenous (r_prep) injection_6\NN|by|immediately|was|where|repeatedly (r_nsubjpass) followed_11\VBN|a (l_agent) by_12\IN|immediately|injection|was|where|repeatedly (l_pobj) asystole_13\NN|NONE
D008787_D006323 CID metoclopramide_3\JJ|patient|during|After|mg (r_dobj) received_2\VBD|it|followed|,|clear|.|was (r_ccomp) is_24\VBZ|NONE (l_advcl) followed_37\VBN|it|,|received|clear|.|was (l_agent) by_38\IN|NONE (l_pobj) asystole_39\NN|NONE
D008787_D006323 CID metoclopramide_30\NN|NONE (r_pobj) of_29\IN|every (r_prep) administration_28\NN|)|(|immediately|within|that (r_nsubj) was_31\VBD|it|followed|,|received|clear|. (r_ccomp) is_24\VBZ|NONE (l_advcl) followed_37\VBN|it|,|received|clear|.|was (l_agent) by_38\IN|NONE (l_pobj) asystole_39\NN|NONE
D008787_D006323 CID metoclopramide_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) caused_8\VBN|of (r_acl) episodes_4\NNS|NONE (l_prep) of_5\IN|caused (l_pobj) arrest_7\NN|NONE
11022397
D010862_D008569 NONE pilocarpine_10\NN|and (r_conj) tropicamide_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) administration_6\NN|NONE (r_pobj) after_5\IN|Pupil|at (r_prep) size_1\NN|in|induced|;|. (r_ccomp) impairment_15\NN|NONE (l_prep) in_16\IN|induced|size|;|. (l_pobj) recall_18\NN|NONE
D014331_D008569 NONE tropicamide_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) administration_6\NN|NONE (r_pobj) after_5\IN|Pupil|at (r_prep) size_1\NN|in|induced|;|. (r_ccomp) impairment_15\NN|NONE (l_prep) in_16\IN|induced|size|;|. (l_pobj) recall_18\NN|NONE
D012601_D008569 CID scopolamine_12\NN| (r_npadvmod) induced_14\VBN|in|size|;|. (r_amod) impairment_15\NN|NONE (l_prep) in_16\IN|induced|size|;|. (l_pobj) recall_18\NN|NONE
D012601_D008569 CID scopolamine_11\NN| (r_npadvmod) induced_13\VBN|greater|in (r_amod) impairment_14\NN|,|after|.|Compared|group|)|recall (r_dobj) had_9\VBD|NONE (l_dobj) recall_17\NN|,|after|.|Compared|group|)|impairment
16047871
D014859_D012871 NONE warfarin_11\NN|for (r_dobj) receiving_10\VBG|NONE (r_pcomp) after_9\IN|that (r_prep) developed_8\VBD|skin (r_relcl) eruptions_6\NNS|NONE
D014859_D012871 NONE warfarin_21\NN|after|was (r_nsubjpass) discontinued_23\VBN|in (r_advcl) resolved_16\VBD|Cutaneous|LV (r_acl) lesions_15\NNS|NONE (r_dobj) confirming_12\VBG|,|available|results|. (r_advcl) were_6\VBD|NONE (l_nsubj) results_1\NNS|,|available|confirming|. (l_prep) of_2\IN|The (l_pobj) biopsies_5\NNS|NONE (l_compound) lesion_4\NN|NONE
D014859_D018366 CID warfarin_21\NN|after|was (r_nsubjpass) discontinued_23\VBN|in (r_advcl) resolved_16\VBD|Cutaneous|LV (r_acl) lesions_15\NNS|NONE
D014859_C535509 NONE Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|leukocytoclastic|. (r_amod) vasculitis_4\NN|NONE
D014859_C535509 NONE warfarin_12\NN|probably|to (r_pobj) due_10\JJ|with| (r_amod) patients_3\NNS|.|We (l_prep) with_4\IN|due| (l_pobj) LV_8\NNP|NONE
D014859_C535509 NONE warfarin_11\JJ|NONE (r_compound) therapy_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|a|adverse|onset (r_acl) reaction_8\NN|.|may|LV (r_attr) be_2\VB|NONE (l_nsubj) LV_0\NNP|reaction|.|may
16364460
D012601_D000647 CID scopolamine_10\NN| (r_npadvmod) induced_12\VBN|in (r_amod) amnesia_13\NN|.|Microinjection
D012601_D000647 CID scopolamine_9\NN|antagonist)induced|(|muscarinic|cholinergic|in (r_nmod) amnesia_14\NN|NONE
D012601_D000647 CID scopolamine_16\NN| (r_npadvmod) induced_18\VBN|the (r_amod) amnesia_19\NN|that|microinjection
D016713_D000647 NONE ritanserin_2\NN|NONE (r_pobj) of_1\IN|into (r_prep) Microinjection_0\NN|.|amnesia (r_nsubj) improves_9\VBZ|NONE (l_dobj) amnesia_13\NN|.|Microinjection
D016713_D000647 NONE ritanserin_3\NN|NONE (r_pobj) of_2\IN|antagonist|The|on (r_prep) effect_1\NN|was|.|MWM (l_prep) on_8\IN|antagonist|The|of (l_pobj) amnesia_14\NN|NONE
D016713_D000647 NONE ritanserin_6\NN|NONE (r_pobj) of_5\IN|into (r_prep) microinjection_4\NN|that|amnesia (r_nsubj) improves_14\VBZ|findings|. (l_dobj) amnesia_19\NN|that|microinjection
16418614
D011441_D014424 NONE PTU_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) vasculitis_3\NN|NONE (l_prep) in_4\IN|.|associated (l_pobj) girl_6\NN|NONE (l_prep) with_7\IN|a (l_pobj) Syndrome_9\NNP|NONE
D011441_D006111 NONE PTU_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) vasculitis_3\NN|NONE (l_prep) in_4\IN|.|associated (l_pobj) girl_6\NN|NONE (l_prep) with_7\IN|a (l_pobj) Syndrome_9\NNP|NONE (l_conj) disease_13\NN|Turner|and
D011441_D014657 CID PTU_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) vasculitis_3\NN|NONE
D011441_D014657 CID propylthiouracil_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) diagnosis_1\NN|.|by|detection|(|vasculitis|was|, (r_nsubjpass) made_8\VBN|NONE (l_nsubjpass) vasculitis_6\NN|diagnosis|.|by|detection|(|was|,
D011441_D014657 CID PTU)-associated_5\VBN|NONE (r_amod) vasculitis_6\NN|diagnosis|.|by|detection|(|was|,
D011441_D014657 CID PTU_37\NNP|NONE (r_pobj) of_36\IN|NONE (r_prep) withdrawal_35\NN|NONE (r_dobj) following_34\VBG|clinical|observed|of|the (r_acl) resolution_31\NN|and|,|of|the (r_conj) detection_17\NN|diagnosis|.|by|(|vasculitis|was|, (r_appos) made_8\VBN|NONE (l_nsubjpass) vasculitis_6\NN|diagnosis|.|by|detection|(|was|,
7263204
D000493_D000741 NONE allopurinol_14\NN|NONE (r_pobj) than_13\IN|NONE (r_prep) other_12\JJ|no (r_amod) drugs_11\NNS|were|in (r_nsubjpass) given_18\VBN|.|is|case (r_relcl) described_7\VBN|NONE (l_nsubjpass) case_1\NN|.|is|given (l_prep) of_2\IN|A (l_pobj) anemia_5\NN|NONE
D007213_D000741 CID indomethacin_5\NN|to (r_pobj) due_3\IN|Fatal|.|lymphocyte|aplastic| (r_amod) anemia_2\NN|NONE
D007213_D000741 CID indomethacin_1\NN|as|Although|been|has (r_nsubjpass) implicated_4\VBN|been|.|role|definitely|not|has|, (l_prep) as_5\IN|Although|been|has|indomethacin (l_pobj) cause_8\NN|NONE (l_prep) of_9\IN|a|possible (l_pobj) anemia_11\NN|NONE
D007213_D000741 CID indomethacin_16\NN|and (r_conj) allopurinol_14\NN|NONE (r_pobj) than_13\IN|NONE (r_prep) other_12\JJ|no (r_amod) drugs_11\NNS|were|in (r_nsubjpass) given_18\VBN|.|is|case (r_relcl) described_7\VBN|NONE (l_nsubjpass) case_1\NN|.|is|given (l_prep) of_2\IN|A (l_pobj) anemia_5\NN|NONE
D007213_D000741 CID indomethacin_6\NN|NONE (r_pobj) with_5\IN|positive|transformation|A (r_prep) test_4\NN|role|.|further (r_nsubj) substantiates_10\VBZ|NONE (l_dobj) role_13\NN|test|.|further (l_prep) in_17\IN|of|potential|the (l_pcomp) causing_18\VBG|NONE (l_dobj) anemia_20\NN|in
9545159
D001393_D016171 CID azole_22\JJ|antifungal (r_amod) agents_24\NNS|or (r_conj) erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|,|.|but|have|been|after|with (l_dobj) pointes_7\FW|Prolongation
D001393_D008133 CID azole_22\JJ|antifungal (r_amod) agents_24\NNS|or (r_conj) erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|,|.|but|have|been|after|with (l_nsubj) Prolongation_0\NN|pointes (l_prep) of_1\IN|, (l_pobj) interval_3\NN|NONE
D004110_D008133 CID diltiazem_9\NN|NONE (r_compound) interaction_10\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|the|QT (r_acl) interval_4\NN|NONE
D004110_D005764 NONE diltiazem_20\NN|and|gastroesophageal|reflux|,|agent (r_conj) disorder_18\NN|NONE
D004917_D008133 CID erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|,|.|but|have|been|after|with (l_nsubj) Prolongation_0\NN|pointes (l_prep) of_1\IN|, (l_pobj) interval_3\NN|NONE
D020117_D006973 NONE cisapride_14\NN|for|was|who|,|for (r_dobj) taking_13\VBG|a|old (l_prep) for_31\IN|cisapride|was|who|,|for (l_pobj) hypertension_32\NN|NONE
D020117_D008133 CID cisapride_7\NN| (r_compound) diltiazem_9\NN|NONE (r_compound) interaction_10\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|the|QT (r_acl) interval_4\NN|NONE
D020117_D005764 NONE cisapride_14\NN|for|was|who|,|for (r_dobj) taking_13\VBG|a|old (l_prep) for_15\IN|cisapride|for|was|who|, (l_pobj) disorder_18\NN|NONE
D004110_D006973 NONE diltiazem_20\NN|and|gastroesophageal|reflux|,|agent (r_conj) disorder_18\NN|NONE (r_pobj) for_15\IN|cisapride|for|was|who|, (r_prep) taking_13\VBG|a|old (l_prep) for_31\IN|cisapride|was|who|,|for (l_pobj) hypertension_32\NN|NONE
D004917_D016171 CID erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|,|.|but|have|been|after|with (l_dobj) pointes_7\FW|Prolongation
D001393_D016757 CID azole_22\JJ|antifungal (r_amod) agents_24\NNS|or (r_conj) erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|,|.|but|have|been|after|with (l_dobj) pointes_7\FW|Prolongation (l_conj) death_12\NN|de|and|,
D020117_D015835 NONE Cisapride_0\NNP|.|widely|for|is (r_nsubjpass) prescribed_13\VBN|NONE (l_prep) for_14\IN|.|widely|Cisapride|is (l_pobj) treatment_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) disorders_20\NNS|NONE
D004917_D016757 CID erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|,|.|but|have|been|after|with (l_dobj) pointes_7\FW|Prolongation (l_conj) death_12\NN|de|and|,
2320800
D007069_D051437 NONE ifosfamide_34\NN| (r_pobj) after_28\IN|the (r_prep) day_27\NN|failure|.|woman|, (r_npadvmod) developed_17\VBD|NONE (l_dobj) failure_22\NN|.|woman|,|day
D007069_D001943 NONE ifosfamide_5\JJ|dose (r_compound) chemotherapy_6\NN|anuria|.|in (r_dobj) complicating_2\VBG|NONE (l_prep) in_7\IN|anuria|chemotherapy|. (l_pobj) patient_11\NN|NONE (l_compound) cancer_10\NN|with|a
D007069_D001943 NONE ifosfamide_34\NN| (r_pobj) after_28\IN|the (r_prep) day_27\NN|failure|.|woman|, (r_npadvmod) developed_17\VBD|NONE (l_nsubj) woman_6\NN|failure|.|,|day (l_prep) with_7\IN|treated|,|old|A|, (l_pobj) cancer_10\NN|NONE
D002945_D001002 NONE cisplatin_15\NN|NONE (r_pobj) with_14\IN|previously (r_prep) treated_13\VBN|with|,|old|A|, (r_acl) woman_6\NN|failure|.|,|day (r_nsubj) developed_17\VBD|NONE (l_dobj) failure_22\NN|.|woman|,|day (l_prep) with_23\IN|irreversible|an|renal|lethal (l_pobj) anuria_24\NN|NONE
D002945_D001002 NONE cisplatin_20\NN|previous (r_amod) chemotherapy_21\NN|having|with|and (r_dobj) received_18\VBN|in (r_advcl) occurring_13\VBG|,|that|anuria|mainly|due (r_advcl) was_7\VBD|We|strongly|. (l_nsubj) anuria_6\NN|,|that|occurring|mainly|due
D007069_D007022 NONE ifosfamide_11\NN|NONE (r_xcomp) due_9\JJ|,|that|anuria|occurring|mainly (r_acomp) was_7\VBD|We|strongly|. (l_advcl) occurring_13\VBG|,|that|anuria|mainly|due (l_advcl) received_18\VBN|in (l_prep) with_23\IN|having|chemotherapy|and (l_pobj) perfusion_26\NN|NONE (l_prep) due_27\IN|poor|kidney (l_pcomp) to_28\IN|NONE (l_pobj) hypotension_30\NN|NONE
D002945_D007022 NONE cisplatin_20\NN|previous (r_amod) chemotherapy_21\NN|having|with|and (r_dobj) received_18\VBN|in (l_prep) with_23\IN|having|chemotherapy|and (l_pobj) perfusion_26\NN|NONE (l_prep) due_27\IN|poor|kidney (l_pcomp) to_28\IN|NONE (l_pobj) hypotension_30\NN|NONE
D002945_D001943 NONE cisplatin_15\NN|NONE (r_pobj) with_14\IN|previously (r_prep) treated_13\VBN|with|,|old|A|, (r_acl) woman_6\NN|failure|.|,|day (l_prep) with_7\IN|treated|,|old|A|, (l_pobj) cancer_10\NN|NONE
D002945_D051437 NONE cisplatin_15\NN|NONE (r_pobj) with_14\IN|previously (r_prep) treated_13\VBN|with|,|old|A|, (r_acl) woman_6\NN|failure|.|,|day (r_nsubj) developed_17\VBD|NONE (l_dobj) failure_22\NN|.|woman|,|day
D007069_D001002 CID ifosfamide_5\JJ|dose (r_compound) chemotherapy_6\NN|anuria|.|in (r_dobj) complicating_2\VBG|NONE (l_nsubj) anuria_1\NN|chemotherapy|.|in
D007069_D001002 CID ifosfamide_34\NN| (r_pobj) after_28\IN|the (r_prep) day_27\NN|failure|.|woman|, (r_npadvmod) developed_17\VBD|NONE (l_dobj) failure_22\NN|.|woman|,|day (l_prep) with_23\IN|irreversible|an|renal|lethal (l_pobj) anuria_24\NN|NONE
D007069_D001002 CID ifosfamide_11\NN|NONE (r_xcomp) due_9\JJ|,|that|anuria|occurring|mainly (r_acomp) was_7\VBD|We|strongly|. (l_nsubj) anuria_6\NN|,|that|occurring|mainly|due
D007069_D007674 CID ifosfamide_5\JJ|dose (r_compound) chemotherapy_6\NN|anuria|.|in (r_dobj) complicating_2\VBG|NONE (l_prep) in_7\IN|anuria|chemotherapy|. (l_pobj) patient_11\NN|NONE (l_prep) with_12\IN|cancer|a (l_pobj) function_16\NN|NONE
D007069_D007674 CID Ifosfamide_0\NNP|.|drug (r_nsubj) is_1\VBZ|NONE (l_attr) drug_5\NN|.|Ifosfamide (l_amod) nephrotoxic_4\JJ|known|a|with
D007069_D007674 CID Ifosfamide_0\NNP|.|drug (r_nsubj) is_1\VBZ|NONE (l_attr) drug_5\NN|.|Ifosfamide (l_prep) with_6\IN|known|nephrotoxic|a (l_pobj) tubulopathies_8\NNS|NONE
D007069_D007674 CID ifosfamide_5\NN|NONE (r_pobj) of_4\IN|in|careful (r_prep) use_3\NN|We|. (l_prep) in_6\IN|careful|of (l_pobj) patients_7\NNS|NONE (l_acl) pretreated_8\VBN|NONE (l_prep) with_9\IN|NONE (l_pobj) chemotherapy_11\NN|NONE (l_amod) nephrotoxic_10\JJ|perfusion|and
16586083
C109794_D002318 NONE peptide_10\NN|such (r_pobj) as_3\IN|Diagnostic (r_prep) markers_1\NNS|might|.|in|avoiding|, (r_nsubj) help_25\VB|NONE (l_advcl) avoiding_36\VBG|might|.|in|markers|, (l_dobj) occurrence_38\NN|thus (l_prep) of_39\IN|the (l_pobj) toxicity_42\NN|NONE
C109794_D002318 NONE proBNP_14\NNP|brain|terminal|or|natriuretic|protein|(|) (r_appos) peptide_10\NN|such (r_pobj) as_3\IN|Diagnostic (r_prep) markers_1\NNS|might|.|in|avoiding|, (r_nsubj) help_25\VB|NONE (l_advcl) avoiding_36\VBG|might|.|in|markers|, (l_dobj) occurrence_38\NN|thus (l_prep) of_39\IN|the (l_pobj) toxicity_42\NN|NONE
D016861_D006973 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|hypertension|, (r_prep) stroke_15\NN|myocardial|, (l_conj) hypertension_17\NN|during|,
D016861_D006333 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|hypertension|, (r_prep) stroke_15\NN|myocardial|, (l_conj) hypertension_17\NN|during|, (l_conj) failure_20\NN|and
D016861_D020521 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|hypertension|, (r_prep) stroke_15\NN|myocardial|,
D016861_D009203 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|hypertension|, (r_prep) stroke_15\NN|myocardial|, (r_conj) infarction_13\NN|NONE
6615052
D006493_D013927 NONE Heparin_0\NNP| (r_npadvmod) induced_2\VBN|,|thrombosis|. (r_amod) thrombocytopenia_3\NN|NONE (l_conj) thrombosis_5\NN|induced|,|.
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|,|thrombosis|. (r_amod) thrombocytopenia_3\NN|NONE
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|a (r_amod) thrombocytopenia_9\NN|NONE
D006493_D013923 CID heparin_17\VBN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|thromboembolic (r_prep) events_13\NNS|or|frequently|,|, (l_compound) thromboembolic_12\JJ|in
D006493_D001791 NONE heparin_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) resistance_10\NN|and|,|added (r_dobj) increased_9\VBN|has|count|testing|.|, (r_conj) revealed_3\VBN|NONE (l_dobj) count_7\NN|has|testing|increased|.|,
D006493_D001791 NONE heparin_24\NN|aggregation|is|when (r_nsubjpass) added_26\VBN|resistance|and|, (r_conj) increased_9\VBN|has|count|testing|.|, (r_conj) revealed_3\VBN|NONE (l_dobj) count_7\NN|has|testing|increased|.|,
D006493_D001791 NONE heparin_15\JJ|patient|using|,|while|is (l_appos) testing_19\NN|, (l_compound) aggregation_18\NN|NONE
D006493_D006470 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|,|thrombosis|. (r_amod) thrombocytopenia_3\NN|NONE (l_conj) thrombosis_5\NN|induced|,|. (l_conj) hemorrhage_8\NN|and|,
D006493_D006470 CID heparin_17\VBN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|thromboembolic (r_prep) events_13\NNS|or|frequently|,|, (r_appos) hemorrhage_6\NN|manifestations|.
14648024
D014212_D015473 NONE acid_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) erythema_7\NN|in|retinoic (r_compound) nodosum_8\NN|. (l_prep) in_9\IN|retinoic|erythema (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D014212_D015473 NONE acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE
D014212_D015473 NONE acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE (l_appos) APL_17\NNP|acute|(|)|promyelocytic
D014212_D015473 NONE ATRA_10\NNP|(|retinoic|)|all (r_appos) acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE
D014212_D015473 NONE ATRA_10\NNP|(|retinoic|)|all (r_appos) acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE (l_appos) APL_17\NNP|acute|(|)|promyelocytic
D014212_D015473 NONE ATRA_12\NNP|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|who|nodosum (r_prep) developed_8\VBD|classic (r_relcl) APL_6\NNP|NONE
D014212_D010146 NONE ATRA_23\NNP|NONE (r_compound) therapy_24\NN|NONE (r_pobj) after_22\IN|,|over|erythematous|multiple|subsequent|painful (r_prep) nodules_6\NNS|.|and (l_amod) painful_4\JJ|,|over|erythematous|multiple|subsequent|after
D014212_D005334 CID ATRA_23\NNP|NONE (r_compound) therapy_24\NN|NONE (r_pobj) after_22\IN|,|over|erythematous|multiple|subsequent|painful (r_prep) nodules_6\NNS|.|and (r_conj) Fever_0\NN|NONE
D013256_D004893 NONE steroid_5\NN|NONE (r_pobj) of_4\IN|term (r_prep) use_3\NN|in|.|effective (r_nsubj) is_6\VBZ|NONE (l_prep) in_9\IN|use|.|effective (l_pobj) nodosum_14\NN|NONE
D014212_D004893 CID acid_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) erythema_7\NN|in|retinoic (r_compound) nodosum_8\NN|.
D014212_D004893 CID acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (r_acl) nodosum_1\NN|.|rare
D014212_D004893 CID ATRA_10\NNP|(|retinoic|)|all (r_appos) acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (r_acl) nodosum_1\NN|.|rare
D014212_D004893 CID ATRA_12\NNP|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|who|nodosum (r_prep) developed_8\VBD|classic (l_dobj) nodosum_10\NN|who|during
D014212_D004893 CID ATRA_23\NNP|NONE (r_compound) therapy_24\NN|NONE (r_pobj) after_22\IN|,|over|erythematous|multiple|subsequent|painful (r_prep) nodules_6\NNS|.|and
D014212_D004893 CID ATRA_0\NNP|.|be (r_nsubj) seemed_1\VBD|NONE (l_xcomp) be_3\VB|.|ATRA (l_attr) etiology_7\NN|to (l_prep) of_8\IN|the|possible (l_pobj) nodosum_10\NN|NONE
D014212_D004893 CID ATRA_10\NNP| (r_npadvmod) induced_12\VBN|erythema (r_amod) nodosum_14\NN|NONE
17490864
D000661_D006948 CID Amphetamine_0\NN| (r_npadvmod) induced_2\VBN|locomotor (r_amod) hyperactivity_4\NN|similar|.
21418164
D008130_D015620 NONE CCNU_0\NNP|.|in|commonly|was (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|.|commonly|was|CCNU (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|, (l_conj) tumour_16\NN|,|mast|cell (l_conj) tumours_19\NNS|brain|,
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D056486 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D064420 NONE CCNU_0\NNP|.|(|)|toxicity (r_npadvmod) lomustine_2\NN|NONE (l_dobj) toxicity_4\NN|.|(|)|CCNU
D008130_D064420 NONE lomustine_2\NN|NONE (l_dobj) toxicity_4\NN|.|(|)|CCNU
D008130_D064420 NONE CCNU_6\NNP|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN|the| (r_acl) dogs_3\NNS|NONE (r_pobj) Of_0\IN|.||,|criteria (r_prep) met_9\VBD|NONE (l_dobj) criteria_12\NNS|.|Of||, (l_prep) for_13\IN|the|inclusion (l_pobj) class_17\NN|NONE (l_prep) of_18\IN|one (l_pobj) toxicity_19\NN|NONE
D008130_D064420 NONE CCNU_0\NN| (r_npadvmod) associated_2\VBN|in (r_amod) toxicity_3\NN|but|.|common|,|is
D008130_D008223 NONE CCNU_0\NNP|.|in|commonly|was (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|.|commonly|was|CCNU (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE
D008130_D008223 NONE CCNU_0\NNP|.|in|commonly|was (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|.|commonly|was|CCNU (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|, (l_conj) tumour_16\NN|,|mast|cell (l_conj) tumours_19\NNS|brain|, (l_conj) lymphoma_22\NN|and|histiocytic
D000409_D064420 NONE alanine_5\NN|elevated (r_compound) transaminase_6\NN|ALT|( (r_nmod) concentration_10\NN|Potential|renal|and (r_conj) toxicity_2\NN|.|were|in
D008130_D001932 NONE CCNU_0\NNP|.|in|commonly|was (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|.|commonly|was|CCNU (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|, (l_conj) tumour_16\NN|,|mast|cell
D008130_D034801 NONE CCNU_0\NNP|.|in|commonly|was (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|.|commonly|was|CCNU (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|,
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D007674 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D005767 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D006402 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
9022662
D008774_D001289 NONE methylphenidate_14\NN|NONE (r_pobj) with_13\IN|without|previously (r_prep) treated_12\VBN|deficit (r_acl) disorder_10\NN|NONE
D010389_D001289 NONE Pemoline_0\NNP|derivative|. (r_nsubj) is_1\VBZ|NONE (l_attr) derivative_4\NN|.|Pemoline (l_relcl) is_6\VBZ|an|oxazolidine (l_conj) used_12\VBN|and|that|different (l_prep) in_13\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D001569_D001264 NONE benzodiazepines_10\NNS|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|gastrointestinal|and (r_conj) decontamination_4\NN|.|in|children (r_dobj) received_2\VBD|NONE (l_prep) in_11\IN|decontamination|.|children (l_pobj) attempt_13\NN|NONE (l_acl) control_15\VB|an (l_dobj) movements_18\NNS|to (l_compound) choreoathetoid_17\JJ|the
C064210_D001289 NONE oxazolidine_3\JJ|an|is (r_compound) derivative_4\NN|.|Pemoline (l_relcl) is_6\VBZ|an|oxazolidine (l_conj) used_12\VBN|and|that|different (l_prep) in_13\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D010389_D001264 CID Pemoline_0\NNP|choreoathetosis (r_nsubj) induced_1\VBD|case|.|of|and|review|: (l_dobj) choreoathetosis_3\NN|Pemoline
D010389_D001264 CID pemoline_9\NN|NONE (l_relcl) experienced_11\VBD|NONE (l_dobj) choreoathetosis_13\NN|who
D010389_D001264 CID pemoline_12\NN|NONE (r_compound) overdose_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) presenting_10\VBG|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|.|should|possibility|be (r_prep) considered_7\VBN|NONE (l_nsubjpass) possibility_1\NN|.|in|should|be (l_prep) of_2\IN|The (l_pobj) movements_4\NNS|NONE (l_compound) choreoathetoid_3\JJ|NONE
D010389_D062787 CID pemoline_12\NN|NONE (r_compound) overdose_13\NN|NONE
D001569_D002819 NONE benzodiazepines_10\NNS|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|gastrointestinal|and (r_conj) decontamination_4\NN|.|in|children (r_dobj) received_2\VBD|NONE (l_prep) in_11\IN|decontamination|.|children (l_pobj) attempt_13\NN|NONE (l_acl) control_15\VB|an (l_dobj) movements_18\NNS|to (l_compound) choreoathetoid_17\JJ|the
D000662_D001289 NONE amphetamines_10\NNS|NONE (r_pobj) from_9\IN|structurally (r_prep) different_8\JJ|used|and|that (r_acomp) is_6\VBZ|an|oxazolidine (l_conj) used_12\VBN|and|that|different (l_prep) in_13\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D010389_D009069 NONE Pemoline_0\NNP|has|not|commonly|as|been|in|. (r_nsubjpass) associated_5\VBN|NONE (l_prep) as_9\IN|Pemoline|has|not|commonly|been|in|. (l_pobj) cause_11\NN|NONE (l_prep) of_12\IN|a (l_pobj) disorders_15\NNS|NONE
D010389_D009069 NONE Pemoline_0\NN|associated|movement (r_nmod) disorder_3\NN|been|has|.|rarely|in
D010389_D002819 CID Pemoline_0\NNP|choreoathetosis (r_nsubj) induced_1\VBD|case|.|of|and|review|: (l_dobj) choreoathetosis_3\NN|Pemoline
D010389_D002819 CID pemoline_9\NN|NONE (l_relcl) experienced_11\VBD|NONE (l_dobj) choreoathetosis_13\NN|who
D010389_D002819 CID pemoline_12\NN|NONE (r_compound) overdose_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) presenting_10\VBG|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|.|should|possibility|be (r_prep) considered_7\VBN|NONE (l_nsubjpass) possibility_1\NN|.|in|should|be (l_prep) of_2\IN|The (l_pobj) movements_4\NNS|NONE (l_compound) choreoathetoid_3\JJ|NONE
839274
D003276_D020518 CID contraceptives_14\NNS|NONE (r_pobj) on_12\IN|of|focal|nodular (r_prep) hyperplasia_5\NN|Hepatic|and
D003276_D020518 CID contraceptives_18\NNS|NONE (r_pobj) of_16\IN|the (r_prep) use_15\NN|NONE (r_pobj) with_13\IN|presumably (r_prep) associated_12\VBD|of (r_acl) one_6\CD|of|Two|and (l_prep) of_7\IN|associated (l_pobj) hyperplasia_10\NN|NONE
D003276_D000236 CID contraceptives_14\NNS|NONE (r_pobj) on_12\IN|of|focal|nodular (r_prep) hyperplasia_5\NN|Hepatic|and (r_conj) adenomas_1\NNS|.|:|case
D003276_D000236 CID contraceptives_18\NNS|NONE (r_pobj) of_16\IN|the (r_prep) use_15\NN|NONE (r_pobj) with_13\IN|presumably (r_prep) associated_12\VBD|of (r_acl) one_6\CD|of|Two|and (r_conj) cases_1\NNS|.|are|, (l_prep) of_2\IN|one|Two|and (l_pobj) adenoma_4\NN|NONE
18177388
D000661_D054549 CID amphetamine_21\NN|NONE (r_compound) use_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) setting_19\NN|NONE (r_pobj) in_17\IN|a|young (r_prep) woman_16\NN|NONE (r_pobj) in_13\IN|cardiomyopathy|syndrome|Reverse|.|) (r_prep) left_3\VBN|NONE (l_dobj) syndrome_7\NN|cardiomyopathy|Reverse|.|in|)
D000661_D054549 CID amphetamine_21\NN|NONE (r_compound) use_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) setting_19\NN|NONE (r_pobj) in_17\IN|a|young (r_prep) woman_16\NN|NONE (r_pobj) in_13\IN|cardiomyopathy|syndrome|Reverse|.|) (r_prep) left_3\VBN|NONE (l_oprd) cardiomyopathy_11\NN|syndrome|Reverse|.|in|)
D000661_D054549 CID amphetamine_26\NN|NONE (r_compound) use_27\NN|NONE (r_pobj) after_25\IN|NONE (r_prep) occurring_24\VBG|rare|this|of (r_acl) type_18\NN|NONE (l_prep) of_19\IN|rare|this|occurring (l_pobj) syndrome_23\NN|NONE
12851669
D016912_D054556 NONE levonorgestrel_42\NN| (r_npadvmod) containing_44\VBG|NONE (r_amod) COCs_45\NNS|NONE (r_pobj) on_41\IN|NONE (r_prep) women_40\NNS|NONE (r_pobj) among_39\IN|women (r_prep) years_38\NNS|NONE (r_pobj) per_34\IN|.|and|(|range|,|,|range (r_prep) range_9\NN|.|risk (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|.|range (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D003277_D054556 CID contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|and|estimates|,|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|and|among|,|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE
D003277_D054556 CID contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|and|estimates|,|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|and|among|,|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|among|venous|)|(
D003277_D054556 CID COCs_32\NNPS|)|oral|combined|( (r_appos) contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|and|estimates|,|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|and|among|,|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE
D003277_D054556 CID COCs_32\NNPS|)|oral|combined|( (r_appos) contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|and|estimates|,|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|and|among|,|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|among|venous|)|(
D003277_D054556 CID COCs_19\NNS|while (r_pobj) on_18\IN|to|have|VTE (r_advcl) had_15\VBN|were|women|,|.|:|During (l_dobj) VTE_16\NNP|on|to|have
D003277_D054556 CID COCs_24\NNS|NONE (r_pobj) on_23\IN|the (r_prep) women_22\NNS|NONE (r_pobj) among_20\IN|women (r_prep) years_19\NNS|NONE (r_pobj) per_15\IN|.|) (r_prep) 3.1_11\CD|.|(|,|,|.|) (r_npadvmod) range_28\NN|.|and|per|(|,|,|range (r_appos) range_9\NN|.|risk (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|.|range (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D003277_D054556 CID COCs_45\NNS|NONE (r_pobj) on_41\IN|NONE (r_prep) women_40\NNS|NONE (r_pobj) among_39\IN|women (r_prep) years_38\NNS|NONE (r_pobj) per_34\IN|.|and|(|range|,|,|range (r_prep) range_9\NN|.|risk (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|.|range (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D003277_D054556 CID COCs_12\NNS|NONE (r_pobj) on_11\IN|Danish (r_prep) women_10\NNS|NONE (r_pobj) among_8\IN|absolute|of|the (r_prep) risk_5\NN|.|results|is (l_prep) of_6\IN|absolute|the|among (l_pobj) VTE_7\NNP|NONE
D017373_D054556 NONE acetate_12\NN|NONE (r_pobj) on_9\IN|NONE (r_prep) women_8\NNS|NONE (r_pobj) in_7\IN|venous (r_prep) thromboembolism_6\NN|NONE
D017373_D054556 NONE acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE
D017373_D054556 NONE acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|among|venous|)|(
D017373_D054556 NONE CPA_19\NNP|(|)|/ (r_nmod) EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|cyproterone|plus (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE
D017373_D054556 NONE CPA_19\NNP|(|)|/ (r_nmod) EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|cyproterone|plus (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|among|venous|)|(
D017373_D054556 NONE CPA_65\NNP|/ (r_nmod) EE_67\NNP|NONE (r_pobj) on_64\IN|the (r_prep) women_63\NNS|NONE (r_pobj) among_61\IN|women (r_prep) years_60\NNS|NONE (r_pobj) per_56\IN|.|,|)|(|. (r_prep) range_50\NN|.|and|per|(|range|,|, (r_conj) range_9\NN|.|risk (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|.|range (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D017373_D054556 NONE CPA_20\NNP|/ (r_nmod) EE_22\NNP|NONE (r_dobj) taking_19\VBG|NONE (r_acl) women_18\NNS|NONE (r_pobj) among_17\IN|NONE (r_prep) that_16\DT|NONE (r_pobj) to_15\IN|NONE (r_prep) similar_14\JJ|NONE (r_acomp) is_13\VBZ|.|risk|results (r_ccomp) suggest_2\VBP|NONE (l_dobj) risk_5\NN|.|results|is (l_prep) of_6\IN|absolute|the|among (l_pobj) VTE_7\NNP|NONE
D004997_D054556 NONE ethinylestradiol_14\NN|combined|cyproterone|and (r_conj) acetate_12\NN|NONE (r_pobj) on_9\IN|NONE (r_prep) women_8\NNS|NONE (r_pobj) in_7\IN|venous (r_prep) thromboembolism_6\NN|NONE
D004997_D054556 NONE ethinylestradiol_17\NN|cyproterone|plus (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE
D004997_D054556 NONE ethinylestradiol_17\NN|cyproterone|plus (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|among|venous|)|(
D004997_D054556 NONE EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|cyproterone|plus (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE
D004997_D054556 NONE EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|cyproterone|plus (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|VTE|venous|)|( (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|among|venous|)|(
D004997_D054556 NONE EE_67\NNP|NONE (r_pobj) on_64\IN|the (r_prep) women_63\NNS|NONE (r_pobj) among_61\IN|women (r_prep) years_60\NNS|NONE (r_pobj) per_56\IN|.|,|)|(|. (r_prep) range_50\NN|.|and|per|(|range|,|, (r_conj) range_9\NN|.|risk (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|.|range (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D004997_D054556 NONE EE_22\NNP|NONE (r_dobj) taking_19\VBG|NONE (r_acl) women_18\NNS|NONE (r_pobj) among_17\IN|NONE (r_prep) that_16\DT|NONE (r_pobj) to_15\IN|NONE (r_prep) similar_14\JJ|NONE (r_acomp) is_13\VBZ|.|risk|results (r_ccomp) suggest_2\VBP|NONE (l_dobj) risk_5\NN|.|results|is (l_prep) of_6\IN|absolute|the|among (l_pobj) VTE_7\NNP|NONE
3670965
D001241_D012202 CID aspirin_16\JJ|NONE (r_compound) ingestion_17\NN|or (r_conj) salicylates_14\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) association_12\NN|NONE (r_pobj) of_11\IN|a|total (r_prep) lack_10\NN|NONE (r_pobj) despite_7\IN|.|may|be|,|from|were|syndrome (r_prep) disappearing_4\VBG|NONE (l_nsubj) syndrome_1\NN|.|may|be|,|despite|from|were
D012459_D012202 NONE salicylates_14\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) association_12\NN|NONE (r_pobj) of_11\IN|a|total (r_prep) lack_10\NN|NONE (r_pobj) despite_7\IN|.|may|be|,|from|were|syndrome (r_prep) disappearing_4\VBG|NONE (l_nsubj) syndrome_1\NN|.|may|be|,|despite|from|were
10692744
D000086_D003221 NONE acetazolamide_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Acute (r_acl) confusion_1\NN|.|reaction
D000086_D005862 CID Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|Gerstmann|. (r_amod) syndrome_4\NN|NONE
D000086_D005862 CID acetazolamide_5\NN| (r_npadvmod) induced_7\VBN|Gerstmann (r_amod) syndrome_9\NN|NONE
D000086_D007674 NONE acetazolamide_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Acute (r_acl) confusion_1\NN|.|reaction (r_nsubj) is_5\VBZ|NONE (l_attr) reaction_11\NN|.|confusion (l_prep) in_12\IN|a|adverse|drug|known (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) impairment_16\NN|NONE
19940105
D006220_D002375 CID haloperidol_22\NN| (r_npadvmod) induced_24\VBN|in (r_amod) catalepsy_25\NN|that|intrastriatal
D006220_D002375 CID haloperidol_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) catalepsy_11\NN|NONE
D018698_D010300 NONE glutamate_1\NN||receptor (r_nmod) subtype_4\NN|.|in|symptoms (r_nsubj) modulates_5\VBZ|NONE (l_prep) in_8\IN|.|subtype|symptoms (l_pobj) models_10\NNS|NONE (l_prep) of_11\IN|rodent (l_pobj) disease_14\NN|NONE
D018698_D010300 NONE glutamate_1\NN|mGlu (r_nmod) receptors_5\NNS|transmission|and|.|represent (r_nsubj) modulate_6\VBP|NONE (l_conj) represent_15\VBP|transmission|receptors|and|. (l_dobj) targets_18\NNS|NONE (l_prep) for_19\IN|therapeutic|promising (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|symptomatic (l_pobj) disease_25\NN|NONE
D018698_D010300 NONE glutamate_1\NN|mGlu (r_nmod) receptors_5\NNS|transmission|and|.|represent (r_nsubj) modulate_6\VBP|NONE (l_conj) represent_15\VBP|transmission|receptors|and|. (l_dobj) targets_18\NNS|NONE (l_prep) for_19\IN|therapeutic|promising (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|symptomatic (l_pobj) disease_25\NN|NONE (l_appos) PD_27\NNP|)|(|Parkinson
C507346_D010300 NONE AMN082_1\NNP|.|in|thus|were (r_nsubjpass) tested_15\VBN|NONE (l_prep) in_16\IN|.|thus|were|AMN (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|rodent|different (l_pobj) PD_21\NNP|NONE
C507346_D010300 NONE AMN082_18\NNP|respond|.|time|,|In (r_nsubj) reverses_19\VBZ|NONE (l_prep) In_0\IN|respond|.|time|,|AMN (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|a|complex (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_prep) of_12\IN|major|akinetic (l_pobj) patients_14\NNS|NONE (l_compound) PD_13\NNP|NONE
C507346_D010300 NONE AMN082_3\NNP|NONE (r_pobj) of_2\IN|Higher (r_prep) doses_1\NNS|.|effect (r_nsubj) have_11\VBP|NONE (l_dobj) effect_13\NN|.|doses (l_prep) on_14\IN|no (l_pobj) models_17\NNS|NONE (l_prep) of_18\IN|the|same (l_pobj) PD_19\NNP|NONE
C507346_D002375 NONE AMN082_20\NNP|NONE (r_pobj) of_19\IN|.|(|)|nmol (r_prep) administration_12\NN|NONE (r_dobj) intrastriatal_11\JJ|catalepsy|that (r_csubj) reverses_21\VBZ|Here|we|.|, (l_dobj) catalepsy_25\NN|that|intrastriatal
C507346_D002375 NONE AMN082_3\NNP|,|duration|In|. (r_nsubj) reduces_4\VBZ|NONE (l_dobj) duration_6\NN|,|AMN|In|. (l_prep) of_7\IN|in|the (l_pobj) catalepsy_11\NN|NONE
C507346_D018476 NONE AMN082_18\NNP|respond|.|time|,|In (r_nsubj) reverses_19\VBZ|NONE (l_prep) In_0\IN|respond|.|time|,|AMN (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|a|complex (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_amod) akinetic_10\JJ|major|of
D016627_D010300 NONE 6-OHDA_31\CD| (r_advmod) lesioned_33\VBN|bilateral (r_amod) rats_34\NNS|NONE (r_pobj) of_29\IN|a (r_prep) cue_28\NN|NONE (r_pobj) to_26\IN|to (r_prep) respond_25\VB|.|time|,|AMN|In (r_xcomp) reverses_19\VBZ|NONE (l_prep) In_0\IN|respond|.|time|,|AMN (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|a|complex (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_prep) of_12\IN|major|akinetic (l_pobj) patients_14\NNS|NONE (l_compound) PD_13\NNP|NONE
D016627_D018476 NONE 6-OHDA_31\CD| (r_advmod) lesioned_33\VBN|bilateral (r_amod) rats_34\NNS|NONE (r_pobj) of_29\IN|a (r_prep) cue_28\NN|NONE (r_pobj) to_26\IN|to (r_prep) respond_25\VB|.|time|,|AMN|In (r_xcomp) reverses_19\VBZ|NONE (l_prep) In_0\IN|respond|.|time|,|AMN (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|a|complex (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_amod) akinetic_10\JJ|major|of
2980315
C053571_D014693 NONE iopentol_14\NN|NONE (r_pobj) after_13\IN|)|than|p|(|less (r_prep) 0.05_11\CD|.|than|lower|Frequencies (r_parataxis) were_4\VBD|NONE (l_nsubj) Frequencies_0\NNS|.|.|than|lower (l_prep) of_1\IN|NONE (l_pobj) fibrillation_3\NN|NONE
D007472_D014693 NONE iohexol_20\NN|%|and (r_conj) iopentol_14\NN|NONE (r_pobj) after_13\IN|)|than|p|(|less (r_prep) 0.05_11\CD|.|than|lower|Frequencies (r_parataxis) were_4\VBD|NONE (l_nsubj) Frequencies_0\NNS|.|.|than|lower (l_prep) of_1\IN|NONE (l_pobj) fibrillation_3\NN|NONE
D008794_D014693 CID metrizoate_27\NN|NONE (r_pobj) after_26\IN|NONE (r_prep) than_25\IN|.|.|lower|Frequencies (r_prep) were_4\VBD|NONE (l_nsubj) Frequencies_0\NNS|.|.|than|lower (l_prep) of_1\IN|NONE (l_pobj) fibrillation_3\NN|NONE
6433367
D011453_D012640 NONE prostaglandin_2\JJ|synthetase (r_amod) inhibitors_4\NNS|NONE (r_pobj) of_1\IN|on|. (r_prep) Effect_0\NN|NONE (l_prep) on_5\IN|of|. (l_pobj) convulsions_8\NNS|NONE
D011453_D012640 NONE prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|To|to (r_dobj) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D011453_D012640 NONE prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|To|to (r_dobj) investigate_1\VB|were|,|.|effects (r_advcl) evaluated_37\VBN|NONE (l_nsubjpass) effects_14\NNS|were|,|.|investigate (l_prep) on_20\IN|of|the (l_pobj) convulsions_21\NNS|NONE
D011453_D012640 NONE PGs_7\NNS|(|) (r_appos) prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|To|to (r_dobj) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D011453_D012640 NONE PGs_7\NNS|(|) (r_appos) prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|To|to (r_dobj) investigate_1\VB|were|,|.|effects (r_advcl) evaluated_37\VBN|NONE (l_nsubjpass) effects_14\NNS|were|,|.|investigate (l_prep) on_20\IN|of|the (l_pobj) convulsions_21\NNS|NONE
D011453_D012640 NONE PGs_4\NNS|picrotoxin|that|in|,|but|are (r_nsubjpass) involved_6\VBN|.|results (l_prep) in_7\IN|picrotoxin|PGs|that|,|but|are (l_pobj) fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|)|the|and|underlying
D011453_D012640 NONE PGs_4\NNS|picrotoxin|that|in|,|but|are (r_nsubjpass) involved_6\VBN|.|results (l_conj) picrotoxin-_21\XX|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS|not|,|electroshock
D010433_D012640 CID pentetrazol_28\NNP|)|electroshock|,|( (r_nmod) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|of|the (r_prep) effects_14\NNS|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D010433_D012640 CID pentetrazol_28\NNP|)|electroshock|,|( (r_nmod) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D010433_D012640 CID PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|of|the (r_prep) effects_14\NNS|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D010433_D012640 CID PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D010433_D012640 CID PTZ_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) convulsions_17\NNS|)|the|and|underlying
D010433_D012640 CID PTZ_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) convulsions_17\NNS|)|the|and|underlying (r_conj) fluorthyl-_12\NNS|NONE (r_pobj) in_7\IN|picrotoxin|PGs|that|,|but|are (r_prep) involved_6\VBN|.|results (l_conj) picrotoxin-_21\XX|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS|not|,|electroshock
D001640_D012640 CID bicuculline_35\NN|or (r_conj) electroshock_33\NN|)|pentetrazol|,|( (r_conj) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|of|the (r_prep) effects_14\NNS|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D001640_D012640 CID bicuculline_35\NN|or (r_conj) electroshock_33\NN|)|pentetrazol|,|( (r_conj) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D001640_D012640 CID bicuculline_26\NN| (r_advmod) induced_28\VBN|or|, (r_conj) electroshock-_23\XX|not|,|convulsions (r_conj) picrotoxin-_21\XX|PGs|that|in|,|but|are (r_conj) involved_6\VBN|.|results (l_prep) in_7\IN|picrotoxin|PGs|that|,|but|are (l_pobj) fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|)|the|and|underlying
D001640_D012640 CID bicuculline_26\NN| (r_advmod) induced_28\VBN|or|, (r_conj) electroshock-_23\XX|not|,|convulsions (r_conj) picrotoxin-_21\XX|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS|not|,|electroshock
D010852_D012640 CID picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|of|the (r_prep) effects_14\NNS|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D010852_D012640 CID picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D010852_D012640 CID picrotoxin-_21\XX|PGs|that|in|,|but|are (r_conj) involved_6\VBN|.|results (l_prep) in_7\IN|picrotoxin|PGs|that|,|but|are (l_pobj) fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|)|the|and|underlying
D010852_D012640 CID picrotoxin-_21\XX|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS|not|,|electroshock
D005481_D012640 CID flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|of|the (r_prep) effects_14\NNS|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|were|,|.|effects (l_prep) to_9\TO|To|relationship (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D005481_D012640 CID flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D005481_D012640 CID fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|)|the|and|underlying
D005481_D012640 CID fluorthyl-_12\NNS|NONE (r_pobj) in_7\IN|picrotoxin|PGs|that|,|but|are (r_prep) involved_6\VBN|.|results (l_conj) picrotoxin-_21\XX|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS|not|,|electroshock
16600756
D011453_D053201 NONE prostaglandins_4\NNS|in|and|growth|Nerve|. (r_conj) factor_2\NN|NONE (l_prep) in_5\IN|and|growth|prostaglandins|Nerve|. (l_pobj) urine_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|female (l_pobj) bladder_13\NN|NONE
D011453_D053201 NONE PGs_7\NNS|urinary|and (l_prep) in_8\IN|NONE (l_pobj) women_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) OAB_11\NNP|NONE
D011453_D053201 NONE PG_8\NNP|and|urinary (r_conj) NGF_6\NNP|NONE (r_pobj) between_4\IN|,|and|parameters (r_prep) correlations_3\NNS|In|,|were|. (l_conj) parameters_12\NNS|between|,|and (l_prep) in_13\IN|urodynamic (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) OAB_16\NNP|NONE
D011453_D053201 NONE PGs_2\NNS|and (r_conj) NGF_0\NNP|roles|. (r_nsubj) have_3\VBP|NONE (l_dobj) roles_5\NNS|NGF|. (l_prep) in_6\IN|important (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) symptoms_11\NNS|NONE (l_compound) OAB_10\NNP|in
D011464_D053201 NONE PGI2_3\NNP|However|different|,|not|. (r_nsubj) was_4\VBD|NONE (l_acomp) different_6\JJ|However|,|not|PGI|. (l_prep) between_7\IN|NONE (l_pobj) controls_8\NNS|NONE (l_prep) with_11\IN|patients|and (l_pobj) OAB_12\NNP|NONE
D011464_D053201 NONE PGI2_5\NNP|and (r_conj) PGF2alpha_3\NNP|Urinary|, (r_appos) NGF_1\NNP|did|.|with|not (r_nsubj) correlate_8\VB|NONE (l_prep) with_9\IN|did|.|not|NGF (l_pobj) parameters_11\NNS|NONE (l_prep) in_12\IN|urodynamic (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) OAB_15\NNP|NONE
D015232_D053201 CID PGE2_3\NNP|Urinary|, (r_conj) NGF_1\NNP|significantly|were|)|compared|.|in (r_nsubjpass) increased_8\VBN|NONE (l_prep) in_9\IN|significantly|were|)|compared|.|NGF (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) OAB_12\NNP|NONE
D015232_D053201 CID PGE2_5\NNP|NONE (l_compound) OAB_3\NNP|urinary
D015237_D053201 CID PGF2alpha_5\NNP|and (r_conj) PGE2_3\NNP|Urinary|, (r_conj) NGF_1\NNP|significantly|were|)|compared|.|in (r_nsubjpass) increased_8\VBN|NONE (l_prep) in_9\IN|significantly|were|)|compared|.|NGF (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) OAB_12\NNP|NONE
D015237_D053201 CID PGF2alpha_3\NNP|Urinary|, (r_appos) NGF_1\NNP|did|.|with|not (r_nsubj) correlate_8\VB|NONE (l_prep) with_9\IN|did|.|not|NGF (l_pobj) parameters_11\NNS|NONE (l_prep) in_12\IN|urodynamic (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) OAB_15\NNP|NONE
8410199
D010862_D012640 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) seizures_17\NNS|NONE
D010862_D012640 CID pilocarpine_8\NN|NONE (r_pobj) with_7\IN|studied|intraperitoneally|,|were|and|rats (r_prep) injected_5\VBN|NONE (l_conj) studied_15\VBN|intraperitoneally|,|were|and|with|rats (l_conj) intervals_27\NNS|,|was|at|and|formation|.|histologically (l_prep) after_28\IN|week (l_pobj) seizures_32\NNS|NONE
D010862_D012640 CID pilocarpine_29\NN| (r_npadvmod) induced_31\VBN|NONE (r_amod) seizures_32\NNS|NONE
D018698_D012640 NONE glutamate_2\NN|NONE (r_compound) decarboxylase_3\NN|containing|in (r_nmod) neurons_7\NNS|NONE (r_pobj) of_1\IN|.|following (r_prep) Loss_0\NN|NONE (l_prep) following_13\VBG|of|. (l_pobj) seizures_17\NNS|NONE
D018698_D012640 NONE acid_10\NN|neurons|(|glutamic (r_compound) decarboxylase_11\NN|if|vulnerable (r_nsubj) are_26\VBP|to (l_acomp) vulnerable_27\JJ|decarboxylase|if (l_prep) to_28\IN|NONE (l_pobj) damage_32\NN|NONE (l_amod) induced_31\VBN|in (l_npadvmod) seizure_29\NN|
D018698_D012640 NONE acid_10\NN|neurons|(|glutamic (r_compound) decarboxylase_11\NN|if|vulnerable (r_nsubj) are_26\VBP|to (l_acomp) vulnerable_27\JJ|decarboxylase|if (l_prep) to_28\IN|NONE (l_pobj) damage_32\NN|NONE (l_prep) in_33\IN|induced (l_pobj) model_35\NN|NONE (l_prep) of_36\IN|a (l_pobj) seizures_38\NNS|NONE
C028911_D009410 NONE violet_6\NN|cresyl|,|methods (r_compound) staining_7\NN|NONE (l_conj) methods_11\NNS|cresyl|,|violet (l_compound) degeneration_10\NN|and|neuronal|localization|,
C028911_D009410 NONE violet_6\NN|cresyl|,|methods (r_compound) staining_7\NN|NONE (r_pobj) including_4\VBG|Additional|,|neuronanatomical|, (r_prep) studies_2\NNS|.|related (r_nsubj) suggested_22\VBD|NONE (l_ccomp) related_36\VBN|.|studies (l_prep) to_37\IN|decrease|was|that (l_pobj) loss_39\NN|than|to
1636026
D014527_D007674 NONE acid_39\NN|NONE (r_pobj) of_37\IN||/|mg (r_prep) dL_36\NN|NONE (r_pobj) of_32\IN|the (r_prep) addition_31\NN|NONE (r_pobj) without_29\IN|or (r_conj) with_27\IN|free (r_prep) buffer_26\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) perfused_21\VBN|recirculating|isolated|rat|the (r_acl) kidney_20\NN|NONE (r_pobj) in_15\IN|.|mg|effects|were (r_prep) compared_14\VBN|NONE (l_nsubjpass) effects_3\NNS|.|mg|in|were (l_amod) nephrotoxic_2\JJ|of|direct|The
D013496_D058186 CID suprofen_1\NN|been|has|Although|with (r_nsubjpass) associated_4\VBN|.|,|mechanism|unclear (l_prep) with_5\IN|been|has|Although|suprofen (l_pobj) development_7\NN|NONE (l_prep) of_8\IN|the|in (l_pobj) failure_11\NN|NONE
D013496_D058186 CID suprofen_3\VB|,|,|declines|.|likely|In (r_nsubj) causes_4\VBZ|NONE (l_dobj) declines_6\NNS|suprofen|,|,|.|likely|In (l_prep) in_7\IN|acute (l_pobj) function_9\NN|NONE
D013496_D007674 NONE suprofen_12\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) mg_10\NN|.|in|effects|were (r_nsubjpass) compared_14\VBN|NONE (l_nsubjpass) effects_3\NNS|.|mg|in|were (l_amod) nephrotoxic_2\JJ|of|direct|The
D014527_D058186 NONE acid_21\NN|NONE (r_pobj) of_19\IN|the|intrarenal (r_prep) distribution_18\NN|directly (r_dobj) altering_15\VBG|NONE (r_pcomp) by_13\IN|most (r_prep) likely_12\JJ|suprofen|,|,|declines|.|In (r_advcl) causes_4\VBZ|NONE (l_dobj) declines_6\NNS|suprofen|,|,|.|likely|In (l_prep) in_7\IN|acute (l_pobj) function_9\NN|NONE
6637851
D000638_D064420 NONE amiodarone_10\NN|dose (r_compound) therapy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) toxicity_5\NN|and|.|term|for
D000638_D064420 NONE amiodarone_4\NN|in|Although|effective (r_nsubj) is_5\VBZ|,|.|it|toxicity (r_advcl) causes_25\VBZ|NONE (l_dobj) toxicity_27\NN|,|is|.|it
D000638_D006323 NONE Amiodarone_0\NNP|.|was|to (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|.|was|Amiodarone (l_pobj) patients_5\NNS|NONE (l_conj) arrest_24\NN|or|sustained||
D000638_D014693 NONE amiodarone_10\NN|dose (r_compound) therapy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) toxicity_5\NN|and|.|term|for (r_conj) efficacy_3\NN|NONE (l_prep) for_12\IN|toxicity|and|.|term (l_pobj) tachycardia_14\NN|NONE (l_conj) fibrillation_17\NN|or|ventricular
D000638_D014693 NONE amiodarone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treatment_7\NN|.|and|percent|had (r_dobj) continued_6\VBD|NONE (l_conj) had_11\VBD|.|and|percent|treatment (l_dobj) recurrence_13\NN|NONE (l_prep) of_14\IN|over|no (l_pobj) VT_16\NNP|NONE (l_conj) fibrillation_19\NN|VF|)|symptomatic|or|(
D000638_D014693 NONE amiodarone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treatment_7\NN|.|and|percent|had (r_dobj) continued_6\VBD|NONE (l_conj) had_11\VBD|.|and|percent|treatment (l_dobj) recurrence_13\NN|NONE (l_prep) of_14\IN|over|no (l_pobj) VT_16\NNP|NONE (l_appos) VF_21\NNP|)|symptomatic|or|fibrillation|(
D000638_D014693 NONE amiodarone_4\NN|in|Although|effective (r_nsubj) is_5\VBZ|,|.|it|toxicity (l_prep) in_8\IN|amiodarone|Although|effective (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the|term (l_pobj) VT_15\NNP|NONE (l_conj) refractory_18\NN|or (l_compound) VF_17\NNP|to
D000638_D014693 NONE amiodarone_31\NN|NONE (r_pobj) with_30\IN|can|,|be|,|successfully|However|adjusted|.|% (r_prep) managed_29\VBN|NONE (l_nsubjpass) %_19\NN|can|,|be|,|successfully|However|adjusted|with|. (l_prep) of_20\IN| (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) VT_23\NNP|NONE (l_conj) VF_25\NNP|or
D000638_D017180 NONE amiodarone_10\NN|dose (r_compound) therapy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) toxicity_5\NN|and|.|term|for (r_conj) efficacy_3\NN|NONE (l_prep) for_12\IN|toxicity|and|.|term (l_pobj) tachycardia_14\NN|NONE
D000638_D017180 NONE Amiodarone_0\NNP|.|was|to (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|.|was|Amiodarone (l_pobj) patients_5\NNS|NONE (l_relcl) sustained_8\VBN|arrest|or|| (l_dobj) tachycardia_12\NN|,|had|who
D000638_D017180 NONE Amiodarone_0\NNP|.|was|to (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|.|was|Amiodarone (l_pobj) patients_5\NNS|NONE (l_relcl) sustained_8\VBN|arrest|or|| (l_dobj) tachycardia_12\NN|,|had|who (l_appos) VT_14\NNP|symptomatic|(|ventricular|)
D000638_D017180 NONE amiodarone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treatment_7\NN|.|and|percent|had (r_dobj) continued_6\VBD|NONE (l_conj) had_11\VBD|.|and|percent|treatment (l_dobj) recurrence_13\NN|NONE (l_prep) of_14\IN|over|no (l_pobj) VT_16\NNP|NONE
D000638_D017180 NONE amiodarone_17\NN|NONE (r_pobj) by_15\IN|were|successfully (r_agent) managed_14\VBN|recurrence|and|percent|. (r_conj) had_5\VBD|NONE (l_dobj) recurrence_8\NN|managed|and|percent|. (l_prep) of_9\IN|a|nonfatal (l_pobj) VT_10\NNP|NONE
D000638_D017180 NONE amiodarone_4\NN|in|Although|effective (r_nsubj) is_5\VBZ|,|.|it|toxicity (l_prep) in_8\IN|amiodarone|Although|effective (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the|term (l_pobj) VT_15\NNP|NONE
D000638_D017180 NONE amiodarone_31\NN|NONE (r_pobj) with_30\IN|can|,|be|,|successfully|However|adjusted|.|% (r_prep) managed_29\VBN|NONE (l_nsubjpass) %_19\NN|can|,|be|,|successfully|However|adjusted|with|. (l_prep) of_20\IN| (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) VT_23\NNP|NONE
12734532
D010665_D009202 NONE PPA_7\NNP|NONE (r_pobj) of_6\IN|with|the (r_prep) abuse_5\NN|reports|involved|.|have|, (l_prep) with_8\IN|the|of (l_pobj) injury_10\NN|NONE
D010665_D009202 NONE Dexatrim_7\NNP|in|PPA)induced|myocardial (r_nmod) injury_11\NN|NONE
D010665_D009202 NONE PPA)-induced_9\VBN|Dexatrim|in|myocardial (r_amod) injury_11\NN|NONE
D010665_D009202 NONE PPA_10\NN|NONE (r_pobj) of_9\IN|the||related|other (r_prep) cases_8\NNS|we|,|In|. (l_acl) related_11\VBN|of|the||other (l_dobj) injury_13\NN|NONE
D010665_D009203 CID Dexatrim_3\NNP|Case|.|: (l_prep) as_7\IN|(|Phenylpropanolamine|) (l_pobj) cause_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) infarction_12\NN|NONE
D010665_D009203 CID Phenylpropanolamine_5\NNP|(|)|as (r_appos) Dexatrim_3\NNP|Case|.|: (l_prep) as_7\IN|(|Phenylpropanolamine|) (l_pobj) cause_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) infarction_12\NN|NONE
D010665_D062787 NONE PPA_7\NNP|NONE (r_pobj) of_6\IN|with|the (r_prep) abuse_5\NN|reports|involved|.|have|, (r_dobj) linked_3\VBN|NONE (l_advcl) involved_16\VBN|reports|.|have|abuse|, (l_nsubjpass) overdose_14\NN|when|especially|is
3535719
D014031_D064420 NONE tobramycin_7\JJ|NONE (l_nsubj) efficacy_1\NN|in|. (l_conj) toxicity_3\NN|Relative|and
D009428_D007239 NONE sulfate_9\NN|NONE (r_pobj) of_7\IN|safety|and|the (r_prep) efficacy_4\NN|prospectively|.|We|in (r_dobj) compared_2\VBD|NONE (l_prep) in_13\IN|prospectively|.|efficacy|We (l_pobj) conjunction_14\NN|NONE (l_prep) in_18\IN|with (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN||immunocompromised (l_pobj) infections_25\NNS|NONE
D010878_D006311 CID piperacillin_12\VB||and (r_conj) netilmicin_10\NNS|NONE (r_pobj) of_8\IN|)|.|four|( (r_prep) %_6\NN|in|and (r_pobj) in_2\IN|Ototoxicity|. (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D010878_D006311 CID piperacillin_24\NN| (r_npadvmod) treated_26\VBN|NONE (r_amod) patients_27\NNS|and| (r_conj) tobramycin_22\NNS|NONE (r_pobj) of_20\IN|||(|) (r_prep) %_18\NN|NONE (r_pobj) in_14\IN|and|% (r_conj) in_2\IN|Ototoxicity|. (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D014031_D006311 CID tobramycin_22\NNS|NONE (r_pobj) of_20\IN|||(|) (r_prep) %_18\NN|NONE (r_pobj) in_14\IN|and|% (r_conj) in_2\IN|Ototoxicity|. (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D014031_D006311 CID tobramycin_18\NNS|NONE (r_pobj) with_17\IN|NONE (r_prep) than_16\IN|with|often (r_prep) reversible_13\JJ|less|and (r_conj) severe_9\JJ|that|ototoxicity (r_acomp) was_7\VBD|.|We (l_nsubj) ototoxicity_6\NN|that|severe
D009428_D006311 CID netilmicin_10\NNS|NONE (r_pobj) of_8\IN|)|.|four|( (r_prep) %_6\NN|in|and (r_pobj) in_2\IN|Ototoxicity|. (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D009428_D006311 CID netilmicin_15\NNS|NONE (r_pobj) with_14\IN|often|than (r_prep) reversible_13\JJ|less|and (r_conj) severe_9\JJ|that|ototoxicity (r_acomp) was_7\VBD|.|We (l_nsubj) ototoxicity_6\NN|that|severe
D009428_D007674 CID netilmicin_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|)|similar|a|%|( (r_prep) proportion_5\NN|NONE (r_pobj) in_2\IN|.|Nephrotoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Nephrotoxicity_0\NN|.|in
D000617_D006311 NONE aminoglycoside_3\NN| (r_npadvmod) associated_5\VBN|NONE (r_amod) ototoxicity_6\NN|that|severe
D010878_D007239 NONE sodium_17\NN|NONE (r_pobj) with_15\IN|in (r_prep) conjunction_14\NN|NONE (l_prep) in_18\IN|with (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN||immunocompromised (l_pobj) infections_25\NNS|NONE
D014031_D007674 CID tobramycin_12\JJ|and (r_conj) netilmicin_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|)|similar|a|%|( (r_prep) proportion_5\NN|NONE (r_pobj) in_2\IN|.|Nephrotoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Nephrotoxicity_0\NN|.|in
D009428_D064420 NONE netilmicin_5\NNS|NONE (r_pobj) of_4\IN|and (r_prep) toxicity_3\NN|Relative|and
D014031_D007239 NONE sulfate_12\NN|or|netilmicin (r_conj) sulfate_9\NN|NONE (r_pobj) of_7\IN|safety|and|the (r_prep) efficacy_4\NN|prospectively|.|We|in (r_dobj) compared_2\VBD|NONE (l_prep) in_13\IN|prospectively|.|efficacy|We (l_pobj) conjunction_14\NN|NONE (l_prep) in_18\IN|with (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN||immunocompromised (l_pobj) infections_25\NNS|NONE
6115999
D011433_D003316 NONE propranolol_10\NN|the (r_amod) group_11\NN|NONE (r_pobj) in_8\IN|to|have (r_prep) occurred_7\VBN|.|disease|is (r_xcomp) known_4\VBN|NONE (l_nsubjpass) disease_2\NN|.|occurred|is
D011433_D011928 CID propranolol_37\NN|NONE (r_dobj) taking_36\VBG|women|and (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|glucose|and|impaired|in|associated|,|,
D001539_D007172 CID bendrofluazide_6\JJ|and|impotence (r_amod) treatment_7\NN|NONE (l_conj) impotence_9\NN|bendrofluazide|and
D001539_D007172 CID bendrofluazide_6\JJ|and|impotence (r_amod) treatment_7\NN|NONE (r_pobj) between_5\IN|an (r_prep) association_4\NN|occurred|,|results|and (r_dobj) show_2\VBP|NONE (l_conj) occurred_14\VBD|association|,|results|and (l_nsubj) impotence_12\NN|.|frequently|in|also
D001539_D006973 NONE bendrofluazide_3\VB|.|Adverse (l_conj) propranolol_5\NN|and|to (l_prep) for_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) hypertension_11\NN|NONE
D001539_D006973 NONE bendrofluazide_21\NN|four|treatment|: (r_amod) groups_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) one_15\CD|NONE (r_pobj) to_14\IN|are|.|randomly|Participants (r_prep) allocated_13\VBN|NONE (l_nsubjpass) Participants_0\NNS|are|.|randomly|to (l_prep) in_1\IN|NONE (l_pobj) trial_7\NN|NONE (l_prep) for_8\IN|the|treatment|Council (l_pobj) hypertension_10\NN|NONE
D001539_D018149 CID bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN|NONE
D001539_D004417 NONE bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN|NONE (l_conj) phenomenon_29\NN|glucose|and|impaired|in|associated|,|, (l_conj) dyspnoea_31\NN|Raynaud|and|in
D001539_D011928 NONE bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN|NONE (l_conj) phenomenon_29\NN|glucose|and|impaired|in|associated|,|,
D011433_D004417 CID propranolol_37\NN|NONE (r_dobj) taking_36\VBG|women|and (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|glucose|and|impaired|in|associated|,|, (l_conj) dyspnoea_31\NN|Raynaud|and|in
D011433_D007172 CID propranolol_20\RB|than (r_dobj) taking_19\VBG|NONE (r_acl) patients_18\NNS|NONE (r_pobj) in_17\IN|.|frequently|impotence|also (r_prep) occurred_14\VBD|association|,|results|and (r_conj) show_2\VBP|NONE (l_dobj) association_4\NN|occurred|,|results|and (l_prep) between_5\IN|an (l_pobj) treatment_7\NN|NONE (l_conj) impotence_9\NN|bendrofluazide|and
D011433_D007172 CID propranolol_20\RB|than (r_dobj) taking_19\VBG|NONE (r_acl) patients_18\NNS|NONE (r_pobj) in_17\IN|.|frequently|impotence|also (r_prep) occurred_14\VBD|association|,|results|and (l_nsubj) impotence_12\NN|.|frequently|in|also
D011433_D006973 NONE propranolol_5\NN|and|to (l_prep) for_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) hypertension_11\NN|NONE
D011433_D006973 NONE propranolol_23\NN|, (r_conj) bendrofluazide_21\NN|four|treatment|: (r_amod) groups_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) one_15\CD|NONE (r_pobj) to_14\IN|are|.|randomly|Participants (r_prep) allocated_13\VBN|NONE (l_nsubjpass) Participants_0\NNS|are|.|randomly|to (l_prep) in_1\IN|NONE (l_pobj) trial_7\NN|NONE (l_prep) for_8\IN|the|treatment|Council (l_pobj) hypertension_10\NN|NONE
D001539_D006073 CID bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN|NONE (l_prep) in_12\IN|glucose|and|phenomenon|impaired|associated|,|, (l_pobj) men_13\NNS|NONE (l_conj) women_15\NNS|in|and (l_conj) gout_17\NN|and
D011433_D018149 NONE propranolol_37\NN|NONE (r_dobj) taking_36\VBG|women|and (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|glucose|and|impaired|in|associated|,|, (r_conj) tolerance_11\NN|NONE
D011433_D006073 NONE propranolol_37\NN|NONE (r_dobj) taking_36\VBG|women|and (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|glucose|and|impaired|in|associated|,|, (r_conj) tolerance_11\NN|NONE (l_prep) in_12\IN|glucose|and|phenomenon|impaired|associated|,|, (l_pobj) men_13\NNS|NONE (l_conj) women_15\NNS|in|and (l_conj) gout_17\NN|and
11847945
D007530_D056486 CID isoflurane_6\RB|NONE (r_pobj) to_5\IN|NONE (r_prep) exposure_4\NN|NONE (r_pobj) after_3\IN|Acute|cholestatic|. (r_prep) hepatitis_2\NN|NONE
D007530_D056486 CID isoflurane_14\RB|NONE (r_pobj) to_10\IN|NONE (r_prep) exposure_9\NN|NONE (r_pobj) following_8\VBG|a|of (r_prep) case_3\NN|.|To (l_prep) of_4\IN|a|following (l_pobj) hepatitis_7\NN|NONE
D007530_D056486 CID Isoflurane_0\NNP|.|hepatitis|,|can (r_nsubj) cause_8\VB|NONE (l_dobj) hepatitis_11\NN|Isoflurane|.|,|can
D004177_D000699 NONE dipyrone_7\NN|NONE (l_prep) for_8\IN|NONE (l_pobj) analgesia_9\NN|NONE
D007530_D002779 CID isoflurane_6\RB|NONE (r_pobj) to_5\IN|NONE (r_prep) exposure_4\NN|NONE (r_pobj) after_3\IN|Acute|cholestatic|. (r_prep) hepatitis_2\NN|NONE
D007530_D002779 CID isoflurane_14\RB|NONE (r_pobj) to_10\IN|NONE (r_prep) exposure_9\NN|NONE (r_pobj) following_8\VBG|a|of (r_prep) case_3\NN|.|To (l_prep) of_4\IN|a|following (l_pobj) hepatitis_7\NN|NONE
D007530_D002779 CID Isoflurane_0\NNP|.|hepatitis|,|can (r_nsubj) cause_8\VB|NONE (l_dobj) hepatitis_11\NN|Isoflurane|.|,|can
12013711
D018967_D001480 NONE risperidone_26\NN|NONE (r_pobj) with_25\IN|.|were|successfully|patients (r_prep) treated_24\VBN|NONE (l_nsubjpass) patients_2\NNS|.|were|successfully|with (l_relcl) had_5\VBD|,|schizophrenic|,|Two (l_conj) developed_16\VBN|history|and|who (l_dobj) EPS_17\NNP|with|had|previously|who
D008238_D010468 NONE LSD_16\NNP|NONE (r_compound) abuse_17\NN|NONE (r_pobj) of_15\IN|past|a (r_prep) history_14\NN|NONE (r_pobj) with_11\IN|,|benign|.|visual|transient|in|associated (r_prep) disturbances_7\NNS|NONE
D008238_D010468 NONE LSD_14\NNP|prior (r_compound) consumption_15\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|"|" (r_acl) flashbacks_9\NNS|NONE (r_pobj) as_7\IN|previously (r_prep) experienced_6\VBN|visual (r_acl) disturbances_4\NNS|imagery|.
D018967_D012559 NONE Risperidone_0\NNP| (r_npadvmod) associated_2\VBN|,|benign|.|visual|transient|in|with (r_amod) disturbances_7\NNS|NONE (l_prep) in_8\IN|,|benign|.|visual|transient|with|associated (l_pobj) patients_10\NNS|NONE (l_amod) schizophrenic_9\JJ|NONE
D018967_D012559 NONE risperidone_26\NN|NONE (r_pobj) with_25\IN|.|were|successfully|patients (r_prep) treated_24\VBN|NONE (l_nsubjpass) patients_2\NNS|.|were|successfully|with (l_amod) schizophrenic_1\JJ|,|had|,|Two
D008238_D001480 NONE LSD_10\NNP|NONE (r_compound) abuse_11\NN|NONE (r_pobj) of_9\IN|a|prior (r_prep) history_8\NN|developed|and|who (r_dobj) had_5\VBD|,|schizophrenic|,|Two (l_conj) developed_16\VBN|history|and|who (l_dobj) EPS_17\NNP|with|had|previously|who
D008238_D012559 NONE LSD_16\NNP|NONE (r_compound) abuse_17\NN|NONE (r_pobj) of_15\IN|past|a (r_prep) history_14\NN|NONE (r_pobj) with_11\IN|,|benign|.|visual|transient|in|associated (r_prep) disturbances_7\NNS|NONE (l_prep) in_8\IN|,|benign|.|visual|transient|with|associated (l_pobj) patients_10\NNS|NONE (l_amod) schizophrenic_9\JJ|NONE
D008238_D012559 NONE LSD_10\NNP|NONE (r_compound) abuse_11\NN|NONE (r_pobj) of_9\IN|a|prior (r_prep) history_8\NN|developed|and|who (r_dobj) had_5\VBD|,|schizophrenic|,|Two (r_relcl) patients_2\NNS|.|were|successfully|with (l_amod) schizophrenic_1\JJ|,|had|,|Two
D018967_D010468 CID Risperidone_0\NNP| (r_npadvmod) associated_2\VBN|,|benign|.|visual|transient|in|with (r_amod) disturbances_7\NNS|NONE
D018967_D010468 CID risperidone_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_dobj) starting_14\VBG|NONE (r_pcomp) after_13\IN|immediately|which (r_prep) appeared_11\VBD|visual|transient|, (r_relcl) disturbances_8\NNS|NONE
D018967_D010468 CID Risperidone_0\NNP|NONE (r_compound) administration_1\NN|was|wore|and (r_nsubjpass) continued_3\VBN|NONE (l_conj) wore_9\VBD|administration|was|and (l_nsubj) disturbances_7\NNS|.|gradually|off
19923525
D009553_D008569 NONE Nimodipine_0\NNP|impairment|. (r_nsubj) prevents_1\VBZ|NONE (l_dobj) impairment_3\NN|Nimodipine|.
D002118_D007022 NONE calcium_13\NN|NONE (r_compound) homeostasis_14\NN|NONE (r_pobj) of_12\IN|the|during (r_prep) preservation_11\NN|NONE (l_prep) during_15\IN|the|of (l_pobj) hypotension_16\NN|NONE
D005996_D008569 CID nitroglycerin_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|memory (r_acl) impairment_3\NN|Nimodipine|.
D009553_D007022 NONE Nimodipine_0\NNP|impairment|. (r_nsubj) prevents_1\VBZ|NONE (l_dobj) impairment_3\NN|Nimodipine|. (l_acl) caused_4\VBN|memory (l_agent) by_5\IN|NONE (l_pobj) hypotension_9\NN|NONE
D009553_D007022 NONE nimodipine_5\NN|at (r_nsubj) administered_9\VBN|the (r_acl) hypothesis_3\NN|We (r_dobj) tested_1\VBD|memory|(|would|.|hypotension (r_ccomp) preserve_19\VB|NONE (l_nsubj) hypotension_17\NN|memory|(|would|.|tested
D009553_D007022 NONE NIMO_7\NNP|that|(|) (r_appos) nimodipine_5\NN|at (r_nsubj) administered_9\VBN|the (r_acl) hypothesis_3\NN|We (r_dobj) tested_1\VBD|memory|(|would|.|hypotension (r_ccomp) preserve_19\VB|NONE (l_nsubj) hypotension_17\NN|memory|(|would|.|tested
D009553_D007022 NONE NIMO_27\NN|+ (r_conj) NTG_25\NNP|, (r_appos) saline_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) injected_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|or|delayed|decrease|, (r_prep) showed_5\VBD|Mice|to|. (r_conj) subjected_1\VBN|NONE (l_prep) to_2\IN|showed|Mice|. (l_pobj) episodes_4\NNS|NONE (l_amod) hypotensive_3\JJ|NONE
D009553_D007022 NONE NIMO_0\NN|disruption|improve|but|. (r_advmod) attenuated_1\VBD|NONE (l_conj) improve_17\VB|disruption|but|.|NIMO (l_prep) in_19\IN|latency|not|did (l_pobj) absence_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) hypotension_23\NN|NONE
D009553_D007022 NONE NIMO_4\NNP|NONE (r_pobj) of_3\IN|The|observed (r_prep) effect_2\NN|,|attributable|.|were|may|have (r_nsubj) been_7\VBN|NONE (l_acomp) attributable_8\JJ|,|effect|.|were|may|have (l_prep) to_9\IN|NONE (l_pobj) preservation_11\NN|NONE (l_prep) during_15\IN|the|of (l_pobj) hypotension_16\NN|NONE
D005996_D007022 CID nitroglycerin_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE
D005996_D007022 CID nitroglycerin_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) onset_12\NN|NONE (r_pobj) at_10\IN|nimodipine (r_prep) administered_9\VBN|the (r_acl) hypothesis_3\NN|We (r_dobj) tested_1\VBD|memory|(|would|.|hypotension (r_ccomp) preserve_19\VB|NONE (l_nsubj) hypotension_17\NN|memory|(|would|.|tested
D005996_D007022 CID NTG)-induced_16\JJ|NONE (r_amod) hypotension_17\NN|memory|(|would|.|tested
D005996_D007022 CID NTG_25\NNP|, (r_appos) saline_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) injected_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|or|delayed|decrease|, (r_prep) showed_5\VBD|Mice|to|. (r_conj) subjected_1\VBN|NONE (l_prep) to_2\IN|showed|Mice|. (l_pobj) episodes_4\NNS|NONE (l_amod) hypotensive_3\JJ|NONE
D005996_D007022 CID NTG_31\NNP|respectively|) (r_dobj) delayed_30\VBN|or|compared|decrease|, (r_conj) showed_5\VBD|Mice|to|. (r_conj) subjected_1\VBN|NONE (l_prep) to_2\IN|showed|Mice|. (l_pobj) episodes_4\NNS|NONE (l_amod) hypotensive_3\JJ|NONE
D005996_D007022 CID NTG_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) injection_7\NN|impairment|,|had|In|.|after|, (r_nsubj) produced_13\VBD|NONE (l_conj) had_30\VBD|injection|impairment|,|In|.|after|, (l_advcl) delayed_27\VBN|effect (l_dobj) hypotension_29\NN|whereas
D005996_D007022 CID NTG_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_agent) caused_11\VBN|term (r_acl) memory_10\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) consolidation_5\NN|NONE (r_pobj) in_4\IN|the (r_prep) disruption_3\NN|improve|but|.|NIMO (r_dobj) attenuated_1\VBD|NONE (l_conj) improve_17\VB|disruption|but|.|NIMO (l_prep) in_19\IN|latency|not|did (l_pobj) absence_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) hypotension_23\NN|NONE
6436733
D000641_D006970 CID Ammonia_0\NN|higher|in|.|,|)|were (r_nsubj) was_4\VBD|NONE (l_prep) in_6\IN|higher|.|Ammonia|,|)|were (l_pobj) patients_7\NNS|NONE (l_relcl) complained_14\VBD|NONE (l_prep) of_15\IN|during|,|,|who|than (l_pobj) drowsiness_16\NN|NONE
D000641_D006970 CID NH3_2\NNP|NONE (r_appos) Ammonia_0\NN|higher|in|.|,|)|were (r_nsubj) was_4\VBD|NONE (l_prep) in_6\IN|higher|.|Ammonia|,|)|were (l_pobj) patients_7\NNS|NONE (l_relcl) complained_14\VBD|NONE (l_prep) of_15\IN|during|,|,|who|than (l_pobj) drowsiness_16\NN|NONE
D014635_D006970 CID VPA_35\NNP|plasma (r_compound) levels_37\NNS|similar|although (r_nsubj) were_38\VBD|higher|in|.|Ammonia|,|) (r_advcl) was_4\VBD|NONE (l_prep) in_6\IN|higher|.|Ammonia|,|)|were (l_pobj) patients_7\NNS|NONE (l_relcl) complained_14\VBD|NONE (l_prep) of_15\IN|during|,|,|who|than (l_pobj) drowsiness_16\NN|NONE
D014635_D004827 NONE acid_1\NN|.|to|was (r_nsubjpass) given_6\VBN|NONE (l_dative) to_7\IN|.|acid|was (l_pobj) patients_10\NNS|NONE (l_amod) epileptic_9\JJ||treated
D014635_D004827 NONE VPA_3\NNP|)|(|Valproic (r_appos) acid_1\NN|.|to|was (r_nsubjpass) given_6\VBN|NONE (l_dative) to_7\IN|.|acid|was (l_pobj) patients_10\NNS|NONE (l_amod) epileptic_9\JJ||treated
20533999
D004298_D020258 NONE Dopamine_0\NN|essential|not|. (r_nsubj) is_1\VBZ|NONE (l_acomp) essential_3\JJ|Dopamine|not|. (l_prep) for_4\IN|NONE (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) neurotoxicity_11\NN|NONE
D004298_D020258 NONE DA_29\NNP|induced (r_compound) neurotoxicity_30\NN|NONE
D004298_D020258 NONE DA_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) deficient_10\JJ|to (r_acomp) be_9\VB|genetically|develop|that|mice (r_xcomp) engineered_7\VBN|Further|,|.|we (l_conj) develop_14\VBP|genetically|that|be|mice (l_dobj) neurotoxicity_16\NN|long|,
D004298_D020258 NONE DA_7\NNP|not|and|essential|suggest|that (r_nsubj) is_8\VBZ|.|Taken|findings|, (l_acomp) essential_10\JJ|not|and|DA|suggest|that (l_prep) for_11\IN|NONE (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) neurotoxicity_19\NN|NONE
D004298_D020258 NONE DA_26\JJ|NONE (r_pobj) of_25\IN|NONE (r_prep) independent_24\JJ|NONE (r_amod) mechanisms_23\NNS|investigation|that (r_nsubj) warrant_27\NN|NONE (r_ccomp) suggest_21\VBP|not|and|essential|DA|that (r_conj) is_8\VBZ|.|Taken|findings|, (l_acomp) essential_10\JJ|not|and|DA|suggest|that (l_prep) for_11\IN|NONE (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) neurotoxicity_19\NN|NONE
D004298_D009461 NONE DA_13\NNP|unilateral (r_compound) deficits_14\NNS|to (r_dobj) have_10\VB|genetically|mice|that|develop (r_xcomp) engineered_8\VBN|we|,|.|In (l_conj) develop_15\VBP|genetically|mice|that|have (l_dobj) deficits_20\NNS|NONE
D019805_D020258 NONE tyrosine_24\NN|NONE (l_prep) on_25\IN||para (l_pobj) neurotoxicity_30\NN|NONE
D008694_D020258 CID methamphetamine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) neurotoxicity_11\NN|NONE
D008694_D020258 CID METH_26\NNP| (r_npadvmod) induced_28\VBN|DA (r_amod) neurotoxicity_30\NN|NONE
D008694_D020258 CID METH_15\NNP|NONE (r_compound) neurotoxicity_16\NN|long|,
D008694_D020258 CID METH_25\NNP|NONE (r_pobj) of_24\IN|the|thermic (r_prep) effects_23\NNS|are|as (r_nsubjpass) preserved_27\VBN|as (r_advcl) long_19\RB|neurotoxicity|, (r_advmod) develop_14\VBP|genetically|that|be|mice (l_dobj) neurotoxicity_16\NN|long|,
D008694_D020258 CID METH_15\NNP| (r_npadvmod) induced_17\VBN|dopaminergic (r_amod) neurotoxicity_19\NN|NONE
D007980_D020258 NONE dihydroxyphenylalanine_11\NN|NONE (r_pobj) of_8\IN|the|reverse|reported (r_prep) ability_7\NN|also|is|by|that (l_acl) reverse_13\VB|of|the|reported (l_dobj) effect_16\NN|to (l_prep) of_17\IN|protective|the (l_pobj) tyrosine_24\NN|NONE (l_prep) on_25\IN||para (l_pobj) neurotoxicity_30\NN|NONE
D008694_D009461 NONE METH_16\NN| (r_npadvmod) induced_18\VBN|are|dopaminergic (r_amod) deficits_20\NNS|NONE
D004298_D064420 NONE dopamine_5\NN|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ|It|widely|.|is (l_dobj) methamphetamine_10\NN|decrease|dopamine|that (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE dopamine_5\NN|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN|because|drugs|enhance|,
D004298_D064420 NONE dopamine_5\NN|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_advcl) enhance_35\VB|because|drugs|toxicity|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE DA_7\NNP|NONE (r_appos) dopamine_5\NN|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ|It|widely|.|is (l_dobj) methamphetamine_10\NN|decrease|dopamine|that (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE DA_7\NNP|NONE (r_appos) dopamine_5\NN|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN|because|drugs|enhance|,
D004298_D064420 NONE DA_7\NNP|NONE (r_appos) dopamine_5\NN|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_advcl) enhance_35\VB|because|drugs|toxicity|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE DA_24\NNP|NONE (r_compound) neurotransmission_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) interfere_22\VBP|NONE (r_relcl) drugs_20\NNS|because|toxicity|enhance|, (r_nsubj) decrease_26\NN|dopamine|that|methamphetamine (r_advcl) mediates_9\VBZ|It|widely|.|is (l_dobj) methamphetamine_10\NN|decrease|dopamine|that (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE DA_24\NNP|NONE (r_compound) neurotransmission_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) interfere_22\VBP|NONE (r_relcl) drugs_20\NNS|because|toxicity|enhance|, (r_nsubj) decrease_26\NN|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN|because|drugs|enhance|,
D004298_D064420 NONE DA_24\NNP|NONE (r_compound) neurotransmission_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) interfere_22\VBP|NONE (r_relcl) drugs_20\NNS|because|toxicity|enhance|, (r_nsubj) decrease_26\NN|dopamine|that|methamphetamine (l_advcl) enhance_35\VB|because|drugs|toxicity|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE DA_33\NNP|NONE (r_compound) neurotransmission_34\NN|that (r_dobj) increase_32\VBP|NONE (r_relcl) drugs_30\NNS|whereas|toxicity (r_nsubj) enhance_35\VB|because|drugs|toxicity|, (r_advcl) decrease_26\NN|dopamine|that|methamphetamine (r_advcl) mediates_9\VBZ|It|widely|.|is (l_dobj) methamphetamine_10\NN|decrease|dopamine|that (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE DA_33\NNP|NONE (r_compound) neurotransmission_34\NN|that (r_dobj) increase_32\VBP|NONE (r_relcl) drugs_30\NNS|whereas|toxicity (r_nsubj) enhance_35\VB|because|drugs|toxicity|, (r_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN|because|drugs|enhance|,
D004298_D064420 NONE DA_33\NNP|NONE (r_compound) neurotransmission_34\NN|that (r_dobj) increase_32\VBP|NONE (r_relcl) drugs_30\NNS|whereas|toxicity (r_nsubj) enhance_35\VB|because|drugs|toxicity|, (l_dobj) toxicity_36\NN|drugs|whereas
D008694_D064420 NONE methamphetamine_10\NN|decrease|dopamine|that (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D008694_D064420 NONE methamphetamine_10\NN|decrease|dopamine|that (r_dobj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN|because|drugs|enhance|,
D008694_D064420 NONE methamphetamine_10\NN|decrease|dopamine|that (r_dobj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_advcl) enhance_35\VB|because|drugs|toxicity|, (l_dobj) toxicity_36\NN|drugs|whereas
D008694_D064420 NONE METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D008694_D064420 NONE METH)-induced_12\JJ|(|, (r_acl) methamphetamine_10\NN|decrease|dopamine|that (r_dobj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN|because|drugs|enhance|,
D008694_D064420 NONE METH)-induced_12\JJ|(|, (r_acl) methamphetamine_10\NN|decrease|dopamine|that (r_dobj) mediates_9\VBZ|It|widely|.|is (l_advcl) decrease_26\NN|dopamine|that|methamphetamine (l_advcl) enhance_35\VB|because|drugs|toxicity|, (l_dobj) toxicity_36\NN|drugs|whereas
15517007
D018943_D006331 NONE anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN|caution|,|is|However|. (l_prep) in_14\IN|are|patients|cyclophosphamide|for|,|when|, (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) damage_21\NN|NONE
D008942_D012595 NONE mitoxantrone_11\NN|such (r_pobj) as_10\IN|NONE (r_prep) anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN|caution|,|is|However|. (l_dobj) patients_28\NNS|in|are|cyclophosphamide|for|,|when|, (l_compound) sclerosis_27\NN|systemic
D003520_D006331 CID cyclophosphamide_6\NN|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN|caution|,|is|However|. (l_prep) in_14\IN|are|patients|cyclophosphamide|for|,|when|, (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) damage_21\NN|NONE
D018943_D012595 NONE anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN|caution|,|is|However|. (l_dobj) patients_28\NNS|in|are|cyclophosphamide|for|,|when|, (l_compound) sclerosis_27\NN|systemic
D008942_D006331 CID mitoxantrone_11\NN|such (r_pobj) as_10\IN|NONE (r_prep) anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN|caution|,|is|However|. (l_prep) in_14\IN|are|patients|cyclophosphamide|for|,|when|, (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) damage_21\NN|NONE
D003520_D012595 NONE cyclophosphamide_6\NN|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN|caution|,|is|However|. (l_dobj) patients_28\NNS|in|are|cyclophosphamide|for|,|when|, (l_compound) sclerosis_27\NN|systemic
16157917
C047781_C562694 NONE Lamotrigine_0\NNP|NONE (l_acl) associated_1\VBD|. (l_prep) with_2\IN|NONE (l_pobj) exacerbation_3\NN|NONE (l_prep) in_8\IN|or|myoclonus (l_pobj) epilepsies_11\NNS|NONE
C047781_C562694 NONE lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|with|experienced|. (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE
C047781_C562694 NONE lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|with|experienced|. (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE (l_appos) IGE_7\NNP|)|generalized|idiopathic|(
C047781_C562694 NONE LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|with|experienced|. (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE
C047781_C562694 NONE LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|with|experienced|. (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE (l_appos) IGE_7\NNP|)|generalized|idiopathic|(
C047781_D009207 CID Lamotrigine_0\NNP|NONE (l_acl) associated_1\VBD|. (l_prep) with_2\IN|NONE (l_pobj) exacerbation_3\NN|NONE (l_conj) myoclonus_7\NN|or|in
C047781_D009207 CID lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|with|.|patients (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE
C047781_D009207 CID lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|with|.|patients (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE (l_appos) MJ_25\NNP|(|)|myoclonic
C047781_D009207 CID LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|with|.|patients (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE
C047781_D009207 CID LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|with|.|patients (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE (l_appos) MJ_25\NNP|(|)|myoclonic
C047781_D009207 CID LTG_4\NNP|in|MJ|In|.|, (r_nsubj) exacerbated_5\VBD|NONE (l_dobj) MJ_6\NNP|in|In|.|LTG|,
C047781_D009207 CID LTG_3\NNP|NONE (r_compound) dose_4\NN|was|when|by (r_nsubjpass) decreased_6\VBN|MJ|. (r_advcl) disappeared_1\VBD|NONE (l_nsubj) MJ_0\NNP|.|decreased
C047781_D009207 CID LTG_4\NNP|MJ|,|in|,|In|.|with (r_nsubj) exacerbated_5\VBD|NONE (l_dobj) MJ_6\NNP|,|LTG|in|,|In|.|with
C047781_D009207 CID LTG_4\NNP|MJ|,|in|,|In|.|with (r_nsubj) exacerbated_5\VBD|NONE (l_prep) with_15\IN|MJ|,|LTG|in|,|In|. (l_pobj) status_17\NN|NONE
C047781_D009207 CID LTG_22\NNP|NONE (r_compound) withdrawal_23\NN|NONE (r_pobj) after_21\IN|that|only (r_prep) ceased_20\VBD|myoclonic (r_relcl) status_17\NN|NONE (r_pobj) with_15\IN|MJ|,|LTG|in|,|In|. (r_prep) exacerbated_5\VBD|NONE (l_dobj) MJ_6\NNP|,|LTG|in|,|In|.|with
C047781_D009207 CID LTG_22\NNP|NONE (r_compound) withdrawal_23\NN|NONE (r_pobj) after_21\IN|that|only (r_prep) ceased_20\VBD|myoclonic (r_relcl) status_17\NN|NONE
12911170
D002939_D000744 NONE Ciprofloxacin_0\NNP|nephritis|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephritis_5\NN|.|Ciprofloxacin| (l_conj) anemia_9\NN|interstitial|acute|and
D002939_D000744 NONE ciprofloxacin_9\NNS| (r_npadvmod) induced_11\VBN|and|anemia|interstitial (r_amod) nephritis_13\NN|NONE (l_conj) anemia_17\NN|and|induced|interstitial
D002939_D000743 CID Ciprofloxacin_0\NNP|been|has|.|with (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|been|has|.|Ciprofloxacin (l_pobj) effects_7\NNS|NONE (l_prep) including_8\VBG|several|side (l_pobj) nephritis_10\NN|NONE (l_conj) anemia_13\NN|and|interstitial
D002939_D009395 CID Ciprofloxacin_0\NNP|nephritis|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephritis_5\NN|.|Ciprofloxacin|
D002939_D009395 CID Ciprofloxacin_0\NNP|been|has|.|with (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|been|has|.|Ciprofloxacin (l_pobj) effects_7\NNS|NONE (l_prep) including_8\VBG|several|side (l_pobj) nephritis_10\NN|NONE
D002939_D009395 CID ciprofloxacin_9\NNS| (r_npadvmod) induced_11\VBN|and|anemia|interstitial (r_amod) nephritis_13\NN|NONE
D013256_D000743 NONE steroid_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) initiation_8\NN|and|the (r_conj) drug_6\NN|NONE (r_dobj) stopping_4\VBG|NONE (r_pcomp) after_3\IN|.|anemia (r_prep) improved_2\VBD|NONE (l_nsubj) anemia_1\NN|after|.
2886572
D004837_D006973 CID epinephrine_7\NN| (r_npadvmod) induced_9\VBN|hypertensive (r_amod) rats_11\NNS|NONE (l_amod) hypertensive_10\JJ|induced
2322844
D015232_D006930 CID E2_1\NNP|lasted|,|effect|but (r_nsubj) showed_2\VBD|NONE (l_dobj) effect_5\NN|lasted|,|E|but (l_amod) hyperalgesic_4\JJ|a|at
D015232_D006930 CID E2-induced_3\NNP|prostaglandin (r_amod) hyperalgesia_4\NN|but|,|was|Conversely|by|by|.
D015232_D006930 CID E2_9\NNP|both|prostaglandin|and (r_conj) D2_6\NN|hyperalgesia|that|in|but|, (r_nsubj) exert_10\VBP|results|. (l_dobj) hyperalgesia_11\NN|that|in|D|but|,
C053876_D006930 NONE AH6809_28\NN|not (r_pobj) by_27\IN|by|effect|was|.|but (r_agent) blocked_7\VBN|NONE (l_nsubjpass) effect_2\NN|by|was|.|but|by (l_amod) hyperalgesic_1\JJ|The|of
C053876_D006930 NONE AH6809_8\NN|NONE (r_pobj) by_7\IN|but|,|was|Conversely|hyperalgesia|by|. (r_agent) blocked_6\VBN|NONE (l_nsubjpass) hyperalgesia_4\NN|but|,|was|Conversely|by|by|.
D011453_D006930 NONE pg_10\NN|NONE (r_pobj) of_8\IN|to (r_prep) doses_7\NNS|NONE (r_pobj) at_6\IN|a|hyperalgesic (r_prep) effect_5\NN|lasted|,|E|but (l_amod) hyperalgesic_4\JJ|a|at
D015237_D010146 NONE alpha_2\NN|effect|. (r_nsubj) had_3\VBD|NONE (l_dobj) effect_5\NN|alpha|. (l_prep) on_6\IN|little (l_pobj) responses_8\NNS|NONE (l_compound) pain_7\NN|NONE
D019342_D010146 NONE acid_21\NN|hot|and (r_conj) plate_18\NN|writhing (r_dobj) using_16\VBG|NONE (r_pcomp) by_15\IN|effects|were|. (r_prep) evaluated_14\VBN|NONE (l_nsubjpass) effects_1\NNS|by|were|. (l_prep) on_7\IN|of|The (l_pobj) responses_9\NNS|NONE (l_compound) pain_8\NN|in
D011453_D010146 NONE prostaglandins_6\NNS|NONE (r_pobj) of_5\IN|intrathecal (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The|on (r_prep) effects_1\NNS|by|were|. (l_prep) on_7\IN|of|The (l_pobj) responses_9\NNS|NONE (l_compound) pain_8\NN|in
D015230_D006930 CID D2_1\NN|during|action|. (r_nsubj) had_10\VBD|NONE (l_dobj) action_13\NN|D|during|. (l_amod) hyperalgesic_12\JJ|a|on
D015230_D006930 CID D2_32\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) that_29\DT|NONE (r_pobj) than_28\IN|shorter|)|(| (r_prep) min_26\NN|effect|. (r_dobj) lasted_20\VBD|,|E|effect|but (r_conj) showed_2\VBD|NONE (l_dobj) effect_5\NN|lasted|,|E|but (l_amod) hyperalgesic_4\JJ|a|at
D015230_D006930 CID D2_5\NN|NONE (r_pobj) of_3\IN|hyperalgesic|The (r_prep) effect_2\NN|by|was|.|but|by (l_amod) hyperalgesic_1\JJ|The|of
D015230_D006930 CID D2_6\NN|hyperalgesia|that|in|but|, (r_nsubj) exert_10\VBP|results|. (l_dobj) hyperalgesia_11\NN|that|in|D|but|,
6150641
D002927_D006402 NONE cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D002927_D006402 NONE cimetidine_60\NN|NONE (r_compound) therapy_61\NN|NONE (r_pobj) with_59\IN|than (r_prep) seen_58\VBN|a|lower|creatinine (r_advcl) level_56\NN|NONE (r_pobj) with_50\IN|.|therapy|was (r_prep) associated_49\VBN|,|was|but|Treatment|not|with (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D002927_D007172 CID cimetidine_12\NN|while|and|disappeared (r_dobj) taking_11\VBG|changes|percent|. (r_advcl) developed_5\VBD|NONE (l_dobj) changes_7\NNS|taking|percent|. (l_conj) impotence_9\NN|breast|or
D002927_D007172 CID cimetidine_21\NN|was|by|when (r_nsubjpass) replaced_23\VBN|changes|in (r_advcl) disappeared_19\VBD|while|cimetidine|and (r_conj) taking_11\VBG|changes|percent|. (r_advcl) developed_5\VBD|NONE (l_dobj) changes_7\NNS|taking|percent|. (l_conj) impotence_9\NN|breast|or
D002927_D056486 NONE cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D002927_D056486 NONE cimetidine_60\NN|NONE (r_compound) therapy_61\NN|NONE (r_pobj) with_59\IN|than (r_prep) seen_58\VBN|a|lower|creatinine (r_advcl) level_56\NN|NONE (r_pobj) with_50\IN|.|therapy|was (r_prep) associated_49\VBN|,|was|but|Treatment|not|with (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D003404_D006402 NONE creatinine_55\NN|a|lower|seen (r_compound) level_56\NN|NONE (r_pobj) with_50\IN|.|therapy|was (r_prep) associated_49\VBN|,|was|but|Treatment|not|with (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D003404_D056486 NONE creatinine_55\NN|a|lower|seen (r_compound) level_56\NN|NONE (r_pobj) with_50\IN|.|therapy|was (r_prep) associated_49\VBN|,|was|but|Treatment|not|with (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D011899_D056486 NONE ranitidine_18\NN|,|months|)|or (r_conj) median_12\NN|(|months|; (r_conj) cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D011899_D056486 NONE ranitidine_46\NN|NONE (r_compound) therapy_47\NN|.|with|was (r_nsubjpass) associated_49\VBN|,|was|but|Treatment|not|with (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D011899_D007172 NONE ranitidine_25\NN|NONE (r_pobj) by_24\IN|cimetidine|was|when (r_agent) replaced_23\VBN|changes|in (r_advcl) disappeared_19\VBD|while|cimetidine|and (r_conj) taking_11\VBG|changes|percent|. (r_advcl) developed_5\VBD|NONE (l_dobj) changes_7\NNS|taking|percent|. (l_conj) impotence_9\NN|breast|or
D011899_D006402 NONE ranitidine_18\NN|,|months|)|or (r_conj) median_12\NN|(|months|; (r_conj) cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
D011899_D006402 NONE ranitidine_46\NN|NONE (r_compound) therapy_47\NN|.|with|was (r_nsubjpass) associated_49\VBN|,|was|but|Treatment|not|with (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN|NONE
15075188
D011692_D001201 CID PAN_4\NNP|NONE (r_compound) treatment_5\NN|proteinuria|After|, (r_nsubj) induced_6\VBD|.|,|excretion (r_advcl) decreased_12\VBD|NONE (l_dobj) excretion_15\NN|.|,|induced (l_conj) ascites_19\NNS|,|sodium|and
D012964_D001201 NONE sodium_14\NN|,|and|ascites (r_compound) excretion_15\NN|.|,|induced (l_conj) ascites_19\NNS|,|sodium|and
D012964_D004487 NONE sodium_6\NN|and|edema (r_compound) retention_7\NN|NONE (l_conj) edema_10\NN|and|sodium
D012964_D009404 NONE sodium_6\NN|and|edema (r_compound) retention_7\NN|NONE (r_pobj) by_5\IN|often|.|syndrome|is (r_agent) accompanied_4\VBN|NONE (l_nsubjpass) syndrome_1\NN|often|.|by|is
D012964_D009404 NONE sodium_34\NN|the|associated (r_compound) retention_35\NN|NONE (l_acl) associated_36\VBN|sodium|the (l_prep) with_37\IN|NONE (l_pobj) syndrome_42\NN|NONE
D011692_D034141 CID PAN_4\NNP|NONE (r_compound) treatment_5\NN|proteinuria|After|, (r_nsubj) induced_6\VBD|.|,|excretion (l_dobj) proteinuria_8\NN|treatment|After|, (l_appos) hypoalbuminemia_10\NN|,|significant
D012964_D011507 NONE sodium_14\NN|,|and|ascites (r_compound) excretion_15\NN|.|,|induced (r_dobj) decreased_12\VBD|NONE (l_advcl) induced_6\VBD|.|,|excretion (l_dobj) proteinuria_8\NN|treatment|After|,
D012964_D034141 NONE sodium_14\NN|,|and|ascites (r_compound) excretion_15\NN|.|,|induced (r_dobj) decreased_12\VBD|NONE (l_advcl) induced_6\VBD|.|,|excretion (l_dobj) proteinuria_8\NN|treatment|After|, (l_appos) hypoalbuminemia_10\NN|,|significant
D011692_D009404 CID aminonucleoside_11\RB| (r_advmod) induced_13\VBN|puromycin|nephrotic|in (r_amod) syndrome_15\NN|NONE
D011692_D009404 CID PAN_38\NNP| (r_npadvmod) induced_40\VBN|nephrotic (r_amod) syndrome_42\NN|NONE
D011692_D011507 CID PAN_4\NNP|NONE (r_compound) treatment_5\NN|proteinuria|After|, (r_nsubj) induced_6\VBD|.|,|excretion (l_dobj) proteinuria_8\NN|treatment|After|,
16006300
C019248_D006934 NONE Pamidronate_0\JJ|NONE (r_compound) treatment_1\NN|is|,|in|with|. (r_nsubjpass) associated_3\VBN|NONE (l_prep) in_11\IN|is|,|with|treatment|. (l_pobj) cases_12\NNS|even (l_prep) of_13\IN|NONE (l_pobj) hypercalcemia_16\NN|NONE
D002118_D006934 NONE calcium_18\NN|>|(|and|review (r_dobj) corrected_16\VBN|We|.|data (r_parataxis) report_1\VBP|NONE (l_dobj) data_6\NNS|We|.|corrected (l_prep) in_7\IN|the|clinical (l_pobj) patients_9\NNS|NONE (l_relcl) presented_11\VBD| (l_prep) with_12\IN|who (l_pobj) hypercalcemia_14\NN|NONE
D002118_D006934 NONE calcium_18\NN|>|(|and|review (r_dobj) corrected_16\VBN|We|.|data (l_conj) review_28\VB|>|(|calcium|and (l_dobj) literature_31\NN|NONE (l_prep) on_32\IN|pertinent|the (l_pobj) syndrome_36\NN|NONE
D002119_D064420 NONE carbonate_1\NN|:|syndrome|. (r_compound) toxicity_2\NN|NONE
C019248_D006996 CID pamidronate_10\JJ|NONE (l_relcl) caused_22\VBD|.|mg|intravenously|patients|, (l_dobj) hypocalcemia_24\NN|which
C019248_D006996 CID Pamidronate_0\JJ|NONE (r_compound) treatment_1\NN|is|,|in|with|. (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|is|,|in|treatment|. (l_pobj) risk_6\NN|NONE (l_prep) for_7\IN|considerable (l_pobj) hypocalcemia_8\NN|NONE
D002119_D006934 CID carbonate_1\NN|:|syndrome|. (r_compound) toxicity_2\NN|NONE (l_appos) syndrome_9\NN|carbonate|:|.
D002119_D006934 CID carbonate_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) hypercalcemia_9\NN|NONE
D002119_D006934 CID carbonate_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) hypercalcemia_9\NN|NONE (r_pobj) with_4\IN| (r_prep) patients_3\NNS|gain|and|.|To (r_dobj) describe_1\VB|NONE (l_conj) gain_11\VB|patients|and|.|To (l_dobj) insights_12\NNS|NONE (l_prep) into_13\IN|NONE (l_pobj) cause_15\NN|NONE (l_prep) of_18\IN|and|management|the (l_pobj) syndrome_23\NN|NONE
D002119_D006934 CID carbonate_23\NN|NONE (r_pobj) of_19\IN|in|small (r_prep) amounts_18\NNS|NONE (r_pobj) by_16\IN|can|be (r_agent) precipitated_15\VBN|cause|and|.|may|syndrome (r_conj) be_5\VB|NONE (l_nsubj) syndrome_3\NN|precipitated|cause|and|.|may
D002119_D006934 CID carbonate_23\NN|NONE (r_pobj) of_19\IN|in|small (r_prep) amounts_18\NNS|NONE (r_pobj) by_16\IN|can|be (r_agent) precipitated_15\VBN|cause|and|.|may|syndrome (r_conj) be_5\VB|NONE (l_attr) cause_8\NN|precipitated|and|.|may|syndrome (l_prep) of_9\IN|common|a (l_pobj) hypercalcemia_11\NN|NONE
D002118_D006996 NONE calcium_7\NN|higher|received|the (r_compound) concentrations_8\NNS|NONE (r_pobj) with_3\IN|The| (r_prep) patients_2\NNS|.|mg|intravenously|caused|, (r_nsubj) pamidronate_10\JJ|NONE (l_relcl) caused_22\VBD|.|mg|intravenously|patients|, (l_dobj) hypocalcemia_24\NN|which
C097949_D000471 NONE D_27\JJ|NONE (r_compound) concentrations_28\NNS|,|and|related (r_conj) peptide_23\NN|(|,|low|PTH|parathyroid|) (r_conj) hormone_15\NN|metabolic|,|relative|and (r_conj) alkalosis_10\NN|acute|renal|,
C097949_D058186 NONE D_27\JJ|NONE (r_compound) concentrations_28\NNS|,|and|related (r_conj) peptide_23\NN|(|,|low|PTH|parathyroid|) (r_conj) hormone_15\NN|metabolic|,|relative|and (r_conj) alkalosis_10\NN|acute|renal|, (r_conj) insufficiency_6\NN|patients|.
3115150
D015760_D009127 CID alfentanil_3\NN| (r_npadvmod) induced_5\VBN|muscle (r_amod) rigidity_7\NN|pretreatment|.
D015760_D009127 CID alfentanil_29\NN|pretreatment|significantly|.|rigidity (r_advcl) attenuated_14\VBD|NONE (l_dobj) rigidity_17\NN|alfentanil|pretreatment|significantly|.
D015760_D009127 CID alfentanil_15\NNS|NONE (r_pobj) by_14\IN|NONE (r_agent) produced_13\VBN|the (r_acl) rigidity_12\NN|to|significantly
D015760_D009127 CID alfentanil_19\NNS|NONE (r_pobj) by_18\IN|,|Despite|animals (r_agent) followed_17\VBN|.|motionless (l_prep) Despite_0\IN|by|,|animals (l_pobj) absence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) rigidity_4\NN|NONE
D015760_D009127 CID alfentanil_35\NN|alone (r_advmod) receiving_34\VBG|NONE (r_acl) animals_33\NNS|than (r_nsubj) were_32\VBD|less|to (r_advcl) responsive_27\JJ|,|,|and (r_conj) flaccid_23\JJ|NONE (r_conj) motionless_21\JJ|.|followed (r_acomp) were_20\VBD|NONE (l_csubj) followed_17\VBN|.|motionless (l_prep) Despite_0\IN|by|,|animals (l_pobj) absence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) rigidity_4\NN|NONE
D007650_D009127 NONE Ketanserin_0\JJ|NONE (r_compound) pretreatment_1\NN|rigidity|. (r_nsubj) reverses_2\VBZ|NONE (l_dobj) rigidity_7\NN|pretreatment|.
D007650_D009127 NONE ketanserin_3\NN|NONE (r_pobj) with_2\IN|antagonist|,|,|Systemic (r_prep) pretreatment_1\NN|alfentanil|significantly|.|rigidity (r_nsubj) attenuated_14\VBD|NONE (l_dobj) rigidity_17\NN|alfentanil|pretreatment|significantly|.
D007650_D009127 NONE ketanserin_9\JJ|that (r_dobj) received_8\VBD|mg/kg (r_relcl) animals_6\NNS|by|,|Despite (r_nsubj) followed_17\VBN|.|motionless (l_prep) Despite_0\IN|by|,|animals (l_pobj) absence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) rigidity_4\NN|NONE
D012701_D002318 NONE serotonin_3\NN|NONE (r_compound) antagonists_4\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|.|,|may|useful|be (r_nsubj) be_6\VB|NONE (l_advcl) be_20\VB|Pretreatment|.|,|may|useful (l_xcomp) assess_23\VB|studies|although|will|necessary (l_dobj) interaction_25\NN|to (l_prep) of_26\IN|the (l_pobj) CNS_29\NNP|NONE (l_conj) cardiovascular_31\JJ|,|enhanced (l_conj) depression_35\NN|and|,
D002707_D009127 NONE Chlordiazepoxide_0\VB|.|influence (r_nsubj) failed_7\VBD|NONE (l_xcomp) influence_10\VB|.|Chlordiazepoxide (l_dobj) rigidity_12\NN|to|significantly
D012701_D009127 NONE serotonin_9\NN|specific|receptor|a (r_compound) antagonist_11\NN|,|,|with|Systemic (r_appos) pretreatment_1\NN|alfentanil|significantly|.|rigidity (r_nsubj) attenuated_14\VBD|NONE (l_dobj) rigidity_17\NN|alfentanil|pretreatment|significantly|.
D012701_D009127 NONE serotonin_3\NN|NONE (r_compound) antagonists_4\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|.|,|may|useful|be (r_nsubj) be_6\VB|NONE (l_acomp) useful_8\JJ|Pretreatment|.|,|may|be (l_prep) in_9\IN|clinically (l_pcomp) attenuating_10\VBG|NONE (l_dobj) rigidity_14\NN|NONE
D012701_D012131 NONE serotonin_3\NN|NONE (r_compound) antagonists_4\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|.|,|may|useful|be (r_nsubj) be_6\VB|NONE (l_advcl) be_20\VB|Pretreatment|.|,|may|useful (l_xcomp) assess_23\VB|studies|although|will|necessary (l_dobj) interaction_25\NN|to (l_prep) of_26\IN|the (l_pobj) CNS_29\NNP|NONE (l_conj) cardiovascular_31\JJ|,|enhanced (l_conj) depression_35\NN|and|,
18513945
D010121_D007022 CID Oxytocin_0\NN|uterotonic|. (r_nsubj) is_1\VBZ|NONE (l_attr) uterotonic_5\NN|.|Oxytocin (l_relcl) cause_8\VB|a|used (l_dobj) hypotension_13\NN|that|can|,|given
D010121_D007022 CID Oxytocin_0\NN| (r_npadvmod) induced_2\VBN|at (r_amod) hypotension_3\NN|incorrectly|may|be|.|to
D010121_D007022 CID oxytocin_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) response_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Hypotension_0\NN|with|was|.
D010121_D020521 NONE oxytocin_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) response_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Hypotension_0\NN|with|was|. (r_nsubjpass) associated_6\VBN|NONE (l_prep) with_7\IN|was|Hypotension|. (l_pobj) decrease_9\NN|NONE (l_conj) increase_17\NN|in|a|and (l_prep) in_18\IN|compensatory|a (l_pobj) volume_20\NN|NONE (l_compound) stroke_19\NN|rate|,
D010121_D006473 NONE Oxytocin_0\NN| (r_npadvmod) induced_2\VBN|at (r_amod) hypotension_3\NN|incorrectly|may|be|.|to (r_nsubjpass) attributed_10\VBN|NONE (l_prep) to_11\IN|incorrectly|hypotension|may|be|. (l_pobj) loss_13\NN|NONE
2722224
D006854_D006973 CID Hydrocortisone_0\NNP|:||hypertension|responsiveness|. (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypertension_3\NN|:||Hydrocortisone|responsiveness|.
D006854_D006973 CID hydrocortisone_7\NN|NONE (r_pobj) with_6\IN|blood (r_prep) pressure_5\NN|NONE
D006854_D016534 NONE hydrocortisone_7\NN|NONE (r_pobj) with_6\IN|blood (r_prep) pressure_5\NN|NONE (r_dobj) resting_3\VBG|NONE (r_pcomp) in_2\IN|The (r_prep) rise_1\NN|.|is|with (r_nsubjpass) associated_9\VBN|NONE (l_prep) with_10\IN|rise|.|is (l_pobj) output_14\NN|NONE
16720068
D000525_D014202 NONE alprazolam_7\NN|NONE (r_compound) treatment_8\NN|and (r_conj) paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|.|patient|retardation|, (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|On|.|patient|, (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|and|, (l_prep) with_23\IN|severe|muscle (l_pobj) tremors_24\NNS|NONE
D000525_D009127 NONE alprazolam_7\NN|NONE (r_compound) treatment_8\NN|and (r_conj) paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|.|patient|retardation|, (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|On|.|patient|, (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|and|,
D017374_D009127 NONE paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|.|patient|retardation|, (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|On|.|patient|, (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|and|,
D017374_D009459 CID paroxetine_9\NN|NONE (r_pobj) with_8\IN|concomitant (r_prep) treatment_7\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) related_4\VBN|neuroleptic|malignant|Possible|. (r_acl) syndrome_3\NN|NONE
D017374_D009459 CID paroxetine_24\NN|NONE (r_pobj) after_22\IN|that|symptoms|can (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|.|with|,|patient (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE
D017374_D009459 CID paroxetine_24\NN|NONE (r_pobj) after_22\IN|that|symptoms|can (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|.|with|,|patient (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE (l_appos) NMS_10\NNP|malignant|neuroleptic
D017374_D009459 CID paroxetine_24\NN|NONE (r_pobj) after_22\IN|that|symptoms|can (r_prep) occur_21\VB|thus (l_nsubj) symptoms_19\NNS|that|after|can (l_amod) like_18\JJ|NONE (l_npadvmod) NMS_16\NNP|
D000525_D009459 CID alprazolam_11\NN|and (r_conj) paroxetine_9\NN|NONE (r_pobj) with_8\IN|concomitant (r_prep) treatment_7\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) related_4\VBN|neuroleptic|malignant|Possible|. (r_acl) syndrome_3\NN|NONE
D000525_D009459 CID alprazolam_26\NN|NONE (r_compound) treatment_27\NN|and|combined (r_conj) paroxetine_24\NN|NONE (r_pobj) after_22\IN|that|symptoms|can (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|.|with|,|patient (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE
D000525_D009459 CID alprazolam_26\NN|NONE (r_compound) treatment_27\NN|and|combined (r_conj) paroxetine_24\NN|NONE (r_pobj) after_22\IN|that|symptoms|can (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|.|with|,|patient (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE (l_appos) NMS_10\NNP|malignant|neuroleptic
D000525_D009459 CID alprazolam_26\NN|NONE (r_compound) treatment_27\NN|and|combined (r_conj) paroxetine_24\NN|NONE (r_pobj) after_22\IN|that|symptoms|can (r_prep) occur_21\VB|thus (l_nsubj) symptoms_19\NNS|that|after|can (l_amod) like_18\JJ|NONE (l_npadvmod) NMS_16\NNP|
D017374_D011596 NONE paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|.|patient|retardation|, (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|On|.|patient|,
D017374_D014202 NONE paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|.|patient|retardation|, (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|On|.|patient|, (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|and|, (l_prep) with_23\IN|severe|muscle (l_pobj) tremors_24\NNS|NONE
D000525_D011596 NONE alprazolam_7\NN|NONE (r_compound) treatment_8\NN|and (r_conj) paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|.|patient|retardation|, (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|On|.|patient|,
19721134
D010862_D001145 NONE pilocarpine_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) effects_7\NNS|to|and|explore (r_dobj) evaluate_5\VB|was|.|study (l_conj) explore_11\VB|to|effects|and (l_conj) using_17\VBG|,|mechanism (l_dobj) rat_22\NN|NONE (l_conj) models_30\NNS|induced|both|and (l_compound) arrhythmia_29\NN|induced
D010862_D001145 NONE pilocarpine_5\NN|delayed|of|that (r_amod) onset_8\NN|data (l_prep) of_9\IN|delayed|pilocarpine|that (l_pobj) arrhythmias_10\NNS|NONE
D010862_D001145 NONE pilocarpine_5\NN|delayed|of|that (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|,|,|course|score (r_ccomp) decreased_12\VBD|NONE (l_npadvmod) score_24\NN|.|showed|,|,|course (l_compound) arrhythmia_23\NN|reduced|and|increased|,
D010862_D001145 NONE pilocarpine_5\NN|delayed|of|that (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|,|,|course|score (r_ccomp) decreased_12\VBD|NONE (l_npadvmod) score_24\NN|.|showed|,|,|course (l_conj) increased_27\VBD|reduced|arrhythmia|and|, (l_dobj) time_30\NN|NONE (l_prep) of_31\IN|the|survival (l_pobj) rats_33\NNS|NONE (l_amod) arrhythmic_32\JJ|pigs|and
D010862_D001145 NONE pilocarpine_4\NN|that|actions (r_nsubj) produced_5\VBD|.|data (l_dobj) actions_7\NNS|pilocarpine|that (l_prep) on_8\IN|antiarrhythmic (l_pobj) models_14\NNS|NONE (l_nmod) rat_10\NN|induced|pig (l_amod) arrhythmic_9\JJ|and
D010042_D001145 CID ouabain_24\NN| (r_npadvmod) induced_26\VBN|arrhythmia (r_amod) models_30\NNS|induced|both|and (l_compound) arrhythmia_29\NN|induced
D010042_D001145 CID ouabain_19\RB|or (r_conj) aconitine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|rat|pig (r_acl) models_14\NNS|NONE (l_nmod) rat_10\NN|induced|pig (l_amod) arrhythmic_9\JJ|and
D010862_D014693 NONE pilocarpine_5\NN|delayed|of|that (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|,|,|course|score (r_ccomp) decreased_12\VBD|NONE (l_dobj) course_15\NN|.|showed|,|,|score (l_prep) of_16\IN|the|time (l_pobj) tachycardia_18\NN|NONE (l_conj) fibrillation_20\NN|ventricular|and
D010862_D017180 NONE pilocarpine_5\NN|delayed|of|that (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|,|,|course|score (r_ccomp) decreased_12\VBD|NONE (l_dobj) course_15\NN|.|showed|,|,|score (l_prep) of_16\IN|the|time (l_pobj) tachycardia_18\NN|NONE (l_conj) fibrillation_20\NN|ventricular|and
D000157_D001145 CID aconitine_19\NN| (r_npadvmod) induced_21\VBN|both|and|models (r_amod) rat_22\NN|NONE (l_conj) models_30\NNS|induced|both|and (l_compound) arrhythmia_29\NN|induced
D000157_D001145 CID aconitine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|rat|pig (r_acl) models_14\NNS|NONE (l_nmod) rat_10\NN|induced|pig (l_amod) arrhythmic_9\JJ|and
D002118_D001145 NONE Ca(2_34\NNP|NONE (r_pobj) of_33\IN|the (r_prep) improvement_32\NN|NONE (r_pobj) to_30\IN|may|mechanism|be (r_prep) related_29\VBN|the (r_relcl) cardiac_23\JJ|NONE (r_dobj) stimulating_21\VBG|NONE (r_pcomp) via_20\IN|NONE (r_prep) ouabain_19\RB|or (r_conj) aconitine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|rat|pig (r_acl) models_14\NNS|NONE (l_nmod) rat_10\NN|induced|pig (l_amod) arrhythmic_9\JJ|and
21294084
D010406_D004827 NONE penicillin_12\NN| (r_npadvmod) induced_14\VBN|epilepsy|in (r_amod) model_16\NN|NONE (r_pobj) in_11\IN|epileptic|cortical (r_prep) discharges_10\NNS|NONE (l_amod) epileptic_9\JJ|cortical|in
D010406_D004827 NONE penicillin_12\NN| (r_npadvmod) induced_14\VBN|epilepsy|in (r_amod) model_16\NN|NONE (l_compound) epilepsy_15\NN|induced|in
D010406_D004827 NONE penicillin_17\NN| (r_npadvmod) induced_19\VBN|epilepsy (r_amod) model_21\NN|NONE (r_pobj) in_16\IN|cortical|epileptic (r_prep) activity_15\NN|NONE (l_amod) epileptic_14\JJ|cortical|in
D010406_D004827 NONE penicillin_17\NN| (r_npadvmod) induced_19\VBN|epilepsy (r_amod) model_21\NN|NONE (l_compound) epilepsy_20\NN|induced
D010406_D004827 NONE penicillin_7\NN| (r_npadvmod) induced_9\VBN|independent|the|cortical|acute|epileptic (r_amod) activity_12\NN|DBS|. (l_amod) epileptic_11\JJ|independent|the|cortical|acute|induced
14742097
D020280_D020018 CID sertraline_8\NN|,|either (r_conj) fluoxetine_6\NN|NONE (r_dobj) receiving_4\VBG|dysfunctional|Nineteen (r_acl) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|receiving|Nineteen
D004809_D020018 NONE ephedrine_10\NN|NONE (r_pobj) of_9\IN|A|,|controlled|.|,|randomized|for|crossover (r_prep) study_8\NN|NONE (l_prep) for_11\IN|A|,|controlled|.|of|,|randomized|crossover (l_pobj) dysfunction_17\NN|NONE
D004809_D020018 NONE ephedrine_9\NN|effects|whether|, (r_nsubj) has_28\VBZ|to (l_dobj) effects_30\NNS|whether|ephedrine|, (l_prep) in_31\IN|beneficial (l_pcomp) reversing_32\VBG|NONE (l_dobj) dysfunction_37\NN|NONE
D004809_D020018 NONE ephedrine_35\NN|NONE (r_pobj) of_34\IN|the|on|mg (r_prep) effects_33\NNS|NONE (r_pobj) of_31\IN|blind|cross|controlled|week|,|,|,|an (r_prep) study_30\NN|NONE (r_pobj) in_13\IN|.|women (r_prep) participated_12\VBD|NONE (l_nsubj) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|receiving|Nineteen
D005473_D020018 CID fluoxetine_6\NN|NONE (r_dobj) receiving_4\VBG|dysfunctional|Nineteen (r_acl) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|receiving|Nineteen
D017374_D020018 CID paroxetine_11\NN|,|or (r_conj) sertraline_8\NN|,|either (r_conj) fluoxetine_6\NN|NONE (r_dobj) receiving_4\VBG|dysfunctional|Nineteen (r_acl) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|receiving|Nineteen
11868798
D013148_D009503 NONE spironolactone_9\NN|NONE (r_pobj) of_8\IN|reduce|the (r_prep) ability_7\NN|to (l_acl) reduce_11\VB|of|the (l_conj) prevent_16\VB|to|requirements|and (l_dobj) hypokalemia_17\NN|to (l_prep) in_18\IN|NONE (l_pobj) patients_20\NNS|NONE (l_amod) neutropenic_19\JJ|on
D013148_D009503 NONE spironolactone_4\NN|requirements|and|prevent|that|can (r_nsubj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|requirements|and|spironolactone|that|can (l_prep) by_12\IN|hypokalemia (l_pcomp) reducing_13\VBG|NONE (l_dobj) loss_16\NN|NONE (l_prep) in_17\IN|potassium|urinary (l_pobj) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D011188_D007008 NONE potassium_12\NN|NONE (r_compound) requirements_13\NNS|to|and|prevent (r_dobj) reduce_11\VB|of|the (l_conj) prevent_16\VB|to|requirements|and (l_dobj) hypokalemia_17\NN|to
D011188_D007008 NONE potassium_7\NN|NONE (r_compound) requirements_8\NNS|and|prevent|spironolactone|that|can (r_dobj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN|by
D011188_D007008 NONE potassium_15\NN|in|urinary (r_compound) loss_16\NN|NONE (r_dobj) reducing_13\VBG|NONE (r_pcomp) by_12\IN|hypokalemia (r_prep) prevent_10\VBP|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN|by
D013148_D007008 NONE Spironolactone_0\NNP|it|drug|:|? (r_npadvmod) is_2\VBZ|NONE (l_attr) drug_6\NN|Spironolactone|it|:|? (l_prep) for_7\IN|a|novel (l_pobj) prevention_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypokalemia_15\NN|NONE
D013148_D007008 NONE spironolactone_9\NN|NONE (r_pobj) of_8\IN|reduce|the (r_prep) ability_7\NN|to (l_acl) reduce_11\VB|of|the (l_conj) prevent_16\VB|to|requirements|and (l_dobj) hypokalemia_17\NN|to
D013148_D007008 NONE spironolactone_4\NN|requirements|and|prevent|that|can (r_nsubj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN|by
D000666_D009369 NONE B_12\NN| (r_npadvmod) related_14\VBN|in (r_amod) hypokalemia_15\NN|NONE (l_prep) in_16\IN|related (l_pobj) patients_18\NNS|NONE (l_compound) cancer_17\NN|NONE
D000666_D009503 NONE AmB_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) on_21\IN|neutropenic (r_prep) patients_20\NNS|NONE (l_amod) neutropenic_19\JJ|on
D000666_D009503 NONE AmB_21\JJ|NONE (r_compound) treatment_22\NN|NONE (r_pobj) on_20\IN|neutropenic (r_prep) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D013148_D006402 NONE spironolactone_21\NN|alone|either|AmB|or|intravenous (r_conj) AmB_15\VB|to|twice|developing|daily (r_dobj) receive_12\VB|patients|were|.|In (r_xcomp) randomized_10\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|In|receive (l_prep) with_5\IN| (l_pobj) disorders_8\NNS|NONE
D013148_D009369 NONE Spironolactone_0\NNP|it|drug|:|? (r_npadvmod) is_2\VBZ|NONE (l_attr) drug_6\NN|Spironolactone|it|:|? (l_prep) for_7\IN|a|novel (l_pobj) prevention_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypokalemia_15\NN|NONE (l_prep) in_16\IN|related (l_pobj) patients_18\NNS|NONE (l_compound) cancer_17\NN|NONE
D000666_D007674 NONE B_9\NNP|NONE (r_pobj) of_7\IN|major|the|adverse (r_prep) effect_6\NN|,|Nephrotoxicity|.|:|limiting (r_attr) is_2\VBZ|NONE (l_nsubj) Nephrotoxicity_1\NN|effect|,|.|:|limiting
D000666_D007674 NONE AmB_11\NNP|amphotericin (r_appos) B_9\NNP|NONE (r_pobj) of_7\IN|major|the|adverse (r_prep) effect_6\NN|,|Nephrotoxicity|.|:|limiting (r_attr) is_2\VBZ|NONE (l_nsubj) Nephrotoxicity_1\NN|effect|,|.|:|limiting
D000666_D064420 NONE AmB._24\NNP|NONE (r_compound) Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|profound|the|potassium (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|toxicity|potentiates (r_xcomp) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|be|potentiates
D000666_D064420 NONE AmB._24\NNP|NONE (r_compound) Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|profound|the|potassium (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|toxicity|potentiates (r_xcomp) seems_5\VBZ|NONE (l_conj) potentiates_28\VBZ|toxicity|be (l_dobj) toxicity_31\NN|also
D000666_D064420 NONE AmB._33\NN|NONE (r_pobj) of_32\IN|tubular|the (r_prep) toxicity_31\NN|also (r_dobj) potentiates_28\VBZ|toxicity|be (r_conj) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|be|potentiates
D000666_D064420 NONE AmB._33\NN|NONE (r_pobj) of_32\IN|tubular|the (r_prep) toxicity_31\NN|also
D000666_D007008 CID B_12\NN| (r_npadvmod) related_14\VBN|in (r_amod) hypokalemia_15\NN|NONE
D000666_D007008 CID AmB_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) on_21\IN|neutropenic (r_prep) patients_20\NNS|NONE (r_pobj) in_18\IN|NONE (r_prep) hypokalemia_17\NN|to
D000666_D007008 CID AmB_21\JJ|NONE (r_compound) treatment_22\NN|NONE (r_pobj) on_20\IN|neutropenic (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|potassium|urinary (r_prep) loss_16\NN|NONE (r_dobj) reducing_13\VBG|NONE (r_pcomp) by_12\IN|hypokalemia (r_prep) prevent_10\VBP|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN|by
D000666_D006402 NONE AmB_15\VB|to|twice|developing|daily (r_dobj) receive_12\VB|patients|were|.|In (r_xcomp) randomized_10\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|In|receive (l_prep) with_5\IN| (l_pobj) disorders_8\NNS|NONE
D000666_D006402 NONE AmB_18\JJ|alone|either|spironolactone|or|intravenous (r_conj) AmB_15\VB|to|twice|developing|daily (r_dobj) receive_12\VB|patients|were|.|In (r_xcomp) randomized_10\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|In|receive (l_prep) with_5\IN| (l_pobj) disorders_8\NNS|NONE
D011188_D009503 NONE potassium_12\NN|NONE (r_compound) requirements_13\NNS|to|and|prevent (r_dobj) reduce_11\VB|of|the (l_conj) prevent_16\VB|to|requirements|and (l_dobj) hypokalemia_17\NN|to (l_prep) in_18\IN|NONE (l_pobj) patients_20\NNS|NONE (l_amod) neutropenic_19\JJ|on
D011188_D009503 NONE potassium_7\NN|NONE (r_compound) requirements_8\NNS|and|prevent|spironolactone|that|can (r_dobj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|requirements|and|spironolactone|that|can (l_prep) by_12\IN|hypokalemia (l_pcomp) reducing_13\VBG|NONE (l_dobj) loss_16\NN|NONE (l_prep) in_17\IN|potassium|urinary (l_pobj) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D011188_D009503 NONE potassium_15\NN|in|urinary (r_compound) loss_16\NN|NONE (l_prep) in_17\IN|potassium|urinary (l_pobj) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D000666_D009181 NONE AmB_15\VB|to|twice|developing|daily (r_dobj) receive_12\VB|patients|were|.|In (l_advcl) developing_27\VBG|to|twice|AmB|daily (l_dobj) infection_33\NN|when
D000666_D009181 NONE AmB_18\JJ|alone|either|spironolactone|or|intravenous (r_conj) AmB_15\VB|to|twice|developing|daily (r_dobj) receive_12\VB|patients|were|.|In (l_advcl) developing_27\VBG|to|twice|AmB|daily (l_dobj) infection_33\NN|when
D013148_D009181 NONE spironolactone_21\NN|alone|either|AmB|or|intravenous (r_conj) AmB_15\VB|to|twice|developing|daily (r_dobj) receive_12\VB|patients|were|.|In (l_advcl) developing_27\VBG|to|twice|AmB|daily (l_dobj) infection_33\NN|when
D011188_D064420 NONE potassium_12\NN|profound|is|the (r_compound) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|toxicity|potentiates (r_xcomp) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|be|potentiates
D011188_D064420 NONE potassium_12\NN|profound|is|the (r_compound) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|toxicity|potentiates (r_xcomp) seems_5\VBZ|NONE (l_conj) potentiates_28\VBZ|toxicity|be (l_dobj) toxicity_31\NN|also
D011188_D064420 NONE Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|profound|the|potassium (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|toxicity|potentiates (r_xcomp) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|be|potentiates
D011188_D064420 NONE Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|profound|the|potassium (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|toxicity|potentiates (r_xcomp) seems_5\VBZ|NONE (l_conj) potentiates_28\VBZ|toxicity|be (l_dobj) toxicity_31\NN|also
12549952
D016642_D017114 CID bupropion_5\NN|NONE (r_pobj) with_3\IN|.|Acute|liver (r_prep) failure_2\NN|NONE
D016642_D017114 CID bupropion_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of (r_acl) evidence_4\NN|is (r_dobj) increasing_3\VBG|,|.|case|this (r_advcl) is_12\VBZ|NONE (l_attr) case_15\NN|,|.|increasing|this (l_relcl) resulted_21\VBN|first|of|the (l_prep) from_22\IN|on|could|that|have (l_pobj) failure_25\NN|NONE
D016642_D017114 CID bupropion_30\NN|NONE (r_dobj) receiving_29\VBG|a (r_acl) patient_28\JJ|NONE (r_pobj) in_26\IN|liver|acute (r_prep) failure_25\NN|NONE
D016642_D017114 CID bupropion_13\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) induced_11\VBN|acute|liver (r_acl) insult_10\NN|NONE
D016642_D056486 CID bupropion_3\NN|in|that|hepatotoxicity (r_nsubj) induced_4\VBD|The (l_dobj) hepatotoxicity_5\NN|in|that|bupropion
D016642_D056486 CID bupropion_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of (r_acl) evidence_4\NN|is (l_prep) of_5\IN|induced (l_pobj) hepatotoxicity_6\NN|NONE
D016642_D056486 CID bupropion_30\NN|NONE (r_dobj) receiving_29\VBG|a (r_acl) patient_28\JJ|NONE (r_pobj) in_26\IN|liver|acute (r_prep) failure_25\NN|NONE (r_pobj) from_22\IN|on|could|that|have (r_prep) resulted_21\VBN|first|of|the (r_relcl) case_15\NN|,|.|increasing|this (r_attr) is_12\VBZ|NONE (l_advcl) increasing_3\VBG|,|.|case|this (l_dobj) evidence_4\NN|is (l_prep) of_5\IN|induced (l_pobj) hepatotoxicity_6\NN|NONE
D016642_D056486 CID bupropion_13\NN|NONE (l_acl) given_14\VBN|NONE (l_prep) with_16\IN|concurrently (l_pobj) drugs_19\NNS|NONE (l_amod) hepatotoxic_18\JJ|other
D002231_D017093 NONE carbimazole_16\NN|and (r_conj) bupropion_14\NN|NONE (r_pobj) of_13\IN|concurrent (r_prep) use_12\NN|NONE (r_pobj) with_10\IN|possibly (r_prep) associated_9\VBN|liver|fatal (r_acl) failure_7\NN|NONE
D011433_D006980 NONE propranolol_17\NN|man|had|with|.|and|been (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_5\NN|had|with|propranolol|.|and|been (l_prep) with_6\IN|Chinese|A|old (l_pobj) history_8\NN|NONE (l_prep) of_9\IN|a (l_pobj) hyperthyroidism_10\NN|NONE
D002231_D017114 CID carbimazole_7\NN|NONE (r_compound) therapy_8\NN|and|concurrent (r_conj) bupropion_5\NN|NONE (r_pobj) with_3\IN|.|Acute|liver (r_prep) failure_2\NN|NONE
D002231_D017114 CID carbimazole_36\NN|NONE (r_pobj) with_35\IN|concomitant (r_prep) treatment_34\NN|while (r_pobj) on_32\IN|from|could|that|have (r_prep) resulted_21\VBN|first|of|the (l_prep) from_22\IN|on|could|that|have (l_pobj) failure_25\NN|NONE
D002231_D006980 NONE carbimazole_15\NN|NONE (r_pobj) with_14\IN|man|had|propranolol|.|and|been (r_prep) treated_13\VBN|NONE (l_nsubjpass) man_5\NN|had|with|propranolol|.|and|been (l_prep) with_6\IN|Chinese|A|old (l_pobj) history_8\NN|NONE (l_prep) of_9\IN|a (l_pobj) hyperthyroidism_10\NN|NONE
D016642_D017093 NONE bupropion_14\NN|NONE (r_pobj) of_13\IN|concurrent (r_prep) use_12\NN|NONE (r_pobj) with_10\IN|possibly (r_prep) associated_9\VBN|liver|fatal (r_acl) failure_7\NN|NONE
D002231_D056486 CID carbimazole_36\NN|NONE (r_pobj) with_35\IN|concomitant (r_prep) treatment_34\NN|while (r_pobj) on_32\IN|from|could|that|have (r_prep) resulted_21\VBN|first|of|the (r_relcl) case_15\NN|,|.|increasing|this (r_attr) is_12\VBZ|NONE (l_advcl) increasing_3\VBG|,|.|case|this (l_dobj) evidence_4\NN|is (l_prep) of_5\IN|induced (l_pobj) hepatotoxicity_6\NN|NONE
7197363
D011814_D009069 CID quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced
D011814_D009069 CID quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|)|(|or|after (r_conj) reduced_13\VBN|aggressiveness|twitches|.|,|and|hr (r_conj) increased_6\VBD|NONE (l_conj) twitches_35\NNS|aggressiveness|.|,|reduced|and|hr
D001058_D009069 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|twitches|and (r_amod) aggressiveness_13\NN|NONE (l_conj) twitches_19\NNS|and|induced
D001058_D009069 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD|NONE (l_conj) twitches_35\NNS|aggressiveness|.|,|reduced|and|hr
D011814_D012892 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced (r_conj) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|of|The (r_prep) effects_1\NNS|.|were (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE
D011814_D012892 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced (r_conj) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|of|The (r_prep) effects_1\NNS|.|were (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE (l_appos) REMD_7\NNP|sleep|(|REM|)
D011814_D012892 NONE quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|)|(|or|after (r_conj) reduced_13\VBN|aggressiveness|twitches|.|,|and|hr (r_conj) increased_6\VBD|NONE (l_nsubj) hr_3\NN|aggressiveness|twitches|.|,|reduced|and (l_prep) of_4\IN|eight (l_pobj) REMD_5\NNP|NONE
D011814_D012892 NONE quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|)|(|or|after (r_conj) reduced_13\VBN|aggressiveness|twitches|.|,|and|hr (l_prep) after_16\IN|)|(|or|increased (l_pcomp) completing_17\VBG|immediately (l_prep) of_18\IN|NONE (l_pobj) REMD_19\NNP|NONE
D011814_D012892 NONE quipazine_31\NN|NONE (l_nmod) REMD_29\NNP|)|
D011814_D001523 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced (r_conj) aggressiveness_13\NN|NONE
D011814_D001523 NONE quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|)|(|or|after (r_conj) reduced_13\VBN|aggressiveness|twitches|.|,|and|hr (r_conj) increased_6\VBD|NONE (l_dobj) aggressiveness_10\NN|twitches|.|,|reduced|and|hr
D001058_D001523 CID apomorphine_10\NN| (r_npadvmod) induced_12\VBN|twitches|and (r_amod) aggressiveness_13\NN|NONE
D001058_D001523 CID apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|twitches|.|,|reduced|and|hr
D001058_D012892 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|twitches|and (r_amod) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|of|The (r_prep) effects_1\NNS|.|were (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE
D001058_D012892 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|twitches|and (r_amod) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|of|The (r_prep) effects_1\NNS|.|were (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE (l_appos) REMD_7\NNP|sleep|(|REM|)
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD|NONE (l_nsubj) hr_3\NN|aggressiveness|twitches|.|,|reduced|and (l_prep) of_4\IN|eight (l_pobj) REMD_5\NNP|NONE
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD|NONE (l_conj) reduced_13\VBN|aggressiveness|twitches|.|,|and|hr (l_prep) after_16\IN|)|(|or|increased (l_pcomp) completing_17\VBG|immediately (l_prep) of_18\IN|NONE (l_pobj) REMD_19\NNP|NONE
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD|NONE (l_conj) reduced_13\VBN|aggressiveness|twitches|.|,|and|hr (l_conj) increased_22\VBN|)|(|or|after (l_prep) after_26\IN|hr (l_pcomp) completing_27\VBG|NONE (l_prep) of_28\IN|NONE (l_pobj) quipazine_31\NN|NONE (l_nmod) REMD_29\NNP|)|
8665051
D013256_D009336 NONE steroid_18\NN|the (r_compound) groups_19\NNS|NONE (r_pobj) in_16\IN|atrophy|and|fiber|IIb (r_prep) atrophy_15\NN|ATPase|revealed|.|, (r_dobj) showed_11\VBD|NONE (l_advcl) revealed_32\VBD|ATPase|.|,|atrophy (l_dobj) pattern_36\NN|examinations|whereas (l_prep) with_37\IN|a|normal|muscular (l_pobj) absence_38\NN|NONE (l_prep) of_39\IN|NONE (l_pobj) necrosis_40\NN|NONE
D013256_D009336 NONE steroids_14\NNS|NONE (r_pobj) of_13\IN|massive (r_prep) doses_12\NNS|NONE (r_pobj) with_10\IN|term||)|( (r_prep) treatment_9\NN|wasting|that (r_nsubj) induced_15\VBD|We (r_ccomp) conclude_1\VBP|atrophy|resulting|;||,|types (r_ccomp) induced_30\VBD|steroid||;|necrosis (r_ccomp) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (l_dobj) necrosis_53\NN|steroid|induced||;
D013256_D009336 NONE steroids_29\NNS|NONE (r_pobj) of_28\IN|both (r_prep) types_27\NNS|atrophy|resulting|;||conclude|, (r_nsubj) induced_30\VBD|steroid||;|necrosis (r_ccomp) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (l_dobj) necrosis_53\NN|steroid|induced||;
D013256_D009336 NONE steroid_50\NN|induced||;|necrosis (r_nsubj) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (l_dobj) necrosis_53\NN|steroid|induced||;
D013256_D013746 NONE steroid_8\NN|both (r_compound) groups_9\NNS|NONE (r_pobj) in_6\IN|was|,|was|time|and (r_prep) prolonged_5\VBN|NONE (l_conj) was_16\VBD|in|,|was|time|and (l_advcl) were_24\VBD|tension|.|longer|,|with (l_nsubj) tensions_23\NNS|whereas|similar (l_compound) tetanic_22\JJ|NONE
D013256_D009133 NONE steroid_18\NN|the (r_compound) groups_19\NNS|NONE (r_pobj) in_16\IN|atrophy|and|fiber|IIb (r_prep) atrophy_15\NN|ATPase|revealed|.|,
D013256_D009133 NONE steroid_18\NN|the (r_compound) groups_19\NNS|NONE (r_pobj) in_16\IN|atrophy|and|fiber|IIb (r_prep) atrophy_15\NN|ATPase|revealed|.|, (l_conj) atrophy_25\NN|and|in|fiber|IIb
D013256_D009133 NONE steroids_14\NNS|NONE (r_pobj) of_13\IN|massive (r_prep) doses_12\NNS|NONE (r_pobj) with_10\IN|term||)|( (r_prep) treatment_9\NN|wasting|that (r_nsubj) induced_15\VBD|We (r_ccomp) conclude_1\VBP|atrophy|resulting|;||,|types (r_ccomp) induced_30\VBD|steroid||;|necrosis (r_ccomp) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (r_ccomp) caused_63\VBN|NONE (l_nsubjpass) atrophy_60\NN|(|;|caused|by|was|.|alone|not
D013256_D009133 NONE steroids_29\NNS|NONE (r_pobj) of_28\IN|both (r_prep) types_27\NNS|atrophy|resulting|;||conclude|, (r_nsubj) induced_30\VBD|steroid||;|necrosis (r_ccomp) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (r_ccomp) caused_63\VBN|NONE (l_nsubjpass) atrophy_60\NN|(|;|caused|by|was|.|alone|not
D013256_D009133 NONE steroid_50\NN|induced||;|necrosis (r_nsubj) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (r_ccomp) caused_63\VBN|NONE (l_nsubjpass) atrophy_60\NN|(|;|caused|by|was|.|alone|not
D014221_D000855 CID triamcinolone_24\NN|or|,|M (r_conj) methylprednisolone_18\NN|(|saline|)|, (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D014221_D000855 CID T_26\NNP|NONE (r_appos) triamcinolone_24\NN|or|,|M (r_conj) methylprednisolone_18\NN|(|saline|)|, (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D014221_D000855 CID T_67\NNP|and|, (r_conj) M_65\NNP|NONE (r_pobj) in_64\IN|NONE (r_prep) %_63\NN|treated||(|the (r_appos) groups_58\NNS|NONE (r_pobj) in_53\IN|a|significant|of (r_prep) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D008775_D000855 CID methylprednisolone_18\NN|(|saline|)|, (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D008775_D000855 CID M_20\NNP|or|,|triamcinolone (r_appos) methylprednisolone_18\NN|(|saline|)|, (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D008775_D000855 CID M_65\NNP|NONE (r_pobj) in_64\IN|NONE (r_prep) %_63\NN|treated||(|the (r_appos) groups_58\NNS|NONE (r_pobj) in_53\IN|a|significant|of (r_prep) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D013256_D001284 NONE steroids_14\NNS|NONE (r_pobj) of_13\IN|massive (r_prep) doses_12\NNS|NONE (r_pobj) with_10\IN|term||)|( (r_prep) treatment_9\NN|wasting|that (r_nsubj) induced_15\VBD|We (r_ccomp) conclude_1\VBP|atrophy|resulting|;||,|types (r_ccomp) induced_30\VBD|steroid||;|necrosis (l_dobj) atrophy_34\NN|resulting|;||conclude|,|types
D013256_D001284 NONE steroids_29\NNS|NONE (r_pobj) of_28\IN|both (r_prep) types_27\NNS|atrophy|resulting|;||conclude|, (r_nsubj) induced_30\VBD|steroid||;|necrosis (l_dobj) atrophy_34\NN|resulting|;||conclude|,|types
D013256_D001284 NONE steroid_50\NN|induced||;|necrosis (r_nsubj) caused_51\VBD|atrophy|(|;|by|was|.|alone|not (l_ccomp) induced_30\VBD|steroid||;|necrosis (l_dobj) atrophy_34\NN|resulting|;||conclude|,|types
D014221_D009133 CID T_27\NNP|NONE (r_pobj) with_26\IN|IIa|also (r_prep) atrophy_25\NN|and|in|fiber|IIb (r_conj) atrophy_15\NN|ATPase|revealed|.|,
D014221_D009133 CID T_27\NNP|NONE (r_pobj) with_26\IN|IIa|also (r_prep) atrophy_25\NN|and|in|fiber|IIb
D014221_D009133 CID T_18\NNP|, (r_conj) C_16\NNP||(|) (r_appos) rats_14\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) performed_11\VBN|PF|(|,|)|,|fed|a (r_acl) study_9\NN|was|.|,|Finally (r_nsubj) showed_24\VBD|NONE (l_ccomp) was_28\VBD|study|.|,|Finally (l_nsubj) atrophy_27\NN|pronounced|that
D014221_D009133 CID T_37\NNP| (r_npadvmod) treated_39\VBN|NONE (r_amod) animals_40\NNS|NONE (r_pobj) in_36\IN|NONE (r_prep) than_35\IN|in|less (r_prep) pronounced_31\VBN|atrophy|that (r_acomp) was_28\VBD|study|.|,|Finally (l_nsubj) atrophy_27\NN|pronounced|that
D013256_D000855 NONE steroid_55\NN| (r_npadvmod) treated_57\VBN||(|the|% (r_amod) groups_58\NNS|NONE (r_pobj) in_53\IN|a|significant|of (r_prep) reduction_49\NN|)|respectively (l_prep) of_50\IN|in|a|significant (l_pobj) intake_52\NN|NONE
D008775_D013746 NONE M_19\NNP|NONE (r_pobj) with_18\IN|tension|were|.|longer|, (r_prep) was_16\VBD|in|,|was|time|and (l_advcl) were_24\VBD|tension|.|longer|,|with (l_nsubj) tensions_23\NNS|whereas|similar (l_compound) tetanic_22\JJ|NONE
D014221_D009336 NONE T_27\NNP|NONE (r_pobj) with_26\IN|IIa|also (r_prep) atrophy_25\NN|and|in|fiber|IIb (r_conj) atrophy_15\NN|ATPase|revealed|.|, (r_dobj) showed_11\VBD|NONE (l_advcl) revealed_32\VBD|ATPase|.|,|atrophy (l_dobj) pattern_36\NN|examinations|whereas (l_prep) with_37\IN|a|normal|muscular (l_pobj) absence_38\NN|NONE (l_prep) of_39\IN|NONE (l_pobj) necrosis_40\NN|NONE
D000305_D009135 NONE corticosteroids_17\NNS|NONE (r_pobj) of_16\IN|massive (r_prep) doses_15\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) treated_12\VBN|NONE (r_acl) patients_11\NNS|NONE (r_pobj) in_10\IN|may|myopathy|that (r_prep) occur_9\VB|reports|have|. (l_nsubj) myopathy_7\NN|may|that|in
2709684
D005839_D058186 CID gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE
D005839_D058186 CID gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (l_appos) ARF_48\NNP|acute|renal|induced
D005839_D058186 CID gentamicin_8\NN|,|decrease|P|(| (r_compound) ARF_10\NNP|;|.|,|less|did|not|In|day|P
D013311_D003920 CID streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE
D013311_D003920 CID streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (l_appos) DM_9\NNP|diabetes
D010695_D006029 NONE Phlorizin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) glycosuria_3\NN|nephrotoxicity|.|does|not
D010695_D006029 NONE P_13\NN|treated|the (r_nmod) animals_15\NNS|NONE (r_pobj) of_11\IN|NONE (r_prep) that_10\DT|NONE (r_pobj) to_9\IN|NONE (r_prep) degree_8\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) similar_6\JJ|)|mild|( (r_amod) glycosuria_4\NN|NONE
D010695_D006029 NONE P_4\NN|CCr|glycosuria|,|I|In|and (r_nsubj) induced_5\VBD|NONE (l_dobj) glycosuria_10\NN|CCr|P|,|I|In|and
D005839_D007674 NONE gentamicin_7\NN|in (r_compound) nephrotoxicity_8\NN|.|glycosuria|does|not
D005839_D007674 NONE gentamicin_3\NN|NONE (r_amod) nephrotoxicity_4\NN|NONE
D005839_D007674 NONE gentamicin_11\NN|NONE (r_pobj) of_10\IN|)|Nephrotoxic|(|body (r_prep) doses_1\NNS|to|.|during|to|were (l_amod) Nephrotoxic_0\JJ|of|)|(|body
D013311_D006029 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rats_1\NNS|Because|diuresis (r_nsubj) have_11\VBP|have|,|.|be|we (l_dobj) diuresis_15\NN|rats|Because (l_appos) glycosuria_17\NN|solute|)|(|a
D005839_D009956 NONE gentamicin_8\NN|,|decrease|P|(| (r_compound) ARF_10\NNP|;|.|,|less|did|not|In|day|P (r_dobj) prevent_7\VB|NONE (l_conj) day_34\NN|;|.|,|less|did|not|In|ARF|P (l_conj) score_39\NN|;|micrograms|and|/ (l_compound) necrosis_38\NN|.|)|,|tubular
D005947_D003920 NONE glucose_21\NN|with|tubular (r_compound) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D010695_D007674 NONE Phlorizin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) glycosuria_3\NN|nephrotoxicity|.|does|not (r_nsubj) prevent_6\VB|NONE (l_dobj) nephrotoxicity_8\NN|.|glycosuria|does|not
D010695_D007674 NONE phlorizin_24\NN|NONE (r_pobj) with_23\IN|tubular|glucose (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (r_pobj) in_7\IN|protection|.|was (r_prep) studied_6\VBN|NONE (l_nsubjpass) protection_1\NN|in|.|was (l_prep) from_2\IN|The (l_pobj) nephrotoxicity_4\NN|NONE
D010695_D007674 NONE P_26\NN|(|) (r_appos) phlorizin_24\NN|NONE (r_pobj) with_23\IN|tubular|glucose (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (r_pobj) in_7\IN|protection|.|was (r_prep) studied_6\VBN|NONE (l_nsubjpass) protection_1\NN|in|.|was (l_prep) from_2\IN|The (l_pobj) nephrotoxicity_4\NN|NONE
D010695_D007674 NONE P_4\NN|CCr|glycosuria|,|I|In|and (r_nsubj) induced_5\VBD|NONE (l_conj) CCr_33\IN|P|glycosuria|,|I|In|and (l_nsubj) evidence_27\NN|min|.|score|baseline (l_prep) of_28\IN|no|functional (l_pobj) dysfunction_30\NN|NONE
D010695_D003920 NONE phlorizin_24\NN|NONE (r_pobj) with_23\IN|tubular|glucose (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D010695_D003920 NONE P_26\NN|(|) (r_appos) phlorizin_24\NN|NONE (r_pobj) with_23\IN|tubular|glucose (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D010695_D003920 NONE P_13\NN|treated|the (r_nmod) animals_15\NNS|NONE (r_pobj) of_11\IN|NONE (r_prep) that_10\DT|NONE (r_pobj) to_9\IN|NONE (r_prep) degree_8\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) similar_6\JJ|)|mild|( (r_amod) glycosuria_4\NN|NONE (r_pobj) with_2\IN|DM (r_prep) rats_1\NNS|.|were|also (l_compound) DM_0\NNP|with
D010695_D003920 NONE P_3\NN|Group|P|for|;|II (r_nsubj) received_6\VBD|NONE (l_conj) II_19\NNP|Group|P|for|P|; (l_conj) III_27\NNP|Group|P|;|( (l_acl) gentamicin_29\NN|.|Group|( (l_conj) IV_34\NNP|alone|and|) (l_appos) DM_37\NNP|Group
D010695_D003920 NONE P_7\NN|Group|for|P|;|II (r_dobj) received_6\VBD|NONE (l_conj) II_19\NNP|Group|P|for|P|; (l_conj) III_27\NNP|Group|P|;|( (l_acl) gentamicin_29\NN|.|Group|( (l_conj) IV_34\NNP|alone|and|) (l_appos) DM_37\NNP|Group
D010695_D003920 NONE P_21\NN|III|Group|;|( (r_appos) II_19\NNP|Group|P|for|P|; (l_conj) III_27\NNP|Group|P|;|( (l_acl) gentamicin_29\NN|.|Group|( (l_conj) IV_34\NNP|alone|and|) (l_appos) DM_37\NNP|Group
D010695_D058186 NONE P_4\NN|;|.|,|less|did|not|In|ARF|day (r_nsubj) prevent_7\VB|NONE (l_dobj) ARF_10\NNP|;|.|,|less|did|not|In|day|P
D010695_D058186 NONE P_21\NN|,|decrease|(||gentamicin (r_appos) ARF_10\NNP|;|.|,|less|did|not|In|day|P
D005839_D006029 NONE gentamicin_7\NN|in (r_compound) nephrotoxicity_8\NN|.|glycosuria|does|not (r_dobj) prevent_6\VB|NONE (l_nsubj) glycosuria_3\NN|nephrotoxicity|.|does|not
D005839_D006029 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (r_pobj) to_40\IN|their (r_prep) resistance_39\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) responsible_36\JJ|that|may|in|this (r_acomp) be_35\VB|have|have|,|.|we (r_ccomp) suggested_29\VBN|NONE (l_advcl) have_11\VBP|have|,|.|be|we (l_dobj) diuresis_15\NN|rats|Because (l_appos) glycosuria_17\NN|solute|)|(|a
D005839_D003920 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (r_pobj) to_40\IN|their (r_prep) resistance_39\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) responsible_36\JJ|that|may|in|this (r_acomp) be_35\VB|have|have|,|.|we (r_ccomp) suggested_29\VBN|NONE (l_advcl) have_11\VBP|have|,|.|be|we (l_nsubj) rats_1\NNS|Because|diuresis (l_prep) with_2\IN|NONE (l_pobj) mellitus_7\NN|NONE
D005839_D003920 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (r_pobj) to_40\IN|their (r_prep) resistance_39\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) responsible_36\JJ|that|may|in|this (r_acomp) be_35\VB|have|have|,|.|we (r_ccomp) suggested_29\VBN|NONE (l_advcl) have_11\VBP|have|,|.|be|we (l_nsubj) rats_1\NNS|Because|diuresis (l_prep) with_2\IN|NONE (l_pobj) mellitus_7\NN|NONE (l_appos) DM_9\NNP|diabetes
D005839_D003920 NONE gentamicin_3\NN|NONE (r_amod) nephrotoxicity_4\NN|NONE (r_pobj) from_2\IN|The (r_prep) protection_1\NN|in|.|was (r_nsubjpass) studied_6\VBN|NONE (l_prep) in_7\IN|protection|.|was (l_pobj) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D005839_D003920 NONE gentamicin_23\NN|+|) (r_conj) P_21\NN|III|Group|;|( (r_appos) II_19\NNP|Group|P|for|P|; (l_conj) III_27\NNP|Group|P|;|( (l_acl) gentamicin_29\NN|.|Group|( (l_conj) IV_34\NNP|alone|and|) (l_appos) DM_37\NNP|Group
D005839_D003920 NONE gentamicin_29\NN|.|Group|( (l_conj) IV_34\NNP|alone|and|) (l_appos) DM_37\NNP|Group
D005839_D003920 NONE gentamicin_39\NN|mild|(|+|) (r_conj) DM_37\NNP|Group
D013311_D058186 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rats_1\NNS|Because|diuresis (r_nsubj) have_11\VBP|have|,|.|be|we (r_advcl) suggested_29\VBN|NONE (l_ccomp) be_35\VB|have|have|,|.|we (l_acomp) responsible_36\JJ|that|may|in|this (l_prep) for_37\IN|NONE (l_pobj) resistance_39\NN|NONE (l_prep) to_40\IN|their (l_pobj) failure_46\NN|NONE
D013311_D058186 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rats_1\NNS|Because|diuresis (r_nsubj) have_11\VBP|have|,|.|be|we (r_advcl) suggested_29\VBN|NONE (l_ccomp) be_35\VB|have|have|,|.|we (l_acomp) responsible_36\JJ|that|may|in|this (l_prep) for_37\IN|NONE (l_pobj) resistance_39\NN|NONE (l_prep) to_40\IN|their (l_pobj) failure_46\NN|NONE (l_appos) ARF_48\NNP|acute|renal|induced
D010695_D009956 NONE P_4\NN|CCr|glycosuria|,|I|In|and (r_nsubj) induced_5\VBD|NONE (l_conj) CCr_33\IN|P|glycosuria|,|I|In|and (l_dobj) score_49\NN|evidence|min|.|baseline (l_compound) necrosis_48\NN|zero|(|)|[|tubular||]|maximum|,
D010695_D009956 NONE P_4\NN|;|.|,|less|did|not|In|ARF|day (r_nsubj) prevent_7\VB|NONE (l_conj) day_34\NN|;|.|,|less|did|not|In|ARF|P (l_conj) score_39\NN|;|micrograms|and|/ (l_compound) necrosis_38\NN|.|)|,|tubular
D010695_D009956 NONE P_21\NN|,|decrease|(||gentamicin (r_appos) ARF_10\NNP|;|.|,|less|did|not|In|day|P (r_dobj) prevent_7\VB|NONE (l_conj) day_34\NN|;|.|,|less|did|not|In|ARF|P (l_conj) score_39\NN|;|micrograms|and|/ (l_compound) necrosis_38\NN|.|)|,|tubular
D005947_D007674 NONE glucose_21\NN|with|tubular (r_compound) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (r_pobj) in_7\IN|protection|.|was (r_prep) studied_6\VBN|NONE (l_nsubjpass) protection_1\NN|in|.|was (l_prep) from_2\IN|The (l_pobj) nephrotoxicity_4\NN|NONE
15531665
D001205_D050197 NONE C_12\NN|NONE (r_pobj) of_10\IN|high|in|a (r_prep) intake_9\NN|might|that|atherosclerosis (r_nsubj) promote_17\VB|to (l_dobj) atherosclerosis_18\NN|might|that|intake
D005492_D002318 NONE folate_21\NN|,|,|and|vitamin|carotene (r_nmod) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (r_conj) type_8\NN|risk|, (r_appos) factors_6\NNS|NONE (l_compound) risk_5\NN|type|, (l_compound) disease_4\NN|NONE
D005492_D002318 NONE folate_21\NN|,|,|and|vitamin|carotene (r_nmod) E_24\NN|NONE (l_conj) carotene_29\NN|,|,|and|folate|vitamin (l_appos) risks_34\NNS|,|beta| (l_prep) of_35\IN|relative|adjusted|the (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|cardiovascular|total
D014810_D002318 NONE E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (r_conj) type_8\NN|risk|, (r_appos) factors_6\NNS|NONE (l_compound) risk_5\NN|type|, (l_compound) disease_4\NN|NONE
D014810_D002318 NONE E_24\NN|NONE (l_conj) carotene_29\NN|,|,|and|folate|vitamin (l_appos) risks_34\NNS|,|beta| (l_prep) of_35\IN|relative|adjusted|the (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|cardiovascular|total
D019207_D003920 NONE carotene_29\NN|,|,|and|folate|vitamin (r_conj) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (r_conj) type_8\NN|risk|, (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D019207_D003920 NONE carotene_29\NN|,|,|and|folate|vitamin (r_conj) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (l_prep) of_15\IN|,|and|intakes (l_pobj) diabetes_16\NNS|NONE
D019207_D002318 NONE carotene_29\NN|,|,|and|folate|vitamin (r_conj) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (r_conj) type_8\NN|risk|, (r_appos) factors_6\NNS|NONE (l_compound) risk_5\NN|type|, (l_compound) disease_4\NN|NONE
D019207_D002318 NONE carotene_29\NN|,|,|and|folate|vitamin (l_appos) risks_34\NNS|,|beta| (l_prep) of_35\IN|relative|adjusted|the (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|cardiovascular|total
D001205_D003324 NONE C_6\NN|from|and|mortality (r_compound) intake_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relation_3\NN|We|,|)|disease|. (r_dobj) studied_1\VBD|NONE (l_dep) disease_22\NN|We|relation|,|)|.
D001205_D002318 CID C_3\NN|Does|risk|? (r_nsubj) increase_4\VB|NONE (l_dobj) risk_7\NN|Does|?|C (l_compound) disease_6\NN|in
D001205_D002318 CID C_10\NN|mortality|from|and (r_compound) intake_11\NN|NONE (l_prep) from_14\IN|C|mortality|and (l_pobj) disease_16\NN|NONE
D001205_D002318 CID C_6\NN|from|and|mortality (r_compound) intake_7\NN|NONE (l_prep) from_10\IN|C|and|mortality (l_pobj) disease_13\NN|NONE
D001205_D002318 CID C_63\NN|total|from (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|,|,|.|P|.|( (r_prep) 1.0_41\CD|adjustment|.|After (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|.|.|After (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_compound) risk_5\NN|type|, (l_compound) disease_4\NN|NONE
D001205_D002318 CID C_63\NN|total|from (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|,|,|.|P|.|( (r_prep) 1.0_41\CD|adjustment|.|After (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|.|.|After (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_appos) type_8\NN|risk|, (l_conj) duration_14\NN|used|of (l_conj) intakes_19\NNS|,|and|of (l_prep) of_20\IN|NONE (l_pobj) E_24\NN|NONE (l_conj) carotene_29\NN|,|,|and|folate|vitamin (l_appos) risks_34\NNS|,|beta| (l_prep) of_35\IN|relative|adjusted|the (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|cardiovascular|total
D001205_D002318 CID C_1\NN|NONE (r_compound) intake_2\NN|.|unrelated (r_nsubj) was_3\VBD|NONE (l_acomp) unrelated_4\JJ|intake|. (l_prep) to_5\IN|NONE (l_pobj) mortality_6\NN|NONE (l_prep) from_7\IN|in (l_pobj) disease_9\NN|NONE
D001205_D002318 CID C_3\NN|A|high|from (r_compound) intake_4\NN|is|with|. (r_nsubjpass) associated_8\VBN|NONE (l_prep) with_9\IN|is|intake|. (l_pobj) risk_12\NN|NONE (l_prep) of_13\IN|increased|an (l_pobj) mortality_16\NN|NONE (l_compound) disease_15\NN|in|cardiovascular
D005492_D003920 NONE folate_21\NN|,|,|and|vitamin|carotene (r_nmod) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (r_conj) type_8\NN|risk|, (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D005492_D003920 NONE folate_21\NN|,|,|and|vitamin|carotene (r_nmod) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (l_prep) of_15\IN|,|and|intakes (l_pobj) diabetes_16\NNS|NONE
D001205_D020521 NONE C_6\NN|from|and|mortality (r_compound) intake_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relation_3\NN|We|,|)|disease|. (r_dobj) studied_1\VBD|NONE (l_dep) disease_22\NN|We|relation|,|)|. (l_conj) stroke_30\NN|and|coronary|,||artery|n
D014810_D003920 NONE E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (r_conj) type_8\NN|risk|, (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D014810_D003920 NONE E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|,|and|of (r_conj) duration_14\NN|used|of (l_prep) of_15\IN|,|and|intakes (l_pobj) diabetes_16\NNS|NONE
D001205_D003920 NONE C_3\NN|Does|risk|? (r_nsubj) increase_4\VB|NONE (l_dobj) risk_7\NN|Does|?|C (l_prep) in_8\IN|disease (l_pobj) women_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) diabetes_11\NNS|NONE
D001205_D003920 NONE C_12\NN|NONE (r_pobj) of_10\IN|high|in|a (r_prep) intake_9\NN|might|that|atherosclerosis (l_prep) in_13\IN|high|of|a (l_pobj) persons_15\NNS|NONE (l_amod) diabetic_14\JJ|NONE
D001205_D003920 NONE C_6\NN|from|and|mortality (r_compound) intake_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relation_3\NN|We|,|)|disease|. (r_dobj) studied_1\VBD|NONE (l_dep) disease_22\NN|We|relation|,|)|. (l_conj) stroke_30\NN|and|coronary|,||artery|n (l_prep) in_36\IN|)||(|n (l_pobj) women_39\NNS|NONE (l_relcl) reported_41\VBD||postmenopausal (l_xcomp) being_42\VBG|who (l_acomp) diabetic_43\JJ|NONE
D001205_D003920 NONE C_63\NN|total|from (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|,|,|.|P|.|( (r_prep) 1.0_41\CD|adjustment|.|After (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|.|.|After (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_appos) type_8\NN|risk|, (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D001205_D003920 NONE C_63\NN|total|from (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|,|,|.|P|.|( (r_prep) 1.0_41\CD|adjustment|.|After (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|.|.|After (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_appos) type_8\NN|risk|, (l_conj) duration_14\NN|used|of (l_prep) of_15\IN|,|and|intakes (l_pobj) diabetes_16\NNS|NONE
D001205_D003920 NONE C_3\NN|A|high|from (r_compound) intake_4\NN|is|with|. (r_nsubjpass) associated_8\VBN|NONE (l_prep) with_9\IN|is|intake|. (l_pobj) risk_12\NN|NONE (l_prep) of_13\IN|increased|an (l_pobj) mortality_16\NN|NONE (l_prep) in_17\IN|disease|cardiovascular (l_pobj) women_19\NNS|NONE (l_prep) with_20\IN|postmenopausal (l_pobj) diabetes_21\NNS|NONE
16563323
D005045_D011537 NONE etomidate_10\NN|NONE (l_prep) without_12\IN|Pretreatment|.|induction|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|, (l_conj) pruritus_24\NN|or|,
C071741_D001049 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|.|induction|without|after (r_nsubj) etomidate_10\NN|NONE (l_prep) without_12\IN|Pretreatment|.|induction|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|,
D005045_D001049 NONE etomidate_10\NN|NONE (l_prep) without_12\IN|Pretreatment|.|induction|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|,
C071741_D011537 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|.|induction|without|after (r_nsubj) etomidate_10\NN|NONE (l_prep) without_12\IN|Pretreatment|.|induction|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|, (l_conj) pruritus_24\NN|or|,
C071741_D009325 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|.|induction|without|after (r_nsubj) etomidate_10\NN|NONE (l_prep) without_12\IN|Pretreatment|.|induction|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|,
D005045_D009325 NONE etomidate_10\NN|NONE (l_prep) without_12\IN|Pretreatment|.|induction|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|,
D005045_D009207 CID etomidate_5\NN|.|myoclonus|pretreatment (r_advcl) reduces_2\VBZ|NONE (l_dobj) myoclonus_3\NN|etomidate|.|pretreatment
D005045_D009207 CID etomidate_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) induction_30\NN|NONE (r_amod) anesthesia_29\NN|NONE (r_pobj) after_28\IN|on|the|of (r_prep) effect_20\NN|and|with (l_prep) on_23\IN|the|after|of (l_pobj) incidence_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) myoclonus_27\NN|NONE
D005045_D009207 CID etomidate_16\NN|,|In|.|with|were|patients (r_advcl) associated_8\VBN|NONE (l_prep) with_9\IN|,|In|.|were|patients|etomidate (l_pobj) incidence_12\NN|NONE (l_prep) of_13\IN|increased (l_pobj) myoclonus_14\NN|NONE
D005045_D009207 CID etomidate_10\NN|NONE (l_nsubj) Pretreatment_0\NN|.|induction|without|after (l_appos) myoclonus_8\NN|with
D005045_D009207 CID etomidate_9\NN|.|incidence|experience (r_advcl) increased_2\VBD|NONE (l_dobj) incidence_3\NN|etomidate|.|experience (l_prep) of_4\IN|NONE (l_pobj) myoclonus_5\NN|NONE
C071741_D009207 NONE Remifentanil_0\NNP|NONE (r_compound) pretreatment_1\NN|etomidate|.|myoclonus (r_nsubj) reduces_2\VBZ|NONE (l_dobj) myoclonus_3\NN|etomidate|.|pretreatment
C071741_D009207 NONE remifentanil_13\NN|/|microg| (r_nmod) kg_17\NNS|NONE (r_pobj) with_12\IN|and|effect (r_prep) pretreatment_11\NN|NONE (l_conj) effect_20\NN|and|with (l_prep) on_23\IN|the|after|of (l_pobj) incidence_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) myoclonus_27\NN|NONE
C071741_D009207 NONE remifentanil_9\NN|%|)|(|the (r_compound) group_10\NN|NONE (r_pobj) in_7\IN|than|significantly (r_prep) lower_6\JJR|P|incidence|(|. (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|P|(|.|lower (l_prep) of_2\IN|The (l_pobj) myoclonus_3\NN|NONE
C071741_D009207 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|.|induction|without|after (l_appos) myoclonus_8\NN|with
16584858
C009591_D017202 NONE chloride_10\NN|used|TTC (r_nmod) test_14\NN|NONE (l_acl) used_15\VBN|TTC|chloride (l_prep) for_16\IN|NONE (l_pobj) assay_20\NN|NONE (l_prep) of_21\IN|mapping|macroscopic (l_pobj) myocardium_24\NN|NONE
C009591_D017202 NONE TTC_12\NNP|used|chloride (r_nmod) test_14\NN|NONE (l_acl) used_15\VBN|TTC|chloride (l_prep) for_16\IN|NONE (l_pobj) assay_20\NN|NONE (l_prep) of_21\IN|mapping|macroscopic (l_pobj) myocardium_24\NN|NONE
D007501_D009202 NONE iron_58\NN|binding|reduced (r_nmod) capacity_60\NN|and|acid|uric (r_conj) level_54\NN|.|caused|, (r_dobj) increased_51\VBN|NONE (l_ccomp) caused_20\VBD|.|level|, (l_dobj) damage_22\NN|injection|creatine
C013592_D017202 NONE mangiferin_4\NN|NONE (r_pobj) of_3\IN|The|protective (r_prep) role_2\NN|was|by|. (r_nsubjpass) analyzed_6\VBN|NONE (l_agent) by_7\IN|was|role|. (l_pobj) test_14\NN|NONE (l_acl) used_15\VBN|TTC|chloride (l_prep) for_16\IN|NONE (l_pobj) assay_20\NN|NONE (l_prep) of_21\IN|mapping|macroscopic (l_pobj) myocardium_24\NN|NONE
C013592_D009203 NONE mangiferin_2\NN|NONE (l_prep) on_3\IN|NONE (l_pobj) alterations_5\NNS|NONE (l_prep) in_9\IN|biochemical|and|status (l_pobj) infarction_14\NN|NONE
C013592_D009203 NONE mangiferin_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) pretreatment_1\NN|NONE (r_pobj) Upon_0\IN|weight|.|in|given|(|protected (r_prep) suspended_9\VBN|NONE (l_prep) given_17\VBN|weight|.|in|Upon|(|protected (l_prep) to_22\IN|for|intraperitoneally (l_pobj) rats_24\NNS|NONE (l_compound) MI_23\NNP|NONE
C013592_D009203 NONE mangiferin_16\JJ|NONE (r_compound) administration_17\NN|NONE (r_pobj) upon_15\IN|significantly|tissue|.|compared (r_prep) rose_13\VBD|NONE (l_prep) compared_19\VBN|significantly|tissue|.|upon (l_prep) to_20\IN|as (l_pobj) rats_25\NNS|NONE (l_compound) MI_24\NNP|induced
C013592_D009203 NONE mangiferin_8\NN|due|that|effect (r_nsubj) exerts_9\VBZ|is|.|From|it (l_dobj) effect_12\NN|due|that|mangiferin (l_prep) against_13\IN|beneficial|a (l_pobj) MI_17\NNP|NONE
D014527_D009202 NONE acid_53\NN|and|capacity|uric (r_compound) level_54\NN|.|caused|, (r_dobj) increased_51\VBN|NONE (l_ccomp) caused_20\VBD|.|level|, (l_dobj) damage_22\NN|injection|creatine
C013592_D006331 NONE mangiferin_8\NN|due|that|effect (r_nsubj) exerts_9\VBZ|is|.|From|it (l_prep) due_18\IN|that|mangiferin|effect (l_pcomp) to_19\IN|NONE (l_pobj) potential_22\NN|NONE (l_relcl) regulated_25\VBD|its|antioxidant|, (l_prep) against_30\IN|which|system (l_pobj) damage_32\NN|NONE
D001205_D009203 NONE C_31\NN|, (r_conj) cerruloplasmin_28\NN|such (r_pobj) as_27\IN|enzymic|levels (r_prep) antioxidants_25\NNS|,|catalase|superoxide|, (r_appos) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D019344_D009202 NONE lactate_36\NN|LDH|(|) (r_compound) dehydrogenase_37\NN|NONE (r_pobj) of_34\IN|increased|the (r_prep) activity_33\NN|NONE (r_pobj) by_30\IN|was|which|and (r_agent) determined_29\VBN|rat|, (r_relcl) heart_25\NN|NONE (r_pobj) in_23\IN|myocardial (r_prep) damage_22\NN|injection|creatine
D005978_D009203 NONE glutathione_12\NN|,|transferase (r_compound) peroxidase_13\NN|, (r_conj) catalase_10\NNP|antioxidants|,|superoxide|, (r_conj) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D005978_D009203 NONE glutathione_15\NN|and|activities (r_compound) transferase_16\NN|,|glutathione (r_conj) peroxidase_13\NN|, (r_conj) catalase_10\NNP|antioxidants|,|superoxide|, (r_conj) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D005978_D009203 NONE glutathione_18\NN|NONE (r_compound) reductase_19\NN|NONE (r_compound) activities_20\NNS|glutathione|and (r_conj) transferase_16\NN|,|glutathione (r_conj) peroxidase_13\NN|, (r_conj) catalase_10\NNP|antioxidants|,|superoxide|, (r_conj) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D005978_D009203 NONE glutathione_36\NN|and|Vitamin (r_conj) E_34\NN|,|Vitamin (r_conj) C_31\NN|, (r_conj) cerruloplasmin_28\NN|such (r_pobj) as_27\IN|enzymic|levels (r_prep) antioxidants_25\NNS|,|catalase|superoxide|, (r_appos) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D007545_D009202 NONE ISPH_3\NNP|NONE (r_pobj) of_2\IN|to|Subcutaneous (r_prep) injection_1\NN|damage|creatine (r_nsubj) caused_20\VBD|.|level|, (l_dobj) damage_22\NN|injection|creatine
D003401_D009202 NONE creatine_42\NN|injection|damage (r_conj) caused_20\VBD|.|level|, (l_dobj) damage_22\NN|injection|creatine
D014810_D009203 NONE E_34\NN|,|Vitamin (r_conj) C_31\NN|, (r_conj) cerruloplasmin_28\NN|such (r_pobj) as_27\IN|enzymic|levels (r_prep) antioxidants_25\NNS|,|catalase|superoxide|, (r_appos) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D004121_D009203 NONE sulphoxide_15\RB|NONE (r_pobj) of_13\IN|)| (r_prep) ml_12\NNS|NONE (r_pobj) in_10\IN|weight|.|given|Upon|(|protected (r_prep) suspended_9\VBN|NONE (l_prep) given_17\VBN|weight|.|in|Upon|(|protected (l_prep) to_22\IN|for|intraperitoneally (l_pobj) rats_24\NNS|NONE (l_compound) MI_23\NNP|NONE
D013481_D009203 NONE superoxide_7\JJ|antioxidants|,|catalase|, (r_amod) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|were|. (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|tissue|were|. (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D007545_D006331 NONE ISPH_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) MI_17\NNP|NONE (r_pobj) against_13\IN|beneficial|a (r_prep) effect_12\NN|due|that|mangiferin (r_dobj) exerts_9\VBZ|is|.|From|it (l_prep) due_18\IN|that|mangiferin|effect (l_pcomp) to_19\IN|NONE (l_pobj) potential_22\NN|NONE (l_relcl) regulated_25\VBD|its|antioxidant|, (l_prep) against_30\IN|which|system (l_pobj) damage_32\NN|NONE
D007545_D009203 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|in|myocardial (r_amod) infarction_14\NN|NONE
D007545_D009203 CID isoproterenol_5\NN|NONE (r_pobj) on_4\IN|MI|(|in|)|(|through|myocardial|ISPH)induced (r_prep) infarction_9\NN|,|)|.|(
D007545_D009203 CID isoproterenol_5\NN|NONE (r_pobj) on_4\IN|MI|(|in|)|(|through|myocardial|ISPH)induced (r_prep) infarction_9\NN|,|)|.|( (l_appos) MI_11\NNP|(|in|)|(|through|myocardial|on|ISPH)induced
D007545_D009203 CID ISPH)-induced_7\JJ|MI|(|in|)|(|through|myocardial|on (r_amod) infarction_9\NN|,|)|.|(
D007545_D009203 CID ISPH)-induced_7\JJ|MI|(|in|)|(|through|myocardial|on (r_amod) infarction_9\NN|,|)|.|( (l_appos) MI_11\NNP|(|in|)|(|through|myocardial|on|ISPH)induced
D007545_D009203 CID ISPH_21\NNP| (r_npadvmod) induced_23\VBN|MI (r_amod) rats_25\NNS|NONE (l_compound) MI_24\NNP|induced
D007545_D009203 CID ISPH_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) MI_17\NNP|NONE
2004
D000639_D002037 CID Elavil_5\NNP|nortriptyline (r_conj) Aventyl_0\NNP|left|produced|branch|each|in|. (r_nsubj) block_14\NN|NONE
D000639_D002037 CID amitriptyline_7\FW|NONE (r_appos) Elavil_5\NNP|nortriptyline (r_conj) Aventyl_0\NNP|left|produced|branch|each|in|. (r_nsubj) block_14\NN|NONE
D013881_D017180 CID Mellaril_8\NNP|,|was|receiving|be|. (r_nsubj) appeared_12\VBD|NONE (l_xcomp) be_14\VB|,|was|receiving|Mellaril|. (l_acomp) responsible_15\JJ|to (l_prep) for_16\IN|NONE (l_pobj) cases_18\NNS|NONE (l_prep) of_19\IN|,|five (l_pobj) tachycardia_21\NN|NONE
D013881_D017180 CID thioridazine_10\NNP|) (r_appos) Mellaril_8\NNP|,|was|receiving|be|. (r_nsubj) appeared_12\VBD|NONE (l_xcomp) be_14\VB|,|was|receiving|Mellaril|. (l_acomp) responsible_15\JJ|to (l_prep) for_16\IN|NONE (l_pobj) cases_18\NNS|NONE (l_prep) of_19\IN|,|five (l_pobj) tachycardia_21\NN|NONE
D010640_D005117 NONE phenothiazines_16\NNS|NONE (r_dobj) receiving_15\VBG|NONE (r_acl) patients_14\NNS|NONE (r_pobj) to_13\IN|cardiac (r_prep) complications_12\NNS|NONE
D008012_D001145 NONE lidocaine_8\NN|NONE (r_pobj) of_7\IN|intravenous (r_prep) administration_6\NN|and (r_pobj) to_4\IN|arrhythmias|direct (r_prep) responded_3\VBD|was|;|in|pacing|. (l_nsubj) arrhythmias_2\NNS|to|direct
D011433_D001145 NONE propranolol_27\NN|NONE (r_pobj) of_26\IN|combined|and|some|administration (r_prep) instances_22\NNS|NONE (r_pobj) in_20\IN|was|;|responded|pacing|. (r_prep) required_19\VBN|NONE (l_ccomp) responded_3\VBD|was|;|in|pacing|. (l_nsubj) arrhythmias_2\NNS|to|direct
D002746_D013617 NONE Thorazine_7\NN|NONE (r_dobj) receiving_6\VBG|one (r_acl) patient_5\NN|NONE (r_pobj) in_3\IN|tachycardia|. (r_prep) developed_2\VBN|NONE (l_nsubj) tachycardia_1\NN|in|.
D002746_D013617 NONE chlorpromazine_9\NN|NONE (r_appos) Thorazine_7\NN|NONE (r_dobj) receiving_6\VBG|one (r_acl) patient_5\NN|NONE (r_pobj) in_3\IN|tachycardia|. (r_prep) developed_2\VBN|NONE (l_nsubj) tachycardia_1\NN|in|.
D009661_D002037 CID Aventyl_0\NNP|left|produced|branch|each|in|. (r_nsubj) block_14\NN|NONE
D009661_D002037 CID nortriptyline_2\NN|Elavil (r_appos) Aventyl_0\NNP|left|produced|branch|each|in|. (r_nsubj) block_14\NN|NONE
12745515
D016642_D012892 NONE bupropion_9\NN|and|sleep (r_conj) deprivation_4\NN|NONE
D016642_D012892 NONE bupropion_12\NN|and|release|deprivation (r_compound) use_13\NN|NONE (l_conj) deprivation_16\NN|and|bupropion|release
D016642_D012892 NONE bupropion_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) seizures_14\NNS|NONE (r_pobj) of_10\IN|the (r_prep) risk_9\NN|NONE (r_pobj) to_7\IN|deprivation|that|may (r_prep) add_6\VB|We|. (l_nsubj) deprivation_4\NN|that|may|to
D016642_D012640 CID bupropion_9\NN|and|sleep (r_conj) deprivation_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Seizure_0\NN|NONE
D016642_D012640 CID bupropion_12\NN|and|release|deprivation (r_compound) use_13\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|a|generalized (r_acl) seizure_6\NN|.|report
D016642_D012640 CID bupropion_4\NN|NONE (r_compound) use_5\NN|NONE (r_pobj) of_3\IN| (r_prep) weeks_2\NNS|NONE (r_pobj) After_0\IN|seizure|subject|,|.|after (r_prep) experienced_9\VBD|NONE (l_dobj) seizure_14\NN|After|subject|,|.|after
D016642_D012640 CID bupropion_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) seizures_14\NNS|NONE
3708922
D000666_D007674 NONE B_24\NN|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|,|a|nephrotoxic (r_prep) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|,|as|a
D000666_D064420 NONE B_24\NN|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|,|a|nephrotoxic (r_prep) potential_12\NN|NONE (r_pobj) with_9\IN|The|combined|drugs|of (r_prep) administration_2\NN|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|administration|.|not|did|CSA (l_dobj) toxicity_42\NN|NONE
D007654_D007674 NONE ketoconazole_26\NN|amphothericin|and (r_conj) B_24\NN|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|,|a|nephrotoxic (r_prep) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|,|as|a
D016572_D064420 NONE CSA_4\NNP|NONE (r_pobj) of_3\IN|The|with|combined|drugs (r_prep) administration_2\NN|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|administration|.|not|did|CSA (l_dobj) toxicity_42\NN|NONE
D016572_D064420 NONE CSA_40\NNP|administration|induced|.|not|did (r_dobj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|administration|.|not|did|CSA (l_dobj) toxicity_42\NN|NONE
D007654_D064420 NONE ketoconazole_26\NN|amphothericin|and (r_conj) B_24\NN|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|,|a|nephrotoxic (r_prep) potential_12\NN|NONE (r_pobj) with_9\IN|The|combined|drugs|of (r_prep) administration_2\NN|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|administration|.|not|did|CSA (l_dobj) toxicity_42\NN|NONE
D005839_D007674 NONE gentamicin_16\NN|such (r_pobj) as_15\IN|,|a|nephrotoxic (r_prep) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|,|as|a
D005839_D007674 NONE Gentamicin_0\NNP|,|however|.|nephrotoxicity|, (r_nsubj) increased_7\VBD|NONE (l_dobj) nephrotoxicity_9\NN|,|however|.|,|Gentamicin
D016572_D007674 CID cyclosporine_1\NN|Experimental|.|risk|: (r_compound) nephrotoxicity_2\NN|NONE
D016572_D007674 CID cyclosporine_3\NN|in|or (r_pobj) of_2\IN|The (l_conj) in_9\IN|cyclosporine|or (l_pobj) combination_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) chemotherapeutics_13\NNS|NONE (l_prep) in_14\IN|various (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) toxicity_19\NN|NONE
D016572_D007674 CID CSA_5\NNP|NONE (r_appos) cyclosporine_3\NN|in|or (r_pobj) of_2\IN|The (l_conj) in_9\IN|cyclosporine|or (l_pobj) combination_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) chemotherapeutics_13\NNS|NONE (l_prep) in_14\IN|various (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) toxicity_19\NN|NONE
D016572_D007674 CID CSA_4\NNP|NONE (r_pobj) of_3\IN|The|with|combined|drugs (r_prep) administration_2\NN|induced|.|not|did|CSA (l_prep) with_9\IN|The|combined|drugs|of (l_pobj) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|,|as|a
D016572_D007674 CID CSA_40\NNP|administration|induced|.|not|did (r_dobj) aggravate_38\VB|NONE (l_nsubj) administration_2\NN|induced|.|not|did|CSA (l_prep) with_9\IN|The|combined|drugs|of (l_pobj) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|,|as|a
D016572_D007674 CID CSA_8\NNP|NONE (r_compound) nephrotoxicity_9\NN|,|however|.|,|Gentamicin
D016572_D007674 CID CSA_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|the (r_acl) nephrotoxicity_3\NN|,|mechanism|Thus|.
D005839_D064420 NONE gentamicin_16\NN|such (r_pobj) as_15\IN|,|a|nephrotoxic (r_prep) potential_12\NN|NONE (r_pobj) with_9\IN|The|combined|drugs|of (r_prep) administration_2\NN|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|administration|.|not|did|CSA (l_dobj) toxicity_42\NN|NONE
15266215
C406224_D001168 NONE valdecoxib_6\NNS|NONE (l_prep) versus_7\IN|inhibitor|the|specific|cyclooxygenase (l_pobj) agents_10\NNS|NONE (l_conj) placebo_12\NN|antiinflammatory|and|nonsteroidal (l_prep) on_13\IN|NONE (l_pobj) events_16\NNS|NONE (l_prep) in_17\IN|cardiovascular|thrombotic (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) arthritis_20\NN|NONE
D009288_D013927 NONE naproxen_46\NN|and|,|tid|or|data (r_conj) ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|.|incidence|was|by|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|cardiovascular|(|)|thrombotic
D009288_D013927 NONE naproxen_46\NN|and|,|tid|or|data (r_conj) ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|.|incidence|was|by|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|cardiovascular|(|)|thrombotic
D009288_D010003 NONE naproxen_46\NN|and|,|tid|or|data (r_conj) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
D007052_D010003 NONE ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
C406224_D010003 NONE valdecoxib_6\NNS|NONE (r_pobj) for_5\IN|cardiovascular|event|inhibitor|, (r_prep) data_4\NNS|We|. (l_appos) inhibitor_11\NN|cardiovascular|event|for|, (l_prep) in_12\IN|COXspecific|treated|a|new (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN| (l_pobj) osteoarthritis_17\NN|NONE
C406224_D010003 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|.|incidence|was|NSAID|, (r_prep) determined_19\VBN|NONE (l_appos) NSAID_33\NNP|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
C406224_D010003 NONE valdecoxib_24\NN|NONE (r_compound) doses_25\NNS|term|Short|with (r_conj) treatment_5\NN|not|was|.|with (r_nsubjpass) associated_28\VBN|NONE (l_prep) with_29\IN|not|treatment|was|. (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|an|increased (l_pobj) events_35\NNS|NONE (l_amod) relative_36\JJ|thrombotic (l_prep) to_37\IN|NONE (l_pobj) NSAIDs_39\NNPS|NONE (l_prep) in_42\IN|placebo|in|nonselective|or (l_pobj) patients_47\NNS|NONE (l_nmod) osteoarthritis_43\NN|arthritis
D004008_D013927 NONE diclofenac_35\NN|,|mg (r_nmod) bid_38\NN|(|ibuprofen|nonselective (r_appos) NSAID_33\NNP|.|incidence|was|by|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|cardiovascular|(|)|thrombotic
D004008_D013927 NONE diclofenac_35\NN|,|mg (r_nmod) bid_38\NN|(|ibuprofen|nonselective (r_appos) NSAID_33\NNP|.|incidence|was|by|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|cardiovascular|(|)|thrombotic
D004008_D001172 NONE diclofenac_35\NN|,|mg (r_nmod) bid_38\NN|(|ibuprofen|nonselective (r_appos) NSAID_33\NNP|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|osteoarthritis|were
C406224_D001172 NONE valdecoxib_6\NNS|NONE (r_pobj) for_5\IN|cardiovascular|event|inhibitor|, (r_prep) data_4\NNS|We|. (l_appos) inhibitor_11\NN|cardiovascular|event|for|, (l_prep) in_12\IN|COXspecific|treated|a|new (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN| (l_pobj) osteoarthritis_17\NN|NONE (l_conj) arthritis_20\NN|and
C406224_D001172 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|.|incidence|was|NSAID|, (r_prep) determined_19\VBN|NONE (l_appos) NSAID_33\NNP|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|osteoarthritis|were
C406224_D001172 NONE valdecoxib_24\NN|NONE (r_compound) doses_25\NNS|term|Short|with (r_conj) treatment_5\NN|not|was|.|with (r_nsubjpass) associated_28\VBN|NONE (l_prep) with_29\IN|not|treatment|was|. (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|an|increased (l_pobj) events_35\NNS|NONE (l_amod) relative_36\JJ|thrombotic (l_prep) to_37\IN|NONE (l_pobj) NSAIDs_39\NNPS|NONE (l_prep) in_42\IN|placebo|in|nonselective|or (l_pobj) patients_47\NNS|NONE (l_compound) arthritis_46\NN|osteoarthritis
C406224_D013927 NONE valdecoxib_6\NNS|NONE (l_prep) versus_7\IN|inhibitor|the|specific|cyclooxygenase (l_pobj) agents_10\NNS|NONE (l_conj) placebo_12\NN|antiinflammatory|and|nonsteroidal (l_prep) on_13\IN|NONE (l_pobj) events_16\NNS|NONE (l_amod) thrombotic_15\JJ|in|cardiovascular
C406224_D013927 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|.|incidence|was|NSAID|, (r_prep) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|cardiovascular|(|)|thrombotic
C406224_D013927 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|.|incidence|was|NSAID|, (r_prep) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|cardiovascular|(|)|thrombotic
C406224_D013927 NONE valdecoxib_12\NNS|NONE (r_pobj) for_11\IN|NONE (r_prep) similar_10\JJ|incidences|. (r_acomp) were_9\VBD|NONE (l_nsubj) incidences_5\NNS|.|similar (l_prep) of_6\IN|Crude|adjusted (l_pobj) events_8\NNS|NONE (l_amod) thrombotic_7\JJ|NONE
C406224_D013927 NONE valdecoxib_11\NN|each (r_compound) dose_12\NN|NONE (r_pobj) for_9\IN|NONE (r_prep) similar_8\JJ|.|risk|also (r_acomp) was_6\VBD|NONE (l_nsubj) risk_1\NN|.|similar|also (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|serious
C406224_D013927 NONE valdecoxib_23\NN|;|,|% (r_conj) placebo_15\NN|)|(|of (r_appos) nonusers_11\NNS|NONE (r_pobj) than_10\IN|aspirin (r_prep) users_9\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) users_6\NNS|NONE (r_pobj) for_5\IN|risk|higher|. (r_prep) was_2\VBD|NONE (l_nsubj) risk_1\NN|for|higher|. (l_amod) Thrombotic_0\JJ|NONE
C406224_D013927 NONE valdecoxib_24\NN|NONE (r_compound) doses_25\NNS|term|Short|with (r_conj) treatment_5\NN|not|was|.|with (r_nsubjpass) associated_28\VBN|NONE (l_prep) with_29\IN|not|treatment|was|. (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|an|increased (l_pobj) events_35\NNS|NONE (l_amod) thrombotic_34\JJ|relative
D007052_D013927 NONE ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|.|incidence|was|by|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|cardiovascular|(|)|thrombotic
D007052_D013927 NONE ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|.|incidence|was|by|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|.|was|by|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|cardiovascular|(|)|thrombotic
D001241_D013927 CID aspirin_8\NN|than (r_compound) users_9\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) users_6\NNS|NONE (r_pobj) for_5\IN|risk|higher|. (r_prep) was_2\VBD|NONE (l_nsubj) risk_1\NN|for|higher|. (l_amod) Thrombotic_0\JJ|NONE
D001241_D013927 CID aspirin_13\NN|NONE (r_pobj) of_12\IN|)|placebo|( (r_prep) nonusers_11\NNS|NONE (r_pobj) than_10\IN|aspirin (r_prep) users_9\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) users_6\NNS|NONE (r_pobj) for_5\IN|risk|higher|. (r_prep) was_2\VBD|NONE (l_nsubj) risk_1\NN|for|higher|. (l_amod) Thrombotic_0\JJ|NONE
D009288_D001172 NONE naproxen_46\NN|and|,|tid|or|data (r_conj) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|osteoarthritis|were
D007052_D001172 NONE ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|osteoarthritis|were
D004008_D010003 NONE diclofenac_35\NN|,|mg (r_nmod) bid_38\NN|(|ibuprofen|nonselective (r_appos) NSAID_33\NNP|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|and|,|tid|naproxen|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
3311455
D016572_D007674 CID cyclosporine_17\NN|NONE (r_pobj) with_16\IN|term (r_prep) therapy_15\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) secondary_10\JJ|chronic (r_amod) nephrotoxicity_9\NN|NONE
D016572_D007674 CID cyclosporine_8\NN|NONE (r_pobj) of_7\IN|lower|these|even (r_prep) dosages_6\NNS|required|that|nephrotoxicity|can (r_nsubj) cause_10\VB|We|. (l_dobj) nephrotoxicity_12\NN|required|dosages|that|can
20635749
D000638_D009230 CID amiodarone_6\NN|presenting (r_pobj) on_5\IN|Severe|report|failure|.|: (l_pcomp) presenting_7\VBG|amiodarone (l_prep) with_8\IN|NONE (l_pobj) coma_10\NN|NONE
D000638_D009230 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|.|report|This
D000638_D009230 CID amiodarone_19\NN|term (r_compound) therapy_20\NN|NONE (r_pobj) during_16\IN|case|one|of (r_prep) report_12\NN|.|there|To (l_prep) of_13\IN|during|case|one (l_pobj) coma_15\NN|NONE
D000638_D003128 CID amiodarone_6\NN|presenting (r_pobj) on_5\IN|Severe|report|failure|.|: (l_pcomp) presenting_7\VBG|amiodarone (l_prep) with_8\IN|NONE (l_pobj) coma_10\NN|NONE
D000638_D003128 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|.|report|This
D000638_D003128 CID amiodarone_19\NN|term (r_compound) therapy_20\NN|NONE (r_pobj) during_16\IN|case|one|of (r_prep) report_12\NN|.|there|To (l_prep) of_13\IN|during|case|one (l_pobj) coma_15\NN|NONE
D000638_D006333 NONE amiodarone_6\NN|presenting (r_pobj) on_5\IN|Severe|report|failure|.|: (r_prep) patient_4\NN|NONE (l_compound) failure_3\NN|Severe|report|.|on|:
D000638_D006333 NONE amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|.|report|This (l_prep) in_14\IN|to|secondary (l_pobj) patient_16\NN|NONE (l_prep) with_17\IN|a (l_pobj) failure_21\NN|NONE
D000638_D006333 NONE amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|.|report|This (l_prep) in_14\IN|to|secondary (l_pobj) patient_16\NN|NONE (l_prep) with_17\IN|a (l_pobj) failure_21\NN|NONE (l_appos) CHF_23\NNP|heart|severe
D000638_D006333 NONE amiodarone_4\NN|NONE (r_pobj) on_3\IN|with (r_prep) Patients_0\NNS|,|morbidity|.|and|deserve|may (l_prep) with_1\IN|on (l_pobj) CHF_2\NNP|NONE
D000638_D006333 NONE amiodarone_13\NN|NONE (l_prep) among_14\IN|NONE (l_pobj) patients_16\NNS|NONE (l_compound) CHF_15\NNP|NONE
D000638_D007037 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE
D000638_D007037 CID amiodarone_4\NN|NONE (r_pobj) on_3\IN|with (r_prep) Patients_0\NNS|,|morbidity|.|and|deserve|may (r_nsubj) suffer_6\VB|NONE (l_dobj) morbidity_8\NN|,|Patients|.|and|deserve|may (l_prep) from_11\IN|serious|and|mortality (l_pobj) hypothyroidism_12\NN|NONE
17042884
C069541_D017109 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|,|akathisia (r_prep) including_10\VBG|symptoms|,|To (l_pobj) akathisia_11\NN|,|with
C069541_D017109 NONE quetiapine_16\NN|%|)|( (r_amod) monotherapy_17\NN|NONE (r_pobj) with_15\IN|than|no (r_prep) different_14\JJ|incidence|. (r_acomp) was_12\VBD|NONE (l_nsubj) incidence_1\NN|different|. (l_prep) including_9\VBG|,|The|,|of (l_pobj) akathisia_10\NN|NONE
C069541_D017109 NONE quetiapine_9\NN|(|)|placebo|and|% (r_amod) monotherapy_10\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) similar_7\JJ|and (r_conj) low_5\JJ|,|incidence|with|.|and (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|,|with|low|.|and (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
C069541_D017109 NONE QTP_24\NNP|NONE (r_pobj) with_23\IN|,|incidence|low|.|and (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|,|with|low|.|and (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
C069541_D017109 NONE quetiapine_41\NN|NONE (r_pcomp) than_40\IN|,|%|and|,|syndrome|)|( (r_prep) tremor_21\NN|incidence|.|Haloperidol (r_npadvmod) induced_1\VBD|NONE (l_dobj) incidence_5\NN|.|tremor|Haloperidol (l_appos) 0.001_9\CD|a|higher (l_prep) of_11\IN|<|p|(|) (l_pobj) akathisia_12\NN|NONE
C069541_D017109 NONE quetiapine_13\NN|NONE (r_amod) therapy_14\NN|.|In|,|with|incidence|similar (r_nsubj) is_15\VBZ|NONE (l_nsubj) incidence_5\NN|.|In|,|with|therapy|similar (l_prep) including_9\VBG|the|,|of|, (l_pobj) akathisia_10\NN|NONE
D006220_D017109 CID Haloperidol_0\NNP|incidence|.|tremor (r_nsubj) induced_1\VBD|NONE (l_dobj) incidence_5\NN|.|tremor|Haloperidol (l_appos) 0.001_9\CD|a|higher (l_prep) of_11\IN|<|p|(|) (l_pobj) akathisia_12\NN|NONE
D006220_D014202 CID Haloperidol_0\NNP|incidence|.|tremor (r_nsubj) induced_1\VBD|NONE (l_npadvmod) tremor_21\NN|incidence|.|Haloperidol
C069541_D014202 NONE quetiapine_20\NN|NONE (r_pobj) than_19\IN|.|)|%|(|higher|a|%|)|( (r_prep) incidence_7\NN|NONE (l_appos) 0.05_11\CD|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN|<|)|p|( (l_pobj) tremor_14\NN|NONE
C069541_D014202 NONE quetiapine_20\NN|NONE (r_pobj) than_19\IN|.|)|%|(|higher|a|%|)|( (r_prep) incidence_7\NN|NONE (r_pobj) with_3\IN|was|Lithium (r_prep) associated_2\VBN|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN|NONE (l_nsubj) tremor_27\NN|may|have|.|;|to|associated
C069541_D014202 NONE quetiapine_20\NN|NONE (r_pobj) than_19\IN|.|)|%|(|higher|a|%|)|( (r_prep) incidence_7\NN|NONE (r_pobj) with_3\IN|was|Lithium (r_prep) associated_2\VBN|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN|NONE (l_prep) to_41\IN|may|have|.|;|tremor|associated (l_pobj) rate_44\NN|NONE (l_prep) of_45\IN|the|in|elevated (l_pobj) tremor_46\NN|NONE
C069541_D014202 NONE quetiapine_41\NN|NONE (r_pcomp) than_40\IN|,|%|and|,|syndrome|)|( (r_prep) tremor_21\NN|incidence|.|Haloperidol
D006220_D001480 CID haloperidol_13\NN|NONE (r_pobj) with_12\IN|whereas (r_prep) treated_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) of_9\IN|. (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|)|events (r_prep) occurred_5\VBD|NONE (l_nsubj) events_1\NNS|)|in (l_acl) related_2\VBN|Adverse (l_prep) to_3\IN|NONE (l_pobj) EPS_4\NNP|NONE
D006220_D001480 CID Haloperidol_0\NNP|incidence|.|tremor (r_nsubj) induced_1\VBD|NONE (l_npadvmod) tremor_21\NN|incidence|.|Haloperidol (l_conj) syndrome_32\NN|,|than|%|and|,|)|(
C069541_D001480 NONE quetiapine_11\NN|NONE (r_pobj) with_10\IN|of|.|level (r_prep) incidence_3\NN|NONE (l_prep) of_4\IN|with|.|level (l_pobj) symptoms_6\NNS|NONE
C069541_D001480 NONE quetiapine_11\NN|NONE (r_pobj) with_10\IN|of|.|level (r_prep) incidence_3\NN|NONE (l_prep) of_4\IN|with|.|level (l_pobj) symptoms_6\NNS|NONE (l_appos) EPS_8\NNP|extrapyramidal
C069541_D001480 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|,|akathisia (r_prep) including_10\VBG|symptoms|,|To (r_prep) evaluate_3\VB|:|. (l_dobj) symptoms_5\NNS|including|,|To
C069541_D001480 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|,|akathisia (r_prep) including_10\VBG|symptoms|,|To (r_prep) evaluate_3\VB|:|. (l_dobj) symptoms_5\NNS|including|,|To (l_appos) EPS_7\NNP|extrapyramidal
C069541_D001480 NONE quetiapine_16\NN|%|)|( (r_amod) monotherapy_17\NN|NONE (r_pobj) with_15\IN|than|no (r_prep) different_14\JJ|incidence|. (r_acomp) was_12\VBD|NONE (l_nsubj) incidence_1\NN|different|. (l_prep) of_2\IN|,|The|,|including (l_pobj) events_7\NNS|NONE (l_amod) related_5\VBN|adverse (l_npadvmod) EPS_3\NNP|
C069541_D001480 NONE QTP_8\NNP|NONE (r_pobj) with_7\IN|related|adverse (r_prep) events_6\NNS|,|different|Similarly|. (l_amod) related_4\VBN|adverse|with (l_npadvmod) EPS_2\NNP|
C069541_D001480 NONE quetiapine_41\NN|NONE (r_pcomp) than_40\IN|,|%|and|,|syndrome|)|( (r_prep) tremor_21\NN|incidence|.|Haloperidol (l_conj) syndrome_32\NN|,|than|%|and|,|)|(
C069541_D001480 NONE quetiapine_13\NN|NONE (r_amod) therapy_14\NN|.|In|,|with|incidence|similar (r_nsubj) is_15\VBZ|NONE (l_nsubj) incidence_5\NN|.|In|,|with|therapy|similar (l_prep) of_6\IN|the|,|including|, (l_pobj) EPS_7\NNP|NONE
C069541_D001714 NONE quetiapine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) studies_14\NNS|NONE (l_prep) of_15\IN|controlled (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) mania_19\NN|NONE
C069541_D001714 NONE quetiapine_14\NN|NONE (l_prep) in_15\IN|NONE (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) mania_19\NN|NONE
C069541_D001714 NONE quetiapine_13\NN|NONE (r_amod) therapy_14\NN|.|In|,|with|incidence|similar (r_nsubj) is_15\VBZ|NONE (l_prep) In_0\IN|.|,|with|incidence|therapy|similar (l_pobj) mania_2\NN|NONE
D008094_D001480 CID Li_10\NNP|)|%|(|/ (r_nmod) DVP_12\NNP|+ (r_conj) QTP_8\NNP|NONE (r_pobj) with_7\IN|related|adverse (r_prep) events_6\NNS|,|different|Similarly|. (l_amod) related_4\VBN|adverse|with (l_npadvmod) EPS_2\NNP|
D008094_D001480 CID Li_24\NNP|/|)|(|% (r_nmod) DVP_26\NNP|+ (r_conj) PBO_22\NNP|NONE (r_pobj) with_21\IN|NONE (r_prep) than_20\IN|no (r_prep) different_19\JJ|,|Similarly|.|events (r_acomp) were_17\VBD|NONE (l_nsubj) events_6\NNS|,|different|Similarly|. (l_amod) related_4\VBN|adverse|with (l_npadvmod) EPS_2\NNP|
D008094_D001480 CID lithium_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treated_26\VBN|NONE (r_acl) patients_25\NNS|NONE (r_pobj) of_24\IN|. (r_prep) %_23\NN|NONE (r_pobj) whereas_21\IN|with (r_prep) treated_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) of_9\IN|. (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|)|events (r_prep) occurred_5\VBD|NONE (l_nsubj) events_1\NNS|)|in (l_acl) related_2\VBN|Adverse (l_prep) to_3\IN|NONE (l_pobj) EPS_4\NNP|NONE
D008094_D017109 NONE Li_26\NNP|/|%|)|(|and|PBO (r_nmod) DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|,|incidence|low|.|and (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|,|with|low|.|and (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
D008094_D017109 NONE Li_36\NNP|/ (r_compound) DVP_38\NNP|(|+|)|% (r_conj) PBO_34\NNP|Li|/|%|)|(|and (r_conj) DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|,|incidence|low|.|and (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|,|with|low|.|and (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
D008094_D014202 CID Lithium_0\NN|was|with (r_nsubjpass) associated_2\VBN|may|have|.|;|to|tremor (l_prep) with_3\IN|was|Lithium (l_pobj) incidence_7\NN|NONE (l_appos) 0.05_11\CD|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN|<|)|p|( (l_pobj) tremor_14\NN|NONE
D008094_D014202 CID Lithium_0\NN|was|with (r_nsubjpass) associated_2\VBN|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN|NONE (l_nsubj) tremor_27\NN|may|have|.|;|to|associated
D008094_D014202 CID Lithium_0\NN|was|with (r_nsubjpass) associated_2\VBN|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN|NONE (l_prep) to_41\IN|may|have|.|;|tremor|associated (l_pobj) rate_44\NN|NONE (l_prep) of_45\IN|the|in|elevated (l_pobj) tremor_46\NN|NONE
D008094_D014202 CID lithium_36\NN|NONE (r_pobj) of_35\IN|a|known|adverse (r_prep) effect_34\NN|which (r_attr) is_30\VBZ|,|cerebellar|, (r_relcl) tremor_27\NN|may|have|.|;|to|associated (r_nsubj) contributed_40\VBN|NONE (l_ccomp) associated_2\VBN|may|have|.|;|to|tremor (l_prep) with_3\IN|was|Lithium (l_pobj) incidence_7\NN|NONE (l_appos) 0.05_11\CD|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN|<|)|p|( (l_pobj) tremor_14\NN|NONE
D008094_D014202 CID lithium_36\NN|NONE (r_pobj) of_35\IN|a|known|adverse (r_prep) effect_34\NN|which (r_attr) is_30\VBZ|,|cerebellar|, (r_relcl) tremor_27\NN|may|have|.|;|to|associated
D008094_D014202 CID lithium_36\NN|NONE (r_pobj) of_35\IN|a|known|adverse (r_prep) effect_34\NN|which (r_attr) is_30\VBZ|,|cerebellar|, (r_relcl) tremor_27\NN|may|have|.|;|to|associated (r_nsubj) contributed_40\VBN|NONE (l_prep) to_41\IN|may|have|.|;|tremor|associated (l_pobj) rate_44\NN|NONE (l_prep) of_45\IN|the|in|elevated (l_pobj) tremor_46\NN|NONE
D008094_D014202 CID lithium_50\NN|NONE (r_compound) therapy_51\NN|NONE (r_dobj) receiving_49\VBG|NONE (r_acl) patients_48\NNS|NONE (r_pobj) in_47\IN|of|the|elevated (r_prep) rate_44\NN|NONE (r_pobj) to_41\IN|may|have|.|;|tremor|associated (r_prep) contributed_40\VBN|NONE (l_ccomp) associated_2\VBN|may|have|.|;|to|tremor (l_prep) with_3\IN|was|Lithium (l_pobj) incidence_7\NN|NONE (l_appos) 0.05_11\CD|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN|<|)|p|( (l_pobj) tremor_14\NN|NONE
D008094_D014202 CID lithium_50\NN|NONE (r_compound) therapy_51\NN|NONE (r_dobj) receiving_49\VBG|NONE (r_acl) patients_48\NNS|NONE (r_pobj) in_47\IN|of|the|elevated (r_prep) rate_44\NN|NONE (r_pobj) to_41\IN|may|have|.|;|tremor|associated (r_prep) contributed_40\VBN|NONE (l_nsubj) tremor_27\NN|may|have|.|;|to|associated
D008094_D014202 CID lithium_50\NN|NONE (r_compound) therapy_51\NN|NONE (r_dobj) receiving_49\VBG|NONE (r_acl) patients_48\NNS|NONE (r_pobj) in_47\IN|of|the|elevated (r_prep) rate_44\NN|NONE (l_prep) of_45\IN|the|in|elevated (l_pobj) tremor_46\NN|NONE
D014635_D001480 NONE DVP_12\NNP|+ (r_conj) QTP_8\NNP|NONE (r_pobj) with_7\IN|related|adverse (r_prep) events_6\NNS|,|different|Similarly|. (l_amod) related_4\VBN|adverse|with (l_npadvmod) EPS_2\NNP|
D014635_D001480 NONE DVP_26\NNP|+ (r_conj) PBO_22\NNP|NONE (r_pobj) with_21\IN|NONE (r_prep) than_20\IN|no (r_prep) different_19\JJ|,|Similarly|.|events (r_acomp) were_17\VBD|NONE (l_nsubj) events_6\NNS|,|different|Similarly|. (l_amod) related_4\VBN|adverse|with (l_npadvmod) EPS_2\NNP|
D014635_D017109 NONE DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|,|incidence|low|.|and (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|,|with|low|.|and (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
D014635_D017109 NONE DVP_38\NNP|(|+|)|% (r_conj) PBO_34\NNP|Li|/|%|)|(|and (r_conj) DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|,|incidence|low|.|and (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|,|with|low|.|and (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
85485
D001556_D006528 CID hexachloride_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|.|in (r_acl) Changes_0\NNS|NONE (l_prep) in_1\IN|induced|. (l_pobj) peroxisomes_2\NNS|NONE (l_prep) in_3\IN|NONE (l_pobj) liver_5\NN|NONE (l_conj) hepatoma_7\NN|preneoplastic|and
D001556_D006528 CID hexachloride_17\NN|NONE (r_pobj) by_11\IN|examined|.|in|Peroxisomes (r_prep) induced_8\VBN|NONE (l_nsubj) Peroxisomes_0\NNS|examined|.|in|by (l_prep) in_1\IN|NONE (l_pobj) hepatomas_2\NNS|lesions
D001556_D017093 NONE hexachloride_17\NN|NONE (r_pobj) by_11\IN|examined|.|in|Peroxisomes (r_prep) induced_8\VBN|NONE (l_nsubj) Peroxisomes_0\NNS|examined|.|in|by (l_prep) in_1\IN|NONE (l_pobj) lesions_7\NNS|hepatomas
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN| (r_appos) alpha_27\NN|NONE (r_appos) ethyl_25\NN|NONE (r_pobj) to_24\IN|.|did|not|,|were|cells|with (r_prep) respond_23\VB|NONE (l_advcl) were_5\VBD|.|did|not|,|cells|to|with (l_attr) tumors_9\NNS|contained|most|Although|and
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN| (r_appos) alpha_27\NN|NONE (r_appos) ethyl_25\NN|NONE (r_pobj) to_24\IN|.|did|not|,|were|cells|with (r_prep) respond_23\VB|NONE (l_nsubj) cells_20\NNS|.|did|not|,|were|to|with (l_compound) tumor_19\NN|the
C012282_D006528 NONE chlorophenoxyisobutyrate_31\NN| (r_appos) alpha_27\NN|NONE (r_appos) ethyl_25\NN|NONE (r_pobj) to_24\IN|.|did|not|,|were|cells|with (r_prep) respond_23\VB|NONE (l_advcl) were_5\VBD|.|did|not|,|cells|to|with (l_nsubj) most_1\JJS|contained|Although|and|tumors (l_prep) of_2\IN|NONE (l_pobj) hepatomas_4\NNS|NONE
14975762
D004317_D006333 CID doxorubicin_11\RB| (r_compound) induced_13\VBN|NONE (r_pobj) from_10\IN|cardiac|p|protects (r_prep) myocytes_9\NNS|NONE (r_pobj) of_5\IN|that (r_prep) overexpression_4\NN|reduces|and (r_nsubj) apoptosis_14\NN|findings|. (l_conj) reduces_16\VBZ|overexpression|and (l_dobj) extent_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) failure_22\NN|NONE
D004317_D009369 NONE Doxorubicin_0\NNP|agent (r_nsubj) is_1\VBZ|. (l_attr) agent_6\NN|Doxorubicin (l_compound) tumor_5\NN|represses|an
15930398
D015742_D000647 CID propofol_12\NN|NONE (r_pobj) with_11\IN|procedural (r_prep) sedation_10\NN|NONE (r_pobj) during_8\IN|the|of|persistence|and (r_prep) onset_3\NN|NONE (l_prep) of_6\IN|the|during|persistence|and (l_pobj) amnesia_7\NN|NONE
18201582
C084178_D006973 NONE telmisartan_32\NN|monotherapy (r_pobj) of_31\IN|a|with|dose (r_prep) combination_30\NN|NONE (l_prep) with_41\IN|a|of|dose (l_pobj) hypertension_44\NN|NONE
C084178_D006973 NONE telmisartan_23\NNP|NONE (r_pobj) of_22\IN|FDC|new|a|dose|)|( (r_prep) combination_18\NN|NONE (r_pobj) of_12\IN|and|tolerability|the (r_prep) efficacy_9\NN|amlodipine|+|mg|to (r_dobj) evaluate_7\VB|.|aim (l_conj) amlodipine_27\NN|+|efficacy|mg|to (l_prep) compared_33\VBN|mg|) (l_prep) with_34\IN|NONE (l_pobj) amlodipine_35\NN|NONE (l_appos) monotherapy_37\NN|NONE (l_prep) in_41\IN|mg|A (l_pobj) patients_44\NNS|NONE (l_prep) with_45\IN|Indian|adult (l_pobj) hypertension_48\NN|NONE
D017311_D006973 NONE amlodipine_34\NN|and|versus (r_conj) telmisartan_32\NN|monotherapy (r_pobj) of_31\IN|a|with|dose (r_prep) combination_30\NN|NONE (l_prep) with_41\IN|a|of|dose (l_pobj) hypertension_44\NN|NONE
D017311_D006973 NONE amlodipine_36\NN|NONE (r_pobj) versus_35\IN|and|amlodipine (r_prep) telmisartan_32\NN|monotherapy (r_pobj) of_31\IN|a|with|dose (r_prep) combination_30\NN|NONE (l_prep) with_41\IN|a|of|dose (l_pobj) hypertension_44\NN|NONE
D017311_D006973 NONE amlodipine_27\NN|+|efficacy|mg|to (l_prep) compared_33\VBN|mg|) (l_prep) with_34\IN|NONE (l_pobj) amlodipine_35\NN|NONE (l_appos) monotherapy_37\NN|NONE (l_prep) in_41\IN|mg|A (l_pobj) patients_44\NNS|NONE (l_prep) with_45\IN|Indian|adult (l_pobj) hypertension_48\NN|NONE
D017311_D006973 NONE amlodipine_35\NN|NONE (l_appos) monotherapy_37\NN|NONE (l_prep) in_41\IN|mg|A (l_pobj) patients_44\NNS|NONE (l_prep) with_45\IN|Indian|adult (l_pobj) hypertension_48\NN|NONE
19917396
D016559_D006332 CID tacrolimus_5\NNS|NONE (r_pobj) by_4\IN|NONE (r_agent) induced_3\VBN|Reversible|myocardial (r_acl) hypertrophy_2\NN|.|:|case
D016559_D006332 CID tacrolimus_8\NNS|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|myocardial|transient (r_acl) hypertrophy_5\NN|Herein|.|we
D016559_D006332 CID tacrolimus_10\NN|NONE (r_pobj) of_9\IN|the|target (r_prep) concentration_8\NN|NONE (r_dobj) reducing_5\VBG|NONE (r_pcomp) upon_4\IN|hypertrophy|.|and|recur|completely (r_prep) resolved_3\VBN|NONE (l_nsubj) hypertrophy_1\NN|upon|.|and|recur|completely
D016559_D006332 CID tacrolimus_5\NN|hypertrophy|that (r_nsubj) induces_6\VBZ|.|,|we|Thus (l_dobj) hypertrophy_9\NN|that|tacrolimus
10074612
D008775_D007022 CID methylprednisolone_11\NN|NONE (r_pobj) after_6\IN|NONE (r_prep) asystole_5\NN|and|, (r_conj) bradycardia_2\NNP|,|. (r_conj) Hypotension_0\NN|NONE
D008775_D007022 CID methylprednisolone_18\NN|NONE (r_pobj) of_14\IN|intravenous|in (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) asystole_10\NN|and|, (r_conj) bradycardia_7\NNP|, (r_conj) hypotension_5\NN|NONE
D008775_D003645 NONE methylprednisolone_16\NN|NONE (r_pobj) of_14\IN|a|high (r_prep) dose_13\NN|NONE (r_pobj) after_10\IN|.|study|mechanisms (r_prep) reviews_2\VBZ|NONE (l_dobj) mechanisms_6\NNS|.|after|study (l_prep) of_7\IN|current|proposed|the (l_pobj) death_9\NN|NONE
D008775_D003645 NONE IVMP_18\NN|intravenous (r_appos) methylprednisolone_16\NN|NONE (r_pobj) of_14\IN|a|high (r_prep) dose_13\NN|NONE (r_pobj) after_10\IN|.|study|mechanisms (r_prep) reviews_2\VBZ|NONE (l_dobj) mechanisms_6\NNS|.|after|study (l_prep) of_7\IN|current|proposed|the (l_pobj) death_9\NN|NONE
D008775_D006323 CID methylprednisolone_11\NN|NONE (r_pobj) after_6\IN|NONE (r_prep) asystole_5\NN|and|,
D008775_D006323 CID methylprednisolone_18\NN|NONE (r_pobj) of_14\IN|intravenous|in (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) asystole_10\NN|and|,
D008775_D001919 CID methylprednisolone_11\NN|NONE (r_pobj) after_6\IN|NONE (r_prep) asystole_5\NN|and|, (r_conj) bradycardia_2\NNP|,|.
D008775_D001919 CID methylprednisolone_18\NN|NONE (r_pobj) of_14\IN|intravenous|in (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) asystole_10\NN|and|, (r_conj) bradycardia_7\NNP|,
11704023
D013999_D005901 NONE timolol_6\NN|NONE (l_prep) on_9\IN|ophthalmic|with|aqueous (l_pobj) response_14\NN|NONE (l_prep) in_15\IN|the|hour|rate (l_pobj) patients_16\NNS|NONE (l_prep) on_17\IN|NONE (l_pobj) treatment_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) glaucoma_20\NN|NONE
D013999_D005901 NONE timolol_11\NN|of|the|, (l_conj) suspension_21\NN|%|)|aqueous|solution|and|( (l_relcl) forms_23\VBZ|a|%|timolol (l_prep) on_26\IN|that|gel (l_pobj) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|the|hour|heart (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|currently|quantify|being (l_pobj) glaucoma_46\NN|NONE
D013999_D005901 NONE timolol_13\NN|NONE (r_compound) solution_14\NN|%|)|aqueous|and|suspension|( (r_appos) timolol_11\NN|of|the|, (l_conj) suspension_21\NN|%|)|aqueous|solution|and|( (l_relcl) forms_23\VBZ|a|%|timolol (l_prep) on_26\IN|that|gel (l_pobj) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|the|hour|heart (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|currently|quantify|being (l_pobj) glaucoma_46\NN|NONE
D013999_D005901 NONE timolol_20\NN|a|forms|% (r_compound) suspension_21\NN|%|)|aqueous|solution|and|( (l_relcl) forms_23\VBZ|a|%|timolol (l_prep) on_26\IN|that|gel (l_pobj) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|the|hour|heart (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|currently|quantify|being (l_pobj) glaucoma_46\NN|NONE
D013999_D005901 NONE timolol_32\NN|)|( (r_compound) gellan_33\NN|the (r_appos) conjunctiva_30\NN|NONE (r_pobj) to_28\IN|on (r_prep) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|the|hour|heart (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|currently|quantify|being (l_pobj) glaucoma_46\NN|NONE
D013999_D009798 NONE timolol_56\NN|gellan|morning|,|or|(|) (r_compound) solution_57\NN|over|)|in|to|, (r_conj) crossed_32\VBN|patients|were|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|crossed|were|.|and (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE (l_conj) hypertension_13\NN|or|angle|primary
D013999_D009798 NONE timolol_68\NN|morning|)|( (r_compound) gellan_69\NN|morning|timolol|,|or|(|) (r_conj) solution_57\NN|over|)|in|to|, (r_conj) crossed_32\VBN|patients|were|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|crossed|were|.|and (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE (l_conj) hypertension_13\NN|or|angle|primary
D013999_D005902 NONE timolol_56\NN|gellan|morning|,|or|(|) (r_compound) solution_57\NN|over|)|in|to|, (r_conj) crossed_32\VBN|patients|were|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|crossed|were|.|and (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE
D013999_D005902 NONE timolol_68\NN|morning|)|( (r_compound) gellan_69\NN|morning|timolol|,|or|(|) (r_conj) solution_57\NN|over|)|in|to|, (r_conj) crossed_32\VBN|patients|were|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|crossed|were|.|and (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE
19135948
C107135_D009190 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE
C107135_D009190 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|undergoing|myelodysplastic|either (l_nmod) MDS_24\NNP|(|myeloid|AML|(|)
D016559_D006504 CID tacrolimus_10\NN|and (r_conj) everolimus_8\NN|NONE (r_pobj) with_7\IN|disease|Graft (r_prep) prophylaxis_6\VBN|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|is|.|microangiopathy|prophylaxis|and (l_pobj) incidence_16\NN|NONE (l_prep) of_17\IN|a|high (l_pobj) syndrome_20\NN|NONE
C107135_D015470 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|undergoing|myelodysplastic|either
C107135_D015470 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|undergoing|myelodysplastic|either (l_appos) AML_35\NNP|(|MDS|myeloid|(|)
D016559_D006086 NONE tacrolimus_10\NN|and (r_conj) everolimus_8\NN|NONE (r_pobj) with_7\IN|disease|Graft (r_prep) prophylaxis_6\VBN|is|.|with|microangiopathy|and (l_compound) disease_5\NN|Graft|with
D016559_D015470 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|undergoing|myelodysplastic|either
D016559_D015470 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|undergoing|myelodysplastic|either (l_appos) AML_35\NNP|(|MDS|myeloid|(|)
C107135_D006504 CID everolimus_8\NN|NONE (r_pobj) with_7\IN|disease|Graft (r_prep) prophylaxis_6\VBN|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|is|.|microangiopathy|prophylaxis|and (l_pobj) incidence_16\NN|NONE (l_prep) of_17\IN|a|high (l_pobj) syndrome_20\NN|NONE
D008727_D006086 NONE methotrexate_5\NNP|NONE (r_pobj) with_4\IN|NONE (r_prep) combined_3\VBN|calcineurin|A (r_acl) inhibitor_2\NN|prophylaxis|. (r_nsubj) is_6\VBZ|NONE (l_attr) prophylaxis_9\NN|.|inhibitor (l_prep) for_10\IN|standard|the|after (l_pobj) disease_16\NN|NONE
D008727_D006086 NONE methotrexate_5\NNP|NONE (r_pobj) with_4\IN|NONE (r_prep) combined_3\VBN|calcineurin|A (r_acl) inhibitor_2\NN|prophylaxis|. (r_nsubj) is_6\VBZ|NONE (l_attr) prophylaxis_9\NN|.|inhibitor (l_prep) for_10\IN|standard|the|after (l_pobj) disease_16\NN|NONE (l_appos) GVHD_18\NNP|graft|)|(
D016559_D009190 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE
D016559_D009190 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|a|in|with (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|of|a|in (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|undergoing|myelodysplastic|either (l_nmod) MDS_24\NNP|(|myeloid|AML|(|)
C107135_D006086 NONE everolimus_8\NN|NONE (r_pobj) with_7\IN|disease|Graft (r_prep) prophylaxis_6\VBN|is|.|with|microangiopathy|and (l_compound) disease_5\NN|Graft|with
D016559_D014652 CID tacrolimus_10\NN|and (r_conj) everolimus_8\NN|NONE (r_pobj) with_7\IN|disease|Graft (r_prep) prophylaxis_6\VBN|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN|NONE (l_conj) microangiopathy_22\NN|is|.|with|prophylaxis|and
C107135_D014652 CID everolimus_8\NN|NONE (r_pobj) with_7\IN|disease|Graft (r_prep) prophylaxis_6\VBN|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN|NONE (l_conj) microangiopathy_22\NN|is|.|with|prophylaxis|and
10091616
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE
D001058_D004409 CID apomorphine_69\NN|NONE (r_pobj) of_68\IN|single|effective|an (r_prep) dose_67\NN|NONE (r_pobj) of_63\IN|NONE (r_prep) administration_62\NN|NONE (r_pobj) following_61\VBG|the|of (r_prep) worsening_55\VBG|NONE (r_pobj) on_53\IN|) (r_prep) tasks_52\NNS|aloud (r_dobj) speaking_49\VBG|role|to|, (r_dep) evaluate_16\VB|in|were|.|patients (r_advcl) included_11\VBN|NONE (l_nsubjpass) patients_1\NNS|in|were|evaluate|. (l_relcl) had_3\VBD|Ten (l_prep) with_7\IN|who|disease (l_pcomp) disabling_8\VBG|NONE (l_dobj) dyskinesia_9\NN|NONE
D001058_D004409 CID apomorphine_69\NN|NONE (r_pobj) of_68\IN|single|effective|an (r_prep) dose_67\NN|NONE (r_pobj) of_63\IN|NONE (r_prep) administration_62\NN|NONE (r_pobj) following_61\VBG|the|of (r_prep) worsening_55\VBG|NONE (l_prep) of_56\IN|following|the (l_pobj) dyskinesia_60\JJ|NONE
D001058_D010300 NONE apomorphine_69\NN|NONE (r_pobj) of_68\IN|single|effective|an (r_prep) dose_67\NN|NONE (r_pobj) of_63\IN|NONE (r_prep) administration_62\NN|NONE (r_pobj) following_61\VBG|the|of (r_prep) worsening_55\VBG|NONE (r_pobj) on_53\IN|) (r_prep) tasks_52\NNS|aloud (r_dobj) speaking_49\VBG|role|to|, (r_dep) evaluate_16\VB|in|were|.|patients (r_advcl) included_11\VBN|NONE (l_nsubjpass) patients_1\NNS|in|were|evaluate|. (l_relcl) had_3\VBD|Ten (l_dobj) disease_6\NN|who|with
950631
D010396_D007674 CID penicillamine_2\NN| (r_npadvmod) induced_4\VBN|glomerular (r_amod) disease_6\NN|NONE
D010396_D001172 NONE penicillamine_18\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|NONE (r_pobj) of_13\IN| (r_prep) months_12\NNS|NONE (r_pobj) after_8\IN|.|patients|proteinuria (r_prep) developed_5\VBD|NONE (l_nsubj) patients_1\NNS|.|after|proteinuria (l_prep) with_2\IN|Four (l_pobj) arthritis_4\NN|NONE
D010396_D011507 CID penicillamine_18\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|NONE (r_pobj) of_13\IN| (r_prep) months_12\NNS|NONE (r_pobj) after_8\IN|.|patients|proteinuria (r_prep) developed_5\VBD|NONE (l_dobj) proteinuria_7\NN|.|patients|after
7803371
D003915_D003072 CID dextromethorphan_8\NN|NONE (r_pobj) of_7\IN|term (r_prep) abuse_6\NN|NONE (r_pobj) from_2\IN|.|:|report|Cognitive (r_prep) deterioration_1\NN|NONE
D003915_D003072 CID DM_13\NN|NONE (r_pobj) of_12\IN|prolonged (r_prep) use_11\NN|NONE (r_pobj) from_9\IN|NONE (r_prep) resulting_8\VBG|cognitive (r_acl) deterioration_7\NN|NONE
9105126
D013256_D018658 CID steroid_9\NN|term (r_compound) therapy_10\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|ventricular|septal|Postinfarction|. (r_acl) defect_3\NN|NONE
D013256_D018658 CID steroid_13\NN|term (r_compound) therapy_14\NN|NONE (r_pobj) on_9\IN|NONE (r_prep) patients_8\NNS|NONE (r_pobj) in_7\IN|septal|postinfarction|ventricular (r_prep) rupture_6\NN|NONE
D013256_D018658 CID steroid_4\NN|rupture|and (r_compound) therapy_5\NN|NONE (l_conj) rupture_10\NN|steroid|and
15276120
D014859_D006470 CID warfarin_3\RB| (r_npadvmod) associated_5\VBN|NONE (r_amod) hemorrhage_6\NN|NONE
D014859_D006470 CID warfarin_4\RB| (r_npadvmod) related_6\VBN|at (r_amod) bleeding_7\NN|NONE
11694026
D000082_D014581 NONE paracetamol_4\NN|and (r_conj) nimesulide_2\NN|NONE (r_pobj) of_1\IN|in|. (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|.|of (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE (l_nmod) urticaria_11\NN|NONE
D000082_D014581 NONE paracetamol_11\NN|and (r_conj) nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|we|.|In|in (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|we|tolerability|.|In (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|documented|an|exclusive (l_pobj) angioedema_32\NN|NONE (l_nmod) urticaria_30\NN|/
D000082_D014581 NONE paracetamol_12\NNP|or (r_conj) nimesulide_10\NN|NONE (r_pobj) with_9\IN|oral|challenge|A|controlled (r_prep) procedure_8\NN|was|to|with|. (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|was|to|procedure|. (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE (l_nmod) urticaria_25\NN|/
D000082_D014581 NONE paracetamol_12\NN|and (r_conj) nimesulide_10\NN|NONE (r_pobj) of_9\IN|the|in|good (r_prep) tolerability_8\NN|results|,|.|Taken (l_prep) in_13\IN|the|of|good (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who (l_nmod) urticaria_17\NN|caused
D000894_D014581 NONE NSAID_8\NNP| (r_npadvmod) induced_10\VBN|/ (r_amod) urticaria_11\NN|NONE
D000894_D014581 NONE NSAID_27\NNP| (r_npadvmod) induced_29\VBN|NONE (r_amod) urticaria_30\NN|/
D000894_D014581 NONE NSAID_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_amod) urticaria_25\NN|/
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|or|(|alone|angioedema (r_nmod) angioedema_26\NN|NONE (r_pobj) of_20\IN|with|an (r_prep) history_19\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) subjects_16\NNS|NONE (r_pobj) of_15\IN|. (r_prep) %_14\NN|of|and|a (r_conj) history_8\NN|NONE (l_prep) of_9\IN|and|a|% (l_pobj) urticaria_11\NN|NONE
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|or|(|alone|angioedema
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|or|(|alone|angioedema (r_nmod) angioedema_26\NN|NONE (r_pobj) of_20\IN|with|an (r_prep) history_19\NN|NONE (l_prep) with_31\IN|of|an (l_conj) without_33\IN|or (l_pobj) urticaria_35\NN|NONE
D000894_D014581 NONE NSAIDs_22\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|urticaria (r_acl) angioedema_19\NNP|who (l_nmod) urticaria_17\NN|caused
D000894_D014581 NONE NSAID_29\NNP| (r_npadvmod) induced_31\VBN|NONE (r_amod) angioedema_32\NN|NONE (r_pobj) of_28\IN|a (r_prep) history_27\NN|NONE (r_pobj) by_25\IN|,|.|by|,|all|However|risk|and|statistically|,|is (r_prep) increased_13\VBN|NONE (l_agent) by_14\IN|,|.|by|,|all|However|risk|and|statistically|,|is (l_pobj) history_16\NN|NONE (l_prep) of_17\IN|a (l_pobj) urticaria_19\NN|NONE
D000082_D000799 CID paracetamol_4\NN|and (r_conj) nimesulide_2\NN|NONE (r_pobj) of_1\IN|in|. (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|.|of (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE
D000082_D000799 CID paracetamol_11\NN|and (r_conj) nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|we|.|In|in (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|we|tolerability|.|In (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|documented|an|exclusive (l_pobj) angioedema_32\NN|NONE
D000082_D000799 CID paracetamol_12\NNP|or (r_conj) nimesulide_10\NN|NONE (r_pobj) with_9\IN|oral|challenge|A|controlled (r_prep) procedure_8\NN|was|to|with|. (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|was|to|procedure|. (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE
D000082_D000799 CID paracetamol_12\NN|and (r_conj) nimesulide_10\NN|NONE (r_pobj) of_9\IN|the|in|good (r_prep) tolerability_8\NN|results|,|.|Taken (l_prep) in_13\IN|the|of|good (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who
C012655_D000799 CID nimesulide_2\NN|NONE (r_pobj) of_1\IN|in|. (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|.|of (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE
C012655_D000799 CID nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|we|.|In|in (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|we|tolerability|.|In (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|documented|an|exclusive (l_pobj) angioedema_32\NN|NONE
C012655_D000799 CID nimesulide_10\NN|NONE (r_pobj) with_9\IN|oral|challenge|A|controlled (r_prep) procedure_8\NN|was|to|with|. (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|was|to|procedure|. (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE
C012655_D000799 CID nimesulide_10\NN|NONE (r_pobj) of_9\IN|the|in|good (r_prep) tolerability_8\NN|results|,|.|Taken (l_prep) in_13\IN|the|of|good (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who
C012655_D014581 NONE nimesulide_2\NN|NONE (r_pobj) of_1\IN|in|. (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|.|of (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE (l_nmod) urticaria_11\NN|NONE
C012655_D014581 NONE nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|we|.|In|in (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|we|tolerability|.|In (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|documented|an|exclusive (l_pobj) angioedema_32\NN|NONE (l_nmod) urticaria_30\NN|/
C012655_D014581 NONE nimesulide_10\NN|NONE (r_pobj) with_9\IN|oral|challenge|A|controlled (r_prep) procedure_8\NN|was|to|with|. (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|was|to|procedure|. (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE (l_nmod) urticaria_25\NN|/
C012655_D014581 NONE nimesulide_10\NN|NONE (r_pobj) of_9\IN|the|in|good (r_prep) tolerability_8\NN|results|,|.|Taken (l_prep) in_13\IN|the|of|good (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who (l_nmod) urticaria_17\NN|caused
D000894_D000799 CID NSAID_8\NNP| (r_npadvmod) induced_10\VBN|/ (r_amod) urticaria_11\NN|NONE (r_nmod) angioedema_13\NN|NONE
D000894_D000799 CID NSAID_27\NNP| (r_npadvmod) induced_29\VBN|NONE (r_amod) urticaria_30\NN|/ (r_nmod) angioedema_32\NN|NONE
D000894_D000799 CID NSAID_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_amod) urticaria_25\NN|/ (r_nmod) angioedema_27\NN|NONE
D000894_D000799 CID NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|or|(|alone|angioedema (r_nmod) angioedema_26\NN|NONE
D000894_D000799 CID NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|or|(|alone|angioedema (r_nmod) angioedema_26\NN|NONE (l_conj) angioedema_28\NN|or|urticaria|(|alone
D000894_D000799 CID NSAIDs_22\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|urticaria (r_acl) angioedema_19\NNP|who
D000894_D000799 CID NSAID_29\NNP| (r_npadvmod) induced_31\VBN|NONE (r_amod) angioedema_32\NN|NONE
19707748
D064704_D012640 CID levofloxacin_3\NNS|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|:|presentation|. (r_acl) Seizures_0\NNS|NONE
D064704_D012640 CID levofloxacin_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|discuss|and (r_dobj) initiating_12\VBG|shortly|as (r_pcomp) after_11\IN|who|seizures (r_prep) developed_8\VBD|,|of|a (l_dobj) seizures_9\NNS|after|who
D064704_D012640 CID levofloxacin_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|discuss|and (r_dobj) initiating_12\VBG|shortly|as (r_pcomp) after_11\IN|who|seizures (r_prep) developed_8\VBD|,|of|a (r_relcl) patient_6\NN|NONE (l_prep) of_47\IN|developed|,|a (l_pobj) seizures_51\NNS|NONE
D064704_D012640 CID levofloxacin_48\NN| (r_npadvmod) induced_50\VBN|NONE (r_amod) seizures_51\NNS|NONE (r_pobj) of_47\IN|developed|,|a (r_prep) patient_6\NN|NONE (l_relcl) developed_8\VBD|,|of|a (l_dobj) seizures_9\NNS|after|who
D064704_D012640 CID levofloxacin_48\NN| (r_npadvmod) induced_50\VBN|NONE (r_amod) seizures_51\NNS|NONE
D064704_D012640 CID levofloxacin_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) seizures_6\NNS|NONE
15811908
C037689_D010673 NONE benzamide_14\JJ|substituted (r_amod) drugs_15\NNS|NONE (r_pobj) of_12\IN|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|symptoms|often|but|are|,|is (r_prep) associated_8\VBN|NONE (l_nsubjpass) symptoms_3\NNS|often|but|are|,|is|with (l_prep) of_4\IN|induced (l_pobj) pheochromocytoma_5\NN|NONE
D063325_D006973 CID tiapride_21\NN|NONE (r_compound) therapy_22\NN|and (r_conj) amisulpride_19\NN|the|hypertensive|and (r_conj) crisis_17\NN|NONE (l_amod) hypertensive_16\JJ|the|and|amisulpride
D063325_D006973 CID tiapride_16\NN| (r_npadvmod) induced_18\VBN|hypertensive (r_amod) crisis_20\NN|and (l_amod) hypertensive_19\JJ|induced
D063325_D010673 NONE tiapride_5\NN|and (r_conj) amisulpride_3\NN|NONE (r_pobj) by_2\IN|Pheochromocytoma|. (r_prep) unmasked_1\VBD|NONE (l_nsubj) Pheochromocytoma_0\NNP|by|.
D063325_D010673 NONE tiapride_13\NN|and (r_conj) amisulpride_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN|a (r_acl) patient_8\NN|NONE (r_pobj) in_6\IN|of|the (r_prep) unmasking_3\NN|.|To (l_prep) of_4\IN|in|the (l_pobj) pheochromocytoma_5\NN|NONE
D063325_D010673 NONE tiapride_16\NN| (r_npadvmod) induced_18\VBN|hypertensive (r_amod) crisis_20\NN|and (r_conj) amisulpride-_14\JJ|NONE (r_pobj) of_13\IN|first|the|reported|in (r_prep) case_12\NN|As|,|this|. (l_prep) in_21\IN|first|the|reported|of (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|a (l_pobj) pheochromocytoma_25\NN|NONE
C012052_D014839 CID amisulpride_21\NN|NONE (r_pobj) of_20\IN|the|first (r_prep) doses_19\NNS|hours (r_pobj) after_16\IN|NONE (r_prep) vomiting_13\NN|man|hypertension|and
C012052_D006261 CID amisulpride_21\NN|NONE (r_pobj) of_20\IN|the|first (r_prep) doses_19\NNS|hours (r_pobj) after_16\IN|NONE (r_prep) vomiting_13\NN|man|hypertension|and (r_conj) developed_6\VBD|NONE (l_dobj) hypertension_8\NN|man|and|vomiting (l_prep) with_9\IN|acute (l_pobj) headache_11\NN|NONE
C012052_D010673 NONE amisulpride_3\NN|NONE (r_pobj) by_2\IN|Pheochromocytoma|. (r_prep) unmasked_1\VBD|NONE (l_nsubj) Pheochromocytoma_0\NNP|by|.
C012052_D010673 NONE amisulpride_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN|a (r_acl) patient_8\NN|NONE (r_pobj) in_6\IN|of|the (r_prep) unmasking_3\NN|.|To (l_prep) of_4\IN|in|the (l_pobj) pheochromocytoma_5\NN|NONE
C012052_D010673 NONE amisulpride-_14\JJ|NONE (r_pobj) of_13\IN|first|the|reported|in (r_prep) case_12\NN|As|,|this|. (l_prep) in_21\IN|first|the|reported|of (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|a (l_pobj) pheochromocytoma_25\NN|NONE
C012052_D006973 CID amisulpride_21\NN|NONE (r_pobj) of_20\IN|the|first (r_prep) doses_19\NNS|hours (r_pobj) after_16\IN|NONE (r_prep) vomiting_13\NN|man|hypertension|and (r_conj) developed_6\VBD|NONE (l_dobj) hypertension_8\NN|man|and|vomiting
C012052_D006973 CID amisulpride_19\NN|the|hypertensive|and (r_conj) crisis_17\NN|NONE (l_amod) hypertensive_16\JJ|the|and|amisulpride
C012052_D006973 CID amisulpride-_14\JJ|NONE (l_conj) crisis_20\NN|and (l_amod) hypertensive_19\JJ|induced
19719056
D002351_D010146 CID carrageenan_17\NN| (r_npadvmod) induced_19\VBN|paw|edema|,|rat (r_amod) model_23\NN|)|and (r_conj) mice_14\NNS|( (r_appos) model_12\NN|respectively (r_attr) writhing_11\VBG|NONE
D019342_D010146 NONE acid_9\NN|NONE (r_dobj) using_7\VBG|.|activities|induced|were (r_advcl) ascertained_6\VBN|NONE (l_conj) induced_10\VBD|.|activities|using|were (l_xcomp) writhing_11\VBG|NONE
D019342_D004487 NONE acid_9\NN|NONE (r_dobj) using_7\VBG|.|activities|induced|were (r_advcl) ascertained_6\VBN|NONE (l_conj) induced_10\VBD|.|activities|using|were (l_xcomp) writhing_11\VBG|NONE (l_attr) model_12\NN|respectively (l_appos) mice_14\NNS|( (l_conj) model_23\NN|)|and (l_compound) edema_22\NN|induced|paw|,|rat
D002351_D004487 CID carrageenan_17\NN| (r_npadvmod) induced_19\VBN|paw|edema|,|rat (r_amod) model_23\NN|)|and (l_compound) edema_22\NN|induced|paw|,|rat
7707116
D015474_D064420 NONE RA_24\NNP|NONE (r_pobj) of_21\IN|,|and|pharmacokinetics|administered (r_prep) toxicities_17\NNS|following|tolerated|the|,|)|(|MTD
D015474_D064420 NONE RA_6\NNP|after|was (r_nsubjpass) discontinued_8\VBN|toxicities|. (r_advcl) resolved_2\VBD|NONE (l_nsubj) toxicities_1\NNS|discontinued|.
D015474_D009447 NONE acid_7\NN|NONE (r_pobj) of_3\IN|in|following (r_prep) trial_2\NN|.|Phase (l_prep) in_8\IN|of|following (l_pobj) children_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) neuroblastoma_11\NN|NONE
D015474_D009447 NONE acid_11\NN|NONE (r_pobj) with_7\IN|cell|neuroblastoma (r_prep) lines_6\NNS|NONE (l_compound) neuroblastoma_4\NN|cell|with
D015474_D009447 NONE RA_15\NNP|retinoic (r_appos) acid_11\NN|NONE (r_pobj) with_7\IN|cell|neuroblastoma (r_prep) lines_6\NNS|NONE (l_compound) neuroblastoma_4\NN|cell|with
D015474_D009447 NONE RA_3\NNP|responses|Since|has (r_nsubj) demonstrated_5\VBN|may|,|it|.|effective (l_dobj) responses_7\NNS|RA|Since|has (l_prep) in_8\IN|clinical (l_pobj) patients_10\NNS|NONE (l_compound) neuroblastoma_9\NN|NONE
D015474_D009447 NONE RA_24\NNP|NONE (r_pobj) of_21\IN|,|and|pharmacokinetics|administered (r_prep) toxicities_17\NNS|following|tolerated|the|,|)|(|MTD (l_acl) administered_25\VBD|,|of|and|pharmacokinetics (l_prep) on_26\IN|NONE (l_pobj) schedule_29\NN|NONE (l_prep) in_30\IN|an|intermittent (l_pobj) children_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) neuroblastoma_33\NN|NONE
D015474_D006934 CID RA_13\NNP|serum (r_compound) levels_14\NNS|NONE (r_pobj) by_9\IN|be|may (r_agent) predicted_8\VBN|DLT|hypercalcemia|and|,|. (r_conj) included_2\VBD|NONE (l_dobj) hypercalcemia_3\NN|DLT|and|,|predicted|.
11858397
D008787_D002037 NONE metoclopramide_5\NN|NONE (r_pobj) by_4\IN|with|in (r_agent) induced_3\VBN|.|Torsade|de (l_prep) with_10\IN|by|in (l_pobj) block_16\NN|NONE
D008787_D002037 NONE metoclopramide_26\NN|NONE (r_pobj) of_25\IN|intravenous (r_prep) administration_24\NN|NONE (r_pobj) after_20\IN|who|pointes (r_prep) developed_16\VBD|old|with|a (r_relcl) woman_7\NN|NONE (l_prep) with_8\IN|old|developed|a (l_pobj) block_14\NN|NONE
D020117_D016171 CID cisapride_8\RB|were|simultaneously|when (r_nsubjpass) given_12\VBN|pointes|also|.|patient (r_advcl) developed_3\VBD|NONE (l_dobj) pointes_6\FW|given|also|.|patient
D008787_D016171 CID metoclopramide_5\NN|NONE (r_pobj) by_4\IN|with|in (r_agent) induced_3\VBN|.|Torsade|de (r_acl) pointes_2\NNS|NONE
D008787_D016171 CID metoclopramide_26\NN|NONE (r_pobj) of_25\IN|intravenous (r_prep) administration_24\NN|NONE (r_pobj) after_20\IN|who|pointes (r_prep) developed_16\VBD|old|with|a (l_dobj) pointes_19\NNS|who|after
D008787_D016171 CID metoclopramide_6\NN|that|pointes|clinically (r_nsubj) provokes_7\VBZ|the|first (l_dobj) pointes_10\FW|that|metoclopramide|clinically
D008787_D016171 CID Metoclopramide_0\NNP|be|cautiously|in|.|should (r_nsubjpass) used_3\VBN|NONE (l_prep) in_5\IN|Metoclopramide|be|cautiously|.|should (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) risk_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) pointes_13\FW|NONE
D004917_D016171 CID erythromycin_10\NNP|and (r_conj) cisapride_8\RB|were|simultaneously|when (r_nsubjpass) given_12\VBN|pointes|also|.|patient (r_advcl) developed_3\VBD|NONE (l_dobj) pointes_6\FW|given|also|.|patient
7007443
D000082_D017114 CID paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE (r_pobj) after_25\IN|who|failure (r_prep) survived_21\VBD|NONE (l_dobj) failure_24\NN|who|after
D000082_D017114 CID paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE (r_pobj) after_25\IN|who|failure (r_prep) survived_21\VBD|NONE (r_relcl) those_19\DT|NONE (r_pobj) in_18\IN|nearly (r_prep) fourfold_17\RB|who|and (r_conj) died_14\VBD|NONE (r_relcl) patients_12\NNS|NONE (r_pobj) in_11\IN|.|tenfold|was|increased|activity|, (r_prep) increased_8\VBN|NONE (l_advcl) increased_32\VBN|.|in|tenfold|was|activity|, (l_prep) in_34\IN|survived|equally|whereas|activities|were (l_pobj) patients_35\NNS|NONE (l_prep) with_36\IN|NONE (l_pobj) failure_39\NN|NONE
D000082_D006525 NONE paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE (r_pobj) after_25\IN|who|failure (r_prep) survived_21\VBD|NONE (r_relcl) those_19\DT|NONE (r_pobj) in_18\IN|nearly (r_prep) fourfold_17\RB|who|and (r_conj) died_14\VBD|NONE (r_relcl) patients_12\NNS|NONE (r_pobj) in_11\IN|.|tenfold|was|increased|activity|, (r_prep) increased_8\VBN|NONE (l_advcl) increased_32\VBN|.|in|tenfold|was|activity|, (l_prep) in_34\IN|survived|equally|whereas|activities|were (l_pobj) patients_35\NNS|NONE (l_prep) with_36\IN|NONE (l_pobj) failure_39\NN|NONE (l_amod) due_40\IN|fulminant|hepatic (l_pcomp) to_41\IN|NONE (l_pobj) hepatitis_43\NN|NONE
D000082_D062787 NONE paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE
3653576
C001335_D007674 NONE HCBD_4\NNP|NONE (r_pobj) by_3\IN|NONE (r_agent) produced_2\VBN|Tubular (r_acl) damage_1\NN|quantitatively|.|was|from (r_nsubjpass) discriminated_8\VBN|NONE (l_prep) from_13\IN|quantitatively|.|was|damage (l_pobj) damage_15\NN|NONE
C004504_D058186 CID 2-bromoethylamine_36\NN|NONE (r_punct) ._42\.|PAN|,|produced|and (r_punct) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|.|PAN|,|and (l_nsubjpass) models_2\NNS|were|,|by (l_prep) of_3\IN|Acute|experimental (l_pobj) damage_5\NN|NONE
C004504_D058186 CID BEA_38\NNP|respectively|, (r_nmod) 2-bromoethylamine_36\NN|NONE (r_punct) ._42\.|PAN|,|produced|and (r_punct) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|.|PAN|,|and (l_nsubjpass) models_2\NNS|were|,|by (l_prep) of_3\IN|Acute|experimental (l_pobj) damage_5\NN|NONE
C004504_D007674 NONE BEA_6\NNP|or (r_conj) HCBD_4\NNP|NONE (r_pobj) by_3\IN|NONE (r_agent) produced_2\VBN|Tubular (r_acl) damage_1\NN|quantitatively|.|was|from (r_nsubjpass) discriminated_8\VBN|NONE (l_prep) from_13\IN|quantitatively|.|was|damage (l_pobj) damage_15\NN|NONE
D011692_D058186 CID aminonucleoside_30\NN|(|) (r_nmod) PAN_32\NNP|.|,|produced|and (r_npadvmod) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|.|PAN|,|and (l_nsubjpass) models_2\NNS|were|,|by (l_prep) of_3\IN|Acute|experimental (l_pobj) damage_5\NN|NONE
D011692_D058186 CID PAN_32\NNP|.|,|produced|and (r_npadvmod) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|.|PAN|,|and (l_nsubjpass) models_2\NNS|were|,|by (l_prep) of_3\IN|Acute|experimental (l_pobj) damage_5\NN|NONE
C001335_D058186 CID hexachloro-1:3-butadiene_24\,|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) by_21\IN|were|models|, (r_agent) produced_20\VBN|.|PAN|,|and (l_nsubjpass) models_2\NNS|were|,|by (l_prep) of_3\IN|Acute|experimental (l_pobj) damage_5\NN|NONE
C001335_D058186 CID HCBD_26\NNP|)|( (r_appos) hexachloro-1:3-butadiene_24\,|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) by_21\IN|were|models|, (r_agent) produced_20\VBN|.|PAN|,|and (l_nsubjpass) models_2\NNS|were|,|by (l_prep) of_3\IN|Acute|experimental (l_pobj) damage_5\NN|NONE
D011692_D007674 NONE PAN_18\NNP|NONE (r_pobj) by_17\IN|NONE (r_agent) produced_16\VBN|glomerular (r_acl) damage_15\NN|NONE
3084782
D008625_D003872 CID Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|been|.|association|between|and|between|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
D008625_D003872 CID Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|been|.|association|between|and|between|has|, (r_prep) found_5\VBN|NONE (l_prep) between_28\IN|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN|due
D006046_D009393 NONE gold_32\NN|and|B (r_compound) thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|been|.|association|due|between|and|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE
-1_D009393 NONE thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|been|.|association|due|between|and|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE
D006046_D003872 CID gold_32\NN|and|B (r_compound) thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|been|.|association|due|between|and|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
D006046_D003872 CID gold_32\NN|and|B (r_compound) thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN|due
D008625_D009393 CID Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|been|.|association|between|and|between|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE
D008625_D009393 CID Tiopronin_17\NNP|NONE (r_npadvmod) related_18\VBN|the|nephritis (r_amod) group_20\NN|NONE (l_compound) nephritis_19\NN|the|related
D008625_D001172 NONE Tiopronin_17\NNP|NONE (r_npadvmod) related_18\VBN|the|nephritis (r_amod) group_20\NN|NONE (r_pobj) for_15\IN|NONE (r_prep) except_14\IN|with (r_prep) patients_11\NNS|NONE (l_prep) with_12\IN|except (l_pobj) RA_13\NNP|NONE
D010396_D003872 NONE Penicillamine_17\NN|)|(|class|BCw|and (r_appos) Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|been|.|association|between|and|between|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
D010396_D003872 NONE Penicillamine_17\NN|)|(|class|BCw|and (r_appos) Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|been|.|association|between|and|between|has|, (r_prep) found_5\VBN|NONE (l_prep) between_28\IN|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN|due
D010396_D009393 NONE Penicillamine_17\NN|)|(|class|BCw|and (r_appos) Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|been|.|association|between|and|between|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE
-1_D003872 NONE thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|been|.|association|due|between|and|has|, (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
-1_D003872 NONE thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN|due
3703509
D011241_D011141 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN|NONE (l_conj) polydipsia_15\NN|, (l_conj) polyphagia_17\NN|, (l_conj) polyuria_20\NN|and|,
D019344_D007662 NONE lactate_13\NN|a|known (r_compound) level_14\NN|NONE (r_pobj) without_9\IN|in (r_prep) present_4\JJ|.|was|acidosis (l_prep) in_5\IN|without (l_pobj) one_6\CD|NONE (l_conj) ketosis_8\NN|and
D011241_D006963 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN|NONE (l_conj) polydipsia_15\NN|, (l_conj) polyphagia_17\NN|,
D011241_D053609 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD|NONE (l_dobj) lethargy_10\NN|increasing|Following|,|.|,|boys
D011241_D059606 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN|NONE (l_conj) polydipsia_15\NN|,
D011241_D006970 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN|NONE
D019344_D000140 NONE lactate_13\NN|a|known (r_compound) level_14\NN|NONE (r_pobj) without_9\IN|in (r_prep) present_4\JJ|.|was|acidosis (r_acomp) was_3\VBD|NONE (l_nsubj) acidosis_2\NN|present|.|was
1687392
D015647_D002375 NONE 38393_5\CD|agonist|or|agonist||D (r_nummod) SKF_4\NNP|NONE (r_nmod) quinpirole_9\NN|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_12\NN|quinpirole|.
D015647_D002375 NONE 38393_3\CD|NONE (r_nummod) SKF_2\NNP|NONE (r_pobj) of_1\IN|with (r_prep) Combination_0\NN|not|.|did|potentiated (r_nsubj) cause_8\VB|NONE (l_ccomp) potentiated_9\VBN|Combination|not|.|did (l_dobj) effect_11\NN|NONE (l_prep) on_12\IN|induced|inhibitory (l_pobj) catalepsy_13\NN|NONE
D005476_D002375 CID fluphenazine_2\NN|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
D005476_D002375 CID fluphenazine_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|the (r_acl) catalepsy_12\NN|quinpirole|.
C534628_D002375 CID 23390_7\CD|antagonist|D|or (r_nummod) SCH_6\NNP|Dopamine|antagonist|, (r_appos) fluphenazine_2\NN|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
C534628_D002375 CID 23390_3\CD|NONE (r_nummod) SCH_2\NNP|NONE (r_pobj) of_1\IN|with (r_prep) Combination_0\NN|.|did|potentiation|not (r_nsubj) induce_8\VB|NONE (l_dobj) potentiation_10\NN|.|did|Combination|not (l_compound) catalepsy_9\NN|NONE
C534628_D002375 CID 23390_18\CD|or|sulpiride (r_nummod) SCH_17\NNP|, (r_appos) fluphenazine_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|the (r_acl) catalepsy_12\NN|quinpirole|.
D019257_D002375 NONE quinpirole_9\NN|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_12\NN|quinpirole|.
D019257_D002375 NONE quinpirole_5\NN|NONE (r_pobj) with_4\IN|of (r_prep) Combination_0\NN|not|.|did|potentiated (r_nsubj) cause_8\VB|NONE (l_ccomp) potentiated_9\VBN|Combination|not|.|did (l_dobj) effect_11\NN|NONE (l_prep) on_12\IN|induced|inhibitory (l_pobj) catalepsy_13\NN|NONE
D004298_D002375 NONE dopamine_6\NN|both (r_compound) receptors_7\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Blockade_0\NN|.|catalepsy|may|in (r_nsubj) induce_9\VB|NONE (l_dobj) catalepsy_10\NN|.|may|in|Blockade
D004298_D002375 NONE dopamine_4\NN|NONE (r_compound) antagonists_5\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) catalepsy_1\NN|been|determined|and|has
D004298_D002375 NONE dopamine_4\NN|NONE (r_compound) antagonists_5\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) catalepsy_1\NN|been|determined|and|has (r_nsubjpass) tested_8\VBN|NONE (l_conj) determined_18\VBN|been|and|has|catalepsy (l_nsubjpass) subtypes_13\NNS|.|was (l_acl) involved_14\VBN|the|possible|dopamine (l_prep) in_15\IN|NONE (l_pobj) catalepsy_16\NN|NONE
D004298_D002375 NONE dopamine_12\NN|the|possible|involved (r_compound) subtypes_13\NNS|.|was (r_nsubjpass) determined_18\VBN|been|and|has|catalepsy (r_conj) tested_8\VBN|NONE (l_nsubjpass) catalepsy_1\NN|been|determined|and|has
D004298_D002375 NONE dopamine_12\NN|the|possible|involved (r_compound) subtypes_13\NNS|.|was (l_acl) involved_14\VBN|the|possible|dopamine (l_prep) in_15\IN|NONE (l_pobj) catalepsy_16\NN|NONE
D004298_D002375 NONE Dopamine_0\NN|antagonist|,|SCH (r_compound) fluphenazine_2\NN|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
D004298_D002375 NONE dopamine_16\NN|NONE (r_compound) antagonists_17\NNS|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|inhibitory|on (r_acl) effect_11\NN|NONE (l_prep) on_12\IN|induced|inhibitory (l_pobj) catalepsy_13\NN|NONE
D013469_D002375 CID sulpiride_11\NN|.|catalepsy|fluphenazine (r_npadvmod) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
D013469_D002375 CID sulpiride_5\NN|NONE (r_pobj) with_4\IN|of (r_prep) Combination_0\NN|.|did|potentiation|not (r_nsubj) induce_8\VB|NONE (l_dobj) potentiation_10\NN|.|did|Combination|not (l_compound) catalepsy_9\NN|NONE
D013469_D002375 CID sulpiride_20\NN||or (r_conj) SCH_17\NNP|, (r_appos) fluphenazine_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|the (r_acl) catalepsy_12\NN|quinpirole|.
4090988
D000082_D008113 CID paracetamol_2\NN|NONE (l_prep) of_3\IN|in (l_pobj) tumours_7\NNS|NONE
D000082_D008113 CID paracetamol_8\NN| (r_npadvmod) treated_10\VBN|NONE (r_amod) rats_11\NNS|NONE (r_pobj) of_7\IN|the (r_prep) livers_6\NNS|NONE (r_pobj) of_4\IN|An|microscope (r_prep) study_3\NN|changes|. (r_nsubj) revealed_12\VBD|NONE (l_dobj) changes_14\NNS|.|study (l_relcl) resemble_19\VBP|in|ultrastructural (l_dobj) those_20\DT|that (l_relcl) result_22\NN|NONE (l_prep) from_23\IN|that (l_pobj) exposure_24\NN|NONE (l_prep) to_25\IN|NONE (l_pobj) variety_27\NN|NONE (l_prep) of_28\IN|a (l_pobj) hepatocarcinogens_30\NNS|NONE
D000082_D009369 NONE paracetamol_12\JJ|NONE (r_compound) feeding_13\NN|NONE (r_dobj) following_11\VBG|yield|also|. (r_prep) arose_10\VBD|NONE (l_nsubj) yield_2\NN|following|also|. (l_prep) of_3\IN|low|A|at (l_pobj) tumours_4\NNS|NONE
D000082_D001749 CID paracetamol_2\NN|NONE (l_prep) of_3\IN|in (l_pobj) tumours_7\NNS|NONE
D000082_D001749 CID paracetamol_11\RB| (r_npadvmod) treated_13\VBN|all (r_amod) groups_14\NNS|NONE (r_pobj) in_9\IN|and|bore|,|Papillomas (r_prep) developed_8\VBN|NONE (l_conj) bore_19\VBD|and|in|,|Papillomas (l_dobj) carcinomas_21\NNS|.|rats
D000082_D006965 CID paracetamol_7\NN| (r_npadvmod) treated_9\VBN|NONE (r_amod) rats_10\NNS|NONE (r_pobj) of_6\IN| (r_prep) %_5\NN|hyperplasia|Additionally|,|. (r_nsubj) developed_11\VBD|NONE (l_dobj) hyperplasia_12\NN|%|Additionally|,|.
D000082_D001744 NONE paracetamol_7\NN| (r_npadvmod) treated_9\VBN|NONE (r_amod) rats_10\NNS|NONE (r_pobj) of_6\IN| (r_prep) %_5\NN|hyperplasia|Additionally|,|. (r_nsubj) developed_11\VBD|NONE (l_dobj) hyperplasia_12\NN|%|Additionally|,|. (l_prep) of_13\IN|NONE (l_pobj) epithelium_16\NN|NONE (l_relcl) was_19\VBD|bladder|,|the (l_acomp) coincident_21\JJ|not|which (l_prep) with_22\IN|NONE (l_pobj) presence_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) calculi_27\NNS|NONE
D000082_D010212 NONE paracetamol_11\RB| (r_npadvmod) treated_13\VBN|all (r_amod) groups_14\NNS|NONE (r_pobj) in_9\IN|and|bore|,|Papillomas (r_prep) developed_8\VBN|NONE (l_nsubj) Papillomas_0\NNP|and|in|bore|,
11524350
C037663_D012640 CID ropivacaine_6\VBP|and (r_conj) levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|cumulative|The (r_prep) doses_2\NNS|and|similar|.|seizures|were (r_nsubj) were_10\VBD|NONE (l_nsubj) seizures_9\NNS|and|similar|doses|.|were
D002045_D064420 NONE bupivacaine-_5\DT|NONE (r_nmod) rats_13\NNS|NONE (r_pobj) in_4\IN|.|Systemic|and|resuscitation (r_prep) toxicity_1\NN|NONE
D002045_D064420 NONE bupivacaine_6\NN|NONE (r_pobj) of_5\IN|systemic|the|levobupivacaine|, (r_prep) toxicity_4\NN|We|.
D002045_D064420 NONE bupivacaine_15\NN|and (r_conj) ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|that|toxicity|administered (r_acomp) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
D002045_D064420 NONE bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|when|at|and (r_conj) administered_17\VBN|intermediate|that|toxicity (r_advcl) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C476513_D001145 CID levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|The|cumulative|produced (r_prep) doses_2\NNS|were|smaller|but|, (l_relcl) produced_6\VBD|of|The|cumulative (l_dobj) dysrhythmias_7\NNS|that
D002045_D012640 NONE bupivacaine_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) those_16\DT|NONE (r_pobj) than_15\IN|NONE (r_prep) larger_14\JJR|NONE (r_acomp) were_13\VBD|and|similar|doses|.|seizures (r_conj) were_10\VBD|NONE (l_nsubj) seizures_9\NNS|and|similar|doses|.|were
C476513_D006323 CID levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|The|cumulative|produced (r_prep) doses_2\NNS|were|smaller|but|, (l_relcl) produced_6\VBD|of|The|cumulative (l_dobj) dysrhythmias_7\NNS|that (l_conj) asystole_9\NN|and
C476513_D006323 CID levobupivacaine_7\NN|NONE (r_pobj) of_6\IN|systemic|the (r_prep) toxicity_5\NN|intermediate|that|administered (r_nsubj) is_8\VBZ|We (l_advcl) administered_17\VBN|intermediate|that|toxicity (l_conj) appears_29\VBZ|when|at|and (l_nsubj) arrest_28\NN|be|.
C476513_D006323 CID levobupivacaine_42\NN|or (r_conj) bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|when|at|and (l_nsubj) arrest_28\NN|be|.
D002045_D001145 NONE bupivacaine_26\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) those_24\DT|NONE (r_pobj) than_23\IN|NONE (r_prep) larger_22\JJR|.|they (r_acomp) were_21\VBD|smaller|but|,|doses (r_conj) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|smaller|but|, (l_relcl) produced_6\VBD|of|The|cumulative (l_dobj) dysrhythmias_7\NNS|that
C476513_D064420 NONE levobupivacaine-_7\JJ|, (r_conj) bupivacaine-_5\DT|NONE (r_nmod) rats_13\NNS|NONE (r_pobj) in_4\IN|.|Systemic|and|resuscitation (r_prep) toxicity_1\NN|NONE
C476513_D064420 NONE levobupivacaine_8\NN|systemic|the|of|, (r_conj) toxicity_4\NN|We|.
C476513_D064420 NONE levobupivacaine_7\NN|NONE (r_pobj) of_6\IN|systemic|the (r_prep) toxicity_5\NN|intermediate|that|administered
C476513_D064420 NONE levobupivacaine_42\NN|or (r_conj) bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|when|at|and (r_conj) administered_17\VBN|intermediate|that|toxicity (r_advcl) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C476513_D012640 CID levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|cumulative|The (r_prep) doses_2\NNS|and|similar|.|seizures|were (r_nsubj) were_10\VBD|NONE (l_nsubj) seizures_9\NNS|and|similar|doses|.|were
C037663_D064420 NONE ropivacaine_10\NN| (r_npadvmod) infused_12\VBN|,|or (r_conj) levobupivacaine-_7\JJ|, (r_conj) bupivacaine-_5\DT|NONE (r_nmod) rats_13\NNS|NONE (r_pobj) in_4\IN|.|Systemic|and|resuscitation (r_prep) toxicity_1\NN|NONE
C037663_D064420 NONE ropivacaine_11\NN|and|, (r_conj) levobupivacaine_8\NN|systemic|the|of|, (r_conj) toxicity_4\NN|We|.
C037663_D064420 NONE ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|that|toxicity|administered (r_acomp) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C037663_D064420 NONE ropivacaine_24\NN| (r_npadvmod) induced_26\VBN|cardiac|that (r_amod) arrest_28\NN|be|. (r_nsubj) appears_29\VBZ|when|at|and (r_conj) administered_17\VBN|intermediate|that|toxicity (r_advcl) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C037663_D006323 CID ropivacaine_17\NN|NONE (r_pobj) of_16\IN|the|corresponding (r_prep) doses_15\NNS|NONE (r_pobj) than_12\IN|NONE (r_prep) smaller_11\JJR|were|but|,|doses (r_acomp) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|smaller|but|, (l_relcl) produced_6\VBD|of|The|cumulative (l_dobj) dysrhythmias_7\NNS|that (l_conj) asystole_9\NN|and
C037663_D006323 CID ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|that|toxicity|administered (r_acomp) is_8\VBZ|We (l_advcl) administered_17\VBN|intermediate|that|toxicity (l_conj) appears_29\VBZ|when|at|and (l_nsubj) arrest_28\NN|be|.
C037663_D006323 CID ropivacaine_24\NN| (r_npadvmod) induced_26\VBN|cardiac|that (r_amod) arrest_28\NN|be|.
C037663_D001145 CID ropivacaine_17\NN|NONE (r_pobj) of_16\IN|the|corresponding (r_prep) doses_15\NNS|NONE (r_pobj) than_12\IN|NONE (r_prep) smaller_11\JJR|were|but|,|doses (r_acomp) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|smaller|but|, (l_relcl) produced_6\VBD|of|The|cumulative (l_dobj) dysrhythmias_7\NNS|that
D002045_D006323 NONE bupivacaine_26\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) those_24\DT|NONE (r_pobj) than_23\IN|NONE (r_prep) larger_22\JJR|.|they (r_acomp) were_21\VBD|smaller|but|,|doses (r_conj) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|smaller|but|, (l_relcl) produced_6\VBD|of|The|cumulative (l_dobj) dysrhythmias_7\NNS|that (l_conj) asystole_9\NN|and
D002045_D006323 NONE bupivacaine_15\NN|and (r_conj) ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|that|toxicity|administered (r_acomp) is_8\VBZ|We (l_advcl) administered_17\VBN|intermediate|that|toxicity (l_conj) appears_29\VBZ|when|at|and (l_nsubj) arrest_28\NN|be|.
D002045_D006323 NONE bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|when|at|and (l_nsubj) arrest_28\NN|be|.
8106150
D016291_D004409 NONE MK-801_15\NNP|NONE (r_punct) ,_16\,|markedly|movements|drugs|at|.|but (r_punct) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ|the
D015632_D004409 NONE MPTP_12\NNP| (r_npadvmod) treated_14\VBN|NONE (r_amod) monkeys_15\NNS|NONE (r_pobj) in_11\IN|induced (r_prep) dyskinesias_10\NNS|NONE
D010830_D004409 NONE physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ|the
D008614_D004409 NONE meperidine_4\RB|and (r_conj) yohimbine_2\NN|.|movements|However|,|predominantly (r_nsubj) reduced_5\VBN|NONE (l_dobj) movements_9\NNS|.|yohimbine|However|,|predominantly (l_amod) dyskinetic_8\JJ|the
D003000_D020734 NONE clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D001418_D004409 NONE Baclofen_0\NNP|also|.|useful (r_nsubj) was_1\VBD|NONE (l_acomp) useful_3\JJ|also|.|Baclofen (l_prep) against_7\IN|in (l_pobj) form_11\NN|NONE (l_prep) of_12\IN|a|dystonic (l_pobj) dyskinesia_13\NN|NONE
D001418_D020821 NONE Baclofen_0\NNP|also|.|useful (r_nsubj) was_1\VBD|NONE (l_acomp) useful_3\JJ|also|.|Baclofen (l_prep) against_7\IN|in (l_pobj) form_11\NN|NONE (l_amod) dystonic_10\JJ|a|of
D001285_D002819 NONE Atropine_0\NNP|into|movements|. (r_nsubj) converted_1\VBD|NONE (l_prep) into_5\IN|movements|.|Atropine (l_pobj) chorea_6\NN|NONE
D011433_D004409 NONE propranolol_12\NN|MDOT|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ|the
D016291_D020734 NONE MK-801_15\NNP|NONE (r_punct) ,_16\,|markedly|movements|drugs|at|.|but (r_punct) reduced_18\VBD|NONE (l_conj) at_23\IN|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D008784_D020734 NONE methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D008784_D004409 NONE methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ|the
D007980_D004409 NONE dopa_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) dyskinesias_10\NNS|NONE
D007980_D004409 NONE DOPA_19\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) combination_15\NN|NONE (r_pobj) in_14\IN|were|.|then|see|series (r_prep) tested_13\VBN|NONE (l_advcl) see_21\VB|were|.|then|in|series (l_ccomp) modified_28\VBN|to (l_nsubjpass) movements_25\NNS|would|be|if (l_amod) dyskinetic_24\JJ|the
D003000_D004409 NONE clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ|the
D011433_D020734 NONE propranolol_12\NN|MDOT|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
-1_D020734 NONE 5-MDOT_10\CD|propranolol|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D015632_D020734 CID MPTP_11\NNP|NONE (r_pobj) with_8\IN|NONE (r_prep) parkinsonian_7\NN|was|.|group
D001285_D020821 NONE Atropine_0\NNP|into|movements|. (r_nsubj) converted_1\VBD|NONE (l_dobj) movements_4\NNS|into|.|Atropine (l_amod) dystonic_3\JJ|the
D015016_D004409 NONE yohimbine_2\NN|.|movements|However|,|predominantly (r_nsubj) reduced_5\VBN|NONE (l_dobj) movements_9\NNS|.|yohimbine|However|,|predominantly (l_amod) dyskinetic_8\JJ|the
-1_D004409 NONE 5-MDOT_10\CD|propranolol|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ|the
D004298_D004409 NONE dopamine_10\NN|NONE (r_pobj) than_9\IN|NONE (r_prep) other_8\JJ|NONE (r_amod) neurotransmitters_7\NNS|NONE (r_pobj) on_6\IN|primarily (r_prep) acting_4\VBG|NONE (r_acl) agents_3\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|were|.|then|in|see (r_nsubjpass) tested_13\VBN|NONE (l_advcl) see_21\VB|were|.|then|in|series (l_ccomp) modified_28\VBN|to (l_nsubjpass) movements_25\NNS|would|be|if (l_amod) dyskinetic_24\JJ|the
D010830_D020734 NONE physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
3431591
C031662_D064420 NONE 3717_1\CD|acid|,|, (r_nummod) CB_0\NN|.|inhibitor (r_nsubj) is_6\VBZ|NONE (l_attr) inhibitor_11\NN|.|CB (l_relcl) mediated_21\VBN|of|binding|a (l_nsubjpass) cytotoxicity_19\NN|through|is
C031662_D064420 NONE acid_4\NN|,|,| (r_appos) CB_0\NN|.|inhibitor (r_nsubj) is_6\VBZ|NONE (l_attr) inhibitor_11\NN|.|CB (l_relcl) mediated_21\VBN|of|binding|a (l_nsubjpass) cytotoxicity_19\NN|through|is
C031662_D064420 NONE 3717_28\CD|, (r_nummod) CB_27\NNP|NONE (r_pobj) than_26\IN|more (r_prep) potent_25\JJ||,|,| (r_amod) 26-_17\NNPS|,|respectively|As|and|be (r_attr) are_16\VBP|NONE (l_conj) be_39\VB|,||respectively|As|and (l_attr) determinant_42\NN|formation|,|may|.|therefore|, (l_prep) of_43\IN|an|important (l_pobj) cytotoxicity_46\NN|NONE
C031662_D064420 NONE 3717_45\CD|CB (r_nummod) cytotoxicity_46\NN|NONE
C031662_D010051 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|clinical|early (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|,|in|been|has|activity|. (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|,|In|been|has|activity|. (l_pobj) cancer_14\NN|NONE (l_conj) cancer_17\NN|breast|,
C031662_D001943 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|clinical|early (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|,|in|been|has|activity|. (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|,|In|been|has|activity|. (l_pobj) cancer_14\NN|NONE
C031662_D008654 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|clinical|early (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|,|in|been|has|activity|. (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|,|In|been|has|activity|. (l_pobj) cancer_14\NN|NONE (l_conj) cancer_17\NN|breast|, (l_conj) hepatoma_19\NN|ovarian|, (l_conj) mesothelioma_22\NN|,|and
C031662_D006528 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|clinical|early (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|,|in|been|has|activity|. (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|,|In|been|has|activity|. (l_pobj) cancer_14\NN|NONE (l_conj) cancer_17\NN|breast|, (l_conj) hepatoma_19\NN|ovarian|,
18589141
D006493_D013927 NONE sodium_2\NN|is|prevent|at|in|. (r_nsubjpass) used_16\VBN|NONE (l_xcomp) prevent_24\VB|is|at|in|sodium|. (l_dobj) thrombosis_25\NN|to|after
D006493_D013927 NONE UFH_4\NNP|heparin|Unfractionated|(|or|)|heparin (r_appos) sodium_2\NN|is|prevent|at|in|. (r_nsubjpass) used_16\VBN|NONE (l_xcomp) prevent_24\VB|is|at|in|sodium|. (l_dobj) thrombosis_25\NN|to|after
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|.|after (r_amod) thrombocytopenia_3\NN|NONE
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|HIT (r_amod) thrombocytopenia_3\NN|decreases|reaction|,|.|resulting
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|HIT (r_amod) thrombocytopenia_3\NN|decreases|reaction|,|.|resulting (l_appos) HIT_5\NNP|induced
D006493_D013921 CID heparin_15\NN|NONE (r_pobj) to_14\IN|an|mediated|adverse (r_prep) reaction_13\NN|decreases|,|thrombocytopenia|.|resulting (r_attr) is_7\VBZ|NONE (l_nsubj) thrombocytopenia_3\NN|decreases|reaction|,|.|resulting
D006493_D013921 CID heparin_15\NN|NONE (r_pobj) to_14\IN|an|mediated|adverse (r_prep) reaction_13\NN|decreases|,|thrombocytopenia|.|resulting (r_attr) is_7\VBZ|NONE (l_nsubj) thrombocytopenia_3\NN|decreases|reaction|,|.|resulting (l_appos) HIT_5\NNP|induced
D006493_D013921 CID 4/heparin_10\NN| (r_nummod) reactive_12\JJ|NONE (r_amod) antibody_13\NN|)|in|(|antibody (r_nmod) positivity_18\NN|The|after|of (r_conj) frequencies_1\NNS|.|however|,|unknown|, (l_prep) of_2\IN|The|after|positivity (l_pobj) HIT_3\NN|NONE
D006493_D013921 CID 4/heparin_10\NN| (r_nummod) reactive_12\JJ|NONE (r_amod) antibody_13\NN|)|in|(|antibody (r_nmod) positivity_18\NN|The|after|of (l_nmod) antibody_16\NN|)|in|(|antibody (l_nmod) HIT_15\NNP|NONE
D006493_D013921 CID UFH_7\NN| (r_npadvmod) related_9\VBN|NONE (r_amod) HIT_10\NN|.|None
D006493_D001791 NONE heparin_1\NN| (r_npadvmod) induced_3\VBN|aggregation|The (r_amod) test_6\NN|.|in|negative (l_compound) aggregation_5\NN|induced|The
D006495_D013927 NONE heparin_11\NN|heparin|Unfractionated|(|or|)|UFH (r_conj) sodium_2\NN|is|prevent|at|in|. (r_nsubjpass) used_16\VBN|NONE (l_xcomp) prevent_24\VB|is|at|in|sodium|. (l_dobj) thrombosis_25\NN|to|after
7337133
D000082_D017093 CID acetaminophen_9\NN|NONE (r_compound) overdose_10\NN|NONE (r_pobj) in_8\IN|fulminant|hepatic (r_prep) failure_7\NN|NONE
D000082_D017093 CID acetaminophen_6\RB| (r_advmod) induced_8\VBN|hepatic|fatal|fulminant (r_amod) failure_11\NN|NONE
D000082_D001929 CID acetaminophen_9\NN|NONE (r_compound) overdose_10\NN|NONE (r_pobj) in_8\IN|fulminant|hepatic (r_prep) failure_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|:|role|.|Massive|cerebral (r_acl) edema_2\NN|NONE
D000082_D001929 CID acetaminophen_6\RB| (r_advmod) induced_8\VBN|hepatic|fatal|fulminant (r_amod) failure_11\NN|NONE (r_pobj) with_4\IN|a (r_prep) patient_3\NN|We|with|.|, (r_dobj) present_1\VBP|NONE (l_prep) with_13\IN|We|.|,|patient (l_pobj) signs_14\NNS|NONE (l_prep) of_17\IN|and|symptoms (l_pobj) edema_19\NN|NONE
D000082_D062787 NONE acetaminophen_9\NN|NONE (r_compound) overdose_10\NN|NONE
10539815
D004232_D003920 NONE diuretic_49\JJ|, (r_conj) antiplatelet_47\JJ|NONE (r_pobj) of_46\IN|NONE (r_prep) use_45\NN|,|and (r_conj) diabetes_42\NNS|,
D004232_D003920 NONE diuretic_14\JJ|,|diabetes|and (r_amod) therapy_15\NN|,|older (l_conj) diabetes_18\NNS|,|and|diuretic
D004656_D018487 NONE enalapril_26\NN|NONE (r_pobj) of_25\IN|controlled|randomized|,|blind|a|for|, (r_prep) trial_24\NN|SOLVD|,|(|)|Ventricular|Left (r_appos) Dysfunction_9\NNP|NONE
D003404_D051437 NONE creatinine_10\NN|NONE (r_pobj) in_8\IN|a (r_prep) rise_7\NN|NONE (r_pobj) as_5\IN|was|>|function|/=. (r_prep) defined_4\VBN|NONE (l_nsubjpass) function_2\NN|was|>|as|/=.
D003404_D003920 NONE creatinine_25\NN|,|ejection (r_conj) fraction_22\NN|history|,|, (r_conj) age_18\NN|NONE (l_appos) history_38\NN|fraction|,|, (l_prep) of_39\IN|NONE (l_pobj) hypertension_40\NN|NONE (l_conj) diabetes_42\NNS|,
D004656_D051437 CID enalapril_4\NN|NONE (r_pobj) to_3\IN|randomly (r_prep) assigned_2\VBN|NONE (r_acl) Patients_0\NNS|.|likelihood (r_nsubj) had_5\VBD|NONE (l_dobj) likelihood_10\NN|.|Patients (l_prep) of_11\IN|a|greater (l_pobj) function_14\NN|NONE
D004656_D051437 CID enalapril_9\NN|NONE (r_compound) groups_10\NNS|age|both|and|the (r_conj) placebo_7\NN|NONE (r_pobj) in_4\IN|,|with|were|were|.|,|By (r_prep) associated_20\VBN|NONE (l_prep) with_21\IN|,|in|were|were|.|,|By (l_pobj) function_24\NN|NONE
D004656_D051437 CID enalapril_23\JJ|ratio|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|significantly|,|so|interval (r_prep) more_19\RBR|,|but|was|age|with (r_conj) associated_3\VBN|NONE (l_prep) with_4\IN|,|but|was|age|more (l_pobj) risk_7\NN|NONE (l_prep) of_8\IN|a|greater (l_pcomp) developing_9\VBG|NONE (l_dobj) function_12\NN|NONE
D004656_D051437 CID enalapril_26\NN|RR|[|(|]|risk|:|years (r_dep) ratio_29\NN|the|enalapril (r_appos) group_24\NN|NONE (r_pobj) in_21\IN|significantly|,|so|interval (r_prep) more_19\RBR|,|but|was|age|with (r_conj) associated_3\VBN|NONE (l_prep) with_4\IN|,|but|was|age|more (l_pobj) risk_7\NN|NONE (l_prep) of_8\IN|a|greater (l_pcomp) developing_9\VBG|NONE (l_dobj) function_12\NN|NONE
D004656_D051437 CID enalapril_15\JJ|)|%|(|the (r_compound) group_16\NN|NONE (r_pobj) in_13\IN|renal|decreased (r_prep) function_12\NN|NONE
D004656_D051437 CID Enalapril_0\NNP|NONE (r_compound) use_1\NN|.|increase (r_nsubj) caused_2\VBD|NONE (l_dobj) increase_6\NN|.|use (l_prep) in_7\IN|%|a (l_pobj) risk_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) function_13\NN|NONE
D004656_D051437 CID enalapril_23\JJ|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|compared|.|risk|was (r_prep) reduced_20\VBN|but|,|Diabetes|with|was (r_conj) associated_2\VBN|NONE (l_prep) with_3\IN|but|,|Diabetes|reduced|was (l_pobj) risk_6\NN|NONE (l_prep) of_7\IN|increased|an (l_pobj) impairment_9\NN|NONE
D004232_D051437 CID diuretic_14\JJ|,|diabetes|and (r_amod) therapy_15\NN|,|older (r_conj) age_12\NN|both|and|groups|the (r_conj) placebo_7\NN|NONE (r_pobj) in_4\IN|,|with|were|were|.|,|By (r_prep) associated_20\VBN|NONE (l_prep) with_21\IN|,|in|were|were|.|,|By (l_pobj) function_24\NN|NONE
D004232_D051437 CID Diuretic_0\JJ|NONE (r_compound) therapy_1\NN|likewise|was|.|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|likewise|therapy|was|. (l_pobj) risk_8\NN|NONE (l_prep) of_9\IN|greater|a|than (l_pobj) function_12\NN|NONE
D004656_D006333 NONE enalapril_26\NN|NONE (r_pobj) of_25\IN|controlled|randomized|,|blind|a|for|, (r_prep) trial_24\NN|SOLVD|,|(|)|Ventricular|Left (l_prep) for_27\IN|controlled|randomized|,|blind|a|,|of (l_pobj) treatment_29\NN|NONE (l_prep) of_30\IN|the (l_pobj) CHF_31\NNP|NONE
D004656_D006333 NONE Enalapril_0\NNP|NONE (r_compound) use_1\NN|.|increase (r_nsubj) caused_2\VBD|NONE (l_dobj) increase_6\NN|.|use (l_prep) in_7\IN|%|a (l_pobj) risk_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) function_13\NN|NONE (l_prep) in_14\IN|decreased|renal (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) CHF_17\NNP|NONE
D004656_D006333 NONE enalapril_23\JJ|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|compared|.|risk|was (r_prep) reduced_20\VBN|but|,|Diabetes|with|was (r_conj) associated_2\VBN|NONE (l_prep) with_3\IN|but|,|Diabetes|reduced|was (l_pobj) risk_6\NN|NONE (l_prep) of_7\IN|increased|an (l_pobj) impairment_9\NN|NONE (l_prep) in_10\IN|renal (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|all (l_pobj) CHF_14\NNP|NONE
D003404_D006973 NONE creatinine_25\NN|,|ejection (r_conj) fraction_22\NN|history|,|, (r_conj) age_18\NN|NONE (l_appos) history_38\NN|fraction|,|, (l_prep) of_39\IN|NONE (l_pobj) hypertension_40\NN|NONE
D000809_D051437 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|NONE (r_amod) enzyme_14\NN|inhibitor (r_compound) therapy_16\NN|NONE (r_pobj) during_10\IN|with (r_prep) patients_6\NNS|NONE (r_pobj) in_5\IN|renal|decreased (r_prep) function_4\NN|NONE
D000809_D051437 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|NONE (r_amod) enzyme_4\NN|inhibitor (r_compound) therapy_6\NN|rates|Although|in (r_nsubj) reduces_7\VBZ|also|it|,|.|function|may (r_advcl) cause_23\VB|NONE (l_dobj) function_26\NN|also|reduces|it|,|.|may
D000809_D051437 NONE angiotensin_17\NN| (r_npadvmod) converting_19\VBG|NONE (r_amod) enzyme_20\NN|inhibitor (r_compound) therapy_22\NN|who|are (r_dobj) prescribed_16\VBN|NONE (r_relcl) CHF_13\NNP|NONE (r_pobj) with_12\IN|NONE (r_prep) patients_11\NNS|NONE (r_pobj) in_10\IN|in (r_prep) reduction_6\NN|NONE (l_prep) in_7\IN|in (l_pobj) function_9\NN|NONE
D000809_D018487 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|NONE (r_amod) enzyme_14\NN|inhibitor (r_compound) therapy_16\NN|NONE (r_pobj) during_10\IN|with (r_prep) patients_6\NNS|NONE (r_pobj) in_5\IN|renal|decreased (r_prep) function_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Predictors_0\NNS|from|: (r_dep) results_18\NNS|NONE (l_prep) from_19\IN|Predictors|: (l_pobj) studies_21\NNS|NONE (l_prep) of_22\IN|the (l_pobj) dysfunction_25\NN|NONE
D004232_D006973 NONE diuretic_49\JJ|, (r_conj) antiplatelet_47\JJ|NONE (r_pobj) of_46\IN|NONE (r_prep) use_45\NN|,|and (r_conj) diabetes_42\NNS|, (r_conj) hypertension_40\NN|NONE
D004656_D003920 NONE enalapril_9\NN|NONE (r_compound) groups_10\NNS|age|both|and|the (r_conj) placebo_7\NN|NONE (l_conj) age_12\NN|both|and|groups|the (l_conj) therapy_15\NN|,|older (l_conj) diabetes_18\NNS|,|and|diuretic
D004656_D003920 NONE enalapril_2\NN|RR|effect|.|,|Conversely (r_nsubj) had_3\VBD|NONE (l_npadvmod) RR_9\NN|enalapril|effect|.|,|Conversely (l_nummod) 1.33_10\CD|( (l_prep) compared_19\VBN|NONE (l_prep) with_20\IN|, (l_pobj) placebo_21\NN|NONE (l_appos) CI_28\NNP|( (l_prep) in_33\IN|)|%|RR|,|. (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) diabetes_36\NNS|NONE
D004656_D003920 NONE enalapril_23\JJ|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|compared|.|risk|was (r_prep) reduced_20\VBN|but|,|Diabetes|with|was (r_conj) associated_2\VBN|NONE (l_nsubjpass) Diabetes_0\NN|but|,|with|reduced|was
D000809_D006333 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|NONE (r_amod) enzyme_14\NN|inhibitor (r_compound) therapy_16\NN|NONE (r_pobj) during_10\IN|with (r_prep) patients_6\NNS|NONE (l_prep) with_7\IN|during (l_pobj) failure_9\NN|NONE
D000809_D006333 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|NONE (r_amod) enzyme_4\NN|inhibitor (r_compound) therapy_6\NN|rates|Although|in (r_nsubj) reduces_7\VBZ|also|it|,|.|function|may (l_prep) in_10\IN|rates|therapy|Although (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) failure_15\NN|NONE
D000809_D006333 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|NONE (r_amod) enzyme_4\NN|inhibitor (r_compound) therapy_6\NN|rates|Although|in (r_nsubj) reduces_7\VBZ|also|it|,|.|function|may (l_prep) in_10\IN|rates|therapy|Although (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) failure_15\NN|NONE (l_appos) CHF_17\NNP|congestive|heart
D000809_D006333 NONE angiotensin_17\NN| (r_npadvmod) converting_19\VBG|NONE (r_amod) enzyme_20\NN|inhibitor (r_compound) therapy_22\NN|who|are (r_dobj) prescribed_16\VBN|NONE (r_relcl) CHF_13\NNP|NONE
18441470
D008094_D012804 CID lithium_14\NN|NONE (r_pobj) of_13\IN|cardiovascular|the|adverse (r_prep) effects_12\NNS|NONE (r_pobj) among_8\IN|has|dysfunction|.|been|frequently (r_prep) reported_5\VBN|NONE (l_nsubjpass) dysfunction_2\NN|among|has|.|been|frequently
D008094_D013575 NONE lithium_17\NN|NONE (r_compound) therapy_18\NN|NONE (r_pobj) to_16\IN|,|necessitating|block|.|,|secondary|In (r_prep) developed_14\VBD|NONE (l_nsubj) block_10\NN|,|necessitating|to|.|,|secondary|In (l_prep) with_11\IN|)|(|AV|complete|atrioventricular (l_pobj) attacks_13\NNS|NONE
D008094_D013575 NONE lithium_1\NN|NONE (r_compound) levels_2\NNS|during|.|under (r_nsubj) remained_3\VBD|NONE (l_prep) during_10\IN|levels|.|under (l_pobj) attacks_13\NNS|NONE
D008094_D054537 CID lithium_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) secondary_3\JJ|atrioventricular|Complete|. (r_amod) block_2\NN|NONE
D008094_D054537 CID lithium_17\NN|NONE (r_compound) therapy_18\NN|NONE (r_pobj) to_16\IN|,|necessitating|block|.|,|secondary|In (r_prep) developed_14\VBD|NONE (l_nsubj) block_10\NN|,|necessitating|to|.|,|secondary|In
3973521
11230490
D003520_D001943 NONE cyclophosphamide_12\NN|and|encapsulated (r_conj) doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN|NONE (l_prep) compared_13\VBN|.|Reduced|and|efficacy (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|a|randomized|, (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_18\NN|conventional|and (r_conj) doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|.|Reduced|and|efficacy (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|a|randomized|, (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) combination_22\NN|NONE (r_pobj) in_21\IN|Corporation|,|Liposome|)|The (r_prep) Company_12\NNP|determine|providing|.|significantly|cardiotoxicity|; (r_nsubj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D003520_D001943 NONE cyclophosphamide_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) combination_22\NN|NONE (r_pobj) in_21\IN|Corporation|,|Liposome|)|The (r_prep) Company_12\NNP|determine|providing|.|significantly|cardiotoxicity|; (r_nsubj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D003520_D001943 NONE cyclophosphamide_46\NN|NONE (r_pobj) of_45\IN|)|with (r_prep) combination_38\NN|NONE (r_pobj) in_37\IN|doxorubicin|to|,|,|m(|weeks (r_prep) receive_18\VB|.|patients|were (r_xcomp) randomized_16\VBN|NONE (l_nsubjpass) patients_5\NNS|receive|.|were (l_prep) with_6\IN|seven|and|chemotherapy (l_pobj) MBC_7\NNP|NONE
D003520_D001943 NONE cyclophosphamide_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) combination_24\NN|NONE (r_pobj) in_23\IN|when|as (r_prep) used_22\VBN|efficacy|, (l_prep) as_27\IN|when|in (l_pobj) therapy_31\NN|NONE (l_prep) for_32\IN|line (l_pobj) MBC_33\NNP|NONE
D003520_D064420 NONE cyclophosphamide_46\NN|NONE (r_pobj) of_45\IN|)|with (r_prep) combination_38\NN|NONE (r_pobj) in_37\IN|doxorubicin|to|,|,|m(|weeks (r_prep) receive_18\VB|.|patients|were (l_npadvmod) weeks_53\NNS|doxorubicin|in|to|,|,|m( (l_prep) until_54\IN|every| (l_pobj) progression_56\NN|NONE (l_conj) toxicity_59\NN|disease|or
D003520_D009503 CID cyclophosphamide_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) combination_24\NN|NONE (r_pobj) in_23\IN|when|as (r_prep) used_22\VBN|efficacy|, (r_advcl) provides_16\VBZ|Myocet|neutropenia|and|by|index|. (r_conj) improves_1\VBZ|NONE (l_dobj) neutropenia_14\NN|Myocet|provides|and|by|index|.
D004317_D066126 NONE doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN|NONE
D004317_D066126 NONE doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|.|Reduced|and|efficacy (r_prep) cardiotoxicity_1\NN|NONE
D004317_D066126 NONE Myocet_3\NNP|whether|encapsulated (r_nmod) doxorubicin_8\NN|To (r_dobj) determine_1\VB|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ|NONE (l_dobj) cardiotoxicity_28\NN|Company|determine|providing|.|significantly|;
D004317_D066126 NONE doxorubicin_8\NN|To (r_dobj) determine_1\VB|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ|NONE (l_dobj) cardiotoxicity_28\NN|Company|determine|providing|.|significantly|;
D004317_D066126 NONE doxorubicin_27\NN|NONE (r_compound) cardiotoxicity_28\NN|Company|determine|providing|.|significantly|;
D004317_D066126 NONE Myocet_0\NNP|provides|neutropenia|and|by|index|. (r_nsubj) improves_1\VBZ|NONE (l_prep) by_7\IN|Myocet|provides|neutropenia|and|index|. (l_pcomp) reducing_9\VBG|NONE (l_dobj) cardiotoxicity_10\NN|significantly
D004317_D066126 NONE doxorubicin_6\NN|NONE (r_pobj) of_5\IN|the|therapeutic (r_prep) index_4\NN|Myocet|provides|neutropenia|and|by|. (r_dobj) improves_1\VBZ|NONE (l_prep) by_7\IN|Myocet|provides|neutropenia|and|index|. (l_pcomp) reducing_9\VBG|NONE (l_dobj) cardiotoxicity_10\NN|significantly
D004317_D001943 NONE doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN|NONE (l_prep) compared_13\VBN|.|Reduced|and|efficacy (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|a|randomized|, (l_pobj) cancer_28\NN|NONE
D004317_D001943 NONE doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|.|Reduced|and|efficacy (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|a|randomized|, (l_pobj) cancer_28\NN|NONE
D004317_D001943 NONE Myocet_3\NNP|whether|encapsulated (r_nmod) doxorubicin_8\NN|To (r_dobj) determine_1\VB|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D004317_D001943 NONE Myocet_3\NNP|whether|encapsulated (r_nmod) doxorubicin_8\NN|To (r_dobj) determine_1\VB|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D004317_D001943 NONE doxorubicin_8\NN|To (r_dobj) determine_1\VB|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D004317_D001943 NONE doxorubicin_8\NN|To (r_dobj) determine_1\VB|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D004317_D001943 NONE doxorubicin_27\NN|NONE (r_compound) cardiotoxicity_28\NN|Company|determine|providing|.|significantly|; (r_dobj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D004317_D001943 NONE doxorubicin_27\NN|NONE (r_compound) cardiotoxicity_28\NN|Company|determine|providing|.|significantly|; (r_dobj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN|while|efficacy (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D004317_D001943 NONE Myocet_26\NNP|(|) (r_nmod) M_28\NNP|NONE (r_pobj) of_25\IN|)|/||mg|or|either (r_prep) m(2_23\NN|doxorubicin|in|to|,|,|weeks (r_dobj) receive_18\VB|.|patients|were (r_xcomp) randomized_16\VBN|NONE (l_nsubjpass) patients_5\NNS|receive|.|were (l_prep) with_6\IN|seven|and|chemotherapy (l_pobj) MBC_7\NNP|NONE
D004317_D001943 NONE doxorubicin_32\NN|in|to|,|,|m(|weeks (r_dobj) receive_18\VB|.|patients|were (r_xcomp) randomized_16\VBN|NONE (l_nsubjpass) patients_5\NNS|receive|.|were (l_prep) with_6\IN|seven|and|chemotherapy (l_pobj) MBC_7\NNP|NONE
D004317_D001943 NONE Myocet_0\NNP|provides|neutropenia|and|by|index|. (r_nsubj) improves_1\VBZ|NONE (l_conj) provides_16\VBZ|Myocet|neutropenia|and|by|index|. (l_advcl) used_22\VBN|efficacy|, (l_prep) as_27\IN|when|in (l_pobj) therapy_31\NN|NONE (l_prep) for_32\IN|line (l_pobj) MBC_33\NNP|NONE
D004317_D001943 NONE doxorubicin_6\NN|NONE (r_pobj) of_5\IN|the|therapeutic (r_prep) index_4\NN|Myocet|provides|neutropenia|and|by|. (r_dobj) improves_1\VBZ|NONE (l_conj) provides_16\VBZ|Myocet|neutropenia|and|by|index|. (l_advcl) used_22\VBN|efficacy|, (l_prep) as_27\IN|when|in (l_pobj) therapy_31\NN|NONE (l_prep) for_32\IN|line (l_pobj) MBC_33\NNP|NONE
D004317_D009503 CID Myocet_0\NNP|provides|neutropenia|and|by|index|. (r_nsubj) improves_1\VBZ|NONE (l_dobj) neutropenia_14\NN|Myocet|provides|and|by|index|.
D004317_D009503 CID doxorubicin_6\NN|NONE (r_pobj) of_5\IN|the|therapeutic (r_prep) index_4\NN|Myocet|provides|neutropenia|and|by|. (r_dobj) improves_1\VBZ|NONE (l_dobj) neutropenia_14\NN|Myocet|provides|and|by|index|.
D003520_D066126 NONE cyclophosphamide_12\NN|and|encapsulated (r_conj) doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN|NONE
D003520_D066126 NONE cyclophosphamide_18\NN|conventional|and (r_conj) doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|.|Reduced|and|efficacy (r_prep) cardiotoxicity_1\NN|NONE
D003520_D066126 NONE cyclophosphamide_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) combination_22\NN|NONE (r_pobj) in_21\IN|Corporation|,|Liposome|)|The (r_prep) Company_12\NNP|determine|providing|.|significantly|cardiotoxicity|; (r_nsubj) reduces_26\VBZ|NONE (l_dobj) cardiotoxicity_28\NN|Company|determine|providing|.|significantly|;
D003520_D066126 NONE cyclophosphamide_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) combination_24\NN|NONE (r_pobj) in_23\IN|when|as (r_prep) used_22\VBN|efficacy|, (r_advcl) provides_16\VBZ|Myocet|neutropenia|and|by|index|. (r_conj) improves_1\VBZ|NONE (l_prep) by_7\IN|Myocet|provides|neutropenia|and|index|. (l_pcomp) reducing_9\VBG|NONE (l_dobj) cardiotoxicity_10\NN|significantly
D004317_D064420 NONE Myocet_26\NNP|(|) (r_nmod) M_28\NNP|NONE (r_pobj) of_25\IN|)|/||mg|or|either (r_prep) m(2_23\NN|doxorubicin|in|to|,|,|weeks (r_dobj) receive_18\VB|.|patients|were (l_npadvmod) weeks_53\NNS|doxorubicin|in|to|,|,|m( (l_prep) until_54\IN|every| (l_pobj) progression_56\NN|NONE (l_conj) toxicity_59\NN|disease|or
D004317_D064420 NONE doxorubicin_32\NN|in|to|,|,|m(|weeks (r_dobj) receive_18\VB|.|patients|were (l_npadvmod) weeks_53\NNS|doxorubicin|in|to|,|,|m( (l_prep) until_54\IN|every| (l_pobj) progression_56\NN|NONE (l_conj) toxicity_59\NN|disease|or
11467664
D008687_D056486 NONE metformin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) initiation_10\NN|wk (r_pobj) after_8\IN|the|of (r_prep) onset_2\NN|NONE (r_pobj) Given_0\VBN|represents|,|we (r_prep) believe_15\VBP|case|.|, (l_ccomp) represents_19\VBZ|Given|,|we (l_dobj) example_21\NN|that|case (l_prep) of_22\IN|an (l_pobj) hepatotoxicity_26\NN|NONE
D008687_D056486 NONE metformin_23\NN| (r_npadvmod) associated_25\VBN|NONE (r_amod) hepatotoxicity_26\NN|NONE
D008687_D041781 CID metformin_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) use_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Cholestatic|. (r_acl) jaundice_1\NN|NONE
D008687_D041781 CID hydrochloride_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) initiation_10\NN|shortly (r_pobj) after_9\IN|who|jaundice (r_prep) developed_5\VBD|a (l_dobj) jaundice_7\NN|who|after
D008687_D007565 NONE hydrochloride_1\NN|resolved|,|was|and (r_nsubjpass) discontinued_3\VBN|NONE (l_conj) resolved_10\VBN|,|hydrochloride|was|and (l_nsubj) jaundice_9\NN|.|slowly|over
D008687_D007565 NONE metformin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) initiation_10\NN|wk (r_pobj) after_8\IN|the|of (r_prep) onset_2\NN|NONE (l_prep) of_3\IN|the|after (l_pobj) jaundice_5\NN|NONE
D008687_D007565 NONE metformin_23\NN| (r_npadvmod) associated_25\VBN|NONE (r_amod) hepatotoxicity_26\NN|NONE (r_pobj) of_22\IN|an (r_prep) example_21\NN|that|case (r_dobj) represents_19\VBZ|Given|,|we (r_ccomp) believe_15\VBP|case|.|, (l_prep) Given_0\VBN|represents|,|we (l_pobj) onset_2\NN|NONE (l_prep) of_3\IN|the|after (l_pobj) jaundice_5\NN|NONE
19319147
D014859_D006470 NONE warfarin_12\RB| (r_npadvmod) associated_14\VBN|intracerebral (r_amod) hemorrhage_16\NN|NONE (r_pobj) of_11\IN|mouse|a (r_prep) model_10\NN|NONE (r_pobj) in_7\IN|volume|reversal|. (r_prep) reduces_4\VBZ|NONE (l_dobj) volume_6\NN|in|reversal|. (l_compound) hemorrhage_5\NN|NONE
C025667_D002543 NONE PCC_5\NNP|treatment|to|in (r_nsubj) be_7\VB|NONE (l_attr) treatment_11\NN|to|PCC|in (l_prep) for_12\IN|an|effective|acute (l_pobj) ICH_15\NNP|NONE
D014859_D002543 CID warfarin_12\RB| (r_npadvmod) associated_14\VBN|intracerebral (r_amod) hemorrhage_16\NN|NONE
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|ICH|intracerebral|) (r_amod) hemorrhage_4\NN|.|type
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|ICH|intracerebral|) (r_amod) hemorrhage_4\NN|.|type (l_appos) ICH_8\NNP|intracerebral|)|associated
D014859_D020521 NONE Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|ICH|intracerebral|) (r_amod) hemorrhage_4\NN|.|type (r_nsubj) is_10\VBZ|NONE (l_attr) type_13\NN|.|hemorrhage (l_prep) of_14\IN|a|severe (l_pobj) stroke_15\NN|NONE
2557556
D009020_D006930 NONE Morphine_0\NNP|did|hyperalgesia|,|not|,|however|. (r_nsubj) alter_6\VB|NONE (l_dobj) hyperalgesia_8\NN|Morphine|did|,|not|,|however|.
D015232_D006930 CID E2-induced_23\VBN|prostaglandin (r_amod) hyperalgesia_24\NN|NONE
D015124_D006930 CID monophosphate_14\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|the (r_acl) hyperalgesia_8\NN|Morphine|did|,|not|,|however|.
4069770
D005839_D058186 CID gentamicin_18\NN|NONE (r_pobj) with_17\IN|day|penicillin|and (r_prep) therapy_16\NN|NONE (r_pobj) after_15\IN|of|who (r_prep) died_10\VBD|a|premature (l_prep) of_11\IN|who|after (l_pobj) failure_14\NN|NONE
D005839_D007674 NONE Gentamicin_0\NNP|.|in (r_amod) nephropathy_1\NN|NONE
D010406_D058186 NONE penicillin_28\NN|with|day|and (r_conj) therapy_16\NN|NONE (r_pobj) after_15\IN|of|who (r_prep) died_10\VBD|a|premature (l_prep) of_11\IN|who|after (l_pobj) failure_14\NN|NONE
D005839_D001002 NONE gentamicin_2\NN|The|serum (r_compound) concentration_3\NN|.|levels|had|developed (r_nsubj) reached_5\VBN|NONE (l_advcl) developed_10\VBD|concentration|.|levels|had (l_nsubj) anuria_9\NN|when
2840807
D000324_D004421 CID ACTH_10\NNP|of|neuropeptide|) (r_nmod) stimulation_12\NN|NONE (r_pobj) after_5\IN|A|like|. (r_prep) syndrome_4\NN|NONE (l_amod) like_3\JJ|A|.|after (l_npadvmod) dystonia_1\NN|
D009074_D004421 CID MSH_8\NNP|/|( (r_nmod) ACTH_10\NNP|of|neuropeptide|) (r_nmod) stimulation_12\NN|NONE (r_pobj) after_5\IN|A|like|. (r_prep) syndrome_4\NN|NONE (l_amod) like_3\JJ|A|.|after (l_npadvmod) dystonia_1\NN|
D000324_D009069 NONE ACTH_20\NNP||N (r_compound) terminal_23\NN|at|resulted|the (r_compound) fragments_24\NNS|NONE (r_pobj) by_18\IN|;|were|(|receptors|)|a (r_agent) stimulated_17\VBN|,|However|certain|not|it|cause|.|,|released (r_ccomp) is_3\VBZ|NONE (l_conj) cause_57\VB|,|However|certain|not|it|stimulated|.|,|released (l_ccomp) resulted_94\VBD|indeed|did (l_nsubj) depression_62\NN|in|inhibition|,|c|whether (l_relcl) resulted_74\VBD|term|the|at|targets|(|described|)|; (l_prep) in_75\IN|that (l_pobj) duration_78\NN|NONE (l_prep) of_79\IN|long|the (l_pobj) disorder_82\NN|NONE
D000324_D003866 NONE ACTH_20\NNP||N (r_compound) terminal_23\NN|at|resulted|the (r_compound) fragments_24\NNS|NONE (r_pobj) by_18\IN|;|were|(|receptors|)|a (r_agent) stimulated_17\VBN|,|However|certain|not|it|cause|.|,|released (r_ccomp) is_3\VBZ|NONE (l_conj) cause_57\VB|,|However|certain|not|it|stimulated|.|,|released (l_ccomp) resulted_94\VBD|indeed|did (l_nsubj) depression_62\NN|in|inhibition|,|c|whether
2533791
D017325_D006509 NONE vaccine_25\NN|.|injections (r_dobj) derived_22\VBN|and|infants|with|are (r_conj) treated_3\VBN|NONE (l_prep) with_4\IN|derived|and|infants|are (l_pobj) injections_6\NNS|NONE (l_prep) of_7\IN|two (l_pobj) globulin_11\NN|NONE (l_compound) B_9\NNP|immune|HBIG
18808529
D007545_D007022 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|myocardial (r_amod) damage_7\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|but|is|unknown|, (r_nsubj) is_8\VBZ|NONE (l_conj) is_25\VBZ|but|unknown|mechanism|, (l_nsubj) mismatch_13\NN|.|explanation (l_prep) vs._17\IN|of|a (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE (l_nmod) hypotension_21\NN|myocardial
D010100_D007022 NONE oxygen_15\NN|NONE (r_compound) supply_16\NN|NONE (r_pobj) of_14\IN|vs.|a (r_prep) mismatch_13\NN|.|explanation (l_prep) vs._17\IN|of|a (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE (l_nmod) hypotension_21\NN|myocardial
D010100_D009202 NONE oxygen_15\NN|NONE (r_compound) supply_16\NN|NONE (r_pobj) of_14\IN|vs.|a (r_prep) mismatch_13\NN|.|explanation (r_nsubj) is_25\VBZ|but|unknown|mechanism|, (r_conj) is_8\VBZ|NONE (l_nsubj) mechanism_1\NN|but|is|unknown|, (l_prep) of_2\IN|The (l_pobj) damage_7\NN|NONE
D010100_D009202 NONE oxygen_15\NN|NONE (r_compound) supply_16\NN|NONE (r_pobj) of_14\IN|vs.|a (r_prep) mismatch_13\NN|.|explanation (l_prep) vs._17\IN|of|a (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE
D007545_D009202 CID Isoproterenol_0\NN|correlation|:|loss|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) correlation_10\NN|Isoproterenol|:|loss|. (l_prep) with_11\IN|NONE (l_pobj) injury_13\NN|NONE
D007545_D009202 CID isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|myocardial (r_amod) damage_7\NN|NONE
D007545_D009202 CID isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|myocardial (r_amod) damage_7\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|but|is|unknown|, (r_nsubj) is_8\VBZ|NONE (l_conj) is_25\VBZ|but|unknown|mechanism|, (l_nsubj) mismatch_13\NN|.|explanation (l_prep) vs._17\IN|of|a (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE
D007545_D007511 CID isoproterenol_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) induced_27\VBN|severe|the|in (r_acl) alterations_11\NNS|changes|. (r_dobj) explain_8\VBP|NONE (l_nsubj) changes_1\NNS|alterations|. (l_acl) related_3\VBN|These|,|, (l_prep) to_4\IN|NONE (l_pobj) injury_6\NN|NONE
9952311
D004317_D009202 NONE adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|NONE (r_amod) cardiomyopathy_10\NN|NONE
D004317_D028361 CID adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|NONE (r_amod) cardiomyopathy_10\NN|NONE (r_pobj) in_6\IN|suppression|:|Structural|.|of|in (r_prep) impairment_3\NN|NONE (l_prep) of_4\IN|in|suppression|:|Structural|.|in (l_pobj) mitochondria_5\NN|NONE
D004317_D028361 CID ADR_21\NNP|NONE (r_pobj) of_20\IN|the|deteriorating|on (r_prep) effects_19\NNS|impairment|that (r_nsubj) involve_25\VBP|.|,|we|Knowing (l_dobj) impairment_30\NN|that|effects
D004317_D009369 NONE adriamycin_3\NNS|NONE (r_pobj) of_2\IN|in|The (r_prep) use_1\NN|has|due|.|been (l_prep) in_7\IN|of|The (l_pobj) chemotherapy_9\NN|NONE (l_compound) cancer_8\NN|NONE
D004317_D009369 NONE ADR_5\NNP|(|) (r_appos) adriamycin_3\NNS|NONE (r_pobj) of_2\IN|in|The (r_prep) use_1\NN|has|due|.|been (l_prep) in_7\IN|of|The (l_pobj) chemotherapy_9\NN|NONE (l_compound) cancer_8\NN|NONE
D004317_D002318 NONE adriamycin_3\NNS|NONE (r_pobj) of_2\IN|in|The (r_prep) use_1\NN|has|due|.|been (r_nsubjpass) limited_12\VBN|NONE (l_prep) due_13\IN|has|use|.|been (l_pcomp) to_14\IN|NONE (l_pobj) toxicity_18\NN|NONE
D004317_D002318 NONE ADR_5\NNP|(|) (r_appos) adriamycin_3\NNS|NONE (r_pobj) of_2\IN|in|The (r_prep) use_1\NN|has|due|.|been (r_nsubjpass) limited_12\VBN|NONE (l_prep) due_13\IN|has|use|.|been (l_pcomp) to_14\IN|NONE (l_pobj) toxicity_18\NN|NONE
D004317_D001145 NONE ADR_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) mice_8\NNS|NONE (r_pobj) of_7\IN| (r_prep) treatment_6\NN|arrhythmias|swelling|that (r_nsubj) caused_11\VBD|results|. (l_dobj) arrhythmias_13\NNS|swelling|that|treatment
D004317_D004487 NONE ADR_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) mice_8\NNS|NONE (r_pobj) of_7\IN| (r_prep) treatment_6\NN|arrhythmias|swelling|that (r_nsubj) caused_11\VBD|results|. (l_ccomp) swelling_51\NN|arrhythmias|that|treatment
D004317_D001919 CID ADR_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) mice_8\NNS|NONE (r_pobj) of_7\IN| (r_prep) treatment_6\NN|arrhythmias|swelling|that (r_nsubj) caused_11\VBD|results|. (l_dobj) arrhythmias_13\NNS|swelling|that|treatment (l_acl) characterized_14\VBN|cardiovascular (l_agent) by_15\IN|NONE (l_pobj) bradycardia_16\NNP|NONE
10523326
D009569_D006973 NONE oxide_1\NN|NONE (r_compound) synthase_2\NN|Nitric|in|. (r_compound) expression_3\NN|NONE (l_prep) in_4\IN|Nitric|synthase|. (l_pobj) course_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) hypertension_11\NN|NONE
D009569_D006973 NONE NO_15\DT|)|NOx|( (r_det) metabolites_16\NNS|NONE (r_pobj) of_14\IN|reduced|urinary (r_prep) excretion_13\NN|species|increased|and|,|We|.|recently (r_dobj) showed_2\VBD|NONE (l_conj) increased_22\VBD|species|and|,|We|.|recently|excretion (l_dobj) sequestration_24\NN|NONE (l_prep) as_25\IN|NO (l_pobj) nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D009569_D006973 NONE NO_23\DT|as (r_det) sequestration_24\NN|NONE (l_prep) as_25\IN|NO (l_pobj) nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D009569_D006973 NONE NO_25\DT|depressed (r_det) synthase_26\NN|NOS|(|) (r_nmod) expression_30\NN|to (r_pobj) due_22\IN|,|reduction|whether|in|, (r_prep) is_17\VBZ|to (l_nsubj) reduction_8\NN|,|whether|in|,|due (l_prep) in_12\IN|the|in (l_pobj) hypertension_16\NN|NONE
D009569_D006973 NONE NO_11\DT|,|inhibition|mediated (r_compound) inactivation_12\NN|to (l_appos) inhibition_17\NN|,|NO|mediated (l_conj) actions_25\NNS|,|and|associated|of (l_prep) of_26\IN|stimulatory|perhaps (l_pobj) stress_29\NN|NONE (l_acl) associated_30\VBN|shear|increased (l_prep) with_31\IN|NONE (l_pobj) hypertension_32\NN|NONE
C002744_D006973 NONE nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D007854_D006973 CID lead_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) hypertension_11\NN|NONE
D007854_D006973 CID lead_33\NN| (r_npadvmod) induced_35\VBN|NONE (r_amod) hypertension_36\NN|NONE
D007854_D006973 CID lead_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) hypertension_16\NN|NONE
D007854_D006973 CID lead_3\NN| (r_npadvmod) induced_5\VBN|in (r_amod) hypertension_6\NN|with|was|.|,|In
D007854_D006973 CID lead_14\NN| (r_npadvmod) associated_16\VBN|,|and|actions|of (r_amod) inhibition_17\NN|,|NO|mediated (l_conj) actions_25\NNS|,|and|associated|of (l_prep) of_26\IN|stimulatory|perhaps (l_pobj) stress_29\NN|NONE (l_acl) associated_30\VBN|shear|increased (l_prep) with_31\IN|NONE (l_pobj) hypertension_32\NN|NONE
D010100_D006973 NONE oxygen_5\NN|reactive|(|,|)|elevated|ROS (r_compound) species_6\NNS|increased|and|,|We|.|recently|excretion (r_dobj) showed_2\VBD|NONE (l_conj) increased_22\VBD|species|and|,|We|.|recently|excretion (l_dobj) sequestration_24\NN|NONE (l_prep) as_25\IN|NO (l_pobj) nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D014810_D006973 NONE E_1\NN|NONE (r_compound) supplementation_2\NN|hypertension|lowered|,|. (r_nsubj) ameliorated_3\VBD|NONE (l_dobj) hypertension_4\NN|supplementation|lowered|,|.
D008315_D006973 NONE MDA_8\NNP|plasma (r_compound) concentration_9\NN|raised|,|eNOS|and (r_dobj) lowered_6\VBD|hypertension|supplementation|,|. (r_conj) ameliorated_3\VBD|NONE (l_dobj) hypertension_4\NN|supplementation|lowered|,|.
1610717
D003042_D012640 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|behavior|.|and|brainstem (r_amod) seizures_4\NNS|NONE
783197
D010042_D006333 NONE ouabain_5\NN|NONE (r_pobj) of_4\IN|)|on|weight|the (r_prep) effects_3\NNS|We|. (l_prep) on_12\IN|)|of|weight|the (l_pobj) parameters_19\NNS|NONE (l_prep) without_29\IN|in|metabolic|volumetric (l_pobj) failure_33\NN|NONE
D010042_D006333 NONE ouabain_26\JJ|NONE (r_compound) administration_27\NN|NONE (r_pobj) after_25\IN|is (r_prep) falls_24\VBZ|We|.|left (r_conj) conclude_1\VBP|NONE (l_ccomp) left_18\VBD|We|falls|. (l_nsubj) patients_4\NNS|volume|in|that (l_prep) with_5\IN|NONE (l_pobj) disease_9\NN|NONE (l_relcl) are_11\VBP|chronic|coronary|artery (l_prep) in_13\IN|not|who (l_pobj) failure_17\NN|NONE
D010042_D003324 NONE ouabain_2\NN|NONE (l_prep) on_3\IN|NONE (l_pobj) supply_6\NN|NONE (l_conj) demand_8\NN|oxygen|myocardial|and (l_prep) in_9\IN|NONE (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) disease_15\NN|NONE
D010042_D003324 NONE ouabain_5\NN|NONE (r_pobj) of_4\IN|)|on|weight|the (r_prep) effects_3\NNS|We|. (l_prep) on_12\IN|)|of|weight|the (l_pobj) parameters_19\NNS|NONE (l_prep) in_20\IN|metabolic|without|volumetric (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN| (l_pobj) disease_28\NN|NONE
D010042_D003324 NONE ouabain_26\JJ|NONE (r_compound) administration_27\NN|NONE (r_pobj) after_25\IN|is (r_prep) falls_24\VBZ|We|.|left (r_conj) conclude_1\VBP|NONE (l_ccomp) left_18\VBD|We|falls|. (l_nsubj) patients_4\NNS|volume|in|that (l_prep) with_5\IN|NONE (l_pobj) disease_9\NN|NONE
D010100_D003324 NONE oxygen_5\NN|demand|myocardial|and (r_compound) supply_6\NN|NONE (l_conj) demand_8\NN|oxygen|myocardial|and (l_prep) in_9\IN|NONE (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) disease_15\NN|NONE
D010100_D003324 NONE oxygen_7\NN|and|demand|myocardial (r_compound) supply_8\NN|NONE (r_pobj) on_5\IN|digitalis (r_prep) glycosides_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|measured|of|but|, (r_nsubj) are_11\VBP|NONE (l_prep) of_12\IN|.|effects|measured|but|, (l_pobj) interest_14\NN|NONE (l_prep) in_15\IN|particular (l_pobj) presence_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) disease_22\NN|NONE
D004071_D003324 NONE glycosides_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|measured|of|but|, (r_nsubj) are_11\VBP|NONE (l_prep) of_12\IN|.|effects|measured|but|, (l_pobj) interest_14\NN|NONE (l_prep) in_15\IN|particular (l_pobj) presence_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) disease_22\NN|NONE
D010042_D002303 CID ouabain_26\JJ|NONE (r_compound) administration_27\NN|NONE (r_pobj) after_25\IN|is (r_prep) falls_24\VBZ|We|.|left
2893236
D018698_D012133 NONE glutamate_11\NN|,|respiratory (r_conj) paralysis_9\NN|control|Naloxone|.
D005680_D012133 NONE GABA_0\NNP|in (r_compound) involvement_1\NN|reversal|. (r_nsubj) induced_4\VBN|NONE (l_dobj) reversal_5\NN|involvement|. (l_prep) of_6\IN|NONE (l_pobj) paralysis_8\NN|NONE
D005680_D012133 NONE GABA_13\NNP|and|levels (r_conj) glutamate_11\NN|,|respiratory (r_conj) paralysis_9\NN|control|Naloxone|.
D005680_D012133 NONE GABA_12\NNP|in (r_dobj) involves_11\VBZ|and|naloxone|paralysis (r_conj) reverses_4\VBZ|data|. (l_dobj) paralysis_6\NN|involves|and|naloxone
D005680_D012131 NONE GABA_12\NNP|NONE (r_pobj) in_11\IN|decrease|further|and (r_prep) increase_10\NN|NONE (r_pobj) with_8\IN|produced|,|respiratory|i.v.|mg/kg (r_prep) arrest_7\NN|without|.
D018698_D012131 NONE glutamate_16\NN|NONE (r_pobj) in_15\IN|in|again (r_prep) decrease_14\NN|further|in|and (r_conj) increase_10\NN|NONE (r_pobj) with_8\IN|produced|,|respiratory|i.v.|mg/kg (r_prep) arrest_7\NN|without|.
D009270_D012133 NONE naloxone_3\NN|NONE (r_pobj) in_2\IN|GABA (r_prep) involvement_1\NN|reversal|. (r_nsubj) induced_4\VBN|NONE (l_dobj) reversal_5\NN|involvement|. (l_prep) of_6\IN|NONE (l_pobj) paralysis_8\NN|NONE
D009270_D012133 NONE naloxone_3\NN|.|paralysis|In (r_nsubj) reversed_4\VBD|NONE (l_dobj) paralysis_6\NN|naloxone|.|In
D009270_D012133 NONE Naloxone_0\NN|paralysis|control|. (r_nsubj) reversed_7\VBD|NONE (l_dobj) paralysis_9\NN|control|Naloxone|.
D009270_D012133 NONE naloxone_3\NN|involves|and|paralysis (r_nsubj) reverses_4\VBZ|data|. (l_dobj) paralysis_6\NN|involves|and|naloxone
D013874_D012133 CID thiopental_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) produced_9\VBN|respiratory (r_acl) paralysis_8\NN|NONE
D013874_D012133 CID thiopental_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|respiratory (r_acl) paralysis_6\NN|naloxone|.|In
D013874_D012133 CID thiopental_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) produced_7\VBN|respiratory (r_acl) paralysis_6\NN|involves|and|naloxone
D000596_D012131 NONE acids_29\NNS|NONE (r_pobj) of_26\IN|NONE (r_prep) any_25\DT|NONE (r_dobj) affecting_24\VBG|NONE (r_pcomp) without_23\IN|arrest|. (r_prep) stem_22\NN|NONE (l_nsubj) arrest_7\NN|without|.
D013874_D012131 NONE thiopental_4\NN|NONE (r_npadvmod) produced_5\VBD|,|with|respiratory|i.v.|mg/kg (r_amod) arrest_7\NN|without|.
8677458
D015080_D064420 NONE mesna_15\NN|along (r_dobj) administering_14\VBG|NONE (r_pcomp) by_13\IN|can|be|that (r_agent) prevented_12\VBN|of|a|major|potential (r_relcl) toxicity_6\NN|cystitis|.
D007069_D006470 CID ifosfamide_7\RB| (r_advmod) induced_9\VBN|hemorrhagic (r_amod) cystitis_11\NN|to
D007069_D006470 CID ifosfamide_8\NN|NONE (r_pobj) of_7\IN|prevented|a|major|potential (r_prep) toxicity_6\NN|cystitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|toxicity|.
D015080_D003556 CID mesna_4\NN|NONE (r_pobj) of_3\IN|Continuous|subcutaneous|prevent|. (r_prep) administration_2\NN|NONE (l_relcl) prevent_6\VB|Continuous|of|subcutaneous|. (l_dobj) cystitis_11\NN|to
D015080_D003556 CID mesna_15\NN|along (r_dobj) administering_14\VBG|NONE (r_pcomp) by_13\IN|can|be|that (r_agent) prevented_12\VBN|of|a|major|potential (r_relcl) toxicity_6\NN|cystitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|toxicity|.
D007069_D003556 CID ifosfamide_7\RB| (r_advmod) induced_9\VBN|hemorrhagic (r_amod) cystitis_11\NN|to
D007069_D003556 CID ifosfamide_8\NN|NONE (r_pobj) of_7\IN|prevented|a|major|potential (r_prep) toxicity_6\NN|cystitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|toxicity|.
D015080_D006470 CID mesna_4\NN|NONE (r_pobj) of_3\IN|Continuous|subcutaneous|prevent|. (r_prep) administration_2\NN|NONE (l_relcl) prevent_6\VB|Continuous|of|subcutaneous|. (l_dobj) cystitis_11\NN|to
D015080_D006470 CID mesna_15\NN|along (r_dobj) administering_14\VBG|NONE (r_pcomp) by_13\IN|can|be|that (r_agent) prevented_12\VBN|of|a|major|potential (r_relcl) toxicity_6\NN|cystitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|toxicity|.
D007069_D064420 NONE ifosfamide_8\NN|NONE (r_pobj) of_7\IN|prevented|a|major|potential (r_prep) toxicity_6\NN|cystitis|.
D007069_D014839 NONE ifosfamide_33\RB| (r_advmod) induced_35\VBN|severe (r_amod) emesis_36\NN|and|who|is
D015080_D014839 NONE mesna_19\NN|,|inadequate|as (r_compound) concentrations_20\NNS|NONE (l_prep) as_23\IN|,|inadequate|mesna (l_prep) in_24\IN|such (l_pobj) patient_26\NN|NONE (l_relcl) experiences_31\VBZ|a|taking (l_dobj) emesis_36\NN|and|who|is
D015080_D014839 NONE mesna_29\NN|NONE (r_dobj) taking_27\VBG|a|experiences (r_acl) patient_26\NN|NONE (l_relcl) experiences_31\VBZ|a|taking (l_dobj) emesis_36\NN|and|who|is
3411101
D011802_D056486 NONE Quinidine_0\NN|.|responsible|may (r_nsubj) be_5\VB|NONE (l_acomp) responsible_6\JJ|Quinidine|.|may (l_prep) for_7\IN|NONE (l_pobj) hepatitis_9\NN|NONE
C033457_D056486 CID phenylethylbarbiturate_1\NN|Quinidine|hepatitis|.|in| (r_npadvmod) induced_3\VBN|NONE (l_dobj) hepatitis_5\NN|Quinidine|.|phenylethylbarbiturate|in|
C033457_D056486 CID phenylethylbarbiturate_28\NN|NONE (r_pobj) of_26\IN|a|month (r_prep) administration_25\NN|NONE (r_pobj) after_22\IN|by|during (r_prep) affected_11\VBN|a|old|Laotian (l_agent) by_12\IN|after|during (l_pobj) hepatitis_14\NN|NONE
C033457_D056486 CID phenylethylbarbiturate_3\NN|or|itself (r_conj) Quinidine_0\NN|.|responsible|may (r_nsubj) be_5\VB|NONE (l_acomp) responsible_6\JJ|Quinidine|.|may (l_prep) for_7\IN|NONE (l_pobj) hepatitis_9\NN|NONE
17943461
D015215_D002311 CID zidovudine_12\NNP|HAART|AZT|;|the (r_appos) component_11\NN|whether|pathway|and|cause (r_nsubj) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|pathway|and (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14\CD|NONE (r_appos) zidovudine_12\NNP|HAART|AZT|;|the (r_appos) component_11\NN|whether|pathway|and|cause (r_nsubj) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|pathway|and (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID AZT_16\NNP|HAART|;|zidovudine|the (r_appos) component_11\NN|whether|pathway|and|cause (r_nsubj) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|pathway|and (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID AZT_69\NNP|NONE (r_pobj) of_68\IN|different (r_prep) concentrations_67\NNS|NONE (r_dobj) containing_65\VBG|ad (r_acl) libitum_64\NN|mice|In|METHODS|.|: (r_dobj) received_61\VBD|NONE (l_prep) In_4\IN|mice|libitum|METHODS|.|: (l_pobj) order_5\NN|NONE (l_acl) investigate_7\VB|NONE (l_ccomp) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|pathway|and (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID AZT_3\NNP| (r_npadvmod) treated_5\VBN|NONE (r_amod) FasL_6\NNPS|Tg (r_compound) mice_8\NNS|with|.|in|,|,|dilation|In (r_nsubj) developed_9\VBD|NONE (l_dobj) dilation_11\NN|with|.|in|mice|,|,|In
D015215_D009202 CID AZT_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) cardiomyopathy_10\NN|NONE
11027904
D020910_D010146 NONE ketorolac_48\RB|analgesic (r_nmod) agents_53\NNS|,|before|.|was|By (r_conj) examined_23\VBN|NONE (l_prep) By_0\IN|,|before|.|agents|was (l_pcomp) using_1\VBG|NONE (l_dobj) tolerance_13\NN|,|design (l_prep) to_14\IN|NONE (l_pobj) pain_21\NN|NONE
D008691_D010146 NONE methadone_3\NN| (r_npadvmod) maintained_5\VBN|opioid (r_amod) abusers_7\NNS|NONE (r_pobj) in_2\IN|Pain|. (r_prep) responses_1\NNS|NONE (l_compound) Pain_0\NN|in|.
D008691_D010146 NONE methadone_19\NN| (r_compound) maintenance_21\NN|(|)|n|MM|(||) (r_nmod) treatment_25\NN|NONE (r_pobj) in_18\IN|in (r_prep) stabilized_17\VBD|of|a (r_acl) sample_13\NN|NONE (r_pobj) in_11\IN|and|response|pain (r_prep) tolerance_7\NN|to (l_compound) pain_6\NN|in|and|response
D004091_D010146 NONE hydromorphone_38\NN|common (r_parataxis) opioid_36\NN|NONE (r_pobj) of_34\IN|therapeutic (r_prep) doses_33\NNS|NONE (r_pobj) of_31\IN|oral (r_prep) administration_30\NN|NONE (r_pobj) after_28\IN|both|and (r_conj) before_26\IN|,|.|agents|was|By (r_advmod) examined_23\VBN|NONE (l_prep) By_0\IN|,|before|.|agents|was (l_pcomp) using_1\VBG|NONE (l_dobj) tolerance_13\NN|,|design (l_prep) to_14\IN|NONE (l_pobj) pain_21\NN|NONE
D008691_D009293 NONE methadone_19\NN| (r_compound) maintenance_21\NN|(|)|n|MM|(||) (r_nmod) treatment_25\NN|NONE (r_pobj) in_18\IN|in (r_prep) stabilized_17\VBD|of|a (r_acl) sample_13\NN|NONE (l_prep) of_14\IN|stabilized|a (l_pobj) addicts_16\NNS|NONE
11705128
D012254_D019698 NONE ribavirin_19\RB|and (r_conj) interferon_15\NN|NONE (r_pobj) with_14\IN|combination (r_prep) therapy_13\NN|NONE (r_pobj) of_11\IN|increased|and|effectiveness (r_prep) efficacy_6\NN|studies|compared|.|have (r_dobj) demonstrated_4\VBN|NONE (l_prep) compared_20\VBN|efficacy|studies|.|have (l_prep) with_21\IN|NONE (l_pobj) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE
D012254_D019698 NONE ribavirin_19\RB|and (r_conj) interferon_15\NN|NONE (r_pobj) with_14\IN|combination (r_prep) therapy_13\NN|NONE (r_pobj) of_11\IN|increased|and|effectiveness (r_prep) efficacy_6\NN|studies|compared|.|have (r_dobj) demonstrated_4\VBN|NONE (l_prep) compared_20\VBN|efficacy|studies|.|have (l_prep) with_21\IN|NONE (l_pobj) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE (l_appos) CHC_34\NNP|(|)|hepatitis|chronic
D012254_D000743 CID ribavirin_3\RB| (r_npadvmod) induced_5\VBN|hemolytic|in (r_amod) anemia_7\NN|NONE
D012254_D000743 CID ribavirin_11\RB||anemia|.|associated|: (r_npadvmod) induced_13\VBN|NONE (l_dobj) anemia_15\NN|ribavirin||.|associated|:
D012254_D000743 CID ribavirin_11\RB||anemia|.|associated|: (r_npadvmod) induced_13\VBN|NONE (l_dobj) anemia_15\NN|ribavirin||.|associated|: (l_appos) RIHA_17\NNP|hemolytic|(|)
D012254_D000743 CID ribavirin_14\JJ|the (r_compound) dosage_15\NN|NONE (r_pobj) of_12\IN|discontinuation|or (r_prep) reduction_9\NN|.|standard (r_attr) is_8\VBZ|NONE (l_nsubj) standard_1\NN|reduction|. (l_prep) for_4\IN|The|of (l_pobj) management_5\NN|NONE (l_prep) of_6\IN|NONE (l_pobj) RIHA_7\NNP|NONE
D012254_D000743 CID ribavirin_7\NN|NONE (r_pobj) of_6\IN|optimal|incidence|the|and (r_prep) dose_5\NN|NONE (l_conj) incidence_10\NN|optimal|of|the|and (l_prep) of_11\IN|in|the (l_pobj) RIHA_12\NNP|NONE
D012254_D006526 NONE ribavirin_3\RB| (r_npadvmod) induced_5\VBN|hemolytic|in (r_amod) anemia_7\NN|NONE (l_prep) in_8\IN|hemolytic|induced (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) C_13\NNP|NONE
D016898_D019698 NONE alpha_24\NN|in (r_compound) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE
D016898_D019698 NONE alpha_24\NN|in (r_compound) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE (l_appos) CHC_34\NNP|(|)|hepatitis|chronic
17975693
D002939_D001008 CID ciprofloxacin-_5\JJ|NONE (r_nmod) rats_10\NNS|in|behaviour|that (r_nsubj) showed_11\VBD|.|results|:|studied (l_dobj) behaviour_13\NN|in|rats|that
D009643_D001008 CID norfloxacin_7\NNS| (r_npadvmod) treated_9\VBN|and (r_conj) ciprofloxacin-_5\JJ|NONE (r_nmod) rats_10\NNS|in|behaviour|that (r_nsubj) showed_11\VBD|.|results|:|studied (l_dobj) behaviour_13\NN|in|rats|that
18627295
D004317_D009202 CID Doxorubicin_0\NNP|.|are|by (l_dobj) inflammation_4\NN|and|apoptosis (l_amod) induced_3\VBN|NONE (l_npadvmod) cardiomyopathy_1\NN|
D004317_D009202 CID DOX_17\NNP|NONE (r_compound) cardiomyopathy_18\NN|NONE
D004317_D009202 CID DOX_17\NNP|NONE (r_compound) cardiomyopathy_18\NN|NONE (r_pobj) of_16\IN|the (r_prep) development_15\NN|NONE (r_pobj) during_13\IN|role|To|) (r_prep) elucidate_1\VB|mice|by|.|,|we (r_advcl) studied_21\VBD|NONE (l_prep) by_29\IN|mice|.|,|elucidate|we (l_pcomp) investigating_30\VBG|NONE (l_conj) apoptosis_34\NN|inflammation|and (l_prep) after_35\IN|NONE (l_pobj) induction_36\NN|NONE (l_prep) of_37\IN|NONE (l_pobj) cardiomyopathy_41\NN|NONE
D004317_D009202 CID DOX_38\NNP| (r_npadvmod) induced_40\VBN|NONE (r_amod) cardiomyopathy_41\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) induction_36\NN|NONE (r_pobj) after_35\IN|NONE (r_prep) apoptosis_34\NN|inflammation|and (r_conj) investigating_30\VBG|NONE (r_pcomp) by_29\IN|mice|.|,|elucidate|we (r_prep) studied_21\VBD|NONE (l_advcl) elucidate_1\VB|mice|by|.|,|we (l_prep) during_13\IN|role|To|) (l_pobj) development_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) cardiomyopathy_18\NN|NONE
D004317_D009202 CID DOX_38\NNP| (r_npadvmod) induced_40\VBN|NONE (r_amod) cardiomyopathy_41\NN|NONE
D004317_D009202 CID DOX_8\NNP|NONE (r_pobj) in_7\IN|that|BR|detrimental|cardiomyopathy|mediates (r_prep) is_5\VBZ|findings|. (l_acl) cardiomyopathy_9\NN|in|that|BR|detrimental|mediates
D004317_D009202 CID DOX_16\NNP|NONE (r_compound) cardiomyopathy_17\NN|NONE
D004317_D007249 NONE Doxorubicin_0\NNP|.|are|by (l_dobj) inflammation_4\NN|and|apoptosis
D004317_D007249 NONE DOX_17\NNP|NONE (r_compound) cardiomyopathy_18\NN|NONE (r_pobj) of_16\IN|the (r_prep) development_15\NN|NONE (r_pobj) during_13\IN|role|To|) (r_prep) elucidate_1\VB|mice|by|.|,|we (r_advcl) studied_21\VBD|NONE (l_prep) by_29\IN|mice|.|,|elucidate|we (l_pcomp) investigating_30\VBG|NONE (l_dobj) inflammation_32\NN|and|apoptosis
D004317_D007249 NONE DOX_38\NNP| (r_npadvmod) induced_40\VBN|NONE (r_amod) cardiomyopathy_41\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) induction_36\NN|NONE (r_pobj) after_35\IN|NONE (r_prep) apoptosis_34\NN|inflammation|and (r_conj) investigating_30\VBG|NONE (l_dobj) inflammation_32\NN|and|apoptosis
D004317_D066126 NONE doxorubicin_5\NN|NONE (r_pobj) of_2\IN|Clinical (r_prep) use_1\NN|is|by|. (r_nsubjpass) limited_10\VBN|NONE (l_agent) by_11\IN|is|use|. (l_pobj) effects_14\NNS|NONE (l_amod) cardiotoxic_13\JJ|its|,|attributed
D004317_D066126 NONE DOX_7\NNP|the|anthracycline|) (r_appos) doxorubicin_5\NN|NONE (r_pobj) of_2\IN|Clinical (r_prep) use_1\NN|is|by|. (r_nsubjpass) limited_10\VBN|NONE (l_agent) by_11\IN|is|use|. (l_pobj) effects_14\NNS|NONE (l_amod) cardiotoxic_13\JJ|its|,|attributed
D004317_D006331 NONE DOX_0\NN|NONE (r_compound) control_1\NN|NONE (r_compound) mice_2\NNS|.|dysfunction (r_nsubj) showed_3\VBD|NONE (l_dobj) dysfunction_5\NN|.|mice
D004317_D006331 NONE DOX_1\NNP|BR(/|) (r_nmod) mice_4\NNS|NONE (r_pobj) In_0\IN|compared|dysfunction|was|,|. (r_prep) improved_9\VBN|NONE (l_nsubjpass) dysfunction_7\NN|compared|was|,|In|.
D004317_D006331 NONE DOX_12\NNP|control|,|associated (r_compound) mice_14\NNS|NONE (r_pobj) to_11\IN|NONE (r_prep) compared_10\VBN|dysfunction|was|,|In|. (r_prep) improved_9\VBN|NONE (l_nsubjpass) dysfunction_7\NN|compared|was|,|In|.
D018943_D066126 NONE anthracycline_4\NN|the|)|DOX (r_amod) doxorubicin_5\NN|NONE (r_pobj) of_2\IN|Clinical (r_prep) use_1\NN|is|by|. (r_nsubjpass) limited_10\VBN|NONE (l_agent) by_11\IN|is|use|. (l_pobj) effects_14\NNS|NONE (l_amod) cardiotoxic_13\JJ|its|,|attributed
2564649
D011224_D009127 NONE prazosin_32\NN|NONE (r_pobj) with_25\IN|of|prior|electrolytic (r_prep) lesions_18\NNS|NONE (r_pobj) by_15\IN|even (r_agent) reduced_14\VBN|rigidity|was|.|or|significantly (r_conj) antagonized_11\VBN|NONE (l_nsubjpass) rigidity_4\NN|was|.|reduced|or|significantly
D005283_D009127 CID fentanyl_8\NN| (r_npadvmod) induced_10\VBN|in|muscular (r_amod) rigidity_12\NN|NONE
D005283_D009127 CID fentanyl_17\NN|dose (r_compound) anesthesia_18\NN|NONE (r_pobj) with_13\IN|is|that (r_prep) associated_12\VBN|side|known|a (r_relcl) effect_9\NN|rigidity|Whereas (r_attr) is_3\VBZ|,|paucity|)|with|. (l_nsubj) rigidity_2\NN|Whereas|effect
D005283_D009127 CID fentanyl_10\NN|NONE (r_pobj) by_9\IN|muscular (r_prep) rigidity_8\NN|NONE
7542793
D016559_D007674 CID FK506_5\NNP|and|:|inhibition|.|of (r_conj) Nephrotoxicity_0\NN|NONE
D016559_D007674 CID FK506_10\NNP|that|likely|is|through|effects (r_nsubjpass) mediated_13\VBN|results|. (l_nsubjpass) effects_6\NNS|FK|that|likely|is|through (l_amod) nephrotoxic_5\JJ|the|of|and
D016572_D064420 NONE CsA_4\NNP|NONE (l_conj) toxicity_7\NN|and
D018942_D006984 NONE macrolide_21\NN|(|not|mg/kg|immunosuppressant|related|the|) (r_amod) rapamycin_23\NNS|but|,|FK|mg/kg|(|; (r_conj) Fujimycine_9\NNP|and||) (r_conj) mg/kg_6\NN|CsA|,|Cyclosporin|; (r_appos) A_1\NNP|given|.|reduction (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|A|given|. (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|,|and
D016572_D006984 NONE A_1\NNP|given|.|reduction (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|A|given|. (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|,|and
D016572_D006984 NONE CsA_3\NNP|,|Cyclosporin|;|mg/kg (r_appos) A_1\NNP|given|.|reduction (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|A|given|. (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|,|and
D016572_D007674 CID A_3\NNP|NONE (r_pobj) of_1\IN|and|:|inhibition|.|FK (r_prep) Nephrotoxicity_0\NN|NONE
D016572_D007674 CID CsA_8\NNP|NONE (r_pobj) of_7\IN|the|nephrotoxic|and (r_prep) effects_6\NNS|FK|that|likely|is|through (l_amod) nephrotoxic_5\JJ|the|of|and
D016559_D064420 NONE FK506_6\NNP|NONE (r_compound) toxicity_7\NN|and
D016559_D006984 NONE Fujimycine_9\NNP|and||) (r_conj) mg/kg_6\NN|CsA|,|Cyclosporin|; (r_appos) A_1\NNP|given|.|reduction (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|A|given|. (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|,|and
D016559_D006984 NONE FK506_11\NNP|but|,|mg/kg|(|rapamycin|; (r_appos) Fujimycine_9\NNP|and||) (r_conj) mg/kg_6\NN|CsA|,|Cyclosporin|; (r_appos) A_1\NNP|given|.|reduction (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|A|given|. (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|,|and
D020123_D006984 NONE rapamycin_23\NNS|but|,|FK|mg/kg|(|; (r_conj) Fujimycine_9\NNP|and||) (r_conj) mg/kg_6\NN|CsA|,|Cyclosporin|; (r_appos) A_1\NNP|given|.|reduction (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|A|given|. (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|,|and
1300436
D003404_D058186 NONE creatinine_46\NN|NONE (r_pobj) in_44\IN|from|a (r_prep) rise_43\NN|NONE (r_pobj) with_41\IN|,|significantly|)|in|were|occurred|,|. (r_prep) deteriorated_26\VBD|NONE
D005665_D007674 NONE furosemide_4\NN|NONE (r_pobj) of_3\IN|deleterious|Potential|.|in (r_prep) effect_2\NN|NONE (l_prep) in_5\IN|of|deleterious|Potential|. (l_pobj) nephropathy_7\NN|NONE
D005665_D007674 NONE furosemide_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) efficacy_9\NN|to|in (r_dobj) determine_7\VB|purpose|. (l_prep) in_12\IN|to|efficacy (l_pobj) addition_13\NN|NONE (l_prep) in_17\IN|to (l_pobj) prevention_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) nephropathy_22\NN|NONE
D005665_D007674 NONE Furosemide_0\NNP|.|may|deleterious|in (r_nsubj) be_2\VB|NONE (l_prep) in_4\IN|.|may|deleterious|Furosemide (l_pobj) prevention_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) nephropathy_9\NN|NONE
D005665_D015431 NONE furosemide_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|weight (r_prep) loss_6\NN|NONE
D005665_D051437 NONE furosemide_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|weight (r_prep) loss_6\NN|NONE (r_pobj) with_4\IN|.|failure|was (r_prep) associated_3\VBN|NONE (l_nsubjpass) failure_1\NN|.|with|was
D005665_D058186 CID furosemide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) pretreated_30\VBN|the (r_acl) group_29\NN|NONE (r_pobj) in_27\IN|,|with|significantly|)|were|occurred|,|. (r_prep) deteriorated_26\VBD|NONE
12101159
D002118_D006323 NONE calcium_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) resuscitation_8\NN|arrest|;|. (r_dep) Delayed_0\VBN|NONE (l_dobj) arrest_3\NN|;|.|resuscitation (l_amod) asystolic_1\JJ|after|cardiac
D002118_D006323 NONE calcium_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) resuscitation_8\NN|arrest|;|. (r_dep) Delayed_0\VBN|NONE (l_dobj) arrest_3\NN|;|.|resuscitation
D002118_D006323 NONE calcium_12\NN|aggressive|dose|in|intravenous (r_compound) therapy_13\NN|NONE (r_pobj) for_7\IN|,|with|a (r_prep) role_6\NN|there (l_prep) with_20\IN|,|for|a (l_pobj) onset_22\NN|particularly (l_prep) of_23\IN|the (l_pobj) asystole_24\NN|NONE
D004110_D062787 CID diltiazem_5\NN|NONE (r_compound) overdose_6\NN|NONE
D004110_D062787 CID diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|man|.
D004110_D062787 CID diltiazem_16\NN|severe (r_compound) overdose_17\NN|NONE
D004110_D062787 CID diltiazem_11\NN|NONE (r_compound) overdose_12\NN|NONE
D000431_D062787 NONE alcohol_25\NN|isosorbide|,|and (r_conj) nitrate_22\NN|, (r_conj) aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|man|.
D002118_D062787 NONE calcium_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) resuscitation_8\NN|arrest|;|. (r_dep) Delayed_0\VBN|NONE (l_dobj) arrest_3\NN|;|.|resuscitation (l_prep) after_4\IN|asystolic|cardiac (l_pobj) overdose_6\NN|NONE
D002118_D062787 NONE calcium_12\NN|aggressive|dose|in|intravenous (r_compound) therapy_13\NN|NONE (l_prep) in_14\IN|calcium|aggressive|dose|intravenous (l_pobj) overdose_17\NN|NONE
D004110_D006323 CID diltiazem_5\NN|NONE (r_compound) overdose_6\NN|NONE (r_pobj) after_4\IN|asystolic|cardiac (r_prep) arrest_3\NN|;|.|resuscitation (l_amod) asystolic_1\JJ|after|cardiac
D004110_D006323 CID diltiazem_5\NN|NONE (r_compound) overdose_6\NN|NONE (r_pobj) after_4\IN|asystolic|cardiac (r_prep) arrest_3\NN|;|.|resuscitation
D004110_D006323 CID diltiazem_16\NN|severe (r_compound) overdose_17\NN|NONE (r_pobj) in_14\IN|calcium|aggressive|dose|intravenous (r_prep) therapy_13\NN|NONE (r_pobj) for_7\IN|,|with|a (r_prep) role_6\NN|there (l_prep) with_20\IN|,|for|a (l_pobj) onset_22\NN|particularly (l_prep) of_23\IN|the (l_pobj) asystole_24\NN|NONE
D004110_D006323 CID diltiazem_11\NN|NONE (r_compound) overdose_12\NN|NONE (r_pobj) after_10\IN|of (r_prep) cases_6\NNS|NONE (l_prep) of_7\IN|after (l_pobj) arrest_9\NN|NONE
D009566_D062787 NONE nitrate_22\NN|, (r_conj) aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|man|.
D001241_D062787 NONE aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|man|.
D007547_D062787 NONE isosorbide_21\JJ|alcohol|,|and (r_compound) nitrate_22\NN|, (r_conj) aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|man|.
D000082_D062787 NONE paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|man|.
11099450
D007980_D004409 CID levodopa_33\RB| (r_npadvmod) induced_35\VBN|LID|)|( (r_amod) dyskinesias_36\NNS|off|and|parkinsonian
D007980_D004409 CID levodopa_33\RB| (r_npadvmod) induced_35\VBN|LID|)|( (r_amod) dyskinesias_36\NNS|off|and|parkinsonian (l_appos) LID_38\NNP|induced|)|(
D007980_D004409 CID levodopa_8\JJ|of|responsiveness|the|preoperative|and (r_compound) responsiveness_9\NN|NONE (r_pobj) between_5\IN|positive|significant|Program (r_prep) correlations_4\NNS|We|was|.|in|, (r_dobj) found_1\VBD|NONE (l_advcl) was_45\VBD|We|.|correlations|in|, (l_attr) correlation_47\NN|whereas|there (l_prep) with_48\IN|no (l_pobj) improvement_50\NN|NONE (l_prep) in_51\IN|the (l_pobj) LID_52\NNP|NONE
D007980_D004409 CID levodopa_15\JJ|of|the (r_compound) responsiveness_16\NN|of|the|levodopa|preoperative|and (r_conj) responsiveness_9\NN|NONE (r_pobj) between_5\IN|positive|significant|Program (r_prep) correlations_4\NNS|We|was|.|in|, (r_dobj) found_1\VBD|NONE (l_advcl) was_45\VBD|We|.|correlations|in|, (l_attr) correlation_47\NN|whereas|there (l_prep) with_48\IN|no (l_pobj) improvement_50\NN|NONE (l_prep) in_51\IN|the (l_pobj) LID_52\NNP|NONE
D007980_D004409 CID levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_conj) LID_17\NNP|parkinsonian|off|and
D007980_D004409 CID levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_conj) LID_17\NNP|parkinsonian|off|and (l_conj) correlations_21\NNS|and (l_prep) of_22\IN|the|different (l_pobj) volume_25\NN|NONE (l_prep) with_26\IN|ventral|lesion (l_pobj) dyskinesias_27\NNS|NONE
D007980_D004409 CID levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (r_pobj) of_4\IN|differential|predictive|The (r_prep) value_3\NN|.|be (r_nsubj) indicate_34\VBP|NONE (l_ccomp) be_42\VB|.|value (l_acomp) responsible_43\JJ|may|substrates|that (l_prep) for_44\IN|NONE (l_pobj) signs_52\NNS|generation (l_conj) dyskinesias_54\NNS|off|and
D007980_D010300 NONE levodopa_33\RB| (r_npadvmod) induced_35\VBN|LID|)|( (r_amod) dyskinesias_36\NNS|off|and|parkinsonian (r_conj) signs_31\NNS|NONE (l_poss) parkinsonian_27\NN|off|and|dyskinesias
D007980_D010300 NONE levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_poss) parkinsonian_11\NN|LID|off|and
D007980_D010300 NONE levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_conj) LID_17\NNP|parkinsonian|off|and (l_conj) correlations_21\NNS|and (l_prep) of_22\IN|the|different (l_pobj) volume_25\NN|NONE (l_prep) with_26\IN|ventral|lesion (l_pobj) dyskinesias_27\NNS|NONE (l_conj) parkinsonian_29\NN|and|signs
D007980_D010300 NONE levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (r_pobj) of_4\IN|differential|predictive|The (r_prep) value_3\NN|.|be (r_nsubj) indicate_34\VBP|NONE (l_ccomp) be_42\VB|.|value (l_acomp) responsible_43\JJ|may|substrates|that (l_prep) for_44\IN|NONE (l_pobj) generation_46\NN|signs (l_prep) of_47\IN|the (l_pobj) parkinsonian_48\NN|NONE
1079693
D002738_D012164 NONE chloroquine_2\NN|found|.|and|We (r_xcomp) used_1\VBD|NONE (l_conj) found_11\VBD|.|chloroquine|and|We (l_dobj) case_14\NN|NONE (l_prep) of_15\IN|one (l_pobj) chorioretinopathy_16\JJ|NONE
D000305_D014605 NONE corticosteroids_27\NNS|NONE (r_pobj) with_26\IN|intensive|topical (r_prep) treatment_25\NN|NONE (r_pobj) of_22\IN|six (r_prep) months_21\NNS|NONE (r_pobj) to_17\IN|not|did|after|.|,|% (r_prep) respond_16\VB|NONE (l_nsubj) %_9\NN|to|not|did|after|.|, (l_prep) of_10\IN| (l_pobj) cases_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) uveitis_13\NN|NONE
D000305_D002386 NONE corticosteroids_2\NNS|Systemically (r_dobj) administered_1\VBN|were|in (r_csubjpass) used_4\VBN|;|.|number|was (r_ccomp) found_19\VBN|NONE (l_nsubjpass) number_13\NN|;|used|.|was (l_prep) of_14\IN|a|significant (l_pobj) cataracts_17\NNS|NONE
D006886_D012164 CID hydroxychloroquine_4\NN|or (r_conj) chloroquine_2\NN|found|.|and|We (r_xcomp) used_1\VBD|NONE (l_conj) found_11\VBD|.|chloroquine|and|We (l_dobj) case_14\NN|NONE (l_prep) of_15\IN|one (l_pobj) chorioretinopathy_16\JJ|NONE
11195262
D014635_D004830 NONE VPA_4\NNP|was|.|had|been|for|He (r_dobj) taking_3\VBG|NONE (l_prep) for_5\IN|VPA|was|.|had|been|He (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) convulsions_13\NNS|NONE
D014635_D007177 CID valproate_3\NN|NONE (l_prep) to_4\IN|.|Contribution (l_pobj) syndrome_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) secretion_9\NN|NONE (l_prep) of_10\IN|inappropriate (l_pobj) hormone_12\NN|NONE
D014635_D007177 CID valproate_14\NN|of|the (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|who|subsequently (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE
D014635_D007177 CID valproate_14\NN|of|the (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|who|subsequently (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE (l_appos) SIADH_31\NNP|(|antidiuretic|)
D014635_D007177 CID VPA_16\NNP|)|and|developed|( (r_npadvmod) valproate_14\NN|of|the (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|who|subsequently (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE
D014635_D007177 CID VPA_16\NNP|)|and|developed|( (r_npadvmod) valproate_14\NN|of|the (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|who|subsequently (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE (l_appos) SIADH_31\NNP|(|antidiuretic|)
D014635_D007177 CID VPA_30\NNP|NONE (r_pobj) of_29\IN|term|the (r_prep) administration_28\NN|of|and|a (r_conj) weakness_17\NN|NONE (r_pobj) including_15\VBG|NONE (r_prep) factors_14\NNS|NONE (r_pobj) of_13\IN|a (r_prep) combination_12\NN|NONE (r_pobj) of_10\IN|the (r_prep) result_9\NN|to|episode (r_attr) be_7\VB|We|. (l_nsubj) episode_3\NN|to|result (l_prep) of_4\IN|this (l_pobj) SIADH_5\NNP|NONE
D014635_D002493 NONE VPA_30\NNP|NONE (r_pobj) of_29\IN|term|the (r_prep) administration_28\NN|of|and|a (r_conj) weakness_17\NN|NONE (l_prep) of_18\IN|administration|and|a (l_pobj) system_22\NN|NONE
2334179
D010396_D011507 CID Penicillamine_2\NN|syndrome|in (r_nsubj) caused_3\VBD|insufficiency|;|none|. (l_prep) in_6\IN|Penicillamine|syndrome (l_pobj) patient_8\NN|NONE (l_conj) proteinuria_12\NN||and
D010396_D012594 NONE penicillamine_2\NN|NONE (l_prep) in_3\IN|D|.| (l_pobj) treatment_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) scleroderma_8\NN|NONE
D010396_D012594 NONE penicillamine_17\NN|NONE (r_pobj) with_14\IN|who|were (r_prep) treated_13\VBN|with| (r_relcl) patients_4\NNS|NONE (l_prep) with_5\IN|treated| (l_pobj) scleroderma_10\NN|NONE
D010396_D012594 NONE penicillamine_6\NN|may|that|effective (r_nsubj) be_8\VB|data|. (l_acomp) effective_9\JJ|may|that|penicillamine (l_prep) in_10\IN|NONE (l_pobj) cases_12\NNS|NONE (l_prep) of_13\IN|severe (l_pobj) scleroderma_15\NN|NONE
D010396_D009404 CID Penicillamine_2\NN|syndrome|in (r_nsubj) caused_3\VBD|insufficiency|;|none|. (l_dobj) syndrome_5\NN|Penicillamine|in
D010396_D051437 NONE Penicillamine_2\NN|syndrome|in (r_nsubj) caused_3\VBD|insufficiency|;|none|. (r_ccomp) developed_19\VBD|NONE (l_dobj) insufficiency_21\NN|;|caused|none|.
18657397
D010400_D004827 CID potassium_20\NN|recorded|into (r_dobj) injecting_14\VBG|NONE (r_pcomp) by_13\IN|After|was|.|focus|, (r_prep) induced_12\VBN|NONE (l_nsubjpass) focus_10\NN|by|After|was|.|, (l_amod) epileptic_9\JJ|NONE
D010406_D004827 NONE penicillin_5\NN| (r_npadvmod) induced_7\VBN|in|epileptiform (r_amod) activity_9\NN|NONE
D010406_D004827 NONE Penicillin_0\NNP|NONE (r_compound) model_1\NN|model|. (r_nsubj) is_2\VBZ|NONE (l_attr) model_7\NN|.|model (l_prep) for_8\IN|a|experimental|used (l_pobj) research_10\NN|NONE (l_compound) epilepsy_9\NN|NONE
D010406_D004827 NONE penicillin_13\NN| (r_npadvmod) induced_15\VBN|epileptiform (r_amod) activity_17\NN|NONE
D010406_D004827 NONE penicillin_7\NN| (r_npadvmod) induced_9\VBN|activity|the (r_amod) periods_12\NNS|latent|and (l_compound) activity_11\NN|induced|the
9270571
D004298_D010300 NONE dopamine_4\NN|NONE (r_pobj) of_3\IN|clinical|The|agonists (r_prep) utility_2\NN|.|unclear|still (l_appos) agonists_10\NNS|of|clinical|The (l_prep) in_11\IN|receptor|D|)|(|DA (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE
D004298_D010300 NONE dopamine_4\NN|NONE (r_pobj) of_3\IN|clinical|The|agonists (r_prep) utility_2\NN|.|unclear|still (l_appos) agonists_10\NNS|of|clinical|The (l_prep) in_11\IN|receptor|D|)|(|DA (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE (l_appos) PD_19\NNP|(|)|Parkinson
D004298_D010300 NONE DA_6\NNP|in|receptor|D|)|( (r_nmod) agonists_10\NNS|of|clinical|The (l_prep) in_11\IN|receptor|D|)|(|DA (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE
D004298_D010300 NONE DA_6\NNP|in|receptor|D|)|( (r_nmod) agonists_10\NNS|of|clinical|The (l_prep) in_11\IN|receptor|D|)|(|DA (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE (l_appos) PD_19\NNP|(|)|Parkinson
D004298_D010300 NONE DA_1\NNP|Potent (r_compound) D1_2\NN|receptor|with|A (r_compound) agents_4\NNS|tools|. (r_nsubj) are_23\VBP|NONE (l_attr) tools_26\NNS|.|agents (l_prep) in_27\IN|and|therapeutic|merit|potential (l_pobj) PD_28\NNP|NONE
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|We|study|evaluate|.|therefore
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|We|study|evaluate|.|therefore (r_dobj) conducted_2\VBD|NONE (l_advcl) evaluate_25\VB|We|study|dyskinesias|.|therefore (l_dobj) effects_30\NNS|to (l_amod) locomotor_27\NN|on|the (l_conj) dyskinetic_29\JJ|and
D007980_D004409 CID levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (r_pcomp) in_7\IN|as (r_prep) efficacious_6\JJ|but|administration|.|A|was|, (r_acomp) was_4\VBD|NONE (l_conj) was_19\VBD|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|than|to
D007980_D004409 CID levodopa_25\RB| (r_npadvmod) induced_27\VBN|the|in (r_amod) dyskinesias_28\NNS|than|to
D007980_D004409 CID levodopa_40\NN|NONE (r_pobj) of_39\IN|LY (r_prep) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|dyskinesias|to (r_prep) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|than|to
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|the|acute|present (r_prep) study_9\NN|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|We|study|evaluate|.|therefore
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|the|acute|present (r_prep) study_9\NN|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD|NONE (l_advcl) evaluate_25\VB|We|study|dyskinesias|.|therefore (l_dobj) effects_30\NNS|to (l_amod) locomotor_27\NN|on|the (l_conj) dyskinetic_29\JJ|and
D015632_D004409 NONE MPTP)-exposed_14\VBN|cynomolgus|primed|( (r_amod) monkeys_16\NNS|four (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|the|acute|present (r_prep) study_9\NN|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|We|study|evaluate|.|therefore
D015632_D004409 NONE MPTP)-exposed_14\VBN|cynomolgus|primed|( (r_amod) monkeys_16\NNS|four (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|the|acute|present (r_prep) study_9\NN|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD|NONE (l_advcl) evaluate_25\VB|We|study|dyskinesias|.|therefore (l_dobj) effects_30\NNS|to (l_amod) locomotor_27\NN|on|the (l_conj) dyskinetic_29\JJ|and
D015632_D004409 NONE MPTP_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) parkinsonism_12\NN|as (r_dobj) alleviating_8\VBG|NONE (r_pcomp) in_7\IN|as (r_prep) efficacious_6\JJ|but|administration|.|A|was|, (r_acomp) was_4\VBD|NONE (l_conj) was_19\VBD|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|than|to
C095427_D010300 NONE A-86929_13\NNS|receptor|with|D (r_punct) agents_4\NNS|tools|. (r_nsubj) are_23\VBP|NONE (l_attr) tools_26\NNS|.|agents (l_prep) in_27\IN|and|therapeutic|merit|potential (l_pobj) PD_28\NNP|NONE
C095427_D020734 NONE A-86929_0\NNS|NONE (l_dep) study_4\NN|.|: (l_prep) in_5\IN|an|acute (l_pobj) monkeys_10\NNS|NONE (l_amod) parkinsonian_6\JJ|primed
C095427_D020734 NONE A-86929_3\NNS|but|administration|.|efficacious|was|, (r_punct) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|but|administration|.|A|was|, (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
C095427_D004409 NONE A-86929_44\NNS|) (r_punct) ,_57\,|from|four|)|of|(|agonist (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|locomotor|the (r_prep) effects_30\NNS|to (r_dobj) evaluate_25\VB|We|study|dyskinesias|.|therefore (r_advcl) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|We|study|evaluate|.|therefore
C095427_D004409 NONE A-86929_44\NNS|) (r_punct) ,_57\,|from|four|)|of|(|agonist (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|locomotor|the (r_prep) effects_30\NNS|to (l_amod) locomotor_27\NN|on|the (l_conj) dyskinetic_29\JJ|and
C095427_D004409 NONE 10-diol_55\JJ|NONE (r_punct) )_56\-RRB-|A (r_punct) ,_57\,|from|four|)|of|(|agonist (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|locomotor|the (r_prep) effects_30\NNS|to (r_dobj) evaluate_25\VB|We|study|dyskinesias|.|therefore (r_advcl) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|We|study|evaluate|.|therefore
C095427_D004409 NONE 10-diol_55\JJ|NONE (r_punct) )_56\-RRB-|A (r_punct) ,_57\,|from|four|)|of|(|agonist (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|locomotor|the (r_prep) effects_30\NNS|to (l_amod) locomotor_27\NN|on|the (l_conj) dyskinetic_29\JJ|and
C095427_D004409 NONE A-86929_3\NNS|but|administration|.|efficacious|was|, (r_punct) was_4\VBD|NONE (l_conj) was_19\VBD|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|than|to
D007980_D020734 NONE levodopa_7\NN| (r_npadvmod) primed_9\VBN|parkinsonian (r_amod) monkeys_10\NNS|NONE (l_amod) parkinsonian_6\JJ|primed
D007980_D020734 NONE levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D007980_D020734 NONE levodopa_25\RB| (r_npadvmod) induced_27\VBN|the|in (r_amod) dyskinesias_28\NNS|than|to (r_dobj) reproduce_23\VB|less (r_xcomp) likely_21\JJ|NONE (r_acomp) was_19\VBD|but|administration|.|A|efficacious|, (r_conj) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|but|administration|.|A|was|, (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D007980_D020734 NONE levodopa_40\NN|NONE (r_pobj) of_39\IN|LY (r_prep) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|dyskinesias|to (r_prep) reproduce_23\VB|less (r_xcomp) likely_21\JJ|NONE (r_acomp) was_19\VBD|but|administration|.|A|efficacious|, (r_conj) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|but|administration|.|A|was|, (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D015632_D020734 CID MPTP_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) parkinsonism_12\NN|as
D004298_D004409 NONE DA_62\NNP|a|selective|Dlike|with|receptor (r_compound) agonist_65\NN|from|four|)|of|(|, (r_appos) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|locomotor|the (r_prep) effects_30\NNS|to (r_dobj) evaluate_25\VB|We|study|dyskinesias|.|therefore (r_advcl) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|We|study|evaluate|.|therefore
D004298_D004409 NONE DA_62\NNP|a|selective|Dlike|with|receptor (r_compound) agonist_65\NN|from|four|)|of|(|, (r_appos) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|locomotor|the (r_prep) effects_30\NNS|to (l_amod) locomotor_27\NN|on|the (l_conj) dyskinetic_29\JJ|and
C416545_D020734 NONE LY-171555_16\NNP|and (r_conj) levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
C416545_D020734 NONE LY-171555_35\NNP|of (r_amod) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|dyskinesias|to (r_prep) reproduce_23\VB|less (r_xcomp) likely_21\JJ|NONE (r_acomp) was_19\VBD|but|administration|.|A|efficacious|, (r_conj) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|but|administration|.|A|was|, (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
C416545_D004409 NONE LY-171555_16\NNP|and (r_conj) levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (r_pcomp) in_7\IN|as (r_prep) efficacious_6\JJ|but|administration|.|A|was|, (r_acomp) was_4\VBD|NONE (l_conj) was_19\VBD|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|than|to
C416545_D004409 NONE LY-171555_35\NNP|of (r_amod) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|dyskinesias|to (r_prep) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|than|to
8305357
D003630_D000163 NONE daunorubicin_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) safety_15\NN|the|and|in (r_conj) efficacy_13\NN|to (l_prep) in_22\IN|the|and|safety (l_pobj) treatment_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) AIDS_26\NNP|NONE
D003630_D012514 NONE daunorubicin_1\NN|NONE (l_dobj) sarcoma_6\NN|.|in|Liposomal
D003630_D012514 NONE daunorubicin_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) safety_15\NN|the|and|in (r_conj) efficacy_13\NN|to (r_dobj) assess_11\VB|randomized|II|clinical|a (r_relcl) trial_9\NN|We|.|related (r_dobj) report_1\VBP|NONE (l_ccomp) related_27\VBD|We|.|trial (l_dobj) sarcoma_30\NN|NONE
D003630_D012514 NONE daunorubicin_7\NN|,|agent|.|In (r_nsubj) was_8\VBD|NONE (l_attr) agent_14\NN|,|daunorubicin|.|In (l_prep) in_15\IN|an|effective (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) sarcoma_21\NN|NONE
15985056
D003907_D006606 NONE dexamethasone_2\NN|benzodiazepines|(|)|, (r_appos) Corticosteroids_0\NNS|have|agents|. (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|have|.|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|frequently|in (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
D017963_D006606 CID azithromycin_1\RB| (r_advmod) associated_3\VBN|.|Possible (r_amod) hiccups_4\NNS|NONE
D017963_D006606 CID azithromycin_9\CD|NONE (r_amod) therapy_10\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) associated_7\VBN|persistent (r_acl) hiccups_6\NNS|NONE
D017963_D006606 CID azithromycin_11\RB|for (r_advmod) beginning_10\VBG|NONE (r_pcomp) after_9\IN|man|.|with (r_prep) presented_5\VBN|NONE (l_prep) with_6\IN|man|after|. (l_pobj) hiccups_8\NNS|NONE
D017963_D006606 CID azithromycin_2\NNP|NONE (r_pobj) of_1\IN|and|therapy (r_prep) Discontinuation_0\NN|hiccups|.|finally (r_nsubj) resolved_8\VBD|NONE (l_dobj) hiccups_9\NNS|Discontinuation|.|finally
D017963_D006606 CID azithromycin_9\WP|NONE (r_pobj) by_8\IN|NONE (r_agent) mediated_7\VBN|a|vagal (r_acl) mechanism_6\NN|that|pathogenesis|could (r_nsubj) be_11\VB|hypothesis|. (l_attr) pathogenesis_13\NN|that|could|mechanism (l_prep) of_14\IN|the (l_pobj) hiccups_15\NNS|NONE
D008775_D006606 NONE methylprednisolone_4\NN|and (r_conj) dexamethasone_2\NN|benzodiazepines|(|)|, (r_appos) Corticosteroids_0\NNS|have|agents|. (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|have|.|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|frequently|in (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
D001569_D006606 NONE benzodiazepines_7\NNS|(|dexamethasone|)|, (r_appos) Corticosteroids_0\NNS|have|agents|. (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|have|.|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|frequently|in (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
D001418_D006606 CID baclofen_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) therapy_4\NN|and|of (r_conj) Discontinuation_0\NN|hiccups|.|finally (r_nsubj) resolved_8\VBD|NONE (l_dobj) hiccups_9\NNS|Discontinuation|.|finally
D018942_D006606 NONE macrolide_12\NN|NONE (r_amod) antimicrobials_13\NNS|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|cases|been|have|. (r_oprd) reported_9\VBN|NONE (l_nsubjpass) cases_1\NNS|related|been|have|. (l_prep) of_2\IN|Few (l_pobj) hiccups_6\NNS|NONE
D018942_D006606 NONE macrolides_36\NNS|NONE (r_pobj) with_34\IN|this|absence|and (r_prep) reaction_33\NN|NONE (l_conj) absence_39\NN|with|this|and (l_prep) of_40\IN|the (l_pobj) explanation_43\NN|NONE (l_prep) for_44\IN|alternative|any (l_pobj) hiccups_45\NNS|NONE
D018942_D006606 NONE macrolide_2\NN|NONE (r_amod) antimicrobials_3\NNS|.|,|been|explain|However|have|associated (r_nsubjpass) reported_6\VBN|NONE (l_xcomp) associated_9\VBN|.|,|been|explain|However|have|antimicrobials (l_prep) with_10\IN|be|to (l_pobj) mechanism_14\NN|NONE (l_nmod) hiccups_11\NNS|vagal
D017963_D010612 NONE azithromycin_11\RB|for (r_advmod) beginning_10\VBG|NONE (l_prep) for_12\IN|azithromycin (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) pharyngitis_16\NN|NONE
D008874_D006606 NONE midazolam_9\NN|(|anaesthesia (r_appos) benzodiazepines_7\NNS|(|dexamethasone|)|, (r_appos) Corticosteroids_0\NNS|have|agents|. (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|have|.|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|frequently|in (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
6794356
D008094_D001282 NONE lithium_18\NN|high|a (r_compound) level_19\NN|and|heart|, (r_conj) failure_12\NN|atrial|, (r_conj) flutter_8\JJ|massive|tricuspid|,
D008094_D001282 NONE lithium_26\NN|NONE (r_compound) compounds_27\NNS|NONE (r_pobj) to_25\IN|in (r_prep) exposed_24\VBN|NONE (r_acl) infants_23\NNS|NONE (r_pobj) among_22\IN|cardiac (r_prep) disease_21\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patient_18\NN|th|. (r_dobj) described_17\VBN|,|patient|and|This (r_conj) is_1\VBZ|NONE (l_attr) patient_4\NN|,|and|described|This (l_relcl) manifest_7\VB|first|the (l_dobj) regurgitation_9\NN|initially|to (l_conj) flutter_12\NN|and|tricuspid
D008094_D014262 NONE lithium_18\NN|high|a (r_compound) level_19\NN|and|heart|, (r_conj) failure_12\NN|atrial|, (r_conj) flutter_8\JJ|massive|tricuspid|, (r_conj) regurgitation_5\NN|NONE
D008094_D014262 NONE lithium_26\NN|NONE (r_compound) compounds_27\NNS|NONE (r_pobj) to_25\IN|in (r_prep) exposed_24\VBN|NONE (r_acl) infants_23\NNS|NONE (r_pobj) among_22\IN|cardiac (r_prep) disease_21\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patient_18\NN|th|. (r_dobj) described_17\VBN|,|patient|and|This (r_conj) is_1\VBZ|NONE (l_attr) patient_4\NN|,|and|described|This (l_relcl) manifest_7\VB|first|the (l_dobj) regurgitation_9\NN|initially|to
D008094_D006331 NONE lithium_26\NN|NONE (r_compound) compounds_27\NNS|NONE (r_pobj) to_25\IN|in (r_prep) exposed_24\VBN|NONE (r_acl) infants_23\NNS|NONE (r_pobj) among_22\IN|cardiac (r_prep) disease_21\NN|NONE
D016651_D014262 NONE carbonate_5\NN|NONE (r_compound) toxicity_6\NN|valve|.|Tricuspid|in|and (r_conj) regurgitation_2\NN|NONE
D016651_D006331 NONE carbonate_1\NN|in|may|.|factor|taken (r_nsubj) be_3\VB|NONE (l_prep) in_6\IN|carbonate|may|.|factor|taken (l_pobj) incidence_9\NN|NONE (l_prep) of_10\IN|the|increasing (l_pobj) disease_13\NN|NONE
D016651_D064420 NONE carbonate_5\NN|NONE (r_compound) toxicity_6\NN|valve|.|Tricuspid|in|and
D008094_D006333 NONE lithium_18\NN|high|a (r_compound) level_19\NN|and|heart|, (r_conj) failure_12\NN|atrial|,
11999899
D016291_D014202 NONE MK-801_16\NNP|also|tremor|Reserpine|. (r_punct) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|Reserpine|.
D016291_D014202 NONE MK-801_2\NNP|However|injection|.|,|increase (r_punct) produced_4\VBD|NONE (l_dobj) increase_7\NN|However|injection|.|,|MK (l_prep) of_8\IN|a|in|significant (l_pobj) tremor_9\NN|NONE
D016291_D014202 NONE MK-801_17\NNP|On|.|compared|reserpine|increases|, (r_punct) induced_6\VBN|NONE (l_dobj) increases_7\NNS|MK|On|.|compared|reserpine|, (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE
D016291_D014202 NONE MK-801_33\NNP|)|mg/kg (r_punct) injection_38\NN| (r_nsubj) min_40\NN|effects|test|whereas|before (r_nsubj) reversed_44\VBD|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE
D012110_D004409 CID Reserpine_0\NN|increases|. (r_nsubj) produced_15\VBD|NONE (l_dobj) increases_16\NNS|.|Reserpine (l_prep) in_17\IN|NONE (l_pobj) dyskinesia_19\NN|NONE (l_relcl) are_30\VBP|protrusion|,|,|orofacial (l_attr) signs_31\NNS|which (l_amod) indicative_32\JJ|NONE (l_prep) of_33\IN|NONE (l_pobj) dyskinesia_35\NN|NONE
D012110_D004409 CID reserpine_4\NN|that|movements (r_nsubj) produces_5\VBZ|results|. (l_dobj) movements_9\NNS|that|reserpine
D012110_D004409 CID reserpine_4\NN|that|movements (r_nsubj) produces_5\VBZ|results|. (l_dobj) movements_9\NNS|that|reserpine (l_relcl) related_13\VBN|different|, (l_conj) considered_22\VBN|which|are|and|to (l_prep) as_23\IN|be|can (l_pobj) signs_30\NNS|NONE (l_compound) dsykinesia_29\NN|parkinsonian
D016202_D002375 NONE NMDA_5\NNP|NONE (r_pobj) by_4\IN|NONE (r_agent) produced_3\VBN|The|glutamatergic (r_acl) blockage_2\NN|.|signs|according|can (r_nsubj) restore_7\VB|NONE (l_dobj) signs_9\NNS|.|blockage|according|can (l_prep) as_12\IN|these|, (l_pobj) movements_15\NNS|such (l_conj) protrusions_18\NNS|chewing|,|vacuous (l_conj) catalepsy_20\NN|tongue|,
D016291_D002375 NONE MK-801_16\NNP|also|tremor|Reserpine|. (r_punct) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|Reserpine|. (l_conj) catalepsy_5\NN|,|and|are
D016291_D002375 NONE MK-801_17\NNP|On|.|compared|reserpine|increases|, (r_punct) induced_6\VBN|NONE (l_dobj) increases_7\NNS|MK|On|.|compared|reserpine|, (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE (l_conj) catalepsy_11\NN|and
D016291_D002375 NONE MK-801_33\NNP|)|mg/kg (r_punct) injection_38\NN| (r_nsubj) min_40\NN|effects|test|whereas|before (r_nsubj) reversed_44\VBD|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE (l_conj) catalepsy_30\NN|and
D012110_D014202 CID Reserpine_0\NN|MK|also|tremor|. (r_nsubj) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|Reserpine|.
D012110_D014202 CID reserpine_11\NN| (r_npadvmod) treated_13\VBN|NONE (r_amod) mice_14\NNS|NONE (r_pobj) in_10\IN|of|a|significant (r_prep) increase_7\NN|However|injection|.|,|MK (l_prep) of_8\IN|a|in|significant (l_pobj) tremor_9\NN|NONE
D012110_D014202 CID reserpine_5\NN|MK|On|.|compared|increases|, (r_nsubj) induced_6\VBN|NONE (l_dobj) increases_7\NNS|MK|On|.|compared|reserpine|, (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE
D012110_D014202 CID reserpine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|tremor|the|and (r_acl) catalepsy_7\NN|.|administration|( (l_conj) tremor_9\NN|the|and|induced
D012110_D014202 CID reserpine_2\NN|NONE (r_pobj) with_1\IN|produced (r_prep) Pretreatment_0\NN|NONE (l_acl) produced_13\VBD|with (l_conj) increases_26\NNS|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE
D012110_D014202 CID reserpine_48\NN|NONE (r_pobj) of_47\IN|the (r_prep) effects_46\NNS|test|whereas|before|min (r_dobj) reversed_44\VBD|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE
D012110_D009069 NONE Reserpine_0\NN|increases|. (r_nsubj) produced_15\VBD|NONE (l_dobj) increases_16\NNS|.|Reserpine (l_prep) in_17\IN|NONE (l_pobj) dyskinesia_19\NN|NONE
D012110_D009069 NONE Reserpine_0\NN|and|followed|before (r_nsubj) administered_6\VBN|,|in|not|did|dyskinesia|. (r_ccomp) produce_29\VB|NONE (l_dobj) dyskinesia_31\NN|,|administered|in|not|did|.
D001058_D009069 NONE apomophine_15\JJ|min (r_amod) injection_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) followed_13\VBN|and|before|Reserpine (r_conj) administered_6\VBN|,|in|not|did|dyskinesia|. (r_ccomp) produce_29\VB|NONE (l_dobj) dyskinesia_31\NN|,|administered|in|not|did|.
D016202_D014202 NONE NMDA_5\NNP|NONE (r_pobj) by_4\IN|NONE (r_agent) produced_3\VBN|The|glutamatergic (r_acl) blockage_2\NN|.|signs|according|can (r_nsubj) restore_7\VB|NONE (l_dobj) signs_9\NNS|.|blockage|according|can (l_prep) as_12\IN|these|, (l_pobj) movements_15\NNS|such (l_conj) protrusions_18\NNS|chewing|,|vacuous (l_conj) catalepsy_20\NN|tongue|, (l_conj) tremor_22\NN|and
D016291_D010300 NONE MK-801_16\NNP|also|tremor|Reserpine|. (r_punct) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|Reserpine|. (l_relcl) are_8\VBP|,|and|catalepsy (l_attr) signs_9\NNS|which (l_amod) suggestive_10\JJ|NONE (l_prep) of_11\IN|NONE (l_pobj) disease_14\NN|NONE
D012110_D010300 NONE Reserpine_0\NN|MK|also|tremor|. (r_nsubj) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|Reserpine|. (l_relcl) are_8\VBP|,|and|catalepsy (l_attr) signs_9\NNS|which (l_amod) suggestive_10\JJ|NONE (l_prep) of_11\IN|NONE (l_pobj) disease_14\NN|NONE
D012110_D010300 NONE reserpine_4\NN|that|movements (r_nsubj) produces_5\VBZ|results|. (l_dobj) movements_9\NNS|that|reserpine (l_relcl) related_13\VBN|different|, (l_conj) considered_22\VBN|which|are|and|to (l_prep) as_23\IN|be|can (l_pobj) signs_30\NNS|NONE (l_amod) parkinsonian_24\JJ|dsykinesia
D012110_D002375 CID Reserpine_0\NN|MK|also|tremor|. (r_nsubj) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|Reserpine|. (l_conj) catalepsy_5\NN|,|and|are
D012110_D002375 CID reserpine_25\NN|NONE (r_pobj) by_24\IN|NONE (r_agent) induced_23\VBN|vacuous|the|,|chewing|protrusions (r_acl) movements_17\NNS|mg/kg|. (l_conj) protrusions_20\NNS|vacuous|the|induced|,|chewing (l_conj) catalepsy_22\NN|and|tongue
D012110_D002375 CID reserpine_5\NN|MK|On|.|compared|increases|, (r_nsubj) induced_6\VBN|NONE (l_dobj) increases_7\NNS|MK|On|.|compared|reserpine|, (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE (l_conj) catalepsy_11\NN|and
D012110_D002375 CID reserpine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|tremor|the|and (r_acl) catalepsy_7\NN|.|administration|(
D012110_D002375 CID reserpine_2\NN|NONE (r_pobj) with_1\IN|produced (r_prep) Pretreatment_0\NN|NONE (l_acl) produced_13\VBD|with (l_conj) increases_26\NNS|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE (l_conj) catalepsy_30\NN|and
D012110_D002375 CID reserpine_48\NN|NONE (r_pobj) of_47\IN|the (r_prep) effects_46\NNS|test|whereas|before|min (r_dobj) reversed_44\VBD|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE (l_conj) catalepsy_30\NN|and
9205462
D013629_D001943 NONE tamoxifen_9\NN|NONE (r_pobj) with_8\IN|for|.|was|woman (r_prep) treated_7\VBN|NONE (l_prep) for_10\IN|with|.|was|woman (l_pobj) carcinoma_18\NN|NONE
D013629_D017093 CID tamoxifen_2\NN| (r_npadvmod) induced_4\VBN|liver (r_amod) dysfunction_6\NN|NONE
D013629_D017093 CID tamoxifen_20\NN|NONE (r_compound) metabolism_21\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) alterations_18\NNS|of (r_pobj) because_16\IN|at|Patients|.|may (r_prep) be_8\VB|NONE (l_nsubj) Patients_0\NNS|at|.|may|because (l_prep) with_1\IN|NONE (l_pobj) dysfunction_6\NN|NONE
D013629_D009369 NONE tamoxifen_8\NN|and|tumors (r_compound) use_9\NN|NONE (l_conj) tumors_12\NNS|and|tamoxifen
D013629_C537296 CID tamoxifen_9\NN|antecedent (r_compound) use_10\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|the (r_acl) ovary_5\NN|NONE
D004967_D001943 NONE estrogen_13\NN|II|positive|stage|breast (r_compound) carcinoma_18\NN|NONE
D013629_D006106 NONE tamoxifen_2\NN| (r_npadvmod) induced_4\VBN|liver (r_amod) dysfunction_6\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Patients_0\NNS|at|.|may|because (r_nsubj) be_8\VB|NONE (l_prep) at_9\IN|Patients|.|may|because (l_pobj) risk_11\NN|NONE (l_prep) for_12\IN|increased (l_pobj) tumors_15\NNS|NONE
D013629_D006106 NONE tamoxifen_20\NN|NONE (r_compound) metabolism_21\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) alterations_18\NNS|of (r_pobj) because_16\IN|at|Patients|.|may (r_prep) be_8\VB|NONE (l_prep) at_9\IN|Patients|.|may|because (l_pobj) risk_11\NN|NONE (l_prep) for_12\IN|increased (l_pobj) tumors_15\NNS|NONE
19105845
D016642_D012640 CID hydrochloride_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) seizures_11\NNS|NONE
D016642_D012640 CID bupropion_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) seizures_18\NNS|NONE
D016642_D012640 CID HCl_12\NNP|NONE (r_pobj) of_10\IN|infusion|the|intraperitoneal (r_prep) rates_9\NNS|mg/kg (r_dobj) varying_5\VBG|NONE (r_pcomp) of_4\IN|,|the|CD (r_prep) effect_3\NN|We|on|.|, (l_appos) CD50_22\NNP|of|,|the (l_amod) convulsive_18\JJ|dose|)|a|(
D016642_D012640 CID HCl_12\NNP|NONE (r_pobj) of_10\IN|infusion|the|intraperitoneal (r_prep) rates_9\NNS|mg/kg (r_dobj) varying_5\VBG|NONE (r_pcomp) of_4\IN|,|the|CD (r_prep) effect_3\NN|We|on|.|, (r_dobj) investigated_1\VBD|NONE (l_prep) on_25\IN|We|.|effect|, (l_pobj) incidence_27\NN|NONE (l_prep) of_30\IN|and|the|severity (l_pobj) convulsions_34\NNS|NONE
D016642_D012640 CID bupropion_31\NN| (r_npadvmod) induced_33\VBN|in (r_amod) convulsions_34\NNS|NONE (r_pobj) of_30\IN|and|the|severity (r_prep) incidence_27\NN|NONE (r_pobj) on_25\IN|We|.|effect|, (r_prep) investigated_1\VBD|NONE (l_dobj) effect_3\NN|We|on|.|, (l_appos) CD50_22\NNP|of|,|the (l_amod) convulsive_18\JJ|dose|)|a|(
D016642_D012640 CID bupropion_31\NN| (r_npadvmod) induced_33\VBN|in (r_amod) convulsions_34\NNS|NONE
D016642_D012640 CID HCl_9\NNP|.|results|by|mg/kg|:|induced|% (r_ccomp) showed_3\VBD|NONE (l_advcl) induced_15\VBD|.|results|by|mg/kg|:|%|HCl (l_dobj) convulsions_16\NNS|NONE
D016642_D012640 CID HCl_27\NNP|NONE (r_pobj) of_25\IN|the|infusion (r_prep) time_24\NN|mg/kg (r_dobj) increasing_20\VBG|odds|=|)|and|;|. (r_conj) ratio_15\NN|was|with|compared (r_nsubjpass) associated_31\VBN|analysis|was|. (l_prep) with_32\IN|ratio|was|compared (l_pobj) odds_37\NNS|NONE (l_prep) of_38\IN|reduced|%|a (l_pobj) convulsions_39\NNS|NONE
D016642_D012640 CID bupropion_19\NN|NONE (r_pobj) of_18\IN|and|fixed|a|risk (r_prep) dose_17\NN|NONE (l_amod) fixed_14\JJ|and|of|a|risk (l_conj) convulsive_16\JJ|and
D016642_D012640 CID bupropion_19\NN|NONE (r_pobj) of_18\IN|and|fixed|a|risk (r_prep) dose_17\NN|NONE (l_conj) risk_22\NN|and|of|fixed|a (l_prep) of_23\IN|the (l_pobj) convulsions_24\NNS|NONE
9067481
D002251_D064420 NONE tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
D000082_D066126 NONE acetaminophen_35\RB|CCl|,|, (l_conj) against_39\IN|and|and|galactosamine (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D005688_D064420 NONE galactosamine_52\NN| (r_npadvmod) induced_54\VBN|and (r_conj) chloroform-_50\JJ|NONE (r_nmod) toxicity_55\NN|,|carbon|acetaminophen
D004317_D066126 CID adriamycin_49\NNS|NONE (r_amod) administration_50\NN|NONE (r_pobj) of_48\IN|cardiotoxic|) (r_prep) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
C103872_D064420 NONE acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
D002725_D064420 NONE chloroform-_50\JJ|NONE (r_nmod) toxicity_55\NN|,|carbon|acetaminophen
D004317_D056486 NONE adriamycin_49\NNS|NONE (r_amod) administration_50\NN|NONE (r_pobj) of_48\IN|cardiotoxic|) (r_prep) effect_47\NN|(|and|the (r_conj) lethal_41\JJ|NONE (r_pobj) against_39\IN|and|and|galactosamine (r_conj) acetaminophen_35\RB|CCl|,|, (r_conj) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|hepatotoxic|the (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
D004317_D064420 NONE adriamycin-_45\JJ|,|, (r_conj) acetaminophen-_43\NN|,|carbon|toxicity (r_nmod) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
D002251_D066126 NONE CCl4_31\NNP|acetaminophen|,|, (r_nmod) CHCl3_33\NNP|NONE (l_conj) acetaminophen_35\RB|CCl|,|, (l_conj) against_39\IN|and|and|galactosamine (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D002725_D056486 CID CHCl3_33\NNP|NONE (r_pobj) of_30\IN|hepatotoxic|the (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
D005688_D056486 CID galactosamine_37\NN|against|and|and (r_conj) acetaminophen_35\RB|CCl|,|, (r_conj) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|hepatotoxic|the (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
D005688_D056486 CID galactosamine_30\NN|NONE (r_amod) hepatotoxicity_31\NN|NONE
D000082_D064420 NONE acetaminophen-_43\NN|,|carbon|toxicity (r_nmod) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
D002725_D066126 NONE CHCl3_33\NNP|NONE (l_conj) acetaminophen_35\RB|CCl|,|, (l_conj) against_39\IN|and|and|galactosamine (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D002251_D056486 CID tetrachloride_35\NN|CCl|hepatotoxic|the|of (r_advmod) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|CCl|tetrachloride|the|of
D002251_D056486 CID CCl4_37\NNP|tetrachloride|hepatotoxic|the|of (r_appos) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|CCl|tetrachloride|the|of
D002251_D056486 CID CCl4_31\NNP|acetaminophen|,|, (r_nmod) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|hepatotoxic|the (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
-1_D056486 NONE salt_17\NN|)|tris|(|CS (r_nmod) administration_21\NN|,|cholesteryl (r_conj) hemisuccinate_14\NN|,|of|stabilizer (r_conj) rigidifier_9\NN|NONE (r_pobj) as_5\IN|its (r_prep) use_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|.|also|protect|been|has (r_prep) shown_25\VBN|NONE (l_xcomp) protect_27\VB|.|also|been|In|has (l_prep) from_29\IN|to|rats (l_pobj) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|CCl|tetrachloride|the|of
-1_D056486 NONE CS_19\NNP|)|tris|salt|( (r_nmod) administration_21\NN|,|cholesteryl (r_conj) hemisuccinate_14\NN|,|of|stabilizer (r_conj) rigidifier_9\NN|NONE (r_pobj) as_5\IN|its (r_prep) use_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|.|also|protect|been|has (r_prep) shown_25\VBN|NONE (l_xcomp) protect_27\VB|.|also|been|In|has (l_prep) from_29\IN|to|rats (l_pobj) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|CCl|tetrachloride|the|of
-1_D056486 NONE CS_13\NNP|mg|)|(|i.p.|/|, (r_nmod) kg_17\NNS|NONE (r_pobj) of_12\IN|single|a (r_prep) dose_11\NN|NONE (r_pobj) with_8\IN|of|h|A (r_prep) pretreatment_2\NN|,|in|. (r_nsubj) resulted_22\VBD|NONE (l_prep) in_23\IN|,|pretreatment|. (l_pobj) protection_25\NN|NONE (l_prep) against_26\IN|significant (l_pobj) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
-1_D056486 NONE CS_3\NNP|NONE (r_compound) protection_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|does|not|be|.|) (r_nsubj) appear_7\VB|NONE (l_xcomp) be_9\VB|does|not|.|mechanism|) (l_acomp) dependent_10\JJ|to (l_prep) on_11\IN|NONE (l_pobj) inhibition_13\NN|NONE (l_prep) to_17\IN|the|of (l_pobj) in_23\IN|NONE (l_pobj) light_24\NN|intermediate|( (l_prep) of_25\IN|NONE (l_pobj) protection_27\NN|NONE (l_acl) observed_28\VBN|the (l_prep) against_29\IN|NONE (l_pobj) hepatotoxicity_31\NN|NONE
-1_D064420 NONE CS_8\NNP|NONE (r_compound) cytoprotection_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) mechanism_6\NN|NONE (r_pobj) of_4\IN|our (r_prep) understanding_3\NN|To (r_dobj) further_1\VB|we|mice|.|,|and|in (r_advmod) examined_12\VBD|NONE (l_conj) mice_16\NNS|we|.|further|,|and|in (l_dobj) abilities_19\NNS|NONE (l_prep) of_20\IN|protective|the (l_pobj) CS_21\NNP|NONE (l_conj) form_28\NN|and (l_prep) of_29\IN|hydrolyzable|ether|the (l_pobj) CS_30\NNP|NONE (l_conj) acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
-1_D064420 NONE CS_21\NNP|NONE (l_conj) form_28\NN|and (l_prep) of_29\IN|hydrolyzable|ether|the (l_pobj) CS_30\NNP|NONE (l_conj) acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
-1_D064420 NONE CS_30\NNP|NONE (l_conj) acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
-1_D064420 NONE salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
-1_D064420 NONE CSE_40\NNP|tris|against (r_appos) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|,|carbon|acetaminophen
D000082_D056486 CID acetaminophen_35\RB|CCl|,|, (r_conj) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|hepatotoxic|the (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
C013440_D056486 NONE hemisuccinate_14\NN|,|of|stabilizer (r_conj) rigidifier_9\NN|NONE (r_pobj) as_5\IN|its (r_prep) use_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|.|also|protect|been|has (r_prep) shown_25\VBN|NONE (l_xcomp) protect_27\VB|.|also|been|In|has (l_prep) from_29\IN|to|rats (l_pobj) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|CCl|tetrachloride|the|of
-1_D066126 NONE CS_13\NNP|mg|)|(|i.p.|/|, (r_nmod) kg_17\NNS|NONE (r_pobj) of_12\IN|single|a (r_prep) dose_11\NN|NONE (r_pobj) with_8\IN|of|h|A (r_prep) pretreatment_2\NN|,|in|. (r_nsubj) resulted_22\VBD|NONE (l_prep) in_23\IN|,|pretreatment|. (l_pobj) protection_25\NN|NONE (l_prep) against_26\IN|significant (l_pobj) effects_29\NNS|NONE (l_prep) of_30\IN|hepatotoxic|the (l_pobj) CHCl3_33\NNP|NONE (l_conj) acetaminophen_35\RB|CCl|,|, (l_conj) against_39\IN|and|and|galactosamine (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D005688_D066126 NONE galactosamine_37\NN|against|and|and (r_conj) acetaminophen_35\RB|CCl|,|, (l_conj) against_39\IN|and|and|galactosamine (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
2422478
D012701_D006973 NONE serotonin_19\NN|midline|the|cell|in (r_compound) group_21\NN|NONE (r_pobj) of_15\IN|the (r_prep) area_14\NN|NONE (r_pobj) into_12\IN|of (r_prep) microinjection_9\NN|,|hypertensive|prone|, (r_conj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|,|microinjection|prone|,
D012701_D006973 NONE serotonin_51\NN|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|,|microinjection|prone|,
D012701_D020521 NONE serotonin_19\NN|midline|the|cell|in (r_compound) group_21\NN|NONE (r_pobj) of_15\IN|the (r_prep) area_14\NN|NONE (r_pobj) into_12\IN|of (r_prep) microinjection_9\NN|,|hypertensive|prone|, (r_conj) rats_7\NNS|NONE (l_amod) prone_6\JJ|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN|
D012701_D020521 NONE serotonin_51\NN|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS|NONE (l_amod) prone_6\JJ|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN|
D015116_D020521 NONE 5,7-dihydroxytryptamine_53\CD|serotonin|the (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS|NONE (l_amod) prone_6\JJ|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN|
D015116_D020521 NONE 5,7-DHT_55\NNP|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD|serotonin|the (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS|NONE (l_amod) prone_6\JJ|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN|
D008750_D007022 CID methyldopa_13\NN|NONE (r_pobj) of_12\IN|hypotensive (r_prep) effect_11\NN|NONE (l_amod) hypotensive_10\JJ|of
D008750_D007022 CID methyldopa_10\NN|NONE (r_pobj) of_9\IN|onto (r_prep) microinjection_8\NN|that|response (r_nsubj) elicits_23\VBZ|.|have|experiments (l_dobj) response_26\NN|that|microinjection (l_amod) hypotensive_25\JJ|mediated|a
D008750_D007022 CID methyldopa_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|,|hypertensive|prone|, (r_conj) rats_7\NNS|NONE (r_pobj) In_0\IN|hypotension|and|abolished|h|. (r_prep) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|and|abolished|h|.|In
D008750_D007022 CID methyldopa_14\NN| (r_npadvmod) induced_16\VBN|a (r_amod) hypotension_17\NN|which|via
D008750_D007022 CID methyldopa_14\NN| (r_npadvmod) induced_16\VBN|a (r_amod) hypotension_17\NN|which|via (r_dobj) mediate_12\VBP|the|ventrolateral|B (r_relcl) cells_10\NNS|NONE (r_pobj) unlike_6\IN|,|that|cells|by|,|,|to (r_prep) contribute_30\VB|It|.|therefore|is (l_prep) to_31\IN|,|that|cells|by|unlike|,|, (l_pobj) action_34\NN|NONE (l_amod) hypotensive_33\JJ|the|of
D008750_D007022 CID methyldopa_36\NN|NONE (r_pobj) of_35\IN|the|hypotensive (r_prep) action_34\NN|NONE (r_pobj) to_31\IN|,|that|cells|by|unlike|,|, (r_prep) contribute_30\VB|It|.|therefore|is (l_prep) unlike_6\IN|,|that|cells|by|,|,|to (l_pobj) cells_10\NNS|NONE (l_relcl) mediate_12\VBP|the|ventrolateral|B (l_dobj) hypotension_17\NN|which|via
D008750_D007022 CID methyldopa_36\NN|NONE (r_pobj) of_35\IN|the|hypotensive (r_prep) action_34\NN|NONE (l_amod) hypotensive_33\JJ|the|of
D008750_D006973 NONE methyldopa_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|,|hypertensive|prone|, (r_conj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|,|microinjection|prone|,
D008750_D020521 NONE methyldopa_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|,|hypertensive|prone|, (r_conj) rats_7\NNS|NONE (l_amod) prone_6\JJ|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN|
D015116_D006973 NONE 5,7-dihydroxytryptamine_53\CD|serotonin|the (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|,|microinjection|prone|,
D015116_D006973 NONE 5,7-DHT_55\NNP|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD|serotonin|the (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|,|microinjection|prone|,
D012701_D007022 NONE serotonin_2\NN|in (r_compound) nerves_3\NNS|are|.|in (r_nsubjpass) involved_8\VBN|NONE (l_prep) in_9\IN|are|.|nerves (l_pobj) effect_11\NN|NONE (l_amod) hypotensive_10\JJ|of
D012701_D007022 NONE serotonin_18\NN|the (r_compound) neurons_19\NNS|NONE (r_pobj) of_15\IN|in|the|ventrolateral (r_prep) cells_14\NNS|NONE (r_pobj) onto_11\IN|of (r_prep) microinjection_8\NN|that|response (r_nsubj) elicits_23\VBZ|.|have|experiments (l_dobj) response_26\NN|that|microinjection (l_amod) hypotensive_25\JJ|mediated|a
D012701_D007022 NONE serotonin_19\NN|midline|the|cell|in (r_compound) group_21\NN|NONE (r_pobj) of_15\IN|the (r_prep) area_14\NN|NONE (r_pobj) into_12\IN|of (r_prep) microinjection_9\NN|,|hypertensive|prone|, (r_conj) rats_7\NNS|NONE (r_pobj) In_0\IN|hypotension|and|abolished|h|. (r_prep) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|and|abolished|h|.|In
D012701_D007022 NONE serotonin_51\NN|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|and|abolished|h|.|In
D012701_D007022 NONE serotonin_15\NN|in (r_compound) projections_16\NNS|only (r_dobj) descending_14\VBG|NONE (r_pcomp) of_12\IN|selective|a (r_prep) lesion_11\NN|to (r_dobj) produce_7\VB|intraspinal|of (r_relcl) injection_3\NN|not|did|,|hypotension|However|. (r_nsubj) affect_23\VB|NONE (l_dobj) hypotension_25\NN|not|did|,|injection|However|.
D012701_D007022 NONE serotonin_24\NN|in|the|midline|B (r_compound) cells_26\NNS|,|that|by|unlike|,|,|to (r_nsubj) contribute_30\VB|It|.|therefore|is (l_prep) unlike_6\IN|,|that|cells|by|,|,|to (l_pobj) cells_10\NNS|NONE (l_relcl) mediate_12\VBP|the|ventrolateral|B (l_dobj) hypotension_17\NN|which|via
D012701_D007022 NONE serotonin_24\NN|in|the|midline|B (r_compound) cells_26\NNS|,|that|by|unlike|,|,|to (r_nsubj) contribute_30\VB|It|.|therefore|is (l_prep) to_31\IN|,|that|cells|by|unlike|,|, (l_pobj) action_34\NN|NONE (l_amod) hypotensive_33\JJ|the|of
D015116_D007022 NONE 5,7-dihydroxytryptamine_53\CD|serotonin|the (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|and|abolished|h|.|In
D015116_D007022 NONE 5,7-DHT_55\NNP|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD|serotonin|the (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|hypotension|and|h|.|In (r_conj) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|and|abolished|h|.|In
D015116_D007022 NONE 5,7-DHT_5\CD|NONE (r_pobj) of_4\IN|produce|intraspinal (r_prep) injection_3\NN|not|did|,|hypotension|However|. (r_nsubj) affect_23\VB|NONE (l_dobj) hypotension_25\NN|not|did|,|injection|However|.
7421734
D004967_D009369 NONE estrogens_4\NNS|NONE (r_pobj) on_2\IN|Young (r_prep) women_1\NNS|after|therapy|have|also|and|.|may|risk|examined (r_nsubj) increased_14\VBN|NONE (l_nsubj) therapy_10\NN|after|have|also|women|and|.|may|risk|examined (l_compound) cancer_9\NN|NONE
D004967_D016889 CID estrogens_16\NNS|treatment (r_dobj) received_14\VBD|.|failure|and|She|, (l_npadvmod) treatment_19\NN|estrogens (l_acl) implicated_20\VBN|a|, (l_prep) in_21\IN|NONE (l_pobj) development_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) cancer_26\NN|NONE
D004967_D016889 CID estrogens_4\NNS|NONE (r_pobj) on_2\IN|Young (r_prep) women_1\NNS|after|therapy|have|also|and|.|may|risk|examined (r_nsubj) increased_14\VBN|NONE (l_dobj) risk_15\NN|after|therapy|have|also|women|and|.|may|examined (l_prep) of_16\IN|NONE (l_pobj) carcinoma_18\NN|NONE
D004967_D010049 NONE estrogens_16\NNS|treatment (r_dobj) received_14\VBD|.|failure|and|She|, (r_conj) had_1\VBD|NONE (l_dobj) failure_3\NN|.|and|She|,|received
D004967_D010049 NONE estrogens_4\NNS|NONE (l_prep) for_5\IN|replacement (l_pobj) failure_7\NN|NONE
D004967_D006689 NONE estrogens_16\NNS|treatment (r_dobj) received_14\VBD|.|failure|and|She|, (r_conj) had_1\VBD|NONE (l_dobj) failure_3\NN|.|and|She|,|received (l_prep) after_4\IN|ovarian (l_pobj) irradiation_6\NN|NONE (l_prep) for_9\IN|abdominal|and|chemotherapy (l_pobj) disease_11\NN|NONE
7843916
D013256_D005901 NONE Steroid_0\NN|NONE (r_compound) treatment_1\NN|.|in (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|.|treatment (l_pobj) changes_5\NNS|NONE (l_prep) in_6\IN|morphologic (l_pobj) meshwork_9\NN|NONE (l_amod) similar_10\JJ|the|trabecular (l_prep) to_11\IN|NONE (l_pobj) those_12\DT|NONE (l_acl) reported_13\VBN|NONE (l_prep) for_14\IN|NONE (l_pobj) glaucoma_16\NN|NONE
D003907_D009798 CID Dexamethasone_0\NN|hypertension|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypertension_4\NN|.||Dexamethasone
D003907_D009798 CID dexamethasone_4\NN| (r_npadvmod) treated_6\VBN|hypertensive|the (r_amod) eyes_8\NNS|had|,|.|beams|,|decreased|In
D003907_D009798 CID Dexamethasone_0\NN|of (r_compound) treatment_1\NN|.|to (r_nsubj) led_10\VBD|NONE (l_prep) to_11\IN|treatment|. (l_pobj) generation_13\NN|NONE (l_prep) of_14\IN|the|in (l_pobj) hypertension_16\NN|NONE
D003907_D009798 CID dexamethasone_23\NN| (r_npadvmod) treated_25\VBN|the (r_amod) eyes_26\NNS|NONE (r_pobj) of_21\IN| (r_prep) %_20\NN|NONE (r_pobj) in_17\IN|the|of (r_prep) generation_13\NN|NONE (l_prep) of_14\IN|the|in (l_pobj) hypertension_16\NN|NONE
D013256_D005902 NONE Steroid_0\NN|NONE (r_compound) treatment_1\NN|.|in (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|.|treatment (l_pobj) changes_5\NNS|NONE (l_prep) in_6\IN|morphologic (l_pobj) meshwork_9\NN|NONE (l_amod) similar_10\JJ|the|trabecular (l_prep) to_11\IN|NONE (l_pobj) those_12\DT|NONE (l_acl) reported_13\VBN|NONE (l_prep) for_14\IN|NONE (l_pobj) glaucoma_16\NN|NONE (l_conj) glaucoma_20\NN|and|corticosteroid
6415512
D002220_D004831 CID carbamazepine_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_pobj) of_9\IN|in (r_prep) institution_8\NN|NONE (r_dobj) following_7\VBG|Myoclonic|. (r_prep) seizures_6\NNS|NONE
D002220_D004831 CID carbamazepine_11\NN|NONE (r_pobj) with_10\IN|,|.|children|had (r_prep) treated_9\VBN|NONE (l_conj) had_15\VBD|,|.|children|with (l_dobj) reaction_19\NN|NONE (l_acl) characterized_20\VBN|acute|aberrant|an (l_agent) by_21\IN|NONE (l_pobj) onset_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) absence_28\NN|NONE (l_conj) seizures_35\NNS|,|atypical|and/or|myoclonic
D002220_D004832 CID carbamazepine_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_pobj) of_9\IN|in (r_prep) institution_8\NN|NONE (r_dobj) following_7\VBG|Myoclonic|. (r_prep) seizures_6\NNS|NONE
D002220_D004832 CID carbamazepine_11\NN|NONE (r_pobj) with_10\IN|,|.|children|had (r_prep) treated_9\VBN|NONE (l_conj) had_15\VBD|,|.|children|with (l_dobj) reaction_19\NN|NONE (l_acl) characterized_20\VBN|acute|aberrant|an (l_agent) by_21\IN|NONE (l_pobj) onset_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) absence_28\NN|NONE (l_conj) seizures_35\NNS|,|atypical|and/or|myoclonic
D002220_D012640 NONE carbamazepine_2\NN|was|When (r_nsubjpass) discontinued_4\VBN|to|,|quickly|two (r_advcl) returned_10\VBD|and|,|,|two|had|resolve (r_ccomp) had_19\VBD|NONE (l_ccomp) resolve_24\VBP|and|,|,|two|had|returned (l_nsubj) seizures_23\NNS|in
D002220_D012640 NONE carbamazepine_2\NN|was|When (r_nsubjpass) discontinued_4\VBN|to|,|quickly|two (r_advcl) returned_10\VBD|and|,|,|two|had|resolve (r_ccomp) had_19\VBD|NONE (l_conj) had_33\VBD|and|,|,|two|returned|resolve (l_ccomp) persist_36\VB|.|one (l_nsubj) seizures_35\NNS|NONE
D002220_D004827 NONE carbamazepine_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) epilepsy_13\NN|NONE
1969772
D004298_D007022 NONE dopamine-1_4\NNS|receptor|causes|selective|a (r_punct) agonist_9\NN|.|Fenoldopam (l_relcl) causes_11\VBZ|receptor|selective|dopamine|a (l_conj) preserves_23\VBZ|vasodilatation|that|to|and (l_prep) during_29\IN|flow (l_pobj) hypotension_31\NN|NONE
D012964_D007022 NONE sodium_25\NN|P|)|(|induced (r_amod) hypotension_29\NN|NONE (r_pobj) during_24\IN||+/ (r_prep) decreased_18\VBD|.|and|during|flow (r_conj) increased_6\VBD|NONE (l_prep) during_7\IN|.|and|decreased|flow (l_pobj) hypotension_11\NN|NONE
D012964_D007022 NONE sodium_25\NN|P|)|(|induced (r_amod) hypotension_29\NN|NONE
D018818_D007022 CID fenoldopam_9\NN|NONE (r_pobj) with_8\IN|.|Preservation|in (r_prep) induced_7\VBN|NONE (l_nsubj) Preservation_0\NN|.|with|in (l_prep) during_5\IN|of (l_pobj) hypotension_6\NN|NONE
D018818_D007022 CID fenoldopam_3\NN|The (r_relcl) hypothesis_1\NN|induce|be|could|.|tested (r_nsubjpass) used_6\VBN|NONE (l_xcomp) induce_8\VB|be|could|.|tested|hypothesis (l_dobj) hypotension_9\NN|and|preserve|to
D018818_D007022 CID fenoldopam_8\NN| (r_npadvmod) induced_10\VBN|+/|| (r_amod) hypotension_11\NN|NONE
D018818_D007022 CID fenoldopam_8\NN| (r_npadvmod) induced_10\VBN|+/|| (r_amod) hypotension_11\NN|NONE (r_pobj) during_7\IN|.|and|decreased|flow (r_prep) increased_6\VBD|NONE (l_conj) decreased_18\VBD|.|and|during|flow (l_prep) during_24\IN||+/ (l_pobj) hypotension_29\NN|NONE
D009599_D007022 CID nitroprusside_26\RB| (r_advmod) induced_28\VBN|sodium|P|)|( (r_amod) hypotension_29\NN|NONE (r_pobj) during_24\IN||+/ (r_prep) decreased_18\VBD|.|and|during|flow (r_conj) increased_6\VBD|NONE (l_prep) during_7\IN|.|and|decreased|flow (l_pobj) hypotension_11\NN|NONE
D009599_D007022 CID nitroprusside_26\RB| (r_advmod) induced_28\VBN|sodium|P|)|( (r_amod) hypotension_29\NN|NONE
D009599_D007022 CID nitroprusside_1\NN|vasodilator|. (r_nsubj) is_2\VBZ|NONE (l_attr) vasodilator_10\NN|nitroprusside|. (l_relcl) produce_13\VB|arteriolar|venous (l_prep) during_22\IN|that|can|redistribution (l_pobj) hypotension_24\NN|NONE
3686155
D001971_D011605 CID bromocriptine_4\NN|NONE (r_pobj) by_3\IN|.|psychosis (r_prep) induced_2\VBN|NONE (l_nsubj) psychosis_1\NN|.|by
D001971_D011605 CID bromocriptine_16\NN|for|having (r_dobj) received_15\VBN|,|.|were|with|patients (r_advcl) seen_9\VBN|NONE (l_prep) with_10\IN|received|,|.|were|patients (l_pobj) psychosis_12\NN|NONE
D001971_D011605 CID Bromocriptine_0\NNP|been|has|with|. (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|been|has|Bromocriptine|. (l_pobj) psychosis_9\NN|NONE
D001971_D011605 CID bromocriptine_4\NN|may|psychosis|given (r_nsubj) cause_6\VB|.|cases (l_dobj) psychosis_7\NN|bromocriptine|may|given
D001971_D010300 NONE Bromocriptine_0\NNP|been|has|with|. (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|been|has|Bromocriptine|. (l_pobj) psychosis_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) patients_11\NNS|NONE (l_acl) receiving_12\VBG|NONE (l_dobj) drug_14\NN|NONE (l_prep) for_15\IN|the (l_pobj) disease_18\NN|NONE
D001971_D001523 NONE bromocriptine_16\NN|for|having (r_dobj) received_15\VBN|,|.|were|with|patients (r_advcl) seen_9\VBN|NONE (l_nsubjpass) patients_2\NNS|received|,|.|were|with (l_prep) with_3\IN|multigravida|Two (l_pobj) history_7\NN|NONE (l_amod) psychiatric_6\JJ|prior|no
D001971_D007775 NONE bromocriptine_16\NN|for|having (r_dobj) received_15\VBN|,|.|were|with|patients (l_prep) for_17\IN|having|bromocriptine (l_pobj) inhibition_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) lactation_20\NN|NONE
3120485
982002
D012293_D058186 CID rifampicin_8\NNS|NONE (r_pobj) of_7\IN|the (r_prep) administration_6\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) subsequent_3\JJ|.|renal|Acute (r_amod) failure_2\NN|NONE
D012293_D051437 NONE rifampicin_12\NNS|NONE (r_pobj) of_11\IN|intermittent|the (r_prep) administration_10\NN|NONE (r_pobj) after_7\IN|failure|had|.|patients (r_prep) developed_3\VBN|NONE (l_dobj) failure_6\NN|had|.|after|patients
3950060
D000583_D007674 CID amikacin_10\JJ|NONE (r_dobj) receiving_9\VBG|NONE (r_acl) patients_8\NNS|NONE (r_pobj) in_7\IN|outcome|and (r_prep) nephrotoxicity_3\NN|NONE
D000583_D007674 CID amikacin_6\JJ|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN| (r_acl) patients_3\NNS|NONE (r_pobj) from_1\IN|NONE (r_prep) Data_0\NNS|.|were|for (r_nsubjpass) analyzed_8\VBN|NONE (l_prep) for_9\IN|.|Data|were (l_pobj) factors_10\NNS|NONE (l_acl) associated_11\VBN|NONE (l_prep) with_12\IN|NONE (l_pobj) nephrotoxicity_13\NN|NONE
16574713
D018817_D008569 CID MDMA_12\NNP|moderate (r_compound) users_13\NNS|NONE (r_pobj) in_10\IN|.|,|evidence|In|was (r_prep) observed_9\VBN|NONE (l_nsubjpass) evidence_4\NN|.|,|in|In|was (l_prep) of_5\IN|no (l_pobj) impairment_7\NN|NONE
D018817_D008569 CID MDMA_4\NNP|NONE (r_pobj) of_3\IN|in|the (r_prep) use_2\NN|.|to|use|may|While (l_prep) in_5\IN|of|the (l_pobj) quantities_6\NNS|NONE (l_relcl) considered_10\VBN|NONE (l_oprd) associated_16\VBN|be|may|that (l_prep) with_17\IN|is|not|"|" (l_pobj) functioning_20\VBG|NONE
D018817_D008569 CID MDMA_4\NNP|NONE (r_pobj) of_3\IN|in|the (r_prep) use_2\NN|.|to|use|may|While (r_nsubj) lead_28\VB|NONE (l_prep) to_29\IN|.|use|may|use|While (l_pobj) impairments_33\NNS|NONE
D018817_D008569 CID MDMA_25\NNP|NONE (r_compound) use_26\NN|NONE (r_pobj) of_24\IN|heavy (r_prep) use_23\NN|.|to|may|use|While (r_nsubj) lead_28\VB|NONE (l_nsubj) use_2\NN|.|to|use|may|While (l_prep) in_5\IN|of|the (l_pobj) quantities_6\NNS|NONE (l_relcl) considered_10\VBN|NONE (l_oprd) associated_16\VBN|be|may|that (l_prep) with_17\IN|is|not|"|" (l_pobj) functioning_20\VBG|NONE
D018817_D008569 CID MDMA_25\NNP|NONE (r_compound) use_26\NN|NONE (r_pobj) of_24\IN|heavy (r_prep) use_23\NN|.|to|may|use|While (r_nsubj) lead_28\VB|NONE (l_prep) to_29\IN|.|use|may|use|While (l_pobj) impairments_33\NNS|NONE
D012701_D020258 NONE serotonin_13\NN|to (r_dobj) damage_11\VB|MDMA|has|,methylenedioxymethamphetamine|Although|been (r_xcomp) shown_9\VBN|,|is|about|.|little (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|,|is|shown|.|little (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D012701_D020258 NONE 5-HT_15\CD|in|humans|(|)|and (r_nmod) neurons_17\NNS|brain (r_appos) serotonin_13\NN|to (r_dobj) damage_11\VB|MDMA|has|,methylenedioxymethamphetamine|Although|been (r_xcomp) shown_9\VBN|,|is|about|.|little (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|,|is|shown|.|little (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D012701_D020258 NONE 5-HT_37\CD|neurotoxic|on|induced (r_nummod) lesions_39\NNS|NONE
D012701_D020258 NONE 5-HT_44\CD|in|is (r_nsubjpass) involved_46\VBN|,|as (r_relcl) functions_41\NNS|NONE (r_pobj) on_40\IN|neurotoxic|induced|HT (r_prep) lesions_39\NNS|NONE
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1\CD|MDMA|damage|has|Although|been (r_nsubjpass) shown_9\VBN|,|is|about|.|little (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|,|is|shown|.|little (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D018817_D020258 NONE MDMA_3\NNP|damage|has|,methylenedioxymethamphetamine|Although|been (r_nsubjpass) shown_9\VBN|,|is|about|.|little (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|,|is|shown|.|little (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D018817_D020258 NONE ecstasy_5\NN|or|(|) (r_conj) MDMA_3\NNP|damage|has|,methylenedioxymethamphetamine|Although|been (r_nsubjpass) shown_9\VBN|,|is|about|.|little (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|,|is|shown|.|little (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D018817_D020258 NONE MDMA_34\NNP| (r_npadvmod) induced_36\VBN|neurotoxic|on|HT (r_amod) lesions_39\NNS|NONE
4038130
D008619_D009135 CID mepivacaine_19\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|especially (r_pobj) after_16\IN|.|was|also|,|in|In|damage|, (r_prep) seen_10\VBN|NONE (l_prep) In_0\IN|.|was|after|also|,|in|damage|, (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) damage_4\NN|NONE
D008012_D009135 CID lidocaine_21\NN|plus|epinephrine|and (r_conj) mepivacaine_19\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|especially (r_pobj) after_16\IN|.|was|also|,|in|In|damage|, (r_prep) seen_10\VBN|NONE (l_prep) In_0\IN|.|was|after|also|,|in|damage|, (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) damage_4\NN|NONE
D004837_D009135 NONE epinephrine_23\NN|plus|lidocaine|and (r_conj) mepivacaine_19\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|especially (r_pobj) after_16\IN|.|was|also|,|in|In|damage|, (r_prep) seen_10\VBN|NONE (l_prep) In_0\IN|.|was|after|also|,|in|damage|, (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) damage_4\NN|NONE
8800187
D003891_D064420 NONE desipramine_8\JJ|in (r_amod) toxicity_9\NN|NONE
D015761_D064420 NONE 4-aminopyridine_5\CD|on (r_compound) therapy_6\NN|and|calcium (l_prep) on_7\IN|aminopyridine (l_pobj) toxicity_9\NN|NONE
D002122_D007022 NONE CaCl2_3\NNP|or (r_pobj) of_2\IN|The (r_prep) administration_1\NN|hypotension|.|not|did (r_nsubj) reverse_8\VB|NONE (l_dobj) hypotension_13\NN|.|not|administration|did
D003891_D001919 CID desipramine_6\NN|antidepressant|the (r_compound) IP_7\NNP|rats|produce|. (r_dobj) received_2\VBD|NONE (l_advcl) produce_9\VB|rats|IP|. (l_dobj) prolongation_13\NN|,|to|hypotension (l_conj) bradycardia_16\NN|and|QRS|,
D002118_D007022 NONE calcium_7\NN|NONE (r_compound) channel_8\NN|in (r_compound) blockade_9\NN|NONE (l_prep) in_10\IN|channel (l_pobj) hypotension_15\NN|NONE
D002118_D007022 NONE calcium_8\NN|NONE (r_compound) channel_9\NN|in (r_compound) inhibition_10\NN|NONE (l_prep) in_11\IN|channel (l_pobj) pathogenesis_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) hypotension_19\NN|NONE
D015761_D007022 NONE 4-aminopyridine_5\NN|NONE (r_punct) did_6\VBD|hypotension|.|not|administration (r_aux) reverse_8\VB|NONE (l_dobj) hypotension_13\NN|.|not|administration|did
D002122_D001145 CID CaCl2_19\NNP|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|.|(|) (r_prep) seizures_11\NNS|ventricular|.|and (r_conj) arrhythmias_4\NNS|NONE
D002122_D002318 NONE CaCl2_0\NNP|NONE (r_compound) therapy_1\NN|may|toxicity|possibly|. (r_nsubj) worsen_4\VB|NONE (l_dobj) toxicity_11\NN|may|therapy|possibly|.
D002118_D062787 NONE calcium_14\NN|NONE (r_compound) channel_15\NN|blocker (r_compound) overdose_17\NN|NONE
D002122_D002493 NONE CaCl2_0\NNP|NONE (r_compound) therapy_1\NN|may|toxicity|possibly|. (r_nsubj) worsen_4\VB|NONE (l_dobj) toxicity_11\NN|may|therapy|possibly|.
D017693_D007022 NONE NaHCO3_0\NNP|.|hypotension (r_nsubj) reversed_6\VBD|NONE (l_dobj) hypotension_7\NN|.|NaHCO
D002122_D012640 NONE CaCl2_19\NNP|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|.|(|) (r_prep) seizures_11\NNS|ventricular|.|and
D002122_D064420 NONE chloride_3\NN|NONE (l_conj) therapy_6\NN|and|calcium (l_prep) on_7\IN|aminopyridine (l_pobj) toxicity_9\NN|NONE
D003891_D007022 CID desipramine_6\NN|antidepressant|the (r_compound) IP_7\NNP|rats|produce|. (r_dobj) received_2\VBD|NONE (l_advcl) produce_9\VB|rats|IP|. (l_dobj) hypotension_10\NN|,|to|prolongation
8546130
D017291_D007676 NONE Clarithromycin_0\NN| (r_npadvmod) associated_2\VBN|in|visual|. (r_amod) hallucinations_4\NNS|NONE (l_prep) in_5\IN|visual|associated|. (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) failure_11\NN|NONE
D017291_D007676 NONE clarithromycin_8\NN|NONE (r_pobj) of_7\IN|a|high|in|in (r_prep) dose_6\NN|NONE (l_prep) in_9\IN|of|a|high|in (l_pobj) face_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) failure_14\NN|NONE
D017291_D020258 NONE clarithromycin_8\NN|NONE (r_pobj) of_7\IN|a|high|in|in (r_prep) dose_6\NN|NONE (r_pobj) of_2\IN|,|with|,|The (r_prep) combination_1\NN|.|appearance|have|may (r_nsubj) facilitated_28\VBN|NONE (l_dobj) appearance_30\NN|.|have|combination|may (l_prep) of_31\IN|the (l_pobj) effect_35\NN|NONE (l_amod) neurotoxic_33\JJ|this|side
D018942_D006212 NONE macrolide_13\NN|,|clarithromycin|the|new (r_amod) antibiotic_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) association_9\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) occurring_7\VBG|visual (r_acl) hallucinations_6\NNS|in|is|.
D000535_D020258 NONE aluminum_23\NN|underlying (r_compound) intoxication_24\NN|NONE (r_pobj) with_21\IN|,|,|The|of (r_prep) combination_1\NN|.|appearance|have|may (r_nsubj) facilitated_28\VBN|NONE (l_dobj) appearance_30\NN|.|have|combination|may (l_prep) of_31\IN|the (l_pobj) effect_35\NN|NONE (l_amod) neurotoxic_33\JJ|this|side
D017291_D006212 CID Clarithromycin_0\NN| (r_npadvmod) associated_2\VBN|in|visual|. (r_amod) hallucinations_4\NNS|NONE
D017291_D006212 CID clarithromycin_16\NN|,|the|macrolide|new (r_appos) antibiotic_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) association_9\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) occurring_7\VBG|visual (r_acl) hallucinations_6\NNS|in|is|.
D000535_D007676 NONE aluminum_23\NN|underlying (r_compound) intoxication_24\NN|NONE (r_pobj) with_21\IN|,|,|The|of (r_prep) combination_1\NN|.|appearance|have|may (l_prep) of_2\IN|,|with|,|The (l_pobj) dose_6\NN|NONE (l_prep) in_9\IN|of|a|high|in (l_pobj) face_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) failure_14\NN|NONE
9121607
D016202_D012640 NONE aspartate_6\NNP|NONE (l_appos) seizures_9\NNS|methyl||D|.
D016202_D012640 NONE NMDA)-induced_8\JJ|in|( (r_amod) seizures_9\NNS|methyl||D|.
D016202_D012640 NONE NMDA_10\NNP|NONE (r_pobj) in_9\IN|dependent|(|mg/kg|a (r_prep) delay_8\NN|but|,|also|protect|.|steroids (r_dobj) caused_3\VBD|NONE (l_conj) protect_22\VB|but|,|also|.|steroids|delay (l_prep) against_23\IN|not|completely|did (l_pobj) seizures_25\NNS|NONE
D016202_D012640 NONE NMDA_24\NNP|lethality|or (r_compound) seizures_25\NNS|NONE
D007608_D013226 CID acid_7\NN| (r_npadvmod) induced_9\VBN|limbic|status|and|pilocarpine (r_amod) seizures_11\NNS|NONE (r_pobj) against_3\IN|.|epilepticus|steroids (r_prep) protect_2\VBP|NONE (l_advcl) epilepticus_14\NN|.|steroids|against
D007608_D013226 CID acid_23\NN| (r_npadvmod) induced_25\VBN|and|limbic|kainic|epilepticus (r_amod) seizures_27\NNS|NONE (l_conj) epilepticus_30\NN|and|induced|limbic|kainic
D007608_D013226 CID acid_14\NN| (r_npadvmod) induced_16\VBN|status|and|pilocarpine (r_amod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP|We|. (l_advcl) epilepticus_20\NN|and|that|be|steroids|effective|,
D007608_D013226 CID acid_14\NN| (r_npadvmod) induced_16\VBN|status|and|pilocarpine (r_amod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP|We|. (l_conj) be_26\VB|and|that|steroids|epilepticus|effective|, (l_advmod) epilepticus_37\NN|may|of|in
D013256_D012640 NONE steroids_1\NNS|.|epilepticus|against (r_nsubj) protect_2\VBP|NONE (l_prep) against_3\IN|.|epilepticus|steroids (l_pobj) seizures_11\NNS|NONE
D013256_D012640 NONE Steroids_0\NNS|effective|.|values|mg/kg (r_nsubj) were_19\VBD|NONE (l_parataxis) mg/kg_28\NNS|effective|.|values|Steroids (l_conj) s.c.)-induced_30\VBN|,||( (l_dobj) seizures_33\NNS|NONE
D013256_D012640 NONE steroids_3\NNS|Although|potent (r_nsubj) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ|Although|steroids (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|the|than (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D013256_D012640 NONE steroids_3\NNS|Although|potent (r_nsubj) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE steroids_18\NNS|clonazepam|values|,|,|indicating|.|were (r_nsubj) had_26\VBD|NONE (l_advcl) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ|Although|steroids (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|the|than (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D013256_D012640 NONE steroids_18\NNS|clonazepam|values|,|,|indicating|.|were (r_nsubj) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE steroids_52\NNS|that|may|toxicity (r_nsubj) have_54\VB|NONE (r_ccomp) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (r_advcl) had_26\VBD|NONE (l_advcl) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ|Although|steroids (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|the|than (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D013256_D012640 NONE steroids_52\NNS|that|may|toxicity (r_nsubj) have_54\VB|NONE (r_ccomp) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE Steroids_0\NNS|configurations|delay|also|,|but|protect|. (r_nsubj) produced_13\VBD|NONE (l_dobj) delay_18\NN|configurations|also|,|but|protect|.|Steroids (l_prep) in_19\IN|a|dependent|induced (l_pobj) onset_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) seizures_24\NNS|NONE
D013256_D012640 NONE Steroids_0\NNS|configurations|delay|also|,|but|protect|. (r_nsubj) produced_13\VBD|NONE (l_conj) protect_40\VB|configurations|delay|also|,|but|.|Steroids (l_prep) against_41\IN|did|completely|not (l_pobj) seizures_43\NNS|NONE
D013256_D012640 NONE steroid_8\NN|NONE (r_pobj) of_6\IN|second|a (r_prep) dose_5\NN|when|was (r_nsubjpass) administered_10\VBN||,|However|after (r_advcl) hr_12\NN|,|complete|from (r_nmod) protection_19\NN|.|was (l_prep) from_20\IN|hr|,|complete (l_pobj) seizures_27\NNS|NONE
D013256_D012640 NONE steroids_1\NNS|but|,|also|protect|.|delay (r_nsubj) caused_3\VBD|NONE (l_conj) protect_22\VB|but|,|also|.|steroids|delay (l_prep) against_23\IN|not|completely|did (l_pobj) seizures_25\NNS|NONE
D013256_D012640 NONE steroids_4\NNS|and|that|be|epilepticus|effective|, (r_nsubj) are_5\VBP|We|. (l_acomp) effective_7\JJ|and|that|be|steroids|epilepticus|, (l_prep) in_8\IN|highly (l_pcomp) protecting_9\VBG|NONE (l_prep) against_10\IN|NONE (l_pobj) seizures_17\NNS|NONE
D001569_D012640 NONE benzodiazepine_10\JJ|in|the|than (r_amod) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|the|than (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D001569_D012640 NONE benzodiazepine_10\JJ|in|the|than (r_amod) clonazepam_11\NN|less (r_advcl) potent_7\JJ|Although|steroids (r_acomp) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D013226 NONE steroids_1\NNS|.|epilepticus|against (r_nsubj) protect_2\VBP|NONE (l_advcl) epilepticus_14\NN|.|steroids|against
D013256_D013226 NONE Steroids_0\NNS|effective|.|values|mg/kg (r_nsubj) were_19\VBD|NONE (l_npadvmod) values_39\NNS|effective|.|mg/kg|Steroids (l_amod) epilepticus_36\NN|(|mg/kg|)|,|ED
D013256_D013226 NONE steroid_8\NN|NONE (r_pobj) of_6\IN|second|a (r_prep) dose_5\NN|when|was (r_nsubjpass) administered_10\VBN||,|However|after (r_advcl) hr_12\NN|,|complete|from (r_nmod) protection_19\NN|.|was (l_prep) from_20\IN|hr|,|complete (l_pobj) seizures_27\NNS|NONE (l_conj) epilepticus_30\NN|and|induced|limbic|kainic
D013256_D013226 NONE steroids_4\NNS|and|that|be|epilepticus|effective|, (r_nsubj) are_5\VBP|We|. (l_advcl) epilepticus_20\NN|and|that|be|steroids|effective|,
D013256_D013226 NONE steroids_4\NNS|and|that|be|epilepticus|effective|, (r_nsubj) are_5\VBP|We|. (l_conj) be_26\VB|and|that|steroids|epilepticus|effective|, (l_advmod) epilepticus_37\NN|may|of|in
D010862_D013226 CID pilocarpine-_4\NN|induced|limbic|status|and (r_nmod) seizures_11\NNS|NONE (r_pobj) against_3\IN|.|epilepticus|steroids (r_prep) protect_2\VBP|NONE (l_advcl) epilepticus_14\NN|.|steroids|against
D010862_D013226 CID pilocarpine_25\NN|NONE (r_pobj) against_24\IN|NONE (r_prep) protecting_23\VBG|NONE (r_pcomp) in_22\IN|highly (r_prep) effective_21\JJ|.|values|mg/kg|Steroids (r_acomp) were_19\VBD|NONE (l_npadvmod) values_39\NNS|effective|.|mg/kg|Steroids (l_amod) epilepticus_36\NN|(|mg/kg|)|,|ED
D010862_D013226 CID pilocarpine-_11\NN|status|and|induced (r_nmod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP|We|. (l_advcl) epilepticus_20\NN|and|that|be|steroids|effective|,
D010862_D013226 CID pilocarpine-_11\NN|status|and|induced (r_nmod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP|We|. (l_conj) be_26\VB|and|that|steroids|epilepticus|effective|, (l_advmod) epilepticus_37\NN|may|of|in
D001569_D064420 NONE benzodiazepine_10\JJ|in|the|than (r_amod) clonazepam_11\NN|less (r_advcl) potent_7\JJ|Although|steroids (r_acomp) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
D013256_D064420 NONE steroids_3\NNS|Although|potent (r_nsubj) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
D013256_D064420 NONE steroids_18\NNS|clonazepam|values|,|,|indicating|.|were (r_nsubj) had_26\VBD|NONE (l_advcl) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
D013256_D064420 NONE steroids_52\NNS|that|may|toxicity (r_nsubj) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
D002998_D064420 NONE clonazepam_11\NN|less (r_advcl) potent_7\JJ|Although|steroids (r_acomp) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
D002998_D064420 NONE clonazepam_46\NN|values|steroids|,|,|indicating|.|were (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
D002998_D012640 NONE clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|the|than (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D002998_D012640 NONE clonazepam_11\NN|less (r_advcl) potent_7\JJ|Although|steroids (r_acomp) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D002998_D012640 NONE clonazepam_46\NN|values|steroids|,|,|indicating|.|were (r_advcl) had_26\VBD|NONE (l_advcl) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ|Although|steroids (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|the|than (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D002998_D012640 NONE clonazepam_46\NN|values|steroids|,|,|indicating|.|were (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D010862_D012640 CID pilocarpine-_4\NN|induced|limbic|status|and (r_nmod) seizures_11\NNS|NONE
D010862_D012640 CID pilocarpine_25\NN|NONE (r_pobj) against_24\IN|NONE (r_prep) protecting_23\VBG|NONE (r_pcomp) in_22\IN|highly (r_prep) effective_21\JJ|.|values|mg/kg|Steroids (r_acomp) were_19\VBD|NONE (l_parataxis) mg/kg_28\NNS|effective|.|values|Steroids (l_conj) s.c.)-induced_30\VBN|,||( (l_dobj) seizures_33\NNS|NONE
D010862_D012640 CID pilocarpine_15\NN|NONE (r_amod) seizures_16\NNS|NONE
D010862_D012640 CID pilocarpine_15\NN|NONE (r_amod) seizures_16\NNS|NONE (r_pobj) against_14\IN|NONE (r_prep) protecting_13\VBG|NONE (r_pcomp) in_12\IN|benzodiazepine|the|than (r_prep) clonazepam_11\NN|less (r_advcl) potent_7\JJ|Although|steroids (r_acomp) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|steroids|,|,|indicating|.|were (l_appos) TD50_34\NNP|comparable|protective|)|(|index (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D010862_D012640 CID pilocarpine-_11\NN|status|and|induced (r_nmod) seizures_17\NNS|NONE
D007608_D012640 CID acid_7\NN| (r_npadvmod) induced_9\VBN|limbic|status|and|pilocarpine (r_amod) seizures_11\NNS|NONE
D007608_D012640 CID acid_28\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) induced_25\VBN|a|in|dependent (r_acl) delay_18\NN|configurations|also|,|but|protect|.|Steroids (l_prep) in_19\IN|a|dependent|induced (l_pobj) onset_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) seizures_24\NNS|NONE
D007608_D012640 CID acid_28\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) induced_25\VBN|a|in|dependent (r_acl) delay_18\NN|configurations|also|,|but|protect|.|Steroids (r_dobj) produced_13\VBD|NONE (l_conj) protect_40\VB|configurations|delay|also|,|but|.|Steroids (l_prep) against_41\IN|did|completely|not (l_pobj) seizures_43\NNS|NONE
D007608_D012640 CID acid_23\NN| (r_npadvmod) induced_25\VBN|and|limbic|kainic|epilepticus (r_amod) seizures_27\NNS|NONE
D007608_D012640 CID acid_14\NN| (r_npadvmod) induced_16\VBN|status|and|pilocarpine (r_amod) seizures_17\NNS|NONE
D010862_D064420 NONE pilocarpine_15\NN|NONE (r_amod) seizures_16\NNS|NONE (r_pobj) against_14\IN|NONE (r_prep) protecting_13\VBG|NONE (r_pcomp) in_12\IN|benzodiazepine|the|than (r_prep) clonazepam_11\NN|less (r_advcl) potent_7\JJ|Although|steroids (r_acomp) were_4\VBD|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|steroids|that|may
9226773
D008094_D018500 CID lithium_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_dobj) following_4\VBG|.|diabetes (r_prep) insipidus_3\NN|NONE
D008094_D018500 CID lithium_9\NN| (r_npadvmod) induced_11\VBN|diabetes (r_amod) insipidus_14\NN|to
D008094_D018500 CID lithium_17\NN|NONE (r_compound) therapy_18\NN|.|had|been (r_nsubjpass) discontinued_21\VBN|have|had|previously|and|,|he|years|been (r_conj) diagnosed_6\VBN|NONE (l_xcomp) have_8\VB|discontinued|had|previously|and|,|he|years|been (l_dobj) insipidus_14\NN|to
D008094_D018500 CID lithium_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) cessation_6\NN|NONE (r_pobj) despite_5\IN|NONE (r_prep) polyuric_4\JJ|and (r_conj) thirsty_2\JJ|.|showed|He (r_acomp) remained_1\VBD|NONE (l_conj) showed_13\VBD|.|thirsty|He (l_ccomp) have_16\VB|NONE (l_prep) with_24\IN|to|thirst|,|him (l_pobj) evidence_26\NN|NONE (l_prep) of_27\IN|clear (l_pobj) insipidus_30\NN|NONE
D008094_D018500 CID Lithium_0\NN|insipidus (r_nsubj) induced_1\VBD|.|is|be (l_dobj) insipidus_4\NN|Lithium
D008094_D018500 CID lithium_24\NN|after|was (r_nsubjpass) stopped_26\VBN|reversible|to (r_advcl) be_8\VB|.|induced|is (r_xcomp) considered_6\VBN|NONE (l_csubjpass) induced_1\VBD|.|is|be (l_dobj) insipidus_4\NN|Lithium
D008094_D018500 CID lithium_14\NN| (r_npadvmod) induced_16\VBN|diabetes (r_amod) insipidus_19\NN|NONE
D008094_D011141 CID lithium_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) cessation_6\NN|NONE (r_pobj) despite_5\IN|NONE (r_prep) polyuric_4\JJ|and
D008094_D011141 CID Lithium_0\NN|insipidus (r_nsubj) induced_1\VBD|.|is|be (r_csubjpass) considered_6\VBN|NONE (l_xcomp) be_8\VB|.|induced|is (l_acomp) reversible_9\JJ|to|stopped (l_prep) on_10\IN|NONE (l_pobj) cessation_11\NN|NONE (l_prep) of_12\IN|persisted (l_pobj) therapy_13\NN|NONE (l_conj) polyuria_15\NN|but
D008094_D011141 CID lithium_24\NN|after|was (r_nsubjpass) stopped_26\VBN|reversible|to (r_advcl) be_8\VB|.|induced|is (l_acomp) reversible_9\JJ|to|stopped (l_prep) on_10\IN|NONE (l_pobj) cessation_11\NN|NONE (l_prep) of_12\IN|persisted (l_pobj) therapy_13\NN|NONE (l_conj) polyuria_15\NN|but
D014667_D011141 NONE vasopressin_21\NN|NONE (r_compound) secretion_22\NN|and|normal|osmoregulated (r_conj) thirst_19\NN|to|,|with|him (r_dobj) have_16\VB|NONE (r_ccomp) showed_13\VBD|.|thirsty|He (r_conj) remained_1\VBD|NONE (l_acomp) thirsty_2\JJ|.|showed|He (l_conj) polyuric_4\JJ|and
D014667_D018500 NONE vasopressin_21\NN|NONE (r_compound) secretion_22\NN|and|normal|osmoregulated (r_conj) thirst_19\NN|to|,|with|him (r_dobj) have_16\VB|NONE (l_prep) with_24\IN|to|thirst|,|him (l_pobj) evidence_26\NN|NONE (l_prep) of_27\IN|clear (l_pobj) insipidus_30\NN|NONE
3780697
D005283_D009127 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) after_4\IN|operative|. (r_prep) rigidity_3\NN|NONE
D005283_D009127 CID fentanyl_29\NN|NONE (r_pobj) of_28\IN|a|moderate (r_prep) dose_27\NN|who (r_dobj) received_24\VBD|elderly|an (r_relcl) patient_22\NN|NONE (r_pobj) in_19\IN|the|operative (r_prep) period_18\NN|NONE (r_pobj) in_13\IN|.|is|case (r_prep) described_12\VBN|NONE (l_nsubjpass) case_1\NN|.|is|in (l_prep) of_2\IN|A (l_pobj) rigidity_6\NN|NONE
D005283_D012131 NONE fentanyl_29\NN|NONE (r_pobj) of_28\IN|a|moderate (r_prep) dose_27\NN|who (r_dobj) received_24\VBD|elderly|an (r_relcl) patient_22\NN|NONE (r_pobj) in_19\IN|the|operative (r_prep) period_18\NN|NONE (r_pobj) in_13\IN|.|is|case (r_prep) described_12\VBN|NONE (l_nsubjpass) case_1\NN|.|is|in (l_prep) of_2\IN|A (l_pobj) rigidity_6\NN|NONE (l_acl) leading_7\VBG|abdominal (l_prep) to_8\IN|NONE (l_pobj) failure_10\NN|NONE
19203554
D013256_D010996 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|,|red (l_conj) titer_17\NN|chest|, (l_prep) of_18\IN|NONE (l_pobj) protein_22\NN|NONE (l_prep) of_25\IN|volume|and|reactive (l_pobj) effusions_28\NNS|NONE
D013256_D010996 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD|NONE (l_conj) increased_45\VBD|rose|,|,|we|resulted|therapy (l_conj) remained_56\VBD|count|,|,|and|to (l_nsubj) effusion_55\NN|.
D013256_D010996 NONE steroid_3\NN|NONE (r_compound) therapy_4\NN|month (r_pobj) after_2\IN|effusion|,|and|,|normalized (r_prep) disappeared_9\VBD|NONE (l_nsubj) effusion_8\NN|after|,|and|,|normalized
D012460_D005334 CID sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|Although|in (r_nsubj) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE
D012460_D005921 NONE sulphasalazine_10\JJ|NONE (r_compound) treatment_11\NN|NONE (r_dobj) restarting_9\VBG|NONE (r_pcomp) after_8\IN|cytoplasmic|glomerulonephritis|.|Proteinase|antineutrophil (r_prep) antibody-(PR3-ANCA_3\NNS|NONE (l_appos) glomerulonephritis_7\NN|cytoplasmic|after|.|Proteinase|antineutrophil
D012460_D005921 NONE sulphasalazine_4\NN|glomerulonephritis|that|can (r_nsubj) induce_6\VB|case|. (l_dobj) glomerulonephritis_11\NN|that|sulphasalazine|can
D012460_D002637 NONE sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|Although|in (r_nsubj) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|,|red
D013256_D005128 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|,
D012460_D004802 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|woman|eyes|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|after|. (l_conj) effusion_13\NN|,|red (l_conj) eosinophilia_15\NN|pleural|,
D012460_D003093 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|woman|eyes|. (r_prep) developed_8\VBD|NONE (l_nsubj) woman_4\NN|after|eyes|. (l_prep) with_5\IN|A|old (l_pobj) colitis_7\NN|NONE
D012460_D001745 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|woman|eyes|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|after|. (l_conj) effusion_13\NN|,|red (l_conj) eosinophilia_15\NN|pleural|, (l_conj) abnormalities_18\NNS|and
D012460_D005128 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|woman|eyes|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|after|.
D012460_D005128 NONE sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|Although|in (r_nsubj) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|,
D013256_D005334 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE
D012460_D010996 CID sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|woman|eyes|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|after|. (l_conj) effusion_13\NN|,|red
D012460_D010996 CID sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|Although|in (r_nsubj) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|,|red (l_conj) titer_17\NN|chest|, (l_prep) of_18\IN|NONE (l_pobj) protein_22\NN|NONE (l_prep) of_25\IN|volume|and|reactive (l_pobj) effusions_28\NNS|NONE
D012460_D010996 CID sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|Although|in (r_nsubj) resulted_5\VBD|rose|,|,|increased|we|therapy (r_advcl) initiated_31\VBD|NONE (l_conj) increased_45\VBD|rose|,|,|we|resulted|therapy (l_conj) remained_56\VBD|count|,|,|and|to (l_nsubj) effusion_55\NN|.
D013256_D002637 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|rose|,|,|increased|we|therapy (l_prep) in_6\IN|Although|cessation (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|,|red
12842176
D000431_D064420 NONE ethanol_35\NN|or (r_conj) PB_33\NNP|P|inducible (r_nmod) isoenzymes_38\NNS|NONE (r_pobj) by_32\IN|NONE (r_agent) formed_31\VBN|its (r_acl) metabolites_30\NNS|per|or (r_conj) lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (l_prep) in_41\IN|are|lindane|that (l_pobj) toxicity_44\NN|NONE
D001556_D064420 NONE lindane_7\NN|NONE (r_pobj) of_6\IN|Pmediated|the (r_prep) metabolism_5\NN|was|by|when (r_nsubjpass) blocked_9\VBN|was|indicating|Similarly|.|in|, (r_advcl) increased_17\VBN|NONE (l_advcl) indicating_23\VBG|blocked|was|Similarly|.|in|, (l_ccomp) involved_40\VBN|NONE (l_prep) in_41\IN|are|lindane|that (l_pobj) toxicity_44\NN|NONE
D001556_D064420 NONE lindane_22\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) treated_20\VBN|NONE (r_acl) animals_19\NNS|NONE (r_pobj) in_18\IN|blocked|was|indicating|Similarly|.|, (r_prep) increased_17\VBN|NONE (l_advcl) indicating_23\VBG|blocked|was|Similarly|.|in|, (l_ccomp) involved_40\VBN|NONE (l_prep) in_41\IN|are|lindane|that (l_pobj) toxicity_44\NN|NONE
D001556_D064420 NONE lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (l_prep) in_41\IN|are|lindane|that (l_pobj) toxicity_44\NN|NONE
D000431_D012640 NONE ethanol_46\NN|inducer|,|B/B|of|or|an (r_conj) inducer_41\NN|PB|,|)|( (r_appos) phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|that|produce
D000431_D012640 NONE ethanol_46\NN|inducer|,|B/B|of|or|an (r_conj) inducer_41\NN|PB|,|)|( (r_appos) phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|that|produce (r_dobj) induced_30\VBN|further|studies|have (r_ccomp) shown_4\VBN|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS|NONE
D000431_D012640 NONE ethanol_35\NN|or (r_conj) PB_33\NNP|P|inducible (r_nmod) isoenzymes_38\NNS|NONE (r_pobj) by_32\IN|NONE (r_agent) formed_31\VBN|its (r_acl) metabolites_30\NNS|per|or (r_conj) lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (r_ccomp) indicating_23\VBG|blocked|was|Similarly|.|in|, (r_advcl) increased_17\VBN|NONE (l_advcl) blocked_9\VBN|was|indicating|Similarly|.|in|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
C018021_D012640 NONE chloride_12\NN|of (r_compound) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D008748_D012640 NONE 3-methylcholanthrene_9\NN|MC (r_pobj) of_8\IN|inducer|, (r_prep) pretreatment_7\NN|,|not|did|effect|while (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|studies|have (l_dobj) convulsions_31\NNS|that|produce
D008748_D012640 NONE 3-methylcholanthrene_9\NN|MC (r_pobj) of_8\IN|inducer|, (r_prep) pretreatment_7\NN|,|not|did|effect|while (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|studies|have (r_ccomp) shown_4\VBN|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS|NONE
D008748_D012640 NONE MC_11\NNP|methylcholanthrene (r_pobj) of_8\IN|inducer|, (r_prep) pretreatment_7\NN|,|not|did|effect|while (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|studies|have (l_dobj) convulsions_31\NNS|that|produce
D008748_D012640 NONE MC_11\NNP|methylcholanthrene (r_pobj) of_8\IN|inducer|, (r_prep) pretreatment_7\NN|,|not|did|effect|while (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|studies|have (r_ccomp) shown_4\VBN|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS|NONE
D010634_D012640 NONE phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|that|produce
D010634_D012640 NONE phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|that|produce (r_dobj) induced_30\VBN|further|studies|have (r_ccomp) shown_4\VBN|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS|NONE
D001556_D020258 NONE lindane_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|influence|.|neurotoxicity (r_nsubj) induced_16\VBN|NONE (l_dobj) neurotoxicity_17\NN|Effect|influence|.
D001556_D020258 NONE lindane_15\NN|NONE (r_pobj) in_14\IN|P (r_prep) modulation_13\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) influence_10\NN|Effect|.|neurotoxicity (r_nsubj) induced_16\VBN|NONE (l_dobj) neurotoxicity_17\NN|Effect|influence|.
C018021_D064420 NONE chloride_12\NN|of (r_compound) incidence_13\NN|NONE (r_pobj) by_10\IN|was|when|metabolism (r_agent) blocked_9\VBN|was|indicating|Similarly|.|in|, (r_advcl) increased_17\VBN|NONE (l_advcl) indicating_23\VBG|blocked|was|Similarly|.|in|, (l_ccomp) involved_40\VBN|NONE (l_prep) in_41\IN|are|lindane|that (l_pobj) toxicity_44\NN|NONE
D001556_D012640 CID lindane_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) incidence_27\NN|NONE (r_pobj) in_25\IN|any|significant (r_prep) effect_24\NN|,|not|pretreatment|did|while (r_dobj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|studies|have (l_dobj) convulsions_31\NNS|that|produce
D001556_D012640 CID lindane_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) incidence_27\NN|NONE (r_pobj) in_25\IN|any|significant (r_prep) effect_24\NN|,|not|pretreatment|did|while (r_dobj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|studies|have (r_ccomp) shown_4\VBN|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS|NONE
D001556_D012640 CID lindane_61\NN|NONE (r_pobj) of_60\IN|the (r_prep) incidence_59\NN|significantly|shown|.|induced|, (r_dobj) increased_57\VBD|NONE (l_ccomp) shown_4\VBN|significantly|.|incidence|induced|, (l_ccomp) induced_30\VBN|further|studies|have (l_dobj) convulsions_31\NNS|that|produce
D001556_D012640 CID lindane_61\NN|NONE (r_pobj) of_60\IN|the (r_prep) incidence_59\NN|significantly|shown|.|induced|, (r_dobj) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS|NONE
D001556_D012640 CID lindane_7\NN|NONE (r_pobj) of_6\IN|Pmediated|the (r_prep) metabolism_5\NN|was|by|when (r_nsubjpass) blocked_9\VBN|was|indicating|Similarly|.|in|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D001556_D012640 CID lindane_22\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) treated_20\VBN|NONE (r_acl) animals_19\NNS|NONE (r_pobj) in_18\IN|blocked|was|indicating|Similarly|.|, (r_prep) increased_17\VBN|NONE (l_advcl) blocked_9\VBN|was|indicating|Similarly|.|in|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D001556_D012640 CID lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (r_ccomp) indicating_23\VBG|blocked|was|Similarly|.|in|, (r_advcl) increased_17\VBN|NONE (l_advcl) blocked_9\VBN|was|indicating|Similarly|.|in|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
6699841
D012459_D007681 NONE salicylates_22\NNS|fenoprofen|, (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man
D012459_D007681 NONE salicylates_22\NNS|fenoprofen|, (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D013467_D007681 NONE sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man
D013467_D007681 NONE sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D013467_D007681 NONE sulindac_15\NN|NONE (r_pobj) of_14\IN|possible (r_prep) advantages_13\NNS|NONE (r_dobj) discuss_11\VB|RPN|and|to (r_conj) linking_4\VBG|previous (l_dobj) RPN_5\NNP|and|to|discuss
D009288_D001172 NONE naproxen_39\NN|NONE (r_compound) therapy_40\NN|NONE (r_pobj) of_38\IN|NONE (r_prep) institution_37\NN|months (r_pobj) after_36\IN|necrosis|.|man (r_prep) developed_27\VBD|NONE (l_nsubj) man_4\NN|after|necrosis|. (l_prep) with_5\IN|,|A|old|treated|, (l_pobj) arthritis_7\NN|NONE
D006046_D001172 NONE gold_24\NN|NONE (r_compound) salts_25\NNS|and|high|dose (r_conj) salicylates_22\NNS|fenoprofen|, (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (l_prep) with_5\IN|,|A|old|treated|, (l_pobj) arthritis_7\NN|NONE
D005279_D001172 NONE calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (l_prep) with_5\IN|,|A|old|treated|, (l_pobj) arthritis_7\NN|NONE
D005279_D007681 NONE calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man
D005279_D007681 NONE calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D013467_D007674 NONE sulindac_15\NN|NONE (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_relcl) experienced_20\VBN|NONE (l_dobj) toxicity_22\NN|who|have
D009288_D007681 CID naproxen_5\NN|to (r_pobj) due_3\IN|Renal|.|papillary (r_prep) necrosis_2\NN|NONE
D009288_D007681 CID naproxen_39\NN|NONE (r_compound) therapy_40\NN|NONE (r_pobj) of_38\IN|NONE (r_prep) institution_37\NN|months (r_pobj) after_36\IN|necrosis|.|man (r_prep) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man
D009288_D007681 CID naproxen_39\NN|NONE (r_compound) therapy_40\NN|NONE (r_pobj) of_38\IN|NONE (r_prep) institution_37\NN|months (r_pobj) after_36\IN|necrosis|.|man (r_prep) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D006046_D007681 NONE gold_24\NN|NONE (r_compound) salts_25\NNS|and|high|dose (r_conj) salicylates_22\NNS|fenoprofen|, (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man
D006046_D007681 NONE gold_24\NN|NONE (r_compound) salts_25\NNS|and|high|dose (r_conj) salicylates_22\NNS|fenoprofen|, (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|after|.|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D013467_D001172 NONE sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (l_prep) with_5\IN|,|A|old|treated|, (l_pobj) arthritis_7\NN|NONE
D012459_D001172 NONE salicylates_22\NNS|fenoprofen|, (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|had|been|who|previously (r_prep) treated_13\VBN|with|,|A|old|, (r_relcl) man_4\NN|after|necrosis|. (l_prep) with_5\IN|,|A|old|treated|, (l_pobj) arthritis_7\NN|NONE
1545575
D015080_D006470 NONE mesna_19\NN|NONE (r_pobj) with_18\IN|,|a|of|feasibility|neutralizes (r_prep) trial_15\NN|,|.|we|In (l_relcl) neutralizes_22\VBZ|,|a|of|with|feasibility (l_dobj) metabolite_25\NN|which (l_relcl) causes_29\VBZ|hepatic|of|the (l_dobj) cystitis_31\NN|that
D015080_D006470 NONE mesna_10\JJ|NONE (r_amod) uroprophylaxis_11\NNS|who|before (r_dobj) received_9\VBD|consecutive|four (r_relcl) patients_7\NNS|,|In|cystitis|.|for (r_nsubj) had_17\VBD|NONE (l_dobj) cystitis_20\NN|,|In|patients|.|for
D003520_D006470 CID cyclophosphamide_11\NN|administered|dose (r_compound) therapy_12\NN|NONE (r_pobj) of_7\IN|serious|a (r_prep) complication_6\NN|cystitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|complication|.
D003520_D006470 CID cyclophosphamide_27\NN|NONE (r_pobj) of_26\IN|causes|hepatic|the (r_prep) metabolite_25\NN|which (l_relcl) causes_29\VBZ|hepatic|of|the (l_dobj) cystitis_31\NN|that
D015080_D003556 NONE mesna_19\NN|NONE (r_pobj) with_18\IN|,|a|of|feasibility|neutralizes (r_prep) trial_15\NN|,|.|we|In (l_relcl) neutralizes_22\VBZ|,|a|of|with|feasibility (l_dobj) metabolite_25\NN|which (l_relcl) causes_29\VBZ|hepatic|of|the (l_dobj) cystitis_31\NN|that
D015080_D003556 NONE mesna_10\JJ|NONE (r_amod) uroprophylaxis_11\NNS|who|before (r_dobj) received_9\VBD|consecutive|four (r_relcl) patients_7\NNS|,|In|cystitis|.|for (r_nsubj) had_17\VBD|NONE (l_dobj) cystitis_20\NN|,|In|patients|.|for
D003520_D003556 CID cyclophosphamide_11\NN|administered|dose (r_compound) therapy_12\NN|NONE (r_pobj) of_7\IN|serious|a (r_prep) complication_6\NN|cystitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|complication|.
D003520_D003556 CID cyclophosphamide_27\NN|NONE (r_pobj) of_26\IN|causes|hepatic|the (r_prep) metabolite_25\NN|which (l_relcl) causes_29\VBZ|hepatic|of|the (l_dobj) cystitis_31\NN|that
12452237
D008012_D063806 NONE lidocaine_9\JJ|on (r_compound) pretreatment_10\NN|NONE (l_prep) on_11\IN|lidocaine (l_pobj) reduction_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) myalgia_17\NN|NONE
D013390_D010149 CID succinylcholine_3\NN|?|Can|lidocaine|induced (r_dobj) reduce_2\VB|NONE (l_conj) induced_4\VBD|succinylcholine|?|Can|lidocaine (l_dobj) myalgia_6\NN|NONE
D013390_D010149 CID succinylcholine_4\NN|where|is (r_nsubjpass) used_6\VBN|be|lidocaine|is|,|,|In|. (r_advcl) proven_10\VBN|NONE (l_xcomp) be_12\VB|lidocaine|used|is|,|,|In|. (l_attr) agent_16\NN|to (l_prep) for_17\IN|useful|pretreatment|the (l_pobj) reduction_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) myalgia_22\NN|NONE
D008012_D010149 NONE lidocaine_1\RB|succinylcholine|?|Can|induced (r_nsubj) reduce_2\VB|NONE (l_conj) induced_4\VBD|succinylcholine|?|Can|lidocaine (l_dobj) myalgia_6\NN|NONE
D008012_D010149 NONE lidocaine_8\NN|be|used|is|,|,|In|. (r_nsubjpass) proven_10\VBN|NONE (l_xcomp) be_12\VB|lidocaine|used|is|,|,|In|. (l_attr) agent_16\NN|to (l_prep) for_17\IN|useful|pretreatment|the (l_pobj) reduction_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) myalgia_22\NN|NONE
D013390_D063806 NONE succinylcholine_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) myalgia_17\NN|NONE
16826348
D003561_D010523 CID arabinoside_8\NN|in|dose|cytosine (r_amod) treatment_9\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|.|Peripheral (r_acl) neuropathy_1\NNS|NONE
D003561_D010523 CID arabinoside_14\NN|therapy|,|play|and|are|, (r_nsubj) is_15\VBZ|NONE (l_advcl) are_6\VBP|therapy|,|arabinoside|play|and|, (l_nsubj) mechanisms_2\NNS|Although|unclear|still (l_prep) of_3\IN|the (l_pobj) neuropathy_5\NN|NONE
D003561_D015470 NONE arabinoside_8\NN|in|dose|cytosine (r_amod) treatment_9\NN|NONE (l_prep) in_10\IN|arabinoside|dose|cytosine (l_pobj) patient_12\NN|NONE (l_prep) with_13\IN|a (l_pobj) leukemia_16\NN|NONE
D003561_D006987 NONE arabinoside_8\NN|NONE (r_pobj) of_3\IN|first|The (r_prep) course_2\NN|but|,|in|complained (r_nsubj) resulted_9\VBD|NONE (l_conj) complained_28\VBD|course|but|,|in (l_prep) of_29\IN|.|on|patient|in|, (l_pobj) numbness_30\NN|NONE
D008775_D006086 NONE methylprednisolone_38\NN|NONE (r_pobj) to_37\IN|subsequently|symptoms|. (r_prep) responded_36\VBD|received|and|,|symptoms|with|,|, (r_conj) worsened_19\VBD|NONE (l_prep) with_21\IN|responded|received|and|,|symptoms|,|, (l_pobj) development_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) disease_30\NN|NONE
D003561_D064420 NONE arabinoside_10\NN|NONE (r_pobj) of_5\IN|The|system|central (r_prep) toxicity_4\NN|but|is|well|,|reported
D003561_D064420 NONE arabinoside_10\NN|NONE (r_pobj) of_5\IN|The|system|central (r_prep) toxicity_4\NN|but|is|well|,|reported (r_nsubjpass) recognized_13\VBN|NONE (l_conj) reported_29\VBN|but|toxicity|is|well|, (l_nsubjpass) toxicity_17\NN|has|infrequently|been|.
D003561_D064420 NONE arabinoside_20\NN|NONE (r_pobj) of_18\IN|the (r_prep) toxicity_17\NN|has|infrequently|been|. (r_nsubjpass) reported_29\VBN|but|toxicity|is|well|, (r_conj) recognized_13\VBN|NONE (l_nsubjpass) toxicity_4\NN|but|is|well|,|reported
D003561_D064420 NONE arabinoside_20\NN|NONE (r_pobj) of_18\IN|the (r_prep) toxicity_17\NN|has|infrequently|been|.
D008775_D009422 NONE methylprednisolone_38\NN|NONE (r_pobj) to_37\IN|subsequently|symptoms|. (r_prep) responded_36\VBD|received|and|,|symptoms|with|,|, (r_conj) worsened_19\VBD|NONE (l_ccomp) received_11\VBD|responded|and|,|symptoms|with|,|, (l_ccomp) resolving_4\VBG|;|after|transplantation|patient|,|however (l_nsubj) neuropathy_1\NN|was|gradually
3123611
D003276_D002819 CID contraception_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Chorea_0\NNP|NONE
D003276_D002819 CID contraceptives_7\NNS|while (r_dobj) receiving_5\VBG|.|patients|chorea (r_advcl) developed_2\VBD|NONE (l_dobj) chorea_3\NN|receiving|.|patients
D003276_D002819 CID contraception_12\NN|NONE (r_pobj) after_9\IN|chorea|patient|. (r_prep) had_3\VBD|NONE (l_dobj) chorea_8\NN|after|patient|.
D000661_D002819 CID amphetamine_5\NN| (r_npadvmod) induced_7\VBN|acute (r_amod) chorea_8\NN|after|patient|.
10411803
D015313_D000743 CID cefotetan_9\NN|NONE (r_pobj) of_8\IN|prophylactic|in (r_prep) use_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|.|immune|Severe|hemolytic (r_acl) anemia_3\NN|NONE
D015313_D000743 CID cefotetan_8\JJ|generation|,|, (r_appos) cephalosporins_5\NNS|and (r_conj) Second-_0\NNP|are|.|with|increasingly (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|Second|are|.|increasingly (l_pobj) anemia_20\NN|NONE
D015313_D000743 CID cefotetan_9\NN| (r_npadvmod) induced_11\VBN|hemolytic (r_amod) anemias_13\NNS|NONE
D015313_D000743 CID cefotetan_20\JJ|had|who|for|prophylactically (r_dobj) received_19\VBN|NONE (r_relcl) patients_16\NNS|NONE (r_pobj) in_15\IN|that| (r_prep) were_14\VBD|We|. (l_nsubj) 10_3\CD|in|that (l_prep) of_4\IN|NONE (l_pobj) cases_7\NNS|NONE (l_prep) of_8\IN|our| (l_pobj) anemias_13\NNS|NONE
D002511_D000743 NONE cephalosporins_5\NNS|and (r_conj) Second-_0\NNP|are|.|with|increasingly (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|Second|are|.|increasingly (l_pobj) anemia_20\NN|NONE
16596970
D010862_D012640 NONE Pilocarpine_0\NNP|NONE (r_amod) seizures_1\NNS|.|impairment
D010862_D012640 NONE Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|.|epilepticus|;|had|,|in (r_ccomp) resulted_12\VBD|NONE (l_prep) in_13\IN|.|epilepticus|;|had|,|induced (l_pobj) loss_16\NN|NONE (l_conj) seizures_19\NNS|CA|cell|and
D010862_D012640 NONE Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|.|epilepticus|;|had|,|in (r_ccomp) resulted_12\VBD|NONE (l_advcl) had_24\VBD|.|epilepticus|;|,|induced|in (l_dobj) loss_27\NN|whereas|rats (l_conj) seizures_30\NNS|or|cell|no
D010862_D001308 CID Pilocarpine_0\NNP|NONE (r_amod) seizures_1\NNS|.|impairment (r_nsubj) cause_2\IN|NONE (l_dobj) impairment_6\NN|seizures|. (l_prep) in_7\IN|dependent (l_pobj) discrimination_10\NN|NONE
D010862_D013226 CID Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|.|epilepticus|;|had|,|in (l_advmod) epilepticus_6\NN|Pilocarpine|status
D010862_D013226 CID Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|.|epilepticus|;|had|,|in (r_ccomp) resulted_12\VBD|NONE (l_nsubj) epilepticus_9\NN|.|;|had|,|induced|in
2576810
D009627_D006948 CID nomifensine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) hyperactivity_1\NN|.|unaffected
D016666_D006948 CID fluvoxamine_4\NNP|NONE (r_pobj) with_3\IN|(|daily|)|A|repeated (r_prep) treatment_2\NN|.|hyperactivity|in|weaker (r_nsubj) potentiated_12\VBN|NONE (l_dobj) hyperactivity_25\NN|.|in|treatment|weaker
D016666_D006948 CID fluvoxamine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_prep) unaffected_8\JJ|.|hyperactivity (r_acomp) remained_7\VBD|NONE (l_nsubj) hyperactivity_1\NN|.|unaffected
D000661_D006948 CID amphetamine_22\NN| (r_npadvmod) induced_24\VBN|the (r_amod) hyperactivity_25\NN|.|in|treatment|weaker
12091028
D003975_D006212 NONE Diazepam_0\NNP|drug|.|,|contraindicated|, (r_nsubj) remains_7\VBZ|NONE (l_attr) drug_12\NN|.|,|contraindicated|,|Diazepam (l_relcl) ketamine_14\NN|only|necessary|the|complementary (l_advcl) buffers_17\VBZ|to (l_conj) decreases_22\VBZ|and|as|it|response (l_dobj) duration_24\NN|NONE (l_prep) of_27\IN|intensity|the|and (l_pobj) hallucinations_31\NNS|NONE
D007649_D006212 CID ketamine_14\NN|only|necessary|the|complementary (l_advcl) buffers_17\VBZ|to (l_conj) decreases_22\VBZ|and|as|it|response (l_dobj) duration_24\NN|NONE (l_prep) of_27\IN|intensity|the|and (l_pobj) hallucinations_31\NNS|NONE
11245434
D016190_D000740 CID carboplatin_8\NN|NONE (r_pobj) of_7\IN|resulting|i.v.|)|single|a (r_prep) dose_6\NN|NONE (r_dobj) using_3\VBG|.|was|Anemia (r_xcomp) induced_2\VBN|NONE (l_nsubjpass) Anemia_0\NN|.|was|using
D016190_D000740 CID carboplatin_29\NN|NONE (r_amod) application_30\NN|NONE (r_pobj) before_28\IN| (r_prep) days_27\NNS|NONE (r_dobj) starting_25\VBG|week|s.c. (r_advcl) administered_19\VBN|by|.|development|In|was|, (r_conj) prevented_10\VBN|NONE (l_nsubjpass) development_6\NN|by|.|In|administered|was|, (l_prep) of_7\IN|the (l_pobj) anemia_8\NN|NONE
D003520_D064420 NONE cyclophosphamide_8\NN|in (r_compound) cytotoxicity_9\NN|NONE
D003520_D064420 NONE cyclophosphamide_25\NN|NONE (r_pobj) of_24\IN|the|in (r_prep) cytotoxicity_23\NN|NONE
D003520_D064420 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|anemia|increases|,
D010100_D064420 NONE oxygen_37\NN|to|an|improved (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|anemia|, (r_advcl) reduces_8\VBZ|results|. (l_dobj) cytotoxicity_9\NN|that|anemia|increases|,
D016190_D009369 NONE carboplatin_3\NN|NONE (r_amod) treatment_4\NN|days (r_pobj) after_2\IN|tumors|.|s.c.|,|onto|were (r_prep) implanted_16\VBN|NONE (l_nsubjpass) tumors_6\NNS|.|s.c.|,|after|onto|were
D016190_D009369 NONE carboplatin_1\NN|NONE (l_conj) influenced_5\VBN|.|treatment|Neither|nor (l_dobj) rate_8\NN|se (l_compound) tumor_6\NN|growth
D010100_D000740 NONE oxygen_37\NN|to|an|improved (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|anemia|, (r_advcl) reduces_8\VBZ|results|. (l_nsubj) anemia_7\NN|cytotoxicity|that|increases|,
D010100_D000740 NONE oxygen_37\NN|to|an|improved (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|anemia|, (l_nsubj) correction_16\NN|,|as|sensitivity|whereas (l_prep) of_17\IN|by (l_pobj) anemia_18\NN|NONE
D010100_D009369 NONE oxygen_37\NN|to|an|improved (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|anemia|, (r_advcl) reduces_8\VBZ|results|. (l_dobj) cytotoxicity_9\NN|that|anemia|increases|, (l_prep) in_12\IN|of (l_pobj) tumors_13\NNS|NONE
D010100_D009369 NONE oxygen_37\NN|to|an|improved (r_compound) supply_38\NN|NONE (l_prep) to_39\IN|oxygen|an|improved (l_pobj) tissue_41\NN|NONE (l_compound) tumor_40\NN|NONE
D016190_D012509 NONE carboplatin_3\NN|NONE (r_amod) treatment_4\NN|days (r_pobj) after_2\IN|tumors|.|s.c.|,|onto|were (r_prep) implanted_16\VBN|NONE (l_nsubjpass) tumors_6\NNS|.|s.c.|,|after|onto|were (l_appos) sarcoma_10\NN|)|(
D003520_D009369 NONE cyclophosphamide_8\NN|in (r_compound) cytotoxicity_9\NN|NONE (l_prep) in_10\IN|cyclophosphamide (l_pobj) tumors_12\NNS|NONE
D003520_D009369 NONE cyclophosphamide_25\NN|NONE (r_pobj) of_24\IN|the|in (r_prep) cytotoxicity_23\NN|NONE (l_prep) in_26\IN|of|the (l_pobj) tumors_29\NNS|NONE
D003520_D009369 NONE cyclophosphamide_9\NN|NONE (r_pobj) of_8\IN|a|single|(|mg/kg|) (r_prep) dose_7\NN|NONE (r_pobj) with_4\IN|after|were|When|tumors (r_prep) treated_3\VBN|delay|was|,|. (l_nsubjpass) tumors_1\NNS|after|with|were|When
D003520_D009369 NONE cyclophosphamide_9\NN|NONE (r_pobj) of_8\IN|a|single|(|mg/kg|) (r_prep) dose_7\NN|NONE (r_pobj) with_4\IN|after|were|When|tumors (r_prep) treated_3\VBN|delay|was|,|. (r_advcl) observed_31\VBN|NONE (l_nsubjpass) delay_22\NN|treated|was|,|. (l_prep) with_23\IN|a|growth (l_pobj) regrowth_26\NN|NONE (l_prep) of_27\IN|a|subsequent (l_pobj) tumors_29\NNS|NONE
D003520_D009369 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|anemia|increases|, (l_prep) in_12\IN|of (l_pobj) tumors_13\NNS|NONE
D003520_D009369 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|anemia|increases|, (r_dobj) reduces_8\VBZ|results|. (l_advcl) increases_26\VBZ|cytotoxicity|that|anemia|, (l_prep) as_31\IN|,|correction|sensitivity|whereas (l_pobj) result_33\NN|probably (l_prep) of_34\IN|a (l_pobj) supply_38\NN|NONE (l_prep) to_39\IN|oxygen|an|improved (l_pobj) tissue_41\NN|NONE (l_compound) tumor_40\NN|NONE
D003520_D000740 NONE cyclophosphamide_8\NN|in (r_compound) cytotoxicity_9\NN|NONE (r_pobj) in_7\IN|induced|the (r_prep) reduction_6\NN|Erythropoietin|. (l_amod) induced_5\VBN|in|the (l_npadvmod) anemia_3\NN|
D003520_D000740 NONE cyclophosphamide_25\NN|NONE (r_pobj) of_24\IN|the|in (r_prep) cytotoxicity_23\NN|NONE (r_pobj) on_21\IN|)|rHuEPO|erythropoietin|( (r_prep) treatment_20\NN|NONE (r_pobj) by_13\IN|the|of (r_prep) impact_9\NN|to (l_prep) of_10\IN|the|by (l_pobj) prevention_12\NN|NONE (l_compound) anemia_11\NN|NONE
D003520_D000740 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|anemia|increases|, (r_dobj) reduces_8\VBZ|results|. (l_nsubj) anemia_7\NN|cytotoxicity|that|increases|,
D003520_D000740 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|anemia|increases|, (r_dobj) reduces_8\VBZ|results|. (l_advcl) increases_26\VBZ|cytotoxicity|that|anemia|, (l_nsubj) correction_16\NN|,|as|sensitivity|whereas (l_prep) of_17\IN|by (l_pobj) anemia_18\NN|NONE
6203632
D007545_D006332 CID isoproterenol_2\NN| (r_npadvmod) induced_4\VBN|cardiac (r_amod) hypertrophy_6\NN|NONE
D007545_D006332 CID isoproterenol_17\NN|NONE (r_pobj) of_16\IN|)|ISO|subcutaneous|daily|(|weight (r_prep) injections_15\NNS|NONE (r_pobj) following_12\VBG|in|development|.|was (r_prep) studied_6\VBN|NONE (l_nsubjpass) development_1\NN|in|.|was|following (l_prep) of_2\IN|The (l_pobj) hypertrophy_4\NN|NONE
D007545_D006332 CID ISO_19\NN|)|subcutaneous|daily|(|weight|of (r_appos) injections_15\NNS|NONE (r_pobj) following_12\VBG|in|development|.|was (r_prep) studied_6\VBN|NONE (l_nsubjpass) development_1\NN|in|.|was|following (l_prep) of_2\IN|The (l_pobj) hypertrophy_4\NN|NONE
D007545_D006984 NONE ISO_8\NN|NONE (r_pobj) to_7\IN|adaptive|the (r_prep) response_6\NN|that|phase (r_nsubj) shows_9\VBZ|.|data (l_dobj) phase_13\NN|response|that (l_amod) hypertrophic_12\JJ|early|(|characterized|)|days|an
8607407
D002110_D006973 CID caffeine_5\NN|NONE (r_pobj) with_4\IN|.|pressure|Acute|in (r_prep) elevations_3\NNS|NONE (l_prep) in_6\IN|.|pressure|Acute|with (l_pobj) men_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) hypertension_11\NN|NONE
D002110_D006973 CID caffeine_5\NN|NONE (r_pobj) of_4\IN|the|vasoconstrictive (r_prep) actions_3\NNS|Whether|in|are (r_nsubjpass) enhanced_7\VBN|.|has|not|been (l_prep) in_8\IN|actions|Whether|are (l_pobj) persons_10\NNS|NONE (l_amod) hypertensive_9\JJ|NONE
D002110_D006973 CID caffeine_24\NN|NONE (r_compound) ingestion_25\NN|NONE (r_pobj) after_23\IN|.|levels|,|Consequently|%|,|exhibited (r_prep) achieved_19\VBD|NONE (l_dobj) levels_22\NNS|.|,|Consequently|after|%|,|exhibited (l_amod) hypertensive_20\JJ|BP
D002110_D006973 CID caffeine_10\NN|NONE (r_pobj) to_9\IN|exaggerated (r_prep) responses_8\NNS|selective|,|:|.|replicated|Thus|,|consistent|in|, (r_nsubj) were_11\VBD|NONE (l_prep) in_2\IN|responses|selective|,|:|.|replicated|Thus|,|consistent|, (l_pobj) men_5\NNS|NONE (l_amod) hypertensive_4\JJ|borderline
D002110_D006973 CID caffeine_10\NN|NONE (r_pobj) to_9\IN|exaggerated (r_prep) responses_8\NNS|selective|,|:|.|replicated|Thus|,|consistent|in|, (r_nsubj) were_11\VBD|NONE (l_advcl) replicated_23\VBN|responses|selective|,|:|.|Thus|,|consistent|in|, (l_conj) representative_29\NN|and|,|in (l_prep) of_30\IN|NONE (l_pobj) hypertensives_34\NNS|NONE
8473723
D016666_D012640 CID fluvoxamine_6\NN|combined (r_compound) treatment_7\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
D016666_D012640 CID fluvoxamine_8\NN|combined|induced (r_nmod) seizures_12\NNS|NONE
D008728_D012640 CID levomepromazine_4\JJ| (r_amod) fluvoxamine_6\NN|combined (r_compound) treatment_7\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
D008728_D012640 CID levomepromazine_6\JJ| (r_amod) fluvoxamine_8\NN|combined|induced (r_nmod) seizures_12\NNS|NONE
17194457
D012701_D001523 NONE 5-HT_16\CD|NONE (r_pobj) with_13\IN|AAS|pubertal (r_prep) users_12\NNS|prone|that|may (r_nsubj) be_18\VB|,|can|it|.|be|Based (l_acomp) prone_20\JJ|that|users|may (l_xcomp) exhibit_22\VB|especially (l_dobj) behavior_24\NN|to
D013739_D001523 CID T_0\NNP|effect|but|.|preference (r_nsubj) had_2\VBD|NONE (l_dobj) effect_4\NN|but|.|T|preference (l_prep) on_5\IN|no (l_pobj) locomotion_6\NN|NONE (l_conj) irritability_8\NN|,
D013739_D001523 CID T_0\NNP|effect|but|.|preference (r_nsubj) had_2\VBD|NONE (l_conj) preference_16\NN|effect|but|.|T (l_conj) aggression_18\NN|and|partner|increased
-1_D001523 NONE PCPA_3\NNP|NONE (r_pobj) to_2\IN|alone|Chronic (r_prep) exposure_1\NN|had|and|activity|.|significantly|but|increased (r_nsubj) decreased_6\VBD|NONE (l_conj) increased_10\VBN|had|and|activity|.|significantly|but|exposure (l_dobj) irritability_11\NN|NONE
-1_D001523 NONE PCPA_3\NNP|NONE (r_pobj) to_2\IN|alone|Chronic (r_prep) exposure_1\NN|had|and|activity|.|significantly|but|increased (r_nsubj) decreased_6\VBD|NONE (l_conj) had_13\VBD|and|activity|.|significantly|but|exposure|increased (l_dobj) effect_15\NN|NONE (l_prep) on_16\IN|no (l_pobj) behavior_18\NN|NONE (l_conj) preference_21\NN|,|sexual (l_conj) aggression_24\NN|or|,|partner
20394767
C015068_D012021 CID mCPP_12\NNS|,|suppressed|yohimbine|,|startle|Furthermore (r_advcl) increased_3\VBN|NONE (l_dobj) startle_5\NN|,|mCPP|suppressed|yohimbine|,|Furthermore
C015068_D012021 CID mCPP_12\NNS|,|suppressed|yohimbine|,|startle|Furthermore (r_advcl) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|,|mCPP|yohimbine|,|startle|Furthermore (l_dobj) startle_15\NN|and|suppressed
C015068_D012021 CID mCPP_12\NNS|,|suppressed|yohimbine|,|startle|Furthermore (r_advcl) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|,|mCPP|yohimbine|,|startle|Furthermore (l_conj) suppressed_24\VBD|and|startle (l_dobj) startle_26\NN|PTZ|.
D015016_D012021 CID yohimbine_2\NN|,|mCPP|suppressed|,|startle|Furthermore (r_nsubj) increased_3\VBN|NONE (l_dobj) startle_5\NN|,|mCPP|suppressed|yohimbine|,|Furthermore
D015016_D012021 CID yohimbine_2\NN|,|mCPP|suppressed|,|startle|Furthermore (r_nsubj) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|,|mCPP|yohimbine|,|startle|Furthermore (l_dobj) startle_15\NN|and|suppressed
D015016_D012021 CID yohimbine_2\NN|,|mCPP|suppressed|,|startle|Furthermore (r_nsubj) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|,|mCPP|yohimbine|,|startle|Furthermore (l_conj) suppressed_24\VBD|and|startle (l_dobj) startle_26\NN|PTZ|.
D010433_D012021 CID PTZ_23\NNP|startle|. (r_nsubj) suppressed_24\VBD|and|startle (r_conj) suppressed_13\VBD|,|mCPP|yohimbine|,|startle|Furthermore (r_conj) increased_3\VBN|NONE (l_dobj) startle_5\NN|,|mCPP|suppressed|yohimbine|,|Furthermore
D010433_D012021 CID PTZ_23\NNP|startle|. (r_nsubj) suppressed_24\VBD|and|startle (r_conj) suppressed_13\VBD|,|mCPP|yohimbine|,|startle|Furthermore (l_dobj) startle_15\NN|and|suppressed
D010433_D012021 CID PTZ_23\NNP|startle|. (r_nsubj) suppressed_24\VBD|and|startle (l_dobj) startle_26\NN|PTZ|.
9228650
D012601_D000647 CID scopolamine_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) amnesia_9\NN|and
D012601_D000647 CID scopolamine_7\NN| (r_npadvmod) induced_9\VBN|and|movement (r_amod) amnesia_10\NN|,|effects|and|compared|.|were
D012601_D000647 CID scopolamine_14\NN|NONE (r_pobj) by_13\IN|in (r_agent) induced_12\VBN|the (r_acl) amnesia_11\NN|.|significantly|p.o.|compounds
D012601_D000647 CID scopolamine_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) amnesia_20\NN|but|affect|NIK|that
C049860_D000647 CID NIK-247_2\NNP|NONE (l_prep) on_3\IN|NONE (l_pobj) cholinesterase_4\NN|NONE (l_conj) amnesia_9\NN|and
C049860_D000647 CID NIK-247_3\NNP|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|,|and|compared|.|were|amnesia (r_nsubjpass) examined_15\VBN|NONE (l_nsubjpass) amnesia_10\NN|,|effects|and|compared|.|were
C049860_D000647 CID NIK-247_4\NNP|but|affect|that|amnesia (r_nsubj) improves_16\VBZ|.|findings (l_dobj) amnesia_20\NN|but|affect|NIK|that
C076946_D000647 CID E-2020_29\NNS|and (r_conj) tacrine_27\NN|the|cholinesterase|known (r_appos) inhibitors_26\NNS|NONE (r_pobj) of_20\IN|NONE (r_prep) those_19\DT|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|,|effects|and|.|were|amnesia (r_conj) examined_15\VBN|NONE (l_nsubjpass) amnesia_10\NN|,|effects|and|compared|.|were
C049860_D000544 NONE NIK-247_4\NNP|may|that|drug (r_nsubj) be_6\VB|findings|. (l_attr) drug_9\NN|may|NIK|that (l_prep) for_10\IN|useful|a (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) disease_16\NN|NONE
D013619_D000647 CID tacrine_27\NN|the|cholinesterase|known (r_appos) inhibitors_26\NNS|NONE (r_pobj) of_20\IN|NONE (r_prep) those_19\DT|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|,|effects|and|.|were|amnesia (r_conj) examined_15\VBN|NONE (l_nsubjpass) amnesia_10\NN|,|effects|and|compared|.|were
17702969
D005473_D006976 CID fluoxetine_3\NN|to|hypertension (r_advmod) induces_4\VBZ|.|Prenatal (l_dobj) hypertension_7\NN|to|fluoxetine
D005473_D006976 CID fluoxetine_4\NN|NONE (r_amod) exposure_5\NN|prevalence|prenatally|that (r_nsubj) increases_7\VBZ|.|data (l_dobj) prevalence_9\NN|exposure|prenatally|that (l_prep) of_10\IN|the (l_pobj) syndrome_14\NN|NONE
D005473_D006976 CID fluoxetine_20\NN|protective|in (r_amod) effect_21\NN|the|of|current (r_appos) evidence_14\NN|NONE (l_prep) of_15\IN|effect|the|current (l_pobj) hypertension_18\NN|NONE
D005473_D006976 CID fluoxetine_5\NN|NONE (r_amod) exposure_6\NN|,|compared|.|in|and|evidenced|by (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|,|exposure|compared|.|and|evidenced|by (l_pobj) hypertension_11\NN|NONE
D005473_D006976 CID fluoxetine_6\NN|in (r_amod) exposure_7\NN|hypertension|as|.|In|, (r_nsubj) induces_10\VBZ|NONE (l_dobj) hypertension_12\NN|exposure|as|.|In|,
D005473_D005315 CID fluoxetine_3\NN|to|hypertension (r_advmod) induces_4\VBZ|.|Prenatal (l_dobj) hypertension_7\NN|to|fluoxetine
D005473_D005315 CID fluoxetine_5\NN|NONE (r_amod) exposure_6\NN|,|compared|.|in|and|evidenced|by (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|,|exposure|compared|.|and|evidenced|by (l_pobj) hypertension_11\NN|NONE
17490790
D007501_D009410 NONE iron_6\NN|peripheral|loss|and (r_compound) overload_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relationship_3\NN|To (r_dobj) demonstrate_1\VB|,|in|we|voltammetry|. (r_advcl) used_25\VBD|NONE (l_dobj) voltammetry_28\NN|,|in|we|.|demonstrate (l_conj) immunohistochemistry_35\NN|fast|cyclic|, (l_conj) staining_40\NN|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN|Perls|,|and|iron|content (l_acl) study_51\VB|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_39\NN|Perls|,|detection|and|content (r_compound) staining_40\NN|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN|Perls|,|and|iron|content (l_acl) study_51\VB|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_59\NN|in|increased (r_compound) content_60\NN|Perls|,|detection|and|iron (r_conj) staining_40\NN|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN|Perls|,|and|iron|content (l_acl) study_51\VB|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_10\NN|in|causes|the|, (r_compound) level_11\NN|dextran|that|can (l_relcl) causes_19\VBZ|in|the|iron|, (l_dobj) degeneration_21\NN|iron|where (l_prep) of_22\IN|the (l_pobj) neurons_24\NNS|NONE
D007501_D009410 NONE iron_18\NN|degeneration|where (r_nsubj) causes_19\VBZ|in|the|iron|, (l_dobj) degeneration_21\NN|iron|where (l_prep) of_22\IN|the (l_pobj) neurons_24\NNS|NONE
D014443_D009410 NONE tyrosine_30\NN|(|hydroxylase|TH|,|staining|) (r_det) immunohistochemistry_35\NN|fast|cyclic|, (l_conj) staining_40\NN|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN|Perls|,|and|iron|content (l_acl) study_51\VB|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D010300 NONE Iron_0\NN|NONE (r_compound) accumulation_1\NN|involved|.|is (r_nsubjpass) considered_3\VBN|NONE (l_xcomp) involved_6\VBN|accumulation|.|is (l_prep) in_7\IN|to|be (l_pobj) pathogenesis_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) disease_13\NN|NONE
D007505_D009410 CID dextran_2\NN|.|degeneration (r_nsubj) induced_3\VBD|NONE (l_dobj) degeneration_4\NN|.|dextran (l_prep) of_5\IN|NONE (l_pobj) neurons_7\NNS|NONE
D007505_D009410 CID dextran_66\NN|overloaded|iron (r_amod) animals_68\NNS|NONE (r_pobj) of_64\IN|the (r_prep) SN_63\NN|NONE (r_pobj) in_61\IN|increased|iron (r_prep) content_60\NN|Perls|,|detection|and|iron (r_conj) staining_40\NN|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN|Perls|,|and|iron|content (l_acl) study_51\VB|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007505_D009410 CID dextran_6\NN|level|that|can (r_nsubj) increase_8\VB|results|. (l_dobj) level_11\NN|dextran|that|can (l_relcl) causes_19\VBZ|in|the|iron|, (l_dobj) degeneration_21\NN|iron|where (l_prep) of_22\IN|the (l_pobj) neurons_24\NNS|NONE
11752998
D002211_D004342 NONE capsaicin_27\NN| (r_npadvmod) evoked_29\VBN|mechanical (r_amod) hypersensitivity_31\NN|noxious|and|acute|both
D002211_D004342 NONE capsaicin_20\NN|peripheral (r_compound) injection_21\NN|NONE (r_pobj) after_18\IN|sensitization|to (r_prep) reflect_13\VB|NONE (r_xcomp) presumed_11\VBN|,|inhibition|.|results (r_advcl) show_2\VBP|NONE (l_dobj) inhibition_4\NN|,|presumed|.|results (l_prep) by_5\IN|selective (l_pobj) adenosine_7\NN|NONE (l_prep) of_8\IN|intrathecal (l_pobj) hypersensitivity_9\NN|NONE
D002211_D010146 NONE capsaicin_82\NN|intradermal (r_compound) injection_83\NN|NONE (r_pobj) after_80\IN|areas|and|heat|acute (r_prep) stimuli_72\NNS|NONE (r_pobj) to_69\IN|NONE (r_prep) response_68\NN|NONE (r_pobj) in_67\IN|pain (r_prep) ratings_66\NNS|were|. (l_compound) pain_65\NN|in
D002211_D010146 NONE capsaicin_22\NN|intradermal (r_compound) injection_23\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) allodynia_19\NN|mechanical|for|reduced|and (r_conj) hyperalgesia_17\NN|but|acute|noxious|thermal (r_conj) stimulation_13\NN|NONE (r_pobj) to_7\IN|effect|Adenosine (r_prep) produced_1\VBD|NONE (l_dobj) effect_3\NN|to|Adenosine (l_prep) on_4\IN|no (l_pobj) report_6\NN|NONE (l_compound) pain_5\NN|NONE
D000241_D059787 NONE adenosine_4\NN|NONE (r_pobj) of_2\IN|Preclinical (r_prep) studies_1\NNS|be|and|suggests (r_nsubj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|studies|and|suggests (l_acomp) effective_9\JJ|,|may|it (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D059787 NONE adenosine_33\NN|NONE (r_pobj) of_32\IN|Swedish|a (r_prep) formulation_31\NN|NONE (r_pobj) with_28\IN|and|patients (r_prep) volunteers_25\NNS|NONE (r_pobj) in_24\IN|preliminary (r_prep) studies_23\NNS|.|be (r_nsubj) suggests_34\VBZ|studies|be|and (r_conj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|studies|and|suggests (l_acomp) effective_9\JJ|,|may|it (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D006930 NONE adenosine_34\NN|intrathecal|of|trial|and (r_amod) doses_35\NNS|NONE (r_pobj) with_32\IN|label|an|,|escalating|, (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|volunteers|Following|,|were|in (l_conj) determined_85\VBN|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS|were|. (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|after|and|heat|acute (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE
D000241_D006930 NONE adenosine_34\NN|intrathecal|of|trial|and (r_amod) doses_35\NNS|NONE (r_pobj) with_32\IN|label|an|,|escalating|, (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|volunteers|Following|,|were|in (l_conj) determined_85\VBN|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS|were|. (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|after|and|heat|acute (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE (l_conj) allodynia_79\NN|mechanical|and
D000241_D006930 NONE adenosine_52\NN|NONE (r_pobj) of_51\IN|blind|,|a|controlled (r_prep) trial_50\NN|intrathecal|of|adenosine|and (r_conj) doses_35\NNS|NONE (r_pobj) with_32\IN|label|an|,|escalating|, (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|volunteers|Following|,|were|in (l_conj) determined_85\VBN|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS|were|. (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|after|and|heat|acute (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE
D000241_D006930 NONE adenosine_52\NN|NONE (r_pobj) of_51\IN|blind|,|a|controlled (r_prep) trial_50\NN|intrathecal|of|adenosine|and (r_conj) doses_35\NNS|NONE (r_pobj) with_32\IN|label|an|,|escalating|, (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|volunteers|Following|,|were|in (l_conj) determined_85\VBN|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS|were|. (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|after|and|heat|acute (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE (l_conj) allodynia_79\NN|mechanical|and
D000241_D006930 NONE Adenosine_0\NNP|effect|to (r_nsubj) produced_1\VBD|NONE (l_prep) to_7\IN|effect|Adenosine (l_pobj) stimulation_13\NN|NONE (l_conj) hyperalgesia_17\NN|but|acute|noxious|thermal
D000241_D006930 NONE Adenosine_0\NNP|effect|to (r_nsubj) produced_1\VBD|NONE (l_prep) to_7\IN|effect|Adenosine (l_pobj) stimulation_13\NN|NONE (l_conj) hyperalgesia_17\NN|but|acute|noxious|thermal (l_conj) allodynia_19\NN|mechanical|for|reduced|and
D000241_D009437 NONE adenosine_27\NN|NONE (r_pobj) of_26\IN|in|prolonged (r_prep) residence_25\NN|to (r_pobj) due_22\JJ|not (r_acomp) is_20\VBZ|effect|consistent|and|. (r_conj) is_5\VBZ|NONE (l_acomp) consistent_6\JJ|effect|is|and|. (l_prep) with_7\IN|NONE (l_pcomp) observed_9\VBN|NONE (l_prep) in_10\IN|that (l_pobj) reports_12\NNS|NONE (l_prep) of_13\IN|preliminary (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) pain_18\NN|NONE
D000241_D004342 NONE adenosine_4\NN|NONE (r_pobj) of_2\IN|Preclinical (r_prep) studies_1\NNS|be|and|suggests (r_nsubj) suggest_5\VBP|NONE (l_conj) suggests_34\VBZ|studies|be|and (l_ccomp) be_37\VB|.|studies (l_acomp) effective_38\JJ|it|with|but|may (l_prep) in_39\IN|NONE (l_pobj) states_41\NNS|NONE (l_compound) hypersensitivity_40\NN|NONE
D000241_D004342 NONE adenosine_33\NN|NONE (r_pobj) of_32\IN|Swedish|a (r_prep) formulation_31\NN|NONE (r_pobj) with_28\IN|and|patients (r_prep) volunteers_25\NNS|NONE (r_pobj) in_24\IN|preliminary (r_prep) studies_23\NNS|.|be (r_nsubj) suggests_34\VBZ|studies|be|and (l_ccomp) be_37\VB|.|studies (l_acomp) effective_38\JJ|it|with|but|may (l_prep) in_39\IN|NONE (l_pobj) states_41\NNS|NONE (l_compound) hypersensitivity_40\NN|NONE
D000241_D004342 NONE adenosine_15\NN|NONE (r_pobj) of_14\IN|a|different (r_prep) formulation_13\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) efficacy_9\NN|NONE (r_pobj) for_8\IN|to|,|using (r_prep) screen_7\VB|purpose|. (l_advcl) using_21\VBG|for|to|, (l_dobj) stimulation_25\NN|NONE (l_conj) hypersensitivity_31\NN|noxious|and|acute|both
D000241_D004342 NONE adenosine_7\NN|NONE (l_prep) of_8\IN|intrathecal (l_pobj) hypersensitivity_9\NN|NONE
D000241_D059350 NONE adenosine_4\NN|NONE (r_pobj) of_2\IN|Preclinical (r_prep) studies_1\NNS|be|and|suggests (r_nsubj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|studies|and|suggests (l_acomp) effective_9\JJ|,|may|it (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D059350 NONE adenosine_33\NN|NONE (r_pobj) of_32\IN|Swedish|a (r_prep) formulation_31\NN|NONE (r_pobj) with_28\IN|and|patients (r_prep) volunteers_25\NNS|NONE (r_pobj) in_24\IN|preliminary (r_prep) studies_23\NNS|.|be (r_nsubj) suggests_34\VBZ|studies|be|and (r_conj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|studies|and|suggests (l_acomp) effective_9\JJ|,|may|it (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D010146 NONE adenosine_34\NN|intrathecal|of|trial|and (r_amod) doses_35\NNS|NONE (r_pobj) with_32\IN|label|an|,|escalating|, (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|volunteers|Following|,|were|in (l_conj) determined_85\VBN|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS|were|. (l_compound) pain_65\NN|in
D000241_D010146 NONE adenosine_52\NN|NONE (r_pobj) of_51\IN|blind|,|a|controlled (r_prep) trial_50\NN|intrathecal|of|adenosine|and (r_conj) doses_35\NNS|NONE (r_pobj) with_32\IN|label|an|,|escalating|, (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|volunteers|Following|,|were|in (l_conj) determined_85\VBN|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS|were|. (l_compound) pain_65\NN|in
D000241_D010146 NONE Adenosine_0\NNP|effect|to (r_nsubj) produced_1\VBD|NONE (l_dobj) effect_3\NN|to|Adenosine (l_prep) on_4\IN|no (l_pobj) report_6\NN|NONE (l_compound) pain_5\NN|NONE
D002211_D006930 CID capsaicin_82\NN|intradermal (r_compound) injection_83\NN|NONE (r_pobj) after_80\IN|areas|and|heat|acute (r_prep) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|after|and|heat|acute (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE
D002211_D006930 CID capsaicin_82\NN|intradermal (r_compound) injection_83\NN|NONE (r_pobj) after_80\IN|areas|and|heat|acute (r_prep) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|after|and|heat|acute (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE (l_conj) allodynia_79\NN|mechanical|and
D002211_D006930 CID capsaicin_22\NN|intradermal (r_compound) injection_23\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) allodynia_19\NN|mechanical|for|reduced|and (r_conj) hyperalgesia_17\NN|but|acute|noxious|thermal
D002211_D006930 CID capsaicin_22\NN|intradermal (r_compound) injection_23\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) allodynia_19\NN|mechanical|for|reduced|and
11079278
D004280_D017202 CID dobutamine_10\NN| (r_npadvmod) induced_12\VBN|myocardial (r_amod) ischemia_14\NN|NONE
D004280_D017202 CID dobutamine_1\NN|NONE (r_pcomp) During_0\IN|metoprolol|,|.|or|eliminates (r_prep) attenuates_6\VBZ|NONE (l_conj) eliminates_8\VBZ|metoprolol|During|,|.|or (l_dobj) evidence_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) ischemia_12\NN|NONE
D008790_D017202 NONE metoprolol_3\NN|NONE (l_conj) metoprolol_6\NN|intravenous|or (l_conj) glucagon_8\NN|intravenous|plus (l_prep) on_9\IN|NONE (l_pobj) ischemia_14\NN|NONE
D008790_D017202 NONE metoprolol_6\NN|intravenous|or (l_conj) glucagon_8\NN|intravenous|plus (l_prep) on_9\IN|NONE (l_pobj) ischemia_14\NN|NONE
D008790_D017202 NONE metoprolol_5\FW|During|,|.|or|eliminates (r_nsubj) attenuates_6\VBZ|NONE (l_conj) eliminates_8\VBZ|metoprolol|During|,|.|or (l_dobj) evidence_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) ischemia_12\NN|NONE
7416947
D004077_D020018 CID digoxin_13\NN|NONE (r_pobj) of_12\IN|term (r_prep) administration_11\NN|NONE (r_pobj) on_7\IN|NONE (r_prep) patients_6\NNS|NONE (r_pobj) of_5\IN|sexual (r_prep) dysfunction_4\NN|NONE
D004077_D012214 NONE digoxin_10\NN|NONE (r_pobj) without_9\IN|the|(|)|study (r_prep) group_7\NN|NONE (r_pobj) of_2\IN|The (r_prep) patients_1\NNS|.|of|selected|and (r_nsubj) were_12\VBD|NONE (l_conj) selected_29\VBN|.|of|and|patients (l_prep) from_30\IN|randomly|were (l_pobj) patients_35\NNS|NONE (l_compound) disease_34\NN|the|rheumatic
19761039
D010936_D004409 NONE sinensis_7\NN|NONE (r_pobj) of_4\IN|methanolic (r_prep) extract_3\NN|NONE (r_pobj) of_1\IN|)|mg/kg|( (r_prep) Effect_0\NN|was|on|. (r_nsubjpass) studied_15\VBN|NONE (l_prep) on_16\IN|Effect|was|. (l_pobj) dyskinesia_21\JJ|NONE
D010936_D004409 NONE sinensis_10\NN|that|role (r_nsubj) had_11\VBD|results|. (l_dobj) role_14\NN|sinensis|that (l_prep) against_15\IN|a|protective (l_pobj) dyskinesia_20\JJ|NONE
D012110_D004409 CID reserpine_17\NN| (r_npadvmod) induced_19\VBN|and|alterations|orofacial (r_amod) dyskinesia_21\JJ|NONE
D012110_D004409 CID reserpine_16\NN| (r_npadvmod) induced_18\VBN|stress|and|orofacial (r_amod) dyskinesia_20\JJ|NONE
12852481
D001241_D005767 NONE ASA_20\NNP|when|is|on (r_nsubjpass) administered_22\VBN|to|results (r_advcl) compare_7\VB|;|Objectives|. (r_xcomp) were_5\VBD|NONE (l_nsubj) Objectives_0\NNS|compare|;|. (l_acl) compare_33\VB|of (l_conj) test_50\VB|patterns|and|to|; (l_dobj) hypothesis_52\NN|to (l_acl) confounds_57\VBZ|the (l_nsubj) toxicity_56\NN|that|detection|used
D001241_D005767 NONE ASA_65\NNP|NONE (r_pobj) with_64\IN|low|incidence (r_prep) malformations_63\NNS|NONE (r_pobj) of_60\IN|the (r_prep) detection_59\NN|that|toxicity|used (r_dobj) confounds_57\VBZ|the (l_nsubj) toxicity_56\NN|that|detection|used
D001241_D000014 CID Aspirin_0\NNP||induces|(|,|)|,|acid|cyclooxygenase|. (r_nsubj) acetylsalicylic_2\JJ|NONE (l_conj) induces_17\VBZ||(|,|)|,|acid|cyclooxygenase|Aspirin|. (l_dobj) anomalies_19\NNS|administered
D001241_D000014 CID acid_3\NN||induces|(|,|)|,|cyclooxygenase|Aspirin|. (r_npadvmod) acetylsalicylic_2\JJ|NONE (l_conj) induces_17\VBZ||(|,|)|,|acid|cyclooxygenase|Aspirin|. (l_dobj) anomalies_19\NNS|administered
D001241_D000014 CID ASA_5\NNP|NONE (r_appos) acid_3\NN||induces|(|,|)|,|cyclooxygenase|Aspirin|. (r_npadvmod) acetylsalicylic_2\JJ|NONE (l_conj) induces_17\VBZ||(|,|)|,|acid|cyclooxygenase|Aspirin|. (l_dobj) anomalies_19\NNS|administered
D001241_D000014 CID ASA_20\NNP|when|is|on (r_nsubjpass) administered_22\VBN|to|results (r_advcl) compare_7\VB|;|Objectives|. (r_xcomp) were_5\VBD|NONE (l_nsubj) Objectives_0\NNS|compare|;|. (l_acl) compare_33\VB|of (l_conj) test_50\VB|patterns|and|to|; (l_dobj) hypothesis_52\NN|to (l_acl) confounds_57\VBZ|the (l_dobj) detection_59\NN|that|toxicity|used (l_prep) of_60\IN|the (l_pobj) malformations_63\NNS|NONE
D001241_D000014 CID ASA_65\NNP|NONE (r_pobj) with_64\IN|low|incidence (r_prep) malformations_63\NNS|NONE
D001241_D000014 CID ASA_16\NNP|even|though|malformations (r_nsubj) induces_17\VBZ|,|,|;|hence|,|study|on|)|. (r_advcl) focused_9\VBD|NONE (l_prep) on_10\IN|induces|,|,|;|hence|,|study|)|. (l_pobj) malformations_12\NNS|NONE
D001241_D000014 CID ASA_16\NNP|even|though|malformations (r_nsubj) induces_17\VBZ|,|,|;|hence|,|study|on|)|. (l_dobj) malformations_23\NNS|even|ASA|though
D001241_D000014 CID ASA_6\NNP|as|when|was (r_nsubjpass) administered_8\VBN|.|similar|GDs|Variations (r_advcl) were_3\VBD|NONE (l_nsubj) Variations_0\NNS|administered|.|similar|GDs (l_conj) malformations_2\NNS|and
D001241_D000014 CID ASA_38\NNP|NONE (r_pobj) with_37\IN|could|that|,|,|be|malformations|also (r_prep) induced_36\VBN|.|evident|also|It (l_nsubjpass) malformations_17\NNS|could|that|,|,|be|with|also
19058474
D014859_D006470 NONE warfarin_26\NN|NONE (r_pobj) of_25\IN|his|usual (r_prep) dosage_24\NN|while (r_dobj) maintaining_21\VBG|who|for|juice (r_advcl) consumed_13\VBD|elderly|an (r_relcl) man_11\NN|NONE (r_pobj) in_8\IN|of|a (r_prep) case_3\NN|We|. (l_prep) of_4\IN|in|a (l_pobj) haemorrhage_7\NN|NONE
D014859_D010490 NONE warfarin_13\NN|NONE (r_pobj) with_12\IN|possible|of (r_prep) interaction_8\NN|to (r_pobj) due_5\IN|.|haemopericardium (r_prep) haemorrhage_4\NN|NONE (l_nmod) haemopericardium_1\NN|.|due
D014859_D006471 CID warfarin_13\NN|NONE (r_pobj) with_12\IN|possible|of (r_prep) interaction_8\NN|to (r_pobj) due_5\IN|.|haemopericardium (r_prep) haemorrhage_4\NN|NONE
11009181
D001058_D004409 NONE apomorphine_13\NN|continuous (r_compound) infusions_14\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) monotherapy_9\NN|with|that|is (r_nsubjpass) associated_16\VBN|clinical (l_prep) with_17\IN|that|monotherapy|is (l_pobj) reductions_19\NNS|NONE (l_prep) of_20\IN|marked (l_pobj) dyskinesias_25\NNS|NONE
D007980_D004409 CID levodopa_22\NN| (r_npadvmod) induced_24\VBN|preexisting (r_amod) dyskinesias_25\NNS|NONE
D001058_D001523 NONE apomorphine_6\NN|subcutaneous (r_compound) treatment_7\NN|NONE (r_pobj) of_4\IN|side|The|main (r_prep) effects_3\NNS|are|to|play|.|, (r_nsubjpass) related_9\VBN|NONE (l_advcl) play_20\VBP|are|to|.|effects|, (l_nsubj) sedation_16\NN|whereas|role (l_conj) complications_19\NNS|and (l_amod) psychiatric_18\JJ|NONE
D001058_D010300 NONE Apomorphine_0\NNP|NONE (l_appos) therapy_4\NN|.|: (l_prep) for_5\IN|underutilized|an (l_pobj) disease_8\NN|NONE
D001058_D010300 NONE Apomorphine_0\NNP|drug|. (r_nsubj) was_1\VBD|NONE (l_attr) drug_5\NN|Apomorphine|. (l_acl) used_7\VBN|the|dopaminergic|first (l_xcomp) treat_9\VB|ever (l_dobj) symptoms_10\NNS|to (l_prep) of_11\IN|NONE (l_pobj) disease_14\NN|NONE
D001058_D010300 NONE apomorphine_24\NN|NONE (r_pobj) of_23\IN|subcutaneous (r_prep) administration_22\NN|NONE (r_pobj) by_20\IN|disease (r_prep) treating_15\VBG|NONE (l_dobj) disease_19\NN|by
D001058_D010300 NONE apomorphine_8\NN|subcutaneous|in (r_compound) treatment_9\NN|NONE (l_prep) in_10\IN|subcutaneous|apomorphine (l_pobj) disease_14\NN|NONE
15897593
D005047_D015431 CID etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D005047_D015431 CID etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither
D018943_D066126 NONE anthracyclines_1\NNS|are|doxorubicin|and (r_nsubj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN|and
D018943_D066126 NONE anthracycline_9\NN| (r_advmod) induced_11\VBN|NONE (r_amod) cardiotoxicity_12\NN|NONE
D003630_D064420 NONE daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither (l_conj) cytotoxicity_39\NN|,|nor|weight
D005047_D006402 CID etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|in|was|investigated (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN|enhancers|:|was|,|Because
D005047_D006402 CID etoposide_13\NN|NONE (r_pobj) of_12\IN|dexrazoxane (r_prep) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE (r_pobj) with_4\IN|NONE (r_prep) patients_3\NNS|NONE (r_pobj) in_2\IN|Clinical (r_prep) trials_1\NNS|ongoing|. (r_nsubj) is_14\VBZ|NONE (l_acomp) ongoing_15\JJ|trials|. (l_prep) with_16\IN|NONE (l_pobj) aim_18\NN|NONE (l_prep) of_19\IN|the (l_pcomp) improving_20\VBG|NONE (l_prep) without_22\IN|efficacy (l_pcomp) aggravating_23\VBG|NONE (l_dobj) toxicity_25\NN|NONE
D064730_D006402 NONE dexrazoxane_12\NN|NONE (r_pobj) of_11\IN|and (r_prep) coadministration_10\NN|NONE (r_pobj) following_9\VBG|hematologic|the (r_prep) toxicity_8\NN|enhancers|:|was|,|Because
D064730_D006402 NONE dexrazoxane_40\NN|NONE (r_dobj) doxorubicin_38\NN|and|, (r_conj) daunorubicin_35\NNS|, (r_conj) etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|in|was|investigated (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN|enhancers|:|was|,|Because
D064730_D006402 NONE dexrazoxane_8\NN|of (r_nmod) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE (r_pobj) with_4\IN|NONE (r_prep) patients_3\NNS|NONE (r_pobj) in_2\IN|Clinical (r_prep) trials_1\NNS|ongoing|. (r_nsubj) is_14\VBZ|NONE (l_acomp) ongoing_15\JJ|trials|. (l_prep) with_16\IN|NONE (l_pobj) aim_18\NN|NONE (l_prep) of_19\IN|the (l_pcomp) improving_20\VBG|NONE (l_prep) without_22\IN|efficacy (l_pcomp) aggravating_23\VBG|NONE (l_dobj) toxicity_25\NN|NONE
D011034_D001855 NONE epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|,
D011034_D066126 NONE epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN|and
D003630_D001855 NONE daunorubicin_13\NNS|but|and|doxorubicin (r_conj) etoposide_11\NN|against|.|Dexrazoxane (r_advmod) protects_1\VBZ|NONE (l_prep) against_2\IN|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN|NONE
D003630_D001855 NONE daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|,
D003630_D001855 NONE daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE
D003630_D001855 NONE daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses
D064730_D064420 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (r_pobj) of_2\IN|Nontoxic|from|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither (l_conj) cytotoxicity_39\NN|,|nor|weight
D064730_D064420 NONE dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither (l_conj) cytotoxicity_39\NN|,|nor|weight
D004317_D006402 CID doxorubicin_38\NN|and|, (r_conj) daunorubicin_35\NNS|, (r_conj) etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|in|was|investigated (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN|enhancers|:|was|,|Because
D064730_D015431 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D064730_D015431 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (r_pobj) of_2\IN|Nontoxic|from|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither
D064730_D015431 NONE dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D064730_D015431 NONE dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither
D064730_D066126 NONE Dexrazoxane_0\NNP|.|for|is (r_nsubjpass) recommended_5\VBN|NONE (l_prep) for_6\IN|.|is|Dexrazoxane (l_pobj) protection_7\NN|NONE (l_prep) against_8\IN|NONE (l_pobj) cardiotoxicity_12\NN|NONE
D064730_D066126 NONE ICRF-187_2\NN|NONE (r_appos) Dexrazoxane_0\NNP|.|for|is (r_nsubjpass) recommended_5\VBN|NONE (l_prep) for_6\IN|.|is|Dexrazoxane (l_pobj) protection_7\NN|NONE (l_prep) against_8\IN|NONE (l_pobj) cardiotoxicity_12\NN|NONE
D005047_D066126 NONE etoposide_8\NN|the (r_appos) epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN|and
D004317_D066126 NONE doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN|and
D064730_D001855 NONE Dexrazoxane_0\NNP|against|.|etoposide (r_nsubj) protects_1\VBZ|NONE (l_prep) against_2\IN|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN|NONE
D064730_D001855 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE
D064730_D001855 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (r_pobj) of_2\IN|Nontoxic|from|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses
D064730_D001855 NONE dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE
D064730_D001855 NONE dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses
D005047_D064420 NONE etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither (l_conj) cytotoxicity_39\NN|,|nor|weight
D064730_D009362 NONE dexrazoxane_8\NN|of (r_nmod) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE
D005047_D001855 NONE etoposide_11\NN|against|.|Dexrazoxane (r_advmod) protects_1\VBZ|NONE (l_prep) against_2\IN|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN|NONE
D005047_D001855 NONE etoposide_8\NN|the (r_appos) epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|,
D005047_D001855 NONE etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE
D005047_D001855 NONE etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses
D004317_D064420 NONE doxorubicin_41\NN|NONE (r_pobj) from_40\IN|the|vitro (r_prep) cytotoxicity_39\NN|,|nor|weight
D005047_D009362 NONE etoposide_13\NN|NONE (r_pobj) of_12\IN|dexrazoxane (r_prep) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE
D004317_D015431 CID doxorubicin_41\NN|NONE (r_pobj) from_40\IN|the|vitro (r_prep) cytotoxicity_39\NN|,|nor|weight (r_conj) loss_33\NN|,|reduced|neither (r_conj) myelosuppression_30\NN|however|,|;|.|doses (r_dobj) dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D004317_D015431 CID doxorubicin_41\NN|NONE (r_pobj) from_40\IN|the|vitro (r_prep) cytotoxicity_39\NN|,|nor|weight (r_conj) loss_33\NN|,|reduced|neither
D018943_D001855 NONE anthracyclines_1\NNS|are|doxorubicin|and (r_nsubj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|,
D003630_D006402 CID daunorubicin_35\NNS|, (r_conj) etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|in|was|investigated (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN|enhancers|:|was|,|Because
D003630_D066126 NONE daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN|and
D004317_D001855 NONE doxorubicin_16\RB|but|and|daunorubicin (r_conj) etoposide_11\NN|against|.|Dexrazoxane (r_advmod) protects_1\VBZ|NONE (l_prep) against_2\IN|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN|NONE
D004317_D001855 NONE doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|;|daunorubicin|.|however|use|,
D004317_D001855 NONE doxorubicin_41\NN|NONE (r_pobj) from_40\IN|the|vitro (r_prep) cytotoxicity_39\NN|,|nor|weight (r_conj) loss_33\NN|,|reduced|neither (r_conj) myelosuppression_30\NN|however|,|;|.|doses (r_dobj) dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE
D004317_D001855 NONE doxorubicin_41\NN|NONE (r_pobj) from_40\IN|the|vitro (r_prep) cytotoxicity_39\NN|,|nor|weight (r_conj) loss_33\NN|,|reduced|neither (r_conj) myelosuppression_30\NN|however|,|;|.|doses
D003630_D015431 CID daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (l_prep) of_2\IN|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D003630_D015431 CID daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|however|,|;|.|doses (l_conj) loss_33\NN|,|reduced|neither
1595783
D000638_D011014 CID Amiodarone_0\NN|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_5\NN|Amiodarone|. (l_appos) being_19\VBG|antiarrhythmic|limited|effective|,|an (l_attr) pneumonitis_20\NN|problematic|the
D000638_D008171 NONE Amiodarone_0\NN|pulmonary|. (r_amod) toxicity_2\NN|NONE
D000638_D008171 NONE amiodarone_4\NN|NONE (r_pobj) of_3\IN|pulmonary|The (r_prep) toxicity_2\NN|is|.|result
D000638_D008171 NONE amiodarone_6\NN| (r_npadvmod) induced_8\VBN|pulmonary (r_amod) toxicity_10\NN|NONE
D000638_D004342 NONE amiodarone_4\NN|NONE (r_pobj) of_3\IN|pulmonary|The (r_prep) toxicity_2\NN|is|.|result (r_nsubjpass) thought_6\VBN|NONE (l_xcomp) result_8\VB|toxicity|is|. (l_prep) from_9\IN|to (l_pobj) injury_11\NN|NONE (l_acl) related_12\VBN|direct (l_prep) to_13\IN|NONE (l_pobj) accumulation_16\NN|NONE (l_prep) of_17\IN|the|intracellular (l_pobj) pneumonitis_25\NN|NONE
D000638_D000542 NONE amiodarone_4\NN|NONE (r_pobj) of_3\IN|pulmonary|The (r_prep) toxicity_2\NN|is|.|result (r_nsubjpass) thought_6\VBN|NONE (l_xcomp) result_8\VB|toxicity|is|. (l_prep) from_9\IN|to (l_pobj) injury_11\NN|NONE (l_acl) related_12\VBN|direct (l_prep) to_13\IN|NONE (l_pobj) accumulation_16\NN|NONE (l_prep) of_17\IN|the|intracellular (l_pobj) pneumonitis_25\NN|NONE
3952818
D005472_D066126 NONE 5-fluorouracil_3\CD|NONE (r_punct) ._4\.|Cardiac|of (r_punct) toxicity_1\NN|NONE
D005472_D066126 NONE 5-FU_14\CD|NONE (r_pobj) to_13\IN|NONE (r_pcomp) due_12\JJ|cause|,|that|and|used|may|spasm (r_prep) be_7\VB|.|data (l_attr) cause_9\NN|due|,|that|and|used|may|spasm (l_prep) of_10\IN|the (l_pobj) cardiotoxicity_11\NN|NONE
D005472_D066126 NONE 5-FU_14\CD|NONE (r_pobj) to_13\IN|NONE (r_pcomp) due_12\JJ|cause|,|that|and|used|may|spasm (r_prep) be_7\VB|.|data (l_conj) used_23\VBN|cause|due|,|that|and|may|spasm (l_prep) in_24\IN|probably|be|that|antagonists|may (l_pobj) prevention_26\NN|NONE (l_prep) of_29\IN|the|or|treatment (l_pobj) cardiotoxicity_31\NN|NONE
D005472_D066126 NONE 5-FU_30\CD|NONE (r_compound) cardiotoxicity_31\NN|NONE (r_pobj) of_29\IN|the|or|treatment (r_prep) prevention_26\NN|NONE (r_pobj) in_24\IN|probably|be|that|antagonists|may (r_prep) used_23\VBN|cause|due|,|that|and|may|spasm (r_conj) be_7\VB|.|data (l_attr) cause_9\NN|due|,|that|and|used|may|spasm (l_prep) of_10\IN|the (l_pobj) cardiotoxicity_11\NN|NONE
D005472_D066126 NONE 5-FU_30\CD|NONE (r_compound) cardiotoxicity_31\NN|NONE
D009543_D000788 NONE nifedipine_19\NN|NONE (r_pobj) with_18\IN|promptly|.|pain (r_prep) resolved_17\VBD|,|similar|and|evolution (r_conj) was_3\VBD|NONE (l_acomp) similar_4\JJ|,|and|resolved|evolution (l_prep) to_5\IN|NONE (l_pobj) that_6\DT|NONE (l_acl) observed_7\VBN|NONE (l_prep) in_8\IN|NONE (l_pobj) angina_11\NN|NONE
D005472_D002637 CID 5-fluorouracil_18\CD|(|)|FU (r_punct) administration_22\NN|NONE (r_pobj) after_17\IN|who|pain (r_prep) presented_14\VBD|a|with (l_dobj) pain_16\NN|who|after
D005472_D002637 CID 5-FU_20\CD|fluorouracil|(|) (r_nmod) administration_22\NN|NONE (r_pobj) after_17\IN|who|pain (r_prep) presented_14\VBD|a|with (l_dobj) pain_16\NN|who|after
D009543_D002637 NONE nifedipine_19\NN|NONE (r_pobj) with_18\IN|promptly|.|pain (r_prep) resolved_17\VBD|,|similar|and|evolution (l_nsubj) pain_15\NN|promptly|.|with
D005472_D009362 NONE 5-fluorouracil_18\CD|(|)|FU (r_punct) administration_22\NN|NONE (r_pobj) after_17\IN|who|pain (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE (l_conj) metastasis_12\NN|colon|and
D005472_D009362 NONE 5-FU_20\CD|fluorouracil|(|) (r_nmod) administration_22\NN|NONE (r_pobj) after_17\IN|who|pain (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE (l_conj) metastasis_12\NN|colon|and
D005472_D003329 NONE 5-FU_14\CD|NONE (r_pobj) to_13\IN|NONE (r_pcomp) due_12\JJ|cause|,|that|and|used|may|spasm (r_prep) be_7\VB|.|data (l_nsubj) spasm_5\NN|cause|due|,|that|and|used|may
D005472_D003329 NONE 5-FU_30\CD|NONE (r_compound) cardiotoxicity_31\NN|NONE (r_pobj) of_29\IN|the|or|treatment (r_prep) prevention_26\NN|NONE (r_pobj) in_24\IN|probably|be|that|antagonists|may (r_prep) used_23\VBN|cause|due|,|that|and|may|spasm (r_conj) be_7\VB|.|data (l_nsubj) spasm_5\NN|cause|due|,|that|and|used|may
D005472_D003110 NONE 5-fluorouracil_18\CD|(|)|FU (r_punct) administration_22\NN|NONE (r_pobj) after_17\IN|who|pain (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE
D005472_D003110 NONE 5-FU_20\CD|fluorouracil|(|) (r_nmod) administration_22\NN|NONE (r_pobj) after_17\IN|who|pain (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE
D002118_D066126 NONE calcium_18\NN|NONE (r_compound) antagonists_19\NNS|probably|be|that|in|may (r_nsubjpass) used_23\VBN|cause|due|,|that|and|may|spasm (r_conj) be_7\VB|.|data (l_attr) cause_9\NN|due|,|that|and|used|may|spasm (l_prep) of_10\IN|the (l_pobj) cardiotoxicity_11\NN|NONE
D002118_D066126 NONE calcium_18\NN|NONE (r_compound) antagonists_19\NNS|probably|be|that|in|may (r_nsubjpass) used_23\VBN|cause|due|,|that|and|may|spasm (l_prep) in_24\IN|probably|be|that|antagonists|may (l_pobj) prevention_26\NN|NONE (l_prep) of_29\IN|the|or|treatment (l_pobj) cardiotoxicity_31\NN|NONE
D002118_D003329 NONE calcium_18\NN|NONE (r_compound) antagonists_19\NNS|probably|be|that|in|may (r_nsubjpass) used_23\VBN|cause|due|,|that|and|may|spasm (r_conj) be_7\VB|.|data (l_nsubj) spasm_5\NN|cause|due|,|that|and|used|may
8475949
D008274_C537153 NONE magnesium_11\NN|serum|hypomagnesemia|and (r_compound) levels_12\NNS|NONE (l_conj) hypomagnesemia_14\NN|serum|and|magnesium
D008274_D008133 NONE magnesium_8\NN|early (r_compound) supplementation_9\NN|,|observed|is|. (r_nsubjpass) advocated_11\VBN|NONE (l_advcl) observed_5\VBN|,|supplementation|is|. (l_nsubjpass) prolongation_3\NN|is|When
D008274_D016171 NONE magnesium_11\NN|serum|hypomagnesemia|and (r_compound) levels_12\NNS|NONE (r_pobj) to_9\IN|be|induce|pointes|may|. (r_prep) related_8\VBN|NONE (l_nsubjpass) pointes_5\FW|be|induce|may|.|to
D010419_D017180 NONE pentamidine_3\NN|NONE (l_conj) tachycardia_7\NN|and
D010419_D017180 NONE isethionate_1\NN|been|has|.|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|been|has|isethionate|. (l_pobj) tachyarrhythmias_7\NNS|NONE
D010419_D016171 CID isethionate_1\NN|been|has|.|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|been|has|isethionate|. (l_pobj) tachyarrhythmias_7\NNS|NONE (l_prep) including_9\VBG|,|ventricular (l_pobj) pointes_12\FW|NONE
D010419_D016171 CID Pentamidine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|de (r_nmod) pointes_5\FW|be|induce|may|.|to
D010419_D016171 CID pentamidine_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|NONE (r_pobj) of_10\IN| (r_prep) days_9\NNS|NONE (r_pobj) of_7\IN|an (r_prep) average_6\NN|NONE (r_pobj) after_4\IN|.|pointes (r_prep) occurred_3\VBD|NONE (l_nsubj) pointes_2\NNS|.|after
D010419_D016171 CID pentamidine_14\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) discontinuation_12\NN|possibly (r_pobj) without_11\IN|when|early|, (r_prep) recognized_7\VBN|be|can|pointes|. (r_advcl) treated_5\VBN|NONE (l_nsubjpass) pointes_2\FW|recognized|be|can|.
D010419_C537153 NONE Pentamidine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|de (r_nmod) pointes_5\FW|be|induce|may|.|to (r_nsubjpass) related_8\VBN|NONE (l_prep) to_9\IN|be|induce|pointes|may|. (l_pobj) levels_12\NNS|NONE (l_conj) hypomagnesemia_14\NN|serum|and|magnesium
11860495
D012601_D000647 CID scopolamine_21\NN| (r_npadvmod) induced_23\VBN|NONE (r_amod) amnesia_24\NN|NONE
D012601_D000647 CID scopolamine_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) amnesia_28\NN|NONE
D005680_D000647 NONE GABA(A)R_15\NNP|NONE (r_compound) ligands_16\NNS|and (r_conj) NMDAR_13\NNP|NONE (r_pobj) of_12\IN|the|like (r_prep) effects_11\NNS|to (l_amod) like_10\JJ|the|of (l_amod) amnesic_8\JJ|
C018370_D000647 NONE sulphate_13\NN|NONE (r_pobj) of_11\IN|amnesic|the|in (r_prep) effects_10\NNS|.|structure (l_amod) amnesic_9\JJ|the|in|of
C018370_D000647 NONE PREGS_2\NNP|.|able|,|Moreover (r_nsubj) is_3\VBZ|NONE (l_acomp) able_4\JJ|PREGS|.|,|Moreover (l_xcomp) reverse_6\VB|NONE (l_dobj) effects_11\NNS|to (l_amod) like_10\JJ|the|of (l_amod) amnesic_8\JJ|
C018370_D000647 NONE PREGS_6\NNP|NONE (r_pobj) of_5\IN|The|enhancing (r_prep) effects_4\NNS|in|.|were (r_nsubjpass) tested_11\VBN|NONE (l_prep) in_12\IN|.|effects|were (l_pobj) task_16\NN|NONE (l_acl) using_17\VBG|the|passive|avoidance (l_dobj) model_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) amnesia_24\NN|NONE
C018370_D000647 NONE PREGS_10\NNP|NONE (r_pobj) of_8\IN|be|the (r_prep) ability_7\NN|NONE (l_acl) be_12\VB|of|the (l_attr) order_14\NN|to (l_amod) effective_18\JJ|an|of (l_prep) than_19\IN|more (l_pobj) enantiomer_22\NN|NONE (l_prep) in_23\IN|synthetic|its (l_pcomp) reversing_24\VBG|NONE (l_dobj) amnesia_28\NN|NONE
D013256_D000647 NONE Steroid_0\NN|properties|and (r_compound) structure_1\NN|.|effects (r_nsubj) determine_5\VBP|NONE (l_dobj) effects_10\NNS|.|structure (l_amod) amnesic_9\JJ|the|in|of
2257294
C034753_D001855 NONE Benzylacyclouridine_0\NN|.|suppression|without (r_nsubj) reverses_1\VBZ|NONE (l_dobj) suppression_6\NN|.|Benzylacyclouridine|without
C034753_D001855 NONE BAU_11\NNP|.|coadministered|toxicity|, (r_nsubj) reduced_12\VBD|NONE (l_dobj) toxicity_17\NN|.|coadministered|BAU|,
C034753_D064420 NONE benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_prep) Because_0\IN|ability|in|,|,|anemia|.|,|was (l_pobj) toxicities_4\NNS|of
C034753_D064420 NONE BAU_16\NNP|)|( (r_appos) benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_prep) Because_0\IN|ability|in|,|,|anemia|.|,|was (l_pobj) toxicities_4\NNS|of
D014529_D000740 NONE Urd_8\NNP|chronic (r_compound) administration_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|clinical|the (r_acl) toxicities_4\NNS|of (r_pobj) Because_0\IN|ability|in|,|,|anemia|.|,|was (r_prep) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|ability|in|Because|,|,|.|,|was
D014529_D064420 NONE Urd_8\NNP|chronic (r_compound) administration_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|clinical|the (r_acl) toxicities_4\NNS|of
D014529_D064420 NONE Urd_3\NNP|NONE (r_compound) catabolism_4\NN|,|increases|agent|and|. (r_dobj) inhibits_2\VBZ|NONE (l_conj) increases_10\VBZ|catabolism|,|agent|and|. (l_prep) without_23\IN|in|in|concentration|,|, (l_pobj) toxicity_27\NN|NONE
D014529_D064420 NONE Urd_15\NNP|NONE (r_pobj) of_14\IN|the|plasma (r_prep) concentration_13\NN|in|in|without|,|, (r_dobj) increases_10\VBZ|catabolism|,|agent|and|. (l_prep) without_23\IN|in|in|concentration|,|, (l_pobj) toxicity_27\NN|NONE
D014529_D064420 NONE Urd_24\NNP| (r_npadvmod) related_26\VBN|NONE (r_amod) toxicity_27\NN|NONE
C034753_-1 NONE BAU_31\NNP|mg/kg|(|plus|, (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_conj) increased_67\VBN|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN|NONE
D014529_D007970 NONE Urd_8\NNP|chronic (r_compound) administration_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|clinical|the (r_acl) toxicities_4\NNS|of (r_pobj) Because_0\IN|ability|in|,|,|anemia|.|,|was (r_prep) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN|and|induced
D015215_D064420 NONE AZT_24\NNP| (r_npadvmod) induced_26\VBN|and|leukopenia (r_amod) anemia_27\NN|ability|in|Because|,|,|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_prep) Because_0\IN|ability|in|,|,|anemia|.|,|was (l_pobj) toxicities_4\NNS|of
D015215_D001855 CID azidothymidine_2\RB| (r_advmod) induced_4\VBN|marrow (r_amod) suppression_6\NN|.|Benzylacyclouridine|without
D015215_D001855 CID AZT_3\NNP|NONE (r_pobj) with_2\IN|When|from (r_prep) coadministered_1\VBN|.|toxicity|BAU|, (r_advcl) reduced_12\VBD|NONE (l_dobj) toxicity_17\NN|.|coadministered|BAU|,
D015215_D001855 CID AZT_13\NNP| (r_npadvmod) induced_15\VBN|marrow (r_amod) toxicity_17\NN|.|coadministered|BAU|,
D014529_D007153 NONE uridine_4\NN|NONE (r_pobj) of_3\IN|extracellular|Increased (r_prep) concentrations_2\NNS|.|reduce|been|have (r_nsubjpass) reported_10\VBN|NONE (l_xcomp) reduce_12\VB|concentrations|.|been|have (l_dobj) inhibition_20\NN|,|to|in (l_prep) without_28\IN|AZT)induced|of|( (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|its|activity|antihuman
D014529_D007153 NONE Urd_6\NNP|NONE (r_appos) uridine_4\NN|NONE (r_pobj) of_3\IN|extracellular|Increased (r_prep) concentrations_2\NNS|.|reduce|been|have (r_nsubjpass) reported_10\VBN|NONE (l_xcomp) reduce_12\VB|concentrations|.|been|have (l_dobj) inhibition_20\NN|,|to|in (l_prep) without_28\IN|AZT)induced|of|( (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|its|activity|antihuman
D015215_D007970 CID AZT_24\NNP| (r_npadvmod) induced_26\VBN|and|leukopenia (r_amod) anemia_27\NN|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN|and|induced
D015215_D007970 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|(|)|mL|for (r_prep) leukopenic_5\JJ|anemic|and
D015215_D007970 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|(|)|mL|for (r_prep) leukopenic_5\JJ|anemic|and (r_conj) rendered_2\VBD|NONE (r_acl) mice_1\NNS|NONE (r_pobj) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (r_prep) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN|and|P|(|reticulocytes|induced
D015215_D007970 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_conj) leukopenic_5\JJ|anemic|and
D015215_D007970 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN|and|P|(|reticulocytes|induced
D015215_D007970 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (r_dobj) reversed_39\VBD|NONE (l_prep) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_conj) leukopenic_5\JJ|anemic|and
D015215_D007970 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN|and|P|(|reticulocytes|induced
C034753_D000740 NONE benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|ability|in|Because|,|,|.|,|was
C034753_D000740 NONE BAU_16\NNP|)|( (r_appos) benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|ability|in|Because|,|,|.|,|was
C034753_D000740 NONE BAU_31\NNP|mg/kg|(|plus|, (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
C034753_D000740 NONE BAU_31\NNP|mg/kg|(|plus|, (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|administration|,|increased|)|,|partially|In|P|.
C034753_D007153 NONE Benzylacyclouridine_0\NN|.|suppression|without (r_nsubj) reverses_1\VBZ|NONE (l_prep) without_7\IN|.|suppression|Benzylacyclouridine (l_pobj) impairment_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) activity_15\NN|NONE (l_compound) virus_14\NN|human (l_compound) immunodeficiency_13\NN|NONE
D015215_D000740 CID AZT_24\NNP| (r_npadvmod) induced_26\VBN|and|leukopenia (r_amod) anemia_27\NN|ability|in|Because|,|,|.|,|was
D015215_D000740 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|(|)|mL|for (r_prep) leukopenic_5\JJ|anemic|and (r_conj) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
D015215_D000740 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|(|)|mL|for (r_prep) leukopenic_5\JJ|anemic|and (r_conj) rendered_2\VBD|NONE (r_acl) mice_1\NNS|NONE (r_pobj) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (r_prep) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|administration|,|increased|)|,|partially|In|P|.
D015215_D000740 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
D015215_D000740 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|administration|,|increased|)|,|partially|In|P|.
D015215_D000740 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (r_dobj) reversed_39\VBD|NONE (l_prep) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
D015215_D000740 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN|administration|,|increased|)|,|partially|In|P|.
C034753_D007970 NONE benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN|and|induced
C034753_D007970 NONE BAU_16\NNP|)|( (r_appos) benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN|and|induced
C034753_D007970 NONE BAU_31\NNP|mg/kg|(|plus|, (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_conj) leukopenic_5\JJ|anemic|and
C034753_D007970 NONE BAU_31\NNP|mg/kg|(|plus|, (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN|and|P|(|reticulocytes|induced
D015215_-1 NONE AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|(|)|mL|for (r_prep) leukopenic_5\JJ|anemic|and (r_conj) rendered_2\VBD|NONE (r_acl) mice_1\NNS|NONE (r_pobj) In_0\IN|administration|,|increased|)|,|anemia|partially|P|. (r_prep) reversed_39\VBD|NONE (l_conj) increased_67\VBN|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN|NONE
D015215_-1 NONE AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD|NONE (l_conj) increased_67\VBN|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN|NONE
D015215_-1 NONE AZT_40\NNP| (r_npadvmod) induced_42\VBN|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN|administration|,|increased|)|,|partially|In|P|. (r_dobj) reversed_39\VBD|NONE (l_conj) increased_67\VBN|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN|NONE
D015215_D007153 NONE azidothymidine_2\RB| (r_advmod) induced_4\VBN|marrow (r_amod) suppression_6\NN|.|Benzylacyclouridine|without (r_dobj) reverses_1\VBZ|NONE (l_prep) without_7\IN|.|suppression|Benzylacyclouridine (l_pobj) impairment_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) activity_15\NN|NONE (l_compound) virus_14\NN|human (l_compound) immunodeficiency_13\NN|NONE
D015215_D007153 NONE azidothymidine_17\NN|, (r_advmod) vitro_15\FW|NONE (r_amod) in_14\IN|,|to|inhibition (r_prep) reduce_12\VB|concentrations|.|been|have (l_dobj) inhibition_20\NN|,|to|in (l_prep) without_28\IN|AZT)induced|of|( (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|its|activity|antihuman
D015215_D007153 NONE AZT)-induced_19\JJ|of|without|( (r_compound) inhibition_20\NN|,|to|in (l_prep) without_28\IN|AZT)induced|of|( (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|its|activity|antihuman
20103708
D010100_D003928 NONE oxygen_20\NN|)|(|ROS|reactive (r_compound) species_21\NNS|NONE (r_pobj) of_18\IN|the (r_prep) production_17\NN|NONE (r_pobj) by_15\IN|which|is (r_agent) accompanied_14\VBN|,|of|major|the (r_relcl) causes_7\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) one_3\CD|.|nephropathy (r_attr) is_2\VBZ|NONE (l_nsubj) nephropathy_1\NN|.|one
D013311_D058186 NONE streptozotocin_13\RB| (r_npadvmod) induced_15\VBN|renal (r_amod) damage_17\NN|NONE
D010100_D051437 NONE oxygen_20\NN|)|(|ROS|reactive (r_compound) species_21\NNS|NONE (r_pobj) of_18\IN|the (r_prep) production_17\NN|NONE (r_pobj) by_15\IN|which|is (r_agent) accompanied_14\VBN|,|of|major|the (r_relcl) causes_7\NNS|NONE (l_prep) of_8\IN|,|accompanied|major|the (l_pobj) failure_10\NN|NONE
D013311_D003928 CID streptozotocin_6\JJ| (r_npadvmod) induced_8\VBN|diabetic (r_amod) nephropathy_10\NN|NONE
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|nephropathy|in|explore|:|.|a|, (r_amod) model_27\NN|NONE (l_ccomp) explore_2\VBP|nephropathy|in|induced|:|.|a|, (l_dobj) role_5\NN|We (l_prep) against_8\IN|of|the|protective (l_pobj) nephropathy_10\NN|NONE
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|nephropathy|in|explore|:|.|a|, (r_amod) model_27\NN|NONE (l_ccomp) explore_2\VBP|nephropathy|in|induced|:|.|a|, (l_dobj) role_5\NN|We (l_prep) against_8\IN|of|the|protective (l_pobj) nephropathy_10\NN|NONE (l_acl) using_11\VBG|diabetic (l_prep) from_16\IN|tissues (l_pobj) patients_19\NNS|NONE (l_compound) nephropathy_18\NN|diabetic
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|nephropathy|in|explore|:|.|a|, (r_amod) model_27\NN|NONE (l_compound) nephropathy_26\NN|in|explore|induced|:|.|a|,
18997632
D002110_D018879 CID caffeine_1\NN|commonly|and|.|improve|is|tolerated (r_nsubjpass) used_4\VBN|NONE (l_conj) tolerated_18\VBN|commonly|and|.|improve|caffeine|is (l_prep) from_20\IN|is|well|aside|generally (l_pobj) reports_22\NNS|NONE (l_prep) of_23\IN|occasional (l_pobj) ectopy_27\NN|NONE
D002110_D006331 NONE caffeine_25\NN|NONE (r_compound) administration_26\NN|NONE (r_pobj) after_24\IN|who|bigeminy (r_prep) developed_14\VBD|or|arrhythmia|cardiac (r_relcl) disease_10\NN|NONE
D002110_D012640 CID caffeine_1\NN|commonly|and|.|improve|is|tolerated (r_nsubjpass) used_4\VBN|NONE (l_xcomp) improve_6\VB|commonly|and|.|caffeine|is|tolerated (l_dobj) duration_8\NN|to (l_compound) seizure_7\NN|quality|and|in
D002110_D017180 CID caffeine_7\NN|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|ventricular (r_acl) tachycardia_4\NN|NONE
D002110_D017180 CID caffeine_25\NN|NONE (r_compound) administration_26\NN|NONE (r_pobj) after_24\IN|who|bigeminy (r_prep) developed_14\VBD|or|arrhythmia|cardiac (l_dobj) bigeminy_16\JJ|who|after (l_conj) runs_20\NNS|and|sustained (l_prep) of_21\IN||brief (l_pobj) tachycardia_23\NN|NONE
D002110_D001145 NONE caffeine_25\NN|NONE (r_compound) administration_26\NN|NONE (r_pobj) after_24\IN|who|bigeminy (r_prep) developed_14\VBD|or|arrhythmia|cardiac (r_relcl) disease_10\NN|NONE (l_conj) arrhythmia_12\NN|or|developed|cardiac
D002110_D001145 NONE caffeine_2\NN|is|Although|well|generally (r_nsubjpass) tolerated_6\VBN|aware|clinician|,|should|. (r_advcl) be_11\VB|NONE (l_acomp) aware_12\JJ|tolerated|clinician|,|should|. (l_prep) of_13\IN|NONE (l_pobj) potential_15\NN|NONE (l_prep) for_16\IN|the (l_pobj) arrhythmias_21\NNS|NONE
14633084
D015080_D006470 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|.|for|of (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|.|with|of (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D015080_D006470 NONE mesna_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|for|the|of (r_prep) use_9\NN|we|In|.|, (l_prep) for_16\IN|in|the|of (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D015080_D006470 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) combination_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|Dexamethasone|. (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D015080_D006470 NONE mesna_9\NN|NONE (r_pobj) of_8\IN|last|two|with (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|HC|did|,|.|not|However (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|did|,|.|not|However|replacement
D015080_D006470 NONE mesna_16\JJ|with|the (r_amod) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|last|two|of (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|HC|did|,|.|not|However (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|did|,|.|not|However|replacement
D015080_D003556 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|.|for|of (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|.|with|of (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D015080_D003556 NONE mesna_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|for|the|of (r_prep) use_9\NN|we|In|.|, (l_prep) for_16\IN|in|the|of (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D015080_D003556 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) combination_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|Dexamethasone|. (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D015080_D003556 NONE mesna_9\NN|NONE (r_pobj) of_8\IN|last|two|with (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|HC|did|,|.|not|However (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|did|,|.|not|However|replacement
D015080_D003556 NONE mesna_16\JJ|with|the (r_amod) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|last|two|of (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|HC|did|,|.|not|However (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|did|,|.|not|However|replacement
D007069_D003556 CID ifosfamide_9\RB| (r_advmod) induced_11\VBN|hemorrhagic (r_amod) cystitis_13\NN|NONE
D007069_D003556 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D003556 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D003556 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D003556 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D003556 CID IFS_20\NNP| (r_npadvmod) induced_22\VBN|NONE (r_amod) HC_23\NN|NONE
D007069_D003556 CID IFS_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) HC_12\NN|NONE
D007069_D006470 CID ifosfamide_9\RB| (r_advmod) induced_11\VBN|hemorrhagic (r_amod) cystitis_13\NN|NONE
D007069_D006470 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D006470 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D006470 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D006470 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|of|a| (r_prep) effect_12\NN|AIM|. (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D006470 CID IFS_20\NNP| (r_npadvmod) induced_22\VBN|NONE (r_amod) HC_23\NN|NONE
D007069_D006470 CID IFS_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) HC_12\NN|NONE
D003907_D006470 NONE dexamethasone_2\NN|NONE (r_pobj) of_1\IN|.|for|with (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|.|with|of (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D003907_D006470 NONE dexamethasone_11\NN|NONE (r_pobj) of_10\IN|in|for|the (r_prep) use_9\NN|we|In|.|, (l_prep) for_16\IN|in|the|of (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D003907_D006470 NONE Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|Dexamethasone|. (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D003907_D006470 NONE dexamethasone_19\NN|NONE (r_pobj) with_18\IN|mesna|the (r_prep) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|last|two|of (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|HC|did|,|.|not|However (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|did|,|.|not|However|replacement
D003907_D003556 NONE dexamethasone_2\NN|NONE (r_pobj) of_1\IN|.|for|with (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|.|with|of (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D003907_D003556 NONE dexamethasone_11\NN|NONE (r_pobj) of_10\IN|in|for|the (r_prep) use_9\NN|we|In|.|, (l_prep) for_16\IN|in|the|of (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D003907_D003556 NONE Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|Dexamethasone|. (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D003907_D003556 NONE dexamethasone_19\NN|NONE (r_pobj) with_18\IN|mesna|the (r_prep) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|last|two|of (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|HC|did|,|.|not|However (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|did|,|.|not|However|replacement
19274460
D003907_D009101 NONE dexamethasone_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) combination_10\NN|NONE (r_pobj) in_9\IN|for|for|dose (r_prep) definition_5\NN|.|:|XI (l_prep) for_15\IN|in|for|dose (l_pobj) induction_17\NN|NONE (l_prep) in_18\IN|remission (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) myeloma_23\NN|NONE
D003907_D009101 NONE dexamethasone_17\NN|and (r_conj) bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|dose|to|as (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|dose|to|in (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE
D003907_D009101 NONE dexamethasone_17\NN|and (r_conj) bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|dose|to|as (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|dose|to|in (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE (l_appos) MM_34\NNP|diagnosed|multiple
D003907_D009101 NONE dexamethasone_16\NN|that|bortezomib|treatment (r_nsubj) is_17\VBZ|.|results (l_attr) treatment_21\NN|that|bortezomib|dexamethasone (l_prep) for_22\IN|effective|induction|warrants|an (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MM_27\NNP|NONE
C400082_D009101 NONE bortezomib_12\NNS|/ (r_amod) dexamethasone_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) combination_10\NN|NONE (r_pobj) in_9\IN|for|for|dose (r_prep) definition_5\NN|.|:|XI (l_prep) for_15\IN|in|for|dose (l_pobj) induction_17\NN|NONE (l_prep) in_18\IN|remission (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) myeloma_23\NN|NONE
C400082_D009101 NONE bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|dose|to|as (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|dose|to|in (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE
C400082_D009101 NONE bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|dose|to|as (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|dose|to|in (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE (l_appos) MM_34\NNP|diagnosed|multiple
C400082_D009101 NONE bortezomib_4\NNS|that|dexamethasone|treatment (r_nsubj) is_17\VBZ|.|results (l_attr) treatment_21\NN|that|bortezomib|dexamethasone (l_prep) for_22\IN|effective|induction|warrants|an (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MM_27\NNP|NONE
D003520_D009101 NONE cyclophosphamide_8\NN|NONE (r_pobj) for_6\IN|for|in|dose (r_prep) definition_5\NN|.|:|XI (l_prep) for_15\IN|in|for|dose (l_pobj) induction_17\NN|NONE (l_prep) in_18\IN|remission (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) myeloma_23\NN|NONE
D003520_D009101 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|the|recommended (r_prep) dose_9\NN|to|in|as (r_dobj) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|dose|to|in (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE
D003520_D009101 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|the|recommended (r_prep) dose_9\NN|to|in|as (r_dobj) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|dose|to|in (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE (l_appos) MM_34\NNP|diagnosed|multiple
D003520_D009101 NONE cyclophosphamide_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) combination_6\NN|NONE (r_pobj) in_5\IN|at|and (r_prep) bortezomib_4\NNS|that|dexamethasone|treatment (r_nsubj) is_17\VBZ|.|results (l_attr) treatment_21\NN|that|bortezomib|dexamethasone (l_prep) for_22\IN|effective|induction|warrants|an (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MM_27\NNP|NONE
6769133
D004317_D006333 CID adriamycin_13\NNS|average|m|below|considered|cumulative|an (r_compound) dose_14\NN|NONE (r_pobj) at_9\IN|.||failure (r_prep) developed_5\VBD|NONE (l_dobj) failure_8\NN|at|.|
D018943_D009202 NONE anthracycline_10\NN| (r_amod) induced_12\VBN|human (r_amod) cardiomyopathy_13\NN|NONE
D004317_D066126 NONE adriamycin_6\NNS|NONE (r_pobj) of_5\IN|leukemogenic|in|possible (r_prep) effects_4\NNS|and|. (r_conj) Cardiotoxic_0\NNP|NONE
D018943_D001768 NONE anthracycline_10\NN| (r_amod) induced_12\VBN|human (r_amod) cardiomyopathy_13\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) found_7\VBN|NONE (r_acl) those_6\DT|.|,|Histologically|lesions (r_dobj) resembled_5\VBD|NONE (l_nsubj) lesions_4\NNS|.|those|,|Histologically
D004317_D015470 CID adriamycin_16\NNS|NONE (r_pobj) of_15\IN|/|mg| (r_prep) m2_14\CD|NONE (r_dobj) receiving_10\VBG|NONE (r_pcomp) after_9\IN|leukemia| (r_prep) developed_5\VBD|alive|monkey|after|.|; (l_dobj) leukemia_8\NN|after|
D004317_D007938 NONE adriamycin_4\NN|that|than|be|and|cardiotoxin|, (r_nsubj) is_5\VBZ|.|results (l_conj) be_20\VB|that|adriamycin|than|and|cardiotoxin|, (l_nsubj) leukemia_18\NN|may|that|consequence
3762968
D013835_D014899 NONE pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|]|high|[ (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|,|reported|patient|if|also (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|We|enzyme|from|,|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_relcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D013835_D014899 NONE TPP_44\NNP|thiamine|)|( (r_appos) pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|]|high|[ (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|,|reported|patient|if|also (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|We|enzyme|from|,|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_relcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D013835_D014899 NONE TPP_30\NNP|NONE (r_pobj) for_29\IN|its (r_prep) Km_28\NNP|NONE (r_pobj) by_26\IN|as (r_agent) determined_25\VBN|patient|that|transketolase (r_advcl) had_21\VBD|.|We (l_nsubj) patient_7\NN|that|transketolase|determined (l_prep) with_14\IN|the|and|mentioned|one (l_pobj) history_16\NN|NONE (l_prep) of_17\IN|no (l_pobj) encephalopathy_20\NN|NONE
D014042_D020915 NONE tolazamide_24\NN|NONE (r_pobj) with_23\IN|when (r_prep) treated_22\VBN|encephalopathy|who (r_advcl) developed_17\VBD|diabetic|a (r_relcl) patient_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) fibroblasts_11\NNS|NONE (r_pobj) from_10\IN|We|enzyme|in|,|. (r_prep) studied_1\VBD|NONE (l_prep) in_26\IN|We|enzyme|from|,|. (l_pobj) order_27\NN|NONE (l_acl) delineate_29\VB|NONE (l_ccomp) had_34\VBD|to (l_advcl) reported_50\VBN|,|abnormality|patient|if|also (l_prep) in_51\IN|previously|as (l_pobj) syndrome_56\NN|NONE
D014042_D020915 NONE tolazamide_15\NN| (r_npadvmod) induced_17\VBN|from|Wernicke (r_amod) encephalopathy_20\NN|NONE (r_pobj) with_14\IN|the (r_prep) patient_13\NN|postalcoholic|Korsakoff|and (r_conj) syndrome_10\NN|NONE
D013831_D014899 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|,|,|a|transketolase (r_amod) enzyme_6\NN|We|from|in|,|. (r_dobj) studied_1\VBD|NONE (l_prep) from_10\IN|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_relcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D013835_D003920 NONE pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|]|high|[ (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|,|reported|patient|if|also (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|We|enzyme|from|,|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
D013835_D003920 NONE TPP_44\NNP|thiamine|)|( (r_appos) pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|]|high|[ (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|,|reported|patient|if|also (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|We|enzyme|from|,|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
D013835_D003920 NONE TPP_30\NNP|NONE (r_pobj) for_29\IN|its (r_prep) Km_28\NNP|NONE (r_pobj) by_26\IN|as (r_agent) determined_25\VBN|patient|that|transketolase (r_advcl) had_21\VBD|.|We (l_nsubj) patient_7\NN|that|transketolase|determined (l_conj) one_9\CD|the|and|with|mentioned (l_prep) of_10\IN|NONE (l_pobj) kindreds_13\NNS|NONE (l_amod) diabetic_12\JJ|the
D013831_D020915 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|,|,|a|transketolase (r_amod) enzyme_6\NN|We|from|in|,|. (r_dobj) studied_1\VBD|NONE (l_prep) in_26\IN|We|enzyme|from|,|. (l_pobj) order_27\NN|NONE (l_acl) delineate_29\VB|NONE (l_ccomp) had_34\VBD|to (l_advcl) reported_50\VBN|,|abnormality|patient|if|also (l_prep) in_51\IN|previously|as (l_pobj) syndrome_56\NN|NONE
D013835_D020915 NONE pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|]|high|[ (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|,|reported|patient|if|also (r_dobj) had_34\VBD|to (l_advcl) reported_50\VBN|,|abnormality|patient|if|also (l_prep) in_51\IN|previously|as (l_pobj) syndrome_56\NN|NONE
D013835_D020915 NONE TPP_44\NNP|thiamine|)|( (r_appos) pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|]|high|[ (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|,|reported|patient|if|also (r_dobj) had_34\VBD|to (l_advcl) reported_50\VBN|,|abnormality|patient|if|also (l_prep) in_51\IN|previously|as (l_pobj) syndrome_56\NN|NONE
D014042_D014899 CID tolazamide_3\NN| (r_npadvmod) induced_5\VBN|Wernicke (r_amod) encephalopathy_8\NN|NONE
D014042_D014899 CID tolazamide_24\NN|NONE (r_pobj) with_23\IN|when (r_prep) treated_22\VBN|encephalopathy|who (r_advcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D014042_D014899 CID tolazamide_15\NN| (r_npadvmod) induced_17\VBN|from|Wernicke (r_amod) encephalopathy_20\NN|NONE
D014042_D003920 NONE tolazamide_24\NN|NONE (r_pobj) with_23\IN|when (r_prep) treated_22\VBN|encephalopathy|who (r_advcl) developed_17\VBD|diabetic|a (r_relcl) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
D013831_D003920 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|,|,|a|transketolase (r_amod) enzyme_6\NN|We|from|in|,|. (r_dobj) studied_1\VBD|NONE (l_prep) from_10\IN|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
3732088
D000584_D003324 NONE amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|disease|) (r_prep) known_14\VBN|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN|)|after
D011188_D001145 NONE potassium_2\NN|.|,|in (l_conj) arrhythmias_4\NNS|and
D011188_D001145 NONE potassium_9\NN|NONE (r_pobj) in_7\IN|modest (r_prep) changes_6\NNS|can|tendency|that (r_nsubj) alter_11\VB|.|It|been|has (l_dobj) tendency_13\NN|can|changes|that (l_prep) towards_14\IN|the (l_pobj) arrhythmias_16\NNS|NONE
D002752_D006973 NONE chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|similar|in (r_prep) period_35\NN|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D003324 NONE potassium_25\NN| (r_npadvmod) conserving_27\VBG|NONE (r_amod) diuretic_28\JJ|a|( (r_amod) amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|disease|) (r_prep) known_14\VBN|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN|)|after
D011188_D003324 NONE potassium_38\NN| (r_npadvmod) losing_40\VBG|diuretic|(|)|a (r_amod) chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|similar|in (r_prep) period_35\NN|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN|NONE (l_conj) known_14\VBN|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN|)|after
D002752_D018879 CID chlorthalidone_6\NN|the (r_compound) phase_7\NN|period|increased|.|Compared|and|with|,|,|was (r_nsubjpass) associated_9\VBN|NONE (l_prep) with_10\IN|period|increased|.|phase|Compared|and|,|,|was (l_pobj) frequency_13\NN|NONE (l_prep) of_14\IN|grading|an|and|increased (l_pobj) beats_17\NNS|NONE
D011188_D003327 NONE potassium_2\NN|.|,|in (r_conj) Diuretics_0\NNS|NONE (l_prep) in_5\IN|.|,|potassium (l_pobj) disease_8\NN|NONE
D000584_D006973 NONE amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|disease|) (r_prep) known_14\VBN|was|excitability|and|,|in|period|Thus|and|. (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D006973 NONE potassium_2\NN|.|,|in (r_conj) Diuretics_0\NNS|NONE (l_prep) in_5\IN|.|,|potassium (l_pobj) disease_8\NN|NONE (l_amod) hypertensive_6\JJ|coronary
D011188_D006973 NONE potassium_25\NN| (r_npadvmod) conserving_27\VBG|NONE (r_amod) diuretic_28\JJ|a|( (r_amod) amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|disease|) (r_prep) known_14\VBN|was|excitability|and|,|in|period|Thus|and|. (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D006973 NONE potassium_38\NN| (r_npadvmod) losing_40\VBG|diuretic|(|)|a (r_amod) chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|similar|in (r_prep) period_35\NN|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D002752_D003324 NONE chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|similar|in (r_prep) period_35\NN|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN|NONE (l_conj) known_14\VBN|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN|)|after
D000584_D018879 NONE amiloride_2\NN|NONE (r_compound) treatment_3\NN|NONE (r_pobj) to_1\IN|NONE (r_prep) Compared_0\VBN|period|increased|.|phase|and|with|,|,|was (r_prep) associated_9\VBN|NONE (l_prep) with_10\IN|period|increased|.|phase|Compared|and|,|,|was (l_pobj) frequency_13\NN|NONE (l_prep) of_14\IN|grading|an|and|increased (l_pobj) beats_17\NNS|NONE
D011188_D017202 NONE potassium_6\NN| (r_npadvmod) losing_8\VBG|diuretic (r_amod) therapy_10\NN|can|because|excitability (r_nsubj) increase_12\VB|minor|that|in|, (l_dobj) excitability_15\NN|can|therapy|because (l_prep) in_16\IN|electrical|myocardial (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D011188_D017202 NONE potassium_28\NN|plasma (r_compound) concentrations_29\NNS|NONE (r_pobj) in_26\IN|increase|minor|that|, (r_prep) falls_25\VBZ|.|avoided|results (l_advcl) increase_12\VB|minor|that|in|, (l_dobj) excitability_15\NN|can|therapy|because (l_prep) in_16\IN|electrical|myocardial (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
3137399
D016685_D066126 NONE C._12\NNP|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|on|A|prospective (r_acl) study_2\NN|NONE (l_prep) on_3\IN|A|prospective|induced (l_pobj) dependency_6\NN|NONE (l_prep) of_7\IN|the|dose (l_pobj) cardiotoxicity_8\NN|NONE
D016685_D066126 NONE C_3\NNP|combined|Since|be|been|,|.|has (r_nsubjpass) suggested_9\VBN|NONE (l_xcomp) be_11\VB|combined|Since|been|,|.|has|C (l_acomp) cardiotoxic_12\JJ|to
D016685_D066126 NONE MMC_5\NN|mitomycin (r_appos) C_3\NNP|combined|Since|be|been|,|.|has (r_nsubjpass) suggested_9\VBN|NONE (l_xcomp) be_11\VB|combined|Since|been|,|.|has|C (l_acomp) cardiotoxic_12\JJ|to
D016685_D066126 NONE MMC_16\NN| (r_npadvmod) related_18\VBN|NONE (r_amod) cardiotoxicity_19\NN|occurring|dependent|that|,|,|in
D016685_D006333 CID MMC_11\NNP|NONE (r_pobj) after_7\IN|One|.|failure (r_prep) developed_4\VBD|NONE (l_dobj) failure_6\NN|One|after|.
D004317_D006333 CID doxorubicin_17\NN|m|and||mg (r_conj) MMC_11\NNP|NONE (r_pobj) after_7\IN|One|.|failure (r_prep) developed_4\VBD|NONE (l_dobj) failure_6\NN|One|after|.
D004317_D066126 NONE doxorubicin_21\NN|NONE (r_dobj) following_20\VBG|NONE (r_pcomp) given_19\VBN|when|or|with|especially (r_conj) combined_16\VBN|Since|be|been|,|.|has|C (r_advcl) suggested_9\VBN|NONE (l_xcomp) be_11\VB|combined|Since|been|,|.|has|C (l_acomp) cardiotoxic_12\JJ|to
D004317_D066126 NONE doxorubicin_47\NN|NONE (r_pobj) with_46\IN|)|also|(|previously (r_prep) treated_45\VBN|NONE (r_acl) patients_38\NNS|mainly (r_pobj) in_37\IN|occurring|dependent|that|cardiotoxicity|,|, (r_prep) is_20\VBZ|we|Based|.|, (l_nsubj) cardiotoxicity_19\NN|occurring|dependent|that|,|,|in
761833
D000641_D003128 NONE ammonia_2\NN|in (r_compound) coma_3\NN|NONE
D000641_D003128 NONE Ammonia_0\NN|NONE (r_compound) coma_1\NN|.|was|in
D000641_D003128 NONE ammonia_18\NN|the (r_compound) coma_19\NN|nor|affect|not|did
D000641_D003128 NONE ammonia_26\NN|the|blood (r_compound) concentrations_27\NNS|NONE (r_dobj) affect_21\VB|nor|coma|not|did (r_conj) prevent_16\VB|infusion|.|raise (l_dobj) coma_19\NN|nor|affect|not|did
D000641_D003128 NONE ammonia_14\NN|NONE (r_pobj) on_10\IN||coma|L|and (r_prep) dopa_9\NN|NONE (l_conj) coma_18\NN||L|and|on
D000641_D003128 NONE ammonia_17\NN|the (r_compound) coma_18\NN||L|and|on
D000641_D003128 NONE ammonia_8\NN|NONE (r_pobj) in_4\IN|the|and|prevention (r_prep) reduction_3\NN|be|can|.|for|Thus|by|,|, (l_conj) prevention_11\NN|in|the|and (l_prep) of_12\IN|the|after (l_pobj) coma_14\NN|NONE
D000641_D003128 NONE ammonia_13\NN|NONE (r_compound) coma_14\NN|NONE
D064751_D003128 NONE salt_19\NN|the (r_compound) injection_20\NN|minutes (r_pobj) before_16\IN|coma|was|.|with (r_prep) prevented_3\VBN|NONE (l_nsubjpass) coma_1\NN|was|before|.|with
D007980_D001927 NONE dopa_18\NNP|NONE (r_dobj) receiving_15\VBG|encephalopathic|some (r_acl) patients_14\NNS|NONE (l_amod) encephalopathic_13\JJ|some|receiving
D000643_D003128 CID NH4CL_17\NN|NONE (r_pobj) of_14\IN|an (r_prep) intraperitonealinjection_13\NN|NONE (r_pobj) of_11\IN| (r_prep) minutes_10\NNS|NONE (r_pobj) within_6\IN|NONE (r_prep) rats_5\NNS|NONE (r_pobj) in_4\IN|.|was|coma (r_prep) produced_3\VBN|NONE (l_nsubjpass) coma_1\NN|.|was|in
D007980_D003128 NONE dopa_9\NNP|NONE (r_pobj) by_6\IN|NONE (r_prep) rats_5\NNS|NONE (r_pobj) in_4\IN|ammonia (r_prep) coma_3\NN|NONE
D007980_D003128 NONE dopa_9\NN|NONE (r_pobj) with_4\IN|coma|was|before|. (r_prep) prevented_3\VBN|NONE (l_nsubjpass) coma_1\NN|was|before|.|with
D007980_D003128 NONE dopa_9\NN|NONE (l_conj) coma_18\NN||L|and|on
D007980_D003128 NONE dopa_18\NNP|NONE (r_pobj) after_15\IN|the|of (r_prep) prevention_11\NN|in|the|and (l_prep) of_12\IN|the|after (l_pobj) coma_14\NN|NONE
D004298_D003128 NONE dopamine_3\NN|NONE (r_pobj) of_2\IN|Intraventricular (r_prep) infusion_1\NN|prevent|.|raise (r_nsubj) sufficient_4\JJ|NONE (l_conj) prevent_16\VB|infusion|.|raise (l_dobj) coma_19\NN|nor|affect|not|did
D004298_D003128 NONE dopamine_9\NN|to|to (r_dobj) raise_6\VB|prevent|infusion|. (r_xcomp) sufficient_4\JJ|NONE (l_conj) prevent_16\VB|infusion|.|raise (l_dobj) coma_19\NN|nor|affect|not|did
D004298_D003128 NONE dopamine_29\NN|NONE (r_pobj) of_28\IN|the|on|peripheral (r_prep) effect_27\NN|NONE (r_pobj) by_24\IN|be|can|.|for|Thus|reduction|,|, (r_agent) accounted_22\VBN|NONE (l_nsubjpass) reduction_3\NN|be|can|.|for|Thus|by|,|, (l_conj) prevention_11\NN|in|the|and (l_prep) of_12\IN|the|after (l_pobj) coma_14\NN|NONE
8278214
D009020_D006930 CID morphine_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|terminal|cancer (r_acl) patients_6\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) myoclonus_2\NN|.|and (r_conj) Hyperalgesia_0\NNP|NONE
D009020_D006930 CID morphine_16\NN|NONE (r_pobj) of_14\IN|high (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|patients|developed|. (r_prep) treated_10\VBN|NONE (l_advcl) developed_17\VBN|patients|with|. (l_dobj) hyperalgesia_18\NN|NONE
D009020_D006930 CID morphine_16\NN|NONE (r_pobj) of_15\IN|high (r_prep) doses_14\NNS|and|/|hyperalgesia (r_conj) myoclonus_11\NN|NONE (l_nmod) hyperalgesia_9\NN|doses|and|/
D009020_D006930 CID morphine_27\NN|role|that|,|for (r_nsubj) plays_33\VBZ|support|.|,|are (r_ccomp) indicates_25\VBZ|NONE (l_advcl) are_17\VBP|support|.|,|plays (l_nsubj) descriptions_4\NNS|Although|available (l_prep) of_5\IN|clinical|few (l_pobj) relationship_7\NN|NONE (l_prep) between_8\IN|the (l_pobj) myoclonus_11\NN|NONE (l_nmod) hyperalgesia_9\NN|doses|and|/
D009020_D009369 NONE morphine_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|terminal|cancer (r_acl) patients_6\NNS|NONE (l_compound) cancer_5\NN|terminal|treated
D009020_D009369 NONE morphine_16\NN|NONE (r_pobj) of_14\IN|high (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|patients|developed|. (r_prep) treated_10\VBN|NONE (l_nsubj) patients_2\NNS|with|developed|. (l_compound) cancer_1\NN|in|Eight
D009020_D009207 CID morphine_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|terminal|cancer (r_acl) patients_6\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) myoclonus_2\NN|.|and
D009020_D009207 CID morphine_16\NN|NONE (r_pobj) of_15\IN|high (r_prep) doses_14\NNS|and|/|hyperalgesia (r_conj) myoclonus_11\NN|NONE
D009020_D009207 CID morphine_27\NN|role|that|,|for (r_nsubj) plays_33\VBZ|support|.|,|are (r_ccomp) indicates_25\VBZ|NONE (l_advcl) are_17\VBP|support|.|,|plays (l_nsubj) descriptions_4\NNS|Although|available (l_prep) of_5\IN|clinical|few (l_pobj) relationship_7\NN|NONE (l_prep) between_8\IN|the (l_pobj) myoclonus_11\NN|NONE
10728962
D014667_D006333 NONE Vasopressin_0\NN|NONE (l_prep) in_1\IN|. (l_pobj) treatment_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) hypotension_8\NN|NONE (l_prep) in_9\IN|induced (l_pobj) failure_12\NN|NONE
D014667_D006333 NONE vasopressin_16\NN|NONE (r_pobj) of_15\IN|low (r_prep) doses_14\NNS|In|pressure|.|without (r_nsubj) restored_17\VBD|NONE (l_prep) In_0\IN|doses|pressure|.|without (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE
D020105_D006333 NONE milrinone_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) hypotension_8\NN|NONE (l_prep) in_9\IN|induced (l_pobj) failure_12\NN|NONE
D020105_D006333 NONE milrinone_7\NN|such (l_prep) in_8\IN|NONE (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) failure_14\NN|NONE
D020105_D006333 NONE milrinone_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) hypotension_7\NN|NONE (r_pobj) with_6\IN|decompensated|heart (r_prep) failure_5\NN|NONE
D020105_D006333 NONE milrinone_26\NN|NONE (r_pobj) of_25\IN|the|inotropic (r_prep) effect_24\NN|NONE (r_dobj) inhibiting_21\VBG|NONE (r_pcomp) without_20\IN|doses|In|pressure|. (r_prep) restored_17\VBD|NONE (l_prep) In_0\IN|doses|pressure|.|without (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE
D020105_D007022 CID milrinone_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) hypotension_8\NN|NONE
D020105_D007022 CID milrinone_7\NN|such (r_pobj) as_6\IN|phosphodiesterase (r_prep) inhibitors_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|is|frequently|.|cause (r_nsubjpass) restricted_17\VBN|NONE (l_advcl) cause_20\VBP|is|use|frequently|. (l_dobj) vasodilation_21\NN|because|they (l_conj) hypotension_23\NN|and
D020105_D007022 CID milrinone_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) hypotension_7\NN|NONE
D020105_D007022 CID milrinone_26\NN|NONE (r_pobj) of_25\IN|the|inotropic (r_prep) effect_24\NN|NONE (r_dobj) inhibiting_21\VBG|NONE (r_pcomp) without_20\IN|doses|In|pressure|. (r_prep) restored_17\VBD|NONE (l_prep) In_0\IN|doses|pressure|.|without (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE (l_prep) with_6\IN|decompensated|heart (l_pobj) hypotension_7\NN|NONE
D014667_D007022 CID Vasopressin_0\NN|NONE (l_prep) in_1\IN|. (l_pobj) treatment_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) hypotension_8\NN|NONE
D014667_D007022 CID vasopressin_16\NN|NONE (r_pobj) of_15\IN|low (r_prep) doses_14\NNS|In|pressure|.|without (r_nsubj) restored_17\VBD|NONE (l_prep) In_0\IN|doses|pressure|.|without (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE (l_prep) with_6\IN|decompensated|heart (l_pobj) hypotension_7\NN|NONE
343678
D006514_D006509 NONE antigen_43\NN|HBsAG)positive|( (r_nmod) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (r_pcomp) in_29\IN|relative|their (r_prep) efficacies_28\NNS|to (r_dobj) assess_25\VB|were|globulin|.|in (r_advcl) examined_15\VBN|NONE (l_nsubjpass) globulin_3\NN|were|assess|.|in (l_compound) B_1\NN|globulin|and|HBIG|immune
D006514_D006509 NONE antigen_43\NN|HBsAG)positive|( (r_nmod) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (l_dobj) hepatitis_33\NN|after
D006514_D006509 NONE HBsAG)-positive_45\JJ|(|antigen (r_compound) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (r_pcomp) in_29\IN|relative|their (r_prep) efficacies_28\NNS|to (r_dobj) assess_25\VB|were|globulin|.|in (r_advcl) examined_15\VBN|NONE (l_nsubjpass) globulin_3\NN|were|assess|.|in (l_compound) B_1\NN|globulin|and|HBIG|immune
D006514_D006509 NONE HBsAG)-positive_45\JJ|(|antigen (r_compound) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (l_dobj) hepatitis_33\NN|after
430165
D010672_D064420 NONE diphenylhydantoin_7\JJ|NONE (r_compound) toxicity_8\NN|NONE
D010672_D064420 NONE DPH_13\NNP|NONE (r_compound) toxicity_14\NN|to|as
D010672_D002526 CID diphenylhydantoin_6\NN|(|DPH|) (r_nmod) overdose_10\NN|NONE (r_pobj) of_5\IN|the|common|side (r_prep) effects_4\NNS|NONE (r_pobj) Among_0\IN|signs|.|,|those (r_prep) are_18\VBP|NONE (l_nsubj) those_19\DT|signs|.|,|Among (l_prep) of_20\IN|NONE (l_pobj) dysfunction_22\NN|NONE
D010672_D002526 CID DPH_8\NNP|(|)|diphenylhydantoin (r_nmod) overdose_10\NN|NONE (r_pobj) of_5\IN|the|common|side (r_prep) effects_4\NNS|NONE (r_pobj) Among_0\IN|signs|.|,|those (r_prep) are_18\VBP|NONE (l_nsubj) those_19\DT|signs|.|,|Among (l_prep) of_20\IN|NONE (l_pobj) dysfunction_22\NN|NONE
D010672_D062787 CID diphenylhydantoin_6\NN|(|DPH|) (r_nmod) overdose_10\NN|NONE
D010672_D062787 CID DPH_8\NNP|(|)|diphenylhydantoin (r_nmod) overdose_10\NN|NONE
D010672_D062787 CID DPH_10\NNP|NONE (r_compound) overdose_11\NN|to
D010672_D010291 CID diphenylhydantoin_7\JJ|NONE (r_compound) toxicity_8\NN|NONE (r_pobj) of_6\IN|rare|a (r_prep) manifestation_5\NN|Transient|.|: (r_appos) hemiparesis_1\NN|NONE
D010672_D010291 CID DPH_10\NNP|NONE (r_compound) overdose_11\NN|to (r_pobj) due_8\IN|who|hemiparesis (r_prep) suffered_5\VBD|.|are|patients (l_dobj) hemiparesis_7\NN|who|due
D010672_D001927 NONE DPH_13\NNP|NONE (r_compound) toxicity_14\NN|to|as (r_dobj) manifest_12\VB|NONE (r_xcomp) liable_10\JJ|patients|that (r_acomp) are_9\VBP|It|.|is (l_nsubj) patients_4\NNS|liable|that (l_prep) with_5\IN|NONE (l_pobj) damage_8\NN|NONE
1628552
D002738_D006327 NONE Chloroquine_0\NNP|:|block (r_nsubj) related_1\VBD|case|. (l_dobj) block_4\NN|Chloroquine|:
D002738_D006327 NONE chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) features_3\NNS|assessment (r_dobj) revealed_2\VBD|,|.|assessment|features (r_ccomp) revealed_10\VBD|NONE (l_dobj) features_11\NNS|,|.|assessment|revealed (l_conj) block_19\NN|and|of
D002738_D006327 NONE chloroquine_15\NN|NONE (r_amod) discontinuation_16\NN|NONE (r_dobj) following_14\VBG|failure|spontaneously|. (r_prep) resolved_12\VBD|by|block|was|and (r_conj) treated_4\VBN|NONE (l_nsubjpass) block_2\NN|by|resolved|was|and
D002738_D015354 NONE chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|African|A|old|year (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|woman|. (l_pobj) deterioration_14\NN|NONE (l_prep) of_15\IN|progressive|fatiguability|, (l_pobj) vision_16\NN|NONE
D002738_D013575 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|African|A|old|year (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|woman|. (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|progressive|,|of (l_conj) dyspnoea_21\NN|,|easy (l_conj) dizziness_23\NN|, (l_acl) progressing_24\VBG|NONE (l_prep) to_25\IN|NONE (l_pobj) attacks_27\NNS|NONE
D002738_D004417 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|African|A|old|year (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|woman|. (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|progressive|,|of (l_conj) dyspnoea_21\NN|,|easy
D002738_D004244 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|African|A|old|year (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|woman|. (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|progressive|,|of (l_conj) dyspnoea_21\NN|,|easy (l_conj) dizziness_23\NN|,
D002738_D005221 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|African|A|old|year (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|woman|. (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|progressive|,|of
D002738_D001766 CID Chloroquine_0\NNP|:|block (r_nsubj) related_1\VBD|case|. (l_dobj) block_4\NN|Chloroquine|: (l_prep) with_5\IN|heart|complete (l_pobj) blindness_6\NN|NONE
D002738_D006333 CID chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) features_3\NNS|assessment (r_dobj) revealed_2\VBD|,|.|assessment|features (r_ccomp) revealed_10\VBD|NONE (l_dobj) features_11\NNS|,|.|assessment|revealed (l_prep) of_12\IN|block|and (l_pobj) failure_14\NN|NONE
D002738_D006333 CID chloroquine_15\NN|NONE (r_amod) discontinuation_16\NN|NONE (r_dobj) following_14\VBG|failure|spontaneously|. (r_prep) resolved_12\VBD|by|block|was|and (l_nsubj) failure_11\NN|following|spontaneously|.
D002738_D002037 CID chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) features_3\NNS|assessment (r_dobj) revealed_2\VBD|,|.|assessment|features (r_ccomp) revealed_10\VBD|NONE (l_dobj) features_11\NNS|,|.|assessment|revealed (l_conj) block_19\NN|and|of (l_prep) with_20\IN|heart|a|complete (l_pobj) pattern_25\NN|NONE (l_compound) block_24\NN|bundle|right
D002738_D012164 CID chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE
1445986
D015313_D000743 CID Cefotetan_0\NNP| (r_npadvmod) induced_2\VBN|hemolytic|immune|. (r_amod) anemia_5\NN|NONE
D010406_D000743 NONE penicillins_17\NNS|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|has|.|primarily|been|anemia (r_prep) described_12\VBN|NONE (l_nsubjpass) anemia_2\NN|in|has|.|primarily|been
D002511_D000743 NONE cephalosporins_22\NNS|and (r_conj) penicillins_17\NNS|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|has|.|primarily|been|anemia (r_prep) described_12\VBN|NONE (l_nsubjpass) anemia_2\NN|in|has|.|primarily|been
D015313_D000740 NONE cefotetan_10\NN|while (r_dobj) receiving_8\VBG|anemia|who (r_advcl) developed_5\VBD|a (l_dobj) anemia_6\NN|receiving|who
20042557
D015742_D011183 CID propofol_4\NN|light (r_amod) sedation_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|prevalence|. (r_nsubj) decreased_6\VBD|NONE (l_dobj) prevalence_8\NN|.|use (l_prep) of_9\IN|by|the|compared (l_pobj) delirium_11\NN|NONE
D015742_D003704 NONE propofol_39\NN|NONE (r_amod) sedation_40\NN|NONE (r_pobj) with_38\IN|spinal (r_prep) anesthesia_37\NN|NONE (r_pobj) under_35\IN|fracture (r_prep) repair_34\NN|who (r_dobj) underwent_31\VBD|or|dementia|preoperative (r_relcl) delirium_26\NN|NONE (l_conj) dementia_29\NN|or|underwent|preoperative
D015742_D006620 NONE propofol_39\NN|NONE (r_amod) sedation_40\NN|NONE (r_pobj) with_38\IN|spinal (r_prep) anesthesia_37\NN|NONE (r_pobj) under_35\IN|fracture (r_prep) repair_34\NN|who (l_compound) fracture_33\NN|under
D015742_D003693 CID propofol_39\NN|NONE (r_amod) sedation_40\NN|NONE (r_pobj) with_38\IN|spinal (r_prep) anesthesia_37\NN|NONE (r_pobj) under_35\IN|fracture (r_prep) repair_34\NN|who (r_dobj) underwent_31\VBD|or|dementia|preoperative (r_relcl) delirium_26\NN|NONE
D015742_D003693 CID propofol_4\NN|light (r_amod) sedation_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|prevalence|. (r_nsubj) decreased_6\VBD|NONE (l_dobj) prevalence_8\NN|.|use (l_prep) of_9\IN|by|the|compared (l_pobj) delirium_11\NN|NONE
10840460
D009020_D001523 NONE Morphine_0\NNP|.|disorders|dependently (r_nsubj) reversed_4\VBD|NONE (l_dobj) disorders_7\NNS|.|Morphine|dependently
D009020_D004487 NONE morphine_6\NN|NONE (r_pobj) of_5\IN|,|modifications (r_prep) administration_4\NN|NONE (l_appos) modifications_9\NNS|of|, (l_prep) as_16\IN|histological|of|, (l_pobj) edema_21\NN|such
D003520_D059265 NONE Cyclophosphamide_0\NNP| (r_npadvmod) induced_2\VBN|in|.|approach|: (r_amod) cystitis_3\NN|NONE (l_appos) approach_12\NN|in|.|induced|: (l_prep) to_13\IN|behavioral (l_pobj) model_16\NN|NONE (l_prep) of_17\IN|a|new (l_pobj) pain_19\NN|NONE
D003520_D059265 NONE CP_10\NNP| (r_npadvmod) induced_12\VBN|NONE (r_amod) cystitis_13\NN|NONE (r_pobj) of_9\IN|this|experimental (r_prep) model_8\NN|that|,|may|allowing|model (r_nsubj) be_15\VB|,|Overall|results|. (l_attr) model_20\NN|that|,|model|may|allowing (l_prep) of_21\IN|new|interesting|an|behavioral (l_pobj) pain_24\NN|NONE
D003520_D010146 CID CP_10\NNP| (r_npadvmod) induced_12\VBN|NONE (r_amod) cystitis_13\NN|NONE (r_pobj) of_9\IN|this|experimental (r_prep) model_8\NN|that|,|may|allowing|model (r_nsubj) be_15\VB|,|Overall|results|. (l_advcl) allowing_26\VBG|that|,|model|may|model (l_dobj) understanding_29\NN|NONE (l_prep) of_30\IN|a|better|approach|and (l_pobj) syndromes_33\NNS|NONE
D000171_D003556 NONE acrolein_22\NN|NONE (r_pobj) through_17\IN|to|effects (r_prep) produce_10\VB|NONE (r_xcomp) known_8\VBN|antitumoral|an (r_acl) agent_7\NN|,|CP|, (r_appos) Cyclophosphamide_0\NNP|was|induce|. (r_nsubjpass) used_25\VBN|NONE (l_xcomp) induce_27\VB|Cyclophosphamide|was|. (l_dobj) cystitis_28\NN|to
D003520_D003556 CID Cyclophosphamide_0\NNP| (r_npadvmod) induced_2\VBN|in|.|approach|: (r_amod) cystitis_3\NN|NONE
D003520_D003556 CID Cyclophosphamide_0\NNP|was|induce|. (r_nsubjpass) used_25\VBN|NONE (l_xcomp) induce_27\VB|Cyclophosphamide|was|. (l_dobj) cystitis_28\NN|to
D003520_D003556 CID CP_2\NNP|,|,|agent (r_appos) Cyclophosphamide_0\NNP|was|induce|. (r_nsubjpass) used_25\VBN|NONE (l_xcomp) induce_27\VB|Cyclophosphamide|was|. (l_dobj) cystitis_28\NN|to
D003520_D003556 CID CP_10\NNP| (r_npadvmod) induced_12\VBN|NONE (r_amod) cystitis_13\NN|NONE
11860278
D004298_D004827 NONE Dopamine_0\NNP|role|.|in|, (r_nsubj) plays_12\VBZ|NONE (l_prep) in_16\IN|role|.|Dopamine|, (l_pobj) control_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) seizures_21\NNS|NONE
D004298_D004827 NONE DA_2\NNP|through|, (r_appos) Dopamine_0\NNP|role|.|in|, (r_nsubj) plays_12\VBZ|NONE (l_prep) in_16\IN|role|.|Dopamine|, (l_pobj) control_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) seizures_21\NNS|NONE
D004298_D004827 NONE DA_11\NNP|NONE (r_compound) receptors_12\NNS|NONE (r_pobj) of_10\IN|in|the (r_prep) role_9\NN|NONE (l_prep) in_13\IN|the|of (l_pobj) occurrence_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) death_22\NN|NONE (l_amod) induced_19\VBN|cell|neuronal (l_npadvmod) epilepsy_17\NN|
D000109_D012640 NONE acetylcholine_16\NN|both|and (r_conj) glutamate_14\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) induced_11\VBN|NONE (r_acl) seizures_10\NNS|NONE
D010862_D020258 NONE pilocarpine_18\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|/|DR (r_acl) mice_12\NNS|NONE (r_pobj) in_9\IN|neurotoxicity|and (r_prep) seizures_6\NNS|NONE (l_conj) neurotoxicity_8\NN|and|in
D010862_D012640 CID pilocarpine_18\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|/|DR (r_acl) mice_12\NNS|NONE (r_pobj) in_9\IN|neurotoxicity|and (r_prep) seizures_6\NNS|NONE
D010862_D012640 CID pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) seizures_5\NNS|in|,|.|However
D018698_D012640 NONE glutamate_14\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) induced_11\VBN|NONE (r_acl) seizures_10\NNS|NONE
D007608_D012640 CID KA_23\NNP|NONE (r_pobj) to_22\IN|NONE (r_prep) comparison_21\NN|NONE (r_pobj) in_20\IN|widespread|neuronal|a|in (r_prep) death_12\NN|NONE (r_pobj) in_7\IN|seizures|,|.|However (r_prep) result_6\VBP|NONE (l_nsubj) seizures_5\NNS|in|,|.|However
2819587
11302406
D015725_D017180 NONE fluconazole_4\NN|was|when (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|tachycardia|and|:|patient|,|however|until|have|; (r_ccomp) continued_12\VBD|NONE (l_conj) tachycardia_21\NN|resolved|and|:|patient|,|however|until|have|;
D015725_D017180 NONE fluconazole_4\NN|was|when (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|tachycardia|and|:|patient|,|however|until|have|; (r_ccomp) continued_12\VBD|NONE (l_conj) tachycardia_21\NN|resolved|and|:|patient|,|however|until|have|; (l_appos) NSVT_23\NNP|)|nonsustained|ventricular|(
D015725_D017180 NONE fluconazole_22\NN|.|strongly|as|followed (r_dobj) suggests_21\VBZ|NONE (l_csubj) followed_9\VBN|.|strongly|fluconazole|as (l_nsubj) disappearance_2\NN|stopped|by (l_prep) of_3\IN|complete|contractions|The|and (l_pobj) NSVT_4\NNP|NONE
D011188_D003866 NONE potassium_10\NN|rectifier (r_compound) currents_11\NNS|rapidly (r_dobj) activating_7\VBG|NONE (r_pcomp) of_5\IN|NONE (r_prep) depression_4\NN|.|mechanism
D015725_D016171 CID Fluconazole_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|de|. (r_nmod) pointes_5\FW|NONE
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|de|(|)|torsade|TDP (r_amod) pointes_10\FW|NONE
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|de|(|)|torsade|TDP (r_amod) pointes_10\FW|NONE (l_appos) TDP_12\NNP|de|(|)|torsade|associated
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|de|(|)|torsade|TDP (r_amod) pointes_10\FW|NONE (r_pobj) of_4\IN|a (r_prep) case_3\NN|To|discuss|and|. (r_dobj) present_1\VB|NONE (l_conj) discuss_15\VB|To|case|and|. (l_dobj) role_18\NN|NONE (l_prep) in_19\IN|fluconazole (l_pcomp) causing_20\VBG|NONE (l_dobj) TDP_21\NNP|NONE
D015725_D016171 CID fluconazole_16\NN|in (r_poss) role_18\NN|NONE (r_dobj) discuss_15\VB|To|case|and|. (r_conj) present_1\VB|NONE (l_dobj) case_3\NN|To|discuss|and|. (l_prep) of_4\IN|a (l_pobj) pointes_10\FW|NONE
D015725_D016171 CID fluconazole_16\NN|in (r_poss) role_18\NN|NONE (r_dobj) discuss_15\VB|To|case|and|. (r_conj) present_1\VB|NONE (l_dobj) case_3\NN|To|discuss|and|. (l_prep) of_4\IN|a (l_pobj) pointes_10\FW|NONE (l_appos) TDP_12\NNP|de|(|)|torsade|associated
D015725_D016171 CID fluconazole_16\NN|in (r_poss) role_18\NN|NONE (l_prep) in_19\IN|fluconazole (l_pcomp) causing_20\VBG|NONE (l_dobj) TDP_21\NNP|NONE
D015725_D016171 CID fluconazole_21\NN|NONE (r_dobj) commencing_19\VBG|days (r_pcomp) after_18\IN|woman|isolated (r_prep) glabrata_8\NNS|NONE (l_xcomp) isolated_9\VBN|after|woman (l_prep) from_10\IN|NONE (l_pobj) abscess_13\NN|NONE (l_acl) developed_14\VBD|presacral|a (l_dobj) TDP_15\NNP|NONE
D015725_D016171 CID fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|,|for|no|other|including|risk (r_relcl) factors_6\NNS|patient|. (l_prep) for_7\IN|,|was|no|other|including|risk (l_pobj) TDP_8\NNP|NONE
D015725_D016171 CID fluconazole_33\NN|NONE (l_conj) TDP_35\NNP|and
D015725_D016171 CID fluconazole_4\NN|was|when (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|tachycardia|and|:|patient|,|however|until|have|; (l_nsubj) TDP_1\NNP|discontinued
D015725_D016171 CID fluconazole_14\NN|NONE (r_pobj) of_13\IN|development|and|the (r_prep) use_12\NN|NONE (l_conj) development_17\NN|of|and|the (l_prep) of_18\IN|the (l_pobj) TDP_19\NNP|NONE
D015725_D016171 CID fluconazole_5\NN|, (r_ccomp) aware_3\JJ|at|Clinicians|,|should|cause|. (r_acomp) be_2\VB|NONE (l_conj) cause_13\VB|at|Clinicians|,|should|aware|. (l_advcl) leading_20\VBG|,|may|prolongation (l_prep) to_21\IN|NONE (l_pobj) TDP_22\NNP|NONE
D015725_D009202 NONE fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|,|for|no|other|including|risk (r_relcl) factors_6\NNS|patient|. (l_prep) including_10\VBG|,|was|for|no|other|risk (l_pobj) disease_13\NN|NONE (l_amod) cardiomyopathy_15\NN|coronary|artery|,
D015725_D006333 NONE fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|,|for|no|other|including|risk (r_relcl) factors_6\NNS|patient|. (l_prep) including_10\VBG|,|was|for|no|other|risk (l_pobj) disease_13\NN|NONE (l_amod) cardiomyopathy_15\NN|coronary|artery|, (l_conj) failure_19\NN|,
D015725_D008133 NONE fluconazole_5\NN|, (r_ccomp) aware_3\JJ|at|Clinicians|,|should|cause|. (r_acomp) be_2\VB|NONE (l_conj) cause_13\VB|at|Clinicians|,|should|aware|. (l_dobj) prolongation_14\NN|,|may|leading (l_prep) of_15\IN|NONE (l_pobj) interval_18\NN|NONE
D015725_D003324 NONE fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|,|for|no|other|including|risk (r_relcl) factors_6\NNS|patient|. (l_prep) including_10\VBG|,|was|for|no|other|risk (l_pobj) disease_13\NN|NONE
D015725_D018879 NONE fluconazole_4\NN|was|when (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|tachycardia|and|:|patient|,|however|until|have|; (r_ccomp) continued_12\VBD|NONE (l_xcomp) have_14\VB|resolved|tachycardia|and|:|patient|,|however|until|; (l_dobj) contractions_17\NNS|to
D015725_D018879 NONE fluconazole_22\NN|.|strongly|as|followed (r_dobj) suggests_21\VBZ|NONE (l_csubj) followed_9\VBN|.|strongly|fluconazole|as (l_nsubj) disappearance_2\NN|stopped|by (l_conj) contractions_8\NNS|complete|of|The|and
D015725_D001145 NONE fluconazole_7\NN|is|when|in (r_nsubjpass) administered_9\VBN|be|monitoring|.|may (l_prep) in_10\IN|fluconazole|is|when (l_pobj) patients_11\NNS|NONE (l_relcl) are_13\VBP|NONE (l_prep) at_14\IN|who (l_pobj) risk_15\NN|NONE (l_prep) for_16\IN|NONE (l_pobj) arrhythmias_18\NNS|NONE
11271907
D003520_D009205 CID cyclophosphamide_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) to_4\IN|myocarditis|haemorrhagic (r_prep) secondary_3\JJ|. (l_amod) myocarditis_2\NN|haemorrhagic|to
D003520_D009205 CID cyclophosphamide_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|rare|a (r_prep) complication_7\NN|.|myocarditis (r_attr) is_2\VBZ|NONE (l_nsubj) myocarditis_1\NN|.|complication
D003520_D006470 CID cyclophosphamide_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) to_4\IN|myocarditis|haemorrhagic (r_prep) secondary_3\JJ|. (l_amod) myocarditis_2\NN|haemorrhagic|to
D003520_D006470 CID cyclophosphamide_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|rare|a (r_prep) complication_7\NN|.|myocarditis (r_attr) is_2\VBZ|NONE (l_nsubj) myocarditis_1\NN|.|complication
20304337
D003042_-1 NONE cocaine_8\NN|NONE (r_pobj) to_7\IN|.|prenatally|dysgenesis (r_prep) exposed_6\VBN|NONE (l_nsubj) dysgenesis_1\NN|.|prenatally|to
1255900
D006493_D013924 NONE heparin_8\JJ|NONE (r_compound) therapy_9\NN|NONE (r_pobj) of_7\IN|the|for (r_prep) initiation_6\NN|NONE (l_prep) for_10\IN|the|of (l_pobj) thrombophlebitis_13\NN|NONE
18405372
D012460_D001168 NONE sulfasalazine_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) arthritis_6\NN|NONE
D012460_D056486 CID sulfasalazine_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|: (r_acl) Hepatotoxicity_0\NN|NONE
D012460_D056486 CID sulfasalazine_7\NN|NONE (r_pobj) on_6\IN|who|met|and|hepatotoxicity (r_prep) had_4\VBD|,|'|, (l_dobj) hepatotoxicity_5\NN|who|on|met|and
D012460_D056486 CID sulfasalazine_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) hepatotoxicity_4\NN|NONE
D012460_D056486 CID sulfasalazine_7\NN|NONE (r_pobj) with_6\IN|serious (r_prep) hepatotoxicity_5\NN|NONE
D012460_D056486 CID sulfasalazine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Serious (r_acl) hepatotoxicity_1\NN|be|is|.
7565311
D016190_D018233 NONE carboplatin_15\NN|NONE (r_pobj) with_11\IN|was|for|who (r_prep) treated_10\VBN|a||old (l_prep) for_16\IN|was|with|who (l_pobj) rhabdomyosarcoma_20\NN|NONE
D016190_D058186 CID carboplatin_6\NN|dose|high (r_compound) chemotherapy_7\NN|NONE (r_pobj) in_3\IN|.|renal|Acute (r_prep) failure_2\NN|NONE
D016190_D058186 CID Carboplatin_0\NNP|has|cause|.|been (r_nsubjpass) reported_3\VBN|NONE (l_xcomp) cause_5\VB|Carboplatin|has|.|been (l_dobj) failure_8\NN|administered|to
6695415
D010665_D002543 CID phenylpropanolamine_4\NN|NONE (r_pobj) with_3\IN|in (r_prep) associated_2\VBN|Cerebral|. (r_acl) hemorrhage_1\NN|NONE
D010665_D002543 CID PPA_4\NNP|/ (r_nmod) caffeine_6\NN|that|administered|to|can (r_nsubj) lead_8\VB|results|. (l_prep) to_9\IN|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN|NONE
D002110_D006973 CID caffeine_7\NN|if|to|in|can (r_nsubj) lead_9\VB|to (l_prep) in_12\IN|caffeine|if|to|can (l_pobj) rats_16\NNS|NONE (l_amod) normotensive_13\NN|NONE (l_conj) hypertensive_15\JJ|and/or
D002110_D006973 CID caffeine_4\NN|)|single|A|dose|( (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE
D002110_D006973 CID caffeine_4\NN|)|single|A|dose|( (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE (l_prep) in_14\IN|acute (l_pobj) animals_20\NNS|NONE (l_amod) normotensive_17\NN|the|both (l_conj) hypertensive_19\JJ|and
D002110_D006973 CID caffeine_6\NN|that|administered|to|can (r_nsubj) lead_8\VB|results|. (l_prep) to_9\IN|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN|NONE (l_prep) in_12\IN|cerebral (l_pobj) animals_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002110_D002543 CID caffeine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) combination_6\NN|NONE (r_pobj) in_5\IN|with (r_prep) associated_2\VBN|Cerebral|. (r_acl) hemorrhage_1\NN|NONE
D002110_D002543 CID caffeine_6\NN|that|administered|to|can (r_nsubj) lead_8\VB|results|. (l_prep) to_9\IN|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN|NONE
D010665_D006973 CID PPA_5\NNP|/ (r_nmod) caffeine_7\NN|if|to|in|can (r_nsubj) lead_9\VB|to (l_prep) in_12\IN|caffeine|if|to|can (l_pobj) rats_16\NNS|NONE (l_amod) normotensive_13\NN|NONE (l_conj) hypertensive_15\JJ|and/or
D010665_D006973 CID PPA_2\NNP|/ (r_nmod) caffeine_4\NN|)|single|A|dose|( (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE
D010665_D006973 CID PPA_2\NNP|/ (r_nmod) caffeine_4\NN|)|single|A|dose|( (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE (l_prep) in_14\IN|acute (l_pobj) animals_20\NNS|NONE (l_amod) normotensive_17\NN|the|both (l_conj) hypertensive_19\JJ|and
D010665_D006973 CID PPA_4\NNP|/ (r_nmod) caffeine_6\NN|that|administered|to|can (r_nsubj) lead_8\VB|results|. (l_prep) to_9\IN|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN|NONE (l_prep) in_12\IN|cerebral (l_pobj) animals_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002110_D020521 NONE caffeine_7\NN|if|to|in|can (r_nsubj) lead_9\VB|to (l_prep) to_10\IN|caffeine|if|in|can (l_pobj) stroke_11\NN|NONE
D010665_D020521 CID Phenylpropanolamine_0\NNP|.|drug (r_nsubj) is_4\VBZ|NONE (l_attr) drug_6\NN|Phenylpropanolamine|. (l_relcl) associated_10\VBN|a (l_prep) with_11\IN|has|been|that (l_pobj) effects_14\NNS|NONE (l_prep) including_15\VBG|serious|side (l_pobj) stroke_16\NN|NONE
D010665_D020521 CID PPA_2\NNP|(|) (r_appos) Phenylpropanolamine_0\NNP|.|drug (r_nsubj) is_4\VBZ|NONE (l_attr) drug_6\NN|Phenylpropanolamine|. (l_relcl) associated_10\VBN|a (l_prep) with_11\IN|has|been|that (l_pobj) effects_14\NNS|NONE (l_prep) including_15\VBG|serious|side (l_pobj) stroke_16\NN|NONE
D010665_D020521 CID PPA_5\NNP|/ (r_nmod) caffeine_7\NN|if|to|in|can (r_nsubj) lead_9\VB|to (l_prep) to_10\IN|caffeine|if|in|can (l_pobj) stroke_11\NN|NONE
7596955
D000242_D001791 NONE cAMP_19\NNS|NONE (r_pobj) of_17\IN|NONE (r_prep) determination_16\NN|ex|platelet|and (r_conj) aggregation_14\NN|NONE
C045645_D005483 CID CLZ_25\NNP|NONE (r_pobj) of_24\IN|NONE (r_prep) ingestion_23\NN|especially (r_pobj) after_22\IN|,|flush|in (r_prep) accompanying_11\VBG|a|short (l_dobj) flush_13\NN|,|in|after
C045645_D006261 CID CLZ_25\NNP|NONE (r_pobj) of_24\IN|NONE (r_prep) ingestion_23\NN|especially (r_pobj) after_22\IN|,|flush|in (r_prep) accompanying_11\VBG|a|short (r_acl) duration_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) headache_6\NN|.|subjects
C045645_D009325 CID CLZ_25\NNP|NONE (r_pobj) of_24\IN|NONE (r_prep) ingestion_23\NN|especially (r_pobj) after_22\IN|,|flush|in (r_prep) accompanying_11\VBG|a|short (l_dobj) flush_13\NN|,|in|after (l_prep) in_14\IN|facial (l_pobj) one_15\CD|NONE (l_conj) nausea_17\NN|and
20510337
C024989_D058186 NONE Q10_5\NNP|NONE (r_pobj) of_3\IN|nephroprotective|The (r_prep) effect_2\NN|.|was|in|induced (r_nsubjpass) investigated_7\VBN|NONE (l_prep) in_8\IN|.|was|induced|effect (l_pobj) mice_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) injury_13\NN|NONE
D002945_D009369 NONE cisplatin_55\JJ|NONE (r_amod) administration_56\NN|NONE (r_pobj) from_54\IN|NONE (r_prep) resulted_53\VBD|reductions (r_advcl) attenuated_42\VBD|elevations|and|, (r_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
D002945_D007674 NONE cisplatin_5\NN|in|acute (r_amod) nephrotoxicity_6\NN|treatment|.
D002945_D007674 NONE cisplatin_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) mediated_6\VBN|renal|tissue|histopathological (r_acl) damage_5\NN|Also|.|,|was|by
D002945_D007674 NONE cisplatin_15\NN|acute|encountered (r_amod) nephrotoxicity_16\NN|NONE
C024989_D009336 NONE Q10_1\NNP|,|.|decreased|(|)|suppressed|deficits|,|level|significantly (r_nsubj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D005978_D009369 NONE glutathione_12\NN|and|reduced|activity (r_compound) level_13\NN|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
D013481_D009336 NONE superoxide_15\NN|dismutase (r_amod) activity_17\NN|glutathione|and|reduced (r_conj) level_13\NN|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D012643_D009336 NONE selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|and|, (r_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D010984_D009369 NONE platinum_37\NN|NONE (r_compound) ion_38\NN|NONE (r_compound) concentration_39\NN|nitric|and (r_conj) oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
C024989_D009369 NONE Q10_1\NNP|,|.|decreased|(|)|suppressed|deficits|,|level|significantly (r_nsubj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
D010984_D009336 NONE platinum_37\NN|NONE (r_compound) ion_38\NN|NONE (r_compound) concentration_39\NN|nitric|and (r_conj) oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
C024989_D007674 NONE Q10_1\NNP|Coenzyme (r_compound) treatment_2\NN|nephrotoxicity|. (r_nsubj) ameliorates_3\VBZ|NONE (l_dobj) nephrotoxicity_6\NN|treatment|.
C024989_D007674 NONE Q10_13\NNP|coenzyme (r_compound) treatment_14\NN|NONE (r_pobj) by_11\IN|Also|.|damage|,|was (r_agent) ameliorated_10\VBN|NONE (l_nsubjpass) damage_5\NN|Also|.|,|was|by
C024989_D007674 NONE Q10_5\NNP|option|that (r_nsubj) represents_6\VBZ|.|was|It (l_dobj) option_10\NN|Q|that (l_acl) protect_12\VB|therapeutic|a|potential (l_prep) against_13\IN|to (l_pobj) nephrotoxicity_16\NN|NONE
D009569_D009336 NONE oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D015032_D009369 NONE zinc_48\NN|and (r_conj) selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|and|, (r_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
D005978_D009336 NONE glutathione_12\NN|and|reduced|activity (r_compound) level_13\NN|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D013481_D009369 NONE superoxide_15\NN|dismutase (r_amod) activity_17\NN|glutathione|and|reduced (r_conj) level_13\NN|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
D015032_D009336 NONE zinc_48\NN|and (r_conj) selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|and|, (r_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D002945_D058186 CID cisplatin_21\NN|NONE (r_pobj) of_20\IN|i.p.|)|mg/kg|(|a|single (r_prep) injection_19\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|.|was|in|effect (r_advcl) investigated_7\VBN|NONE (l_prep) in_8\IN|.|was|induced|effect (l_pobj) mice_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) injury_13\NN|NONE
D012643_D009369 NONE selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|and|, (r_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
D002945_D009336 NONE cisplatin_55\JJ|NONE (r_amod) administration_56\NN|NONE (r_pobj) from_54\IN|NONE (r_prep) resulted_53\VBD|reductions (r_advcl) attenuated_42\VBD|elevations|and|, (r_conj) decreased_24\VBD|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS|and|attenuated|, (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D009569_D009369 NONE oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) tumor_28\NN|alpha|necrosis
17511042
C417083_D063726 CID alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE
C417083_D063726 CID alpha-2b_17\CD|.|We|woman (r_prep) present_1\VBP|NONE (l_dobj) woman_6\NN|alphab|.|We (l_relcl) developed_8\VBD|old|a (l_dobj) parasitosis_11\NN|who
D012254_D019698 NONE ribavirin_18\JJ|NONE (r_compound) treatment_19\NN|and|interferon|pegylated (r_conj) alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE (l_prep) in_7\IN|during|delusional (l_pobj) patient_12\NN|NONE (l_compound) C_11\NN|chronic|a
D012254_D019698 NONE ribavirin_10\RB|and (r_conj) interferon_8\NN|NONE (r_pobj) with_7\IN|chronic|C (r_prep) patients_6\NNS|NONE (l_compound) C_5\NNP|with|chronic
D012254_D063726 CID ribavirin_18\JJ|NONE (r_compound) treatment_19\NN|and|interferon|pegylated (r_conj) alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE
D012254_D063726 CID ribavirin_20\RB|and (r_conj) weekly_18\RB|NONE (r_amod) alpha-2b_17\CD|.|We|woman (r_prep) present_1\VBP|NONE (l_dobj) woman_6\NN|alphab|.|We (l_relcl) developed_8\VBD|old|a (l_dobj) parasitosis_11\NN|who
C417083_D019698 NONE alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE (l_prep) in_7\IN|during|delusional (l_pobj) patient_12\NN|NONE (l_compound) C_11\NN|chronic|a
1928887
D009270_D062787 NONE Naloxone_0\NN|of|due|. (r_compound) reversal_1\NN|NONE (l_prep) due_4\IN|Naloxone|of|. (l_pobj) overdose_7\NN|to
D009270_D062787 NONE naloxone_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) administration_20\NN|NONE (r_pobj) with_18\IN|that|promptly|, (r_prep) resolved_16\VBD|case|.|We|,|manifested (r_ccomp) report_1\VBP|NONE (l_dobj) case_3\NN|.|We|resolved|,|manifested (l_prep) of_4\IN|a (l_pobj) overdose_8\NN|NONE
D002216_D062787 NONE captopril_6\NN|NONE (r_compound) overdose_7\NN|to
D002216_D062787 NONE captopril_7\NN|intentional|an (r_compound) overdose_8\NN|NONE
D002216_D007022 NONE captopril_6\NN|NONE (r_compound) overdose_7\NN|to (r_pobj) due_4\IN|Naloxone|of|. (r_prep) reversal_1\NN|NONE (l_prep) of_2\IN|Naloxone|due|. (l_pobj) hypotension_3\NN|NONE
D002216_D007022 NONE captopril_15\NN|NONE (r_pobj) of_14\IN|hypotensive|the (r_prep) actions_13\NNS|NONE (l_amod) hypotensive_12\JJ|of|the
D002216_D007022 NONE captopril_7\NN|intentional|an (r_compound) overdose_8\NN|NONE (r_pobj) of_4\IN|a (r_prep) case_3\NN|.|We|resolved|,|manifested (r_dobj) report_1\VBP|NONE (l_advcl) manifested_10\VBN|case|.|We|resolved|, (l_agent) by_11\IN|NONE (l_pobj) hypotension_13\NN|NONE
D002216_D007022 NONE captopril_11\NN| (r_npadvmod) induced_13\VBN|treated (r_amod) hypotension_14\NN|NONE
D002216_D007022 NONE captopril_15\NN|NONE (r_pobj) from_14\IN|NONE (r_prep) resulting_13\VBG|NONE (r_acl) hypotension_12\NN|NONE
D009270_D007022 NONE Naloxone_0\NN|of|due|. (r_compound) reversal_1\NN|NONE (l_prep) of_2\IN|Naloxone|due|. (l_pobj) hypotension_3\NN|NONE
D009270_D007022 NONE naloxone_3\NN|opioid|The (r_appos) antagonist_2\NN|.|has|block|been (r_nsubjpass) shown_6\VBN|NONE (l_xcomp) block_8\VB|.|has|been|antagonist (l_conj) reverse_10\VB|or|to (l_dobj) actions_13\NNS|NONE (l_amod) hypotensive_12\JJ|of|the
D009270_D007022 NONE naloxone_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) administration_20\NN|NONE (r_pobj) with_18\IN|that|promptly|, (r_prep) resolved_16\VBD|case|.|We|,|manifested (r_ccomp) report_1\VBP|NONE (l_advcl) manifested_10\VBN|case|.|We|resolved|, (l_agent) by_11\IN|NONE (l_pobj) hypotension_13\NN|NONE
D009270_D007022 NONE naloxone_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|induced (r_acl) hypotension_14\NN|NONE
D009270_D007022 NONE naloxone_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) reversal_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) hypotension_12\NN|NONE
10354657
D008094_D007037 CID lithium_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) onset_20\NN|years (r_pobj) after_19\IN|.|patients|compared|onset|after|)|)|(|had (r_prep) accelerated_12\VBN|NONE (l_dobj) onset_13\NN|.|patients|compared|after|)|)|(|had|after (l_prep) of_14\IN|( (l_pobj) hypothyroidism_15\NN|NONE
D008094_D007037 CID lithium_38\NN|NONE (r_compound) therapy_39\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) onset_36\NN|years (r_pobj) after_35\IN|.|patients|compared|onset|)|)|(|had|after (r_prep) accelerated_12\VBN|NONE (l_dobj) onset_13\NN|.|patients|compared|after|)|)|(|had|after (l_prep) of_14\IN|( (l_pobj) hypothyroidism_15\NN|NONE
D008094_D007037 CID lithium_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|for|risk|a (r_prep) factor_6\NN|illness|. (l_prep) for_7\IN|risk|during|a (l_pobj) hypothyroidism_8\NN|NONE
D008094_D006934 NONE lithium_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|for|risk|a (r_prep) factor_6\NN|illness|. (l_prep) for_7\IN|risk|during|a (l_pobj) hypothyroidism_8\NN|NONE (l_conj) hypercalcemia_10\NN|and
D008094_D013959 NONE lithium_9\NN|,|age (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|the (r_prep) duration_7\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) respect_4\NN|NONE (r_pobj) with_3\IN|were|had|These|. (r_prep) evaluated_2\VBN|NONE (l_parataxis) had_25\VBD|were|These|.|with (l_dobj) relative_30\NN|not|or|)|(|whether|patient (l_prep) with_31\IN|degree|a (l_pobj) disease_33\NN|NONE
D008094_D013959 NONE lithium_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) onset_20\NN|years (r_pobj) after_19\IN|.|patients|compared|onset|after|)|)|(|had (r_prep) accelerated_12\VBN|NONE (l_nsubj) patients_1\NNS|.|compared|onset|after|)|)|(|had|after (l_acl) having_2\VBG|All (l_dobj) relatives_6\NNS|NONE (l_acl) affected_7\VBN|degree (l_agent) by_8\IN|NONE (l_pobj) illness_10\NN|NONE
D008094_D013959 NONE lithium_38\NN|NONE (r_compound) therapy_39\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) onset_36\NN|years (r_pobj) after_35\IN|.|patients|compared|onset|)|)|(|had|after (r_prep) accelerated_12\VBN|NONE (l_nsubj) patients_1\NNS|.|compared|onset|after|)|)|(|had|after (l_acl) having_2\VBG|All (l_dobj) relatives_6\NNS|NONE (l_acl) affected_7\VBN|degree (l_agent) by_8\IN|NONE (l_pobj) illness_10\NN|NONE
D008094_D013959 NONE lithium_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|for|risk|a (r_prep) factor_6\NN|illness|. (r_attr) is_3\VBZ|NONE (l_nsubj) illness_2\NN|.|factor
D008094_D001714 NONE lithium_16\NN|maintenance|ranging (r_compound) therapy_18\NN|disorder (r_dobj) receiving_15\VBG|NONE (l_nsubj) disorder_14\NN|therapy
18086064
D020927_D009203 NONE Dexmedetomidine_0\NNP|was|with (r_nsubjpass) associated_2\VBN|infarction|CI|%|,|;|(|cause (r_ccomp) mortality_14\NN|NONE (l_appos) infarction_35\NN|associated|CI|%|,|;|(|cause
1899352
D015080_D006417 NONE Mesna_22\NNP|to (r_dobj) adding_21\VBG|.|monitoring|,|essential (r_advcl) is_18\VBZ|precise|and|,|frequency|not (r_conj) are_6\VBP|NONE (l_nsubj) frequency_1\NN|precise|and|is|,|not (l_conj) predictability_3\NN|and|The (l_prep) of_4\IN|NONE (l_pobj) hematuria_5\NN|NONE
D015080_D006417 NONE Mesna_22\NNP|to (r_dobj) adding_21\VBG|.|monitoring|,|essential (l_prep) to_23\IN|Mesna (l_pobj) infusate_25\NN|NONE (l_prep) in_26\IN|the (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|NONE (l_pobj) hematuria_30\NN|NONE
16725121
D003891_D012640 NONE desipramine_12\NN|NONE (r_pobj) of_11\IN|chronic (r_prep) administration_10\NN|NONE (r_pobj) by_8\IN|linking (r_agent) induced_7\VBN|.||Down|of (l_xcomp) linking_13\VBG|by (l_prep) to_14\IN|NONE (l_pobj) alteration_16\NN|NONE (l_prep) of_17\IN|counteraction|and|the (l_pobj) sensitivity_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) convulsions_25\NNS|NONE
D003891_D012640 NONE desipramine_3\NN|NONE (r_pobj) of_2\IN|Daily (r_prep) administration_1\NN|.|decreased|incidence|and (r_nsubj) increased_4\VBD|NONE (l_dobj) incidence_6\NN|.|administration|decreased|and (l_prep) of_7\IN|the (l_pobj) appearance_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) convulsions_13\NNS|NONE
D003891_D012640 NONE desipramine_3\NN|NONE (r_pobj) of_2\IN|Daily (r_prep) administration_1\NN|.|decreased|incidence|and (r_nsubj) increased_4\VBD|NONE (l_conj) decreased_15\VBD|.|administration|incidence|and (l_dobj) that_16\DT|NONE (l_prep) of_17\IN|NONE (l_pobj) convulsions_21\NNS|NONE
D003891_D012640 NONE desipramine_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) lidocaine_4\NN|NONE (r_pobj) of_3\IN|Co| (r_prep) administration_2\NN|.|changes (r_nsubj) reversed_7\VBD|NONE (l_dobj) changes_9\NNS|administration|. (l_prep) of_10\IN|induced|the (l_pobj) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D003891_D012640 NONE desipramine_22\NN|NONE (r_pobj) of_21\IN|repeated (r_prep) administration_20\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|of|the (r_acl) changes_9\NNS|administration|. (l_prep) of_10\IN|induced|the (l_pobj) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D003891_D012640 NONE desipramine_15\NN|NONE (r_pobj) of_14\IN|chronic (r_prep) administration_13\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN||down|of (r_acl) regulation_6\NN|relevant|that|may (r_nsubj) be_17\VB|results|. (l_acomp) relevant_18\JJ|regulation|that|may (l_prep) to_19\IN|NONE (l_pobj) sensitization_23\NN|NONE (l_prep) of_24\IN|induced (l_pobj) convulsions_26\NNS|NONE
D003891_D012640 NONE desipramine_20\NN| (r_advmod) induced_22\VBN|of (r_amod) sensitization_23\NN|NONE (l_prep) of_24\IN|induced (l_pobj) convulsions_26\NNS|NONE
D003891_D012640 NONE Desipramine_0\NN| (r_nsubj) induced_2\VBN|of (r_amod) sensitization_3\NN|.|may|mechanism (l_prep) of_4\IN|induced (l_pobj) seizures_6\NNS|NONE
D009638_D012640 NONE norepinephrine_4\NN|transporter (r_amod) function_6\NN|NONE (r_pobj) of_3\IN|induced|.||Down (r_prep) regulation_2\NN|NONE (l_acl) induced_7\VBN|.||Down|of (l_xcomp) linking_13\VBG|by (l_prep) to_14\IN|NONE (l_pobj) alteration_16\NN|NONE (l_prep) of_17\IN|counteraction|and|the (l_pobj) sensitivity_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) convulsions_25\NNS|NONE
D009638_D012640 NONE norepinephrine_2\NN|NET|) (r_compound) transporter_3\NN|by (r_nmod) function_7\NN|NONE (l_prep) by_8\IN|transporter (l_pobj) inhibition_10\NN|NONE (l_prep) in_13\IN|chronic|of (l_pobj) relation_14\NN|NONE (l_prep) to_15\IN|NONE (l_pobj) sensitization_16\NN|NONE (l_prep) to_17\IN|NONE (l_pobj) seizures_18\NNS|NONE
D003042_D012640 CID cocaine_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induce_19\VB|NONE (r_acl) seizures_18\NNS|NONE
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) convulsions_21\NNS|NONE (r_pobj) of_17\IN|NONE (r_prep) that_16\DT|NONE (r_dobj) decreased_15\VBD|.|administration|incidence|and (r_conj) increased_4\VBD|NONE (l_dobj) incidence_6\NN|.|administration|decreased|and (l_prep) of_7\IN|the (l_pobj) appearance_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) convulsions_13\NNS|NONE
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) convulsions_21\NNS|NONE
D003042_D012640 CID cocaine_16\NN|and (r_conj) lidocaine_14\NN|NONE (r_pobj) of_13\IN|convulsive (r_prep) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D003042_D012640 CID cocaine_19\NN|NONE (r_pobj) of_18\IN|repeated (r_prep) administration_17\NN|NONE (r_pobj) from_15\IN|NONE (r_prep) resulting_14\VBG|NONE (r_acl) kindling_13\VBG|NONE (r_pobj) from_12\IN|NONE (r_prep) distinct_11\JJ|a (r_amod) mechanism_10\NN|.|sensitization|may (r_dobj) have_8\VB|NONE (l_nsubj) sensitization_3\NN|.|may|mechanism (l_prep) of_4\IN|induced (l_pobj) seizures_6\NNS|NONE
D008012_D012640 CID lidocaine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) convulsions_13\NNS|NONE
D008012_D012640 CID lidocaine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) convulsions_13\NNS|NONE (r_pobj) of_9\IN|NONE (r_prep) appearance_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) incidence_6\NN|.|administration|decreased|and (r_dobj) increased_4\VBD|NONE (l_conj) decreased_15\VBD|.|administration|incidence|and (l_dobj) that_16\DT|NONE (l_prep) of_17\IN|NONE (l_pobj) convulsions_21\NNS|NONE
D008012_D012640 CID lidocaine_4\NN|NONE (r_pobj) of_3\IN|Co| (r_prep) administration_2\NN|.|changes (r_nsubj) reversed_7\VBD|NONE (l_dobj) changes_9\NNS|administration|. (l_prep) of_10\IN|induced|the (l_pobj) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D008012_D012640 CID lidocaine_14\NN|NONE (r_pobj) of_13\IN|convulsive (r_prep) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D008012_D012640 CID lidocaine_25\NN|NONE (r_compound) convulsions_26\NNS|NONE
D008012_D012640 CID lidocaine_5\NN|NONE (r_compound) seizures_6\NNS|NONE
2917114
D004491_D001919 CID edrophonium_17\NN|NONE (r_pobj) before_15\IN| (r_prep) min_14\NN|,|,|was (r_dobj) given_12\VBN|micrograms|of|. (l_conj) was_19\VBD|,|,|min (l_acomp) sufficient_20\JJ|NONE (l_xcomp) minimize_22\VB|NONE (l_dobj) bradycardias_28\NNS|to
D004491_D001919 CID edrophonium_25\NN| (r_npadvmod) induced_27\VBN|early|, (r_amod) bradycardias_28\NNS|to
D006024_D001919 NONE glycopyrronium_2\NN|NONE (r_pobj) of_1\IN|micrograms|given|. (r_prep) Use_0\NN|NONE (l_acl) given_12\VBN|micrograms|of|. (l_conj) was_19\VBD|,|,|min (l_acomp) sufficient_20\JJ|NONE (l_xcomp) minimize_22\VB|NONE (l_dobj) bradycardias_28\NNS|to
19139001
D013467_D034381 CID sulindac_14\NN|the|experienced|DFMO (r_compound) group_15\NN|NONE (l_relcl) experienced_17\VBD|sulindac|the|DFMO (l_dobj) loss_21\NN|who|compared
D013467_D015179 NONE sulindac_15\NN|and (l_prep) for_16\IN|NONE (l_pobj) prevention_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) adenomas_21\NNS|NONE
D000518_D015179 NONE difluoromethylornithine_13\NN|NONE (l_conj) sulindac_15\NN|and (l_prep) for_16\IN|NONE (l_pobj) prevention_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) adenomas_21\NNS|NONE
D000518_D064420 NONE DFMO_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treatment_8\NN|NONE (r_pobj) of_7\IN|,|known|a (r_prep) toxicity_6\NN|developed|.|loss
D000518_D034381 NONE DFMO_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treatment_8\NN|NONE (r_pobj) of_7\IN|,|known|a (r_prep) toxicity_6\NN|developed|.|loss (r_attr) is_3\VBZ|NONE (l_nsubj) loss_2\NN|developed|toxicity|.
D000518_D034381 NONE DFMO_12\NN|sulindac|the|experienced (r_nmod) group_15\NN|NONE (l_relcl) experienced_17\VBD|sulindac|the|DFMO (l_dobj) loss_21\NN|who|compared
D013467_D018256 NONE sulindac_22\NN|plus|(|DFMO|) (r_conj) difluoromethylornithine_17\NN|NONE (r_pobj) with_16\IN| (r_prep) months_15\NNS|NONE (r_pobj) for_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|adenomatous (r_prep) polyps_10\NNS|NONE
D000518_D018256 NONE difluoromethylornithine_17\NN|NONE (r_pobj) with_16\IN| (r_prep) months_15\NNS|NONE (r_pobj) for_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|adenomatous (r_prep) polyps_10\NNS|NONE
D000518_D018256 NONE DFMO_19\NN|plus|(|sulindac|) (r_appos) difluoromethylornithine_17\NN|NONE (r_pobj) with_16\IN| (r_prep) months_15\NNS|NONE (r_pobj) for_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|adenomatous (r_prep) polyps_10\NNS|NONE
14745746
8854309
D003042_D010259 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) paranoia_12\NN|NONE
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|(|)|CIP (r_amod) paranoia_3\NN|model|.
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|(|)|CIP (r_amod) paranoia_3\NN|model|. (l_appos) CIP_5\NNP|induced|(|)
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|(|)|CIP (r_amod) paranoia_3\NN|model|. (r_nsubj) remains_7\VBZ|NONE (l_attr) model_13\NN|.|paranoia (l_prep) of_14\IN|an|induced|important (l_pobj) paranoia_16\NN|NONE
D016578_D010259 NONE cocaine_14\NN|endorsing|crack (r_compound) abusers_15\NNS|NONE (l_acl) endorsing_16\VBG|cocaine|crack (l_prep) past_17\IN|from (l_pobj) CIP_18\NNP|NONE
D016578_D010259 NONE cocaine_14\NN|endorsing|crack (r_compound) abusers_15\NNS|NONE (l_acl) endorsing_16\VBG|cocaine|crack (l_prep) from_24\IN|past (l_pobj) group_26\NN|NONE (l_relcl) denied_31\VBD|another|of (l_prep) past_32\IN|who (l_pobj) CIP_33\NNP|NONE
D016578_D010259 NONE crack_28\NN|NONE (r_compound) addicts_29\NNS|NONE (r_pobj) of_27\IN|another|denied (r_prep) group_26\NN|NONE (r_pobj) from_24\IN|past (r_prep) endorsing_16\VBG|cocaine|crack (l_prep) past_17\IN|from (l_pobj) CIP_18\NNP|NONE
D016578_D010259 NONE crack_28\NN|NONE (r_compound) addicts_29\NNS|NONE (r_pobj) of_27\IN|another|denied (r_prep) group_26\NN|NONE (l_relcl) denied_31\VBD|another|of (l_prep) past_32\IN|who (l_pobj) CIP_33\NNP|NONE
D016578_D011681 NONE cocaine_14\NN|endorsing|crack (r_compound) abusers_15\NNS|NONE (r_pobj) of_11\IN|a (r_prep) group_10\NN|significantly|to (r_dobj) distinguish_8\VB|NONE (r_xcomp) able_5\JJ|.|Measures (r_acomp) were_4\VBD|NONE (l_nsubj) Measures_0\NNS|.|able (l_prep) of_1\IN|NONE (l_pobj) oscillation_3\NN|NONE
D016578_D011681 NONE crack_28\NN|NONE (r_compound) addicts_29\NNS|NONE (r_pobj) of_27\IN|another|denied (r_prep) group_26\NN|NONE (r_pobj) from_24\IN|past (r_prep) endorsing_16\VBG|cocaine|crack (r_acl) abusers_15\NNS|NONE (r_pobj) of_11\IN|a (r_prep) group_10\NN|significantly|to (r_dobj) distinguish_8\VB|NONE (r_xcomp) able_5\JJ|.|Measures (r_acomp) were_4\VBD|NONE (l_nsubj) Measures_0\NNS|.|able (l_prep) of_1\IN|NONE (l_pobj) oscillation_3\NN|NONE
D003042_D011681 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) paranoia_12\NN|NONE (r_pobj) of_8\IN|a (r_prep) marker_7\NN|NONE (r_pobj) as_5\IN|A|of|. (r_prep) measure_1\NN|NONE (l_prep) of_2\IN|A|as|. (l_pobj) oscillation_4\NN|NONE
9321531
D007980_D004409 CID levodopa_11\RB| (r_npadvmod) induced_13\VBN|disability|and (r_amod) dyskinesias_14\NNS|pallidotomy|significantly|In|,|.
D007980_D010300 NONE levodopa_11\RB| (r_npadvmod) induced_13\VBN|disability|and (r_amod) dyskinesias_14\NNS|pallidotomy|significantly|In|,|. (r_dobj) reduces_10\VBZ|NONE (l_prep) In_0\IN|pallidotomy|significantly|dyskinesias|,|. (l_pobj) disease_6\NN|NONE
8617710
D020280_D003072 NONE sertraline_4\NN|NONE (r_pobj) of_3\IN|on (r_prep) effect_2\NN|NONE (l_prep) on_5\IN|of (l_pobj) sensitization_9\NN|NONE (l_prep) of_10\IN|based (l_pobj) impairment_12\NN|NONE
D020280_D003072 NONE sertraline_14\NN|concomitant (r_compound) administration_15\NN|NONE (r_pobj) by_12\IN|not|was|that (r_agent) worsened_11\VBN|clear|a|of (r_relcl) profile_4\NN|Haloperidol|. (l_prep) of_5\IN|clear|a|worsened (l_pobj) impairment_7\NN|NONE
D006220_D003072 CID haloperidol_14\NN|NONE (r_pobj) with_13\IN|cognitive (r_prep) impairment_12\NN|NONE
D006220_D003072 CID haloperidol_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) administration_11\NN|hours (r_pobj) after_10\IN|Impairment|.|but|was|was|on (r_prep) observed_5\VBN|NONE (l_nsubjpass) Impairment_0\NN|after|.|but|was|was|on (l_prep) of_1\IN|NONE (l_pobj) function_3\NN|NONE
D006220_D003072 CID Haloperidol_0\NNP|profile|. (r_nsubj) produced_1\VBD|NONE (l_dobj) profile_4\NN|Haloperidol|. (l_prep) of_5\IN|clear|a|worsened (l_pobj) impairment_7\NN|NONE
384871
D004977_D064420 NONE ethambutol_8\NN|to (r_pobj) due_6\IN|of|The (r_amod) hazards_1\NNS|.|are (l_prep) of_2\IN|due|The (l_pobj) toxicity_5\NN|NONE
D004977_D009901 CID ethambutol_6\NN|NONE (r_nmod) treatment_9\NN|to (r_pobj) due_3\IN|.|optic (r_prep) neuropathy_2\NN|NONE
D007538_D009901 CID isoniazid_8\NN|combined|and (r_conj) ethambutol_6\NN|NONE (r_nmod) treatment_9\NN|to (r_pobj) due_3\IN|.|optic (r_prep) neuropathy_2\NN|NONE
16629641
C026956_D000743 NONE Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|to|efficacy (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE
D012254_D007674 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|be|concentrations|and (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|as|concentrations|and (l_conj) comorbid_29\VBN|.|problematic|anemia|can|in (l_dobj) disorders_33\NNS|have|those
D007372_D006526 NONE interferon_12\NN|NONE (r_pobj) with_10\IN|combination (r_prep) therapy_9\NN|.|treatment (r_attr) is_7\VBZ|NONE (l_nsubj) treatment_3\NN|.|therapy (l_prep) for_4\IN|The|current|best (l_pobj) infection_6\NN|NONE
D012254_D002318 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|be|concentrations|and (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|as|concentrations|and (l_conj) comorbid_29\VBN|.|problematic|anemia|can|in (l_dobj) disorders_33\NNS|have|those
D012254_D000740 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|be|concentrations|and (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|as|concentrations|and (l_nsubj) anemia_15\NN|.|comorbid|problematic|can|in
D012254_D000740 NONE ribavirin_1\RB| (r_npadvmod) associated_3\VBN|NONE (r_amod) anemia_4\NN|by|can|be|Although
D012254_D000740 NONE ribavirin_8\RB| (r_npadvmod) associated_10\VBN|NONE (r_amod) anemia_11\NN|to
D012254_D019698 NONE ribavirin_8\NN|NONE (r_pobj) of_7\IN|a|targeting (r_prep) prodrug_6\NN|,|, (r_appos) Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|to|efficacy (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE (l_prep) in_27\IN|hemolytic (l_pobj) patients_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) C._32\NNP|NONE
D012254_D019698 NONE ribavirin_19\RB|NONE (r_pobj) of_18\IN|virologic|the (r_prep) efficacy_17\NN|to|decreasing (r_dobj) maintain_14\VB|the (l_advcl) decreasing_21\VBG|to|efficacy (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE (l_prep) in_27\IN|hemolytic (l_pobj) patients_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) C._32\NNP|NONE
D012254_D006461 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE
D012254_D000743 CID ribavirin_8\NN|NONE (r_pobj) of_7\IN|a|targeting (r_prep) prodrug_6\NN|,|, (r_appos) Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|to|efficacy (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE
D012254_D000743 CID ribavirin_19\RB|NONE (r_pobj) of_18\IN|virologic|the (r_prep) efficacy_17\NN|to|decreasing (r_dobj) maintain_14\VB|the (l_advcl) decreasing_21\VBG|to|efficacy (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE
D012254_D006526 NONE ribavirin_14\NN|pegylated|and (r_conj) interferon_12\NN|NONE (r_pobj) with_10\IN|combination (r_prep) therapy_9\NN|.|treatment (r_attr) is_7\VBZ|NONE (l_nsubj) treatment_3\NN|.|therapy (l_prep) for_4\IN|The|current|best (l_pobj) infection_6\NN|NONE
D012254_D006526 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|be|concentrations|and (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|as|concentrations|and (l_prep) in_19\IN|.|comorbid|problematic|anemia|can (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) infection_23\NN|NONE
C026956_D019698 NONE Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|to|efficacy (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE (l_prep) in_27\IN|hemolytic (l_pobj) patients_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) C._32\NNP|NONE
16132524
D017239_D001929 CID paclitaxel_9\NN|suffered|.|and|Six (r_dobj) received_4\VBD|NONE (l_conj) suffered_11\VBD|paclitaxel|.|and|Six (l_prep) from_12\IN|received|, (l_prep) to_14\TO|moderate (l_pobj) edema_17\NN|NONE
D017239_D001929 CID paclitaxel_30\NN|NONE (r_pobj) of_27\IN|a|only (r_prep) total_26\NN|patients|while (r_dobj) received_23\VBD|from|, (r_advcl) suffered_11\VBD|paclitaxel|.|and|Six (l_prep) from_12\IN|received|, (l_prep) to_14\TO|moderate (l_pobj) edema_17\NN|NONE
D017239_D005909 NONE paclitaxel_3\NN|/ (r_nmod) carboplatin_5\VB|)|crystalline|cubic|for|liquid (r_amod) phases_9\NNS|(|.|Intracavitary (l_prep) for_11\IN|)|crystalline|cubic|liquid|carboplatin (l_pobj) glioblastoma_13\NN|NONE
D017239_D005909 NONE paclitaxel_21\NN|NONE (r_pobj) of_20\IN|surgical|intracavitary|a (r_prep) application_19\NN|NONE (r_pobj) of_15\IN|and|encapsulated|term (r_prep) effects_14\NNS|,|and (r_conj) safety_8\NN|the|, (r_conj) feasibility_6\NN|,|.|are|For|in (r_nsubjpass) examined_31\VBN|NONE (l_prep) For_0\IN|feasibility|,|.|are|in (l_pobj) recurrences_3\NNS|NONE (l_compound) glioblastoma_2\NN|human
D017239_D005909 NONE paclitaxel_22\NN|NONE (r_pobj) of_21\IN|an|intracavitary (r_prep) application_20\NN|phases|and (r_dobj) received_17\VBD|and (r_conj) underwent_12\VBN|a|glioblastoma (r_acl) multiforme_11\NN|NONE (l_compound) glioblastoma_10\NN|a|underwent
D016190_D005909 NONE carboplatin_5\VB|)|crystalline|cubic|for|liquid (r_amod) phases_9\NNS|(|.|Intracavitary (l_prep) for_11\IN|)|crystalline|cubic|liquid|carboplatin (l_pobj) glioblastoma_13\NN|NONE
D016190_D005909 NONE carboplatin_23\NN|by (r_advmod) encapsulated_24\VBN|and|of|term (r_conj) effects_14\NNS|,|and (r_conj) safety_8\NN|the|, (r_conj) feasibility_6\NN|,|.|are|For|in (r_nsubjpass) examined_31\VBN|NONE (l_prep) For_0\IN|feasibility|,|.|are|in (l_pobj) recurrences_3\NNS|NONE (l_compound) glioblastoma_2\NN|human
D016190_D005909 NONE carboplatin_24\VB|cubic|in (r_amod) phases_26\NNS|application|and (r_conj) received_17\VBD|and (r_conj) underwent_12\VBN|a|glioblastoma (r_acl) multiforme_11\NN|NONE (l_compound) glioblastoma_10\NN|a|underwent
8841157
D000804_D006973 NONE II_5\CD|angiotensin|for|a (r_compound) antagonist_6\NN|,|.|study|: (l_prep) for_7\IN|angiotensin|II|a (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypertension_12\NN|NONE
C081489_D006973 NONE Valsartan_0\NNP|NONE (l_appos) antagonist_6\NN|,|.|study|: (l_prep) for_7\IN|angiotensin|II|a (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypertension_12\NN|NONE
C081489_D006973 NONE valsartan_27\NN|to (r_dobj) receive_24\VB|were|outpatients|in|randomly|. (r_advcl) allocated_14\VBN|NONE (l_nsubjpass) outpatients_6\NNS|were|receive|in|randomly|. (l_prep) with_7\IN|hundred|adult|eight (l_pobj) hypertension_11\NN|NONE
C081489_D006973 NONE valsartan_4\NN|effective|that (r_nsubj) is_5\VBZ|.|data (l_acomp) effective_9\JJ|valsartan|that (l_prep) as_10\IN|as|least (l_pobj) amlodipine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) hypertension_19\NN|NONE
D017311_D004487 CID amlodipine_13\NN|the (r_compound) group_14\NN|NONE (r_pobj) in_11\IN|.|at|incidence|%|higher|, (r_prep) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|at|in|%|higher|, (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D004487 CID amlodipine_38\NN|NONE (r_pobj) for_35\IN|%|;|)|.|;|% (r_prep) %_34\NN|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|at|in|%|higher|, (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D004487 CID amlodipine_47\NN|for|plus| (r_conj) %_41\NN|;|)|.|;|%|for (r_conj) %_34\NN|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|at|in|%|higher|, (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D004487 CID amlodipine_54\NN|NONE (r_pobj) for_51\IN|. (r_prep) %_50\NN|%|;|)|.|;|for (r_appos) %_34\NN|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|at|in|%|higher|, (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D006973 NONE amlodipine_23\NN|NONE (r_pobj) against_22\IN|NONE (r_prep) safety_21\NN|and|the (r_conj) efficacy_19\NN|NONE (r_pobj) of_17\IN|comparative|a (r_prep) study_16\NN|antagonist|,|.|: (r_appos) Valsartan_0\NNP|NONE (l_appos) antagonist_6\NN|,|.|study|: (l_prep) for_7\IN|angiotensin|II|a (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypertension_12\NN|NONE
D017311_D006973 NONE amlodipine_31\NN|mg|or| (r_conj) valsartan_27\NN|to (r_dobj) receive_24\VB|were|outpatients|in|randomly|. (r_advcl) allocated_14\VBN|NONE (l_nsubjpass) outpatients_6\NNS|were|receive|in|randomly|. (l_prep) with_7\IN|hundred|adult|eight (l_pobj) hypertension_11\NN|NONE
D017311_D006973 NONE amlodipine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) hypertension_19\NN|NONE
C081489_D004487 CID valsartan_31\NN|NONE (r_pobj) for_28\IN|. (r_prep) %_27\NN|;|a|of|( (r_appos) dose_19\NN|particularly (r_pobj) at_17\IN|.|in|incidence|%|higher|, (r_prep) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|at|in|%|higher|, (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
C081489_D004487 CID valsartan_43\NN|NONE (r_pobj) for_42\IN|amlodipine|plus| (r_prep) %_41\NN|;|)|.|;|%|for (r_conj) %_34\NN|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|at|in|%|higher|, (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
12180796
D009569_D001167 NONE oxide_21\NN|(|factor|nitric|iNOS|,|) (r_compound) synthase_22\NN|NONE (r_pobj) of_19\IN|inducible (r_prep) type_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) expressions_15\NNS|NONE (r_pobj) for_14\IN|was|immunohistochemically|,|. (r_prep) examined_12\VBN|Arteritis|fenoldopam|in|, (r_conj) induced_1\VBN|NONE (l_nsubj) Arteritis_0\NNP|examined|fenoldopam|in|,
D018818_D001167 CID fenoldopam_12\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) rats_10\NNS|NONE (r_pobj) in_9\IN|beta|,|.|vasodilators (r_prep) induced_8\VBN|NONE (l_nsubj) beta1_0\NNP|in|,|.|vasodilators (l_prep) in_6\IN|(|)|beta (l_pobj) arteritis_7\NN|NONE
D018818_D001167 CID fenoldopam_7\NN|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN|NONE (l_nsubj) Arteritis_0\NNP|examined|fenoldopam|in|,
D013806_D001167 CID theophylline_14\NN|and (r_conj) fenoldopam_12\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) rats_10\NNS|NONE (r_pobj) in_9\IN|beta|,|.|vasodilators (r_prep) induced_8\VBN|NONE (l_nsubj) beta1_0\NNP|in|,|.|vasodilators (l_prep) in_6\IN|(|)|beta (l_pobj) arteritis_7\NN|NONE
D013806_D001167 CID theophylline_9\NN|and (r_conj) fenoldopam_7\NN|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN|NONE (l_nsubj) Arteritis_0\NNP|examined|fenoldopam|in|,
D013806_D009369 NONE theophylline_9\NN|and (r_conj) fenoldopam_7\NN|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN|NONE (l_conj) examined_12\VBN|Arteritis|fenoldopam|in|, (l_prep) for_14\IN|was|immunohistochemically|,|. (l_pobj) expressions_15\NNS|NONE (l_prep) of_16\IN|NONE (l_pobj) type_18\NN|NONE (l_prep) of_19\IN|inducible (l_pobj) synthase_22\NN|NONE (l_appos) factor_30\NN|(|oxide|nitric|iNOS|,|) (l_conj) beta1_39\NNP|growth|)|basic|(|bFGF|and (l_compound) factor_37\NN|beta|(|) (l_compound) tumor_35\NN|growth|
D018818_D009369 NONE fenoldopam_7\NN|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN|NONE (l_conj) examined_12\VBN|Arteritis|fenoldopam|in|, (l_prep) for_14\IN|was|immunohistochemically|,|. (l_pobj) expressions_15\NNS|NONE (l_prep) of_16\IN|NONE (l_pobj) type_18\NN|NONE (l_prep) of_19\IN|inducible (l_pobj) synthase_22\NN|NONE (l_appos) factor_30\NN|(|oxide|nitric|iNOS|,|) (l_conj) beta1_39\NNP|growth|)|basic|(|bFGF|and (l_compound) factor_37\NN|beta|(|) (l_compound) tumor_35\NN|growth|
D009569_D009369 NONE oxide_7\NN|NONE (l_appos) factor_15\NN|iNOS|)|nitric|(|, (l_conj) growth_21\NN|growth|)|and|basic|(|bFGF (l_compound) tumor_20\NN|NONE
D009569_D009369 NONE oxide_21\NN|(|factor|nitric|iNOS|,|) (r_compound) synthase_22\NN|NONE (l_appos) factor_30\NN|(|oxide|nitric|iNOS|,|) (l_conj) beta1_39\NNP|growth|)|basic|(|bFGF|and (l_compound) factor_37\NN|beta|(|) (l_compound) tumor_35\NN|growth|
9431903
D005996_D046628 NONE trinitrate_3\NN|NONE (l_prep) on_4\IN|glyceryl (l_pobj) sphincter_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) spasm_9\NN|NONE
D005996_D046628 NONE trinitrate_9\NN|NONE (l_prep) on_10\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D005996_D046628 NONE trinitrate_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) effect_6\NN|.|OBJECTIVE|:|with|in|In|was (r_nsubjpass) evaluated_22\VBN|NONE (l_prep) with_27\IN|.|OBJECTIVE|:|in|In|was|effect (l_pobj) sphincter_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) dyskinesia_31\NN|NONE
D005996_D046628 NONE trinitrate_11\NN|NONE (l_prep) on_12\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|induced|the (l_pobj) spasm_20\NN|NONE
D005996_D046628 NONE trinitrate_2\NN|able|Since (r_nsubj) is_3\VBZ|of|in|.|,|might|it (r_advcl) be_16\VB|NONE (l_prep) in_19\IN|of|.|,|is|might|it (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) sphincter_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) dyskinesia_26\NN|NONE
D009388_D013035 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009388_D013035 CID prostigmine_12\JJ| (r_compound) morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009388_D013035 CID prostigmine_7\JJ| (r_compound) morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009388_D013035 CID prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009388_D013035 CID Prostigmine_1\JJ| (r_compound) morphine_3\NN|NONE (r_compound) provocation_4\NN|:|indicating|.|)|and|.|increases|+/ (r_nsubj) caused_5\VBD|NONE (l_advcl) indicating_97\VBG|:|.|provocation|)|and|.|increases|+/ (l_dobj) spasm_100\NN|NONE
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (r_pobj) on_10\IN|glyceryl (r_prep) trinitrate_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) effect_6\NN|.|OBJECTIVE|:|with|in|In|was (r_nsubjpass) evaluated_22\VBN|NONE (l_prep) with_27\IN|.|OBJECTIVE|:|in|In|was|effect (l_pobj) sphincter_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) dyskinesia_31\NN|NONE
D009388_D046628 CID prostigmine_7\JJ| (r_compound) morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009388_D046628 CID prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009020_D013035 CID morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009020_D013035 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009020_D013035 CID morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009020_D013035 CID morphine_19\NN|(|subcutaneously|and|mg|intramuscularly|) (r_conj) prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009020_D013035 CID morphine_3\NN|NONE (r_compound) provocation_4\NN|:|indicating|.|)|and|.|increases|+/ (r_nsubj) caused_5\VBD|NONE (l_advcl) indicating_97\VBG|:|.|provocation|)|and|.|increases|+/ (l_dobj) spasm_100\NN|NONE
D009020_D013035 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|induced|the (l_pobj) spasm_20\NN|NONE
D005996_D013035 NONE trinitrate_3\NN|NONE (l_prep) on_4\IN|glyceryl (l_pobj) sphincter_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) spasm_9\NN|NONE
D005996_D013035 NONE trinitrate_9\NN|NONE (l_prep) on_10\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D005996_D013035 NONE trinitrate_11\NN|NONE (l_prep) on_12\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|induced|the (l_pobj) spasm_20\NN|NONE
D009020_D046628 CID morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (r_pobj) on_10\IN|glyceryl (r_prep) trinitrate_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) effect_6\NN|.|OBJECTIVE|:|with|in|In|was (r_nsubjpass) evaluated_22\VBN|NONE (l_prep) with_27\IN|.|OBJECTIVE|:|in|In|was|effect (l_pobj) sphincter_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) dyskinesia_31\NN|NONE
D009020_D046628 CID morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009020_D046628 CID morphine_19\NN|(|subcutaneously|and|mg|intramuscularly|) (r_conj) prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|.|spasm|was|and (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|.|by|was|and
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|induced|the (l_pobj) spasm_20\NN|NONE
D009020_D046628 CID morphine_12\NN|NONE (r_pobj) of_11\IN|even|drastic|the (r_prep) effect_10\NN|to (r_dobj) overcome_6\VB|NONE (r_xcomp) able_4\JJ|Since|trinitrate (r_acomp) is_3\VBZ|of|in|.|,|might|it (r_advcl) be_16\VB|NONE (l_prep) in_19\IN|of|.|,|is|might|it (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) sphincter_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) dyskinesia_26\NN|NONE
3015327
D007538_D009422 CID isoniazid_6\NN|in (r_compound) neuropathy_7\NN|NONE
D007538_D009422 CID isoniazid_8\NN|NONE (r_pobj) of_7\IN|in|single|a (r_prep) dose_6\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) neuropathy_1\NN|.|was|with
9201797
D002354_D002375 NONE hydrochloride_5\NN|NONE (r_pobj) of_3\IN|on|attenuating|The|. (r_prep) effect_2\NN|NONE (l_prep) on_13\IN|attenuating|The|.|of (l_pobj) catalepsy_17\NN|NONE
D002354_D002375 NONE carteolol_5\NN|NONE (r_pobj) of_4\IN|the|,|antagonist (r_prep) effects_3\NNS|and|,|were|Therefore|behaviorally|.|compared (l_appos) antagonist_11\NN|the|,|of (l_prep) on_13\IN|a|,|adrenoceptor (l_pobj) catalepsy_17\NN|NONE
D002354_D002375 NONE Carteolol_0\NNP|NONE (l_conj) propranolol_5\NN|as|,|. (l_conj) inhibited_9\VBD|,|and|biperiden (l_dobj) catalepsy_14\NN|NONE
D002354_D002375 NONE carteolol_5\NN|that|expected|catalepsy|via|and (r_nsubj) improves_6\VBZ|strongly|results|. (l_dobj) catalepsy_10\NN|that|carteolol|expected|via|and
D006220_D002375 CID haloperidol_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) catalepsy_17\NN|NONE
D006220_D002375 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|the (r_amod) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|that|carteolol|expected|via|and
D004298_D017109 NONE dopamine_40\NN|NONE (r_nmod) receptor_41\NN|antagonistic|its|postsynaptic (r_nmod) activity_43\NN|NONE (r_pobj) to_37\IN|NONE (r_pcomp) due_36\IN|effects (r_prep) attenuating_30\VBG|NONE (r_pcomp) without_29\IN|the|of (r_prep) treatment_26\NN|NONE (l_prep) of_27\IN|without|the (l_pobj) akathisia_28\NN|NONE
D002354_D009069 NONE Carteolol_0\NNP|signs|not|did|. (r_nsubj) evoke_3\VB|NONE (l_dobj) signs_10\NNS|not|Carteolol|did|. (l_prep) as_12\IN|dopamine|behavioral|postsynaptic|stimulating (l_pobj) stereotypy_13\NN|such (l_conj) hyperlocomotion_15\NN|and|in
D004298_D009069 NONE dopamine_5\NN|behavioral|as|postsynaptic|stimulating (r_nmod) signs_10\NNS|not|Carteolol|did|. (l_prep) as_12\IN|dopamine|behavioral|postsynaptic|stimulating (l_pobj) stereotypy_13\NN|such (l_conj) hyperlocomotion_15\NN|and|in
D004298_D002375 NONE dopamine_40\NN|NONE (r_nmod) receptor_41\NN|antagonistic|its|postsynaptic (r_nmod) activity_43\NN|NONE (r_pobj) to_37\IN|NONE (r_pcomp) due_36\IN|effects (r_prep) attenuating_30\VBG|NONE (r_pcomp) without_29\IN|the|of (r_prep) treatment_26\NN|NONE (r_pobj) in_24\IN|NONE (r_prep) effective_23\JJ|to (r_acomp) be_22\VB|is (r_xcomp) expected_20\VBN|that|carteolol|catalepsy|via|and (r_conj) improves_6\VBZ|strongly|results|. (l_dobj) catalepsy_10\NN|that|carteolol|expected|via|and
D006220_D017109 NONE haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|that|carteolol|expected|via|and (r_dobj) improves_6\VBZ|strongly|results|. (l_conj) expected_20\VBN|that|carteolol|catalepsy|via|and (l_xcomp) be_22\VB|is (l_acomp) effective_23\JJ|to (l_prep) in_24\IN|NONE (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|without|the (l_pobj) akathisia_28\NN|NONE
D001712_D002375 NONE biperiden_30\VBN|and (r_conj) propranolol_28\NN|NONE (r_pobj) of_27\IN|,|antagonist (r_prep) those_26\DT|NONE (r_pobj) with_25\IN|NONE (r_prep) compared_24\VBN|and|effects|,|were|Therefore|behaviorally|. (r_conj) studied_22\VBN|NONE (l_nsubjpass) effects_3\NNS|and|,|were|Therefore|behaviorally|.|compared (l_appos) antagonist_11\NN|the|,|of (l_prep) on_13\IN|a|,|adrenoceptor (l_pobj) catalepsy_17\NN|NONE
D001712_D002375 NONE biperiden_7\RB|,|and|inhibited (r_conj) propranolol_5\NN|as|,|. (l_conj) inhibited_9\VBD|,|and|biperiden (l_dobj) catalepsy_14\NN|NONE
D011433_D002375 NONE propranolol_28\NN|NONE (r_pobj) of_27\IN|,|antagonist (r_prep) those_26\DT|NONE (r_pobj) with_25\IN|NONE (r_prep) compared_24\VBN|and|effects|,|were|Therefore|behaviorally|. (r_conj) studied_22\VBN|NONE (l_nsubjpass) effects_3\NNS|and|,|were|Therefore|behaviorally|.|compared (l_appos) antagonist_11\NN|the|,|of (l_prep) on_13\IN|a|,|adrenoceptor (l_pobj) catalepsy_17\NN|NONE
D011433_D002375 NONE propranolol_5\NN|as|,|. (l_conj) inhibited_9\VBD|,|and|biperiden (l_dobj) catalepsy_14\NN|NONE
D002354_D017109 NONE carteolol_5\NN|that|expected|catalepsy|via|and (r_nsubj) improves_6\VBZ|strongly|results|. (l_conj) expected_20\VBN|that|carteolol|catalepsy|via|and (l_xcomp) be_22\VB|is (l_acomp) effective_23\JJ|to (l_prep) in_24\IN|NONE (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|without|the (l_pobj) akathisia_28\NN|NONE
15042318
D004317_D009136 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|atrial|sudden (r_prep) fibrillation_29\NN|,|and|of|common|the (r_conj) form_20\NN|lymphoma|diffuse|, (l_prep) of_21\IN|,|and|common|the|fibrillation (l_pobj) dystrophy_24\NN|NONE
D004317_C535648 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|atrial|sudden (r_prep) fibrillation_29\NN|,|and|of|common|the (r_conj) form_20\NN|lymphoma|diffuse|, (r_appos) dystrophy_15\NN|NONE (l_nmod) lymphoma_12\NN|form|diffuse|,
D004317_D009223 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|atrial|sudden (r_prep) fibrillation_29\NN|,|and|of|common|the (r_conj) form_20\NN|lymphoma|diffuse|, (r_appos) dystrophy_15\NN|NONE
D004317_D001281 CID doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|atrial|sudden (r_prep) fibrillation_29\NN|,|and|of|common|the
8492347
D011188_D013746 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS|NONE (l_conj) tetany_16\NN|muscle|and
D008274_D013746 NONE magnesium_10\NN|NONE (r_compound) supplementation_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) importance_8\NN|rhabdomyolysis||due|and|. (r_appos) Tetany_0\NNP|NONE
D011188_D007008 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|corrected|hypomagnesemia|.|,|is|with (l_nsubj) hypokalemia_2\NN|weakness|While|may
D002118_C537153 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_nsubjpass) hypomagnesemia_9\NN|corrected|.|cause|,|is|with
D008274_D007008 NONE magnesium_27\NN|NONE (r_compound) depletion_28\NN|NONE (r_pobj) of_26\IN|the (r_prep) effects_25\NNS|not|were|in|. (r_nsubjpass) noted_31\VBN|but|(|)|was|,|in (r_conj) observed_19\VBN|(|hypokalemia|and|has|)||been|in (r_conj) reported_4\VBN|NONE (l_nsubjpass) hypokalemia_1\NN|observed|(|and|has|)||been|in
D008274_D006996 NONE magnesium_27\NN|NONE (r_compound) depletion_28\NN|NONE (r_pobj) of_26\IN|the (r_prep) effects_25\NNS|not|were|in|. (r_nsubjpass) noted_31\VBN|but|(|)|was|,|in (r_conj) observed_19\VBN|(|hypokalemia|and|has|)||been|in (l_prep) in_14\IN|but|(|)|noted|was|, (l_pobj) hypocalcemia_17\NN|NONE
D011188_C537153 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_nsubjpass) hypomagnesemia_9\NN|corrected|.|cause|,|is|with
D011188_D018908 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|corrected|hypomagnesemia|.|,|is|with (l_dobj) weakness_6\NN|hypokalemia|While|may
D002118_D013746 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS|NONE (l_conj) tetany_16\NN|muscle|and
D005665_D012206 CID furosemide_6\NN|to (r_pobj) due_3\JJ|rhabdomyolysis||importance|and|. (r_prep) Tetany_0\NNP|NONE (l_conj) rhabdomyolysis_2\NN||importance|due|and|.
D005665_D013746 CID furosemide_6\NN|to (r_pobj) due_3\JJ|rhabdomyolysis||importance|and|. (r_prep) Tetany_0\NNP|NONE
D008274_D012206 NONE magnesium_10\NN|NONE (r_compound) supplementation_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) importance_8\NN|rhabdomyolysis||due|and|. (r_appos) Tetany_0\NNP|NONE (l_conj) rhabdomyolysis_2\NN||importance|due|and|.
D002118_D007008 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|corrected|hypomagnesemia|.|,|is|with (l_nsubj) hypokalemia_2\NN|weakness|While|may
D002118_D013035 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS|NONE
D002118_D018908 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|corrected|hypomagnesemia|.|,|is|with (l_dobj) weakness_6\NN|hypokalemia|While|may
D011188_D013035 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|can|which|not|be (r_agent) corrected_21\VBN|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS|NONE
10414674
D000082_D001791 NONE acetaminophen_9\NN|the (r_compound) group_10\NN|NONE (r_pobj) in_7\IN|.|aggregation|,|In|on|compared (r_prep) increased_6\VBD|NONE (l_nsubj) aggregation_5\NN|in|.|,|In|on|compared
D000082_D001791 NONE acetaminophen_9\NN|the (r_compound) group_10\NN|NONE (r_pobj) in_7\IN|.|aggregation|,|In|on|compared (r_prep) increased_6\VBD|NONE (l_advcl) compared_17\VBN|in|.|aggregation|,|In|on (l_prep) with_18\IN|as (l_pobj) results_23\NNS|NONE (l_compound) aggregation_22\NN|P|(|the|)
D000082_D013345 NONE acetaminophen_35\RB|,|weak|a|, (r_advmod) NSAID_33\NNP|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|(|.|receive|were|) (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D000082_D013345 NONE acetaminophen_35\RB|,|weak|a|, (r_advmod) NSAID_33\NNP|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|.|receive|were|Patients|) (l_preconj) SAH_6\NNP|NONE
D000082_D013345 NONE acetaminophen_35\RB|,|weak|a|, (r_advmod) NSAID_33\NNP|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (l_parataxis) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D000082_D013345 NONE acetaminophen_45\NN||n|, (r_compound) group_46\NN|(|immediately|after (r_nsubj) starting_52\VBG|ketoprofen|times|group|to (r_parataxis) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|(|.|receive|were|) (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D000082_D013345 NONE acetaminophen_45\NN||n|, (r_compound) group_46\NN|(|immediately|after (r_nsubj) starting_52\VBG|ketoprofen|times|group|to (r_parataxis) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|.|receive|were|Patients|) (l_preconj) SAH_6\NNP|NONE
D000082_D013345 NONE acetaminophen_45\NN||n|, (r_compound) group_46\NN|(|immediately|after (r_nsubj) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D000082_D013345 NONE acetaminophen_3\RB|but (l_dobj) function_6\NN|.|not (l_prep) in_7\IN|impaired|platelet (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) SAH_10\NNP|NONE
D007660_D006470 NONE ketoprofen_1\NN|If|before|is|on (r_nsubjpass) used_3\VBN|factor|may|it|.|, (r_advcl) pose_13\VB|NONE (l_dobj) factor_17\NN|may|it|.|used|, (l_prep) for_18\IN|additional|risk|an (l_pobj) hemorrhage_19\NN|NONE
D007660_D001791 CID ketoprofen_14\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) decreased_10\VBD|.|by|aggregation (r_conj) induced_3\VBN|NONE (l_nsubj) aggregation_2\NN|.|by|decreased
D007660_D013345 NONE ketoprofen_13\JJ|times|group|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|(|.|receive|were|) (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D007660_D013345 NONE ketoprofen_13\JJ|times|group|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|.|receive|were|Patients|) (l_preconj) SAH_6\NNP|NONE
D007660_D013345 NONE ketoprofen_13\JJ|times|group|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (l_parataxis) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D007660_D013345 NONE ketoprofen_23\JJ|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|(|.|receive|were|) (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D007660_D013345 NONE ketoprofen_23\JJ|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|.|receive|were|Patients|) (l_preconj) SAH_6\NNP|NONE
D007660_D013345 NONE ketoprofen_23\JJ|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (l_parataxis) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D007660_D013345 NONE Ketoprofen_0\NNP|NONE (l_conj) acetaminophen_3\RB|but (l_dobj) function_6\NN|.|not (l_prep) in_7\IN|impaired|platelet (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) SAH_10\NNP|NONE
D007660_D017542 NONE ketoprofen_13\JJ|times|group|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (l_parataxis) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D007660_D017542 NONE ketoprofen_23\JJ|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (l_parataxis) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D000082_D017542 NONE acetaminophen_35\RB|,|weak|a|, (r_advmod) NSAID_33\NNP|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN|ketoprofen|times|starting|to (r_dobj) receive_11\VB|(|.|were|Patients|) (l_parataxis) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D000082_D017542 NONE acetaminophen_45\NN||n|, (r_compound) group_46\NN|(|immediately|after (r_nsubj) starting_52\VBG|ketoprofen|times|group|to (l_prep) after_54\IN|(|group|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D007660_D006406 CID ketoprofen_4\JJ|the (r_compound) group_5\NN|NONE (r_pobj) in_2\IN|One (r_prep) patient_1\NN|hematoma|. (r_nsubj) developed_6\VBD|NONE (l_dobj) hematoma_10\NN|.|patient
D000244_D001791 NONE diphosphate_9\NN|NONE (r_pobj) of_7\IN| (r_prep) microM_6\NNS|NONE (r_pobj) by_4\IN|.|aggregation|decreased (r_prep) induced_3\VBN|NONE (l_nsubj) aggregation_2\NN|.|by|decreased
D007660_D002532 NONE ketoprofen_1\NN|If|before|is|on (r_nsubjpass) used_3\VBN|factor|may|it|.|, (l_prep) on_6\IN|If|before|is|ketoprofen (l_pobj) aneurysms_9\NNS|NONE
8643966
D017239_D001943 NONE Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|significant|antineoplastic (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|different|,|tumor
D017239_D001943 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|significant|antineoplastic (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|different|,|tumor
D017239_D010051 NONE Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|significant|antineoplastic (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|different|,|tumor
D017239_D010051 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|significant|antineoplastic (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|different|,|tumor
D017239_D064420 NONE paclitaxel_9\NN|a|in|hour (r_compound) infusion_10\NN|NONE (r_pobj) of_6\IN|the|toxicity|and (r_prep) efficacy_3\NN|We|. (l_conj) toxicity_5\NN|the|of|and
D017239_D064420 NONE Paclitaxel_0\NNP|,|agent|with|.|thus (r_nsubj) is_1\VBZ|NONE (l_prep) with_12\IN|,|agent|.|Paclitaxel|thus (l_pobj) infusion_15\NN|NONE (l_acl) proving_16\VBG|a|hour (l_oprd) effective_18\JJ|NONE (l_prep) to_19\IN|comparably (l_pobj) infusion_22\NN|NONE (l_conj) superior_24\JJ|a|hour|and (l_prep) in_25\IN|NONE (l_pobj) terms_26\NNS|NONE (l_prep) of_27\IN|NONE (l_pobj) incidence_29\NN|NONE (l_prep) of_30\IN|the (l_pobj) toxicity_34\NN|NONE
D017239_D002289 NONE paclitaxel_11\NN|NONE (r_pobj) with_10\IN|lung|inoperable|small|advanced (r_prep) cancer_9\NN|NONE
D017239_D002289 NONE paclitaxel_6\NN|in|hour (r_compound) infusions_7\NNS|NONE (l_prep) in_8\IN|hour|paclitaxel (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|naive (l_pobj) IIIB_15\NNS|NONE (l_conj) cancer_23\NN|or|stage
D017239_D002289 NONE paclitaxel_6\NN|in|hour (r_compound) infusions_7\NNS|NONE (l_prep) in_8\IN|hour|paclitaxel (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|naive (l_pobj) IIIB_15\NNS|NONE (l_conj) cancer_23\NN|or|stage (l_appos) NSCLC_25\NNP|IV|)|lung|small|(
D017239_D002289 NONE paclitaxel_9\NN|a|in|hour (r_compound) infusion_10\NN|NONE (l_prep) in_11\IN|a|paclitaxel|hour (l_pobj) trial_15\NN|NONE (l_prep) in_16\IN|II|phase (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) IIIB_21\NNS|NONE (l_conj) NSCLC_24\NNP|stage|or
D017239_D002289 NONE paclitaxel_5\NN|NONE (r_pobj) with_4\IN|combined|II (r_prep) studies_3\NNS|Further (l_acl) combined_6\VBN|with|II (l_prep) with_7\IN|NONE (l_pobj) drugs_9\NNS|NONE (l_amod) active_10\JJ|other (l_prep) against_11\IN|NONE (l_pobj) NSCLC_12\NNP|NONE
D017239_D002289 NONE paclitaxel_21\NN|with (r_dobj) comparing_20\VBG|III (r_acl) studies_19\NNS|remain (r_dobj) phase_17\NN|and|are|,|phase|. (r_conj) indicated_14\VBN|NONE (l_nsubjpass) phase_1\NN|phase|and|are|,|. (l_dobj) studies_3\NNS|Further (l_acl) combined_6\VBN|with|II (l_prep) with_7\IN|NONE (l_pobj) drugs_9\NNS|NONE (l_amod) active_10\JJ|other (l_prep) against_11\IN|NONE (l_pobj) NSCLC_12\NNP|NONE
D017239_D009369 NONE Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|significant|antineoplastic (l_pobj) types_22\NNS|NONE (l_compound) tumor_21\NN|carcinoma|different|,
D017239_D009369 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|significant|antineoplastic (l_pobj) types_22\NNS|NONE (l_compound) tumor_21\NN|carcinoma|different|,
9041081
D013256_D009798 NONE steroid_13\NN| (r_npadvmod) induced_15\VBN|IOP|(|intraocular|elevated (r_amod) pressure_18\NN|patients|During|,|.
D013256_D009798 NONE steroid_2\NN| (r_npadvmod) induced_4\VBN|IOP (r_amod) rise_6\NN|cause|did|not|.
D000305_D009798 CID corticosteroid_25\NN|NONE (r_compound) therapy_26\NN|after|was (r_nsubjpass) discontinued_28\VBN|that (r_advcl) resolved_23\VBD|) (r_relcl) IOP_20\NNP|(|induced|intraocular|elevated (r_appos) pressure_18\NN|patients|During|,|.
16710500
D004977_D014376 NONE Ethambutol_2\NNP|:|is|in|INTRODUCTION|,|associated|and|. (r_nsubjpass) used_4\VBN|NONE (l_prep) in_5\IN|:|is|INTRODUCTION|,|associated|and|.|Ethambutol (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the|,|is (l_pobj) tuberculosis_9\NN|NONE
D004977_D009901 CID Ethambutol_0\NN| (r_npadvmod) associated_2\VBN|.|optic (r_amod) neuropathy_4\NN|NONE
D004977_D009901 CID ethambutol_3\NN| (r_npadvmod) associated_5\VBN|optic (r_amod) neuropathy_8\NNS|NONE
D004977_D014786 CID Ethambutol_2\NNP|:|is|in|INTRODUCTION|,|associated|and|. (r_nsubjpass) used_4\VBN|NONE (l_conj) associated_22\VBN|:|is|in|INTRODUCTION|,|and|.|Ethambutol (l_prep) with_23\IN|be|can (l_pobj) loss_26\NN|NONE
D004977_D014786 CID Ethambutol_0\NNP|NONE (r_compound) usage_1\NN|.|is|avoided|with|and (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|.|is|avoided|and|usage (l_pobj) loss_7\NN|NONE
12093990
C059262_D009503 CID cidofovir_2\NN|NONE (r_pobj) of_1\IN|in (r_prep) Use_0\NN|was|.|with (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|was|Use|. (l_pobj) failure_11\NN|NONE (l_conj) neutropenia_13\NN|progressive|and|renal
D012254_D000257 NONE ribavirin_1\JJ|.|Intravenous|in|for (r_compound) treatment_2\NN|NONE (l_prep) for_3\IN|.|Intravenous|in|ribavirin (l_pobj) disease_6\NN|NONE
D012254_D000257 NONE ribavirin_7\NN|intravenous (r_compound) therapy_8\NN|NONE (r_pobj) with_5\IN|our|for|in (r_prep) experience_4\NN|and|:|review|We|. (l_prep) for_9\IN|our|in|with (l_pobj) disease_12\NN|NONE
D012254_D000257 NONE ribavirin_12\RB|NONE (r_pobj) with_10\IN|for (r_prep) treated_9\VBN| (l_prep) for_13\IN|with (l_pobj) disease_17\NN|NONE
D012254_D000257 NONE ribavirin_2\NN|effective|not|Although (r_nsubj) was_3\VBD|therapy|.|begun|,|unlikely (l_acomp) effective_5\JJ|not|Although|ribavirin (l_prep) for_6\IN|NONE (l_pobj) children_8\NNS|NONE (l_prep) with_9\IN|all (l_pobj) disease_12\NN|NONE
D012254_D000257 NONE ribavirin_11\RB|NONE (r_pobj) with_9\IN|recovered|.|children (r_prep) treated_8\VBN|NONE (l_nsubj) children_3\NNS|recovered|with|. (l_prep) with_4\IN| (l_pobj) disease_7\NN|NONE
D012254_D000257 NONE ribavirin_33\NN|such (r_pobj) as_31\IN|,|adenoviral|useful|, (r_prep) therapies_28\NNS|NONE (r_pobj) of_22\IN|,|clinical|multicenter|a|large (r_prep) trial_21\NN|especially|, (r_conj) children_14\NNS|,|certain (r_appos) hosts_11\NNS|NONE (r_pobj) in_9\IN|of (r_prep) prevalence_5\NN|the|increasing|and (l_prep) of_6\IN|in (l_pobj) disease_8\NN|NONE
C059262_D000257 NONE cidofovir_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|has|been|by (l_prep) in_4\IN|The|of (l_pobj) infection_7\NN|NONE
D012254_D000740 NONE ribavirin_7\RB|NONE (r_pobj) of_5\IN|common|adverse|The (r_prep) effect_4\NN|anemia|. (r_nsubj) is_8\VBZ|NONE (l_attr) anemia_11\NN|.|effect
D012254_D006482 NONE Ribavirin_0\NNP|is|in|is|and|,|treat|. (r_nsubjpass) licensed_2\VBN|NONE (l_conj) is_27\VBZ|in|is|and|,|Ribavirin|treat|. (l_attr) treatment_29\NN|NONE (l_prep) for_32\IN|the|of (l_pobj) infection_33\NN|NONE (l_prep) with_34\IN|NONE (l_pobj) viruses_37\NNS|NONE
D012254_D006482 NONE ribavirin_26\RB|to|in (r_dobj) treat_22\VB|is|in|is|and|,|Ribavirin|. (r_conj) licensed_2\VBN|NONE (l_conj) is_27\VBZ|in|is|and|,|Ribavirin|treat|. (l_attr) treatment_29\NN|NONE (l_prep) for_32\IN|the|of (l_pobj) infection_33\NN|NONE (l_prep) with_34\IN|NONE (l_pobj) viruses_37\NNS|NONE
D012254_D007239 NONE ribavirin_2\NN|effective|not|Although (r_nsubj) was_3\VBD|therapy|.|begun|,|unlikely (r_advcl) is_22\VBZ|NONE (l_advcl) begun_29\VBN|therapy|.|was|,|unlikely (l_prep) in_31\IN|if (l_pobj) course_33\NN|late (l_prep) of_34\IN|the (l_pobj) infection_36\NN|NONE
C059262_D058186 CID cidofovir_2\NN|NONE (r_pobj) of_1\IN|in (r_prep) Use_0\NN|was|.|with (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|was|Use|. (l_pobj) failure_11\NN|NONE
D012254_D006526 NONE Ribavirin_0\NNP|is|in|is|and|,|treat|. (r_nsubjpass) licensed_2\VBN|NONE (l_conj) treat_22\VB|is|in|is|and|,|Ribavirin|. (l_dobj) ribavirin_26\RB|to|in (l_compound) Intravenous_25\NNP|NONE (l_compound) C._24\NNP|hepatitis
D012254_D006526 NONE ribavirin_26\RB|to|in (l_compound) Intravenous_25\NNP|NONE (l_compound) C._24\NNP|hepatitis
D012254_D018357 NONE Ribavirin_0\NNP|is|in|is|and|,|treat|. (r_nsubjpass) licensed_2\VBN|NONE (l_prep) in_3\IN|is|is|and|,|Ribavirin|treat|. (l_pobj) form_5\NN|NONE (l_prep) for_6\IN|aerosol (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) infection_13\NN|NONE
D012254_D018357 NONE ribavirin_26\RB|to|in (r_dobj) treat_22\VB|is|in|is|and|,|Ribavirin|. (r_conj) licensed_2\VBN|NONE (l_prep) in_3\IN|is|is|and|,|Ribavirin|treat|. (l_pobj) form_5\NN|NONE (l_prep) for_6\IN|aerosol (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) infection_13\NN|NONE
C059262_D007674 NONE cidofovir_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|has|been|by (r_nsubjpass) limited_10\VBN|.|,|nephrotoxicity|significant (r_ccomp) is_20\VBZ|NONE (l_attr) nephrotoxicity_21\NN|.|,|limited|significant
17049862
D010672_D001919 CID phenytoin_1\JJ|NONE (r_compound) administration_2\NN|NONE (r_pobj) Following_0\VBG|,|refractory|.|bradycardia|,|patient (r_prep) developed_6\VBD|NONE (l_dobj) bradycardia_9\NN|,|Following|refractory|.|,|patient
D001285_D001919 NONE atropine_13\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) refractory_11\JJ|,|Following|.|bradycardia|,|patient (r_advcl) developed_6\VBD|NONE (l_dobj) bradycardia_9\NN|,|Following|refractory|.|,|patient
D010672_D012640 NONE phenytoin_1\NN|during|was|. (r_nsubjpass) administered_3\VBN|NONE (l_prep) during_4\IN|was|phenytoin|. (l_pobj) part_7\NN|NONE (l_prep) of_8\IN|later|the (l_pobj) surgery_10\NN|NONE (l_prep) for_11\IN|the (l_pobj) prophylaxis_13\NN|NONE (l_compound) seizure_12\NN|NONE
D004837_D001919 NONE adrenaline_15\NN|and (r_conj) atropine_13\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) refractory_11\JJ|,|Following|.|bradycardia|,|patient (r_advcl) developed_6\VBD|NONE (l_dobj) bradycardia_9\NN|,|Following|refractory|.|,|patient
D010672_D007035 NONE phenytoin_1\JJ|NONE (r_compound) administration_2\NN|?|safe (r_nsubj) Is_0\VBZ|NONE (l_acomp) safe_3\JJ|administration|? (l_prep) in_4\IN|NONE (l_pobj) child_7\NN|NONE (l_amod) hypothermic_6\JJ|a
D010672_D007035 NONE phenytoin_5\NN|NONE (l_conj) hypothermia_7\NN|and
D010672_D007035 NONE phenytoin_2\NN|NONE (r_pobj) of_1\IN|in (r_prep) Administration_0\NN|to|.|may (l_prep) in_3\IN|of (l_pobj) presence_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) hypothermia_7\NN|NONE
11063349
D016572_D064420 NONE cyclosporine_16\NN|NONE (l_appos) CsA_18\NNP|NONE (l_conj) toxicity_25\NN|(|or|)
D016572_D064420 NONE CsA_18\NNP|NONE (l_conj) toxicity_25\NN|(|or|)
D016572_D064420 NONE CsA_6\NNP|indications|. (l_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) CsA_15\NNP|disorder||Tac|,|, (l_conj) toxicity_18\NN|,|or||dysmorphism|acute
D016572_D064420 NONE CsA_15\NNP|disorder||Tac|,|, (l_conj) toxicity_18\NN|,|or||dysmorphism|acute
D003404_D007674 NONE creatinine_17\NN|NONE (r_pobj) in_15\IN|+/|significant|a|to|at (r_prep) decrease_14\NN|there|:|In|.|] (r_attr) was_11\VBD|NONE (l_prep) In_1\IN|there|decrease|:|.|] (l_pobj) patients_4\NNS|NONE (l_acl) switched_5\VBD||the (l_prep) because_6\IN|NONE (l_pobj) nephrotoxicity_9\NN|of
D016572_D056486 NONE CsA_6\NNP|indications|. (l_conj) hepatotoxicity_43\NN|in|chronic|or|and|nephrotoxicity|,
D016572_D056486 NONE CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (r_conj) CsA_6\NNP|indications|. (l_conj) hepatotoxicity_43\NN|in|chronic|or|and|nephrotoxicity|,
D020123_D011014 NONE RAPA_0\NNP|,|in|PTLD|because|.|was (r_nsubjpass) discontinued_2\VBN|NONE (l_prep) because_7\IN|,|in|PTLD|.|RAPA|was (l_pobj) pneumonia_9\NN|of
D016559_-1 NONE Tac_8\NNP|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) CsA_15\NNP|disorder||Tac|,|, (l_conj) dysmorphism_25\NN|toxicity|,|or||acute
D016559_-1 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|,|or||dysmorphism|acute (r_conj) CsA_15\NNP|disorder||Tac|,|, (l_conj) dysmorphism_25\NN|toxicity|,|or||acute
D016572_D007674 CID CsA_6\NNP|indications|. (l_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|,
D016572_D007674 CID CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|,
D016572_D008232 NONE CsA_6\NNP|indications|. (l_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|,
D016572_D008232 NONE CsA_6\NNP|indications|. (l_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|, (l_appos) PTLD_34\NN|(|)|lymphoproliferative|posttransplant
D016572_D008232 NONE CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|,
D016572_D008232 NONE CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|, (l_appos) PTLD_34\NN|(|)|lymphoproliferative|posttransplant
D020123_D013281 NONE RAPA_0\NNP|,|in|PTLD|because|.|was (r_nsubjpass) discontinued_2\VBN|NONE (l_appos) PTLD_13\NN|,|in|because|.|RAPA|was (l_conj) ulcers_20\NNS|in|,|,|and
D016572_-1 NONE CsA_6\NNP|indications|. (l_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) CsA_15\NNP|disorder||Tac|,|, (l_conj) dysmorphism_25\NN|toxicity|,|or||acute
D016572_-1 NONE CsA_15\NNP|disorder||Tac|,|, (l_conj) dysmorphism_25\NN|toxicity|,|or||acute
D016559_D007674 CID Tac_8\NNP|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|,
D016559_D007674 CID Tac_17\NNP|NONE (r_compound) toxicity_18\NN|,|or||dysmorphism|acute (r_conj) CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|,
D016559_D008232 NONE Tac_8\NNP|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|,
D016559_D008232 NONE Tac_8\NNP|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|, (l_appos) PTLD_34\NN|(|)|lymphoproliferative|posttransplant
D016559_D008232 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|,|or||dysmorphism|acute (r_conj) CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|,
D016559_D008232 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|,|or||dysmorphism|acute (r_conj) CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN|CsA||Tac|,|, (l_appos) PTLD_34\NN|(|)|lymphoproliferative|posttransplant
D020123_D008232 NONE RAPA_0\NNP|,|in|PTLD|because|.|was (r_nsubjpass) discontinued_2\VBN|NONE (l_appos) PTLD_13\NN|,|in|because|.|RAPA|was
D020123_D011020 NONE RAPA_6\NNP|drug (r_compound) levels_8\NNS|NONE (r_pobj) to_5\IN|when|patients (r_prep) converting_3\VBG|,|should|avoid|However|be|over (r_csubjpass) monitored_11\VBN|prophylaxis|.|should|be (r_advcl) given_27\VBN|NONE (l_nsubjpass) prophylaxis_24\NN|monitored|.|should|be (l_compound) pneumonia_23\NN|NONE
D020123_D064420 NONE RAPA_11\NNP|in (r_compound) conversion_12\NN|NONE (l_prep) in_13\IN|RAPA (l_pobj) patients_14\NNS|NONE (l_acl) undergoing_15\VBG|NONE (l_dobj) cyclosporine_16\NN|NONE (l_appos) CsA_18\NNP|NONE (l_conj) toxicity_25\NN|(|or|)
D016559_D064420 NONE tacrolimus_21\NN|(|Tac|) (r_nmod) toxicity_25\NN|(|or|)
D016559_D064420 NONE Tac_23\NN|(|tacrolimus|) (r_nmod) toxicity_25\NN|(|or|)
D016559_D064420 NONE Tac_8\NNP|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (l_conj) CsA_15\NNP|disorder||Tac|,|, (l_conj) toxicity_18\NN|,|or||dysmorphism|acute
D016559_D064420 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|,|or||dysmorphism|acute
D016559_D056486 NONE Tac_8\NNP|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (r_conj) CsA_6\NNP|indications|. (l_conj) hepatotoxicity_43\NN|in|chronic|or|and|nephrotoxicity|,
D016559_D056486 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|,|or||dysmorphism|acute (r_conj) CsA_15\NNP|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN|in|chronic|or|hepatotoxicity|and|, (r_conj) CsA_6\NNP|indications|. (l_conj) hepatotoxicity_43\NN|in|chronic|or|and|nephrotoxicity|,
11900788
D018738_D002375 NONE hexamethonium_10\NN|and|, (r_conj) mecamylamine_7\NN|, (r_conj) naloxone_5\NN|of|Intraperitoneal|,|catalepsy|. (r_appos) administration_1\NN|NONE (l_appos) catalepsy_14\NN|naloxone|of|Intraperitoneal|,|.
D018738_D002375 NONE hexamethonium_5\NN|, (r_conj) atropine_3\NN|NONE (r_pobj) of_2\IN|Intracerebroventricular (r_prep) injection_1\NN|also|.|catalepsy (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_11\NN|injection|also|.
D001285_D002375 NONE atropine_3\NN|NONE (r_pobj) of_2\IN|naloxone|Intraperitoneal|,|catalepsy|. (r_prep) administration_1\NN|NONE (l_appos) catalepsy_14\NN|naloxone|of|Intraperitoneal|,|.
D001285_D002375 NONE atropine_3\NN|NONE (r_pobj) of_2\IN|Intracerebroventricular (r_prep) injection_1\NN|also|.|catalepsy (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_11\NN|injection|also|.
D008464_D002375 NONE mecamylamine_7\NN|, (r_conj) naloxone_5\NN|of|Intraperitoneal|,|catalepsy|. (r_appos) administration_1\NN|NONE (l_appos) catalepsy_14\NN|naloxone|of|Intraperitoneal|,|.
D009538_D002375 CID Nicotine_0\NN|of|.|in (r_compound) potentiation_1\NN|NONE (l_prep) of_2\IN|.|Nicotine|in (l_pobj) catalepsy_6\NN|NONE
D009538_D002375 CID nicotine_7\NN|NONE (r_pobj) of_6\IN|induced|on (r_prep) effects_5\NNS|have|,|In|.|been (l_prep) on_8\IN|of|induced (l_pobj) catalepsy_9\NN|NONE
D009538_D002375 CID nicotine_3\NN|but (r_conj) Morphine_0\NNP|.|catalepsy (r_nsubj) induced_4\VBD|NONE (l_dobj) catalepsy_9\NN|.|Morphine
D009538_D002375 CID nicotine_22\NN|NONE (r_pobj) with_21\IN|a|of (r_prep) combination_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|reduced (r_acl) catalepsy_14\NN|naloxone|of|Intraperitoneal|,|.
D009538_D002375 CID nicotine_16\NN|plus (r_conj) morphine_14\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|NONE (r_acl) catalepsy_11\NN|injection|also|.
D009538_D002375 CID nicotine_22\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|the|of (r_acl) potentiation_17\NN|be|through|also|may (r_nsubjpass) mediated_26\VBN|be|by|catalepsy|can|,|and|that (r_conj) elicited_8\VBN|was|It|. (l_nsubjpass) catalepsy_5\NN|be|by|can|,|and|that|mediated
D009020_D002375 CID morphine_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) catalepsy_6\NN|NONE
D009020_D002375 CID morphine_12\NN|NONE (r_pobj) by_11\IN|in (r_agent) induced_10\VBN|of|on (r_acl) effects_5\NNS|have|,|In|.|been (l_prep) on_8\IN|of|induced (l_pobj) catalepsy_9\NN|NONE
D009020_D002375 CID Morphine_0\NNP|.|catalepsy (r_nsubj) induced_4\VBD|NONE (l_dobj) catalepsy_9\NN|.|Morphine
D009020_D002375 CID morphine_20\NN|NONE (r_pobj) of_19\IN|a|with (r_prep) combination_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|reduced (r_acl) catalepsy_14\NN|naloxone|of|Intraperitoneal|,|.
D009020_D002375 CID morphine_14\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|NONE (r_acl) catalepsy_11\NN|injection|also|.
D009020_D002375 CID morphine_4\NN|NONE (r_compound) catalepsy_5\NN|be|by|can|,|and|that|mediated
D009020_D002375 CID morphine_19\NN|NONE (r_pobj) of_18\IN|the|induced (r_prep) potentiation_17\NN|be|through|also|may (r_nsubjpass) mediated_26\VBN|be|by|catalepsy|can|,|and|that (r_conj) elicited_8\VBN|was|It|. (l_nsubjpass) catalepsy_5\NN|be|by|can|,|and|that|mediated
D009270_D002375 NONE naloxone_5\NN|of|Intraperitoneal|,|catalepsy|. (r_appos) administration_1\NN|NONE (l_appos) catalepsy_14\NN|naloxone|of|Intraperitoneal|,|.
D009270_D002375 NONE naloxone_8\NN|and|, (r_conj) hexamethonium_5\NN|, (r_conj) atropine_3\NN|NONE (r_pobj) of_2\IN|Intracerebroventricular (r_prep) injection_1\NN|also|.|catalepsy (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_11\NN|injection|also|.
11583940
C063008_D007674 NONE mofetil_7\NNS|have|,|.|agents (r_dobj) mycophenolate_6\VB|NONE (l_dep) have_14\VBP|,|.|agents|mofetil (l_dobj) nephrotoxicity_16\NN|NONE
D020123_D007674 NONE sirolimus_9\NN|rapamycin|and (r_conj) mofetil_7\NNS|have|,|.|agents (r_dobj) mycophenolate_6\VB|NONE (l_dep) have_14\VBP|,|.|agents|mofetil (l_dobj) nephrotoxicity_16\NN|NONE
D020123_D007674 NONE rapamycin_11\NNS|sirolimus|and (r_appos) mofetil_7\NNS|have|,|.|agents (r_dobj) mycophenolate_6\VB|NONE (l_dep) have_14\VBP|,|.|agents|mofetil (l_dobj) nephrotoxicity_16\NN|NONE
1700207
D006221_D001145 NONE halothane_17\NN| (r_npadvmod) anesthetized_19\VBN|NONE (r_amod) dogs_20\NNS|NONE (r_pobj) in_16\IN|adrenaline (r_prep) infusion_15\NN|NONE (r_pobj) by_13\IN|was|.|arrhythmia (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|by|was|.
D012964_D001145 NONE Na_7\NNP|channel (r_compound) blockers_9\NNS|NONE (r_pobj) by_6\IN|is|which (r_agent) suppressed_5\VBN|,|Digitalis|, (r_relcl) arrhythmia_1\NN|by|was|.
D010042_D001145 CID ouabain_21\NN|NONE (r_pobj) of_20\IN|in|)|i.v.|( (r_prep) injection_19\NN|intermittent (r_appos) intravenous_15\JJ|NONE (r_pobj) by_13\IN|arrhythmia|was|. (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|by|was|.
C032151_D001145 NONE cibenzoline_6\NN|NONE (l_prep) on_7\IN|NONE (l_pobj) arrhythmias_10\NNS|NONE
C032151_D001145 NONE -cibenzoline_6\:|(|+ (r_conj) of_2\IN|and|Antiarrhythmic|examined (r_prep) effects_1\NNS|NONE (l_conj) examined_11\VBN|and|Antiarrhythmic|of (l_advcl) using_12\VBG|)cibenzoline|were|.|( (l_dobj) models_17\NNS|NONE (l_compound) arrhythmia_16\NN|canine|two
C032151_D001145 NONE -)-cibenzoline_9\:|were|using|.|( (r_nsubjpass) examined_11\VBN|and|Antiarrhythmic|of (l_advcl) using_12\VBG|)cibenzoline|were|.|( (l_dobj) models_17\NNS|NONE (l_compound) arrhythmia_16\NN|canine|two
C032151_D001145 NONE -cibenzoline_8\,|) (r_punct) suppressed_9\VBN|,|.|digitalis|i.v.|respectively (r_amod) arrhythmias_15\NNS|NONE
C032151_D001145 NONE -cibenzoline_9\:|arrhythmias (r_punct) for_10\IN|of|The|effective|minimum|plasma (l_pobj) arrhythmias_16\NNS|cibenzoline
C032151_D001145 NONE -)-cibenzoline_9\NNP|,|arrhythmia|( (r_nsubj) suppressed_10\VBD|NONE (l_dobj) arrhythmia_15\NN|,|)cibenzoline|(
C032151_D001145 NONE -)-cibenzoline_9\NNP|,|arrhythmia|( (r_nsubj) suppressed_10\VBD|NONE (r_pcomp) of_7\IN|NONE (r_prep) i.v._6\NN|lower|A|of (r_appos) dose_2\NN|mg/kg|suppress|was|whereas|. (r_nsubjpass) needed_22\VBN|NONE (l_advcl) suppress_24\VB|dose|mg/kg|was|whereas|. (l_dobj) arrhythmias_28\NNS|to
C032151_D001145 NONE -)-cibenzoline_7\:|effective|minimum|of|The|plasma (l_prep) for_8\IN|( (l_pobj) arrhythmia_14\NN|NONE
D004837_D001145 CID adrenaline_14\NN|in (r_amod) infusion_15\NN|NONE (r_pobj) by_13\IN|was|.|arrhythmia (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|by|was|.
D004837_D001145 CID adrenaline_12\NN| (r_npadvmod) induced_14\VBN|and (r_conj) digitalis-_10\NN|,|suppressed|.|i.v.|respectively (r_amod) arrhythmias_15\NNS|NONE
D004837_D001145 CID adrenaline_13\NN| (r_npadvmod) induced_15\VBN|and (r_conj) digitalis-_11\NN|NONE (r_amod) arrhythmias_16\NNS|cibenzoline
D004837_D001145 CID adrenaline_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) arrhythmias_28\NNS|to (r_dobj) suppress_24\VB|dose|mg/kg|was|whereas|. (r_advcl) needed_22\VBN|NONE (l_nsubjpass) dose_2\NN|mg/kg|suppress|was|whereas|. (l_appos) i.v._6\NN|lower|A|of (l_prep) of_7\IN|NONE (l_pcomp) suppressed_10\VBD|NONE (l_dobj) arrhythmia_15\NN|,|)cibenzoline|(
D004837_D001145 CID adrenaline_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) arrhythmias_28\NNS|to
D004837_D001145 CID adrenaline_11\NN| (r_npadvmod) induced_13\VBN|and (r_conj) digitalis-_9\NN|NONE (r_amod) arrhythmia_14\NN|NONE
D010424_D001145 NONE pentobarbital_23\NN| (r_npadvmod) anesthetized_25\VBN|NONE (r_amod) dogs_26\NNS|NONE (r_pobj) in_22\IN|of|)|i.v.|( (r_prep) injection_19\NN|intermittent (r_appos) intravenous_15\JJ|NONE (r_pobj) by_13\IN|arrhythmia|was|. (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|by|was|.
D002118_D001145 NONE Ca_7\NNP|NONE (r_aux) channel_8\NN|NONE (r_compound) blockers_9\NNS|NONE (r_pobj) by_6\IN|is|which (r_agent) suppressed_5\VBN|,|Adrenaline|, (r_relcl) arrhythmia_1\NN|by|was|.
D004070_D001145 NONE Digitalis_0\NNP|,|,|suppressed (r_compound) arrhythmia_1\NN|by|was|.
D004070_D001145 NONE digitalis-_10\NN|,|suppressed|.|i.v.|respectively (r_amod) arrhythmias_15\NNS|NONE
D004070_D001145 NONE digitalis-_11\NN|NONE (r_amod) arrhythmias_16\NNS|cibenzoline
D004070_D001145 NONE digitalis_12\NN| (r_npadvmod) induced_14\VBN|the (r_amod) arrhythmia_15\NN|,|)cibenzoline|(
D004070_D001145 NONE digitalis_12\NN| (r_npadvmod) induced_14\VBN|the (r_amod) arrhythmia_15\NN|,|)cibenzoline|( (r_dobj) suppressed_10\VBD|NONE (r_pcomp) of_7\IN|NONE (r_prep) i.v._6\NN|lower|A|of (r_appos) dose_2\NN|mg/kg|suppress|was|whereas|. (r_nsubjpass) needed_22\VBN|NONE (l_advcl) suppress_24\VB|dose|mg/kg|was|whereas|. (l_dobj) arrhythmias_28\NNS|to
D004070_D001145 NONE digitalis-_9\NN|NONE (r_amod) arrhythmia_14\NN|NONE
6118280
D002998_D009207 NONE clonazepam_4\NN|,|.|Of|be|was (r_nsubjpass) found_12\VBN|NONE (l_xcomp) be_14\VB|,|clonazepam|.|Of|was (l_prep) in_27\IN|potent|mg/kg|to (l_pcomp) blocking_28\VBG|NONE (l_dobj) jerks_31\NNS|NONE
D009118_D009207 CID muscimol_7\NNS|in|.|jerks||drugs (r_npadvmod) induced_9\VBN|NONE (l_dobj) jerks_11\NNS|in|.|muscimol||drugs
D009118_D009207 CID muscimol_5\NNS|In|,|.|jerks (r_nsubj) produced_6\VBD|NONE (l_dobj) jerks_8\NNS|In|muscimol|,|.
D009118_D009207 CID muscimol_22\NN| (r_npadvmod) induced_24\VBN|the (r_amod) myoclonus_25\NN|clinical|, (r_appos) myoclonus_19\NN|NONE
D009118_D009207 CID muscimol_22\NN| (r_npadvmod) induced_24\VBN|the (r_amod) myoclonus_25\NN|clinical|,
D001418_D009207 NONE baclofen_5\JJ|NONE (r_compound) block_6\NN|and (r_conj) benzodiazepines_3\NNS|,|Serotonergic (r_conj) drugs_1\NNS|in|.|muscimol|jerks| (r_nsubj) induced_9\VBN|NONE (l_dobj) jerks_11\NNS|in|.|muscimol||drugs
D001418_D009207 NONE -)-baclofen_11\:|management (r_punct) in_12\IN|possible|the|of (l_pobj) management_14\NN|)baclofen (l_prep) of_15\IN|the (l_pobj) myoclonus_17\NN|NONE
D003975_D009207 NONE diazepam_20\NN|NONE (r_pobj) than_19\IN|fold|more (r_prep) potent_18\JJ|in|mg/kg|to (r_acomp) be_14\VB|,|clonazepam|.|Of|was (l_prep) in_27\IN|potent|mg/kg|to (l_pcomp) blocking_28\VBG|NONE (l_dobj) jerks_31\NNS|NONE
D001569_D009207 NONE benzodiazepines_3\NNS|,|Serotonergic (r_conj) drugs_1\NNS|in|.|muscimol|jerks| (r_nsubj) induced_9\VBN|NONE (l_dobj) jerks_11\NNS|in|.|muscimol||drugs
D001569_D009207 NONE benzodiazepines_2\NNS|NONE (r_pobj) Of_0\IN|,|clonazepam|.|be|was (r_prep) found_12\VBN|NONE (l_xcomp) be_14\VB|,|clonazepam|.|Of|was (l_prep) in_27\IN|potent|mg/kg|to (l_pcomp) blocking_28\VBG|NONE (l_dobj) jerks_31\NNS|NONE
D001569_D009207 NONE benzodiazepines_7\NNS|and (r_conj) 5-HTP_4\NN|that|been|be|have (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|that|HTP|been|have (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE
D001569_D009207 NONE benzodiazepines_7\NNS|and (r_conj) 5-HTP_4\NN|that|been|be|have (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|that|HTP|been|have (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE (l_appos) myoclonus_25\NN|clinical|,
D006916_D009207 NONE 5-HTP_4\NN|that|been|be|have (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|that|HTP|been|have (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE
D006916_D009207 NONE 5-HTP_4\NN|that|been|be|have (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|that|HTP|been|have (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE (l_appos) myoclonus_25\NN|clinical|,
C014896_D009207 NONE MK-212_8\NNP|NONE (r_punct) and_9\CC|( (r_punct) -)-baclofen_11\:|management (r_punct) in_12\IN|possible|the|of (l_pobj) management_14\NN|)baclofen (l_prep) of_15\IN|the (l_pobj) myoclonus_17\NN|NONE
20552622
D000420_D013617 CID salbutamol_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) triggered_5\VBN|induced|report|atrial (r_acl) tachyarrhythmia_4\NN|NONE
D000420_D013617 CID Salbutamol_0\NNP|.|as|is|here (r_nsubjpass) presented_2\VBN|NONE (l_prep) as_4\IN|.|Salbutamol|is|here (l_pobj) trigger_7\NN|NONE (l_prep) for_8\IN|possible|a (l_pobj) SIAT_9\NNP|NONE
D001262_D013610 NONE atenolol_51\NN|such (r_pobj) as_50\IN||beta|a (r_prep) blocker_48\NN|may|that|it (r_nsubj) relieve_60\VB|and|while (r_conj) swallowing_42\VBG|may|agonist|that|trigger (r_advcl) be_31\VB|to (l_nsubj) agonist_21\NN|may|swallowing|that|trigger (l_acl) known_25\VBN|like|beta||a (l_xcomp) induce_27\VB|)|( (l_dobj) tachycardia_28\NN|to
D001262_D001145 NONE atenolol_6\NN|NONE (r_pobj) with_5\IN|arrhythmia|,|but|after|recurred|. (r_prep) resolved_2\VBD|NONE (l_nsubj) arrhythmia_1\NN|,|but|after|with|recurred|.
D001262_D001145 NONE atenolol_13\NN|NONE (r_pobj) with_11\IN|a (r_prep) week_10\NN|NONE (r_pobj) after_8\IN|,|After|arrhythmia|. (r_prep) disappeared_17\VBD|NONE (l_nsubj) arrhythmia_16\NN|,|After|after|.
D000420_D013610 NONE salbutamol_23\NN|NONE (r_pobj) like_22\IN|beta||known|a (r_prep) agonist_21\NN|may|swallowing|that|trigger (l_acl) known_25\VBN|like|beta||a (l_xcomp) induce_27\VB|)|( (l_dobj) tachycardia_28\NN|to
11282081
D002698_D001281 NONE chloralose_21\NN|anesthetized (r_amod) dogs_23\NNS|NONE (r_pobj) to_18\IN|evaluate|we|,|.|verapamil (r_prep) administered_16\VBD|NONE (l_advcl) evaluate_1\VB|we|,|.|verapamil|to (l_dobj) mechanisms_4\NNS|To (l_prep) of_5\IN|potential|the (l_pobj) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D004110_D001281 NONE Diltiazem_0\NNP|,|produced|did|but|ERP|not|. (r_nsubj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN|, (l_compound) AF_6\NNP|cycle|or|duration
D004110_D001281 NONE Diltiazem_0\NNP|,|produced|did|but|ERP|not|. (r_nsubj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN|, (l_conj) duration_11\NN|AF|cycle|or (l_compound) AF_10\NNP|NONE
D004110_D001281 NONE diltiazem_23\NN|NONE (r_pobj) by_22\IN|not (r_agent) shared_21\VBN|an|and|dependent (r_conj) effect_13\NN|,|Verapamil|in|.|by|AF (r_dobj) promotes_1\VBZ|NONE (l_dobj) AF_2\NNP|,|effect|Verapamil|in|.|by
D009020_D001281 NONE morphine_19\NN| (r_npadvmod) chloralose_21\NN|anesthetized (r_amod) dogs_23\NNS|NONE (r_pobj) to_18\IN|evaluate|we|,|.|verapamil (r_prep) administered_16\VBD|NONE (l_advcl) evaluate_1\VB|we|,|.|verapamil|to (l_dobj) mechanisms_4\NNS|To (l_prep) of_5\IN|potential|the (l_pobj) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D002118_D013617 NONE Ca(2_23\NNP|NONE (r_dobj) decreases_19\VBZ|and|occurrence|tachycardia (r_conj) promotes_7\VBZ|.|: (l_nsubj) tachycardia_3\NN|decreases|and|occurrence
D002118_D001281 NONE Ca(2_23\NNP|NONE (r_dobj) decreases_19\VBZ|and|occurrence|tachycardia (r_conj) promotes_7\VBZ|.|: (l_dobj) occurrence_9\NN|decreases|and|tachycardia (l_prep) of_12\IN|and|the|maintenance (l_pobj) fibrillation_14\NN|NONE
D002118_D001281 NONE Ca(2_23\NNP|NONE (r_dobj) decreases_19\VBZ|and|occurrence|tachycardia (r_conj) promotes_7\VBZ|.|: (l_dobj) occurrence_9\NN|decreases|and|tachycardia (l_prep) of_12\IN|and|the|maintenance (l_pobj) fibrillation_14\NN|NONE (l_appos) AF_16\NNP|)|atrial|(
D002118_D001281 NONE Ca(2_11\NN|) (r_nmod) channel_13\NN|acute|type (r_compound) blockade_14\NN|,|can|AF|that|consistent (r_nsubj) promote_16\VB|clinical|a (l_dobj) AF_17\NNP|,|can|that|blockade|consistent
D002118_D001281 NONE Ca(2_11\NN|) (r_nmod) channel_13\NN|acute|type (r_compound) blockade_14\NN|,|can|AF|that|consistent (r_nsubj) promote_16\VB|clinical|a (l_advcl) consistent_19\JJ|,|can|AF|that|blockade (l_prep) with_20\IN|NONE (l_pobj) effect_24\NN|NONE (l_compound) AF_22\NNP|of|an|promoting
D002118_D001281 NONE Ca(2_26\NNP|channel (r_nmod) inhibition_30\NN|NONE (r_pobj) of_25\IN|an|AF|promoting (r_prep) effect_24\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) consistent_19\JJ|,|can|AF|that|blockade (r_advcl) promote_16\VB|clinical|a (l_dobj) AF_17\NNP|,|can|that|blockade|consistent
D002118_D001281 NONE Ca(2_26\NNP|channel (r_nmod) inhibition_30\NN|NONE (r_pobj) of_25\IN|an|AF|promoting (r_prep) effect_24\NN|NONE (l_compound) AF_22\NNP|of|an|promoting
D002118_D001281 NONE Ca(2_9\NNP|channel (r_nmod) blockers_13\NNS|NONE (r_pobj) by_8\IN|AF (r_prep) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D014700_D001281 CID verapamil_2\NN|NONE (r_pobj) of_1\IN|.|determinants|and|on (r_prep) Effects_0\NNS|NONE (l_prep) on_3\IN|.|determinants|and|of (l_pobj) fibrillation_5\NN|NONE
D014700_D001281 CID verapamil_17\NN|evaluate|we|,|.|to (r_dobj) administered_16\VBD|NONE (l_advcl) evaluate_1\VB|we|,|.|verapamil|to (l_dobj) mechanisms_4\NNS|To (l_prep) of_5\IN|potential|the (l_pobj) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D014700_D001281 CID Verapamil_1\NNP|increasing|:|,|promotion|in (r_nsubj) caused_2\VBD|NONE (l_dobj) promotion_4\NN|increasing|:|,|Verapamil|in (l_compound) AF_3\NNP|NONE
D014700_D001281 CID Verapamil_1\NNP|increasing|:|,|promotion|in (r_nsubj) caused_2\VBD|NONE (l_advcl) increasing_9\VBG|:|,|Verapamil|promotion|in (l_dobj) duration_11\NN|NONE (l_prep) of_12\IN|induced|mean (l_pobj) AF_13\NNP|NONE
D014700_D001281 CID verapamil_4\NN|,|from|period|,|mean|accelerated|.|,|decreased|In (r_nsubj) shortened_5\VBN|NONE (l_conj) accelerated_43\VBN|,|from|period|,|mean|.|,|decreased|In|verapamil (l_conj) decreased_47\VBD|heterogeneously|conduction|and (l_dobj) length_50\NN|to (l_prep) of_51\IN|cycle|the (l_pobj) 94+/-4_54\CD|NONE (l_nmod) AF_52\NNP|(
D014700_D001281 CID verapamil_22\NNP|( (r_nmod) n=5_24\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|NONE (r_acl) that_19\DT|NONE (r_pobj) to_18\IN|NONE (r_prep) similar_17\JJ|conduction (r_amod) acceleration_16\NN|) (r_dobj) produced_14\VBD|,|did|but|ERP|not|Diltiazem|. (r_conj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN|, (l_compound) AF_6\NNP|cycle|or|duration
D014700_D001281 CID verapamil_22\NNP|( (r_nmod) n=5_24\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|NONE (r_acl) that_19\DT|NONE (r_pobj) to_18\IN|NONE (r_prep) similar_17\JJ|conduction (r_amod) acceleration_16\NN|) (r_dobj) produced_14\VBD|,|did|but|ERP|not|Diltiazem|. (r_conj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN|, (l_conj) duration_11\NN|AF|cycle|or (l_compound) AF_10\NNP|NONE
D014700_D001281 CID verapamil_7\NN|refractoriness|promote|In|.|, (r_nsubj) failed_8\VBD|NONE (l_xcomp) promote_10\VB|refractoriness|verapamil|In|.|, (l_dobj) AF_11\NNP|increased|and|to
D014700_D001281 CID verapamil_4\NN|by|that|AF (r_nsubj) promoted_5\VBD|.|mapping (l_dobj) AF_6\NNP|by|verapamil|that
D014700_D001281 CID Verapamil_0\NNP|,|effect|in|.|by|AF (r_nsubj) promotes_1\VBZ|NONE (l_dobj) AF_2\NNP|,|effect|Verapamil|in|.|by
7650771
D004456_D064420 NONE iodide_8\NN|eye|echothiophate (r_compound) drops_10\VBZ|NONE (r_pobj) of_6\IN|ocular (r_prep) instillation_5\NN|NONE (r_pobj) from_3\IN|NONE (r_prep) resulting_2\VBG|.|Cholinergic (r_acl) toxicity_1\NN|NONE
D004456_D018908 CID iodide_12\NN|echothiophate|ophthalmic (r_nmod) drops_14\NNS|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) from_7\IN|a|cholinergic|severe (r_prep) syndrome_6\NN|.|,|presented|patient (r_dobj) developed_2\VBD|NONE (l_conj) presented_16\VBN|syndrome|.|,|patient (l_prep) with_17\IN|given|and (l_pobj) weakness_20\NN|NONE
D004456_D009157 NONE iodide_12\NN|echothiophate|ophthalmic (r_nmod) drops_14\NNS|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) from_7\IN|a|cholinergic|severe (r_prep) syndrome_6\NN|.|,|presented|patient (r_dobj) developed_2\VBD|NONE (l_conj) presented_16\VBN|syndrome|.|,|patient (l_conj) given_24\VBN|with|and (l_dobj) diagnosis_26\NN|initially|was (l_prep) of_27\IN|the (l_pobj) gravis_29\NN|NONE
19893084
D005839_D058186 CID gentamicin_12\NN|NONE (r_pcomp) by_11\IN|NONE (r_agent) induced_10\VBN|renal|acute (r_acl) failure_9\NN|NONE
7066357
D011692_D009404 CID aminonucleoside_18\RB|Plasma|.|by|in (r_advmod) induced_12\VBN|NONE (l_nsubj) Plasma_0\NN|.|by|aminonucleoside|in (l_prep) during_6\IN|and|lipids (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) syndrome_11\NN|NONE
D011692_D009404 CID aminonucleoside_19\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|of|the (r_acl) alterations_8\NNS|to|,|whether|,|due|or (l_prep) of_9\IN|induced|the (l_pobj) lipoproteins_11\NNS|NONE (l_acl) found_12\VBN|plasma (l_prep) in_13\IN|NONE (l_pobj) syndrome_15\NN|NONE
D011692_D009404 CID aminonucleoside_19\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|of|the (r_acl) alterations_8\NNS|to|,|whether|,|due|or (r_nsubj) were_20\VBD|to (l_acomp) due_21\JJ|alterations|to|,|whether|,|or (l_prep) to_22\IN|NONE (l_pobj) syndrome_24\NN|NONE
D011692_D009404 CID aminonucleoside_37\NN|NONE (r_pobj) to_35\IN|alterations|,|whether|,|due|or (r_prep) were_20\VBD|to (l_nsubj) alterations_8\NNS|to|,|whether|,|due|or (l_prep) of_9\IN|induced|the (l_pobj) lipoproteins_11\NNS|NONE (l_acl) found_12\VBN|plasma (l_prep) in_13\IN|NONE (l_pobj) syndrome_15\NN|NONE
D011692_D009404 CID aminonucleoside_37\NN|NONE (r_pobj) to_35\IN|alterations|,|whether|,|due|or (r_prep) were_20\VBD|to (l_acomp) due_21\JJ|alterations|to|,|whether|,|or (l_prep) to_22\IN|NONE (l_pobj) syndrome_24\NN|NONE
D011692_D009404 CID aminonucleoside_21\NN|purpose|investigate|. (l_conj) development_32\NN|and|mg/kg (l_prep) of_33\IN|subsequent|the (l_pobj) syndrome_35\NN|NONE
D005227_D009404 NONE acids_10\NNS|NONE (r_pobj) of_8\IN|plasma|the (r_prep) level_7\NN|remained|.|In (r_nsubj) decreased_15\VBD|NONE (l_prep) In_0\IN|remained|.|level (l_pobj) stage_4\NN|NONE (l_amod) nephrotic_3\JJ|NONE
D002788_D009404 NONE esters_22\NNS|while|constant|that (r_nsubj) remained_25\VBD|.|level|In (r_advcl) decreased_15\VBD|NONE (l_prep) In_0\IN|remained|.|level (l_pobj) stage_4\NN|NONE (l_amod) nephrotic_3\JJ|NONE
D014280_D009404 NONE triacylglycerol_12\NN|fatty|, (r_conj) acids_10\NNS|NONE (r_pobj) of_8\IN|plasma|the (r_prep) level_7\NN|remained|.|In (r_nsubj) decreased_15\VBD|NONE (l_prep) In_0\IN|remained|.|level (l_pobj) stage_4\NN|NONE (l_amod) nephrotic_3\JJ|NONE
3962737
D000638_D056486 CID amiodarone_2\NN|NONE (r_pobj) of_1\IN|. (r_prep) Hepatotoxicity_0\NN|NONE
D000638_D056486 CID amiodarone_7\NN|NONE (r_compound) treatment_8\NN|A|due|with (r_appos) patient_1\NN|is|below|given|and (l_prep) with_2\IN|treatment|A|due (l_pobj) hepatitis_4\NN|NONE
D000638_D056486 CID amiodarone_7\NN|NONE (r_compound) treatment_8\NN|A|due|with (r_appos) patient_1\NN|is|below|given|and (r_nsubjpass) presented_10\VBN|NONE (l_conj) given_21\VBN|is|below|and|patient (l_nsubjpass) review_14\NN|is|. (l_prep) of_15\IN|a (l_pobj) hepatotoxicity_17\NN|NONE
D000638_D056486 CID amiodarone_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) hepatotoxicity_17\NN|NONE (r_pobj) of_15\IN|a (r_prep) review_14\NN|is|. (r_nsubjpass) given_21\VBN|is|below|and|patient (r_conj) presented_10\VBN|NONE (l_nsubjpass) patient_1\NN|is|below|given|and (l_prep) with_2\IN|treatment|A|due (l_pobj) hepatitis_4\NN|NONE
D000638_D056486 CID amiodarone_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) hepatotoxicity_17\NN|NONE
D000638_D056486 CID amiodarone_12\NN|,|,|including (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|evidence|that|of (r_prep) exists_6\VBZ|.|It|is (l_prep) of_7\IN|evidence|that|due (l_pobj) injury_9\NN|NONE
D000638_D056486 CID amiodarone_12\NN|,|,|including (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|evidence|that|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE (l_appos) cirrhosis_27\NN|alcoholic|, (l_nmod) hepatitis_24\NN|cholestatic|of
D000638_D013610 NONE Amiodarone_0\NNP|.|effective|has|in (r_nsubj) proved_2\VBN|NONE (l_prep) in_5\IN|.|effective|has|Amiodarone (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) tachyarrhythmias_12\NNS|NONE
D000638_D006519 NONE amiodarone_12\NN|,|,|including (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|evidence|that|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE
D000638_D008103 CID amiodarone_12\NN|,|,|including (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|evidence|that|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE (l_appos) cirrhosis_27\NN|alcoholic|, (l_prep) of_28\IN|hepatitis|cholestatic (l_pobj) liver_30\NN|NONE
D000638_D002779 CID amiodarone_7\NN|NONE (r_compound) treatment_8\NN|A|due|with (r_appos) patient_1\NN|is|below|given|and (l_prep) with_2\IN|treatment|A|due (l_pobj) hepatitis_4\NN|NONE
D000638_D002779 CID amiodarone_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) hepatotoxicity_17\NN|NONE (r_pobj) of_15\IN|a (r_prep) review_14\NN|is|. (r_nsubjpass) given_21\VBN|is|below|and|patient (r_conj) presented_10\VBN|NONE (l_nsubjpass) patient_1\NN|is|below|given|and (l_prep) with_2\IN|treatment|A|due (l_pobj) hepatitis_4\NN|NONE
D000638_D002779 CID amiodarone_12\NN|,|,|including (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|evidence|that|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE (l_appos) cirrhosis_27\NN|alcoholic|, (l_nmod) hepatitis_24\NN|cholestatic|of
D000638_D005234 CID amiodarone_12\NN|,|,|including (r_compound) treatment_13\NN|NONE (l_prep) including_15\VBG|amiodarone|,|, (l_pobj) steatosis_16\NN|NONE
15096016
D007980_D018476 NONE levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|NONE (r_dobj) improving_19\VBG|NONE (r_pcomp) in_18\IN|to (r_prep) be_17\VB|.|strength|;|,|however|improves (r_xcomp) seems_15\VBZ|NONE (l_ccomp) improves_2\VBZ|.|strength|;|,|however|be (l_dobj) bradykinesia_3\JJ|stimulation|to
D007980_D009127 NONE levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|NONE (r_dobj) improving_19\VBG|NONE (r_pcomp) in_18\IN|to (r_prep) be_17\VB|.|strength|;|,|however|improves (r_xcomp) seems_15\VBZ|NONE (l_ccomp) improves_2\VBZ|.|strength|;|,|however|be (l_dobj) bradykinesia_3\JJ|stimulation|to (l_conj) rigidity_5\NN|and
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|NONE
8586822
D017673_D006973 CID chloride_31\NN|dietary (r_compound) supplementation_32\NN|NONE (r_pobj) of_28\IN|hypertensive|the (r_prep) effect_27\NN|NONE (r_pobj) to_24\IN|importantly|test|system|,|. (r_prep) contributes_22\VBZ|NONE (l_advcl) test_1\VB|to|importantly|system|,|. (l_dobj) hypothesis_3\NN|To (l_relcl) treated_10\VBN|the (l_dobj) rats_13\NNS|captopril||in|spontaneously|that|, (l_amod) hypertensive_12\JJ|)|SHR|(
D017673_D006973 CID chloride_31\NN|dietary (r_compound) supplementation_32\NN|NONE (r_pobj) of_28\IN|hypertensive|the (r_prep) effect_27\NN|NONE (l_amod) hypertensive_26\JJ|of|the
D017673_D006973 CID chloride_19\NN| (r_npadvmod) induced_21\VBN|the|sodium|in|in (r_amod) increase_22\NN|that (l_prep) in_23\IN|the|sodium|in|induced (l_pobj) MAP_24\NNP|NONE
D002216_D006973 NONE captopril_12\FW|rats||.|Contribution (r_npadvmod) treated_14\VBN|NONE (l_dobj) rats_17\NNS||.|Contribution|captopril (l_amod) hypertensive_16\JJ|NONE
D002216_D006973 NONE captopril_8\FW||in|rats|spontaneously|that|, (r_npadvmod) treated_10\VBN|the (l_dobj) rats_13\NNS|captopril||in|spontaneously|that|, (l_amod) hypertensive_12\JJ|)|SHR|(
D002216_D006973 NONE captopril_8\FW||in|rats|spontaneously|that|, (r_npadvmod) treated_10\VBN|the (r_relcl) hypothesis_3\NN|To (r_dobj) test_1\VB|to|importantly|system|,|. (r_advcl) contributes_22\VBZ|NONE (l_prep) to_24\IN|importantly|test|system|,|. (l_pobj) effect_27\NN|NONE (l_amod) hypertensive_26\JJ|of|the
D018738_D006973 NONE hexamethonium_6\NN|NONE (r_pobj) of_2\IN|Intravenous (r_prep) infusion_1\NN|in|. (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|.|infusion (l_pobj) decline_11\NN|NONE (l_relcl) eliminated_15\VBD|rapid|a|in (l_dobj) increase_22\NN|that (l_prep) in_23\IN|the|sodium|in|induced (l_pobj) MAP_24\NNP|NONE
7651879
D001569_D012131 NONE benzodiazepine_3\JJ|used|receptor|a (r_amod) antagonist_5\NN|.|Flumazenil (l_acl) used_6\VBD|receptor|a|benzodiazepine (l_xcomp) reverse_8\VB|NONE (l_dobj) sedation_9\NN|to (l_conj) depression_12\NN|induced|and
D001569_D012131 NONE benzodiazepines_15\NNS|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|depression|and (r_acl) sedation_9\NN|to (l_conj) depression_12\NN|induced|and
D005442_D012131 NONE Flumazenil_0\NNP|antagonist|. (r_nsubj) is_1\VBZ|NONE (l_attr) antagonist_5\NN|.|Flumazenil (l_acl) used_6\VBD|receptor|a|benzodiazepine (l_xcomp) reverse_8\VB|NONE (l_dobj) sedation_9\NN|to (l_conj) depression_12\NN|induced|and
D005442_D012640 CID flumazenil_2\JJ|in (r_compound) administration_3\NN|NONE (r_pobj) after_1\IN|. (r_prep) Seizure_0\NN|NONE
D005442_D012640 CID flumazenil_19\JJ|NONE (r_pobj) of_18\IN|the (r_prep) administration_17\NN|NONE (r_pobj) following_15\VBG|pediatric|a (r_acl) patient_14\NN|NONE (r_pobj) in_11\IN|clonic|generalized|a (r_prep) seizure_10\NN|NONE
6402369
D015080_D064420 NONE MESNA_7\NNP|series|and|the (r_compound) series_8\NN|NONE (l_conj) series_13\NN|MESNA|and|the (l_prep) with_14\IN|conventional|the|prophylaxis (l_pobj) respect_15\NN|NONE (l_prep) to_16\IN|NONE (l_pobj) toxicity_21\NN|NONE
D015080_D008175 NONE sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE (r_pobj) of_1\IN|to|. (r_prep) Treatment_0\NN|NONE (l_prep) to_17\IN|of|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) cancer_22\NN|NONE
D015080_D008175 NONE MESNA_15\NNP|sodium|mercaptoethane (r_appos) sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE (r_pobj) of_1\IN|to|. (r_prep) Treatment_0\NN|NONE (l_prep) to_17\IN|of|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) cancer_22\NN|NONE
D015080_D008175 NONE sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|against|The|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|)|was|as|.|(|effect|IF (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D015080_D008175 NONE MESNA_14\NNP|mercaptoethane|sodium|the|compound|thiol (r_appos) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|against|The|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|)|was|as|.|(|effect|IF (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D013438_D001745 NONE thiol_8\JJ|mercaptoethane|sodium|the|compound|MESNA (r_compound) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|against|The|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (l_prep) against_16\IN|The|of|protective (l_pobj) toxicity_18\NN|NONE
D013438_D008175 NONE thiol_8\JJ|mercaptoethane|sodium|the|compound|MESNA (r_compound) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|against|The|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|)|was|as|.|(|effect|IF (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D015080_D001745 NONE sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE
D015080_D001745 NONE MESNA_15\NNP|sodium|mercaptoethane (r_appos) sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE
D015080_D001745 NONE sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|against|The|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (l_prep) against_16\IN|The|of|protective (l_pobj) toxicity_18\NN|NONE
D015080_D001745 NONE MESNA_14\NNP|mercaptoethane|sodium|the|compound|thiol (r_appos) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|against|The|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (l_prep) against_16\IN|The|of|protective (l_pobj) toxicity_18\NN|NONE
D007069_D001745 CID ifosfamide_2\RB| (r_advmod) induced_4\VBN|by|urothelial (r_amod) toxicity_6\NN|NONE
D007069_D001745 CID ifosfamide_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|urothelial (r_acl) toxicity_18\NN|NONE
D007069_D001745 CID IF_23\IN|)|in|was|as|.|(|effect (r_mark) tested_26\VBN|NONE (l_nsubjpass) effect_2\NN|)|in|was|as|.|(|IF (l_prep) against_16\IN|The|of|protective (l_pobj) toxicity_18\NN|NONE
D007069_D001745 CID IF_40\IN|)|/|on|mg||( (r_mark) m2_45\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treatment_38\NN|NONE (r_pobj) under_37\IN|lung|inoperable (r_prep) cancer_36\NN|NONE (r_pobj) with_33\IN| (r_prep) patients_32\NNS|NONE (r_pobj) of_30\IN|a (r_prep) group_29\NN|NONE (r_pobj) in_27\IN|)|was|as|.|(|effect|IF (r_prep) tested_26\VBN|NONE (l_nsubjpass) effect_2\NN|)|in|was|as|.|(|IF (l_prep) against_16\IN|The|of|protective (l_pobj) toxicity_18\NN|NONE
D007069_D008175 NONE ifosfamide_2\RB| (r_advmod) induced_4\VBN|by|urothelial (r_amod) toxicity_6\NN|NONE (r_pobj) of_1\IN|to|. (r_prep) Treatment_0\NN|NONE (l_prep) to_17\IN|of|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) cancer_22\NN|NONE
D007069_D008175 NONE ifosfamide_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|urothelial (r_acl) toxicity_18\NN|NONE (r_pobj) against_16\IN|The|of|protective (r_prep) effect_2\NN|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|)|was|as|.|(|effect|IF (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D007069_D008175 NONE IF_23\IN|)|in|was|as|.|(|effect (r_mark) tested_26\VBN|NONE (l_prep) in_27\IN|)|was|as|.|(|effect|IF (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D007069_D008175 NONE IF_40\IN|)|/|on|mg||( (r_mark) m2_45\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treatment_38\NN|NONE (r_pobj) under_37\IN|lung|inoperable (r_prep) cancer_36\NN|NONE
8958188
C045894_D009369 NONE lometrexol_9\NN|that|activity (r_nsubj) has_10\VBZ|data|have|. (l_dobj) activity_11\NN|that|lometrexol (l_prep) against_12\IN|NONE (l_pobj) tumours_13\NNS|NONE
D005492_D064420 NONE acid_16\NN|folic|dose|,|low (r_compound) administration_17\NN|NONE (r_pobj) by_12\IN|be|following|toxicity|can|that|for (r_agent) prevented_11\VBN|.|studies (l_nsubjpass) toxicity_6\NN|be|following|by|can|that|for
D005492_D064420 NONE acid_13\NN|folic|confirmed (r_compound) supplementation_14\NN|NONE (l_relcl) confirmed_17\VBN|acid|folic (l_ccomp) reduced_26\VBN|has|which (l_nsubjpass) toxicity_20\NN|be|can|markedly|by|that
D005492_D064420 NONE acid_29\NN|folic (r_compound) supplementation_30\NN|NONE (r_pobj) by_27\IN|be|toxicity|can|markedly|that (r_agent) reduced_26\VBN|has|which (l_nsubjpass) toxicity_20\NN|be|can|markedly|by|that
D005492_D064420 NONE folate_13\JJ|plasma (r_compound) elevation_14\NN|NONE (r_pobj) of_11\IN|the (r_prep) extent_10\NN|clinical|and (r_conj) toxicity_7\NN|NONE
D005492_D064420 NONE acid_12\NN|folic (r_compound) administration_13\NN|NONE (r_pobj) by_10\IN|that|not|were|indicating|pharmacokinetics (r_agent) altered_9\VBN|.|studies (l_advcl) indicating_14\VBG|that|not|were|by|pharmacokinetics (l_ccomp) is_17\VBZ|NONE (l_acomp) unlikely_18\JJ|that|supplementation (l_xcomp) reduce_20\VB|NONE (l_dobj) toxicity_21\NN|by|to
D008727_D009369 NONE methotrexate_22\NNP|other|, (r_appos) drugs_19\NNS|NONE (r_pobj) to_17\IN|NONE (r_prep) refractory_16\JJ|which (r_acomp) are_15\VBP|NONE (r_relcl) tumours_13\NNS|NONE
C045894_D064420 NONE lometrexol_7\NN|NONE (r_pobj) of_6\IN|clinical|initial|the (r_prep) development_5\NN|was|However|,|because|. (r_nsubjpass) curtailed_9\VBN|NONE (l_prep) because_10\IN|was|However|development|,|. (l_pobj) toxicities_16\NNS|of
C045894_D064420 NONE lometrexol_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) toxicity_6\NN|be|following|by|can|that|for
C045894_D064420 NONE lometrexol_9\NN|NONE (r_pobj) of_8\IN|I|given|clinical (r_prep) study_7\NN|Phase|observation|. (l_acl) given_10\VBN|of|I|clinical (l_prep) with_11\IN|NONE (l_pobj) supplementation_14\NN|NONE (l_relcl) confirmed_17\VBN|acid|folic (l_ccomp) reduced_26\VBN|has|which (l_nsubjpass) toxicity_20\NN|be|can|markedly|by|that
C045894_D064420 NONE lometrexol_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) toxicity_20\NN|be|can|markedly|by|that
C045894_D064420 NONE lometrexol_4\NN|NONE (r_compound) plasma_5\NN|NONE (r_compound) pharmacokinetics_6\NNS|that|not|were|indicating|by (r_nsubjpass) altered_9\VBN|.|studies (l_advcl) indicating_14\VBG|that|not|were|by|pharmacokinetics (l_ccomp) is_17\VBZ|NONE (l_acomp) unlikely_18\JJ|that|supplementation (l_xcomp) reduce_20\VB|NONE (l_dobj) toxicity_21\NN|by|to
C045894_D064420 NONE lometrexol_24\NN|NONE (r_compound) plasma_25\NN|NONE (r_compound) clearance_26\NN|NONE (r_dobj) enhancing_23\VBG|NONE (r_pcomp) by_22\IN|toxicity|to (r_prep) reduce_20\VB|NONE (l_dobj) toxicity_21\NN|by|to
10743694
1535072
D012701_D001008 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|who|effects (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|,|or (r_conj) anxiety_10\NN|,
D015016_D020018 NONE Yohimbine_0\NNP|.|induced|of (r_compound) treatment_1\NN|NONE (l_prep) of_2\IN|.|Yohimbine|induced (l_pobj) effects_5\NNS|NONE
D015016_D020018 NONE yohimbine_6\NN|may|treat|that|be (r_nsubjpass) used_9\VBN|.|report (l_xcomp) treat_11\VB|yohimbine|may|that|be (l_dobj) effects_15\NNS|to
D015016_D020018 NONE yohimbine_3\NN|.|as|study (r_dobj) evaluated_2\VBD|NONE (l_prep) as_4\IN|.|study|yohimbine (l_pobj) treatment_6\NN|NONE (l_prep) for_7\IN|a (l_pobj) effects_11\NNS|NONE
D015016_D020018 NONE yohimbine_28\NN|.|on|basis|were|patients (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|.|on|basis|were|yohimbine (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|compulsive|obsessive|either|, (l_conj) anxiety_10\NN|, (l_conj) disorders_14\NNS|,|or (l_relcl) suffered_16\VBD|affective (l_dobj) effects_19\NNS|who|after
D015016_D020018 NONE yohimbine_7\NN|treatment|that|may (r_nsubj) be_9\VB|.|results (l_attr) treatment_12\NN|that|may|yohimbine (l_prep) for_13\IN|an|effective (l_pobj) effects_17\NNS|NONE
D012701_D020018 NONE serotonin_8\NN|reuptake (r_compound) blockers_10\NNS|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|.|Yohimbine|of (r_acl) treatment_1\NN|NONE (l_prep) of_2\IN|.|Yohimbine|induced (l_pobj) effects_5\NNS|NONE
D012701_D020018 NONE serotonin_14\NN|reuptake (r_compound) blockers_16\NNS|NONE (r_pobj) by_13\IN|NONE (r_agent) caused_12\VBN|side|the|sexual (r_acl) effects_11\NNS|NONE
D012701_D020018 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|who|effects (r_prep) suffered_16\VBD|affective (l_dobj) effects_19\NNS|who|after
D012701_D020018 NONE serotonin_20\NN|reuptake (r_compound) blockers_22\NNS|NONE (r_pobj) by_19\IN|NONE (r_agent) caused_18\VBN|the|side|sexual (r_acl) effects_17\NNS|NONE
D015016_D009771 NONE yohimbine_28\NN|.|on|basis|were|patients (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|.|on|basis|were|yohimbine (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE
D012701_D019964 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|who|effects (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|,|or
D015016_D014256 NONE yohimbine_28\NN|.|on|basis|were|patients (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|.|on|basis|were|yohimbine (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|compulsive|obsessive|either|,
D015016_D007172 NONE yohimbine_6\NN|behavior|be|that|and (r_nsubj) facilitates_7\VBZ|.|studies (l_conj) be_12\VB|behavior|that|and|yohimbine (l_acomp) helpful_13\JJ|may (l_prep) in_14\IN|NONE (l_pobj) treatment_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) impotence_19\NN|NONE
D012701_D009771 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|who|effects (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|,|or (r_conj) anxiety_10\NN|, (r_conj) trichotillomania_8\NN|compulsive|obsessive|either|, (r_conj) disorder_6\NN|NONE
D002997_D020018 CID clomipramine_17\NN|NONE (r_pobj) of_16\IN|the|side (r_prep) effects_15\NNS|to
D015016_D019964 NONE yohimbine_28\NN|.|on|basis|were|patients (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|.|on|basis|were|yohimbine (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|compulsive|obsessive|either|, (l_conj) anxiety_10\NN|, (l_conj) disorders_14\NNS|,|or
D012701_D014256 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|who|effects (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|,|or (r_conj) anxiety_10\NN|, (r_conj) trichotillomania_8\NN|compulsive|obsessive|either|,
D015016_D001008 NONE yohimbine_28\NN|.|on|basis|were|patients (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|.|on|basis|were|yohimbine (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|compulsive|obsessive|either|, (l_conj) anxiety_10\NN|,
D015016_D001008 NONE yohimbine_3\NN|NONE (r_pobj) of_2\IN|Side (r_prep) effects_1\NNS|.|sweating (r_nsubj) included_4\VBD|NONE (l_dobj) sweating_6\NN|.|effects (l_conj) anxiety_9\NN|excessive|,
7880714
7053705
D013866_D006504 CID 6-thioguanine_7\CD|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|occlusive|.|Hepatic (r_acl) disease_4\NN|NONE
D013866_D006504 CID 6-thioguanine_27\CD|NONE (r_punct) ._28\.|occlusive|reversible|of (r_punct) disease_5\NN|NONE (l_prep) of_6\IN|occlusive|reversible|. (l_pobj) liver_8\NN|NONE
D013866_D006504 CID 6-thioguanine_35\CD|solely (r_pobj) to_34\IN|occlusive (r_prep) related_32\VBN|NONE (r_pobj) of_28\IN|the|first (r_prep) case_27\NN|may (r_attr) be_24\VB|and|,|case|opportunity|. (r_conj) presented_2\VBD|NONE (l_dobj) opportunity_5\NN|and|be|,|case|. (l_acl) observe_7\VB|a|unique (l_dobj) features_10\NNS|to|over (l_prep) of_11\IN|the|histologic (l_pobj) disease_18\NN|NONE
D013866_D054198 NONE 6-thioguanine_27\CD|NONE (r_punct) ._28\.|occlusive|reversible|of (r_punct) disease_5\NN|NONE (l_prep) of_6\IN|occlusive|reversible|. (l_pobj) liver_8\NN|NONE (l_acl) developed_9\VBN|the (l_prep) in_10\IN|after|with (l_pobj) man_15\NN|NONE (l_prep) with_16\IN|old|a (l_pobj) leukemia_19\NN|NONE
8384253
D014750_D008228 NONE vincristine_10\NN|NONE (r_pobj) with_9\IN|investigated|.|between|patients (r_prep) treated_8\VBN|NONE (l_nsubj) patients_1\NNS|investigated|with|.|between (l_prep) with_2\IN|Forty (l_pobj) Lymphoma_7\NNP|NONE
D014750_D008228 NONE vincristine_37\NN|NONE (r_pobj) of_36\IN|on|the|term (r_prep) effects_35\NNS|to (r_dobj) evaluate_31\VB|NONE (r_acl) order_29\NN|NONE (r_pobj) in_28\IN|(|dose|were (r_prep) investigated_27\VBN|with|.|between|patients (r_parataxis) treated_8\VBN|NONE (l_nsubj) patients_1\NNS|investigated|with|.|between (l_prep) with_2\IN|Forty (l_pobj) Lymphoma_7\NNP|NONE
D014750_D009422 NONE vincristine_8\NN|NONE (r_pobj) with_4\IN|that|reversible|signs (r_prep) are_17\VBP|good (l_nsubj) signs_11\NNS|that|reversible|with (l_conj) symptoms_13\NNS|dose|and|schedule (l_prep) of_14\IN|NONE (l_pobj) neuropathy_16\NN|NONE
D014750_D009422 NONE vincristine_15\NN|NONE (r_compound) neuropathy_16\NN|NONE
8111719
D007069_D006212 CID ifosfamide_2\RB| (r_advmod) induced_4\VBN|NONE (r_amod) neurotoxicity_5\NN|.|and (r_conj) Hallucinations_0\NNS|NONE
D007069_D006212 CID ifosfamide_16\NN|NONE (r_pobj) of_15\IN|side|known|a (r_prep) effect_14\NN|.|Hallucinations (r_attr) are_7\VBP|NONE (l_nsubj) Hallucinations_0\NNS|.|effect
D007069_D006212 CID ifosfamide_3\RB| (r_npadvmod) induced_5\VBN|NONE (r_amod) hallucinations_6\NNS|NONE
D007069_D006212 CID ifosfamide_6\RB| (r_npadvmod) induced_8\VBN|NONE (r_amod) hallucinations_9\NNS|NONE
D007069_D006212 CID ifosfamide_7\RB| (r_npadvmod) induced_9\VBN|possible|occur|, (r_amod) hallucinations_10\NNS|NONE
D007069_D020258 NONE ifosfamide_2\RB| (r_advmod) induced_4\VBN|NONE (r_amod) neurotoxicity_5\NN|.|and
D007069_D020258 NONE ifosfamide_16\NN|NONE (r_pobj) of_15\IN|side|known|a (r_prep) effect_14\NN|.|Hallucinations (r_attr) are_7\VBP|NONE (l_nsubj) Hallucinations_0\NNS|.|effect (l_prep) as_1\IN|NONE (l_pobj) symptom_3\NN|NONE (l_prep) of_4\IN|a (l_pobj) neurotoxicity_6\NN|NONE
D007069_D020258 NONE ifosfamide_7\RB| (r_npadvmod) induced_9\VBN|possible|occur|, (r_amod) hallucinations_10\NNS|NONE (l_relcl) occur_14\VB|possible|induced|, (l_prep) without_15\IN|may|which (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|other (l_pobj) neurotoxicity_19\NN|NONE
D006220_D011595 NONE haloperidol_12\NN|potency|)|marked|(|, (r_appos) neuroleptics_8\NNS|may|.|effective (l_amod) marked_3\JJ|potency|haloperidol|)|(|, (l_auxpass) becomes_2\VBZ|NONE (l_nsubj) agitation_1\NN|If
9579567
D013629_D016889 CID tamoxifen_9\NN|treatments|or (r_compound) use_10\NN|and|endometrial (r_conj) cancer_7\NN|NONE
D013629_D016889 CID tamoxifen_4\NN|who|had (r_dobj) received_3\VBN|NONE (r_relcl) Women_0\NNS|likely|. (r_nsubj) were_5\VBD|NONE (l_acomp) likely_8\JJ|.|Women (l_xcomp) have_10\VB|more (l_dobj) cancer_12\NN|to
D013629_D016889 CID tamoxifen_8\NN|had (r_advmod) received_7\VBN|who|cancer|and (r_conj) had_2\VBD|NONE (l_dobj) cancer_4\NN|who|received|and
D013629_D016889 CID tamoxifen_8\NN|had (r_advmod) received_7\VBN|who|cancer|and (r_conj) had_2\VBD|NONE (r_relcl) Women_0\NNS|.|disease (r_nsubj) had_9\VBD|NONE (l_dobj) disease_12\NN|.|Women (l_conj) prognosis_15\NN|advanced|and (l_prep) than_16\IN|poorer (l_pobj) those_17\DT|NONE (l_prep) with_18\IN|received (l_pobj) cancer_20\NN|NONE
D013629_D016889 CID tamoxifen_7\NN|NONE (r_pobj) of_6\IN|a|in|causal (r_prep) role_5\NN|,|results|used|. (l_prep) in_8\IN|a|causal|of (l_pobj) cancer_10\NN|NONE
D013629_D016889 CID tamoxifen_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treated_5\VBN|NONE (r_acl) women_4\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) diagnosed_2\VBD|Endometrial (r_acl) cancers_1\NNS|.|prognosis
D013629_D001943 NONE tamoxifen_1\NN|widely|proposed|in|Since|and|is (r_nsubjpass) used_4\VBN|,|effects|carefully|be|must|. (l_prep) in_5\IN|widely|tamoxifen|proposed|Since|and|is (l_pobj) treatment_8\NN|NONE (l_compound) cancer_7\NN|NONE
D013629_D001943 NONE tamoxifen_1\NN|widely|proposed|in|Since|and|is (r_nsubjpass) used_4\VBN|,|effects|carefully|be|must|. (l_conj) proposed_12\VBN|widely|tamoxifen|in|Since|and|is (l_prep) for_13\IN|has|been (l_pobj) prevention_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) cancer_18\NN|NONE
D013629_D001943 NONE tamoxifen_9\NN|treatments|or (r_compound) use_10\NN|and|endometrial (r_conj) cancer_7\NN|NONE (r_pobj) between_5\IN|treated|the (r_prep) association_4\NN|have|We|. (l_acl) treated_16\VBN|the|between (l_prep) for_17\IN|in (l_pobj) cancer_19\NN|NONE
D013629_D001943 NONE tamoxifen_7\NN|NONE (r_pobj) of_6\IN|a|in|causal (r_prep) role_5\NN|,|results|used|. (r_dobj) suggest_2\VBP|NONE (l_advcl) used_14\VBN|role|,|results|. (l_xcomp) proposed_17\VBN|when|particularly (l_prep) for_18\IN|as|currently (l_pobj) prevention_21\NN|NONE (l_compound) cancer_20\NN|NONE
D013629_D001943 NONE tamoxifen_3\NN|who|for (r_dobj) receive_2\VBP|NONE (l_prep) for_4\IN|who|tamoxifen (l_pobj) cancer_6\NN|NONE
D013629_D001943 NONE tamoxifen_12\NN|NONE (r_pobj) of_11\IN|the|benefit (r_prep) ratio_10\NN|NONE (r_pobj) of_5\IN|term|A|as (r_prep) evaluation_4\NN|clearly|.|is (l_prep) as_13\IN|term|A|of (l_pobj) treatment_16\NN|NONE (l_prep) for_17\IN|a|preventive (l_pobj) cancer_19\NN|NONE
D013629_D020178 NONE tamoxifen_8\NN|had (r_advmod) received_7\VBN|who|cancer|and (r_conj) had_2\VBD|NONE (r_relcl) Women_0\NNS|.|disease (r_nsubj) had_9\VBD|NONE (l_dobj) disease_12\NN|.|Women
9669632
D020117_D010146 NONE cisapride_11\NN|NONE (r_compound) therapy_12\NN|+/|(|P|cisapride|,|,|[|)|after (r_nmod) score_14\NN|patients|score|;|pretreatment|. (r_advcl) had_5\VBD|NONE (l_dobj) score_9\NN|patients|score|;|pretreatment|. (l_compound) pain_8\NN|a|higher
D020117_D010146 NONE cisapride_25\NN|+/|(|P|,|,|therapy|[|)|after (r_conj) score_14\NN|patients|score|;|pretreatment|. (r_advcl) had_5\VBD|NONE (l_dobj) score_9\NN|patients|score|;|pretreatment|. (l_compound) pain_8\NN|a|higher
D020117_D003248 NONE cisapride_36\NN|and (r_conj) before_28\IN|patients|)|daily|.|,|;|manometry|, (r_advmod) underwent_23\VBD|NONE (l_nsubj) patients_3\NNS|before|)|daily|.|,|;|manometry|, (l_prep) with_4\IN|eight (l_pobj) IBS_5\NNP|NONE (l_appos) predominant_9\JJ|( (l_compound) constipation_7\NN||,
D020117_D003248 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|score|predominant|IBS (r_amod) patients_18\NNS|NONE (r_pobj) in_10\IN|scores|lower (r_prep) were_8\VBD|NONE (l_nsubj) scores_1\NNS|in|lower (l_acl) relating_2\VBG|Symptom (l_prep) to_3\IN|NONE (l_pobj) severity_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) constipation_7\NN|NONE
D020117_D003248 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|score|predominant|IBS (r_amod) patients_18\NNS|NONE (l_amod) predominant_16\JJ|score|treated|IBS (l_compound) constipation_14\NN|
D020117_D003967 NONE cisapride_36\NN|and (r_conj) before_28\IN|patients|)|daily|.|,|;|manometry|, (r_advmod) underwent_23\VBD|NONE (l_punct) ;_14\:|patients|before|)|daily|.|,|manometry|, (l_preconj) predominant_17\JJ|NONE (l_compound) diarrhoea_15\NN|
D020117_D003967 NONE cisapride_14\NN|the (r_nmod) groups_17\NNS|NONE (r_pobj) between_12\IN|were|In|differences|. (r_prep) observed_11\VBN|NONE (l_prep) In_0\IN|were|between|differences|. (l_pobj) patients_4\NNS|NONE (l_amod) predominant_3\JJ|NONE (l_npadvmod) diarrhoea_1\NN|
D020117_D003967 NONE cisapride_1\NN| (r_npadvmod) treated_3\VBN|predominant (r_amod) patients_7\NNS|NONE (l_amod) predominant_6\JJ|treated (l_npadvmod) diarrhoea_4\NN|
D020117_D003967 NONE cisapride_11\NN|NONE (r_compound) therapy_12\NN|+/|(|P|cisapride|,|,|[|)|after (r_nmod) score_14\NN|patients|score|;|pretreatment|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|score|;|pretreatment|. (l_amod) predominant_2\JJ|IBS (l_npadvmod) Diarrhoea_0\NN|
D020117_D003967 NONE cisapride_25\NN|+/|(|P|,|,|therapy|[|)|after (r_conj) score_14\NN|patients|score|;|pretreatment|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|score|;|pretreatment|. (l_amod) predominant_2\JJ|IBS (l_npadvmod) Diarrhoea_0\NN|
D020117_D043183 NONE cisapride_2\NN|NONE (r_pobj) of_1\IN|function|.|on|and (r_prep) Effects_0\NNS|NONE (l_conj) function_11\NN|.|on|of|and (l_prep) in_12\IN|motor|bowel|postcibal (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) syndrome_17\NN|NONE
D020117_D043183 NONE cisapride_17\NN|to|effects (l_prep) on_19\IN|, (l_pobj) motility_22\NN|NONE (l_prep) in_25\IN|symptoms|jejunal|and|postprandial (l_pobj) syndrome_29\NN|NONE
D020117_D043183 NONE cisapride_17\NN|to|effects (l_prep) on_19\IN|, (l_pobj) motility_22\NN|NONE (l_prep) in_25\IN|symptoms|jejunal|and|postprandial (l_pobj) syndrome_29\NN|NONE (l_appos) IBS_31\NNP|(|the|irritable|)|bowel
D020117_D043183 NONE cisapride_36\NN|and (r_conj) before_28\IN|patients|)|daily|.|,|;|manometry|, (r_advmod) underwent_23\VBD|NONE (l_nsubj) patients_3\NNS|before|)|daily|.|,|;|manometry|, (l_prep) with_4\IN|eight (l_pobj) IBS_5\NNP|NONE
D020117_D043183 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|score|predominant|IBS (r_amod) patients_18\NNS|NONE (l_compound) IBS_17\NNP|score|treated|predominant
D020117_D043183 NONE cisapride_11\NN|NONE (r_compound) therapy_12\NN|+/|(|P|cisapride|,|,|[|)|after (r_nmod) score_14\NN|patients|score|;|pretreatment|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|score|;|pretreatment|. (l_compound) IBS_3\NNP|predominant
D020117_D043183 NONE cisapride_25\NN|+/|(|P|,|,|therapy|[|)|after (r_conj) score_14\NN|patients|score|;|pretreatment|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|score|;|pretreatment|. (l_compound) IBS_3\NNP|predominant
D020117_D043183 NONE Cisapride_0\NNP|characteristics|. (r_nsubj) affects_1\VBZ|NONE (l_dobj) characteristics_4\NNS|Cisapride|. (l_conj) symptoms_7\NNS|and|jejunal|contraction (l_prep) in_8\IN|some (l_pobj) IBS_9\NNP|NONE
873132
D004997_D002779 CID estradiol_12\NN| (r_npadvmod) induced_14\VBN|in (r_amod) cholestasis_15\NN|hydroxylation|sulfation|.
D003840_D002779 NONE acid_9\NN|NONE (r_pobj) of_7\IN||in|alpha (r_prep) hydroxylation_6\NN|cholestasis|sulfation|. (r_dobj) decreased_3\VBD|NONE (l_dobj) cholestasis_15\NN|hydroxylation|sulfation|.
20973483
D006220_D002375 CID haloperidol_53\NN| (r_npadvmod) induced_55\VBN|,|,|model|model (r_amod) catalepsy_56\NN|NONE
D015632_D002375 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|human|primate (r_amod) model_87\NN|number|and (r_conj) across_37\IN|Compound|after|antagonist|,|,|. (l_pobj) number_39\NN|and|model (l_prep) of_40\IN|a (l_pobj) models_42\NNS|NONE (l_prep) of_43\IN|animal (l_pobj) disease_46\NN|NONE (l_prep) including_47\VBG|Parkinson (l_pobj) models_51\NNS|NONE (l_prep) of_52\IN|mouse (l_pobj) catalepsy_56\NN|NONE
D006220_D004409 NONE haloperidol_53\NN| (r_npadvmod) induced_55\VBN|,|,|model|model (r_amod) catalepsy_56\NN|NONE (l_appos) model_59\NN|,|,|model|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D058915_D010300 NONE antagonist_11\NN|NONE (l_prep) in_12\IN|a|adenosine|receptor|A|AA (l_pobj) models_14\NNS|NONE (l_prep) of_15\IN|animal (l_pobj) disease_18\NN|NONE
D058915_D010300 NONE antagonist_11\NN|NONE (l_prep) in_12\IN|receptor|adenosine|a|A(A)/A(|) (l_pobj) models_15\NNS|NONE (l_prep) of_16\IN|animal|several (l_pobj) disease_19\NN|NONE
D015632_D004409 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|human|primate (r_amod) model_87\NN|number|and (r_conj) across_37\IN|Compound|after|antagonist|,|,|. (l_pobj) number_39\NN|and|model (l_prep) of_40\IN|a (l_pobj) models_42\NNS|NONE (l_prep) of_43\IN|animal (l_pobj) disease_46\NN|NONE (l_prep) including_47\VBG|Parkinson (l_pobj) models_51\NNS|NONE (l_prep) of_52\IN|mouse (l_pobj) catalepsy_56\NN|NONE (l_appos) model_59\NN|,|,|model|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D016627_D002375 NONE 6-hydroxydopamine_67\NN|(|) (r_nmod) 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|,|induced|model (r_appos) catalepsy_56\NN|NONE
D016627_D002375 NONE 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|,|induced|model (r_appos) catalepsy_56\NN|NONE
D012110_D004409 CID reserpine_61\NN| (r_npadvmod) induced_63\VBN|NONE (r_compound) akinesia_64\NN|NONE
D016627_D010300 NONE 6-hydroxydopamine_67\NN|(|) (r_nmod) 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|,|induced|model (r_appos) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D016627_D010300 NONE 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|,|induced|model (r_appos) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D012110_D010300 NONE reserpine_61\NN| (r_npadvmod) induced_63\VBN|NONE (r_compound) akinesia_64\NN|NONE (r_pobj) of_60\IN|mouse (r_prep) model_59\NN|,|,|model|induced (r_appos) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D012110_D002375 NONE reserpine_61\NN| (r_npadvmod) induced_63\VBN|NONE (r_compound) akinesia_64\NN|NONE (r_pobj) of_60\IN|mouse (r_prep) model_59\NN|,|,|model|induced (r_appos) catalepsy_56\NN|NONE
D006220_D010300 NONE haloperidol_53\NN| (r_npadvmod) induced_55\VBN|,|,|model|model (r_amod) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D016627_D004409 NONE 6-hydroxydopamine_67\NN|(|) (r_nmod) 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|,|induced|model (r_appos) catalepsy_56\NN|NONE (l_appos) model_59\NN|,|,|model|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D016627_D004409 NONE 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|,|induced|model (r_appos) catalepsy_56\NN|NONE (l_appos) model_59\NN|,|,|model|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D015632_D010300 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|human|primate (r_amod) model_87\NN|number|and (r_conj) across_37\IN|Compound|after|antagonist|,|,|. (l_pobj) number_39\NN|and|model (l_prep) of_40\IN|a (l_pobj) models_42\NNS|NONE (l_prep) of_43\IN|animal (l_pobj) disease_46\NN|NONE
3183120
C033706_D001927 CID tiazofurin_5\NN|NONE (r_compound) usage_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|Reversible|:|demonstration|cerebral (r_acl) lesions_2\NNS|NONE
9549528
D007980_D020734 NONE dopa_9\NN| (r_npadvmod) induced_11\VBN|dose (r_amod) dyskinesia_15\NN|NONE (r_pobj) with_6\IN|parkinsonian (r_prep) patients_5\NNS|NONE (l_amod) parkinsonian_4\JJ|with
D007980_D020734 NONE dopa_42\NN|, (r_compound) medication_43\NN|NONE (r_pobj) on_39\IN|parkinsonian (r_prep) patients_38\NNS|NONE (l_amod) parkinsonian_37\JJ|on
D007980_D020734 NONE dopa_51\NN|NONE (r_pobj) without_48\IN|first|the (r_prep) one_47\NN|and|dyskinesia|,|of (r_nsubj) induced_52\VBD|have|We|.|flow (r_conj) studied_2\VBN|NONE (l_dobj) flow_7\NN|have|We|induced|. (l_conj) changes_11\NNS|(|blood|cerebral|the|rCBF|regional (l_acl) induced_12\VBN|) (l_agent) by_13\IN|NONE (l_pobj) execution_15\NN|NONE (l_prep) in_26\IN|the|of (l_pobj) cortex_32\NN|NONE (l_prep) of_33\IN|supplementary|motor|the (l_pobj) groups_35\NNS|NONE (l_prep) of_36\IN|two (l_pobj) patients_38\NNS|NONE (l_amod) parkinsonian_37\JJ|on
D007980_D004409 CID dopa_9\NN| (r_npadvmod) induced_11\VBN|dose (r_amod) dyskinesia_15\NN|NONE
D007980_D004409 CID dopa_42\NN|, (r_compound) medication_43\NN|NONE (r_pobj) on_39\IN|parkinsonian (r_prep) patients_38\NNS|NONE (r_pobj) of_36\IN|two (r_prep) groups_35\NNS|NONE (r_pobj) of_33\IN|supplementary|motor|the (r_prep) cortex_32\NN|NONE (r_pobj) in_26\IN|the|of (r_prep) execution_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|) (r_acl) changes_11\NNS|(|blood|cerebral|the|rCBF|regional (r_conj) flow_7\NN|have|We|induced|. (r_dobj) studied_2\VBN|NONE (l_conj) induced_52\VBD|have|We|.|flow (l_dobj) dyskinesia_53\NN|one|and|,|of
D007980_D004409 CID dopa_42\NN|, (r_compound) medication_43\NN|NONE (r_pobj) on_39\IN|parkinsonian (r_prep) patients_38\NNS|NONE (r_pobj) of_36\IN|two (r_prep) groups_35\NNS|NONE (r_pobj) of_33\IN|supplementary|motor|the (r_prep) cortex_32\NN|NONE (r_pobj) in_26\IN|the|of (r_prep) execution_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|) (r_acl) changes_11\NNS|(|blood|cerebral|the|rCBF|regional (r_conj) flow_7\NN|have|We|induced|. (r_dobj) studied_2\VBN|NONE (l_conj) induced_52\VBD|have|We|.|flow (l_dobj) dyskinesia_53\NN|one|and|,|of (l_conj) other_61\JJ||and|)|(|n (l_prep) with_62\IN|the (l_pobj) dyskinesia_67\NN|NONE
D007980_D004409 CID dopa_51\NN|NONE (r_pobj) without_48\IN|first|the (r_prep) one_47\NN|and|dyskinesia|,|of (r_nsubj) induced_52\VBD|have|We|.|flow (l_dobj) dyskinesia_53\NN|one|and|,|of
D007980_D004409 CID dopa_51\NN|NONE (r_pobj) without_48\IN|first|the (r_prep) one_47\NN|and|dyskinesia|,|of (r_nsubj) induced_52\VBD|have|We|.|flow (l_dobj) dyskinesia_53\NN|one|and|,|of (l_conj) other_61\JJ||and|)|(|n (l_prep) with_62\IN|the (l_pobj) dyskinesia_67\NN|NONE
D007980_D004409 CID dopa_17\NN| (r_npadvmod) induced_19\VBN|dose (r_amod) dyskinesia_22\NN|NONE (r_pobj) like_14\IN|hyperkinetic|,|involuntary|abnormal|an (r_prep) movement_12\NN|that|,|due
D007980_D004409 CID dopa_17\NN| (r_npadvmod) induced_19\VBN|dose (r_amod) dyskinesia_22\NN|NONE
D007980_D006948 NONE dopa_17\NN| (r_npadvmod) induced_19\VBN|dose (r_amod) dyskinesia_22\NN|NONE (r_pobj) like_14\IN|hyperkinetic|,|involuntary|abnormal|an (r_prep) movement_12\NN|that|,|due (l_amod) hyperkinetic_9\JJ|,|involuntary|abnormal|like|an
18239197
D014282_D003072 CID trihexyphenidyl_10\JJ|NONE (r_pcomp) after_9\IN|with (r_prep) associated_3\VBN|.|Increased|mental (r_acl) slowing_2\NN|NONE
D014282_D003072 CID trihexyphenidyl_5\JJ|NONE (r_pobj) of_4\IN|oral|A|.mg (r_prep) dose_3\NN|.|in (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|.|dose (l_pobj) ratings_10\NNS|NONE (l_prep) of_11\IN|subjective|increased (l_pobj) slowness_13\NN|NONE
D014282_D003072 CID trihexyphenidyl_10\JJ|NONE (r_pobj) between_7\IN|on|difference (r_prep) scores_6\NNS|NONE (l_prep) on_13\IN|between|difference (l_pobj) ratings_14\NNS|NONE (l_prep) of_15\IN|NONE (l_pobj) slowness_17\NN|NONE
D014282_D003072 CID trihexyphenidyl_14\JJ|anticholinergic (r_amod) challenge_16\NN|NONE (r_pobj) after_13\IN|subjective|mental|increased (r_prep) slowing_12\NN|NONE
D014282_D003221 NONE trihexyphenidyl_19\NN|NONE (l_prep) on_20\IN|NONE (l_pobj) measures_21\NNS|NONE (l_acl) reflecting_22\VBG|NONE (l_dobj) sedation_23\NN|NONE (l_conj) confusion_25\NN|and
D014282_D003221 NONE trihexyphenidyl_32\NN| (r_npadvmod) induced_34\VBN|subjective|and|performance (r_amod) effects_36\NNS|NONE (r_pobj) between_31\IN|the (r_prep) relationship_30\NN|to (r_dobj) investigate_28\VB|and|to|relationship (r_conj) examine_9\VB|objectives|. (l_dobj) relationship_11\NN|and|to|investigate (l_conj) effects_17\NNS|between|the (l_prep) of_18\IN|subjective (l_pobj) trihexyphenidyl_19\NN|NONE (l_prep) on_20\IN|NONE (l_pobj) measures_21\NNS|NONE (l_acl) reflecting_22\VBG|NONE (l_dobj) sedation_23\NN|NONE (l_conj) confusion_25\NN|and
17241657
C107044_D012640 NONE 21_15\CD|NONE (r_nummod) /-)-SM_14\SYM|or|+|( (r_conj) UMB24_10\NNP|NONE (r_pobj) with_9\IN|of (r_prep) pretreatment_4\NN|convulsions|.|lethality|,|,|In|significantly|but (r_nsubj) attenuated_17\VBN|NONE (l_dobj) convulsions_21\NNS|.|lethality|,|,|pretreatment|In|significantly|but
C519696_D012640 NONE UMB24_10\NNP|NONE (r_pobj) with_9\IN|of (r_prep) pretreatment_4\NN|convulsions|.|lethality|,|,|In|significantly|but (r_nsubj) attenuated_17\VBN|NONE (l_dobj) convulsions_21\NNS|.|lethality|,|,|pretreatment|In|significantly|but
D003042_D012640 CID cocaine_21\NN|NONE (r_pobj) of_20\IN|stimulatory|the|lethal|locomotor|,|,|convulsive (r_prep) actions_19\NNS|that|antagonism (l_amod) convulsive_11\JJ|stimulatory|the|lethal|locomotor|of|,|,
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|activity|and (r_amod) convulsions_21\NNS|.|lethality|,|,|pretreatment|In|significantly|but
20558148
D006220_D002375 CID haloperidol_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) catalepsy_15\NN|.|neurotransmission|can
D006220_D002375 CID haloperidol_25\NN|the|receptor (r_appos) blocker_24\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) catalepsy_18\NN|NONE
D006220_D002375 CID Haloperidol_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) catalepsy_3\NN|was|with|.|)|microl|microl
D006220_D002375 CID haloperidol_15\NN|NONE (r_pobj) of_14\IN|systemic (r_prep) injections_13\NNS|NONE (r_pobj) to_11\IN|NONE (r_prep) previous_10\JJ|NONE (r_amod) AP7_9\RB|and|that|intracollicular|of (r_conj) microinjection_5\NN|attenuated|results|. (r_dobj) showed_2\VBD|NONE (l_ccomp) attenuated_17\VBD|microinjection|results|. (l_dobj) catalepsy_19\NN|significantly|indicated|,
D006220_D002375 CID haloperidol_17\NN| (r_npadvmod) induced_19\VBN|influence (r_amod) catalepsy_20\NN|NONE
D018698_D002375 NONE glutamate_11\NN|receptor|, (r_compound) antagonists_14\NNS|NONE (r_pobj) of_10\IN|intracollicular|prior (r_prep) microinjections_9\NNS|NONE (r_pobj) with_6\IN|was|.|)|microl|catalepsy|microl (r_prep) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
D018698_D002375 NONE glutamate_4\NN| (r_npadvmod) mediated_6\VBN|and|participate|in|that (r_amod) mechanisms_7\NNS|findings|. (l_prep) in_8\IN|and|participate|mediated|that (l_pobj) circuits_11\NNS|NONE (l_prep) at_12\IN|the|neural (l_pobj) catalepsy_20\NN|NONE
D016291_D002375 NONE MK-801_16\NNP|mmol/.||of|AP|)|or|(|and (r_punct) microl_22\NN|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
D016291_D002375 NONE MK-801_7\NNP|NONE (r_punct) and_8\CC|AP|that|intracollicular|of (r_cc) microinjection_5\NN|attenuated|results|. (r_dobj) showed_2\VBD|NONE (l_ccomp) attenuated_17\VBD|microinjection|results|. (l_dobj) catalepsy_19\NN|significantly|indicated|,
C031231_D002375 NONE AP7_25\RB|mmol/.||of|)|or|MK|(|and (r_conj) microl_22\NN|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
C031231_D002375 NONE AP7_9\RB|and|that|intracollicular|of (r_conj) microinjection_5\NN|attenuated|results|. (r_dobj) showed_2\VBD|NONE (l_ccomp) attenuated_17\VBD|microinjection|results|. (l_dobj) catalepsy_19\NN|significantly|indicated|,
D004298_D002375 NONE dopamine_22\NN|NONE (r_compound) receptor_23\NN|the|haloperidol (r_compound) blocker_24\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) catalepsy_18\NN|NONE
D016202_D002375 NONE NMDA_4\NNP|NONE (r_compound) receptors_5\NNS|NONE (r_pobj) by_3\IN|in (r_agent) mediated_2\VBN|Glutamatergic (r_acl) neurotransmission_1\NN|.|catalepsy|can (r_nsubj) modulate_11\VB|NONE (l_dobj) catalepsy_15\NN|.|neurotransmission|can
D016202_D002375 NONE NMDA_12\NNP|NONE (r_compound) receptor_13\NN|,|glutamate (r_compound) antagonists_14\NNS|NONE (r_pobj) of_10\IN|intracollicular|prior (r_prep) microinjections_9\NNS|NONE (r_pobj) with_6\IN|was|.|)|microl|catalepsy|microl (r_prep) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
D016202_D002375 NONE NMDA_37\NNP|NMDA|the (r_compound) receptor_38\NN|NONE (r_pobj) of_35\IN|mmol/.||AP|)|or|MK|(|and (r_prep) microl_22\NN|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
D016202_D002375 NONE aspartate_46\NNP|agonist|(|, (r_nmod) NMDA_48\NNP|NMDA|the (r_appos) receptor_38\NN|NONE (r_pobj) of_35\IN|mmol/.||AP|)|or|MK|(|and (r_prep) microl_22\NN|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
D016202_D002375 NONE NMDA_48\NNP|NMDA|the (r_appos) receptor_38\NN|NONE (r_pobj) of_35\IN|mmol/.||AP|)|or|MK|(|and (r_prep) microl_22\NN|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|was|with|.|)|microl|microl
D000596_D002375 NONE acid_9\NN| (r_npadvmod) mediated_11\VBN|excitatory|amino (r_amod) mechanisms_12\NNS|NONE (r_pobj) of_6\IN|on|the|in (r_prep) influence_5\NN|study (l_prep) on_16\IN|of|the|in (l_pobj) catalepsy_18\NN|NONE
10027919
D002117_D001851 CID Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ|NONE (l_conj) has_17\VBZ|therapy|.|in|but|levels (l_dobj) drawbacks_19\NNS|NONE (l_prep) including_21\VBG|,|several (l_pobj) hypercalcemia_22\NN|NONE (l_conj) suppression_25\NN|and/or (l_prep) of_26\IN|marked (l_pobj) turnover_28\NN|NONE
D002117_D001851 CID Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ|NONE (l_conj) has_17\VBZ|therapy|.|in|but|levels (l_dobj) drawbacks_19\NNS|NONE (l_prep) including_21\VBG|,|several (l_pobj) hypercalcemia_22\NN|NONE (l_conj) suppression_25\NN|and/or (l_prep) of_26\IN|marked (l_pobj) turnover_28\NN|NONE (l_relcl) lead_32\VB|bone|, (l_prep) to_33\IN|which|may (l_pobj) disease_36\NN|NONE
D002117_D006934 CID Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ|NONE (l_conj) has_17\VBZ|therapy|.|in|but|levels (l_dobj) drawbacks_19\NNS|NONE (l_prep) including_21\VBG|,|several (l_pobj) hypercalcemia_22\NN|NONE
C051883_D001851 NONE 22-oxacalcitriol_0\JJ|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ|NONE (l_prep) without_4\IN|oxacalcitriol|.|hyperparathyroidism (l_pcomp) inducing_5\VBG|NONE (l_dobj) turnover_8\NN|NONE
C051883_D001851 NONE OCT_6\NNP|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB|may|in|of|it|that|,|induce (r_advcl) be_24\VB|results|. (l_advcl) induce_37\VB|may|in|of|it|that|,|prevent (l_dobj) turnover_40\NN|it|,|does|because|increase|not|and
C051883_D001851 NONE OCT_6\NNP|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB|may|in|of|it|that|,|induce (r_advcl) be_24\VB|results|. (l_advcl) induce_37\VB|may|in|of|it|that|,|prevent (l_conj) increase_47\VB|it|,|does|turnover|because|not|and (l_dobj) risk_49\NN|not|does|therefore|, (l_prep) of_50\IN|the (l_pobj) disease_53\NN|NONE
C051883_-1 NONE OCT_4\NNP|,|.|formation|,|but|alter|In (r_nsubj) reversed_5\VBD|NONE (l_dobj) formation_8\NN|,|.|,|but|alter|In|OCT (l_prep) as_11\IN|bone|,|abnormal (l_pobj) osteoid_13\NN|such
C051883_D006934 CID OCT_6\NNP|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB|may|in|of|it|that|,|induce (l_dobj) occurrence_12\NN|OCT|though|does|completely|even|not (l_prep) of_13\IN|the|in (l_pobj) hypercalcemia_14\NN|NONE
C051883_D005355 NONE OCT_4\NNP|,|.|formation|,|but|alter|In (r_nsubj) reversed_5\VBD|NONE (l_dobj) formation_8\NN|,|.|,|but|alter|In|OCT (l_prep) as_11\IN|bone|,|abnormal (l_pobj) osteoid_13\NN|such (l_conj) fibrosis_15\NN|and|woven
C051883_D006962 NONE 22-oxacalcitriol_0\JJ|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ|NONE (l_dobj) hyperparathyroidism_3\NN|oxacalcitriol|.|without
C051883_D006962 NONE OCT_7\NNP|.|levels|In|,|during (r_nsubj) stabilized_14\VBD|NONE (l_prep) In_0\IN|OCT|.|levels|,|during (l_pobj) hyperparathyroidism_5\NN|NONE
C051883_D006962 NONE OCT_6\NNP|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB|may|in|of|it|that|,|induce (r_advcl) be_24\VB|results|. (l_prep) in_27\IN|may|of|it|that|,|prevent|induce (l_pobj) management_29\NN|NONE (l_prep) of_30\IN|the (l_pobj) hyperparathyroidism_32\NN|NONE
D002117_D051437 NONE Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ|NONE (l_prep) in_11\IN|therapy|.|but|levels|has (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) failure_15\NN|NONE
C051883_D051437 NONE 22-oxacalcitriol_0\JJ|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ|NONE (l_prep) without_4\IN|oxacalcitriol|.|hyperparathyroidism (l_pcomp) inducing_5\VBG|NONE (l_dobj) turnover_8\NN|NONE (l_prep) in_9\IN|low|bone (l_pobj) dogs_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) failure_13\NN|NONE
C051883_D051437 NONE OCT_4\NNP|after|In|levels|,|significantly|. (r_nsubj) decreased_6\VBD|NONE (l_prep) after_11\IN|In|levels|,|significantly|.|OCT (l_pobj) induction_13\NN|soon (l_prep) of_14\IN|the (l_pobj) insufficiency_16\NN|NONE
C051883_D051437 NONE OCT_6\NNP|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB|may|in|of|it|that|,|induce (l_dobj) occurrence_12\NN|OCT|though|does|completely|even|not (l_prep) in_15\IN|the|of (l_pobj) dogs_17\NNS|NONE (l_prep) with_18\IN|experimental (l_pobj) insufficiency_20\NN|NONE
C051883_D007674 NONE OCT_9\NNP|NONE (r_pobj) of_8\IN|the|on (r_prep) effects_7\NNS|to (l_prep) on_10\IN|the|of (l_pobj) levels_13\NNS|NONE (l_conj) turnover_16\NN|and|serum|PTH (l_prep) in_17\IN|bone (l_pobj) states_18\NNS|NONE (l_prep) of_19\IN|NONE (l_pobj) function_24\NN|NONE
7189975
C004616_D012640 CID chloroprocaine_31\NN|the (r_compound) group_32\NN|NONE (r_pobj) of_29\IN| (r_prep) %_28\NN|and|in|, (r_pobj) in_26\IN|.|in|fatal|,|dose (r_prep) was_15\VBD|NONE (l_nsubj) dose_2\NN|.|in|in|fatal|, (l_appos) convulsions_8\NNS|of|)|A|CD
C004616_D012640 CID chloroprocaine_31\NN|the (r_compound) group_32\NN|NONE (r_pobj) of_29\IN| (r_prep) %_28\NN|and|in|, (r_pobj) in_26\IN|.|in|fatal|,|dose (r_prep) was_15\VBD|NONE (l_prep) in_17\IN|.|in|fatal|,|dose (l_pobj) %_19\NN|NONE (l_prep) of_20\IN| (l_pobj) seizures_24\NNS|NONE
D002045_D012640 CID bupivacaine_21\NN| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE (r_pobj) of_20\IN| (r_prep) %_19\NN|NONE (r_pobj) in_17\IN|.|in|fatal|,|dose (r_prep) was_15\VBD|NONE (l_nsubj) dose_2\NN|.|in|in|fatal|, (l_appos) convulsions_8\NNS|of|)|A|CD
D002045_D012640 CID bupivacaine_21\NN| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE
D008012_D012640 CID lidocaine_40\NN|the (r_compound) group_41\NN|NONE (r_pobj) of_38\IN| (r_prep) %_37\NN|NONE (r_pobj) in_35\IN|and|%|, (r_conj) in_26\IN|.|in|fatal|,|dose (r_prep) was_15\VBD|NONE (l_nsubj) dose_2\NN|.|in|in|fatal|, (l_appos) convulsions_8\NNS|of|)|A|CD
D008012_D012640 CID lidocaine_40\NN|the (r_compound) group_41\NN|NONE (r_pobj) of_38\IN| (r_prep) %_37\NN|NONE (r_pobj) in_35\IN|and|%|, (r_conj) in_26\IN|.|in|fatal|,|dose (r_prep) was_15\VBD|NONE (l_prep) in_17\IN|.|in|fatal|,|dose (l_pobj) %_19\NN|NONE (l_prep) of_20\IN| (l_pobj) seizures_24\NNS|NONE
7724492
D003487_D007674 NONE cyanoacrylate_7\JJ|doxorubicin|adriamycin)loaded|( (r_compound) nanoparticles_8\NNS|NONE (r_pobj) of_3\IN|Acute|.|renal (r_prep) toxicity_2\NN|NONE
D004317_D005921 NONE doxorubicin_1\NN| (r_npadvmod) loaded_3\VBN|NONE (r_amod) nanoparticle_4\NN|Acute|renal|DXNP (r_nmod) toxicity_9\NN|.|in|was (r_nsubjpass) explored_11\VBN|NONE (l_prep) in_12\IN|.|was|toxicity (l_pobj) rats_15\NNS|NONE (l_conj) rats_17\NNS|and|both|normal (l_prep) with_18\IN|NONE (l_pobj) glomerulonephritis_20\NN|NONE
D004317_D005921 NONE DX_10\NNP|NONE (r_pobj) given_9\VBN|/ (r_prep) rats_8\NNS|,|within|in|,|In|. (r_nsubj) died_11\VBD|NONE (l_prep) In_0\IN|,|within|in|,|rats|. (l_pobj) rats_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) glomerulonephritis_5\NN|NONE
D004317_D011507 CID DX_16\NNP|NONE (r_pobj) with_15\IN|NONE (r_prep) treated_14\VBN|NONE (r_acl) those_13\DT|NONE (r_pobj) in_12\IN|NONE (r_prep) than_11\IN|with (r_prep) treated_8\VBN|NONE (r_acl) animals_7\NNS|NONE (r_pobj) in_6\IN|.|proteinuria (r_prep) appeared_5\VBD|NONE (l_nsubj) proteinuria_4\NN|.|in
D004317_D011507 CID doxorubicin_22\NN|day (r_compound) treatment_23\NN|NONE (r_pobj) after_21\IN|NONE (r_prep) prolonged_20\VBN|and||.|more (r_conj) intense_13\JJ|,|without (r_acomp) was_7\VBD|.|Proteinuria|,|in|but (r_conj) appeared_1\VBD|NONE (l_nsubj) Proteinuria_0\NNP|.|,|was|in|but
D004317_D011507 CID DX_39\NNP|and (r_conj) DXNP_37\NNP|NONE (r_pobj) between_36\IN|significant (r_prep) difference_35\NN|NONE (r_pobj) without_33\IN|,|intense (r_prep) was_7\VBD|.|Proteinuria|,|in|but (r_conj) appeared_1\VBD|NONE (l_nsubj) Proteinuria_0\NNP|.|,|was|in|but
D004317_D007674 NONE doxorubicin_4\NN|adriamycin)loaded|(|cyanoacrylate (r_nmod) nanoparticles_8\NNS|NONE (r_pobj) of_3\IN|Acute|.|renal (r_prep) toxicity_2\NN|NONE
D004317_D007674 NONE adriamycin)-loaded_6\VBN|doxorubicin|(|cyanoacrylate (r_amod) nanoparticles_8\NNS|NONE (r_pobj) of_3\IN|Acute|.|renal (r_prep) toxicity_2\NN|NONE
D004317_D007674 NONE doxorubicin_1\NN| (r_npadvmod) loaded_3\VBN|NONE (r_amod) nanoparticle_4\NN|Acute|renal|DXNP (r_nmod) toxicity_9\NN|.|in|was
D004317_D007674 NONE DX_16\NNP|NONE (r_pobj) than_14\IN|less (r_prep) animals_13\NNS|,|that|DXNP|,|despite|in|, (r_dobj) killed_11\VBD|.|results (l_prep) despite_18\IN|,|that|DXNP|,|animals|in|, (l_prep) of_19\IN|NONE (l_pobj) toxicity_23\NN|NONE
15565293
D004977_D051437 NONE EMB_7\NNP| (r_npadvmod) induced_9\VBN|optic (r_amod) neuropathy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) management_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) terms_3\NNS|NONE (r_pobj) in_2\IN|reached|.|important|,|Additionally|it|, (r_prep) is_14\VBZ|NONE (l_acomp) important_15\JJ|reached|.|,|Additionally|it|in|, (l_xcomp) manage_18\VB|NONE (l_dobj) dosing_20\VBG|to|properly|achieve|and (l_prep) in_21\IN|ethambutol (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) impairment_25\NN|NONE
D004977_D051437 NONE ethambutol_19\NN|in (r_amod) dosing_20\VBG|to|properly|achieve|and (l_prep) in_21\IN|ethambutol (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) impairment_25\NN|NONE
D004977_D014376 NONE Ethambutol_0\NNP|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|Ethambutol|. (l_acl) used_6\VBD|an|antimycobacterial (l_xcomp) treat_8\VB|often (l_dobj) tuberculosis_9\NN|to
D004977_D009901 CID ethambutol_10\NN| (r_advmod) induced_12\VBN|optic (r_amod) neuropathy_14\NN|NONE
D004977_D009901 CID ethambutol_14\NN| (r_advmod) induced_16\VBN|optic (r_amod) neuropathy_18\NN|NONE
D004977_D009901 CID ethambutol_4\NN|NONE (r_pobj) of_3\IN|A|serious (r_prep) complication_2\NN|.|neuropathy (r_nsubj) is_5\VBZ|NONE (l_attr) neuropathy_8\NN|complication|.
D004977_D009901 CID ethambutol_6\NN|,|and|(|of|optic (r_amod) neuropathy_10\NN|NONE
D004977_D009901 CID EMB)-induced_8\VBN|NONE (r_amod) optic_9\JJ|,|and|(|ethambutol|of (r_compound) neuropathy_10\NN|NONE
D004977_D009901 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|optic (r_amod) neuropathy_10\NN|NONE
D004977_D009901 CID EMB_7\NNP| (r_npadvmod) induced_9\VBN|optic (r_amod) neuropathy_11\NN|NONE
D004977_D009901 CID EMB_7\NNP| (r_npadvmod) induced_9\VBN|optic (r_amod) neuropathy_11\NN|NONE
D004977_D009901 CID ethambutol_19\NN|in (r_amod) dosing_20\VBG|to|properly|achieve|and (r_dobj) manage_18\VB|NONE (r_xcomp) important_15\JJ|reached|.|,|Additionally|it|in|, (r_acomp) is_14\VBZ|NONE (l_prep) in_2\IN|reached|.|important|,|Additionally|it|, (l_pobj) terms_3\NNS|NONE (l_prep) of_4\IN|NONE (l_pobj) management_5\NN|NONE (l_prep) of_6\IN|NONE (l_pobj) neuropathy_11\NN|NONE
D004977_D009410 NONE ethambutol_14\NN| (r_advmod) induced_16\VBN|optic (r_amod) neuropathy_18\NN|NONE (r_pobj) in_13\IN|axonal|using (r_prep) degeneration_12\NN|NONE
D004977_D014786 CID ethambutol_6\NN|,|and|(|of|optic (r_amod) neuropathy_10\NN|NONE (r_pobj) of_5\IN|a (r_prep) history_4\NN|NONE (r_pobj) with_2\IN|Three (r_prep) subjects_1\NNS|.|were|deficits|examination (r_nsubjpass) administered_23\VBN|NONE (l_nsubjpass) deficits_21\NNS|.|were|subjects|examination
D004977_D014786 CID EMB)-induced_8\VBN|NONE (r_amod) optic_9\JJ|,|and|(|ethambutol|of (r_compound) neuropathy_10\NN|NONE (r_pobj) of_5\IN|a (r_prep) history_4\NN|NONE (r_pobj) with_2\IN|Three (r_prep) subjects_1\NNS|.|were|deficits|examination (r_nsubjpass) administered_23\VBN|NONE (l_nsubjpass) deficits_21\NNS|.|were|subjects|examination
D004977_D014786 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|optic (r_amod) neuropathy_10\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) history_4\NN|NONE (r_pobj) with_3\IN|all (r_prep) subjects_2\NNS|NONE (r_pobj) In_0\IN|,|there|loss|,|with|. (r_prep) was_13\VBD|NONE (l_attr) loss_16\NN|,|there|,|In|with|. (l_prep) with_32\IN|a|,|in|mean|of|loss|) (l_pobj) recovery_34\NN|NONE (l_prep) with_48\IN|eventual|of (l_pobj) deficits_51\NNS|NONE
D004977_D014786 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|optic (r_amod) neuropathy_10\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) history_4\NN|NONE (r_pobj) with_3\IN|all (r_prep) subjects_2\NNS|NONE (r_pobj) In_0\IN|,|there|loss|,|with|. (r_prep) was_13\VBD|NONE (l_attr) loss_16\NN|,|there|,|In|with|. (l_conj) loss_55\NN|a|,|in|mean|with|of|) (l_conj) C_58\NN|%|; (l_prep) with_60\IN|,|,|patient|loss (l_pobj) deficits_63\NNS|NONE
17074608
D014635_D002819 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|encephalopathy|and|. (r_amod) chorea_3\NN|NONE
D014635_D002819 CID valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (l_prep) with_23\IN|after|her (l_pobj) encephalopathy_25\NN|NONE (l_conj) chorea_27\NN|acute|and
D005998_D000592 NONE glycine_15\NN|the|cleavage (r_compound) system_17\NN|NONE (r_pobj) in_13\IN|a (r_prep) defect_12\NN|to|in (r_nsubj) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE
D005998_D000592 NONE glycine_23\NN|NONE (r_pobj) of_22\IN|in|an (r_prep) accumulation_21\NN|NONE (r_pobj) to_19\IN|in|defect (r_prep) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE
D005998_D020158 NONE glycine_15\NN|the|cleavage (r_compound) system_17\NN|NONE (r_pobj) in_13\IN|a (r_prep) defect_12\NN|to|in (r_nsubj) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE (r_pobj) of_5\IN|a (r_prep) disorder_4\NN|.|hyperglycinemia (r_attr) is_2\VBZ|NONE (l_nsubj) hyperglycinemia_1\NN|.|disorder
D005998_D020158 NONE glycine_23\NN|NONE (r_pobj) of_22\IN|in|an (r_prep) accumulation_21\NN|NONE (r_pobj) to_19\IN|in|defect (r_prep) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE (r_pobj) of_5\IN|a (r_prep) disorder_4\NN|.|hyperglycinemia (r_attr) is_2\VBZ|NONE (l_nsubj) hyperglycinemia_1\NN|.|disorder
D014635_D020158 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|encephalopathy|and|. (r_amod) chorea_3\NN|NONE (l_conj) encephalopathy_5\JJ|and|.|induced (l_prep) in_6\IN|NONE (l_pobj) hyperglycinemia_9\NN|NONE
D014635_D020158 NONE valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (r_pobj) following_20\VBG|have|was|who (r_prep) found_15\VBN|and|,|mild|retardation|language (l_xcomp) have_17\VB|following|was|who (l_dobj) hyperglycinemia_19\NN|to
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|encephalopathy|and|. (r_amod) chorea_3\NN|NONE (l_conj) encephalopathy_5\JJ|and|.|induced
D014635_D001927 CID valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (l_prep) with_23\IN|after|her (l_pobj) encephalopathy_25\NN|NONE
D014635_D008607 NONE valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (r_pobj) following_20\VBG|have|was|who (r_prep) found_15\VBN|and|,|mild|retardation|language (r_relcl) delay_8\NN|NONE (l_conj) retardation_11\NN|and|found|,|mild|language
D014635_D007805 NONE valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (r_pobj) following_20\VBG|have|was|who (r_prep) found_15\VBN|and|,|mild|retardation|language (r_relcl) delay_8\NN|NONE
15580403
D012254_D019698 NONE ribavirin_3\JJ|in (r_compound) reduction_4\NN|NONE (l_prep) in_5\IN|ribavirin (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) hemolysis_8\NN|NONE (l_prep) during_9\IN|NONE (l_pobj) therapy_11\NN|NONE (l_prep) for_16\IN|of|combination (l_pobj) C._19\NNP|NONE
D012254_D019698 NONE ribavirin_15\RB|and (r_conj) interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (l_prep) for_16\IN|of|combination (l_pobj) C._19\NNP|NONE
D007372_D000743 CID interferon_14\NN|NONE (r_pobj) of_13\IN|the|combination (r_prep) therapy_12\NN|NONE (r_pobj) of_9\IN|adverse|major|the (r_prep) events_8\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) one_3\CD|.|anemia (r_attr) is_2\VBZ|NONE (l_nsubj) anemia_1\NN|.|one
D012254_D000740 NONE ribavirin_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) reduction_7\NN|NONE (r_pobj) with_6\IN| (r_prep) patients_5\NNS|.|therapy|could|,|decreased|However|not (r_nsubj) continue_12\VB|NONE (l_advcl) decreased_24\VBD|.|therapy|could|,|However|patients|not (l_conj) occurred_33\VBD|because|to|values|or (l_nsubj) effects_32\NNS|B|) (l_amod) related_29\VBN|severe|side (l_npadvmod) anemia_27\NN|
D007372_D019698 NONE interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (l_prep) for_16\IN|of|combination (l_pobj) C._19\NNP|NONE
D007372_D006461 NONE interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (r_pobj) during_9\IN|NONE (r_prep) hemolysis_8\NN|NONE
D012254_D006461 NONE ribavirin_3\JJ|in (r_compound) reduction_4\NN|NONE (l_prep) in_5\IN|ribavirin (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) hemolysis_8\NN|NONE
D012254_D006461 NONE ribavirin_15\RB|and (r_conj) interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (r_pobj) during_9\IN|NONE (r_prep) hemolysis_8\NN|NONE
D012254_D006461 NONE ribavirin_13\JJ|in (r_compound) reduction_14\NN|NONE (l_prep) in_15\IN|ribavirin (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) hemolysis_18\NN|NONE
D012254_D000743 CID ribavirin_16\NN|and (r_conj) interferon_14\NN|NONE (r_pobj) of_13\IN|the|combination (r_prep) therapy_12\NN|NONE (r_pobj) of_9\IN|adverse|major|the (r_prep) events_8\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) one_3\CD|.|anemia (r_attr) is_2\VBZ|NONE (l_nsubj) anemia_1\NN|.|one
D012254_D000743 CID ribavirin_2\RB| (r_npadvmod) related_4\VBN|hemolytic (r_amod) anemia_6\NN|of
12600698
D013307_D015837 CID streptomycin_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) vestibulotoxicity_8\NN|NONE
D013307_D015837 CID streptomycin_5\NNS| (r_npadvmod) induced_7\VBN|NONE (r_amod) vestibulotoxicity_8\NN|NONE
D013307_D015837 CID streptomycin_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) vestibulotoxicity_9\NN|edaravone|that
C005435_D015837 NONE edaravone_3\NN|NONE (r_pobj) of_2\IN|.|against|Protective (r_prep) effect_1\NN|NONE (l_prep) against_4\IN|of|.|Protective (l_pobj) vestibulotoxicity_8\NN|NONE
C005435_D015837 NONE edaravone_10\NN|NONE (r_pobj) by_9\IN|in|of (r_prep) alleviation_3\NN|.|study (l_prep) of_4\IN|by|in (l_pobj) vestibulotoxicity_8\NN|NONE
C005435_D015837 NONE edaravone_4\NN|vestibulotoxicity|that (r_nsubj) suppresses_5\VBZ|.|results (l_dobj) vestibulotoxicity_9\NN|edaravone|that
C005435_D002544 NONE Edaravone_0\NNP|and|action|used|. (r_nsubj) has_7\VBZ|NONE (l_conj) used_15\VBN|and|action|.|Edaravone (l_xcomp) treat_20\VB|is|in (l_dobj) infarction_22\NN|to
18541230
D011692_D006402 NONE aminonucleoside_6\NN| (r_advmod) induced_8\VBN|hematological (r_amod) abnormalities_10\NNS|Treatment|.|puromycin
D011692_D009404 NONE aminonucleoside_18\RB| (r_advmod) induced_20\VBN|,|is|puromycin (r_amod) nephrosis_21\NN|NONE (l_relcl) is_24\VBZ|,|puromycin|induced (l_attr) model_27\NN|which (l_prep) of_28\IN|an|experimental (l_pobj) syndrome_31\NN|NONE
D011692_D009404 NONE aminonucleoside_14\RB| (r_advmod) induced_16\VBN|puromycin|nephrotic (r_amod) syndrome_18\NN|NONE
D011692_D009401 CID aminonucleoside_6\JJ|in (r_amod) nephrosis_7\NN|puromycin
D011692_D009401 CID aminonucleoside_18\RB| (r_advmod) induced_20\VBN|,|is|puromycin (r_amod) nephrosis_21\NN|NONE
D011692_D006949 NONE aminonucleoside_1\RB| (r_advmod) induced_3\VBN|renal|hyperlipidemia|and|Puromycin (r_amod) dysfunction_5\NN|.|were|also (l_conj) hyperlipidemia_7\NN|renal|and|induced|Puromycin
D011692_D007674 NONE aminonucleoside_1\RB| (r_advmod) induced_3\VBN|renal|hyperlipidemia|and|Puromycin (r_amod) dysfunction_5\NN|.|were|also
48362
D011802_D056486 CID Quinidine_0\NN|. (r_compound) hepatitis_1\NN|NONE
D011802_D056486 CID quinidine_6\VBN|NONE (r_poss) hepatotoxicity_7\NN|believe|that|and|patient
17263743
D003000_D001008 NONE clonidine_16\NN|NONE (r_pobj) of_15\IN|three (r_prep) doses_14\NNS|Without|during|.|before|,|mother|reduce (r_dobj) administered_12\VBD|NONE (l_advcl) reduce_26\VB|Without|doses|during|.|before|,|mother (l_dobj) anxiety_27\NN|to
D003000_D004827 NONE clonidine_18\NN|for (r_dobj) receiving_17\VBG|We|,|case|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|We|receiving|,|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE
D001418_D002547 NONE baclofen_28\JJ|a (r_compound) pump_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) placement_25\NN|NONE (r_pobj) for_24\IN|who (r_prep) presented_23\VBD|, (r_relcl) restlessness_20\NN|NONE (r_pobj) for_19\IN|clonidine (r_prep) receiving_17\VBG|We|,|case|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|We|receiving|,|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE (l_nmod) palsy_12\JJ|seizure
C009250_D006323 NONE sevoflurane_9\NN|of (r_amod) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|in|Cardiac|. (r_acl) arrest_1\NN|NONE
D003000_D011595 NONE clonidine_18\NN|for (r_dobj) receiving_17\VBG|We|,|case|. (l_prep) for_19\IN|clonidine (l_pobj) restlessness_20\NN|NONE
D003000_D006323 CID clonidine_15\NN|NONE (r_pobj) after_13\IN|NONE (r_prep) anesthesia_12\NN|NONE (r_pobj) of_11\IN|sevoflurane (r_prep) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|in|Cardiac|. (r_acl) arrest_1\NN|NONE
D003000_D006323 CID clonidine_6\NN| (r_npadvmod) associated_8\VBN|cardiac|in (r_amod) arrest_10\NN|NONE
C009250_D002547 NONE sevoflurane_9\NN|of (r_amod) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|in|Cardiac|. (r_acl) arrest_1\NN|NONE (l_prep) in_2\IN|Cardiac|.|undergoing (l_pobj) child_4\NN|NONE (l_prep) with_5\IN|a (l_pobj) palsy_7\JJ|NONE
D003000_D002547 NONE clonidine_15\NN|NONE (r_pobj) after_13\IN|NONE (r_prep) anesthesia_12\NN|NONE (r_pobj) of_11\IN|sevoflurane (r_prep) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|in|Cardiac|. (r_acl) arrest_1\NN|NONE (l_prep) in_2\IN|Cardiac|.|undergoing (l_pobj) child_4\NN|NONE (l_prep) with_5\IN|a (l_pobj) palsy_7\JJ|NONE
D003000_D002547 NONE clonidine_18\NN|for (r_dobj) receiving_17\VBG|We|,|case|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|We|receiving|,|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE (l_nmod) palsy_12\JJ|seizure
D001418_D011595 NONE baclofen_28\JJ|a (r_compound) pump_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) placement_25\NN|NONE (r_pobj) for_24\IN|who (r_prep) presented_23\VBD|, (r_relcl) restlessness_20\NN|NONE
D001418_D004827 NONE baclofen_28\JJ|a (r_compound) pump_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) placement_25\NN|NONE (r_pobj) for_24\IN|who (r_prep) presented_23\VBD|, (r_relcl) restlessness_20\NN|NONE (r_pobj) for_19\IN|clonidine (r_prep) receiving_17\VBG|We|,|case|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|We|receiving|,|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE
10910842
D011239_D009468 NONE prednisolone_8\NN|NONE (r_pobj) after_7\IN|the|neuromuscular (r_prep) dysfunction_6\NN|that|dependent|and|,|derives
D000109_D009133 NONE acetylcholine_22\NN|receptor (r_compound) expression_24\NN|NONE (r_pobj) in_21\IN|NONE (r_prep) changes_20\NNS|NONE (r_pobj) from_19\IN|NONE (r_prep) less_18\JJR|NONE (r_advmod) derive_17\VB|and|primarily|from (r_conj) derive_11\VBP|dependent|that|effects|and (l_prep) from_13\IN|and|primarily|derive (l_pobj) atrophy_15\NN|NONE
D011239_D009133 CID prednisolone_8\NN|NONE (r_pobj) after_7\IN|the|neuromuscular (r_prep) dysfunction_6\NN|that|dependent|and|,|derives (r_nsubj) is_9\VBZ|results|. (l_conj) derives_15\VBZ|that|dependent|and|dysfunction|, (l_prep) from_17\IN|primarily|and|derives (l_pobj) atrophy_19\NN|NONE
D000109_D001284 NONE acetylcholine_13\NN|receptor|altered (r_compound) expression_15\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) than_10\IN|NONE (r_prep) atrophy_9\NN|NONE
D014403_D013746 NONE tubocurarine_27\NN|NONE (r_pobj) of_24\IN|the|response|in (r_prep) curves_23\NNS|,|and (r_conj) fatigability_16\NN|tetanic|,|and (r_conj) tensions_13\NNS|twitch|the|,|evoked|peak (l_compound) tetanic_12\JJ|,|and|fatigability
D011239_D018908 CID Prednisolone_0\NNP| (r_npadvmod) induced_2\VBN|muscle (r_amod) dysfunction_4\NN|is|.|more|by
D000109_D018908 NONE acetylcholine_13\NN|receptor|altered (r_compound) expression_15\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) than_10\IN|NONE (r_prep) atrophy_9\NN|NONE (r_pobj) by_8\IN|is|.|more|dysfunction (r_agent) caused_6\VBN|NONE (l_nsubjpass) dysfunction_4\NN|is|.|more|by
D011239_D001284 NONE Prednisolone_0\NNP| (r_npadvmod) induced_2\VBN|muscle (r_amod) dysfunction_4\NN|is|.|more|by (r_nsubjpass) caused_6\VBN|NONE (l_agent) by_8\IN|is|.|more|dysfunction (l_pobj) atrophy_9\NN|NONE
2750819
D008278_D020879 CID sulfate_4\NN|NONE (r_pobj) with_2\IN|.|Neuromuscular (r_prep) blockade_1\NN|NONE
D008278_D020879 CID sulfate_15\NN|NONE (r_pobj) of_13\IN| (r_prep) mg_12\NN|patient|.|after|was (r_nsubjpass) administered_17\VBN|NONE (l_nsubjpass) patient_1\NN|mg|.|after|was (l_relcl) received_3\VBD|A (l_dobj) tocolysis_4\NN|who (l_prep) with_5\IN|NONE (l_pobj) blockade_9\NN|NONE
D008274_D064420 NONE magnesium_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) toxicity_9\NN|that|seriously|nifedipine|can
D009543_D064420 NONE nifedipine_4\NN|toxicity|that|seriously|can (r_nsubj) potentiate_7\VB|.|reaction (l_dobj) toxicity_9\NN|that|seriously|nifedipine|can
D009543_D020879 CID nifedipine_6\NN|and|magnesium (r_conj) sulfate_4\NN|NONE (r_pobj) with_2\IN|.|Neuromuscular (r_prep) blockade_1\NN|NONE
D009543_D020879 CID nifedipine_6\NN|neuromuscular|developed (r_nmod) blockade_9\NN|NONE
8494478
D002939_D007674 NONE Ciprofloxacin_0\NNP|.|nephrotoxicity| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephrotoxicity_3\NN|.|Ciprofloxacin|
D002939_D007674 NONE ciprofloxacin_3\NNS|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Nephrotoxicity_0\NN|uncommon|.
D002939_D058186 CID ciprofloxacin_13\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|that (r_dobj) followed_10\VBD|acute|renal (r_relcl) failure_8\NN|who
D002939_D058186 CID ciprofloxacin_18\NNS| (r_npadvmod) induced_20\VBN|renal|acute (r_amod) failure_23\NN|NONE
D002939_D009369 NONE Ciprofloxacin_0\NNP|.|nephrotoxicity| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephrotoxicity_3\NN|.|Ciprofloxacin| (l_prep) in_4\IN|NONE (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) cancer_7\NN|NONE
D002939_D009369 NONE ciprofloxacin_13\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|that (r_dobj) followed_10\VBD|acute|renal (r_relcl) failure_8\NN|who (r_dobj) developed_5\VBD|with|Five (r_relcl) patients_1\NNS|and|are|reviewed (l_prep) with_2\IN|developed|Five (l_pobj) cancer_3\NN|NONE
10524660
D005996_D008881 NONE GTN_14\NNP|as|p=.|during|after (r_compound) infusion_15\NN|severe|.|Headache (r_advcl) was_1\VBD|NONE (l_acomp) severe_3\JJ|infusion|.|Headache (l_prep) in_4\IN|more|than (l_pobj) migraineurs_5\NNS|NONE
D005996_D008881 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|the (r_amod) headache_8\NN|gradually|,|In|peak|,|. (r_nsubj) disappeared_10\VBD|NONE (l_advcl) peak_15\JJ|gradually|,|In|headache|,|. (l_prep) in_13\IN|occurred|whereas (l_pobj) migraineurs_14\NNS|NONE
D009569_D020325 NONE NO_5\DT|is|in|that (r_nsubjpass) involved_7\VBN|results|therefore|. (l_prep) in_8\IN|is|NO|that (l_pobj) mechanisms_11\NNS|NONE (l_prep) with_14\IN|the|of|pain (l_pobj) aura_15\NN|NONE
D009569_D020325 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|has|Since|been|depression (r_xcomp) shown_6\VBN|may|understanding|,|.|finding (r_advcl) help_16\VB|NONE (l_dobj) understanding_18\NN|may|,|shown|.|finding (l_prep) of_19\IN|our (l_pobj) coupling_21\NN|NONE (l_prep) between_22\IN|the (l_pobj) depression_25\NN|NONE (l_conj) headache_27\NN|cortical|and|spreading (l_prep) with_30\IN|in (l_pobj) aura_31\NN|NONE
D009569_D010146 NONE oxide_13\NN|in|that|is (r_nsubjpass) involved_18\VBN|.|has|,|In|evidence (l_prep) in_19\IN|oxide|that|is (l_pobj) mechanisms_21\NNS|NONE (l_compound) pain_20\NN|without|of
D009569_D010146 NONE NO_15\NNP|nitric|molecule|)|(|the (r_appos) oxide_13\NN|in|that|is (r_nsubjpass) involved_18\VBN|.|has|,|In|evidence (l_prep) in_19\IN|oxide|that|is (l_pobj) mechanisms_21\NNS|NONE (l_compound) pain_20\NN|without|of
D009569_D010146 NONE NO_5\DT|is|in|that (r_nsubjpass) involved_7\VBN|results|therefore|. (l_prep) in_8\IN|is|NO|that (l_pobj) mechanisms_11\NNS|NONE (l_compound) pain_10\NN|the|with|of
D005996_D020326 CID trinitrate_1\NN|attacks|. (r_nsubj) induces_2\VBZ|NONE (l_dobj) attacks_3\NNS|trinitrate|. (l_prep) without_6\IN|of (l_pobj) aura_7\NN|NONE
D005996_D020325 NONE trinitrate_1\NN|attacks|. (r_nsubj) induces_2\VBZ|NONE (l_dobj) attacks_3\NNS|trinitrate|. (l_prep) without_6\IN|of (l_pobj) aura_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) sufferers_9\NNS|NONE (l_prep) with_12\IN|of (l_pobj) aura_13\NN|NONE
D005996_D020325 NONE trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|min|we|In|.|,|in (r_dobj) examined_19\VBD|NONE (l_prep) In_0\IN|min|response|we|.|,|in (l_pobj) order_1\NN|NONE (l_acl) clarify_3\VB|NONE (l_ccomp) is_7\VBZ|to (l_acomp) true_8\JJ|same|whether (l_prep) for_9\IN|NONE (l_pobj) migraine_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) aura_12\NN|NONE
D005996_D020325 NONE trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|min|we|In|.|,|in (r_dobj) examined_19\VBD|NONE (l_parataxis) min_38\NN|response|we|In|.|,|in (l_prep) in_43\IN|.|(|)|/|for|microg (l_pobj) sufferers_45\NNS|NONE (l_prep) with_48\IN|of| (l_pobj) aura_49\NN|NONE
D005996_D020325 NONE GTN_30\NNP|(|)|glyceryl (r_appos) trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|min|we|In|.|,|in (r_dobj) examined_19\VBD|NONE (l_prep) In_0\IN|min|response|we|.|,|in (l_pobj) order_1\NN|NONE (l_acl) clarify_3\VB|NONE (l_ccomp) is_7\VBZ|to (l_acomp) true_8\JJ|same|whether (l_prep) for_9\IN|NONE (l_pobj) migraine_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) aura_12\NN|NONE
D005996_D020325 NONE GTN_30\NNP|(|)|glyceryl (r_appos) trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|min|we|In|.|,|in (r_dobj) examined_19\VBD|NONE (l_parataxis) min_38\NN|response|we|In|.|,|in (l_prep) in_43\IN|.|(|)|/|for|microg (l_pobj) sufferers_45\NNS|NONE (l_prep) with_48\IN|of| (l_pobj) aura_49\NN|NONE
D009569_D003866 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|has|Since|been|depression (r_xcomp) shown_6\VBN|may|understanding|,|.|finding (l_nsubjpass) depression_3\NN|has|Since|been|liberate
D009569_D003866 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|has|Since|been|depression (r_xcomp) shown_6\VBN|may|understanding|,|.|finding (r_advcl) help_16\VB|NONE (l_dobj) understanding_18\NN|may|,|shown|.|finding (l_prep) of_19\IN|our (l_pobj) coupling_21\NN|NONE (l_prep) between_22\IN|the (l_pobj) depression_25\NN|NONE
D009569_D020326 CID oxide_13\NN|in|that|is (r_nsubjpass) involved_18\VBN|.|has|,|In|evidence (l_prep) in_19\IN|oxide|that|is (l_pobj) mechanisms_21\NNS|NONE (l_prep) without_24\IN|pain|of (l_pobj) aura_25\NN|NONE
D009569_D020326 CID NO_15\NNP|nitric|molecule|)|(|the (r_appos) oxide_13\NN|in|that|is (r_nsubjpass) involved_18\VBN|.|has|,|In|evidence (l_prep) in_19\IN|oxide|that|is (l_pobj) mechanisms_21\NNS|NONE (l_prep) without_24\IN|pain|of (l_pobj) aura_25\NN|NONE
D009569_D006261 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|has|Since|been|depression (r_xcomp) shown_6\VBN|may|understanding|,|.|finding (r_advcl) help_16\VB|NONE (l_dobj) understanding_18\NN|may|,|shown|.|finding (l_prep) of_19\IN|our (l_pobj) coupling_21\NN|NONE (l_prep) between_22\IN|the (l_pobj) depression_25\NN|NONE (l_conj) headache_27\NN|cortical|and|spreading
D005996_D006261 NONE trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|min|we|In|.|,|in (l_compound) headache_21\NN|the|to
D005996_D006261 NONE GTN_30\NNP|(|)|glyceryl (r_appos) trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|min|we|In|.|,|in (l_compound) headache_21\NN|the|to
D005996_D006261 NONE GTN_14\NNP|as|p=.|during|after (r_compound) infusion_15\NN|severe|.|Headache (r_advcl) was_1\VBD|NONE (l_nsubj) Headache_0\NNP|infusion|severe|.
D005996_D006261 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|the (r_amod) headache_8\NN|gradually|,|In|peak|,|.
D005996_D006261 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|the (r_amod) headache_8\NN|gradually|,|In|peak|,|. (r_nsubj) disappeared_10\VBD|NONE (l_advcl) peak_15\JJ|gradually|,|In|headache|,|. (l_ccomp) occurred_18\VBD|in|whereas (l_nsubj) intensity_17\NN|at (l_compound) headache_16\NN|NONE
9154656
D000809_D009404 NONE angiotensin_9\NN|the|system (r_compound) proteins_11\NNS|NONE (r_pobj) of_5\IN|Plasma|and|excretion (r_prep) concentration_1\NN|are|.|in (r_nsubjpass) altered_13\VBN|NONE (l_prep) in_14\IN|are|.|concentration (l_pobj) rats_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) syndrome_18\NN|NONE
D000809_D009404 NONE angiotensin_9\NN|the|system (r_compound) proteins_11\NNS|NONE (r_pobj) of_5\IN|Plasma|and|excretion (r_prep) concentration_1\NN|are|.|in (r_nsubjpass) altered_13\VBN|NONE (l_prep) in_14\IN|are|.|concentration (l_pobj) rats_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) syndrome_18\NN|NONE (l_appos) NS_20\NNP|nephrotic
D011692_D009404 CID nucleoside_11\NN|puromycin|( (r_nmod) PAN_13\NNP|NONE (r_pobj) of_7\IN|single|a (r_prep) injection_6\NN|NONE (r_pobj) by_3\IN|was|.|NS|) (r_agent) induced_2\VBN|NONE (l_nsubjpass) NS_0\NNP|was|.|by|)
D011692_D009404 CID PAN_13\NNP|NONE (r_pobj) of_7\IN|single|a (r_prep) injection_6\NN|NONE (r_pobj) by_3\IN|was|.|NS|) (r_agent) induced_2\VBN|NONE (l_nsubjpass) NS_0\NNP|was|.|by|)
D011692_D009404 CID PAN_19\NNP|NONE (r_compound) injection_20\NN|NONE (r_pobj) after_18\IN|on|excretion|were|Although (r_prep) observed_14\VBN|.|not|established|did|,|,|levels (r_advcl) change_34\VB|NONE (l_advcl) established_26\VBN|.|not|did|observed|,|,|levels (l_nsubjpass) NS_23\NNP|clearly|when|was
D011692_D009404 CID PAN_22\NNP|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|the|of (r_acl) development_15\NN|NONE (l_prep) of_16\IN|the|induced (l_pobj) NS_19\NNP|NONE
7619765
D005047_D009203 CID Etoposide_0\RB| (r_npadvmod) related_2\VBN|myocardial|. (r_amod) infarction_4\NN|NONE
D005047_D009203 CID etoposide_11\RB|NONE (r_dobj) containing_10\VBG|NONE (r_acl) chemotherapy_9\NN|NONE (r_pobj) after_8\IN|is|.|in|occurrence|, (r_prep) reported_7\VBN|NONE (l_nsubjpass) occurrence_1\NN|after|is|.|in|, (l_prep) of_2\IN|The (l_pobj) infarction_5\NN|NONE
D005047_D003327 NONE etoposide_11\RB|NONE (r_dobj) containing_10\VBG|NONE (r_acl) chemotherapy_9\NN|NONE (r_pobj) after_8\IN|is|.|in|occurrence|, (r_prep) reported_7\VBN|NONE (l_prep) in_13\IN|after|is|.|occurrence|, (l_pobj) man_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) factors_19\NNS|NONE (l_prep) for_20\IN|risk|no (l_pobj) disease_23\NN|NONE
12571256
D007472_D007674 CID iohexol_45\NN|nonionic (r_pobj) of_33\IN|NONE (r_prep) those_32\DT|NONE (r_pobj) with_31\IN|of|the|nephrotoxic (r_prep) effects_16\NNS|NONE (l_amod) nephrotoxic_15\JJ|with|of|the
C044834_D007674 NONE iodixanol_29\NN|osmolar|,|dimeric|nonionic|contrast|,|,|an|, (r_appos) medium_27\NN|NONE (r_pobj) of_17\IN|with|the|nephrotoxic (r_prep) effects_16\NNS|NONE (l_amod) nephrotoxic_15\JJ|with|of|the
C044834_D007674 NONE iodixanol_17\NN|than|is|when (r_nsubjpass) used_19\VBN|to|in (r_advcl) develop_10\VB|less (r_xcomp) likely_8\JJ|induced|.|may (r_acomp) be_6\VB|NONE (l_csubj) induced_1\VBN|likely|.|may (l_nsubj) Nephropathy_0\NNP|by
D003404_D003920 NONE creatinine_9\JJ|serum|underwent|of (r_compound) concentrations_10\NNS|NONE (r_pobj) with_7\IN|NONE (r_prep) diabetes_6\NNS|NONE
1848636
D008790_D007008 NONE metoprolol_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) hypokalemia_13\NN|NONE
D013726_D007008 CID terbutaline_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypokalemia_13\NN|NONE
10225068
D008012_D011128 CID lignocaine_10\NN|NONE (r_pobj) with_6\IN|spinal (r_prep) anaesthesia_5\NN|NONE (r_pobj) after_3\IN|:|equina|review|. (r_prep) syndrome_2\NN|NONE
D008012_D011128 CID lignocaine_10\NN|NONE (r_pobj) with_6\IN|spinal (r_prep) anaesthesia_5\NN|NONE (r_pobj) after_3\IN|:|equina|review|. (r_prep) syndrome_2\NN|NONE (l_appos) review_13\NN|:|equina|.|after (l_prep) of_14\IN|a|reported (l_pobj) cases_16\NNS|NONE (l_prep) of_17\IN|six (l_pobj) syndrome_20\NN|NONE
D008012_D020258 NONE lignocaine_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) dose_1\NN|from (r_nsubj) ranged_8\VBD|by|.|likely|were (r_ccomp) caused_21\VBN|NONE (l_agent) by_22\IN|.|ranged|likely|were (l_pobj) neurotoxicity_24\NN|NONE
D008012_D020258 NONE lignocaine_29\NN|NONE (r_pobj) of_25\IN|direct (r_prep) neurotoxicity_24\NN|NONE
11284996
D005996_D018781 NONE trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (l_prep) in_24\IN|by (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) headache_32\NN|NONE
D005996_D018781 NONE GTN_22\NNP|glyceryl|)|(|NO|the (r_appos) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (l_prep) in_24\IN|by (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) headache_32\NN|NONE
D009569_D006261 CID oxide_8\NN| (r_npadvmod) induced_10\VBN|nitric|in (r_amod) headache_11\NN|NONE
D009569_D006261 CID oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|been|.|It|has (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|may|with|be
D009569_D006261 CID NO_8\NNP|(|)|nitric (r_intj) oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|been|.|It|has (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|may|with|be
D009569_D006261 CID NO_17\JJ|glyceryl|)|(|the|GTN (r_det) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (r_acl) headache_13\NN|NONE
D009569_D006261 CID NO_5\RB| (r_intj) induced_7\VBN|immediate (r_amod) headache_9\NN|that|with|not|is
D009569_D051270 NONE oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|been|.|It|has (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|may|with|be (l_prep) in_12\IN|NONE (l_pobj) headaches_14\NNS|NONE
D009569_D051270 NONE NO_8\NNP|(|)|nitric (r_intj) oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|been|.|It|has (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|may|with|be (l_prep) in_12\IN|NONE (l_pobj) headaches_14\NNS|NONE
D009569_D018781 NONE oxide_8\NN| (r_npadvmod) induced_10\VBN|nitric|in (r_amod) headache_11\NN|NONE (l_prep) in_12\IN|induced|nitric (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) headache_19\NN|NONE
D009569_D018781 NONE NO_17\JJ|glyceryl|)|(|the|GTN (r_det) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (l_prep) in_24\IN|by (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) headache_32\NN|NONE
D005996_D006261 CID trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (r_acl) headache_13\NN|NONE
D005996_D006261 CID GTN_22\NNP|glyceryl|)|(|NO|the (r_appos) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (r_acl) headache_13\NN|NONE
D005996_D006261 CID GTN_13\NNP|to (l_conj) placebo_15\NN|or|min (l_prep) over_16\IN|NONE (l_pobj) min_18\NN|NONE (l_prep) on_19\IN| (l_pobj) days_24\NNS|NONE (l_amod) free_23\JJ|two (l_npadvmod) headache_21\NN|
D005996_D006261 CID GTN_11\NNP|the (r_compound) day_12\NN|NONE (r_pobj) on_9\IN|immediate|stronger|than (r_prep) headache_8\NN|and|was|patients
D005996_D006261 CID GTN_11\NNP|the (r_compound) day_12\NN|NONE (r_pobj) on_9\IN|immediate|stronger|than (r_prep) headache_8\NN|and|was|patients (r_dobj) developed_4\VBD|NONE (l_conj) was_21\VBD|and|headache|patients (l_nsubj) headache_20\NN|.|pronounced
921394
D007649_D013610 CID ketamine_18\NN| (r_npadvmod) induced_20\VBN|the (r_amod) tachycardia_21\NN|NONE
D007649_D003866 NONE ketamine_2\NN|NONE (r_pobj) of_1\IN|mg|in|. (r_prep) Injections_0\NNS|NONE (l_dep) mg_10\NN|in|.|of (l_prep) into_11\IN|NONE (l_pobj) artery_13\NN|NONE (l_acl) produced_14\VBD|the (l_dobj) depression_16\NN|by
6817363
C036466_D007859 NONE aniracetam_5\RB|NONE (l_appos) Ro_7\NNP|novel|compound|the|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
C036466_D007859 NONE 5057_10\CD|NONE (r_prep) 13_8\CD|upon|) (r_nummod) Ro_7\NNP|novel|compound|the|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
C036466_D008569 NONE aniracetam_5\RB|NONE (l_appos) Ro_7\NNP|novel|compound|the|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
C036466_D008569 NONE 5057_10\CD|NONE (r_prep) 13_8\CD|upon|) (r_nummod) Ro_7\NNP|novel|compound|the|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
D003513_D000647 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (l_prep) of_75\IN|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN|NONE
D003513_D000647 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
D003513_D000647 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|a|passive|avoidance (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|or|retrieval (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN|for|;||)|of|( (r_conj) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (l_prep) of_75\IN|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN|NONE
D003513_D000647 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|a|passive|avoidance (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|or|retrieval (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN|for|;||)|of|( (r_conj) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
D003513_D006935 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D003513_D006935 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (l_conj) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
D003513_D006935 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|a|passive|avoidance (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|or|retrieval (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN|for|;||)|of|( (r_conj) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D003513_D006935 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|a|passive|avoidance (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|or|retrieval (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
C036466_D006935 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
C036466_D006935 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN|for||complete|against|; (l_conj) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
C036466_D006935 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|,|anisoylpyrrolidinone (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
C036466_D006935 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|,|anisoylpyrrolidinone (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN|for||complete|against|; (l_conj) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD|,| (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD|,| (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN|for||complete|against|; (l_conj) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
D002701_D000647 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (l_prep) of_75\IN|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN|NONE
D002701_D000647 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
D012601_D003072 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|term|the (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|was|on|.|and|effect (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D000647 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_prep) of_75\IN|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN|NONE
C036466_D000647 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
C036466_D000647 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|,|anisoylpyrrolidinone (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_prep) of_75\IN|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN|NONE
C036466_D000647 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|,|anisoylpyrrolidinone (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD|,| (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_prep) of_75\IN|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN|NONE
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD|,| (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|was|on|.|and|effect (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|;|complete||of (l_conj) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
D012601_D006935 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|term|the (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D012601_D006935 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|term|the (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN|for||complete|against|; (l_conj) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
D012601_D000647 CID scopolamine_77\NN| (r_npadvmod) induced_79\VBN|term|the (r_amod) amnesia_83\NN|NONE
D012601_D000647 CID scopolamine_77\NN| (r_npadvmod) induced_79\VBN|term|the (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN|or|)||(|( (l_conj) protection_94\NN|(|for|)|of|mice|;|complete (l_prep) against_95\IN|for||complete|;|prevention (l_pobj) amnesia_96\NN|NONE
D002701_D003072 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|was|on|.|and|effect (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|,|anisoylpyrrolidinone (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10\CD|,| (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|produced|on|.|and (r_nsubjpass) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE aniracetam_12\JJ|of|oral (r_amod) doses_13\NNS|NONE (r_pobj) at_10\IN|were|.|improvements (r_prep) seen_9\VBN|NONE (l_nsubjpass) improvements_1\NNS|were|at|. (l_conj) normalizations_3\NNS|or|These (l_prep) of_4\IN|NONE (l_pobj) functions_7\NNS|NONE
D003513_D003072 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|was|on|.|and|effect (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
D003513_D003072 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|a|passive|avoidance (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|or|retrieval (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN|for|;||)|of|( (r_conj) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|was|on|.|and|effect (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|was|produced|.|and|effect (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
D002701_D006935 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (r_conj) protection_94\NN|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN|or|)||(|( (r_conj) rats_67\NNS|;|complete||of (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|rats|;|complete| (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|a|escape|discrete (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D002701_D006935 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|avoidance|administered|a|passive (r_acl) task_131\NN|NONE (r_pobj) for_127\IN|;||)|reversal|of|( (r_prep) prevention_116\NN|for||complete|against|; (l_conj) reversal_149\NN|for|;||)|of|( (l_conj) prevention_186\NN|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN|(|)||of (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|active|applied|avoidance|an (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
8742498
D000431_D056486 CID ethanol_35\NN|in|simultaneous (r_compound) consumption_36\NN|NONE (r_pobj) of_33\IN|the (r_prep) influence_32\NN|NONE (r_dobj) evaluates_30\VBZ|in|,|PARP|on|and (r_conj) acts_20\VBZ|the (l_prep) in_22\IN|,|PARP|evaluates|on|and (l_pobj) mice_25\NNS|NONE (l_prep) with_26\IN|female|NMRI (l_pobj) hepatitis_28\NN|NONE
D000431_D056486 CID ethanol_25\NN|NONE (r_pobj) by_24\IN|on|in (r_agent) caused_23\VBN|the (r_acl) exacerbation_22\NN|NONE (r_pobj) unlike_20\IN|was|by|damage|.|, (r_prep) inhibited_37\VBN|increases|were|,|and|In|,|in (l_nsubjpass) damage_35\NN|was|by|.|,|unlike
D000431_D056486 CID ethanol_42\NN|NONE (r_pobj) by_41\IN| (r_prep) %_40\NN|NONE (r_pobj) by_38\IN|was|damage|.|,|unlike (r_agent) inhibited_37\VBN|increases|were|,|and|In|,|in (l_nsubjpass) damage_35\NN|was|by|.|,|unlike
D000431_D056486 CID ethanol_15\NN||/|AAP (r_nmod) mice_19\NNS|NONE (r_pobj) to_14\IN|when|was|NAA (r_dative) given_13\VBN|,|.|reduction|was (r_advcl) observed_8\VBN|NONE (l_nsubjpass) reduction_4\NN|,|.|given|was (l_prep) of_5\IN|A|%|further (l_pobj) hepatitis_6\NN|NONE
D000431_D056486 CID ethanol_14\NN|NONE (r_pobj) by_13\IN|its (r_prep) exacerbation_12\NN|and|the|induced (r_conj) hepatitis_9\NN|be|can|that|either|by
D019289_D056486 NONE pyruvate_18\NN|(|GPT|) (r_compound) transaminase_19\NN|(|oxaloacetate|and|)|GOT (r_conj) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|.|were|injuries (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|.|were|as
D018698_D056486 NONE glutamate_8\NN| (r_compound) oxaloacetate_10\NN|(|transaminase|and|)|GOT (r_compound) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|.|were|injuries (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|.|were|as
D018698_D056486 NONE glutamate_16\NN| (r_npadvmod) pyruvate_18\NN|(|GPT|) (r_compound) transaminase_19\NN|(|oxaloacetate|and|)|GOT (r_conj) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|.|were|injuries (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|.|were|as
D009536_D056486 NONE amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|.|,|Recently|,|suggesting|effects|we
D009536_D056486 NONE amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D009536_D056486 NONE NAA_11\NNP|when|was|to (r_nsubjpass) given_13\VBN|,|.|reduction|was (r_advcl) observed_8\VBN|NONE (l_nsubjpass) reduction_4\NN|,|.|given|was (l_prep) of_5\IN|A|%|further (l_pobj) hepatitis_6\NN|NONE
D009536_D056486 NONE NAA_27\NNP|by|or (r_pobj) by_26\IN|product|of (r_prep) inhibition_23\NN|NONE (r_pobj) by_19\IN|be|can|that|hepatitis|either (r_agent) reduced_18\VBN|NONE (l_nsubjpass) hepatitis_9\NN|be|can|that|either|by
D009536_D056486 NONE NAA_6\NNP|NONE (r_pobj) of_5\IN|the|main (r_prep) application_4\NN|.|We|in|as (r_dobj) see_1\VBP|NONE (l_prep) in_17\IN|.|We|as|application (l_pobj) order_18\NN|NONE (l_acl) avoid_20\VB|NONE (l_dobj) damage_22\NN|to
D011064_D056486 NONE )_19\-RRB-|EC|ribose|PARP|)|;|( (r_punct) polymerase_20\NN|NONE (r_pobj) of_15\IN|on|selective|a (r_prep) inhibitor_14\NN|,|nicotinic|acid (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|.|,|Recently|,|suggesting|effects|we
D011064_D056486 NONE )_19\-RRB-|EC|ribose|PARP|)|;|( (r_punct) polymerase_20\NN|NONE (r_pobj) of_15\IN|on|selective|a (r_prep) inhibitor_14\NN|,|nicotinic|acid (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D000082_D056486 CID acetaminophen_9\NN|hepatotoxicity (r_pobj) on_8\IN|of (l_pobj) hepatotoxicity_10\NN|acetaminophen
D000082_D056486 CID acetaminophen_31\NN|NONE (r_pobj) from_30\IN|mice (r_prep) suffering_29\VBG|NONE (r_pcomp) on_27\IN|selective|of|a (r_prep) inhibitor_14\NN|,|nicotinic|acid (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|.|,|Recently|,|suggesting|effects|we
D000082_D056486 CID acetaminophen_31\NN|NONE (r_pobj) from_30\IN|mice (r_prep) suffering_29\VBG|NONE (r_pcomp) on_27\IN|selective|of|a (r_prep) inhibitor_14\NN|,|nicotinic|acid (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D000082_D056486 CID AAP)-hepatitis_33\NNP|.|,|Recently|,|suggesting|effects|we
D000082_D056486 CID AAP)-hepatitis_33\NNP|.|,|Recently|,|suggesting|effects|we (r_npadvmod) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D000082_D056486 CID AAP_38\NNP| (r_npadvmod) induced_40\VBN|the|liver (r_amod) injury_42\NN|that|step (r_nsubj) involves_43\VBZ|NONE (r_ccomp) suggesting_35\VBG|.|,|AAP)hepatitis|Recently|,|effects|we (r_advcl) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|.|,|Recently|,|suggesting|effects|we
D000082_D056486 CID AAP_38\NNP| (r_npadvmod) induced_40\VBN|the|liver (r_amod) injury_42\NN|that|step
D000082_D056486 CID AAP_27\NNP|NONE (r_compound) hepatitis_28\NN|NONE
D000082_D056486 CID AAP_17\NNP|NONE (r_pobj) of_16\IN|the (r_prep) presence_15\NN|NONE (r_pobj) in_13\IN|increases|were|,|and|inhibited|In|, (r_prep) measured_12\VBN|NONE (l_conj) inhibited_37\VBN|increases|were|,|and|In|,|in (l_nsubjpass) damage_35\NN|was|by|.|,|unlike
D000082_D056486 CID AAP_17\NNP|ethanol||/ (r_compound) mice_19\NNS|NONE (r_pobj) to_14\IN|when|was|NAA (r_dative) given_13\VBN|,|.|reduction|was (r_advcl) observed_8\VBN|NONE (l_nsubjpass) reduction_4\NN|,|.|given|was (l_prep) of_5\IN|A|%|further (l_pobj) hepatitis_6\NN|NONE
D000082_D056486 CID AAP_6\NNP| (r_npadvmod) induced_8\VBN|and|the|exacerbation (r_amod) hepatitis_9\NN|be|can|that|either|by
D000082_D056486 CID acetaminophen_16\NN|NONE (r_pobj) of_15\IN|pharmaceutical (r_prep) preparations_14\NNS|NONE (r_pobj) in_12\IN|the|combinational (r_prep) use_11\NN|NONE (r_pobj) for_8\IN|NONE (r_prep) as_7\IN|.|We|in|application (r_prep) see_1\VBP|NONE (l_prep) in_17\IN|.|We|as|application (l_pobj) order_18\NN|NONE (l_acl) avoid_20\VB|NONE (l_dobj) damage_22\NN|to
D062907_D056486 NONE oxaloacetate_10\NN|(|transaminase|and|)|GOT (r_compound) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|.|were|injuries (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|.|were|as
D009243_D056486 NONE NAD_5\NNP| (r_compound) precursors_7\NNS|NONE (r_pobj) of_4\IN|on (r_prep) free_3\JJ|.|of (l_prep) on_8\IN|of (l_pobj) hepatotoxicity_10\NN|acetaminophen
D009243_D056486 NONE NAD_13\NNP|NONE (l_appos) substrate_16\NN|, (l_relcl) acts_20\VBZ|the (l_prep) in_22\IN|,|PARP|evaluates|on|and (l_pobj) mice_25\NNS|NONE (l_prep) with_26\IN|female|NMRI (l_pobj) hepatitis_28\NN|NONE
D009243_D056486 NONE NAD_37\NNP|enzyme (r_appos) substrate_36\NN|NONE (r_pobj) of_32\IN|dietary (r_prep) depletion_31\NN|NONE (r_pobj) by_29\IN|or|NAA (r_conj) by_26\IN|product|of (r_prep) inhibition_23\NN|NONE (r_pobj) by_19\IN|be|can|that|hepatitis|either (r_agent) reduced_18\VBN|NONE (l_nsubjpass) hepatitis_9\NN|be|can|that|either|by
1415380
D011803_D006463 CID quinine_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) ingestion_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|.|uremic (r_acl) syndrome_3\NN|NONE
D011803_D006463 CID quinine_5\NN|NONE (r_compound) ingestion_6\NN|NONE (r_pobj) following_4\VBG|uremic (r_prep) syndrome_3\NN|.|,|phenomenon|with
D011803_D006463 CID Quinine_0\NN| (r_npadvmod) associated_2\VBN|uremic (r_amod) syndrome_6\NN|often|.|probably
8480959
D003401_D009135 NONE creatine_7\NN|NONE (r_compound) kinase_8\NN|greater (r_compound) elevations_9\NNS|NONE (r_pobj) with_6\IN|muscle (r_prep) symptoms_5\NNS|NONE (r_pobj) as_3\IN|, (r_prep) defined_2\VBN|NONE (r_acl) Myopathy_0\NNP|,|and|associated|.|rare
D008148_D006937 NONE lovastatin_4\NN|NONE (r_pobj) of_3\IN|and|tolerability|in|. (r_prep) Efficacy_0\NN|NONE (l_prep) in_5\IN|and|tolerability|of|. (l_pobj) women_7\NNS|NONE (l_prep) with_8\IN| (l_pobj) hypercholesterolemia_10\NN|NONE
D008148_D006937 NONE lovastatin_7\NN|NONE (r_pobj) of_6\IN|and|the|safety|in (r_prep) efficacy_3\NN|.|with|To (r_dobj) evaluate_1\VB|NONE (l_prep) with_10\IN|.|efficacy|To (l_pobj) hypercholesterolemia_12\NN|NONE
D008148_D006937 NONE Lovastatin_0\NNP|tolerated|.|effective|and (r_nsubj) is_1\VBZ|NONE (l_conj) tolerated_7\VBN|.|effective|Lovastatin|and (l_prep) as_8\IN|generally|well (l_pobj) therapy_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) hypercholesterolemia_12\NN|NONE
D008148_D009135 CID lovastatin_31\NN|NONE (r_pobj) of_30\IN|daily|mg|recommended|the (r_prep) dose_29\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) associated_23\VBN|,|and|.|Myopathy|rare (r_conj) was_20\VBD|NONE (l_nsubj) Myopathy_0\NNP|,|and|associated|.|rare
17965424
D004008_D005767 CID diclofenac_14\NNP|NONE (r_pobj) than_13\IN|NONE (r_prep) etoricoxib_12\NN|NONE (r_pobj) with_11\IN|significantly (r_prep) lower_10\JJR|ratio|.|rate|; (r_acomp) was_8\VBD|NONE (l_nsubj) rate_3\NN|ratio|.|lower|; (l_amod) due_4\IN|discontinuation|cumulative|The (l_pcomp) to_5\IN|NONE (l_pobj) AEs_7\NNS|NONE
D004008_D005767 CID diclofenac_17\NNP|from||mg. (r_nmod) Discontinuations_20\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|due|treatment (r_prep) discontinuing_9\VBG|NONE (l_prep) due_11\IN|compared|treatment (l_pcomp) to_12\IN|NONE (l_pobj) AEs_14\NNS|NONE
D004008_D005767 CID diclofenac_17\NNP|from||mg. (r_nmod) Discontinuations_20\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|due|treatment (r_prep) discontinuing_9\VBG|NONE (r_pcomp) for_8\IN|lower|a (r_prep) risk_7\NN|common|Etoricoxib|,|mg (r_dobj) demonstrated_3\VBD|higher|,|. (l_advcl) common_27\JJ|Etoricoxib|risk|,|mg (l_prep) than_28\IN|although|less (l_pobj) discontinuations_29\NNS|NONE (l_prep) from_30\IN|NONE (l_pobj) AEs_32\NNS|NONE
C422649_D004487 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|compared|incidence|;|.|p<. (r_acomp) were_13\VBD|NONE (l_nsubj) incidence_1\NN|compared|higher|;|.|p<. (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_conj) related_11\VBN|hypertension|and| (l_npadvmod) oedema_9\NN|
C422649_D004487 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|compared|incidence|;|.|p<. (r_acomp) were_13\VBD|NONE (l_dep) p<0.001_37\VB|compared|higher|incidence|;|. (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE (l_conj) p<0.01_41\NN|and (l_prep) for_42\IN|NONE (l_pobj) oedema_43\NN|NONE
D004008_D001172 NONE sodium_15\NN|diclofenac|and|II|trial|gastrointestinal (r_compound) tolerability_17\NN|NONE (r_pobj) vs_13\IN|the (r_prep) etoricoxib_12\NN|NONE (r_pobj) of_10\IN|) (r_prep) results_9\NNS|of|:|.|Gastrointestinal (r_appos) tolerability_1\NN|NONE (l_prep) of_2\IN|results|:|.|Gastrointestinal (l_pobj) etoricoxib_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) patients_7\NNS|NONE (l_compound) arthritis_6\NN|rheumatoid
D004008_D001172 NONE diclofenac_22\NN|and (r_conj) etoricoxib_20\NN|NONE (r_pobj) of_19\IN|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|A|,|.|blind|randomised (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE
D004008_D001172 NONE diclofenac_22\NN|and (r_conj) etoricoxib_20\NN|NONE (r_pobj) of_19\IN|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|A|,|.|blind|randomised (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE (l_appos) RA_29\NNP|(|)|rheumatoid
D004008_D001172 NONE diclofenac_28\NN| (r_nmod) mg_30\NN|)||daily (r_compound) twice_31\RB|and|received|years|were|or|. (r_conj) enrolled_15\VBN|NONE (l_nsubjpass) years_9\NNS|twice|and|received|were|or|. (l_acl) diagnosed_11\VBD|age|.|)|A (l_prep) with_12\IN|NONE (l_pobj) RA_13\NNP|NONE
C422649_D006973 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|compared|incidence|;|.|p<. (r_acomp) were_13\VBD|NONE (l_nsubj) incidence_1\NN|compared|higher|;|.|p<. (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_npadvmod) hypertension_5\NN|related|and|
C422649_D006973 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|compared|incidence|;|.|p<. (r_acomp) were_13\VBD|NONE (l_dep) p<0.001_37\VB|compared|higher|incidence|;|. (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE
C422649_D001172 NONE etoricoxib_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) patients_7\NNS|NONE (l_compound) arthritis_6\NN|rheumatoid
C422649_D001172 NONE etoricoxib_12\NN|NONE (r_pobj) of_10\IN|) (r_prep) results_9\NNS|of|:|.|Gastrointestinal (r_appos) tolerability_1\NN|NONE (l_prep) of_2\IN|results|:|.|Gastrointestinal (l_pobj) etoricoxib_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) patients_7\NNS|NONE (l_compound) arthritis_6\NN|rheumatoid
C422649_D001172 NONE etoricoxib_20\NN|NONE (r_pobj) of_19\IN|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|A|,|.|blind|randomised (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE
C422649_D001172 NONE etoricoxib_20\NN|NONE (r_pobj) of_19\IN|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|A|,|.|blind|randomised (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE (l_appos) RA_29\NNP|(|)|rheumatoid
C422649_D001172 NONE etoricoxib_18\RB|daily (r_dobj) received_17\VBN|twice|and|years|were|or|. (r_conj) enrolled_15\VBN|NONE (l_nsubjpass) years_9\NNS|twice|and|received|were|or|. (l_acl) diagnosed_11\VBD|age|.|)|A (l_prep) with_12\IN|NONE (l_pobj) RA_13\NNP|NONE
C422649_D005767 NONE etoricoxib_12\NN|NONE (r_pobj) with_11\IN|significantly (r_prep) lower_10\JJR|ratio|.|rate|; (r_acomp) was_8\VBD|NONE (l_nsubj) rate_3\NN|ratio|.|lower|; (l_amod) due_4\IN|discontinuation|cumulative|The (l_pcomp) to_5\IN|NONE (l_pobj) AEs_7\NNS|NONE
C422649_D005767 NONE Etoricoxib_0\NNP|common|risk|,|mg (r_nsubj) demonstrated_3\VBD|higher|,|. (l_dobj) risk_7\NN|common|Etoricoxib|,|mg (l_prep) for_8\IN|lower|a (l_pcomp) discontinuing_9\VBG|NONE (l_prep) due_11\IN|compared|treatment (l_pcomp) to_12\IN|NONE (l_pobj) AEs_14\NNS|NONE
C422649_D005767 NONE Etoricoxib_0\NNP|common|risk|,|mg (r_nsubj) demonstrated_3\VBD|higher|,|. (l_advcl) common_27\JJ|Etoricoxib|risk|,|mg (l_prep) than_28\IN|although|less (l_pobj) discontinuations_29\NNS|NONE (l_prep) from_30\IN|NONE (l_pobj) AEs_32\NNS|NONE
C422649_D005767 NONE etoricoxib_38\NN|NONE (r_pobj) with_37\IN|significantly (r_prep) higher_36\JJR|demonstrated|,|. (r_acomp) were_34\VBD|NONE (l_ccomp) demonstrated_3\VBD|higher|,|. (l_dobj) risk_7\NN|common|Etoricoxib|,|mg (l_prep) for_8\IN|lower|a (l_pcomp) discontinuing_9\VBG|NONE (l_prep) due_11\IN|compared|treatment (l_pcomp) to_12\IN|NONE (l_pobj) AEs_14\NNS|NONE
C422649_D005767 NONE etoricoxib_38\NN|NONE (r_pobj) with_37\IN|significantly (r_prep) higher_36\JJR|demonstrated|,|. (r_acomp) were_34\VBD|NONE (l_ccomp) demonstrated_3\VBD|higher|,|. (l_advcl) common_27\JJ|Etoricoxib|risk|,|mg (l_prep) than_28\IN|although|less (l_pobj) discontinuations_29\NNS|NONE (l_prep) from_30\IN|NONE (l_pobj) AEs_32\NNS|NONE
D004008_D006973 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|higher|incidence|;|.|p<. (r_prep) were_13\VBD|NONE (l_nsubj) incidence_1\NN|compared|higher|;|.|p<. (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_npadvmod) hypertension_5\NN|related|and|
D004008_D006973 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|higher|incidence|;|.|p<. (r_prep) were_13\VBD|NONE (l_dep) p<0.001_37\VB|compared|higher|incidence|;|. (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE
D004008_D004487 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|higher|incidence|;|.|p<. (r_prep) were_13\VBD|NONE (l_nsubj) incidence_1\NN|compared|higher|;|.|p<. (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_conj) related_11\VBN|hypertension|and| (l_npadvmod) oedema_9\NN|
D004008_D004487 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|higher|incidence|;|.|p<. (r_prep) were_13\VBD|NONE (l_dep) p<0.001_37\VB|compared|higher|incidence|;|. (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE (l_conj) p<0.01_41\NN|and (l_prep) for_42\IN|NONE (l_pobj) oedema_43\NN|NONE
6381653
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|and|thalamotomy|. (r_amod) dyskinesia_3\JJ|NONE
D007980_D004409 CID Levodopa_0\NNP|alleviated|.|dyskinesia| (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesia_3\NN|alleviated|.||Levodopa
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE
D007980_D020821 NONE Levodopa_0\NNP|alleviated|.|dyskinesia| (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesia_3\NN|alleviated|.||Levodopa (l_prep) in_7\IN|of (l_pobj) cases_9\NNS|NONE (l_prep) of_10\IN|thirteen (l_pobj) Parkinsonism_11\NNP|NONE (l_relcl) was_14\VBD|,|, (l_attr) choreic_15\JJ|which (l_conj) ballistic_17\JJ|,|in (l_conj) dystonic_19\JJ|or
D007980_D013786 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE (l_prep) by_6\IN|induced (l_pobj) lesions_8\NNS|NONE
D007980_D010302 NONE Levodopa_0\NNP|alleviated|.|dyskinesia| (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesia_3\NN|alleviated|.||Levodopa (l_prep) in_7\IN|of (l_pobj) cases_9\NNS|NONE (l_prep) of_10\IN|thirteen (l_pobj) Parkinsonism_11\NNP|NONE
D007980_D010302 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE (r_pobj) of_1\IN|in (r_prep) Control_0\NN|.|is (l_prep) in_9\IN|of (l_pobj) course_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|routine (l_pobj) Parkinsonism_16\NNP|NONE
12691807
D007980_D008538 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN|NONE
D007980_D008538 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN|NONE (l_appos) OMD_16\NNP|Oromandibular|)|reversible|(|induced
D007980_D004421 CID Levodopa_0\NNP||.|dystonia (r_npadvmod) induced_2\VBN|NONE (l_dobj) dystonia_4\NN|Levodopa||.
D007980_D004409 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|in|have|been|.
D007980_D019578 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|in|have|been|. (r_nsubjpass) reported_6\VBN|NONE (l_prep) in_7\IN|dyskinesias|have|been|. (l_pobj) disease_10\NN|NONE (l_conj) atrophy_14\NN|and|Parkinson
D007980_D013494 NONE Levodopa_0\NNP||.|dystonia (r_npadvmod) induced_2\VBN|NONE (l_dobj) dystonia_4\NN|Levodopa||. (l_prep) in_5\IN|oromandibular (l_pobj) palsy_8\JJ|NONE
D007980_D013494 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN|NONE (r_pobj) of_8\IN|in|an|unusual (r_prep) case_7\NN|we|highlight|.|In (l_prep) in_18\IN|of|an|unusual (l_pobj) patient_21\NN|NONE (l_compound) PSP_20\NNP|a
D007980_D013494 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN|NONE (r_pobj) of_8\IN|in|an|unusual (r_prep) case_7\NN|we|highlight|.|In (r_dobj) describe_4\VBP|NONE (l_advcl) highlight_23\VB|we|case|.|In (l_dobj) importance_25\NN|to (l_prep) of_26\IN|the (l_pcomp) recognizing_27\VBG|NONE (l_dobj) complication_31\NN|,|discuss|and (l_prep) in_32\IN|related|this (l_pobj) management_34\NN|NONE (l_prep) of_35\IN|the (l_pobj) PSP_36\NNP|NONE
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|in|have|been|. (r_nsubjpass) reported_6\VBN|NONE (l_prep) in_7\IN|dyskinesias|have|been|. (l_pobj) disease_10\NN|NONE
2055425
D018723_D003920 NONE bethanechol_23\NN|and|, (r_conj) ATP_20\NNP|,|nerve (r_conj) stimulation_18\NN|NONE (r_pobj) to_16\TO|from|of|contractile (r_prep) responses_8\NNS|NONE (l_prep) from_13\IN|of|contractile|to (l_pobj) rats_15\NNS|NONE (l_amod) diabetic_14\JJ|NONE
D018723_D003920 NONE bethanechol_22\NN|and|, (r_conj) ATP_19\NNP|nerve|, (r_conj) stimulation_17\NN|NONE (r_pobj) to_15\TO|from|of|contractile (r_prep) responses_7\NNS|NONE (l_prep) from_12\IN|of|to|contractile (l_pobj) rats_14\NNS|NONE (l_amod) diabetic_13\JJ|NONE
D013311_D003920 CID streptozotocin_17\NNS| (r_npadvmod) induced_19\VBN|NONE (r_amod) diabetes_20\NN|NONE (r_compound) mellitus_21\NN|NONE
D013311_D003920 CID streptozotocin_15\JJ| (r_npadvmod) diabetic_17\JJ|NONE
D013311_D003920 CID streptozotocin_7\NNS| (r_npadvmod) induced_9\VBN|on (r_amod) diabetes_10\NNS|NONE
D000255_D003920 NONE ATP_20\NNP|,|nerve (r_conj) stimulation_18\NN|NONE (r_pobj) to_16\TO|from|of|contractile (r_prep) responses_8\NNS|NONE (l_prep) from_13\IN|of|contractile|to (l_pobj) rats_15\NNS|NONE (l_amod) diabetic_14\JJ|NONE
D000255_D003920 NONE ATP_19\NNP|nerve|, (r_conj) stimulation_17\NN|NONE (r_pobj) to_15\TO|from|of|contractile (r_prep) responses_7\NNS|NONE (l_prep) from_12\IN|of|to|contractile (l_pobj) rats_14\NNS|NONE (l_amod) diabetic_13\JJ|NONE
3769769
D014282_D012559 NONE hydrochloride_12\NN|NONE (r_dobj) trihexyphenidyl_11\JJ|was|with|patient|. (r_conj) treated_5\VBN|NONE (l_nsubjpass) patient_3\NN|was|with|trihexyphenidyl|. (l_amod) schizophrenic_2\JJ|A|chronic
D014282_D001919 CID hydrochloride_4\NN|to (r_pobj) due_1\JJ|. (r_amod) Bradycardia_0\NNS|NONE
6674249
D015119_D013345 NONE acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (l_prep) in_17\IN|a|short|EACA|aminocaproic (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|old|a (l_pobj) haemorrhage_26\NN|NONE
D015119_D013345 NONE acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (r_pcomp) of_2\IN|A (r_prep) case_1\NN|(|is|.|) (r_nsubjpass) described_31\VBN|NONE (l_punct) (_27\-LRB-|is|case|.|) (l_preconj) SAH_28\NNP|NONE
D015119_D013345 NONE EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (l_prep) in_17\IN|a|short|EACA|aminocaproic (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|old|a (l_pobj) haemorrhage_26\NN|NONE
D015119_D013345 NONE EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (r_pcomp) of_2\IN|A (r_prep) case_1\NN|(|is|.|) (r_nsubjpass) described_31\VBN|NONE (l_punct) (_27\-LRB-|is|case|.|) (l_preconj) SAH_28\NNP|NONE
D015119_D009336 CID acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
D015119_D009336 CID EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
D015119_D009135 CID acid_5\NN|in|?|myopathy|may|Why (r_nsubj) induce_9\VBP|NONE (l_dobj) myopathy_10\NNS|in|?|acid|may|Why
D015119_D009135 CID EACA_7\NNP|aminocaproic (r_appos) acid_5\NN|in|?|myopathy|may|Why (r_nsubj) induce_9\VBP|NONE (l_dobj) myopathy_10\NNS|in|?|acid|may|Why
D015119_D009135 CID acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
D015119_D009135 CID EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
15686794
D000638_D001281 NONE Amiodarone_0\NNP|.|drug (r_nsubj) represents_1\VBZ|NONE (l_dobj) drug_5\NN|.|Amiodarone (l_prep) for_6\IN|effective|antiarrhythmic|an (l_pobj) cardioversion_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) fibrillation_13\NN|NONE
D000638_D001281 NONE Amiodarone_0\NNP|.|drug (r_nsubj) represents_1\VBZ|NONE (l_dobj) drug_5\NN|.|Amiodarone (l_prep) for_6\IN|effective|antiarrhythmic|an (l_pobj) cardioversion_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) fibrillation_13\NN|NONE (l_appos) AF_15\NNP|onset|(|atrial
D000638_D001281 NONE amiodarone_28\NN|intravenous (r_compound) loading_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) initiation_25\NN|minutes (r_pobj) after_24\IN|who|pain (r_prep) experienced_14\VBD|atrial|onset|, (r_relcl) fibrillation_11\NN|NONE
D000638_D017116 CID amiodarone_8\NN|NONE (r_pobj) of_7\IN|intravenous (r_prep) administration_6\NN|NONE (r_pobj) during_4\IN|:|.|report|Acute|back (r_prep) pain_3\NN|NONE
D000638_D017116 CID amiodarone_28\NN|intravenous (r_compound) loading_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) initiation_25\NN|minutes (r_pobj) after_24\IN|who|pain (r_prep) experienced_14\VBD|atrial|onset|, (l_dobj) pain_20\NN|after|who
3413271
D004837_D003866 NONE epinephrine_1\NN|evidenced|ischemia|. (r_nsubj) produced_4\VBD|NONE (l_advcl) evidenced_8\VBN|ischemia|epinephrine|. (l_agent) by_9\IN|as (l_pobj) depression_12\NN|NONE
D010100_D007511 NONE oxygen_8\NN|increasing|myocardial (r_compound) consumption_9\NN|.|were|during|signs (r_nsubjpass) compared_11\VBN|NONE (l_nsubjpass) signs_1\NNS|.|were|during|consumption (l_prep) of_2\IN|Objective (l_pobj) ischemia_3\NN|NONE
D004837_D000787 NONE epinephrine_1\NN|evidenced|ischemia|. (r_nsubj) produced_4\VBD|NONE (l_advcl) evidenced_8\VBN|ischemia|epinephrine|. (l_agent) by_9\IN|as (l_pobj) depression_12\NN|NONE (l_conj) angina_14\NN|ST|and|segment
D004837_D003324 NONE epinephrine_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) role_1\NN|.|was|in (r_nsubjpass) examined_9\VBN|NONE (l_prep) in_10\IN|.|was|role (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) disease_15\NN|NONE
D004837_D017202 CID epinephrine_6\NN|NONE (r_pobj) by_5\IN|Mechanisms|. (r_prep) induced_4\VBN|NONE (l_nsubj) Mechanisms_0\NNS|.|by (l_prep) of_1\IN|NONE (l_pobj) ischemia_3\NN|NONE
D004837_D017202 CID epinephrine_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) role_1\NN|.|was|in (l_prep) in_4\IN|of|The (l_pcomp) eliciting_5\VBG|NONE (l_dobj) ischemia_7\NN|NONE
D004837_D017202 CID epinephrine_1\NN|evidenced|ischemia|. (r_nsubj) produced_4\VBD|NONE (l_dobj) ischemia_6\NN|evidenced|epinephrine|.
D004837_D017202 CID epinephrine_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of|the (r_acl) mechanisms_3\NNS|However|different|,|. (l_prep) of_4\IN|induced|the (l_pobj) ischemia_6\NN|NONE
D004837_D017202 CID epinephrine_28\NN| (r_npadvmod) induced_30\VBN|NONE (r_amod) ischemia_31\NN|while|was|by (r_nsubjpass) characterized_33\VBN|predominantly|with|by|was|.|ischemia|, (r_advcl) marked_6\VBN|NONE (l_nsubjpass) ischemia_4\NN|predominantly|with|characterized|by|was|.|,
D004837_D007511 NONE epinephrine_6\NN|NONE (l_appos) comparison_8\NN|: (l_prep) with_9\IN|NONE (l_pobj) ischemia_13\NN|NONE
D004837_D007511 NONE epinephrine_13\NN|exercise|and (r_amod) infusion_14\NN|NONE (r_pobj) during_12\IN|.|were|signs|consumption (r_prep) compared_11\VBN|NONE (l_nsubjpass) signs_1\NNS|.|were|during|consumption (l_prep) of_2\IN|Objective (l_pobj) ischemia_3\NN|NONE
D004837_D007511 NONE epinephrine_28\NN| (r_npadvmod) induced_30\VBN|NONE (r_amod) ischemia_31\NN|while|was|by
D004837_D007511 NONE epinephrine_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) produced_5\VBN|that|, (r_acl) ischemia_4\NN|may|as|during
7161250
D006220_D010302 CID haloperidol_10\NN|NONE (r_pobj) of_9\IN|higher (r_prep) doses_8\NNS|and|in (r_pobj) at_6\IN|higher|.|incidence (r_prep) was_4\VBD|NONE (l_nsubj) incidence_1\NN|higher|at|. (l_prep) of_2\IN|The (l_pobj) parkinsonism_3\NN|NONE
D008140_D017109 NONE lorazepam_6\NN|NONE (r_pobj) by_3\IN|were|.|was|,|Akathisia (r_agent) controlled_2\VBN|NONE (l_nsubjpass) Akathisia_0\NNP|were|.|was|,|by
D001569_D017109 NONE benzodiazepine_5\JJ|the|in|out (r_amod) lorazepam_6\NN|NONE (r_pobj) by_3\IN|were|.|was|,|Akathisia (r_agent) controlled_2\VBN|NONE (l_nsubjpass) Akathisia_0\NNP|were|.|was|,|by
19996135
D014148_D012640 CID Acid_4\NNP|with|is|. (r_nsubjpass) associated_6\VBN|NONE (l_prep) with_7\IN|is|.|Acid (l_pobj) seizures_10\NNS|NONE
D014148_D012640 CID TXA_19\NNP|seizures|and (r_compound) usage_20\NN|NONE (l_conj) seizures_22\NNS|TXA|and
D014148_D012640 CID TXA_9\NNP|NONE (r_compound) intraoperatively_10\NN|NONE (r_pobj) of_8\IN|high|ranging (r_prep) doses_7\NNS|.|had|,|patients (r_dobj) received_5\VBD|NONE (l_nsubj) patients_2\NNS|.|had|doses|, (l_prep) with_3\IN||All (l_pobj) seizures_4\NNS|NONE
D014148_D012640 CID TXA_9\NN|NONE (r_pobj) of_5\IN|in|in (r_prep) use_4\NN|that|is|with (r_nsubjpass) associated_25\VBN|results|. (l_prep) with_26\IN|that|is|use (l_pobj) seizures_28\NNS|NONE
